FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Parikh, R
   Pollock, D
   Sharma, J
   Edwards, J
AF Parikh, Rishi
   Pollock, Daniel
   Sharma, Jyotirmay
   Edwards, Jonathan
TI Is There Room for Prevention? Examining the Effect of Outpatient
   Facility Type on the Risk of Surgical Site Infection
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID CARE-ASSOCIATED INFECTIONS; BREAST SURGERY; COSTS; SURVEILLANCE; IMPACT;
   DETERMINANTS; METAANALYSIS; MORTALITY; NETWORK; SYSTEM
AB OBJECTIVE. We compared risk for surgical site infection (SSI) following surgical breast procedures among 2 patient groups: those whose procedures were performed in ambulatory surgery centers (ASCs) and those whose procedures were performed in hospital-based outpatient facilities.
   DESIGN. Cohort study using National Healthcare Safety Network (NHSN) SSI data for breast procedures performed from 2010 to 2014.
   METHODs. Unconditional multivariate logistic regression was used to examine the association between facility type and breast SSI, adjusting for American Society of Anesthesiologists (ASA) Physical Status Classification, patient age, and duration of procedure. Other potential adjustment factors examined were wound classification, anesthesia use, and gender.
   RESULTS. Among 124,021 total outpatient breast procedures performed between 2010 and 2014, 110,987 procedure reports submitted to the NHSN provided complete covariate data and were included in the analysis. Breast procedures performed in ASCs carried a lower risk of SSI compared with those performed in hospital-based outpatient settings. For patients aged <51 years, the adjusted risk ratio was 0.36 (95% CI, 0.25-0.50) and for patients >51 years old, the adjusted risk ratio was 0.32 (95% CI, 0.21-0.49).
   CONCLUSIONS. SSI risk following breast procedures was significantly lower among ASC patients than among hospital-based outpatients. These findings should be placed in the context of study limitations, including the possibility of incomplete ascertainment of SSIs and shortcomings in the data available to control for differences in patient case mix. Additional studies are needed to better understand the role of procedural settings in SSI risk following breast procedures and to identify prevention opportunities.
C1 [Parikh, Rishi; Pollock, Daniel; Edwards, Jonathan] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd Mailstop A-24, Atlanta, GA 30329 USA.
   [Sharma, Jyotirmay] Emory Clin, Dept Surg, Atlanta, GA 30322 USA.
RP Parikh, R (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd Mailstop A-24, Atlanta, GA 30329 USA.
EM yfp2@cdc.gov
NR 25
TC 0
Z9 0
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD OCT
PY 2016
VL 37
IS 10
BP 1179
EP 1185
DI 10.1017/ice.2016.146
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DY4GS
UT WOS:000385057600008
PM 27430647
ER

PT J
AU Pollack, LA
   Plachouras, D
   Sinkowitz-Cochran, R
   Gruhler, H
   Monnet, DL
   Weber, JT
AF Pollack, Lori A.
   Plachouras, Diamantis
   Sinkowitz-Cochran, Ronda
   Gruhler, Heidi
   Monnet, Dominique L.
   Weber, J. Todd
CA Transatlantic Taskforce Antimicrob
TI A Concise Set of Structure and Process Indicators to Assess and Compare
   Antimicrobial Stewardship Programs Among EU and US Hospitals: Results
   From a Multinational Expert Panel
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID INTENSIVE-CARE UNITS; QUALITY INDICATORS; ANTIBIOTIC USE; IMPROVEMENT;
   INFECTIONS; RESISTANCE; INTERVENTIONS; INITIATIVES; PREVENTION;
   STRATEGIES
AB OBJECTIVES. To develop common indicators, relevant to both EU member states and the United States, that characterize and allow for meaningful comparison of antimicrobial stewardship programs among different countries and healthcare systems.
   DESIGN. Modified Delphi process.
   PARTICIPANTS. A multinational panel of 20 experts in antimicrobial stewardship.
   METHODS. Potential indicators were rated on the perceived feasibility to implement and measure each indicator and clinical importance for optimizing appropriate antimicrobial prescribing.
   RESULTS. The outcome was a set of 33 indicators developed to characterize the infrastructure and activities of hospital antimicrobial stewardship programs. Among them 17 indicators were considered essential to characterize an antimicrobial stewardship program and therefore were included in a core set of indicators. The remaining 16 indicators were considered optional indicators and included in a supplemental set.
   CONCLUSIONS. The integration of these indicators in public health surveillance and special studies will lead to a better understanding of best practices in antimicrobial stewardship. Additionally, future studies can explore the association of hospital antimicrobial stewardship programs to antimicrobial use and resistance.
C1 [Pollack, Lori A.; Sinkowitz-Cochran, Ronda; Gruhler, Heidi; Weber, J. Todd] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
   [Plachouras, Diamantis; Monnet, Dominique L.] European Ctr Dis Prevent & Control, Stockholm, Sweden.
RP Pollack, LA (reprint author), 4770 Buford Hwy NE,Mailstop F-76, Atlanta, GA 30341 USA.
EM lpollack@cdc.gov
FU ECDC
FX This work was performed for TATFAR as part of the routine work of the
   ECDC and the CDC. ECDC provided funding for participants to attend the
   Expert Consensus Meeting that took place on June 18, 2014, in Stockholm,
   Sweden.
NR 35
TC 1
Z9 1
U1 3
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD OCT
PY 2016
VL 37
IS 10
BP 1201
EP 1211
DI 10.1017/ice.2016.115
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DY4GS
UT WOS:000385057600011
PM 27418168
ER

PT J
AU Riley, PL
   Rurangirwa, J
   Fowler, L
   Ellenberger, D
   Raizes, E
   Nkengasong, J
AF Riley, Patricia L.
   Rurangirwa, Jacqueline
   Fowler, Latrice
   Ellenberger, Dennis
   Raizes, Elliot
   Nkengasong, John
TI Nursing and Midwifery Knowledge, Attitudes, and Practices Towards Viral
   Load Testing for Managing HIV-Infected Patients in East, Central and
   Southern Africa
SO JOURNAL OF MIDWIFERY & WOMENS HEALTH
LA English
DT Meeting Abstract
C1 [Riley, Patricia L.] Ctr Dis Control & Prevent CDC, ILB, Div Global HIV & TB DGHT, Atlanta, GA USA.
   [Rurangirwa, Jacqueline; Fowler, Latrice; Ellenberger, Dennis] CDC, ILB, DGHT, Atlanta, GA 30333 USA.
   [Raizes, Elliot] CDC, Care & Treatment Branch, DGHT, Atlanta, GA 30333 USA.
   [Nkengasong, John] CDC, ILB, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-9523
EI 1542-2011
J9 J MIDWIFERY WOM HEAL
JI J. Midwifery Women Health
PD OCT
PY 2016
VL 61
IS 5
BP 661
EP 662
DI 10.1111/jmwh.12557
PG 2
WC Nursing
SC Nursing
GA DY0YS
UT WOS:000384822700024
ER

PT J
AU Von Korff, M
   Scher, AI
   Helmick, C
   Carter-Pokras, O
   Dodick, DW
   Goulet, J
   Hamill-Ruth, R
   LeResche, L
   Porter, L
   Tait, R
   Terman, G
   Veasley, C
   Mackey, S
AF Von Korff, Michael
   Scher, Ann I.
   Helmick, Charles
   Carter-Pokras, Olivia
   Dodick, David W.
   Goulet, Joseph
   Hamill-Ruth, Robin
   LeResche, Linda
   Porter, Linda
   Tait, Raymond
   Terman, Gregory
   Veasley, Christin
   Mackey, Sean
TI United States National Pain Strategy for Population Research: Concepts,
   Definitions, and Pilot Data
SO JOURNAL OF PAIN
LA English
DT Article
DE Chronic pain; epidemiology; health services research; prevalence;
   electronic databases
ID CROSS-SECTIONAL SURVEY; CHRONIC BACK-PAIN; SEVERITY; MODERATE; PATIENT;
   MILD; COMORBIDITY; PREVALENCE; DISABILITY; ARTHRITIS
AB National Pain Strategy population research objectives include: estimating chronic pain prevalence, studying pain treatment with electronic health care data, and developing metrics to assess progress in reducing chronic pain impact. In this article, the National Pain Strategy Population Research Workgroup reviews concepts relevant to achieving these aims. High-impact chronic pain was defined as persistent pain with substantial restriction of life activities lasting 6 months or more. In pilot work, we tested a brief assessment of high-impact chronic pain, and used electronic health records data to describe pain-related health care. A mail survey of adult health plan enrollees (N = 770) reported that 14% had high-impact chronic pain. Relative to persons with lower-impact chronic pain, those with high-impact chronic pain were more often frequent users of health care for pain, reported lower quality of life, greater pain-related interference with activities, and more often reported pain at multiple anatomic locations. Analyses of health care data (N = 289,464) reported that pain patients had higher health care costs compared with others and that pain services were typically delivered in primary care. These results support the feasibility of developing data on chronic pain through national health interview surveys and large electronic health care databases.
   Perspective: Pilot analyses supported the feasibility of brief chronic pain assessments suitable for national health surveys and use of electronic health care databases to develop data regarding trends in the delivery of pain treatments, costs, and effectiveness. These methods are relevant to achieving the aims of the US National Pain Strategy. (C) 2016 by the American Pain Society
C1 [Von Korff, Michael] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
   [Scher, Ann I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA.
   [Helmick, Charles] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Carter-Pokras, Olivia] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA.
   [Dodick, David W.] Mayo Clin, Coll Med, Phoenix, AZ USA.
   [Goulet, Joseph] Yale Univ, Sch Med, New Haven, CT USA.
   [Hamill-Ruth, Robin] Univ Virginia Hlth Syst, Charlottesville, VA USA.
   [LeResche, Linda] Univ Washington, Sch Dent, Seattle, WA 98195 USA.
   [Porter, Linda] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Tait, Raymond] St Louis Univ, Sch Med, Dept Psychiat, St Louis, MO 63103 USA.
   [Terman, Gregory] Univ Washington, Sch Med, Seattle, WA 98195 USA.
   [Veasley, Christin] Chron Pain Res Alliance, Milwaukee, WI USA.
   [Mackey, Sean] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
RP Von Korff, M (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
EM vonkorff.m@ghc.org
OI Goulet, Joseph/0000-0002-0842-804X
FU NINDS; IH Inter-Agency Pain Research Coordinating Committee [AG034181];
   Pfizer Inc.; Healthlogix; Haymarket Media Group, Ltd.; SAGE Publishing;
   Synergy; Allergan; Lippincott Williams Wilkins; Oxford University Press;
   Cambridge University Press
FX The pilot data collection reported in this paper was supported by a
   supplemental award from NINDS and the NIH Inter-Agency Pain Research
   Coordinating Committee to a National Institute on Aging grant (AG034181,
   Von Korff, Principal Investigator).; Dr. Von Korff is the Principal
   Investigator of grants to GHRI from Pfizer Inc. that concern opioids.
   Dr. Scher is an advisory board member and consultant for Allergan. Dr.
   Tait's spouse serves on the speaker's bureau for Lilly Pharmaceuticals.
   David W. Dodick, MD, in the past 12 months, has served on advisory
   boards and has consulted for Allergan, Amgen, Alder, CoLucid, Merck,
   ENeura, Eli Lilly & Company, Autonomic Technologies, Teva, Tonix,
   Novartis, Supernus, ScionNeurostim, Boston Scientific. Within the past
   12 months, Dr. Dodick has received royalties, funding for travel,
   speaking, or editorial activities from the following: Healthlogix,
   Haymarket Media Group, Ltd., SAGE Publishing, Synergy, Allergan,
   Lippincott Williams & Wilkins, Oxford University Press, and Cambridge
   University Press; he serves as Editor-in-Chief of Cephalalgia and on the
   editorial boards of The Neurologist, Lancet Neurology, and Postgraduate
   Medicine. The remaining authors report no conflicts.
NR 41
TC 1
Z9 1
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD OCT
PY 2016
VL 17
IS 10
BP 1068
EP 1080
DI 10.1016/j.jpain.2016.06.009
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DY1SF
UT WOS:000384874000003
PM 27377620
ER

PT J
AU Park, S
   Thompson, FE
   McGuire, LC
   Pan, LP
   Galuska, DA
   Blanck, HM
AF Park, Sohyun
   Thompson, Frances E.
   McGuire, Lisa C.
   Pan, Liping
   Galuska, Deborah A.
   Blanck, Heidi M.
TI Sociodemographic and Behavioral Factors Associated with Added Sugars
   Intake among US Adults
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Article
DE Added sugars; Sugar-sweetened beverages; Sweet food; Sociodemographic
   characteristics; Behaviors
ID SWEETENED BEVERAGE INTAKE; FAMILY-HISTORY; CIGARETTE-SMOKING; TASTE
   INTENSITY; YOUNG-ADULTS; HEALTH; ALCOHOLISM; STATES; CONSUMPTION;
   ADDICTION
AB Background Reducing added sugars intake is one, of the Healthy People 2020 objectives. High added sugars intake may be associated with adverse health consequences.
   Objective This cross-sectional study identified sociodemographic and behavioral characteristics associated With added sugars intake among US adults (18 years and older) using the 2010 National Health Interview Survey data (n=24,967).
   Methods The outcome variable was added sugars intake from foods and beverages using scoring algorithms to convert dietary screener frequency responses on nine items to estimates of individual dietary intake of added sugars in teaspoons per day. Added sugars intake was categorized into tertiles (lowest, middle, highest) stratified by sex. The explanatory variables were sociodemographic and behavioral characteristics. Multinomial logistic regression was used to estimate the adjusted odds ratios for the highest and middle tertile added sugars intake groups as compared with the lowest tertile group.
   Results Estimated median added sugars intake was 17.6 tsp/d for men and 11.7 tsp/d for women. For men and women, those who had significantly greater odds for being in the highest tertile of added sugars intake (men: >= 22.0 tsp/d; women: >= 14.6 tsp/d) were younger, less educated, had lower income, were less physically active, were current smokers, and were former or current infrequent/light drinkers, whereas non-Hispanic other/multiracial and those living in the West had significantly lower odds for being in the highest tertile of added sugars intake. Different patterns were found by sex. Non-Hispanic black men had lower odds for being in the highest tertile of added sugars intake, whereas non-Hispanic black women had greater odds for being in the highest tertile.
   Conclusions One in three men consumed >= 22.0 tsp added sugars and one in three women consumed >= 14.6 tsp added sugars daily. Higher added sugars intake was associated with various sociodemographic and behavioral characteristics; this information can inform efforts to design programs and policies specific to high-intake populations.
C1 [Park, Sohyun; Pan, Liping; Galuska, Deborah A.; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F77, Atlanta, GA 30341 USA.
   [McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   [Thompson, Frances E.] NCI, Risk Factor Assessment Branch, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci,NIH, Bethesda, MD 20892 USA.
RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F77, Atlanta, GA 30341 USA.
EM spark3@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 36
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
EI 2212-2680
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD OCT
PY 2016
VL 116
IS 10
BP 1589
EP 1598
DI 10.1016/j.jand.2016.04.012
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DY4GI
UT WOS:000385056600008
PM 27236642
ER

PT J
AU Fulton, JE
   Carlson, SA
   Ainsworth, BE
   Berrigan, D
   Carlson, C
   Dorn, JM
   Heath, GW
   Kohl, HW
   Lee, IM
   Lee, SM
   Masse, LC
   Morrow, JR
   Gabriel, KP
   Pivarnik, JM
   Pronk, NP
   Rodgers, AB
   Saelens, BE
   Sallis, JF
   Troiano, RP
   Tudor-Locke, C
   Wendel, A
AF Fulton, Janet E.
   Carlson, Susan A.
   Ainsworth, Barbara E.
   Berrigan, David
   Carlson, Cynthia
   Dorn, Joan M.
   Heath, Gregory W.
   Kohl, Harold W., III
   Lee, I-Min
   Lee, Sarah M.
   Masse, Louise C.
   Morrow, James R., Jr.
   Gabriel, Kelley Pettee
   Pivarnik, James M.
   Pronk, Nicolaas P.
   Rodgers, Anne B.
   Saelens, Brian E.
   Sallis, James F.
   Troiano, Richard P.
   Tudor-Locke, Catrine
   Wendel, Arthur
TI Strategic Priorities for Physical Activity Surveillance in the United
   States
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE POPULATION HEALTH; MONITORING; EPIDEMIOLOGY; RECOMMENDATIONS; EXERCISE
ID GOOGLE STREET VIEW; NEIGHBORHOOD ENVIRONMENTS; SELF-REPORT; SEDENTARY
   BEHAVIOR; ADULTS; ACCELEROMETER; PREVALENCE; FITNESS; TRENDS; AUDIT
AB Purpose Develop strategic priorities to guide future physical activity surveillance in the United States.
   Methods The Centers for Disease Control and Prevention and the American College of Sports Medicine convened a scientific roundtable of physical activity and measurement experts. Participants summarized the current state of aerobic physical activity surveillance for adults, focusing on practice and research needs in three areas: 1) behavior, 2) human movement, and 3) community supports. Needs and challenges for each area were identified. At the conclusion of the meeting, experts identified one overarching strategy and five strategic priorities to guide future surveillance.
   Results The identified overarching strategy was to develop a national plan for physical activity surveillance similar to the U.S. National Physical Activity Plan for promotion. The purpose of the plan would be to enhance coordination and collaboration within and between sectors, such as transportation and public health, and to address specific strategic priorities identified at the roundtable. These strategic priorities were used 1) to identify and prioritize physical activity constructs; 2) to assess the psychometric properties of instruments for physical activity surveillance; 3) to provide training and technical assistance for those collecting, analyzing, or interpreting surveillance data; 4) to explore accessing data from alternative sources; and 5) to improve communication, translation, and dissemination about estimates of physical activity from surveillance systems.
   Conclusion This roundtable provided strategic priorities for physical activity surveillance in the United States. A first step is to develop a national plan for physical activity surveillance that would provide an operating framework from which to execute these priorities.
C1 [Fulton, Janet E.; Carlson, Susan A.; Dorn, Joan M.; Lee, Sarah M.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Ainsworth, Barbara E.] Arizona State Univ, Phoenix, AZ USA.
   [Berrigan, David; Troiano, Richard P.] NCI, Bethesda, MD 20892 USA.
   [Carlson, Cynthia] Merrimack Coll, N Andover, MA 01845 USA.
   [Carlson, Cynthia] MA England Coll, Henniker, NH USA.
   [Heath, Gregory W.] Univ Tennessee, Chattanooga, TN USA.
   [Kohl, Harold W., III; Gabriel, Kelley Pettee] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Austin Reg Campus, Austin, TX USA.
   [Kohl, Harold W., III] Univ Texas Austin, Austin, TX 78712 USA.
   [Lee, I-Min; Pronk, Nicolaas P.] Harvard Univ, Boston, MA 02115 USA.
   [Masse, Louise C.] Univ British Columbia, Vancouver, BC, Canada.
   [Masse, Louise C.] British Columbia Childrens Hosp, Child & Family Res Inst, Vancouver, BC, Canada.
   [Morrow, James R., Jr.] Univ North Texas, Denton, TX USA.
   [Pivarnik, James M.] Michigan State Univ, E Lansing, MI 48824 USA.
   [Pronk, Nicolaas P.] HealthPartners, Minneapolis, MN USA.
   [Rodgers, Anne B.] Ctr Dis Control & Prevent, Falls Church, VA USA.
   [Saelens, Brian E.] Univ Washington, Seattle, WA 98195 USA.
   [Saelens, Brian E.] Seattle Childrens Res Inst, Seattle, WA USA.
   [Sallis, James F.] Univ Calif Calif, La Jolla, CA USA.
   [Tudor-Locke, Catrine] Univ Massachusetts, Amherst, MA 01003 USA.
   [Wendel, Arthur] Agcy Tox Subst & Dis Registry, Atlanta, GA USA.
RP Fulton, JE (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Highway NE,MS F-77, Atlanta, GA 30341 USA.
EM jkf2@cdc.gov
FU Child and Family Research Institute at the British Columbia Children's
   Hospital
FX LCM received salary support from the Child and Family Research Institute
   at the British Columbia Children's Hospital.
NR 68
TC 1
Z9 1
U1 7
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD OCT
PY 2016
VL 48
IS 10
BP 2057
EP 2069
DI 10.1249/MSS.0000000000000989
PG 13
WC Sport Sciences
SC Sport Sciences
GA DX3TZ
UT WOS:000384298800024
PM 27187094
ER

PT J
AU Rudolf, I
   Betasova, L
   Bischof, V
   Venclikova, K
   Blazejova, H
   Mendel, J
   Hubalek, Z
   Kosoy, M
AF Rudolf, Ivo
   Betasova, Lenka
   Bischof, Vlastimil
   Venclikova, Kristyna
   Blazejova, Hana
   Mendel, Jan
   Hubalek, Zdenek
   Kosoy, Michael
TI Molecular survey of arthropod-borne pathogens in sheep keds (Melophagus
   ovinus), Central Europe
SO PARASITOLOGY RESEARCH
LA English
DT Article
DE Melophagus ovinus; Bartonella melophagi; Rickettsiae; Arboviruses;
   Borrelia burgdorferi; Babesia spp.
ID REAL-TIME PCR; BARTONELLA-MELOPHAGI; BORRELIA-BURGDORFERI; BLOOD; WILD;
   IDENTIFICATION; HIPPOBOSCIDAE; TRANSMISSION; RUMINANTS; FLIES
AB In the study, we screened a total of 399 adult sheep keds (Melophagus ovinus) for the presence of RNA and DNA specific for arboviral, bacterial, and protozoan vector-borne pathogens. All investigated keds were negative for flaviviruses, phleboviruses, bunyaviruses, Borrelia burgdorferi, Rickettsia spp., Anaplasma phagocytophilum, "Candidatus Neoehrlichia mikurensis," and Babesia spp. All ked pools were positive for Bartonella DNA. The sequencing of the amplified fragments of the gltA and 16S-23S rRNA demonstrated a 100 % homology with Bartonella melophagi previously isolated from a sheep ked and from human blood in the USA. The identification of B. melophagi in sheep keds in Central Europe highlights needs extending a list of hematophagous arthropods beyond ticks and mosquitoes for a search of emerging arthropod-borne pathogens.
C1 [Rudolf, Ivo; Betasova, Lenka; Venclikova, Kristyna; Blazejova, Hana; Mendel, Jan; Hubalek, Zdenek] Acad Sci, Inst Vertebrate Biol, Vvi, Kvetna 8, CZ-60365 Brno, Czech Republic.
   [Rudolf, Ivo; Venclikova, Kristyna; Hubalek, Zdenek] Masaryk Univ, Dept Expt Biol, Kotlarska 2, CS-61137 Brno, Czech Republic.
   [Bischof, Vlastimil] Spytihnev 47, Zlin, Czech Republic.
   [Venclikova, Kristyna] Acad Sci Czech Republic, Inst Macromol Chem, Vvi, Prague, Czech Republic.
   [Kosoy, Michael] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Rudolf, I (reprint author), Acad Sci, Inst Vertebrate Biol, Vvi, Kvetna 8, CZ-60365 Brno, Czech Republic.; Rudolf, I (reprint author), Masaryk Univ, Dept Expt Biol, Kotlarska 2, CS-61137 Brno, Czech Republic.
EM rudolf@ivb.cz
RI Mendel, Jan/F-9728-2014; Rudolf, Ivo/G-1112-2014; Hubalek,
   Zdenek/G-1111-2014; Venclikova, Kristyna/F-4017-2016
OI Hubalek, Zdenek/0000-0003-4732-0987; 
FU Operational Programme Education for Competiveness project CEB
   [CZ.1.07/2.3.00/20.0183];  [MUNI/A/1437/2014];  [MUNI/A/1013/2015]
FX We thank the Operational Programme Education for Competiveness project
   CEB (CZ.1.07/2.3.00/20.0183) and projects MUNI/A/1437/2014 and
   MUNI/A/1013/2015.
NR 24
TC 1
Z9 1
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD OCT
PY 2016
VL 115
IS 10
BP 3679
EP 3682
DI 10.1007/s00436-016-5175-2
PG 4
WC Parasitology
SC Parasitology
GA DY5ME
UT WOS:000385143100001
PM 27325400
ER

PT J
AU Eke, PI
   Wei, L
   Borgnakke, WS
   Thornton-Evans, G
   Zhang, XY
   Lu, H
   Mcguire, LC
   Genco, RJ
AF Eke, Paul I.
   Wei, Liang
   Borgnakke, Wenche S.
   Thornton-Evans, Gina
   Zhang, Xingyou
   Lu, Hua
   Mcguire, Lisa C.
   Genco, Robert J.
TI Periodontitis prevalence in adults >= 65 years of age, in the USA
SO PERIODONTOLOGY 2000
LA English
DT Review
ID QUALITY-OF-LIFE; DISEASE SURVEILLANCE PROJECT; EXAMINATION SURVEY
   NHANES; UNITED-STATES; OLDER-ADULTS; TOOTH LOSS; EUROPEAN COUNTRIES;
   HEALTH COMPONENT; CASE DEFINITIONS; NATIONAL-HEALTH
C1 [Eke, Paul I.; Thornton-Evans, Gina; Zhang, Xingyou; Lu, Hua] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA.
   [Wei, Liang] DB Consulting Grp Inc, Atlanta, GA USA.
   [Borgnakke, Wenche S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Mcguire, Lisa C.] Natl Ctr Chron Dis Prevent & Hlth Promot, Healthy Aging Program, Div Populat Hlth, Appl Res & Translat Branch, Atlanta, GA USA.
   [Genco, Robert J.] SUNY Buffalo, Oral Biol & Microbiol, Amherst, NY 14226 USA.
RP Eke, PI (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA.
NR 91
TC 3
Z9 3
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6713
EI 1600-0757
J9 PERIODONTOL 2000
JI Periodontol. 2000
PD OCT
PY 2016
VL 72
IS 1
BP 76
EP 95
DI 10.1111/prd.12145
PG 20
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DY6LO
UT WOS:000385235400006
PM 27501492
ER

PT J
AU Wong, SPY
   Hebert, PL
   Laundry, RJ
   Hammond, KW
   Liu, CF
   Burrows, NR
   O'Hare, AM
AF Wong, Susan P. Y.
   Hebert, Paul L.
   Laundry, Ryan J.
   Hammond, Kenric W.
   Liu, Chuan-Fen
   Burrows, Nilka R.
   O'Hare, Ann M.
TI Decisions about Renal Replacement Therapy in Patients with Advanced
   Kidney Disease in the US Department of Veterans Affairs, 2000-2011
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID UNITED-STATES; MAINTENANCE DIALYSIS; OLDER-ADULTS; END; INITIATION;
   SURVIVAL; FAILURE; COHORT; CARE; PREVALENCE
AB Background and objectives It is not known what proportion of United States patients with advanced CKD go on to receive RRT. In other developed countries, receipt of RRT is highly age dependent and the exception rather than the rule at older ages.
   Design, setting, participants, & measurements We conducted a retrospective study of a national cohort of 28,568 adults who were receiving care within the US Department of Veteran Affairs and had a sustained eGFR, <15 ml/min per 1.73 m(2) between January 1, 2000 to December 31, 2009. We used linked administrative data from the US Renal Data System, US Department of Veteran Affairs, and Medicare to identify cohort members who received RRT during follow-up through October 1, 2011 (n=19,165). For a random 25% sample of the remaining 9403 patients, we performed an in-depth review of their VA-wide electronic medical records to determine the treatment status of their CKD.
   Results Two thirds (67.1%) of cohort members received RRT on the basis of administrative data. On the basis of the results of chart review, we estimate that an additional 7.5% (95% confidence interval, 7.2% to 7.8%) of cohort members had, in fact, received dialysis, that 10.9% (95% confidence interval, 10.6% to 11.3%) were preparing for and/or discussing dialysis but had not started dialysis at most recent follow-up, and that a decision had been made not to pursue dialysis in 14.5% (95% confidence interval, 14.1% to 14.9%). The percentage of cohort members who received or were preparing to receive RRT ranged from 96.2% (95% confidence interval, 94.4% to 97.4%) for those <45 years old to 53.3% (95% confidence interval, 50.7% to 55.9%) for those aged >= 85 years old. Results were similar after stratification by tertile of Gagne comorbidity score.
   Conclusions In this large United States cohort of patients with advanced CKD, the majority received or were preparing to receive RRT. This was true even among the oldest patients with the highest burden of comorbidity.
C1 [Wong, Susan P. Y.; O'Hare, Ann M.] Univ Washington, Dept Med, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA.
   [Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Hammond, Kenric W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Hammond, Kenric W.] Univ Washington, Dept Biomed Informat & Biomed Educ, Seattle, WA 98195 USA.
   [Hebert, Paul L.; Laundry, Ryan J.; Liu, Chuan-Fen; O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.
   [Burrows, Nilka R.] Ctr Dis Control & Prevent, Chron Kidney Dis Initiat, Div Diabet Translat, Atlanta, GA USA.
RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA.
EM spywong@uw.edu
FU Veterans Affairs (VA) Health Services Research and Development grants
   [IIR 09-094, IIR 12-126]; VA Puget Sound [IAA 15FED1505101-0001];
   Centers for Disease Control and Prevention [IAA 15FED1505101-0001];
   Clinical Scientist in Nephrology Fellowship from American Kidney Fund;
   VA Health Services Research and Development Service; National Institutes
   of Health; Centers for Disease Control and Prevention
FX This work was supported by Veterans Affairs (VA) Health Services
   Research and Development grants IIR 09-094 (principal investigator
   P.L.H.) and IIR 12-126 (principal investigator A.M.O.) and Interagency
   Agreement between the VA Puget Sound and the Centers for Disease Control
   and Prevention IAA 15FED1505101-0001 (principal investigator A.M.O.).
   S.P.Y.W. is supported by the Clinical Scientist in Nephrology Fellowship
   from the American Kidney Fund. C.-F.L. receives research funding from
   the VA Health Services Research and Development Service. A.M.O. receives
   research funding from the National Institutes of Health, the Centers for
   Disease Control and Prevention, and the VA Health Services Research and
   Development Service. A.M.O. also receives an honorarium from the
   American Society of Nephrology and royalties from UpToDate.
NR 28
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD OCT
PY 2016
VL 11
IS 10
BP 1825
EP 1833
DI 10.2215/CJN.03760416
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA DY1BS
UT WOS:000384830500016
ER

PT J
AU Marum, E
   Conkling, M
   Kanyanda, J
   Gandi, SB
   Byaruhanga, R
   Alwano, MG
AF Marum, Elizabeth
   Conkling, Martha
   Kanyanda, Jabez
   Gandi, Sheila Birungi
   Byaruhanga, Raymond
   Alwano, Mary Grace
TI HIV Testing Services in Africa: Are They Sustainable?
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE HIV tests; HIV testing services; Sustainability; Integration; Africa
ID MOTHER-TO-CHILD; SUB-SAHARAN AFRICA; DEVELOPING-COUNTRIES;
   RANDOMIZED-TRIAL; HEALTH SYSTEMS; TRANSMISSION; PREVENTION; PROGRAMS;
   UGANDA
AB HIV testing services (HTS) are an essential component of a national response to the HIV epidemic, and in lower and middle income countries, at least 150 million persons are tested annually. HIV testing is necessary to identify persons in need of antiretroviral treatment, which has been documented to be highly effective not only for treatment but also for prevention of HIV transmission to both adults and children. An assessment of the recent literature on sustainability of health and HIV services suggests that organizational performance, flexibility, and integration with other health interventions contribute to sustainability of HIV services and programs. This article describes the experiences of two HIV testing service providers in Uganda and Zambia as well as the track record of services to prevent mother-to-child HIV transmission to illustrate the factors of performance, flexibility, adaptability, and integration which are key to the sustainability of HIV testing services.
C1 [Marum, Elizabeth] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Conkling, Martha] US Ctr Dis Control & Prevent, Lusaka, Zambia.
   [Kanyanda, Jabez] Dev Aid People People, Lusaka, Zambia.
   [Gandi, Sheila Birungi] AIDS Informat Ctr, Kampala, Uganda.
   [Byaruhanga, Raymond] Management Sci Hlth, Kampala, Uganda.
   [Alwano, Mary Grace] US Ctr Dis Control & Prevent, CTS Global, Gaborone, Botswana.
RP Marum, E (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM emarum@cdc.gov
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers
   for Disease Control and Prevention (CDC); US Agency for International
   Development
FX The authors acknowledge the assistance of Rosina Makhubela, Mwansa
   Katunga, and Elise Soerensen of the Development Aid from People to
   People, Zambia; Henry Leku Lulu and Moses Sembatya of the AIDS
   Information Centre, Uganda; and Stephanie Behel of CDC Atlanta. This
   report and the projects described have been supported by the President's
   Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease
   Control and Prevention (CDC) and by the US Agency for International
   Development.
NR 40
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548-3568
EI 1548-3576
J9 CURR HIV-AIDS REP
JI Curr. Hiv/Aids Rep.
PD OCT
PY 2016
VL 13
IS 5
BP 263
EP 268
DI 10.1007/s11904-016-0328-6
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA DX7CO
UT WOS:000384544000004
PM 27510909
ER

PT J
AU Cope, JR
   Ali, IK
AF Cope, Jennifer R.
   Ali, Ibne K.
TI Primary Amebic Meningoencephalitis: What Have We Learned in the Last 5
   Years?
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Review
DE Naegleria fowleri; Primary amebic meningoencephalitis
ID FREE-LIVING AMEBAS; NAEGLERIA-FOWLERI; DRINKING-WATER; PATHOGENIC
   NAEGLERIA; ENVIRONMENTAL WATER; NESTED PCR; TAP WATER; IDENTIFICATION;
   RESERVOIRS; EXPOSURE
AB Primary amebic meningoencephalitis (PAM) is a devastating infection of the brain caused by the thermophilic free-living ameba, Naegleria fowleri. Infection can occur when water containing the ameba enters the body through the nose, usually during recreational water activities such as swimming or diving. Historically, in the USA, cases were mostly reported from the warmer southern-tier states. In the last 5 years, several notable changes have been documented in PAM epidemiology including a northward expansion of infections and new types of water exposures. The recent reports of two PAM survivors provide hope for improved outcomes with early diagnosis and aggressive treatment. Advanced molecular laboratory tools such as genome sequencing might provide more insight into the pathogenicity of N. fowleri. Clinicians treating patients with meningitis and warm freshwater exposure are encouraged to consider PAM in their differential diagnoses.
C1 [Cope, Jennifer R.; Ali, Ibne K.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
RP Cope, JR (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM jcope@cdc.gov; iali@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 38
TC 0
Z9 0
U1 9
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD OCT
PY 2016
VL 18
IS 10
AR 31
DI 10.1007/s11908-016-0539-4
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA DX9LX
UT WOS:000384718000001
PM 27614893
ER

PT J
AU Heiman, KE
   Garalde, VB
   Gronostaj, M
   Jackson, KA
   Beam, S
   Joseph, L
   Saupe, A
   Ricotta, E
   Waechter, H
   Wellman, A
   Adams-Cameron, M
   Ray, G
   Fields, A
   Chen, Y
   Datta, A
   Burall, L
   Sabol, A
   Kucerova, Z
   Trees, E
   Metz, M
   Leblanc, P
   Lance, S
   Griffin, PM
   Tauxe, RV
   Silk, BJ
AF Heiman, K. E.
   Garalde, V. B.
   Gronostaj, M.
   Jackson, K. A.
   Beam, S.
   Joseph, L.
   Saupe, A.
   Ricotta, E.
   Waechter, H.
   Wellman, A.
   Adams-Cameron, M.
   Ray, G.
   Fields, A.
   Chen, Y.
   Datta, A.
   Burall, L.
   Sabol, A.
   Kucerova, Z.
   Trees, E.
   Metz, M.
   Leblanc, P.
   Lance, S.
   Griffin, P. M.
   Tauxe, R. V.
   Silk, B. J.
TI Multistate outbreak of listeriosis caused by imported cheese and
   evidence of cross-contamination of other cheeses, USA, 2012
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Cheese; contamination; Listeria; outbreak
ID MEXICAN-STYLE CHEESE; UNITED-STATES; MONOCYTOGENES INFECTION;
   PASTEURIZED MILK; CONSUMPTION; GERMANY; GROWTH; RISK; MEAT
AB Listeria monocytogenes is a foodborne pathogen that can cause bacteraemia, meningitis, and complications during pregnancy. In July 2012, molecular subtyping identified indistinguishable L. monocytogenes isolates from six patients and two samples of different cut and repackaged cheeses. A multistate outbreak investigation was initiated. Initial analyses identified an association between eating soft cheese and outbreak-related illness (odds ratio 173, 95% confidence interval 20-8257) but no common brand. Cheese inventory data from locations where patients bought cheese and an additional location where repackaged cheese yielded the outbreak strain were compared to identify cheeses for microbiological sampling. Intact packages of imported ricotta salata yielded the outbreak strain. Fourteen jurisdictions reported 22 cases from March-October 2012, including four deaths and a fetal loss. Six patients ultimately reported eating ricotta salata; another reported eating cheese likely cut with equipment also used for contaminated ricotta salata, and nine more reported eating other cheeses that might also have been cross-contaminated. An FDA import alert and US and international recalls followed. Epidemiology-directed microbiological testing of suspect cheeses helped identify the outbreak source. Cross-contamination of cheese highlights the importance of using validated disinfectant protocols and routine cleaning and sanitizing after cutting each block or wheel.
C1 [Heiman, K. E.; Jackson, K. A.; Joseph, L.; Sabol, A.; Kucerova, Z.; Trees, E.; Griffin, P. M.; Tauxe, R. V.; Silk, B. J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
   [Garalde, V. B.; Fields, A.; Chen, Y.; Datta, A.; Burall, L.; Metz, M.; Leblanc, P.; Lance, S.] US FDA, Silver Spring, MD USA.
   [Gronostaj, M.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA.
   [Beam, S.] Calif Dept Food & Agr, Sacramento, CA 95814 USA.
   [Saupe, A.] Minnesota Dept Hlth, St Paul, MN USA.
   [Ricotta, E.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
   [Waechter, H.] New York City Dept Hlth & Hyg, New York, NY USA.
   [Wellman, A.] Virginia Dept Hlth, Richmond, VA USA.
   [Adams-Cameron, M.] New Mexico Dept Hlth, Santa Fe, NM USA.
   [Ray, G.] Dist Columbia Dept Hlth, Washington, DC USA.
RP Heiman, KE (reprint author), 1600 Clifton Rd NE MS A-38, Atlanta, GA 30329 USA.
EM uwj0@cdc.gov
NR 35
TC 3
Z9 3
U1 17
U2 17
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 2016
VL 144
IS 13
BP 2698
EP 2708
DI 10.1017/S095026881500117X
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DX5RG
UT WOS:000384438800002
PM 26122394
ER

PT J
AU Buss, BF
   Joshi, MV
   Dement, JL
   Cantu, V
   Safranek, TJ
AF Buss, B. F.
   Joshi, M. V.
   Dement, J. L.
   Cantu, V.
   Safranek, T. J.
TI Multistate product traceforward investigation to link imported romaine
   lettuce to a US cyclosporiasis outbreak - Nebraska, Texas, and Florida,
   June-August 2013
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Cyclospora; epidemiology; foodborne infections; outbreaks; parasites
ID CAYETANENSIS
AB During June-August 2013, 25 US states reported 631 cyclosporiasis cases including Nebraska and Iowa where a regional investigation implicated common-source imported salad mix served in two chain restaurants. At least two common-origin growing fields were likely sources of contaminated romaine lettuce. Using producer- and distributor-provided data, we conducted a grower-specific traceforward investigation to reveal exposures of ill US residents elsewhere who reported symptom onset during 11 June-1 July 2013, the time period established in the Nebraska and Iowa investigation. Romaine lettuce shipped on 2-6 June from one of these Mexico-origin growing fields likely caused cyclosporiasis in 78 persons reporting illness onsets from 11 June to 1 July in Nebraska, Texas, and Florida. Nationwide, 97% (314/324) of persons confirmed with cyclosporiasis with symptom onset from 11 June to 1 July 2013 resided in 11 central and eastern US states receiving approximately two-thirds of romaine lettuce from this field. This grower's production practices should be investigated to determine potential sources of contamination and to develop recommendations to prevent future illnesses.
C1 [Buss, B. F.; Joshi, M. V.; Safranek, T. J.] Nebraska Dept Hlth & Human Serv, Div Publ Hlth, Lincoln, NE USA.
   [Buss, B. F.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA.
   [Joshi, M. V.] Univ Nebraska Lincoln, Lincoln, NE USA.
   [Dement, J. L.] Florida Dept Hlth, Tallahassee, FL USA.
   [Cantu, V.] Texas Dept State Hlth Serv, Austin, TX USA.
RP Buss, BF (reprint author), Nebraska Dept Hlth & Human Serv, 301 Centennial Mall South,POB 95026, Lincoln, NE 68509 USA.
EM bryan.buss@nebraska.gov
NR 8
TC 2
Z9 2
U1 3
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 2016
VL 144
IS 13
BP 2709
EP 2718
DI 10.1017/S0950268815002320
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DX5RG
UT WOS:000384438800003
PM 26489400
ER

PT J
AU Adam, EA
   Yoder, JS
   Gould, LH
   Hlavsa, MC
   Gargano, JW
AF Adam, E. A.
   Yoder, J. S.
   Gould, L. H.
   Hlavsa, M. C.
   Gargano, J. W.
TI Giardiasis outbreaks in the United States, 1971-2011
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Community outbreaks; foodborne infections; Giardia lamblia; waterborne
   infections; zoonoses
ID DAY-CARE-CENTERS; DISEASE OUTBREAKS; DRINKING-WATER; BATHER DENSITY;
   FRESH PRODUCE; SURVEILLANCE; TRANSMISSION; CRYPTOSPORIDIUM; PATHOGENS;
   LAMBLIA
AB Giardia intestinalis is the leading parasitic aetiology of human enteric infections in the United States, with an estimated 1.2 million cases occurring annually. To better understand transmission, we analysed data on all giardiasis outbreaks reported to the Centers for Disease Control and Prevention for 1971-2011. The 242 outbreaks, affecting similar to 41 000 persons, resulted from waterborne (74.8%), foodborne (15.7%), person-to-person (2.5%), and animal contact (1.2%) transmission. Most (74.6%) waterborne outbreaks were associated with drinking water, followed by recreational water (18.2%). Problems with water treatment, untreated groundwater, and distribution systems were identified most often during drinking water-associated outbreak investigations; problems with water treatment declined after the 1980s. Most recreational water-associated outbreaks were linked to treated swimming venues, with pools and wading pools implicated most often. Produce was implicated most often in foodborne outbreaks. Additionally, foods were most commonly prepared in a restaurant and contaminated by a food handler. Lessons learned from examining patterns in outbreaks over time can help prevent future disease. Groundwater and distribution system vulnerabilities, inadequate pool disinfection, fruit and vegetable contamination, and poor food handler hygiene are promising targets for giardiasis prevention measures.
C1 [Adam, E. A.; Yoder, J. S.; Gould, L. H.; Hlavsa, M. C.; Gargano, J. W.] Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Adam, E. A.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
RP Adam, EA (reprint author), 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30029 USA.
EM wsi7@cdc.gov
FU Centers for Disease Control and Prevention
FX The authors gratefully acknowledge the work of local, state, and
   territorial health departments in investigating and reporting outbreaks
   and thank Virginia Roberts for assistance with extracting and
   interpreting outbreak data, and Sarah Collier for assistance with
   analyses. This research was supported in part by an appointment to the
   Research Participation Program at the Centers for Disease Control and
   Prevention administered by the Oak Ridge Institute for Science and
   Education through and interagency agreement between the U.S. Department
   of Energy and CDC.
NR 47
TC 0
Z9 0
U1 23
U2 23
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 2016
VL 144
IS 13
BP 2790
EP 2801
DI 10.1017/S0950268815003040
PG 12
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DX5RG
UT WOS:000384438800012
PM 26750152
ER

PT J
AU Lu, Y
   Baggett, HC
   Rhodes, J
   Thamthitiwat, S
   Joseph, L
   Gregory, CJ
AF Lu, Y.
   Baggett, H. C.
   Rhodes, J.
   Thamthitiwat, S.
   Joseph, L.
   Gregory, C. J.
TI Bayesian latent class estimation of the incidence of chest
   radiograph-confirmed pneumonia in rural Thailand
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Bayesian latent class; incidence; radiographically confirmed pneumonia;
   radiologist
ID DIAGNOSING PNEUMONIA; CHILDREN; ACCURACY; ADULTS; TESTS; BIAS
AB Pneumonia is a leading cause of mortality and morbidity worldwide with radiographically confirmed pneumonia a key disease burden indicator. This is usually determined by a radiology panel which is assumed to be the best available standard; however, this assumption may introduce bias into pneumonia incidence estimates. To improve estimates of radiographic pneumonia incidence, we applied Bayesian latent class modelling (BLCM) to a large database of hospitalized patients with acute lower respiratory tract illness in Sa Kaeo and Nakhon Phanom provinces, Thailand from 2005 to 2010 with chest radiographs read by both a radiology panel and a clinician. We compared these estimates to those from conventional analysis. For children aged <5 years, estimated radiographically confirmed pneumonia incidence by BLCM was 2394/100 000 person-years (95% credible interval 2185-2574) vs. 1736/100 000 person-years (95% confidence interval 1706-1766) from conventional analysis. For persons aged >= 5 years, estimated radiographically confirmed pneumonia incidence was similar between BLCM and conventional analysis (235 vs. 215/100 000 person-years). BLCM suggests the incidence of radiographically confirmed pneumonia in young children is substantially larger than estimated from the conventional approach using radiology panels as the reference standard.
C1 [Lu, Y.; Baggett, H. C.; Rhodes, J.; Thamthitiwat, S.; Gregory, C. J.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Global Dis Detect Ctr, Int Emerging Infect Program, Nonthaburi, Thailand.
   [Baggett, H. C.; Gregory, C. J.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA.
   [Joseph, L.] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada.
RP Lu, Y (reprint author), Minist Publ Hlth, Dept Dis Control, 3rd Floor,Bldg 7,Tivanon Rd, Nonthaburi 11000, Thailand.
EM vpz9@cdc.gov
NR 18
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 2016
VL 144
IS 13
BP 2858
EP 2865
DI 10.1017/S0950268816000455
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DX5RG
UT WOS:000384438800019
PM 26932149
ER

PT J
AU Grosse, SD
   Khoury, MJ
AF Grosse, Scott D.
   Khoury, Muin J.
TI Epidemiology matters: peering inside the "black box" in economic
   evaluations of genetic testing
SO GENETICS IN MEDICINE
LA English
DT Editorial Material
ID NEWLY-DIAGNOSED PATIENTS; LYNCH SYNDROME; COLORECTAL-CANCER;
   COST-EFFECTIVENESS; STRATEGIES
C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA.
   [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA.
EM sgrosse@cdc.gov
NR 14
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD OCT
PY 2016
VL 18
IS 10
BP 963
EP 965
DI 10.1038/gim.2016.121
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA DX8CN
UT WOS:000384615800010
PM 27608172
ER

PT J
AU Lynch, JA
   Berse, B
   Petkov, V
   Filipski, K
   Zhou, YJ
   Khoury, MJ
   Hassett, M
   Freedman, AN
AF Lynch, Julie A.
   Berse, Brygida
   Petkov, Valentina
   Filipski, Kelly
   Zhou, Yingjun
   Khoury, Muin J.
   Hassett, Michael
   Freedman, Andrew N.
TI Implementation of the 21-gene recurrence score test in the United States
   in 2011
SO GENETICS IN MEDICINE
LA English
DT Article
DE breast cancer; cancer genomics; dissemination; equity; implementation
ID NEGATIVE BREAST-CANCER; GENE-EXPRESSION; ASSAY; POPULATION; ESTROGEN;
   SUBTYPES; RISK; CHEMOTHERAPY; PATTERNS; WOMEN
AB Purpose: We examined hospital use of the 21-gene breast cancer test in the United States. We report state-level differences in utilization and propose a model for predicting implementation of -guideline-recommended genomic testing.
   Methods: Genomic Health provided test orders for calendar year 2011. We summarized utilization at the hospital and state levels. Using logistic regression, we analyzed the association between the likelihood to order the test and the hospital's institutional and regional characteristics.
   Results: In 2011, 45% of 4,712 acute-care hospitals ordered the test, which suggests that 25% of newly diagnosed invasive female breast cancer cases were tested. Significant predictors of testing included participation in National Cancer Institute (NCI) clinical research cooperative groups (odds ratio (OR) 3.73; 95% confidence interval, 2.96-4.70), advanced imaging (OR, 2.19; CI, 1.78-2.68), high-complexity laboratory (OR, 2.15; CI, 1.24-3.70), affiliation with a medical school (OR, 1.57; CI, 1.31-1.88), and reconstructive surgery (OR, 1.23; CI, 1.01-1.50). Significant regional predictors included metropolitan county (OR, 3.77; CI, 2.83-5.03), above-mean income (OR, 1.37; CI, 1.11-1.69), and education (OR, 1.26; CI, 1.03-1.54). Negative predictors included designation as a critical-access hospital (OR, 0.10; CI, 0.07-0.14) and distance from an NCI cancer center (OR, 0.998; CI, 0.997-0.999), with a 15% decrease in likelihood for every 100 miles.
   Conclusion: Despite considerable market penetration of the test, there are significant regional and site-of-care differences in implementation, particularly in rural states.
C1 [Lynch, Julie A.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA.
   [Lynch, Julie A.; Berse, Brygida] RTI Int, Durham, NC 27709 USA.
   [Berse, Brygida] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Berse, Brygida] Vet Hlth Adm, Bedford, MA USA.
   [Petkov, Valentina; Filipski, Kelly; Zhou, Yingjun; Freedman, Andrew N.] NCI, NIH, Bethesda, MD 20892 USA.
   [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
   [Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, NIH, Bethesda, MD 20892 USA.
   [Hassett, Michael] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Hassett, Michael] Harvard Med Sch, Boston, MA USA.
RP Lynch, JA (reprint author), VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA.; Lynch, JA (reprint author), RTI Int, Durham, NC 27709 USA.
EM Julie.Lynch@va.gov
OI Lynch, Julie/0000-0003-0108-2127
FU National Cancer Institute
FX This research was conducted while J.A.L. was a postdoctoral fellow
   within the Center for Healthcare Organization and Implementation
   Research (CHOIR), a Veterans Administration Health Services Research &
   Development Center of Excellence. She and B.B. are funded by the
   National Cancer Institute through an Interagency Agreement. Preliminary
   results were previously presented as a poster at the 49th American
   Society of Clinical Oncology Annual Meeting, 31 May 20.
NR 34
TC 2
Z9 2
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD OCT
PY 2016
VL 18
IS 10
BP 982
EP 990
DI 10.1038/gim.2015.218
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA DX8CN
UT WOS:000384615800013
PM 26890451
ER

PT J
AU Smith-Darden, JP
   Reidy, DE
   Kernsmith, PD
AF Smith-Darden, Joanne P.
   Reidy, Dennis E.
   Kernsmith, Poco D.
TI Adolescent stalking and risk of violence
SO JOURNAL OF ADOLESCENCE
LA English
DT Article
DE Stalking; Youth stalking; Juvenile stalking; Violence; Dating violence;
   Peer violence
ID PSYCHOPATHY; JUVENILES; BEHAVIOR; PROFILE
AB Stalking perpetration and the associated risk for violence among adolescents has generally been neglected. In the present study, 1236 youth completed surveys assessing empirically established stalking indicators, threats and aggression toward stalking victims, dating violence, and violent delinquency. Latent Profile Analysis identified 3 latent classes of boys: non-perpetrators (NP), hyper-intimate pursuit (HIP), and comprehensive stalking perpetrators (CSP) and, and 2 classes for girls: NP and HIP. Boys in the CSP class were the most violent youth on nearly all indices with boys in the HIP class demonstrating an intermediate level of violence compared to NP boys. Girls in the HIP class were more violent than NP girls on all indices. These findings suggest stalking in adolescence merits attention by violence prevention experts. In particular, juvenile stalking may signify youth at risk for multiple forms of violence perpetrated against multiple types of victims, not just the object of their infatuation. (C) 2016 The Foundation for Professionals in Services for Adolescents. Published by Elsevier Ltd. All rights reserved.
C1 [Smith-Darden, Joanne P.; Kernsmith, Poco D.] Wayne State Univ, Sch Social Work, Detroit, MI 48202 USA.
   [Reidy, Dennis E.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA.
RP Smith-Darden, JP (reprint author), Wayne State Univ, Sch Social Work, Detroit, MI 48202 USA.
EM jo.smith-darden@wayne.edu
FU Centers for Disease Control and Prevention [1U01CE002115-01]
FX This work was funded by the Centers for Disease Control and Prevention,
   Cooperative Agreement #1U01CE002115-01.
NR 41
TC 0
Z9 0
U1 6
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0140-1971
EI 1095-9254
J9 J ADOLESCENCE
JI J. Adolesc.
PD OCT
PY 2016
VL 52
BP 191
EP 200
DI 10.1016/j.adolescence.2016.08.005
PG 10
WC Psychology, Developmental
SC Psychology
GA DY0IO
UT WOS:000384780700021
PM 27641644
ER

PT J
AU Teshale, EH
   Xing, J
   Moorman, A
   Holmberg, SD
   Spradling, PR
   Gordon, SC
   Rupp, LB
   Lu, M
   Boscarino, JA
   Trinacity, CM
   Schmidt, MA
   Xu, F
AF Teshale, E. H.
   Xing, J.
   Moorman, A.
   Holmberg, S. D.
   Spradling, P. R.
   Gordon, S. C.
   Rupp, L. B.
   Lu, M.
   Boscarino, J. A.
   Trinacity, C. M.
   Schmidt, M. A.
   Xu, F.
CA CHeCS Investigators
TI Higher all-cause hospitalization among patients with chronic hepatitis
   C: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2013
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE all-cause hospitalization; chronic HCV infection; health burden;
   hepatitis C; hospitalization rate; liver-related hospitalization
ID ADVANCED LIVER-DISEASE; UNITED-STATES; VIRAL-HEPATITIS; VIRUS-INFECTION;
   RESOURCE UTILIZATION; ECONOMIC BURDEN; MORTALITY; CARE; COSTS; INCREASE
AB In the United States, hospitalization among patients with chronic hepatitis C virus (HCV) infection is high. The healthcare burden associated with hospitalization is not clearly known. We analysed data from the Chronic Hepatitis Cohort Study, an observational cohort of patients receiving care at four integrated healthcare systems, collected from 2006 to 2013 to determine all-cause hospitalization rates of patients with chronic HCV infection and the other health system patients. To compare the hospitalization rates, we selected two health system patients for each chronic HCV patient using their propensity score (PS). Propensity score matching was conducted by site, gender, race, age and household income to minimize differences attributable to these characteristics. We also compared primary reason for hospitalization between chronic HCV patients and the other health system patients. Overall, 10 131 patients with chronic HCV infection and 20 262 health system patients were selected from the 1 867 802 health system patients and were matched by PS. All-cause hospitalization rates were 27.4 (27.0-27.8) and 7.4 (7.2-7.5) per 100 persons-year (PY) for chronic HCV patients and for the other health system patients, respectively. Compared to health system patients, hospitalization rates were significantly higher by site, gender, age group, race and household income among chronic HCV patients (P < 0.001). Compared to health system patients, chronic HCV patients were more likely to be hospitalized from liver-related conditions (RR = 24.8, P < 0.001). Hence, patients with chronic HCV infection had approximately 3.7-fold higher all-cause hospitalization rate than other health system patients. These findings highlight the incremental costs and healthcare burden of patients with chronic HCV infection associated with hospitalization.
C1 [Teshale, E. H.; Xing, J.; Moorman, A.; Holmberg, S. D.; Spradling, P. R.; Xu, F.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA.
   [Gordon, S. C.; Rupp, L. B.; Lu, M.] Henry Ford Hosp, Detroit, MI 48202 USA.
   [Boscarino, J. A.] Geisinger Hlth Syst, Danville, PA USA.
   [Trinacity, C. M.] Kaiser Permanente Hawaii, Honolulu, HI USA.
   [Schmidt, M. A.] Kaiser Permanente Northwest, Portland, OR USA.
RP Teshale, EH (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Mailstop G-37,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM eht4@cdc.gov
FU CDC Foundation; AbbVie; Gilead Sciences; Janssen Pharmaceuticals, Inc.;
   Genentech, A Member of the Roche Group; Vertex Pharmaceuticals;
   Bristol-Myers Squibb
FX CHeCS was funded by the CDC Foundation, which currently receives grants
   from AbbVie, Gilead Sciences, and Janssen Pharmaceuticals, Inc. Past
   funders include Genentech, A Member of the Roche Group and Vertex
   Pharmaceuticals. Past partial funders include Bristol-Myers Squibb.
   Granting corporations do not have access to CHeCS data and do not
   contribute to data analysis or writing of manuscripts.
NR 26
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD OCT
PY 2016
VL 23
IS 10
BP 748
EP 754
DI 10.1111/jvh.12548
PG 7
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA DX8GF
UT WOS:000384625400001
PM 27186944
ER

PT J
AU Patrusheva, I
   Perelygina, L
   Torshin, I
   LeCher, J
   Hilliard, J
AF Patrusheva, Irina
   Perelygina, Ludmila
   Torshin, Ivan
   LeCher, Julia
   Hilliard, Julia
TI B Virus (Macacine Herpesvirus 1) Divergence: Variations in Glycoprotein
   D from Clinical and Laboratory Isolates Diversify Virus Entry Strategies
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HERPES-SIMPLEX-VIRUS; FACTOR RECEPTOR SUPERFAMILY; CELL-CELL FUSION;
   POLIOVIRUS RECEPTOR; ADHESION MOLECULE; DENDRITIC CELLS; NECTIN-2 CD112;
   INFECTED-CELLS; PVR CD155; LINKED OLIGOSACCHARIDES
AB B virus (Macacine herpesvirus 1) can cause deadly zoonotic disease in humans. Molecular mechanisms of B virus cell entry are poorly understood for both macaques and humans. Here we investigated the abilities of clinical B virus isolates to use entry receptors of herpes simplex viruses (HSV). We showed that resistant B78H1 cells became susceptible to B virus clinical strains upon expression of either human nectin-2 or nectin-1. Antibody against glycoprotein D (gD) protected these nectin-bearing cells from B virus infection, and a gD-negative recombinant B virus failed to enter these cells, indicating that the nectin-mediated B virus entry depends on gD. We observed that the infectivity of B virus isolates with a single amino acid substitution (D122N) in the IgV-core of the gD ectodomain was impaired on nectin-1-bearing cells. Computational homology-based modeling of the B virus gD-nectin-1 complex revealed conformational differences between the structures of the gD-122N and gD-122D variants that affected the gD-nectin-1 protein-protein interface and binding affinity. Unlike HSV, B virus clinical strains were unable to use herpesvirus entry mediator (HVEM) as a receptor, regardless of conservation of the gD amino acid residues essential for HSV-1 entry via HVEM. Based on the model of the B virus gD-HVEM interface, we predict that residues R7, R11, and G15 are largely responsible for the inability of B virus to utilize HVEM for entry. The ability of B virus to enter cells of a human host by using a combination of receptors distinct from those for HSV-1 or HSV-2 suggests a possible mechanism of enhanced neuropathogenicity associated with zoonotic infections.
   IMPORTANCE
   B virus causes brainstem destruction in infected humans in the absence of timely diagnosis and intervention. Nectins are cell adhesion molecules that are widely expressed in human tissues, including neurons and neuronal synapses. Here we report that human nectin-2 is a target receptor for B virus entry, in addition to the reported receptor human nectin-1. Similar to a B virus lab strain, B virus clinical strains can effectively use both nectin-1 and nectin-2 as cellular receptors for entry into human cells, but unlike HSV-1 and HSV-2, none of the clinical strains uses an HVEM-mediated entry pathway. Ultimately, these differences between B virus and HSV-1 and -2 may provide insight into the neuropathogenicity of B virus during zoonotic infections.
C1 [Patrusheva, Irina; Perelygina, Ludmila; Torshin, Ivan; LeCher, Julia; Hilliard, Julia] Georgia State Univ, Dept Biol, Viral Immunol Ctr, Atlanta, GA 30302 USA.
   [Torshin, Ivan] Moscow MV Lomonosov State Univ, Dept Comp Sci, Moscow, Russia.
   [Perelygina, Ludmila] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Hilliard, J (reprint author), Georgia State Univ, Dept Biol, Viral Immunol Ctr, Atlanta, GA 30302 USA.
EM jhilliard@gsu.edu
FU HHS \ National Institutes of Health (NIH) [R01 RR03163, P40 RR05162]
FX This work, including the efforts of Julia Hilliard, was funded by HHS
   vertical bar National Institutes of Health (NIH) (R01 RR03163 and P40
   RR05162).
NR 100
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD OCT
PY 2016
VL 90
IS 20
BP 9420
EP 9432
DI 10.1128/JVI.00799-16
PG 13
WC Virology
SC Virology
GA DX7NO
UT WOS:000384574900033
PM 27512063
ER

PT J
AU Sharma, AJ
   Vesco, KK
   Bulkley, J
   Callaghan, WM
   Bruce, FC
   Staab, J
   Hornbrook, MC
   Berg, CJ
AF Sharma, Andrea J.
   Vesco, Kimberly K.
   Bulkley, Joanna
   Callaghan, William M.
   Bruce, F. Carol
   Staab, Jenny
   Hornbrook, Mark C.
   Berg, Cynthia J.
TI Rate of Second and Third Trimester Weight Gain and Preterm Delivery
   Among Underweight and Normal Weight Women
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Pregnancy; Gestational weight gain; Weight gain measures; Preterm
   delivery
ID BODY-MASS INDEX; BIRTH; RISK; PREGNANCY; INCREASES; SUBTYPES
AB Objectives Low gestational weight gain (GWG) in the second and third trimesters has been associated with increased risk of preterm delivery (PTD) among women with a body mass index (BMI) < 25 mg/m(2). However, few studies have examined whether this association differs by the assumptions made for first trimester gain or by the reason for PTD. Methods We examined singleton pregnancies during 2000-2008 among women with a BMI < 25 kg/m(2) who delivered a live-birth aeyen28 weeks gestation (n = 12,526). Women received care within one integrated health care delivery system and began prenatal care aecurrency sign13 weeks. Using antenatal weights measured during clinic visits, we interpolated GWG at 13 weeks gestation then estimated rate of GWG (GWG(rate)) during the second and third trimesters of pregnancy. We also estimated GWG(rate) using the common assumption of a 2-kg gain for all women by 13 weeks. We examined the covariate-adjusted association between quartiles of GWG(rate) and PTD (28-36 weeks gestation) using logistic regression. We also examined associations by reason for PTD [premature rupture of membranes (PROM), spontaneous labor, or medically indicated]. Results Mean GWG(rate) did not differ among term and preterm pregnancies regardless of interpolated or assumed GWG at 13 weeks. However, only with GWG(rate) estimated from interpolated GWG at 13 weeks, we observed a U-shaped relationship where odds of PTD increased with GWG(rate) in the lowest (OR 1.36, 95 % CI 1.10, 1.69) or highest quartile (OR 1.49, 95 % CI 1.20, 1.85) compared to GWG(rate) within the second quartile. Further stratifying by reason, GWG(rate) in the lowest quartile was positively associated with spontaneous PTD while GWG(rate) in the highest quartile was positively associated with PROM and medically indicated PTD. Conclusions Accurate estimates of first trimester GWG are needed. Common assumptions applied to all pregnancies may obscure the association between GWG(rate) and PTD. Further research is needed to fully understand whether these associations are causal or related to common antecedents.
C1 [Sharma, Andrea J.; Callaghan, William M.; Bruce, F. Carol; Berg, Cynthia J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA.
   [Vesco, Kimberly K.; Bulkley, Joanna; Staab, Jenny; Hornbrook, Mark C.] Kaiser Permanente Northwest, Ctr Hlth Res, Northwest Hawaii Southeast, Portland, OR USA.
   [Sharma, Andrea J.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA 30341 USA.
RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA.; Sharma, AJ (reprint author), US Publ Hlth Serv Commissioned Corps, Atlanta, GA 30341 USA.
EM AJSharma@cdc.gov
OI Sharma, Andrea/0000-0003-0385-0011
FU Centers for Disease Control and Prevention [CDC 200-2001-00074]
FX Funded by the Centers for Disease Control and Prevention (contract CDC
   200-2001-00074, "Extent of Maternal Morbidity in a Managed Care
   Setting"). The findings and conclusions in this report are those of the
   authors and do not necessarily represent the official position of the
   Centers for Disease Control and Prevention.
NR 25
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD OCT
PY 2016
VL 20
IS 10
BP 2030
EP 2036
DI 10.1007/s10995-016-2032-y
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW3ZQ
UT WOS:000383582000005
PM 27329188
ER

PT J
AU Martin, AS
   Monsour, M
   Kawwass, JF
   Boulet, SL
   Kissin, DM
   Jamieson, DJ
AF Martin, Angela S.
   Monsour, Michael
   Kawwass, Jennifer F.
   Boulet, Sheree L.
   Kissin, Dmitry M.
   Jamieson, Denise J.
TI Risk of Preeclampsia in Pregnancies After Assisted Reproductive
   Technology and Ovarian Stimulation
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Aromatase inhibitors; Assisted reproductive technology; In vitro
   fertilization; Ovarian stimulation; Preeclampsia
ID IN-VITRO FERTILIZATION; LATE-ONSET PREECLAMPSIA; SINGLETON PREGNANCIES;
   PERINATAL OUTCOMES
AB Objective To compare the risk of preeclampsia among spontaneously conceived pregnancies to those after hyperestrogenic ovarian stimulation (hyperestrogenic OS) with and without assisted reproductive technology (ART), and stimulation with non-hyperestrogenic aromatase inhibitor stimulation (non-hyperestrogenic OS). Methods Live-born singleton deliveries among women 20-49 years were identified in the 2004-2012 Truven Health MarketScan Commercial Claims and Encounters Databases using ICD-9 and CPT codes. Maternal characteristics were compared using Chi squared and Fisher exact tests. We performed multilevel multivariable logistic regression, controlling for maternal age, parity, comorbid conditions, and region of delivery, and calculated adjusted odds ratios (aOR) and 95 % confidence intervals for mild and severe preeclampsia. Results 1,014,526 spontaneously conceived, 6881 hyperestrogenic OS with ART, 27,516 hyperestrogenic OS without ART, and 2117 non-hyperestrogenic OS pregnancies were identified. The adjusted odds of developing preeclampsia were increased for deliveries after hyperestrogenic OS with ART (mild preeclampsia aOR 1.42, 1.24-1.62; severe preeclampsia aOR 1.83, 1.59-2.11) and without ART (mild preeclampsia aOR 1.32, 1.24-1.42; severe preeclampsia aOR 1.53, 1.41-1.66). Adjusted odds of preeclampsia were similar between spontaneously conceived and non-hyperestrogenic OS pregnancies. Conclusions for Practice Risk of preeclampsia after ART may in part be related to supraphysiologic estrogen associated with hyperestrogenic OS.
C1 [Martin, Angela S.; Kawwass, Jennifer F.; Kissin, Dmitry M.; Jamieson, Denise J.] Emory Univ, Dept Gynecol & Obstet, 69 Jesse Hill Jr Dr,SE,4th Floor,Glenn Bldg, Atlanta, GA 30303 USA.
   [Martin, Angela S.; Monsour, Michael; Kawwass, Jennifer F.; Boulet, Sheree L.; Kissin, Dmitry M.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
RP Martin, AS (reprint author), Emory Univ, Dept Gynecol & Obstet, 69 Jesse Hill Jr Dr,SE,4th Floor,Glenn Bldg, Atlanta, GA 30303 USA.; Martin, AS (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
EM amatlac@emory.edu
NR 24
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD OCT
PY 2016
VL 20
IS 10
BP 2050
EP 2056
DI 10.1007/s10995-016-2067-0
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW3ZQ
UT WOS:000383582000007
PM 27400915
ER

PT J
AU Kandler, JL
   Acevedo, RV
   Dickinson, MK
   Cash, DR
   Shafer, WM
   Cornelissen, CN
AF Kandler, Justin L.
   Acevedo, Rosuany Velez
   Dickinson, Mary Kathryne
   Cash, Devin R.
   Shafer, William M.
   Cornelissen, Cynthia Nau
TI The genes that encode the gonococcal transferrin binding proteins, TbpB
   and TbpA, are differentially regulated by MisR under iron-replete and
   iron-depleted conditions
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID NEISSERIA-GONORRHOEAE; PATHOGENIC NEISSERIA; ESCHERICHIA-COLI;
   UNTREATABLE GONORRHEA; 2-COMPONENT SYSTEM; ANTIBODY-RESPONSES;
   EPITHELIAL-CELLS; MENINGITIDIS; EXPRESSION; INFECTION
AB Neisseria gonorrhoeae produces two transferrin binding proteins, TbpA and TbpB, which together enable efficient iron transport from human transferrin. We demonstrate that expression of the tbp genes is controlled by MisR, a response regulator in the two-component regulatory system that also includes the sensor kinase MisS. The tbp genes were up-regulated in the misR mutant under iron-replete conditions but were conversely down-regulated in the misR mutant under iron-depleted conditions. The misR mutant was capable of transferrin-iron uptake at only 50% of wild-type levels, consistent with decreased tbp expression. We demonstrate that phosphorylated MisR specifically binds to the tbpBA promoter and that MisR interacts with five regions upstream of the tbpB start codon. These analyses confirm that MisR directly regulates tbpBA expression. The MisR binding sites in the gonococcus are only partially conserved in Neisseria meningitidis, which may explain why tbpBA was not MisR-regulated in previous studies using this related pathogen. This is the first report of a trans-acting protein factor other than Fur that can directly contribute to gonococcal tbpBA regulation.
C1 [Kandler, Justin L.; Shafer, William M.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Shafer, William M.] Emory Univ, Sch Med, Emory Antibiot Resistance Ctr, Atlanta, GA USA.
   [Shafer, William M.] Dept Vet Affairs Med Ctr, Labs Microbial Pathogenesis, Decatur, GA USA.
   [Acevedo, Rosuany Velez; Dickinson, Mary Kathryne; Cash, Devin R.; Cornelissen, Cynthia Nau] Virginia Commonwealth Univ Hlth Syst, Dept Microbiol & Immunol, Richmond, VA USA.
   [Kandler, Justin L.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA.
   [Acevedo, Rosuany Velez] South Univ, Glen Allen, VA USA.
   [Dickinson, Mary Kathryne] Div Consolidated Lab Serv, Richmond, VA USA.
RP Cornelissen, CN (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Microbiol & Immunol, Richmond, VA USA.
EM cynthia.cor-nelissen@vcuhealth.org
FU Public Health Service from the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health [R01 AI047141, R01
   AI065555, R01 AI084400, U19 AI31496, U19 AI 113170, R37 AI21150];
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health [F30 AI112199]; VA Merit Award from the Biomedical
   Laboratory Research and Development Service of the Department of
   Veterans Affairs [510 1BX000112-07]; Biomedical Laboratory Research and
   Development Service of the Department of Veterans Affairs
FX Funding for this work was provided to C.N.C. by Public Health Service
   grants R01 AI047141, R01 AI065555, R01 AI084400, and U19 AI31496 from
   the National Institute of Allergy and Infectious Diseases, National
   Institutes of Health. R.V.A. was supported by a diversity supplement to
   R01 AI047141. D.R.C. was supported by fellowship grant F30 AI112199 from
   the National Institute of Allergy and Infectious Diseases, National
   Institutes of Health. Additional support was provided to W.M.S. by
   Public Health Service grants U19 AI 113170, R37 AI21150, and U19 AI31496
   all from the National Institute of Allergy and Infectious Diseases,
   National Institutes of Health and a VA Merit Award (510 1BX000112-07)
   from the Biomedical Laboratory Research and Development Service of the
   Department of Veterans Affairs. W.M.S. was also supported by a Senior
   Research Career Award from the Biomedical Laboratory Research and
   Development Service of the Department of Veterans Affairs. The funders
   had no role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
NR 59
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0950-382X
EI 1365-2958
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD OCT
PY 2016
VL 102
IS 1
BP 137
EP 151
DI 10.1111/mmi.13450
PG 15
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA DY0TA
UT WOS:000384807900010
PM 27353397
ER

PT J
AU Tao, GY
   Patel, CG
AF Tao, Guoyu
   Patel, Chirag G.
TI State Variation in Enrollment Gap, Sexual Activity, and Chlamydia
   Testing Rate Among Young Medicaid Women
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID TRANSMITTED-DISEASES
AB Objectives To assess state variations in eligibility criteria based on enrollment length and sexual activity on chlamydia testing rates among Medicaid female enrollees aged 15 to 25 years and potential impact of the representatives of testing rates.
   Methods We used 2010 Medicaid Analytic eXtract to estimate and compare the overall and state-level prevalence of gaps in coverage of 2 consecutive months, service utilization associated with sexuality, and chlamydia testing rates among Medicaid female enrollees aged 15 to 25 years who had 1 month of the full scope of Medicaid benefits and had 1 health service claim. The chlamydia testing rate was calculated as the proportion of sexually active Medicaid female enrollees who received a chlamydia test in 2010.
   Results Of 5.7 million women aged 15 to 25 years enrolled in Medicaid in 2010, 42.3% had a 2-month gap of enrollment coverage in 2010. The proportion of women who had a 2-month gap varied from 26.1% to 73.2% across states. The proportion of women identified as sexually active was 59.8% among women who had a 2-month gap and 57.1% among women who had no 2-month gap. The chlamydia testing rate was 44.0% among sexually active women with a 2-month gap and 44.2% among sexually active women without a 2-month gap. Eleven states had 10% difference in sexual activity or chlamydia testing rates between women with a 2-month gap and women without a 2-month gap.
   Conclusions States which exclude a substantial proportion of Medicaid enrollees from inclusion in the chlamydia testing denominator may have less representative testing estimates because those excluded tend to be women aged 19 to 25 years.
C1 [Tao, Guoyu; Patel, Chirag G.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E80, Atlanta, GA 30333 USA.
   [Patel, Chirag G.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
RP Tao, GY (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E80, Atlanta, GA 30333 USA.
EM gat3@cdc.gov
NR 7
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD OCT
PY 2016
VL 43
IS 10
BP 595
EP 598
DI 10.1097/OLQ.0000000000000508
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DX7PH
UT WOS:000384580000001
PM 27626186
ER

PT J
AU Liu, G
   Unger, ER
   Hariri, S
   Steinau, M
   Markowitz, LE
AF Liu, Gui
   Unger, Elizabeth R.
   Hariri, Susan
   Steinau, Martin
   Markowitz, Lauri E.
TI Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in
   the Prevaccine Era, United States, 2003-2006
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID GRADE CERVICAL LESIONS; NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH;
   VACCINE; CANCER; PERSISTENCE; ADOLESCENTS; INFECTION; GENOTYPES; FEMALES
AB Before any vaccine introduction, overall DNA prevalence of any 9-valent human papillomavirus (9vHPV) types, HPV 31/33/45/52/58, and HPV 16/18 was 16.0%, 9.5%, and 6.2%, respectively, among female participants in National Health and Nutrition Examination Survey. Non-Hispanic black females were more likely to have infection with HPV 31/33/45/52/58, but not HPV 16/18, compared to non-Hispanic white females.
C1 [Liu, Gui; Unger, Elizabeth R.; Hariri, Susan; Steinau, Martin; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Markowitz, LE (reprint author), 1600 Clifton Rd NE,MS A-34, Atlanta, GA 33303 USA.
EM lem2@cdc.gov
NR 17
TC 0
Z9 0
U1 7
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD OCT
PY 2016
VL 43
IS 10
BP 633
EP 636
DI 10.1097/OLQ.0000000000000492
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DX7PH
UT WOS:000384580000009
PM 27631358
ER

PT J
AU Smith, CR
   Gillespie, GL
   Brown, KC
   Grubb, PL
AF Smith, Carolyn R.
   Gillespie, Gordon L.
   Brown, Kathryn C.
   Grubb, Paula L.
TI Seeing Students Squirm: Student Nurses' Bullying Experiences in Clinical
   Settings
SO WESTERN JOURNAL OF NURSING RESEARCH
LA English
DT Editorial Material
C1 [Smith, Carolyn R.; Gillespie, Gordon L.] Univ Cincinnati, Cincinnati, OH 45221 USA.
   [Brown, Kathryn C.] Christ Hosp Hlth Network, Cincinnati, OH USA.
   [Grubb, Paula L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Smith, CR (reprint author), Univ Cincinnati, Cincinnati, OH 45221 USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0193-9459
EI 1552-8456
J9 WESTERN J NURS RES
JI West. J. Nurs. Res.
PD OCT
PY 2016
VL 38
IS 10
BP 1397
EP 1398
DI 10.1177/0193945916658207
PG 2
WC Nursing
SC Nursing
GA DX5XC
UT WOS:000384455000022
PM 27655096
ER

PT J
AU Carter, MW
   Gavin, L
   Zapata, LB
   Bornstein, M
   Mautone-Smith, N
   Moskosky, SB
AF Carter, Marion W.
   Gavin, Loretta
   Zapata, Lauren B.
   Bornstein, Marta
   Mautone-Smith, Nancy
   Moskosky, Susan B.
TI Four aspects of the scope and quality of family planning services in US
   publicly funded health centers: Results from a survey of health center
   administrators
SO CONTRACEPTION
LA English
DT Article
DE Contraceptive methods; Contraceptive counseling; Youth-friendly
   services; Title X
ID YOUNG-PEOPLE; RECOMMENDATIONS; IMPACT
AB Objectives: This study aims to describe aspects of the scope and quality of family planning services provided by US publicly funded health centers before the release of relevant federal recommendations.
   Study design: Using nationally representative survey data (N=1615), we describe four aspects of service delivery: family planning services provided, contraceptive methods provided onsite, written contraceptive counseling protocols and youth-friendly services. We created a count index for each issue and used multivariable ordered logistic regression to identify health center characteristics associated with scoring higher on each.
   Results: Half of the sample received Title X funding and about a third each were a community health center or health department clinic. The vast majority reported frequently providing contraceptive services (89%) and STD services (87%) for women in the past 3 months. Service provision to males was substantially lower except for STD screening. A total of 63% and 48% of health centers provided hormonal IUDs and implants onsite in the past 3 months, respectively. Forty percent of health centers included all five recommended contraceptive counseling practices in written protocols. Of youth-friendly services, active promotion of confidential services was among the most commonly reported (83%); offering weekend/evening hours was among the least (42%). In multivariable analyses, receiving Title X funding, having larger volumes of family planning clients and being a Planned Parenthood clinic were associated with higher scores on most indices.
   Conclusion: Many services were consistent with the recommendations for providing quality family planning services, but there was room for improvement across domains and health centers types.
   Implications statement: As assessed in this paper, the scope and quality of these family planning services was relatively high, particularly among Planned Parenthood clinics and Title X-funded centers. However, results point to important areas for improvement. Future studies should assess change as implementation of recent family planning service recommendations continues. Published by Elsevier Inc.
C1 [Carter, Marion W.] Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30329 USA.
   [Gavin, Loretta; Mautone-Smith, Nancy; Moskosky, Susan B.] Off Assistant Secretary Hlth, Off Populat Affairs, 1101 Wootton Pkwy,Suite 700, Rockville, MD 20852 USA.
   [Zapata, Lauren B.] Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,Mailstop F-74, Chamblee, GA 30341 USA.
   [Bornstein, Marta] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30329 USA.
RP Carter, MW (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30329 USA.
EM Acq0@cdc.gov
NR 16
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2016
VL 94
IS 4
BP 340
EP 347
DI 10.1016/j.contraception.2016.04.009
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX0DW
UT WOS:000384033000007
PM 27125894
ER

PT J
AU Zapata, LB
   Curtis, KM
   Whiteman, MK
AF Zapata, L. B.
   Curtis, K. M.
   Whiteman, M. K.
TI CHANGES IN US HEALTH CARE PROVIDER ATTITUDES RELATED TO THE SAFETY OF
   IUDS BEFORE AND AFTER THE RELEASE OF NATIONAL CONTRACEPTIVE GUIDANCE
SO CONTRACEPTION
LA English
DT Meeting Abstract
C1 [Zapata, L. B.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2016
VL 94
IS 4
MA P51
BP 407
EP 407
DI 10.1016/j.contraception.2016.07.092
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX0DW
UT WOS:000384033000092
ER

PT J
AU Papp, JR
   Henning, T
   Khubbar, M
   Kalve, V
   Bhattacharyya, S
   Travanty, E
   Xavier, K
   Jones, K
   Rudrik, JT
   Gaynor, A
   Hagan, C
AF Papp, John R.
   Henning, Tara
   Khubbar, Manjeet
   Kalve, Valdis
   Bhattacharyya, Sanjib
   Travanty, Emily
   Xavier, Karen
   Jones, Kelly
   Rudrik, James T.
   Gaynor, Anne
   Hagan, Celia
TI Recovery of Neisseria gonorrhoeae from 4 commercially available
   transport systems
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Gonorrhea; Transport; Viable
ID TIME PCR ASSAY; ANTIMICROBIAL RESISTANCE; SURVIVAL; SUSCEPTIBILITY;
   SPECIMENS; VIABILITY; AUXOTYPES; MEDIA; MEN
AB Four commercial transport systems for the recovery of Neisseria gonorrhoeae were evaluated in support of the need to obtain culture isolates for the detection of antimicrobial resistance. Bacterial recovery from the InTray GC system was superior with minimal loss of viability in contrast to non-nutritive transport systems. Published by Elsevier Inc.
C1 [Papp, John R.; Henning, Tara] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Khubbar, Manjeet; Kalve, Valdis; Bhattacharyya, Sanjib] City Milwaukee Hlth Dept, Milwaukee, WI USA.
   [Travanty, Emily; Xavier, Karen] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
   [Jones, Kelly; Rudrik, James T.] Michigan Dept Hlth & Human Serv, Lansing, MI USA.
   [Gaynor, Anne; Hagan, Celia] Assoc Publ Hlth Labs, Silver Spring, MD USA.
RP Papp, JR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA.
EM jwp6@cdc.gov
FU Centers for Disease Control and Prevention [U60HM000803]
FX This project was 100% funded with federal funds from a federal program
   of $98,023. The study was supported by Cooperative Agreement #
   U60HM000803 funded by the Centers for Disease Control and Prevention.
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of CDC or the Department of
   Health and Human Services.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD OCT
PY 2016
VL 86
IS 2
BP 144
EP 147
DI 10.1016/j.diagmicrobio.2016.06.019
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA DX5BS
UT WOS:000384395400006
PM 27489119
ER

PT J
AU Miernyk, KM
   Bulkow, LR
   Case, SL
   Zulz, T
   Bruce, MG
   Harker-Jones, M
   Hurlburt, DA
   Hennessy, TW
   Rudolph, KM
AF Miernyk, Karen M.
   Bulkow, Lisa R.
   Case, Samantha L.
   Zulz, Tammy
   Bruce, Michael G.
   Harker-Jones, Marcella
   Hurlburt, Debby A.
   Hennessy, Thomas W.
   Rudolph, Karen M.
TI Population structure of invasive Streptococcus pneumoniae isolates among
   Alaskan children in the conjugate vaccine era, 2001 to 2013
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal conjugate vaccines; Molecular
   epidemiology; Multilocus sequence typing; Antimicrobial susceptibility;
   Serotypes
ID PNEUMOCOCCAL DISEASE; UNITED-STATES; ANTIMICROBIAL SUSCEPTIBILITY;
   NATIONWIDE SURVEILLANCE; SEROTYPE DISTRIBUTION; SPECIES-DIVERSITY;
   EPIDEMIOLOGY; 7-VALENT; IMPACT; OPPORTUNITIES
AB Here we describe the relationships between serotypes, genotypes, and antimicrobial susceptibility among isolates causing invasive pneumococcal disease in Alaskan children during the pneumococcal conjugate vaccine (PCV) era. From 2001 to 2013 we received 271 isolates representing 33 serotypes. The most common serotypes were 19A (29.5%, n= 80), 7F (12.5%, n= 34), 15B/C (6.3%, n= 17), and 22F (4.8%, n= 13). Multilocus sequence typing identified 11 clonal complexes (CC) and 45 singletons. Five CCs accounted for 52% (141/271) of the total: CC199 (21% [n= 57], serotypes 19A, 15B/C), CC191 (122% [n= 33], serotype 7F), CC172 (10.3% [n= 28], serotypes 19A, 23A, 23B), CC433 (4.4% [n= 12], serotype 22F), and CC100 (4.4% [n= 12], serotype 33F). The proportion of isolates nonsusceptible to erythromycin and tetracycline increased after 13-valent PCV use (14% [n= 30] versus 29% [n= 14]; P= 0.010) and (4% [n= 9] versus 22% [n= 11]; P< 0.001), respectively. The genetic diversity also increased after 13-valent PCV use (Simpson's diversity index =0.95 versus 0.91; P= 0.022). Published by Elsevier Inc.
C1 [Miernyk, Karen M.; Bulkow, Lisa R.; Case, Samantha L.; Zulz, Tammy; Bruce, Michael G.; Harker-Jones, Marcella; Hurlburt, Debby A.; Hennessy, Thomas W.; Rudolph, Karen M.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
   [Case, Samantha L.] Ctr Dis Control & Prevent, Alaska Off, Western States Div, Natl Inst Occupat Safety & Hlth, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
RP Miernyk, KM (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
EM kmiernyk@cdc.gov
NR 39
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD OCT
PY 2016
VL 86
IS 2
BP 224
EP 230
DI 10.1016/j.diagmicrobio.2016.07.004
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA DX5BS
UT WOS:000384395400022
PM 27498610
ER

PT J
AU Barile, JP
   Horner-Johnson, W
   Krahn, G
   Zack, M
   Miranda, D
   DeMichele, K
   Ford, D
   Thompson, WW
AF Barile, John P.
   Horner-Johnson, Willi
   Krahn, Gloria
   Zack, Matthew
   Miranda, David
   DeMichele, Kimberly
   Ford, Derek
   Thompson, William W.
TI Measurement characteristics for two health-related quality of life
   measures in older adults: The SF-36 and the CDC Healthy Days items
SO DISABILITY AND HEALTH JOURNAL
LA English
DT Article
DE Health-related quality of life; Measurement; SF-36; Healthy Days;
   Functional limitations
ID INFORMATION-SYSTEM PROMIS; MEASUREMENT INVARIANCE; PERCEIVED HEALTH;
   IQOLA PROJECT; 10 COUNTRIES; DISABILITY; OUTCOMES; PEOPLE;
   QUESTIONNAIRE; INSTRUMENTS
AB Background: The Short Form Health Survey (SF-36) and the Centers for Disease Control and Prevention (CDC) Healthy Days items are well known measures of health-related quality of life. The validity of the SF-36 for older adults and those with disabilities has been questioned.
   Objective: Assess the extent to which the SF-36 and the Centers for Disease Control and Prevention (CDC) Healthy Days items measure the same aspects of health; whether the SF-36 and the CDC unhealthy days items are invariant across gender, functional status, or the presence of chronic health conditions of older adults; and whether each of the SF-36's eight subscales is independently associated with the CDC Healthy Days items.
   Methods: We analyzed data from 66,269 adult Medicare advantage members age 65 and older. We used confirmatory factor analyses and regression modeling to test associations between the CDC Healthy Days items and subscales of the SF-36.
   Results: The CDC Healthy Days items were associated with the SF-36 global measures of physical and mental health. The CDC physically unhealthy days item was associated with the SF-36 subscales for bodily pain, physical role limitations, and general health, while the CDC mentally unhealthy days item was associated with the SF-36 subscales for mental health, emotional role limitations, vitality and social functioning. The SF-36 physical functioning subscale was not independently associated with either of the CDC Healthy Days items.
   Conclusions: The CDC Healthy Days items measure similar domains as the SF-36 but appear to assess HRQOL without regard to limitations in functioning. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Barile, John P.] Univ Hawaii Manoa, Dept Psychol, 2530 Dole St,Sakamaki Hall C404, Honolulu, HI 96822 USA.
   [Horner-Johnson, Willi] Oregon Hlth & Sci Univ, Inst Dev & Disabil, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Krahn, Gloria] Oregon State Univ, Coll Publ Hlth & Human Sci, Hallie Ford Ctr 255, Corvallis, OR 97331 USA.
   [Zack, Matthew] US Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Miranda, David; DeMichele, Kimberly] Ctr Medicare Serv, Div Consumer Assessment & Plan Performance, 7500 Secur Blvd, Baltimore, MD 21244 USA.
   [Miranda, David; DeMichele, Kimberly] Ctr Medicaid Serv, Div Consumer Assessment & Plan Performance, 7500 Secur Blvd, Baltimore, MD 21244 USA.
   [Ford, Derek] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Thompson, William W.] US Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd, Atlanta, GA 30329 USA.
RP Barile, JP (reprint author), Univ Hawaii Manoa, Dept Psychol, 2530 Dole St,Sakamaki Hall C404, Honolulu, HI 96822 USA.
EM Barile@Hawaii.edu
OI Barile, John/0000-0003-4098-0640
FU Intramural CDC HHS [CC999999]
NR 39
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-6574
EI 1876-7583
J9 DISABIL HEALTH J
JI Disabil. Health J.
PD OCT
PY 2016
VL 9
IS 4
BP 567
EP 574
DI 10.1016/j.dhjo.2016.04.008
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health; Rehabilitation
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Rehabilitation
GA DX0BF
UT WOS:000384025800003
PM 27259343
ER

PT J
AU Basler, C
   Nguyen, TA
   Anderson, TC
   Hancock, T
   Behravesh, CB
AF Basler, Colin
   Nguyen, Thai-An
   Anderson, Tara C.
   Hancock, Thane
   Behravesh, Casey Barton
TI Outbreaks of Human Salmonella Infections Associated with Live Poultry,
   United States, USA, 1990-2014
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID MAIL-ORDER HATCHERY; MULTISTATE OUTBREAK; MARCH-SEPTEMBER; ENTERITIDIS;
   CONTACT; CHICKENS; ANIMALS; FLOCKS; OHIO
AB Backyard poultry flocks have increased in popularity concurrent with an increase in live poultry associated salmonellosis (LPAS) outbreaks. Better understanding of practices that contribute to this emerging public health issue is needed. We reviewed outbreak reports to describe the epidemiology of LPAS outbreaks in the United States, examine changes in trends, and inform prevention campaigns. LPAS outbreaks were defined as >= 2 culture-confirmed human Salmonella infections linked to live poultry contact; Outbreak data were obtained through multiple databases and a literature review. During 1990-2014, a total of 53 LPAS outbreaks were documented, involving 2,630 illnesses, 387 hospitalizations, and 5 deaths. Median patient age was 9 years (range <1 to 92 years). Chick and duckling exposure were reported by 85% and 38% of case-patients, respectively. High-risk practices included keeping poultry inside households (46% of case-patients) and kissing birds (13%). Comprehensive One Health strategies are needed to prevent illnesses associated with live poultry.
C1 [Basler, Colin; Nguyen, Thai-An; Anderson, Tara C.; Hancock, Thane; Behravesh, Casey Barton] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30329 USA.
RP Basler, C (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30329 USA.
EM cbasler@cdc.gov
NR 37
TC 0
Z9 0
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1705
EP 1711
DI 10.3201/eid2210.150765
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400001
PM 27649489
ER

PT J
AU Mesher, D
   Soldan, K
   Lehtinen, M
   Beddows, S
   Brisson, M
   Brotherton, JML
   Chow, EPF
   Cummings, T
   Drolet, M
   Fairley, CK
   Garland, SM
   Kahn, JA
   Kavanagh, K
   Markowitz, L
   Pollock, KG
   Soderlund-Strand, A
   Sonnenberg, P
   Tabrizi, SN
   Tanton, C
   Unger, E
   Thomas, SL
AF Mesher, David
   Soldan, Kate
   Lehtinen, Matti
   Beddows, Simon
   Brisson, Marc
   Brotherton, Julia M. L.
   Chow, Eric P. F.
   Cummings, Teresa
   Drolet, Melanie
   Fairley, Christopher K.
   Garland, Suzanne M.
   Kahn, Jessica A.
   Kavanagh, Kimberley
   Markowitz, Lauri
   Pollock, Kevin G.
   Soderlund-Strand, Anna
   Sonnenberg, Pam
   Tabrizi, Sepehr N.
   Tanton, Clare
   Unger, Elizabeth
   Thomas, Sara L.
TI Population-Level Effects of Human Papillomavirus Vaccination Programs on
   Infections with Nonvaccine Genotypes
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INVASIVE CERVICAL-CANCER; HPV-16/18 AS04-ADJUVANTED VACCINE;
   CROSS-PROTECTIVE EFFICACY; BLIND PATRICIA TRIAL; OF-STUDY ANALYSIS;
   INTRAEPITHELIAL NEOPLASIA; REPLACEMENT POSTVACCINATION; PARTICLE
   VACCINE; HERD-IMMUNITY; GENITAL WARTS
AB We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women <= 19 years of age and 23,340 women 20-24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45. For the group this same age group, we also found slight increases in 2 nonvaccine high-risk HPV types (HPV39 and HPV52) and in 2 possible high-risk types (HPV53 and HPV73). However, results between age groups and vaccines used were inconsistent, and the increases had possible alternative explanations; consequently, these data provided no clear evidence for type replacement. Continued monitoring of these HPV genotypes is important.
C1 [Mesher, David; Soldan, Kate; Beddows, Simon] Publ Hlth England, London, England.
   [Mesher, David; Thomas, Sara L.] London Sch Hyg & Trop Med, London, England.
   [Lehtinen, Matti] Univ Tampere, Tampere, Finland.
   [Brisson, Marc] Imperial Coll London, London, England.
   [Brisson, Marc; Drolet, Melanie] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada.
   [Brisson, Marc; Drolet, Melanie] Univ Laval, Quebec City, PQ, Canada.
   [Brotherton, Julia M. L.] Victorian Cytol Serv, Melbourne, Vic, Australia.
   [Brotherton, Julia M. L.; Garland, Suzanne M.; Tabrizi, Sepehr N.] Univ Melbourne, Melbourne, Vic, Australia.
   [Chow, Eric P. F.; Fairley, Christopher K.] Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Chow, Eric P. F.; Fairley, Christopher K.] Monash Univ, Melbourne, Vic, Australia.
   [Cummings, Teresa] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Garland, Suzanne M.; Tabrizi, Sepehr N.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Garland, Suzanne M.; Tabrizi, Sepehr N.] Royal Womens Hosp, Melbourne, Vic, Australia.
   [Kahn, Jessica A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Kahn, Jessica A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
   [Kavanagh, Kimberley] Univ Strathclyde, Glasgow, Lanark, Scotland.
   [Markowitz, Lauri; Unger, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Pollock, Kevin G.] Hlth Protect Scotland, Glasgow, Lanark, Scotland.
   [Soderlund-Strand, Anna] Skane, Lab Med, Div Clin Microbiol, Lund, Sweden.
   [Sonnenberg, Pam; Tanton, Clare] UCL, London, England.
RP Mesher, D (reprint author), Publ Hlth England, HIV & STI Dept, Natl Infect Serv, 61 Colindale Ave, London NW9 5EQ, England.
EM david.mesher@phe.gov.uk
OI Chow, Eric Pui Fung/0000-0003-1766-0657; Sonnenberg,
   Pam/0000-0002-1067-1583
FU Public Health England
FX This research was supported by Public Health England.
NR 39
TC 0
Z9 0
U1 11
U2 11
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1732
EP 1740
DI 10.3201/eid2210.160675
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400005
PM 27648688
ER

PT J
AU Nelson, CA
   Saha, S
   Mead, PS
AF Nelson, Christina A.
   Saha, Shubhayu
   Mead, Paul S.
TI Cat-Scratch Disease in the United States, 2005-2013
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BARTONELLA-HENSELAE; INFECTIONS;
   PREVALENCE; FEVER
AB Cat-scratch disease (CSD) is mostly preventable. More information about the epidemiology and extent of CSD would help direct prevention efforts to those at highest risk. To gain such information, we reviewed the 2005-2013 MarketScan national health insurance claims databases and identified patients <65 years of age with an inpatient admission or outpatient visit that included a CSD code from the International Classification of Diseases, Ninth Revision, Clinical Modification. Incidence of CSD was highest among those who lived in the southern United States (6.4 cases/100,000 population) and among children 5-9 years of age (9.4 cases/100,000 population). Inpatients were significantly more likely than out, patients to be male and 50-64 years of age. We estimate that each year, 12,000 outpatients are given a CSD diagnosis and 500 inpatients are hospitalized for CSD. Prevention measures (e.g., flea control for cats) are particularly helpful in southern states and in households with children.
C1 [Nelson, Christina A.; Mead, Paul S.] Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA.
   [Saha, Shubhayu] Emory Univ, Atlanta, GA 30322 USA.
RP Nelson, CA (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA.
EM wjel@cdc.gov
NR 20
TC 1
Z9 1
U1 9
U2 9
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1741
EP 1746
DI 10.3201/eid2210.160115
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400006
PM 27648778
ER

PT J
AU Kretz, CB
   Retchless, AC
   Sidikou, F
   Issaka, B
   Ousmane, S
   Schwartz, S
   Tate, AH
   Pana, A
   Njanpop-Lafourcade, BM
   Nzeyimana, I
   Nse, RO
   Deghmane, AE
   Hong, E
   Brynildsrud, OB
   Novak, RT
   Meyer, SA
   Oukem-Boyer, OOM
   Ronveaux, O
   Caugant, DA
   Taha, MK
   Wang, X
AF Kretz, Cecilia B.
   Retchless, Adam C.
   Sidikou, Fati
   Issaka, Bassira
   Ousmane, Sani
   Schwartz, Stephanie
   Tate, Ashley H.
   Pana, Assimawe
   Njanpop-Lafourcade, Berthe-Marie
   Nzeyimana, Innocent
   Nse, Ricardo Obama
   Deghmane, Ala-Eddine
   Hong, Eva
   Brynildsrud, Ola Bronstad
   Novak, Ryan T.
   Meyer, Sarah A.
   Oukem-Boyer, Odile Ouwe Missi
   Ronveaux, Olivier
   Caugant, Dominique A.
   Taha, Muhamed-Kheir
   Wang, Xin
CA Niger Response Team
TI Whole-Genome Characterization of Epidemic Neisseria meningitidis
   Serogroup C and Resurgence of Serogroup W, Niger, 2015
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID H BINDING-PROTEIN; MENINGOCOCCAL MENINGITIS; BURKINA-FASO; AFRICA; W135;
   DISEASE; VACCINE; SUSCEPTIBILITY; DIVERSITY; CARRIAGE
AB In 2015, Niger reported the largest epidemic of Neisseria meningitidis serogroup C (NmC) meningitis in sub-Saharan Africa. The NmC epidemic coincided with serogroup W (NmW) cases during the epidemic season, resulting in a total of 9,367 meningococcal cases through June 2015. To clarify the phylogenetic association, genetic evolution, and antibiotic determinants of the meningococcal strains in Niger, we sequenced the genomes of 102 isolates from this epidemic, comprising 81 NmC and 21 NmW isolates. The genomes of 82 isolates were completed, and all 102 were included in the analysis. All NmC isolates had sequence type 10217, which caused the outbreaks in Nigeria during 2013-2014 and for which a clonal complex has not yet been defined. The NmC isolates from Niger were substantially different from other NmC isolates collected globally. All NmW isolates belonged to clonal complex 11 and were closely related to the isolates causing recent outbreaks in Africa.
C1 [Kretz, Cecilia B.; Retchless, Adam C.; Schwartz, Stephanie; Tate, Ashley H.; Novak, Ryan T.; Meyer, Sarah A.; Wang, Xin] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D11, Atlanta, GA 30329 USA.
   [Sidikou, Fati; Issaka, Bassira; Ousmane, Sani; Oukem-Boyer, Odile Ouwe Missi] Ctr Rech Med & Sanit, Niamey, Niger.
   [Njanpop-Lafourcade, Berthe-Marie] Agence Med Prevent, Paris, France.
   [Pana, Assimawe; Nzeyimana, Innocent; Nse, Ricardo Obama] WHO, Niamey, Niger.
   [Deghmane, Ala-Eddine; Hong, Eva; Taha, Muhamed-Kheir] Inst Pasteur, Paris, France.
   [Brynildsrud, Ola Bronstad; Caugant, Dominique A.] Norwegian Inst Publ Hlth, Oslo, Norway.
   [Ronveaux, Olivier] WHO, Geneva, Switzerland.
RP Wang, X (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D11, Atlanta, GA 30329 USA.
EM gqe8@cdc.gov
FU CDC
FX This work was funded by CDC.
NR 37
TC 3
Z9 3
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1762
EP 1768
DI 10.3201/eid2210.160468
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400009
PM 27649262
ER

PT J
AU O'Hagan, JJ
   Carias, C
   Rudd, JM
   Pham, HT
   Haber, Y
   Pesik, N
   Cetron, MS
   Gambhir, M
   Gerber, SI
   Swerdlow, DL
AF O'Hagan, Justin J.
   Carias, Cristina
   Rudd, Jessica M.
   Pham, Huong T.
   Haber, Yonat
   Pesik, Nicki
   Cetron, Martin S.
   Gambhir, Manoj
   Gerber, Susan I.
   Swerdlow, David L.
TI Estimation of Severe Middle East Res or t ry Syndrome Cases in the
   Middle East, 2012-2016
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID MERS-COV
AB Middle East respiratory syndrome has been reported among travelers returning from the Arabian Peninsula, where most cases have been recorded. Using data from travelers, we estimated 3,250 (1,300-6,600) severe cases occurred in the Middle East during September 2012 January 2016. This estimate is 2.3-fold higher than the total laboratory-confirmed cases recorded in these countries.
C1 [O'Hagan, Justin J.; Carias, Cristina] IHRC Inc, Atlanta, GA USA.
   [O'Hagan, Justin J.; Carias, Cristina; Rudd, Jessica M.; Pham, Huong T.; Haber, Yonat; Pesik, Nicki; Cetron, Martin S.; Gambhir, Manoj; Gerber, Susan I.; Swerdlow, David L.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A16, Atlanta, GA 30329 USA.
   [Gambhir, Manoj] Imperial Coll London, London, England.
   [Gambhir, Manoj] Monash Univ, Melbourne, Vic, Australia.
RP O'Hagan, JJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A16, Atlanta, GA 30329 USA.
EM johagan@cdc.gov
NR 11
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1797
EP 1799
DI 10.3201/eid2210.151121
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400015
PM 27648640
ER

PT J
AU Gold, JAW
   Derado, G
   Mody, RK
   Benedict, K
AF Gold, Jeremy A. W.
   Derado, Gordana
   Mody, Rajal K.
   Benedict, Kaitlin
TI Sporotrichosis-Associated Hospitalizations, United States, 2000-2013
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INFECTIONS; DISEASES
AB To determine frequency and risk for sporotrichosis-associated hospitalizations, we analyzed the US 2000-2013 National (Nationwide) Inpatient Sample. An estimated 1,471 hospitalizations occurred (average annual rate 0.35/1 million persons). Hospitalizations were associated with HIV/AIDS, immune-mediated inflammatory diseases, and chronic obstructive pulmonary disease. Although rare, severe sporotrichosis should be considered for at-risk patients.
C1 [Gold, Jeremy A. W.; Derado, Gordana; Mody, Rajal K.; Benedict, Kaitlin] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA.
RP Benedict, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA.
EM jsy8@cdc.gov
NR 14
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1817
EP 1820
DI 10.3201/eid2210.160671
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400020
PM 27648881
ER

PT J
AU Payne, DC
   Iblan, I
   Rha, B
   Alqasrawi, S
   Haddadin, A
   Al Nsour, M
   Alsanouri, T
   Ali, SS
   Harcourt, J
   Miao, CR
   Tamin, A
   Gerber, SI
   Haynes, LM
   Al Abdallat, MM
AF Payne, Daniel C.
   Iblan, Ibrahim
   Rha, Brian
   Alqasrawi, Sultan
   Haddadin, Aktham
   Al Nsour, Mohannad
   Alsanouri, Tarek
   Ali, Sami Sheikh
   Harcourt, Jennifer
   Miao, Congrong
   Tamin, Azaibi
   Gerber, Susan I.
   Haynes, Lia M.
   Al Abdallat, Mohammad Mousa
TI Persistence of Antibodies against Middle East Respiratory Syndrome
   Coronavirus
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
AB To determine how long antibodies against Middle East respiratory syndrome coronavirus persist, we measured long-term antibody responses among persons serologically positive or indeterminate after a 2012 outbreak in Jordan. Antibodies, including neutralizing antibodies, were detectable in 6 (86%) of 7 persons for at least 34 months after the outbreak.
C1 [Payne, Daniel C.; Rha, Brian; Harcourt, Jennifer; Miao, Congrong; Tamin, Azaibi; Gerber, Susan I.; Haynes, Lia M.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30329 USA.
   [Iblan, Ibrahim] Jordan Field Epidemiol Training Program, Amman, Jordan.
   [Alqasrawi, Sultan; Haddadin, Aktham; Alsanouri, Tarek; Ali, Sami Sheikh; Al Abdallat, Mohammad Mousa] Jordan Minist Hlth, Amman, Jordan.
   [Al Nsour, Mohannad; Alsanouri, Tarek] Eastern Mediterranean Publ Hlth Network, Amman, Jordan.
RP Payne, DC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30329 USA.
EM dvp6@cdc.gov
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1824
EP 1826
DI 10.3201/eid2210.160706
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400022
PM 27332149
ER

PT J
AU Semaan, S
AF Semaan, Salaam
TI Geometric Abstract Art and Public Health Data
SO EMERGING INFECTIOUS DISEASES
LA English
DT Editorial Material
ID UNITED-STATES
C1 [Semaan, Salaam] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E37, Atlanta, GA 30329 USA.
RP Semaan, S (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E37, Atlanta, GA 30329 USA.
EM svs5@cdc.gov
NR 9
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2016
VL 22
IS 10
BP 1863
EP 1864
DI 10.32301/eid2210.AC2210
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX4YQ
UT WOS:000384387400043
ER

PT J
AU Wei, BN
   Bernert, JT
   Blount, BC
   Sosnoff, CS
   Wang, LQ
   Richter, P
   Pirkle, JL
AF Wei, Binnian
   Bernert, John T.
   Blount, Benjamin C.
   Sosnoff, Connie S.
   Wang, Lanqing
   Richter, Patricia
   Pirkle, James L.
TI Temporal Trends of Secondhand Smoke Exposure: Nonsmoking Workers in the
   United States (NHANES 2001-2010)
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID ENVIRONMENTAL TOBACCO-SMOKE; CIGARETTE-SMOKING; NATIONAL-HEALTH; SERUM
   COTININE; US POPULATION; WORKPLACE; METABOLITES; PREVALENCE; NICOTINE;
   ADULTS
AB BACKGROUND: The workplace is one of the major locations outside of the home for nonsmokers' exposure to secondhand smoke (SHS). New policies in many U.S. states and localities restrict or prohibit smoking in the workplace, and information on current trends in the exposure of nonsmokers to SHS across various occupational groups is therefore needed.
   OBJECTIVE: We evaluated temporal trends in SHS exposure among nonsmoking workers in the United States and identified those occupations with workers with the highest levels of SHS exposure.
   METHODS: We combined serum cotinine (sCOT) measurements and questionnaire data from five survey cycles of the National Health and Nutrition Examination Survey (NHANES: 2001-2010). Trends in SHS exposure by occupations were determined from percent changes and least-squares geometric means (LSGMs) of sCOT concentrations computed using sample-weighted multiple regression models.
   RESULTS: Between NHANES 2001-2002 and NHANES 2009-2010, LSGMs of sCOT levels had changed -25% (95% CI: -39, -7%) in nonsmoking workers. The largest decrease was identified among food preparation workers [-54% (95% CI: -74, -19%)], followed by white-collar [-40%, (95% CI: -56, -19%)] and blue-collar workers (-32%, 95% CI: -51, -5%). LSGMs of sCOT remained highest in food preparation workers in all survey cycles, but the gap between occupations narrowed in the latest survey cycle (2009-2010). For example, the gap in LSGMs of sCOT between food preparation and science/education workers dropped > 70% during 2000 to 2010.
   CONCLUSIONS: During the period from 2001 to 2010, the overall SHS exposure in nonsmoking workers declined with substantial drops in food preparation/service and blue-collar workers. Although disparities persist in SHS exposure, the gaps among occupations have narrowed.
C1 [Wei, Binnian; Bernert, John T.; Blount, Benjamin C.; Sosnoff, Connie S.; Wang, Lanqing; Richter, Patricia; Pirkle, James L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA.
RP Wei, BN; Bernert, JT (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, 4770 Buford Hwy NE,Mail Stop F44, Atlanta, GA 30341 USA.
EM bwei@cdc.gov; jtb2@cdc.gov
NR 37
TC 0
Z9 0
U1 5
U2 5
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD OCT
PY 2016
VL 124
IS 10
BP 1568
EP 1574
DI 10.1289/EHP165
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA DX4EQ
UT WOS:000384334400020
PM 27164619
ER

PT J
AU Hoepner, LA
   Whyatt, RM
   Widen, EM
   Hassoun, A
   Oberfield, SE
   Mueller, NT
   Diaz, D
   Calafat, AM
   Perera, FP
   Rundle, AG
AF Hoepner, Lori A.
   Whyatt, Robin M.
   Widen, Elizabeth M.
   Hassoun, Abeer
   Oberfield, Sharon E.
   Mueller, Noel T.
   Diaz, Diurka
   Calafat, Antonia M.
   Perera, Frederica P.
   Rundle, Andrew G.
TI Bisphenol A and Adiposity in an Inner-City Birth Cohort
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID BODY-MASS INDEX; NEW-YORK-CITY; PRENATAL EXPOSURE; URINARY
   CONCENTRATIONS; PHTHALATE METABOLITES; SCHOOL-CHILDREN; US CHILDREN; FAT
   MASS; OBESITY; OUTCOMES
AB BACKGROUND: Early-life exposure to the endocrine disruptor bisphenol A (BPA) may contribute to the development of obesity. Prospective evidence in humans on this topic is limited.
   OBJECTIVES: We examined prenatal and early-childhood BPA exposures in relation to childhood measures of adiposity in the Columbia Center for Children's Environmental Health (CCCEH) New York City birth cohort.
   METHODS: BPA concentrations were measured in prenatal (n = 375) and child ages 3 (n = 408) and 5 years (n = 518) spot urine samples. Childhood anthropometric and bioelectrical impedance outcomes included body mass index z-scores (BMIZ) at 5 and 7 years, and fat mass index (FMI), percent body fat (% BF), and waist circumference (WC) at 7 years. Associations were evaluated using multiple linear regression with continuous and tertile BPA concentrations.
   RESULTS: Prenatal urinary BPA concentrations were positively associated with child age 7 FMI (beta = 0.31kg/m(2); 95% CI: 0.01, 0.60, p = 0.04), % BF (beta = 0.79; 95% CI: 0.03, 1.55, p = 0.04), and WC (beta = 1.29 cm; 95% CI: 0.29, 2.30, p = 0.01), but not BMIZ, or change in BMIZ between ages 5 and 7 years (all p-values > 0.1). FMI results were sex-specific. Child urinary BPA concentrations were not associated with child anthropometric outcomes (all p-values > 0.05).
   CONCLUSIONS: Analyses of the CCCEH longitudinal birth cohort found associations between prenatal urinary BPA concentrations and FMI, % BF, and WC. Our results suggest that prenatal BPA exposure may contribute to developmental origins of adiposity. These findings are consistent with several prior studies, raising concern about the pervasiveness of BPA.
C1 [Hoepner, Lori A.; Whyatt, Robin M.; Diaz, Diurka; Perera, Frederica P.; Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA.
   [Hoepner, Lori A.; Whyatt, Robin M.; Diaz, Diurka; Perera, Frederica P.; Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY USA.
   [Hoepner, Lori A.] Suny Downstate Med Ctr, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Brooklyn, NY 11203 USA.
   [Widen, Elizabeth M.; Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Widen, Elizabeth M.] Columbia Univ, Med Ctr, New York Obes Nutr Res Ctr, New York, NY USA.
   [Widen, Elizabeth M.] Columbia Univ, Coll Phys & Surg, Med Ctr, Inst Human Nutr, New York, NY USA.
   [Widen, Elizabeth M.] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Med, New York, NY USA.
   [Hassoun, Abeer; Oberfield, Sharon E.] Columbia Univ, Coll Phys & Surg, Med Ctr, Div Pediat Endocrinol Diabet & Metab,Dept Pediat, New York, NY USA.
   [Mueller, Noel T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
RP Hoepner, LA (reprint author), Columbia Univ, Dept Environm Hlth Sci, Joseph L Mailman Sch Publ Hlth, 722 West 168 St, New York, NY 10032 USA.
EM LAH45@columbia.edu
RI Rundle, Andrew/A-5282-2009
OI Rundle, Andrew/0000-0003-0211-7707
FU National Institutes of Health (NIH) [P01ES09600]; U.S. Environmental
   Protection Agency (EPA) [R82702701, RD832141, RD83450901]; National
   Institute of Environmental Health Sciences/NIH [RC2ES018784]; National
   Institute of Diabetes and Digestive and Kidney Diseases [T32DK091227];
   PepsiCo Global R+D
FX This publication was made possible by National Institutes of Health
   (NIH) grant P01ES09600; U.S. Environmental Protection Agency (EPA)
   grants R82702701, RD832141, RD83450901; National Institute of
   Environmental Health Sciences/NIH grant RC2ES018784; and by the John and
   Wendy Neu Family Foundation. E.M.W. and N.T.M. were supported by the
   National Institute of Diabetes and Digestive and Kidney Diseases
   (T32DK091227). E.M.W. was also supported by an unrestricted fellowship
   to support research in Maternal and Child Health from PepsiCo Global
   R+D.
NR 55
TC 1
Z9 1
U1 12
U2 12
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD OCT
PY 2016
VL 124
IS 10
BP 1644
EP 1650
DI 10.1289/EHP205
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA DX4EQ
UT WOS:000384334400030
PM 27187982
ER

PT J
AU Hoffman, K
   Mendez, M
   Siega-Riz, AM
   Herring, AH
   Sjodin, A
   Daniels, JL
AF Hoffman, Kate
   Mendez, Michelle
   Siega-Riz, Anna Maria
   Herring, Amy H.
   Sjodin, Andreas
   Daniels, Julie L.
TI Lactational Exposure to Polybrominated Diphenyl Ethers and Its Relation
   to Early Childhood Anthropometric Measurements
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID BROMINATED FLAME RETARDANTS; THYROID-HORMONE DISRUPTION; BREAST-MILK;
   HOUSE-DUST; POLYCHLORINATED-BIPHENYLS; DEVELOPMENTAL EXPOSURE; PBDE
   MIXTURE; IN-UTERO; RAT; ASSOCIATIONS
AB Background: Polybrominated diphenyl ethers (PBDEs) are ubiquitous environmental contaminants that may influence growth and development.
   Objective: We investigated the association between exposure to PBDEs via breast milk and anthropometric measurements in early childhood.
   Methods: The Pregnancy Infection and Nutrition (PIN) Babies studies followed a cohort of North Carolina pregnant women and their children through 36 months of age. Breast milk samples obtained at 3 months postpartum were analyzed for PBDEs. We collected height and weight records from well-baby doctor visits and also measured children during study visits (n = 246 children with > 1,400 anthropometric measurements). We assessed the relationship between breast milk concentrations of five PBDE congeners-BDEs 28, 47, 99, 100, and 153-and child's weight-for- age, height-for-age, and weight-for-height z-scores (WAZ, HAZ, and WHZ, respectively), adjusting for age; maternal age, race, prepregnancy BMI; parity; smoking during pregnancy; and breastfeeding, and stratifying by sex.
   Results: Overall, PBDE exposures via breast milk were not associated with early-life anthropometric measures in the PIN Babies cohort. When stratified by sex, PBDEs in milk were inversely associated with WHZ for boys; however, associations did not follow a consistent pattern across the concentration gradient and were imprecisely estimated. Among girls, PBDEs tended to be associated with increased WHZ except for BDE-153, which was inversely associated with WHZ, though all estimates were imprecisely estimated.
   Conclusions: We observed little evidence of associations between early-life PBDE exposures via breast milk and anthropometric measurements overall; however, our results prompt the need for sex-specific investigations in larger cohorts.
C1 [Hoffman, Kate; Mendez, Michelle; Siega-Riz, Anna Maria; Herring, Amy H.; Daniels, Julie L.] UNC, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Hoffman, Kate] Duke Univ, Nicholas Sch Environm, Durham, NC USA.
   [Sjodin, Andreas] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA.
RP Daniels, JL (reprint author), UNC, Gillings Sch Global Publ Hlth, Dept Epidemiol, McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.
EM juliedaniels@unc.edu
FU U.S. Environmental Protection Agency [RD832736]; National Institute of
   Environmental Health Sciences (NIEHS) [P30ES10126]; NIEHS [T32ES007018]
FX This research was supported by grants from the U.S. Environmental
   Protection Agency (RD832736) and the National Institute of Environmental
   Health Sciences (NIEHS) (P30ES10126). The work of K.H. was supported by
   the NIEHS (T32ES007018).
NR 43
TC 0
Z9 0
U1 9
U2 9
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD OCT
PY 2016
VL 124
IS 10
BP 1656
EP 1661
DI 10.1289/EHP201
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA DX4EQ
UT WOS:000384334400032
PM 27153456
ER

PT J
AU Lonnroth, K
   Shah, NS
   Lange, C
AF Lonnroth, Knut
   Shah, N. Sarita
   Lange, Christoph
TI State-of-the-art series on tuberculosis and migration
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Editorial Material
C1 [Lonnroth, Knut] WHO, Global TB Programme, Geneva, Switzerland.
   [Lonnroth, Knut] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
   [Shah, N. Sarita] Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA USA.
   [Lange, Christoph] Res Ctr Borstel, Div Clin Infect Dis, Borstel, Germany.
   [Lange, Christoph] German Ctr Infect Res DZIF, Braunschweig, Germany.
   [Lange, Christoph] Univ Lubeck, Int Hlth Infect Dis, Lubeck, Germany.
   [Lange, Christoph] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Lange, Christoph] Univ Namibia, Sch Med, Dept Med, Windhoek, Namibia.
RP Lonnroth, K (reprint author), WHO, Global TB Programme, Geneva, Switzerland.; Lonnroth, K (reprint author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
EM lonnrothk@who.int
RI Lonnroth, Knut/L-2339-2014
OI Lonnroth, Knut/0000-0001-5054-8240
NR 5
TC 0
Z9 0
U1 1
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD OCT
PY 2016
VL 20
IS 10
BP 1280
EP 1281
DI 10.5588/ijtld.16.0543
PG 2
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA DX5AZ
UT WOS:000384393500002
PM 27725031
ER

PT J
AU Tollefson, D
   Ngari, F
   Mwakala, M
   Gethi, D
   Kipruto, H
   Cain, K
   Bloss, E
AF Tollefson, D.
   Ngari, F.
   Mwakala, M.
   Gethi, D.
   Kipruto, H.
   Cain, K.
   Bloss, E.
TI Under-reporting of sputum smear-positive tuberculosis cases in Kenya
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE surveillance; inventory study; under-reporting; TB
ID RESOURCE-LIMITED COUNTRIES; PULMONARY TUBERCULOSIS; CAPTURE-RECAPTURE;
   INITIAL DEFAULT; SOUTH-AFRICA; SURVEILLANCE SYSTEM; BURDEN;
   COMPLETENESS; INDIA; COMMUNITIES
AB BACKGROUND: Although an estimated three million tuberculosis (TB) cases worldwide are missed by national TB programs annually, the level of under-reporting of diagnosed cases in high TB burden settings is largely unknown.
   OBJECTIVE: To quantify and describe under-reporting of sputum smear-positive TB cases in Kenya.
   DESIGN: A national-level retrospective TB inventory study was conducted. All sputum smear-positive TB cases diagnosed by public or private laboratories during 1 April-30 June 2013 were extracted from laboratory registers in 73 randomly sampled subcounties and matched to TB cases in the national TB surveillance system (TIBU). Bivariate and multivariate analyses were conducted.
   RESULTS : In the subcounties sampled, 715 of 3409 SUMMARY smear-positive TB cases in laboratory registers were not found in 11BU. The estimated level of under-reporting of smear-positive TB cases in Kenya was 20.7% (95 %CI 18.4-23.0). Under-reporting was greatest in subcounties with a high TB burden. Unreported cases were more likely to be patients aged >= 55 years, have scanty smear results, and be diagnosed at large facilities, private facilities, and facilities in high TB burden regions.
   CONCLUSION: In Kenya, one fifth of smear-positive TB cases diagnosed during the study period went unreported, suggesting that the true TB burden is higher than reported. TB surveillance in Kenya should be strengthened to ensure all diagnosed TB cases are reported.
C1 [Tollefson, D.; Bloss, E.] US Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
   [Ngari, F.; Mwakala, M.] Natl TB Leprosy & Lung Dis Program, Nairobi, Kenya.
   [Gethi, D.] Kenya Govt Med Res Ctr, Kisumu, Kenya.
   [Kipruto, H.] WHO, Nairobi, Kenya.
   [Cain, K.] CDC, Kisumu, Kenya.
RP Tollefson, D (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV & TB, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30329 USA.
EM vtu3@cdc.gov
NR 31
TC 0
Z9 0
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD OCT
PY 2016
VL 20
IS 10
BP 1334
EP 1341
DI 10.5588/ijtld.16.0156
PG 8
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA DX5AZ
UT WOS:000384393500015
PM 27725044
ER

PT J
AU Marks, G
   Patel, U
   Stirratt, MJ
   Mugavero, MJ
   Mathews, WC
   Giordano, TP
   Crepaz, N
   Gardner, LI
   Grossman, C
   Davila, J
   Sullivan, M
   Rose, CE
   O'Daniels, C
   Rodriguez, A
   Wawrzyniak, AJ
   Golden, MR
   Dhanireddy, S
   Ellison, J
   Drainoni, ML
   Metsch, LR
   Cachay, ER
AF Marks, Gary
   Patel, Unnati
   Stirratt, Michael J.
   Mugavero, Michael J.
   Mathews, William C.
   Giordano, Thomas P.
   Crepaz, Nicole
   Gardner, Lytt I.
   Grossman, Cynthia
   Davila, Jessica
   Sullivan, Meg
   Rose, Charles E.
   O'Daniels, Christine
   Rodriguez, Allan
   Wawrzyniak, Andrew J.
   Golden, Matthew R.
   Dhanireddy, Shireesha
   Ellison, Jacqueline
   Drainoni, Mari-Lynn
   Metsch, Lisa R.
   Cachay, Edward R.
TI Single Viral Load Measurements Overestimate Stable Viral Suppression
   Among HIV Patients in Care: Clinical and Public Health Implications
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; viral suppression; viral load; care
ID UNITED-STATES; RETENTION; PREVENTION; ATTENDANCE; CONTINUUM; COUNTS;
   TRENDS
AB Background: The HIV continuum of care paradigm uses a single viral load test per patient to estimate the prevalence of viral suppression. We compared this single-value approach with approaches that used multiple viral load tests to examine the stability of suppression.
   Methods: The retrospective analysis included HIV patients who had at least 2 viral load tests during a 12-month observation period. We assessed the (1) percent with suppressed viral load (<200 copies/mL) based on a single test during observation, (2) percent with suppressed viral loads on all tests during observation, (3) percent who maintained viral suppression among patients whose first observed viral load was suppressed, and (4) change in viral suppression status comparing first with last measurement occasions. Prevalence ratios compared demographic and clinical subgroups.
   Results: Of 10,942 patients, 78.5% had a suppressed viral load based on a single test, whereas 65.9% were virally suppressed on all tests during observation. Of patients whose first observed viral load was suppressed, 87.5% were suppressed on all subsequent tests in the next 12 months. More patients exhibited improving status (13.3% went from unsuppressed to suppressed) than worsening status (5.6% went from suppressed to unsuppressed). Stable suppression was less likely among women, younger patients, black patients, those recently diagnosed with HIV, and those who missed >= 1 scheduled clinic visits.
   Conclusions: Using single viral load measurements overestimated the percent of HIV patients with stable suppressed viral load by 16% (relative difference). Targeted clinical interventions are needed to increase the percent of patients with stable suppression.
C1 [Marks, Gary; Crepaz, Nicole; Gardner, Lytt I.; Rose, Charles E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Ave,MS E-45, Atlanta, GA 30333 USA.
   [Patel, Unnati] ICF Int, Atlanta, GA USA.
   [Stirratt, Michael J.; Grossman, Cynthia] NIMH, Div AIDS Res, Bethesda, MD 20892 USA.
   [Mugavero, Michael J.] Univ Alabama Birmingham, HIV AIDS Clin 1917, Birmingham, AL USA.
   [Mugavero, Michael J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Mathews, William C.; Cachay, Edward R.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Giordano, Thomas P.; Davila, Jessica] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Giordano, Thomas P.; Davila, Jessica] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA.
   [Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
   [O'Daniels, Christine] Carter Consulting Inc, Atlanta, GA USA.
   [Rodriguez, Allan] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA.
   [Wawrzyniak, Andrew J.] Univ Miami, Miller Sch Med, Psychiat & Behav Sci, Miami, FL 33136 USA.
   [Golden, Matthew R.] Univ Washington, Ctr AIDS & STD & Publ Health Seattle & King Cty, Seattle, WA 98195 USA.
   [Dhanireddy, Shireesha] Univ Washington, Dept Med, Seattle, WA USA.
   [Ellison, Jacqueline; Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Boston, MA USA.
   [Metsch, Lisa R.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
RP Marks, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Ave,MS E-45, Atlanta, GA 30333 USA.
EM gmarks@cdc.gov
FU NIAID NIH HHS [P30 AI073961]
NR 14
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2016
VL 73
IS 2
BP 205
EP 212
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX1EW
UT WOS:000384109800017
PM 27105049
ER

PT J
AU Auld, AF
   Shiraishi, RW
   Couto, A
   Mbofana, F
   Colborn, K
   Alfredo, C
   Ellerbrock, TV
   Xavier, C
   Jobarteh, K
AF Auld, Andrew F.
   Shiraishi, Ray W.
   Couto, Aleny
   Mbofana, Francisco
   Colborn, Kathryn
   Alfredo, Charity
   Ellerbrock, Tedd V.
   Xavier, Carla
   Jobarteh, Kebba
TI A Decade of Antiretroviral Therapy Scale-up in Mozambique: Evaluation of
   Outcome Trends and New Models of Service Delivery Among More Than
   300,000 Patients Enrolled During 2004-2013
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral therapy; Mozambique; trends; models of service delivery;
   community-based antiretroviral therapy delivery; Option B
ID HIV-INFECTED ADULTS; SUB-SAHARAN AFRICA; FOLLOW-UP; SOUTH-AFRICA;
   TREATMENT PROGRAMS; MULTICENTER COHORT; PREGNANT-WOMEN; MISSING DATA;
   CELL COUNT; CD4 COUNT
AB Background: During 2004-2013 in Mozambique, 455,600 HIV-positive adults (>= 15 years old) initiated antiretroviral therapy (ART). We evaluated trends in patient characteristics and outcomes during 2004-2013, outcomes of universal treatment for pregnant women (Option B+) implemented since 2013, and effect on outcomes of distributing ART to stable patients through Community ART Support Groups (CASG) since 2010.
   Methods: Data for 306,335 adults starting ART during 2004-2013 at 170 ART facilities were analyzed. Mortality and loss to follow-up (LTFU) were estimated using competing risks models. Outcome determinants were estimated using proportional hazards models, including CASG participation as a time-varying covariate.
   Results: Compared with ART enrollees in 2004, enrollees in 2013 were more commonly female (55% vs. 73%), more commonly pregnant if female (<1% vs. 30%), and had a higher median baseline CD4 count (139 vs. 235/mL). During 2004-2013, observed 6-month mortality declined from 7% to 2% but LTFU increased from 24% to 30%. Pregnant women starting ART with CD4 count >350/mu L and WHO stage I/II under Option B+ guidelines in 2013 had low 6-month mortality (0.1%) but high 6-month LTFU (38%). During 2010-2013, 6766 patients joined CASGs. In multivariable analysis, compared with nonparticipation in CASG, CASG participation was associated with 35% lower LTFU but similar mortality.
   Conclusions: Initiation of ART at earlier disease stages in later calendar years might explain observed declines in mortality. Retention interventions are needed to address trends of increasing LTFU overall and the high LTFU among Option B+ pregnant women specifically. Further expansion of CASG could help reduce LTFU.
C1 [Auld, Andrew F.; Shiraishi, Ray W.; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA USA.
   [Couto, Aleny; Mbofana, Francisco] Mozamb Minist Hlth, Maputo, Mozambique.
   [Colborn, Kathryn; Alfredo, Charity; Xavier, Carla; Jobarteh, Kebba] Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, Maputo, Mozambique.
RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, Div Global HIV & TB, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA.
EM aauld@cdc.gov
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S.
   Centers for Disease Control and Prevention
FX Supported by the President's Emergency Plan for AIDS Relief (PEPFAR)
   through the U.S. Centers for Disease Control and Prevention.
NR 64
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2016
VL 73
IS 2
BP E11
EP E22
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX1EW
UT WOS:000384109800001
PM 27454248
ER

PT J
AU Shrestha, RK
   Farnham, PG
   Whitham, HK
   Sansom, SL
AF Shrestha, Ram K.
   Farnham, Paul G.
   Whitham, Hilary K.
   Sansom, Stephanie L.
TI Challenges in Estimating Effectiveness of Condom Distribution Campaigns
   to Prevent HIV Transmission
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID COST-UTILITY ANALYSIS; BEHAVIORAL SURVEILLANCE; DEVELOPING STANDARDS;
   HIV/STD PREVENTION; UNITED-STATES; INTERVENTIONS; METAANALYSIS; US
C1 [Shrestha, Ram K.; Farnham, Paul G.; Whitham, Hilary K.; Sansom, Stephanie L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA.
RP Shrestha, RK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA.
NR 35
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2016
VL 73
IS 2
BP E35
EP E38
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DX1EW
UT WOS:000384109800005
PM 27400404
ER

PT J
AU Mijatovic-Rustempasic, S
   Esona, MD
   Williams, AL
   Bowen, MD
AF Mijatovic-Rustempasic, Slavica
   Esona, Mathew D.
   Williams, Alice L.
   Bowen, Michael D.
TI Sensitive and specific nested PCR assay for detection of rotavirus A in
   samples with a low viral load
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Rotavirus; Nested; RT-PCR; Sensitivity; Specificity
ID POLYMERASE-CHAIN-REACTION; UNITED-STATES; STRAINS; GENOTYPE;
   IDENTIFICATION; VACCINATION; VIRUSES
AB Techniques such as the real-time reverse transcription-polymerase chain reaction (qRT-PCR) can detect RNA in samples with a low viral load. However, these amplicons typically are either too short or at insufficient concentrations for use in subsequent sequencing reactions for genotyping and detection confirmation. The assay developed in this study detects rotavirus G genotypes and P genotypes with viral loads as low as 6.2 and 8.2 copies per reaction, respectively. The assay was validated using a panel of 91 stool samples, 32 reference rotavirus strains, and 6 non-target enteric virus samples. Published by Elsevier B.V.
C1 [Mijatovic-Rustempasic, Slavica; Esona, Mathew D.; Bowen, Michael D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Williams, Alice L.] Furman Univ, Greenville, SC 29613 USA.
RP Bowen, MD (reprint author), 1600 Clifton Rd NE,Mail Stop G-04, Atlanta, GA 30329 USA.
EM mkb6@cdc.gov
FU Centers for Disease Control and Prevention
FX We wish to thank Jennifer J. Hull for her expertise in propagating cell
   culture strains, as well as for her time teaching cell culture
   propagation. We thank M. Leanne Ward for editorial assistance. We also
   would like to thank Rashi Gautam, Sunando Roy, Kunchala
   Rungsrisuriyachai and Jan Vinje. Funding for this study was provided by
   the Centers for Disease Control and Prevention.
NR 30
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD OCT
PY 2016
VL 236
BP 41
EP 46
DI 10.1016/j.jviromet.2016.07.007
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA DW8YR
UT WOS:000383941900008
PM 27421626
ER

PT J
AU Soka, MJ
   Choi, MJ
   Baller, A
   White, S
   Rogers, E
   Purpura, LJ
   Mahmoud, N
   Wasunna, C
   Massaquoi, M
   Abad, N
   Kollie, J
   Dweh, S
   Bemah, PK
   Christie, A
   Ladele, V
   Subah, OC
   Pillai, S
   Mugisha, M
   Kpaka, J
   Kowalewski, S
   German, E
   Stenger, M
   Nichol, S
   Stroher, U
   Vanderende, KE
   Zarecki, SM
   Green, HHW
   Bailey, JA
   Rollin, P
   Marston, B
   Nyenswah, TG
   Gasasira, A
   Knust, B
   Williams, D
AF Soka, Moses J.
   Choi, Mary J.
   Baller, April
   White, Stephen
   Rogers, Emerson
   Purpura, Lawrence J.
   Mahmoud, Nuha
   Wasunna, Christine
   Massaquoi, Moses
   Abad, Neetu
   Kollie, Jomah
   Dweh, Straker
   Bemah, Philip K.
   Christie, Athalia
   Ladele, Victor
   Subah, Oneychachi C.
   Pillai, Satish
   Mugisha, Margaret
   Kpaka, Jonathan
   Kowalewski, Stephen
   German, Emilio
   Stenger, Mark
   Nichol, Stuart
   Stroher, Ute
   Vanderende, Kristin E.
   Zarecki, Shauna Mettee
   Green, Hugh Henry W.
   Bailey, Jeffrey A.
   Rollin, Pierre
   Marston, Barbara
   Nyenswah, Tolbert G.
   Gasasira, Alex
   Knust, Barbara
   Williams, Desmond
TI Prevention of sexual transmission of Ebola in Liberia through a national
   semen testing and counselling programme for survivors: an analysis of
   Ebola virus RNA results and behavioural data
SO LANCET GLOBAL HEALTH
LA English
DT Article
ID PERSISTENCE; EPIDEMIC; QUALITY; AGE
AB Background Ebola virus has been detected in semen of Ebola virus disease survivors after recovery. Liberia's Men's Health Screening Program (MHSP) offers Ebola virus disease survivors semen testing for Ebola virus. We present preliminary results and behavioural outcomes from the first national semen testing programme for Ebola virus.
   Methods The MHSP operates out of three locations in Liberia: Redemption Hospital in Montserrado County, Phebe Hospital in Bong County, and Tellewoyan Hospital in Lofa County. Men aged 15 years and older who had an Ebola treatment unit discharge certificate are eligible for inclusion. Participants' semen samples were tested for Ebola virus RNA by real-time RT-PCR and participants received counselling on safe sexual practices. Participants graduated after receiving two consecutive negative semen tests. Counsellors collected information on sociodemographics and sexual behaviours using questionnaires administered at enrolment, follow up, and graduation visits. Because the programme is ongoing, data analysis was restricted to data obtained from July 7, 2015, to May 6, 2016.
   Findings As of May 6, 2016, 466 Ebola virus disease survivors had enrolled in the programme; real-time RT-PCR results were available from 429 participants. 38 participants (9%) produced at least one semen specimen that tested positive for Ebola virus RNA. Of these, 24 (63%) provided semen specimens that tested positive 12 months or longer after Ebola virus disease recovery. The longest interval between discharge from an Ebola treatment unit and collection of a positive semen sample was 565 days. Among participants who enrolled and provided specimens more than 90 days since their Ebola treatment unit discharge, men older than 40 years were more likely to have a semen sample test positive than were men aged 40 years or younger (p=0.0004). 84 (74%) of 113 participants who reported not using a condom at enrolment reported using condoms at their first follow-up visit (p<0.0001). 176 (46%) of 385 participants who reported being sexually active at enrolment reported abstinence at their follow-up visit (p<0.0001).
   Interpretation Duration of detection of Ebola virus RNA by real-time RT-PCR varies by individual and might be associated with age. By combining behavioural counselling and laboratory testing, the Men's Health Screening Program helps male Ebola virus disease survivors understand their individual risk and take appropriate measures to protect their sexual partners. Copyright This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license.
C1 [Soka, Moses J.; Rogers, Emerson; Massaquoi, Moses; Bemah, Philip K.; Nyenswah, Tolbert G.] Minist Hlth, Monrovia, Liberia.
   [Choi, Mary J.; Purpura, Lawrence J.; Abad, Neetu; Christie, Athalia; Pillai, Satish; Kowalewski, Stephen; German, Emilio; Stenger, Mark; Nichol, Stuart; Stroher, Ute; Vanderende, Kristin E.; Zarecki, Shauna Mettee; Green, Hugh Henry W.; Rollin, Pierre; Marston, Barbara; Knust, Barbara; Williams, Desmond] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Baller, April; Mahmoud, Nuha; Kollie, Jomah; Ladele, Victor; Mugisha, Margaret; Gasasira, Alex] WHO, Monrovia, Liberia.
   [White, Stephen; Wasunna, Christine; Dweh, Straker; Subah, Oneychachi C.; Kpaka, Jonathan; Bailey, Jeffrey A.] Univ Massachusetts, Sch Med, Acad Consortium Combating Ebola Liberia, Worcester, MA 01605 USA.
RP Choi, MJ (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA.
EM whz2@cdc.gov
FU World Health Organization and the US Centers for Disease Control and
   Prevention
FX Funding World Health Organization and the US Centers for Disease Control
   and Prevention.
NR 16
TC 6
Z9 6
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD OCT
PY 2016
VL 4
IS 10
BP E736
EP E743
DI 10.1016/S2214-109X(16)30175-9
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW7RE
UT WOS:000383848000024
PM 27596037
ER

PT J
AU Feasey, NA
   Hadfield, J
   Keddy, KH
   Dallman, TJ
   Jacobs, J
   Deng, X
   Wigley, P
   Barquist, LB
   Langridge, GC
   Feltwell, T
   Harris, SR
   Mather, AE
   Fookes, M
   Aslett, M
   Msefula, C
   Kariuki, S
   Maclennan, CA
   Onsare, RS
   Weill, FX
   Le Hello, S
   Smith, AM
   McClelland, M
   Desai, P
   Parry, CM
   Cheesbrough, J
   French, N
   Campos, J
   Chabalgoity, JA
   Betancor, L
   Hopkins, KL
   Nair, S
   Humphrey, TJ
   Lunguya, O
   Cogan, TA
   Tapia, MD
   Sow, SO
   Tennant, SM
   Bornstein, K
   Levine, MM
   Lacharme-Lora, L
   Everett, DB
   Kingsley, RA
   Parkhill, J
   Heyderman, RS
   Dougan, G
   Gordon, MA
   Thomson, NR
AF Feasey, Nicholas A.
   Hadfield, James
   Keddy, Karen H.
   Dallman, Timothy J.
   Jacobs, Jan
   Deng, Xiangyu
   Wigley, Paul
   Barquist, Lars Barquist
   Langridge, Gemma C.
   Feltwell, Theresa
   Harris, Simon R.
   Mather, Alison E.
   Fookes, Maria
   Aslett, Martin
   Msefula, Chisomo
   Kariuki, Samuel
   Maclennan, Calman A.
   Onsare, Robert S.
   Weill, Francois-Xavier
   Le Hello, Simon
   Smith, Anthony M.
   McClelland, Michael
   Desai, Prerak
   Parry, Christopher M.
   Cheesbrough, John
   French, Neil
   Campos, Josefina
   Chabalgoity, Jose A.
   Betancor, Laura
   Hopkins, Katie L.
   Nair, Satheesh
   Humphrey, Tom J.
   Lunguya, Octavie
   Cogan, Tristan A.
   Tapia, Milagritos D.
   Sow, Samba O.
   Tennant, Sharon M.
   Bornstein, Kristin
   Levine, Myron M.
   Lacharme-Lora, Lizeth
   Everett, Dean B.
   Kingsley, Robert A.
   Parkhill, Julian
   Heyderman, Robert S.
   Dougan, Gordon
   Gordon, Melita A.
   Thomson, Nicholas R.
TI Distinct Salmonella Enteritidis lineages associated with enterocolitis
   in high-income settings and invasive disease in low-income settings
SO NATURE GENETICS
LA English
DT Article
ID ENTERICA SEROVAR ENTERITIDIS; NONTYPHOIDAL SALMONELLA; SEROTYPE
   ENTERITIDIS; TYPHIMURIUM ST313; HOST ADAPTATION; UNITED-KINGDOM;
   EVOLUTION; EPIDEMIC; AFRICA; SURVEILLANCE
AB An epidemiological paradox surrounds Salmonella enterica serovar Enteritidis. In high-income settings, it has been responsible for an epidemic of poultry-associated, self-limiting enterocolitis, whereas in sub-Saharan Africa it is a major cause of invasive nontyphoidal Salmonella disease, associated with high case fatality. By whole-genome sequence analysis of 675 isolates of S. Enteritidis from 45 countries, we show the existence of a global epidemic clade and two new clades of S. Enteritidis that are geographically restricted to distinct regions of Africa. The African isolates display genomic degradation, a novel prophage repertoire, and an expanded multidrug resistance plasmid. S. Enteritidis is a further example of a Salmonella serotype that displays niche plasticity, with distinct clades that enable it to become a prominent cause of gastroenteritis in association with the industrial production of eggs and of multidrug-resistant, bloodstream-invasive infection in Africa.
C1 [Feasey, Nicholas A.; Parry, Christopher M.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   [Feasey, Nicholas A.; Hadfield, James; Langridge, Gemma C.; Feltwell, Theresa; Harris, Simon R.; Mather, Alison E.; Fookes, Maria; Aslett, Martin; Maclennan, Calman A.; Parkhill, Julian; Dougan, Gordon; Thomson, Nicholas R.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Feasey, Nicholas A.; Heyderman, Robert S.; Gordon, Melita A.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Feasey, Nicholas A.; Wigley, Paul; French, Neil; Lacharme-Lora, Lizeth; Everett, Dean B.; Gordon, Melita A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Keddy, Karen H.; Smith, Anthony M.] Natl Inst Communicable Dis, Ctr Enter Dis, Johannesburg, South Africa.
   [Keddy, Karen H.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [Dallman, Timothy J.; Nair, Satheesh] Publ Hlth England, Gastrointestinal Bacteria Reference Unit, Colindale, England.
   [Jacobs, Jan] Inst Trop Med, Antwerp, Belgium.
   [Jacobs, Jan] Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium.
   [Deng, Xiangyu] Univ Georgia, Dept Food Sci & Technol, Ctr Food Safety, Athens, GA 30602 USA.
   [Deng, Xiangyu] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Barquist, Lars Barquist] Univ Wurzburg, Inst Mol Infect Biol, Wurzburg, Germany.
   [Msefula, Chisomo] Univ Malawi, Coll Med, Blantyre, Malawi.
   [Kariuki, Samuel; Onsare, Robert S.] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya.
   [Maclennan, Calman A.] Univ Oxford, Nuffield Dept Med, Jenner Inst, Oxford, England.
   [Weill, Francois-Xavier; Le Hello, Simon] Inst Pasteur, Paris, France.
   [McClelland, Michael; Desai, Prerak] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA USA.
   [Parry, Christopher M.; Thomson, Nicholas R.] London Sch Hyg & Trop Med, London, England.
   [Parry, Christopher M.] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan.
   [Cheesbrough, John] Univ Liverpool, Dept Epidemiol & Populat Hlth, Liverpool, Merseyside, England.
   [Campos, Josefina] Carlos G Malbran Inst, ANLIS, Enteropathogen Div, Buenos Aires, DF, Argentina.
   [Chabalgoity, Jose A.; Betancor, Laura] Univ Republica, Fac Med, Inst Higiene, Montevideo, Uruguay.
   [Hopkins, Katie L.] Publ Hlth England, Antimicrobial Resistance & Healthcare Associated, Colindale, England.
   [Humphrey, Tom J.] Swansea Univ, Swansea Med Sch, Swansea, W Glam, Wales.
   [Lunguya, Octavie] Natl Inst Biomed Res, Kinshasa, DEM REP CONGO.
   [Lunguya, Octavie] Univ Hosp Kinshasa, Kinshasa, DEM REP CONGO.
   [Cogan, Tristan A.] Univ Bristol, Sch Vet Sci, Bristol, Avon, England.
   [Tapia, Milagritos D.; Tennant, Sharon M.; Bornstein, Kristin; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Sow, Samba O.] Ctr Dev Vaccins, Bamako, Mali.
   [Kingsley, Robert A.] Inst Food Res, Norwich, Norfolk, England.
   [Heyderman, Robert S.] UCL, Div Infect & Immun, London, England.
   [Mather, Alison E.] Univ Cambridge, Dept Vet Med, Cambridge, England.
RP Thomson, NR (reprint author), Wellcome Trust Sanger Inst, Cambridge, England.; Thomson, NR (reprint author), London Sch Hyg & Trop Med, London, England.
EM nicholas.feasey@Istmed.ac.uk
OI Barquist, Lars/0000-0003-4732-2667; Nair, Satheesh/0000-0002-7297-1485;
   McClelland, Michael/0000-0003-1788-9347
FU Wellcome Trust [098051, WT092152MA, 101113/Z/13/Z]; Institut Pasteur;
   Institut de Veille Sanitaire; French government 'Investissement
   d'Avenir' program (Integrative Biology of Emerging Infectious Diseases
   Laboratory of Excellence) [ANR-10-LABX-62-IBEID]; NIH [R01 AI099525-02];
   Biotechnology and Biological Sciences Research Council at the University
   of Cambridge [BB/M014088/1]; antibiotic resistance surveillance project
   in the Democratic Republic of the Congo - Belgian Directorate General of
   Development Cooperation (Antwerp, Belgium); antibiotic resistance
   surveillance project in the Democratic Republic of the Congo - Institute
   of Tropical Medicine (Antwerp, Belgium)
FX This work was supported by the Wellcome Trust. We would like to thank
   the members of the Pathogen Informatics Team and the core sequencing
   teams at the Wellcome Trust Sanger Institute (Cambridge, UK). We are
   grateful to D. Harris for work in managing the sequence data.; This work
   was supported by a number of organizations. The authors from the
   Wellcome Trust Sanger Institute were funded by Wellcome Trust award
   098051. N.A.F. was supported by Wellcome Trust research fellowship
   WT092152MA. N.A.F., R.S.H., and this work were supported by a strategic
   award from the Wellcome Trust for the MLW Clinical Research Programme
   (101113/Z/13/Z). The authors from the Institut Pasteur were funded by
   the Institut Pasteur, by the Institut de Veille Sanitaire, and by the
   French government 'Investissement d'Avenir' program (Integrative Biology
   of Emerging Infectious Diseases Laboratory of Excellence, grant
   ANR-10-LABX-62-IBEID). J.J. was supported by the antibiotic resistance
   surveillance project in the Democratic Republic of the Congo, funded by
   Project 2.01 of the Third Framework Agreement between the Belgian
   Directorate General of Development Cooperation and the Institute of
   Tropical Medicine (Antwerp, Belgium). S.K. was supported by NIH grant
   R01 AI099525-02. A.E.M. was supported by Wellcome Trust grant 098051
   while at the Wellcome Trust Sanger Institute and by Biotechnology and
   Biological Sciences Research Council grant BB/M014088/1 at the
   University of Cambridge. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 44
TC 3
Z9 3
U1 7
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 2016
VL 48
IS 10
BP 1211
EP 1217
DI 10.1038/ng.3644
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA DX5AG
UT WOS:000384391600016
PM 27548315
ER

PT J
AU Ellebedy, AH
   Jackson, KJL
   Kissick, HT
   Nakaya, HI
   Davis, CW
   Roskin, KM
   McElroy, AK
   Oshansky, CM
   Elbein, R
   Thomas, S
   Lyon, GM
   Spiropoulou, CF
   Mehta, AK
   Thomas, PG
   Boyd, SD
   Ahmed, R
AF Ellebedy, Ali H.
   Jackson, Katherine J. L.
   Kissick, Haydn T.
   Nakaya, Helder I.
   Davis, Carl W.
   Roskin, Krishna M.
   McElroy, Anita K.
   Oshansky, Christine M.
   Elbein, Rivka
   Thomas, Shine
   Lyon, George M.
   Spiropoulou, Christina F.
   Mehta, Aneesh K.
   Thomas, Paul G.
   Boyd, Scott D.
   Ahmed, Rafi
TI Defining antigen-specific plasmablast and memory B cell subsets in human
   blood after viral infection or vaccination
SO NATURE IMMUNOLOGY
LA English
DT Article
ID INFLUENZA INFECTION; IMMUNE-RESPONSES; VIRUS-INFECTION; COMMITMENT;
   GENERATION; ANTIBODIES; NETWORKS
AB Antigen-specific B cells bifurcate into antibody-secreting cells (ASCs) and memory B cells (MBCs) after infection or vaccination. ASCs (plasmablasts) have been extensively studied in humans, but less is known about B cells that become activated but do not differentiate into plasmablasts. Here we have defined the phenotype and transcriptional program of a subset of antigen-specific B cells, which we have called 'activated B cells' (ABCs), that were distinct from ASCs and were committed to the MBC lineage. We detected ABCs in humans after infection with Ebola virus or influenza virus and also after vaccination. By simultaneously analyzing antigen-specific ASCs and ABCs in human blood after vaccination against influenza virus, we investigated the clonal overlap and extent of somatic hypermutation (SHM) in the ASC (effector) and ABC (memory) lineages. Longitudinal tracking of vaccination-induced hemagglutinin (HA)-specific clones revealed no overall increase in SHM over time, which suggested that repeated annual immunization might have limitations in enhancing the quality of influenza-virus-specific antibody.
C1 [Ellebedy, Ali H.; Davis, Carl W.; Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.
   [Ellebedy, Ali H.; Kissick, Haydn T.; Davis, Carl W.; Ahmed, Rafi] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Jackson, Katherine J. L.; Roskin, Krishna M.; Boyd, Scott D.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.
   [Kissick, Haydn T.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA.
   [Nakaya, Helder I.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [McElroy, Anita K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
   [McElroy, Anita K.; Spiropoulou, Christina F.] US Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA.
   [Oshansky, Christine M.; Thomas, Paul G.] St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Elbein, Rivka; Thomas, Shine; Lyon, George M.; Mehta, Aneesh K.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA.
RP Ahmed, R (reprint author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.; Ahmed, R (reprint author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.; Boyd, SD (reprint author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.
EM sboyd1@stanford.edu; rahmed@emory.edu
RI Nakaya, Helder/A-1397-2010; CEPID, CRID/J-2644-2015; 
OI Nakaya, Helder/0000-0001-5297-9108; Thomas, Paul G./0000-0001-7955-0256
FU National Institute of Allergy and Infectious Diseases of the US National
   Institutes of Health [HHSN266200700006C, 1P01AI097092, U19AI117891,
   T32AI074492, U19AI09525801, UM1AI100663, U01AI104342]; Advanced
   Immunization Technologies [280873]; European Union; National Center for
   Advancing Translational Sciences [UL1TR000454]; National Council for
   Scientific and Technological Development of Brazil
FX We thank R. Karaffa and S. Durham for technical assistance. Supported by
   the National Institute of Allergy and Infectious Diseases of the US
   National Institutes of Health (HHSN266200700006C, 1P01AI097092 and
   U19AI117891 to R.A.; T32AI074492 to A.E.; and U19AI09525801, UM1AI100663
   and U01AI104342 to S.D.B.), Advanced Immunization Technologies (280873),
   the European Union (R.A.), the National Center for Advancing
   Translational Sciences (UL1TR000454 to A.K.M.) and The National Council
   for Scientific and Technological Development of Brazil (H.I.N.). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Allergy and Infectious Diseases or the National Institutes of Health or
   that of the Centers for Disease Control and Prevention.
NR 32
TC 1
Z9 1
U1 6
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD OCT
PY 2016
VL 17
IS 10
BP 1226
EP +
DI 10.1038/ni.3533
PG 11
WC Immunology
SC Immunology
GA DX3VD
UT WOS:000384302900014
PM 27525369
ER

PT J
AU Gordon-Lipkin, E
   Foster, J
   Peacock, G
AF Gordon-Lipkin, Eliza
   Foster, Jessica
   Peacock, Georgina
TI Whittling Down the Wait Time Exploring Models to Minimize the Delay from
   Initial Concern to Diagnosis and Treatment of Autism Spectrum Disorder
SO PEDIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Autism spectrum disorder; Diagnosis; Wait-list Children
ID DISABILITIES MONITORING NETWORK; YOUNG-CHILDREN; BEHAVIORAL
   INTERVENTION; OUTCOMES; PARENTS; IDENTIFICATION; TELEMEDICINE;
   PREVALENCE; INTERVIEW; WORKFORCE
AB The process from initial concerns to diagnosis of autism spectrum disorder (ASD) can be a long and complicated process. The traditional model for evaluation and diagnosis of ASD often consists of long wait-lists and evaluations that result in a 2-year difference between the earliest signs of ASD and mean age of diagnosis. Multiple factors contribute to this diagnostic bottleneck, including time-consuming evaluations, cost of care, lack of providers, and lack of comfort of primary care providers to diagnose autism. This article explores innovative clinical models that have been implemented to address this as well as future directions and opportunities.
C1 [Gordon-Lipkin, Eliza] Kennedy Krieger Inst, Dept Neurol & Dev Med, 716 North Broadway, Baltimore, MD 21205 USA.
   [Foster, Jessica] Akron Childrens Hosp, Sect Dev Pediat, Neuro Dev Sci Ctr, Considine Profess Bldg,215 West Bowery St, Akron, OH 44308 USA.
   [Peacock, Georgina] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Hwy MS-E88, Atlanta, GA 30329 USA.
RP Gordon-Lipkin, E (reprint author), Kennedy Krieger Inst, 716 North Broadway, Baltimore, MD 21205 USA.
EM lipkinE@kennedykrieger.org
NR 48
TC 0
Z9 0
U1 6
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0031-3955
EI 1557-8240
J9 PEDIATR CLIN N AM
JI Pediatr. Clin. N. Am.
PD OCT
PY 2016
VL 63
IS 5
BP 851
EP +
DI 10.1016/j.pcl.2016.06.007
PG 10
WC Pediatrics
SC Pediatrics
GA DX1WF
UT WOS:000384157000008
PM 27565363
ER

PT J
AU Civen, R
   Marin, M
   Zhang, J
   Abraham, A
   Harpaz, R
   Mascola, L
   Bialek, SR
AF Civen, Rachel
   Marin, Mona
   Zhang, John
   Abraham, Amanuel
   Harpaz, Rafael
   Mascola, Laurene
   Bialek, Stephanie R.
TI Update on Incidence of Herpes Zoster Among Children and Adolescents
   After Implementation of Varicella Vaccination, Antelope Valley, CA, 2000
   to 2010
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE herpes zoster; varicella vaccine; varicella-zoster virus; impact of
   varicella vaccination; herpes zoster incidence; active surveillance;
   race; ethnicity
ID UNITED-STATES; CLINICAL CHARACTERISTICS; EPIDEMIOLOGY; POPULATION;
   IMPACT; VIRUS
AB Background: Changes in herpes zoster (HZ) epidemiology are expected with childhood varicella vaccination. We reported previously that during 2000 to 2006 HZ incidence decreased 55% in children <10 years of age, while among 10- to 19-year olds it increased by 63%. We update the analysis with 4 additional years of data.
   Methods: Population-based active surveillance was conducted for HZ in Antelope Valley, California. Structured telephone interviews and medical chart reviews collected data on demographics, varicella vaccinations, disease histories and clinical information. We calculated HZ incidence for 2007 to 2010 and assessed trends since 2000.
   Results: Among children <10 years of age, HZ incidence continued the decreasing trend previously reported. During 2007 to 2010, the average incidence was 12.8 cases/100,000 children compared with 41.6 cases/100,000 children during 2000 to 2006, a 69% decline (P < 0.0001). For the 10- to 19-year olds, during 2007 to 2010 HZ incidence did not continue the increasing trend reported from 2000 to 2006; lower rates than in 2006 were observed in 3 of the 4 additional years evaluated. During 2007 to 2010 the average incidence was 78.2 cases/100,000 children compared with 68.0 cases/100,000 children during 2000 to 2006, a 13% increase (P = 0.123), with substantial fluctuation in annual rates throughout the 11 years of surveillance.
   Conclusions: During the mature varicella vaccination program, declines in HZ incidence among children <10 years of age continued through 2010. Among the 10- to 19-year olds, the increase reported through 2006 did not continue further and lower rates than in 2006 were observed through 2010. Widespread use of varicella vaccine could reduce HZ incidence among vaccinated populations. Ongoing monitoring of HZ incidence is needed to detect and understand changes in HZ epidemiology in the varicella vaccine era.
C1 [Civen, Rachel; Abraham, Amanuel; Mascola, Laurene] Los Angeles Cty Dept Publ Hlth, 313 N Figueroa St,Room 212, Los Angeles, CA 90011 USA.
   [Marin, Mona; Zhang, John; Harpaz, Rafael; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Civen, R (reprint author), Los Angeles Cty Dept Publ Hlth, 313 N Figueroa St,Room 212, Los Angeles, CA 90011 USA.
EM rciven@ph.lacounty.gov
NR 23
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2016
VL 35
IS 10
BP 1132
EP 1136
DI 10.1097/INF.0000000000001249
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DX1KG
UT WOS:000384125600013
PM 27622686
ER

PT J
AU Kittikraisak, W
   Suntarattiwong, P
   Ditsungnoen, D
   Klungthong, C
   Fernandez, S
   Yoon, IK
   Lindblade, K
   Dawood, FS
   Olsen, SJ
   Chotpitayasunondh, T
AF Kittikraisak, Wanitchaya
   Suntarattiwong, Piyarat
   Ditsungnoen, Darunee
   Klungthong, Chonticha
   Fernandez, Stefan
   Yoon, In-Kyu
   Lindblade, Kim
   Dawood, Fatimah S.
   Olsen, Sonja J.
   Chotpitayasunondh, Tawee
TI Effectiveness of the 2013 and 2014 Southern Hemisphere Influenza
   Vaccines Against Laboratory-confirmed Influenza in Young Children Using
   a Test-negative Design, Bangkok, Thailand
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE influenza; vaccination; effectiveness; Thailand; children
ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SEASONAL INFLUENZA;
   UNITED-STATES; VACCINATION; RECOMMENDATIONS; SURVEILLANCE; INFECTIONS;
   PREVENTION; COVERAGE
AB Background: The Thai Advisory Committee on Immunization Practices recommends annual influenza vaccination for children 6 months through 2 years of age, although older children may be vaccinated on request. We evaluated the effectiveness of the 2013 and 2014 inactivated influenza vaccines to reduce medically attended, laboratory-confirmed influenza illness among Thai children aged 7-60 months.
   Methods: From September 2013-May 2015, children with influenza-like illness were screened with a rapid influenza diagnostic test. Enrolled children had nasal and throat swabs tested for influenza viruses using polymerase chain reaction. Cases and controls were subjects testing positive and negative, respectively, for influenza viruses by polymerase chain reaction. Vaccination status was ascertained from vaccination cards. Vaccine effectiveness (VE) was calculated as 100% x (1 - odds ratio of vaccination among cases vs. controls).
   Results: Of the 1377 children enrolled, cases (n = 490) and controls (n = 887) were similar in demographic characteristics. Cases were less likely to receive influenza vaccine than controls in 2013 (6% vs. 14%; P = 0.02), but not in 2014 (6% vs. 7%; P = 0.57). Among cases, 126 (26%) were positive for influenza A(H1N1) pdm09 virus, 239 (49%) for influenza A(H3N2) and 124 (25%) for influenza B. One specimen was positive for both influenza A(H3N2) and B viruses. VE for full vaccination against all viruses was 64% (95% confidence interval: 21% to 84%) in 2013 and 26% (95% confidence interval: -47% to 63%) in 2014.
   Conclusions: Influenza vaccination was low among Thai children in this study, and VE varied by year, highlighting the need for annual monitoring of VE to better understand vaccine program effectiveness.
C1 [Kittikraisak, Wanitchaya; Ditsungnoen, Darunee; Lindblade, Kim] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Influenza Program, Nonthaburi, Thailand.
   [Suntarattiwong, Piyarat; Chotpitayasunondh, Tawee] Minist Publ Hlth, Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand.
   [Klungthong, Chonticha; Fernandez, Stefan] Armed Forces Res Inst Med Sci, Bangkok, Thailand.
   [Yoon, In-Kyu] Int Vaccine Inst, Seoul, South Korea.
   [Lindblade, Kim; Dawood, Fatimah S.; Olsen, Sonja J.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
RP Kittikraisak, W (reprint author), Minist Publ Hlth US Ctr Dis Control & Prevent Col, DDC Bldg 7,Tiwanon Rd, Nonthaburi 11000, Thailand.
EM glr9@cdc.gov
FU US Centers for Disease Control and Prevention [5U01GH000152]
FX Supported by US Centers for Disease Control and Prevention through
   cooperative agreement 5U01GH000152.
NR 39
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2016
VL 35
IS 10
BP E318
EP E325
DI 10.1097/INF.0000000000001280
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DX1KG
UT WOS:000384125600020
PM 27307102
ER

PT J
AU Hagan, JF
   Balachova, T
   Bertrand, J
   Chasnoff, I
   Dang, E
   Fernandez-Baca, D
   Kable, J
   Kosofsky, B
   Senturias, YN
   Singh, N
   Sloane, M
   Weitzman, C
   Zubler, J
AF Hagan, Joseph F., Jr.
   Balachova, Tatiana
   Bertrand, Jacquelyn
   Chasnoff, Ira
   Dang, Elizabeth
   Fernandez-Baca, Daniel
   Kable, Julie
   Kosofsky, Barry
   Senturias, Yasmin N.
   Singh, Natasha
   Sloane, Mark
   Weitzman, Carol
   Zubler, Jennifer
CA Neurobehav Disorder Associated Pre
   Amer Acad Pediat
TI Neurobehavioral Disorder Associated With Prenatal Alcohol Exposure
SO PEDIATRICS
LA English
DT Article
ID ATTENTION-DEFICIT-HYPERACTIVITY; FETAL ALCOHOL; SPECTRUM DISORDERS;
   DEFICIT/HYPERACTIVITY DISORDER; UNITED-STATES; BINGE DRINKING; CHILDREN;
   INTERVENTION; PREVALENCE; PREGNANCY
AB Children and adolescents affected by prenatal exposure to alcohol who have brain damage that is manifested in functional impairments of neurocognition, self-regulation, and adaptive functioning may most appropriately be diagnosed with neurobehavioral disorder associated with prenatal exposure. This Special Article outlines clinical implications and guidelines for pediatric medical home clinicians to identify, diagnose, and refer children regarding neurobehavioral disorder associated with prenatal exposure. Emphasis is given to reported or observable behaviors that can be identified as part of care in pediatric medical homes, differential diagnosis, and potential comorbidities. In addition, brief guidance is provided on the management of affected children in the pediatric medical home. Finally, suggestions are given for obtaining prenatal history of in utero exposure to alcohol for the pediatric patient.
C1 [Hagan, Joseph F., Jr.] Univ Vermont, Coll Med, Burlington, VT USA.
   [Balachova, Tatiana] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Bertrand, Jacquelyn; Dang, Elizabeth; Singh, Natasha; Zubler, Jennifer] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Chasnoff, Ira] Childrens Res Triangle, Chicago, IL USA.
   [Fernandez-Baca, Daniel] Univ Florida, Gainesville, FL USA.
   [Kable, Julie] Emory Univ, Atlanta, GA 30322 USA.
   [Kosofsky, Barry] Weill Cornell Med Coll, New York, NY USA.
   [Senturias, Yasmin N.] Univ N Carolina, Chapel Hill, NC USA.
   [Sloane, Mark] Western Michigan Univ, Portage, MI USA.
   [Weitzman, Carol] Yale Med Sch, New Haven, CT USA.
RP Hagan, JF (reprint author), 128 Lakeside Ave,Suite 115, Burlington, VT 05401 USA.
EM jhagan@aap.net
FU Centers for Disease Control and Prevention [5U58DD000587]
FX Supported by Cooperative Agreement 5U58DD000587, funded by the Centers
   for Disease Control and Prevention.
NR 94
TC 1
Z9 1
U1 5
U2 5
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD OCT
PY 2016
VL 138
IS 4
AR e20151553
DI 10.1542/peds.2015-1553
PG 17
WC Pediatrics
SC Pediatrics
GA DX3ZT
UT WOS:000384317700002
ER

PT J
AU Williams, DJ
   Zhu, YW
   Grijalva, CG
   Self, WH
   Harrell, FE
   Reed, C
   Stockmann, C
   Arnold, SR
   Ampofo, KK
   Anderson, EJ
   Bramley, AM
   Wunderink, RG
   McCullers, JA
   Pavia, AT
   Jain, S
   Edwards, KM
AF Williams, Derek J.
   Zhu, Yuwei
   Grijalva, Carlos G.
   Self, Wesley H.
   Harrell, Frank E., Jr.
   Reed, Carrie
   Stockmann, Chris
   Arnold, Sandra R.
   Ampofo, Krow K.
   Anderson, Evan J.
   Bramley, Anna M.
   Wunderink, Richard G.
   McCullers, Jonathan A.
   Pavia, Andrew T.
   Jain, Seema
   Edwards, Kathryn M.
TI Predicting Severe Pneumonia Outcomes in Children
SO PEDIATRICS
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; CLINICAL DECISION-SUPPORT; HOSPITAL
   ADMISSION DECISION; EMERGENCY-DEPARTMENT; UNITED-STATES; MANAGEMENT;
   INDEX; GUIDELINES; TRIAL; VARIABILITY
AB BACKGROUND: Substantial morbidity and excessive care variation are seen with pediatric pneumonia. Accurate risk-stratification tools to guide clinical decision-making are needed.
   METHODS: We developed risk models to predict severe pneumonia outcomes in children (<18 years) by using data from the Etiology of Pneumonia in the Community Study, a prospective study of community-acquired pneumonia hospitalizations conducted in 3 US cities from January 2010 to June 2012. In-hospital outcomes were organized into an ordinal severity scale encompassing severe (mechanical ventilation, shock, or death), moderate (intensive care admission only), and mild (non-intensive care hospitalization) outcomes. Twenty predictors, including patient, laboratory, and radiographic characteristics at presentation, were evaluated in 3 models: a full model included all 20 predictors, a reduced model included 10 predictors based on expert consensus, and an electronic health record (EHR) model included 9 predictors typically available as structured data within comprehensive EHRs. Ordinal regression was used for model development. Predictive accuracy was estimated by using discrimination (concordance index).
   RESULTS: Among the 2319 included children, 21% had a moderate or severe outcome (14% moderate, 7% severe). Each of the models accurately identified risk for moderate or severe pneumonia (concordance index across models 0.78-0.81). Age, vital signs, chest indrawing, and radiologic infiltrate pattern were the strongest predictors of severity. The reduced and EHR models retained most of the strongest predictors and performed as well as the full model.
   CONCLUSIONS: We created 3 risk models that accurately estimate risk for severe pneumonia in children. Their use holds the potential to improve care and outcomes.
C1 [Williams, Derek J.; Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   [Zhu, Yuwei; Harrell, Frank E., Jr.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA.
   [Grijalva, Carlos G.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA.
   [Self, Wesley H.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN USA.
   [Reed, Carrie; Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Stockmann, Chris; Ampofo, Krow K.; Pavia, Andrew T.] Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA.
   [Arnold, Sandra R.; McCullers, Jonathan A.] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA.
   [Anderson, Evan J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
   [Anderson, Evan J.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
   [Wunderink, Richard G.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.
RP Williams, DJ (reprint author), Vanderbilt Univ, Med Ctr, CCC 5324 Med Ctr North,1161 21st Ave S, Nashville, TN 37212 USA.
EM derek.williams@vanderbilt.edu
OI Wunderink, Richard/0000-0002-8527-4195
FU National Institutes of Health [K23AI104779, K23GM110469]; Agency for
   Healthcare Research and Quality [1R03HS022342]; CTSA award from the
   National Center for Advancing Translational Sciences [UL1TR000445,
   KL2TR000446]; Influenza Division in the National Center for
   Immunizations and Respiratory Diseases at the Centers for Disease
   Control and Prevention; National Institutes of Health (NIH)
FX Supported by the National Institutes of Health under award number
   K23AI104779 to Dr Williams and award number K23GM110469 to Dr Self; by
   the Agency for Healthcare Research and Quality under award number
   1R03HS022342 to Dr Grijalva; and by CTSA award numbers UL1TR000445 and
   KL2TR000446 from the National Center for Advancing Translational
   Sciences. The Etiology of Pneumonia in the Community Study was supported
   by the Influenza Division in the National Center for Immunizations and
   Respiratory Diseases at the Centers for Disease Control and Prevention
   through cooperative agreements with each study site and was based on a
   competitive research funding opportunity. The findings and conclusions
   in this report are those of the authors and do not necessarily represent
   the views of the National Institutes of Health, the Agency for
   Healthcare Research and Quality, or the Centers for Disease Control and
   Prevention. Funded by the National Institutes of Health (NIH).
NR 38
TC 1
Z9 1
U1 11
U2 11
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD OCT
PY 2016
VL 138
IS 4
AR e20161019
DI 10.1542/peds.2016-1019
PG 11
WC Pediatrics
SC Pediatrics
GA DX3ZT
UT WOS:000384317700033
ER

PT J
AU Massetti, GM
   Simon, TR
   Smith, DG
AF Massetti, Greta M.
   Simon, Thomas R.
   Smith, Deborah Gorman
TI Methodological and Design Considerations in Evaluating the Impact of
   Prevention Programs on Violence and Related Health Outcomes
SO PREVENTION SCIENCE
LA English
DT Article
DE Evaluation; Long-term effects; Prevention science
ID YOUTH VIOLENCE; SUBSTANCE INITIATION; RANDOMIZED-TRIAL; DRUG-ABUSE;
   BASE-LINE; RISK; INTERVENTION; FAMILY; DELINQUENCY; COMMUNITIES
AB Drawing on research that has identified specific predictors and trajectories of risk for violence and related negative outcomes, a multitude of small- and large-scale preventive interventions for specific risk behaviors have been developed, implemented, and evaluated. One of the principal challenges of these approaches is that a number of separate problem-specific programs targeting different risk areas have emerged. However, as many negative health behaviors such as substance abuse and violence share a multitude of risk factors, many programs target identical risk factors. There are opportunities to understand whether evidence-based programs can be leveraged for potential effects across a spectrum of outcomes and over time. Some recent work has documented longitudinal effects of evidence-based interventions on generalized outcomes. This work has potential for advancing our understanding of the effectiveness of promising and evidence-based prevention strategies. However, conducting longitudinal follow-up of established interventions presents a number of methodological and design challenges. To answer some of these questions, the Centers for Disease Control and Prevention convened a panel of multidisciplinary experts to discuss opportunities to take advantage of evaluations of early prevention programs and evaluating multiple long-term outcomes. This special section of the journal Prevention Science includes a series of papers that begin to address the relevant considerations for conducting longitudinal follow-up evaluation research. This collection of papers is intended to inform our understanding of the challenges and strategies for conducting longitudinal follow-up evaluation research that could be used to drive future research endeavors.
C1 [Massetti, Greta M.; Simon, Thomas R.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
   [Smith, Deborah Gorman] Univ Chicago, Chicago, IL 60637 USA.
   [Massetti, Greta M.] Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K76, Atlanta, GA 30341 USA.
RP Massetti, GM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.; Massetti, GM (reprint author), Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K76, Atlanta, GA 30341 USA.
EM gmassetti@cdc.gov
NR 30
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-4986
EI 1573-6695
J9 PREV SCI
JI Prev. Sci.
PD OCT
PY 2016
VL 17
IS 7
BP 779
EP 784
DI 10.1007/s11121-016-0704-x
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX4LG
UT WOS:000384352100001
PM 27543077
ER

PT J
AU Moore, LV
   Hamner, HC
   Kim, SA
   Dalenius, K
AF Moore, Latetia V.
   Hamner, Heather C.
   Kim, Sonia A.
   Dalenius, Karen
TI Common ways Americans are incorporating fruits and vegetables into their
   diet: intake patterns by meal, source and form, National Health and
   Nutrition Examination Survey 2007-2010
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Fruit; Vegetables; Recommended amounts; Dietary patterns
AB Objective: We explored how Americans aged >= 2 years who consumed the recommended amount of fruits and vegetables on a given day incorporated fruits and vegetables into their diet compared with those who did not consume recommended amounts.
   Design: We used 1 d of dietary recall data from the National Health and Nutrition Examination Survey (NHANES) 2007-2010 to examine cross-sectional differences in mean intakes of fruits and vegetables in cup-equivalents by meal, source and form between the two groups.
   Setting: USA.
   Subjects: NHANES 2007-2010 participants aged >= 2 years (n 17 571) with 1 d of reliable 24 h recall data.
   Results: On a given day, the proportions of fruits and vegetables consumed at different meals were similar between those who consumed recommended amounts and those who did not. Among adults, 59-64% of their intake of fruits was consumed at breakfast or as a snack and almost 90% came from retail outlets regardless of whether they consumed the recommended amount or not. Adults who consumed the recommended amount of fruits ate more fruits in raw form and with no additions than those who did not. Among children and adults, 52-57% of vegetables were consumed at dinner by both groups. Retail outlets were the main source of vegetables consumed (60-68 %).
   Conclusions: Our findings indicate that habits of when, where and how consumers eat fruits and vegetables might not need to change but increasing the amount consumed would help those not currently meeting the recommendation.
C1 [Moore, Latetia V.; Hamner, Heather C.; Kim, Sonia A.; Dalenius, Karen] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F77, Atlanta, GA 30341 USA.
RP Moore, LV (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F77, Atlanta, GA 30341 USA.
EM lvmoore@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 15
TC 0
Z9 0
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD OCT
PY 2016
VL 19
IS 14
BP 2535
EP 2539
DI 10.1017/S1368980016000586
PG 5
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA DX5IP
UT WOS:000384414900007
PM 27019390
ER

PT J
AU Raiford, JL
   Hall, GJ
   Taylor, RD
   Bimbi, DS
   Parsons, JT
AF Raiford, Jerris L.
   Hall, Grace J.
   Taylor, Raekiela D.
   Bimbi, David S.
   Parsons, Jeffrey T.
TI The Role of Structural Barriers in Risky Sexual Behavior, Victimization
   and Readiness to Change HIV/STI-Related Risk Behavior Among Transgender
   Women
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Transgender; Structural barriers; HIV; African American; Hispanic;
   Condom use
ID STRESS-RELATED GROWTH; TRANSMITTED INFECTIONS; HIV-RISK; CARE
   IMPLICATIONS; SOCIAL SUPPORT; INTERVENTION; PREVENTION; HEALTH; SCALE;
   YOUTH
AB This study examines the role of structural barriers experienced by a community-based sample of 63 HIV-positive and negative transgender women that may elevate HIV infection and transmission risks. Separate hierarchical linear multiple regression analyses tested the association between structural barriers (e.g., unemployment, lack of food, shelter) and condomless anal sex acts, abuse, and readiness to change risk behavior, while controlling for other related factors. Among this primarily Hispanic and African-American sample, HIV-positive and negative transgender women experienced a similar number of structural barriers and experiencing structural barriers was significantly associated with an increased number of condomless anal sex acts (p = .002), victimization (p = .000) and a decreased readiness to change HIV-related risk behavior (p = .014). Structural-level interventions are needed to address this elevated risk among this underserved and hard-to-reach population.
C1 [Raiford, Jerris L.; Hall, Grace J.; Taylor, Raekiela D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
   [Bimbi, David S.] CUNY, LaGuardia Community Coll, Queens, NY USA.
   [Bimbi, David S.; Parsons, Jeffrey T.] CUNY, Grad Ctr, New York, NY USA.
   [Bimbi, David S.; Parsons, Jeffrey T.] Ctr HIV Educ Studies & Training, New York, NY USA.
   [Parsons, Jeffrey T.] CUNY Hunter Coll, New York, NY 10021 USA.
RP Raiford, JL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
EM jraiford@cdc.gov
FU Centers for Disease Control and Prevention of the Department of Health
   and Human Services [UR6/PS000422]; Hunter College, City University of
   New York
FX This study was supported by the Centers for Disease Control and
   Prevention of the Department of Health and Human Services through a
   cooperative agreement (UR6/PS000422; Jeffrey T. Parsons, Principal
   Investigator) with Hunter College, City University of New York. The
   authors acknowledge Dr. Juline Koken, James Kelleher, Catherine Holder,
   Guido Sanchez, Joi-Elle White, Chris Hietikko, and Hudson Pride
   Connections for their contributions to the study, as well as all of the
   transgender women who participated in this project.
NR 38
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD OCT
PY 2016
VL 20
IS 10
BP 2212
EP 2221
DI 10.1007/s10461-016-1424-8
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DV7GG
UT WOS:000383103800006
PM 27167631
ER

PT J
AU Paz-Bailey, G
   Noble, M
   Salo, K
   Tregear, SJ
AF Paz-Bailey, Gabriela
   Noble, Meredith
   Salo, Kathryn
   Tregear, Stephen J.
TI Prevalence of HIV Among US Female Sex Workers: Systematic Review and
   Meta-analysis
SO AIDS AND BEHAVIOR
LA English
DT Review
DE Female sex workers; HIV; United States; Review
ID NEW-YORK-CITY; LOW-INCOME; RISK BEHAVIORS; DRUG-USERS; WOMEN;
   PREVENTION; INFECTION; HEALTH; SEROPOSITIVITY; STREETS
AB Although female sex workers are known to be vulnerable to HIV infection, little is known about the epidemiology of HIV infection among this high-risk population in the United States. We systematically identified and critically assessed published studies reporting HIV prevalence among female sex workers in the United States. We searched for and included original English-language articles reporting data on the prevalence of HIV as determined by testing at least 50 females who exchanged sexual practices for money or drugs. We did not apply any restrictions on date of publication. We included 14 studies from 1987 to 2013 that reported HIV prevalence for a total of 3975 adult female sex workers. Only two of the 14 studies were conducted in the last 10 years. The pooled estimate of HIV prevalence was 17.3 % (95 % CI 13.5-21.9 %); however, the prevalence of HIV across individual studies varied considerably (ranging from 0.3 to 32 %) and statistical heterogeneity was substantial (I-2 = 0.89, Q = 123; p < 0.001). Although the variance across the 14 studies was high, prevalence was generally high (10 % or greater in 11 of the 14 included studies). Very few studies have documented the prevalence of HIV among female sex workers in the United States; however, the available evidence does suggest that HIV prevalence among this vulnerable population is high.
C1 [Paz-Bailey, Gabriela; Salo, Kathryn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30329 USA.
   [Noble, Meredith] MANILA Consulting Grp, Mclean, VA 22101 USA.
   [Tregear, Stephen J.] Booz Allen Hamilton, Mclean, VA USA.
RP Paz-Bailey, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30329 USA.
EM gmb5@cdc.gov
FU Centers for Disease Control and Prevention
FX Funding was provided by the Centers for Disease Control and Prevention.
NR 49
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD OCT
PY 2016
VL 20
IS 10
BP 2318
EP 2331
DI 10.1007/s10461-016-1332-y
PG 14
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DV7GG
UT WOS:000383103800015
PM 26914165
ER

PT J
AU McKee, CD
   Hayman, DTS
   Kosoy, MY
   Webb, CT
AF McKee, Clifton D.
   Hayman, David T. S.
   Kosoy, Michael Y.
   Webb, Colleen T.
TI Phylogenetic and geographic patterns of bartonella host shifts among bat
   species
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Bartonella; Bats; Parasite diversification; Host-parasite relationships;
   Cophylogeny; Phylogeography
ID POPULATION-STRUCTURE; SPP.; PARASITE; RODENTS; FLIES; NYCTERIBIIDAE;
   COEVOLUTION; ADAPTATION; DIVERSITY; EVOLUTION
AB The influence of factors contributing to parasite diversity in individual hosts and communities are increasingly studied, but there has been less focus on the dominant processes leading to parasite diversification. Using bartonella infections in bats as a model system, we explored the influence of three processes that can contribute to bartonella diversification and lineage formation: (1) spatial correlation in the invasion and transmission of bartonella among bats (phylogeography); (2) divergent adaptation of bartonellae to bat hosts and arthropod vectors; and (3) evolutionary codivergence between bats and bartonellae. Using a combination of global fit techniques and ancestral state reconstruction, we found that codivergence appears to be the dominant process leading to diversification of bartonella in bats, with lineages of bartonellae corresponding to separate bat suborders, superfamilies, and families. Furthermore, we estimated the rates at which bartonellae shift bat hosts across taxonomic scales (suborders, superfamilies, and families) and found that transition rates decrease with increasing taxonomic distance, providing support for a mechanism that can contribute to the observed evolutionary congruence between bats and their associated bartonellae. While bartonella diversification is associated with host sympatry, the influence of this factor is minor compared to the influence of codivergence and there is a clear indication that some bartonella lineages span multiple regions, particularly between Africa and Southeast Asia. Divergent adaptation of bartonellae to bat hosts and arthropod vectors is apparent and can dilute the overall pattern of codivergence, however its importance in the formation of Bartonella lineages in bats is small relative to codivergence. We argue that exploring all three of these processes yields a more complete understanding of batbartonella relationships and the evolution of the genus Bartonella, generally. Application of these methods to other infectious bacteria and viruses could uncover common processes that lead to parasite diversification and the formation of host-parasite relationships. Published by Elsevier B.V.
C1 [McKee, Clifton D.; Webb, Colleen T.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.
   [McKee, Clifton D.; Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
   [Hayman, David T. S.] Massey Univ, Infect Dis Res Ctr, Mol Epidemiol & Publ Hlth Lab, Palmerston North 4442, New Zealand.
RP McKee, CD (reprint author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.; McKee, CD (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
EM clifton.mckee@colostate.edu
FU Wellcome Trust [086789/ZA/08/Z]; Research and Policy for Infectious
   Disease Dynamics (RAPIDD) program of the Science and Technology
   Directorate (US Department of Homeland Security); Fogarty International
   Center (NIH)
FX We would like to thank Chris Funk, Tony Schountz, and the members of the
   Webb and Kosoy labs for their guidance throughout this work. This
   project was partially supported by the Wellcome Trust (grant number
   086789/ZA/08/Z) and the Research and Policy for Infectious Disease
   Dynamics (RAPIDD) program of the Science and Technology Directorate (US
   Department of Homeland Security) and the Fogarty International Center
   (NIH).
NR 84
TC 5
Z9 5
U1 18
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD OCT
PY 2016
VL 44
BP 382
EP 394
DI 10.1016/j.meegid.2016.07.033
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA DW0ZA
UT WOS:000383371100053
PM 27473781
ER

PT J
AU Blake, RG
   Yoder, J
   Kou, J
AF Blake, Robert G.
   Yoder, Jonathan
   Kou, John
TI Updated Drinking Water Advisory Communication Toolkit
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
AB NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal.
   In these columns, EHSB and guest authors share insights and information about environmental health programs, trends, issues, and resources. The conclusions in this article are those of the author(s) and do not necessarily represent the views of CDC.
   Rob Blake is a health scientist at CDC's Division of Emergency and Environmental Health Services, and has been working in the environmental health field for more than 30 years. Jonathan Yoder is the acting branch chief of CDC's Waterborne Diseases Prevention Branch. John Kou is a student at Baylor University and was a student intern in CDC's Summer Undergraduate Program in Environmental Health during summer 2015.
C1 [Blake, Robert G.; Yoder, Jonathan] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Kou, John] Baylor Univ, Waco, TX 76798 USA.
RP Blake, RG (reprint author), Ctr Dis Control & Prevent, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA.
EM rgblake@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD OCT
PY 2016
VL 79
IS 3
BP 40
EP 41
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DW0FP
UT WOS:000383316600006
ER

PT J
AU Losch, J
AF Losch, Jena
TI Sharing Is Caring: Nurturing the Tracking Network Through Multilevel
   Partnerships
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
ID HEALTH
AB As part of our continuing effort to highlight innovative approaches and tools to improve the health and environment of communities, the Journal is pleased to publish a bimonthly column from the Centers for Disease Control and Prevention's (CDC's) Environmental Public Health Tracking Network (Tracking Network). The Tracking Network is a system of integrated health, exposure, and hazard information and data from a variety of national, state, and city sources. The Tracking Network brings together data concerning health and environmental problems with the goal of providing information to help improve where we live, work, and play.
   Environmental causes of chronic diseases are hard to identify. Measuring amounts of hazardous substances in our environment in a standard way, tracing the spread of these over time and area, seeing how they show up in human tissues, and understanding how they may cause illness is critical. The Tracking Network is a tool that can help connect these efforts. Through these columns, readers will learn about the program and the resources, tools, and information available from CDC's Tracking Network.
   The conclusions of this article are those of the author(s) and do not necessarily represent the views of CDC.
   Jena Losch is a health communication specialist in CDC's Environmental Health Tracking Branch.
C1 [Losch, Jena] Ctr Dis Control & Prevent, Environm Publ Hlth Tracking, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA.
RP Losch, J (reprint author), Ctr Dis Control & Prevent, Environm Publ Hlth Tracking, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA.
EM jlosch@cdc.gov
NR 4
TC 0
Z9 0
U1 2
U2 2
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD OCT
PY 2016
VL 79
IS 3
BP 42
EP 44
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DW0FP
UT WOS:000383316600007
ER

PT J
AU Harper, CR
   Liddon, N
   Dunville, R
   Habel, MA
AF Harper, Christopher R.
   Liddon, Nicole
   Dunville, Richard
   Habel, Melissa A.
TI High School Students' Self-Reported Use of School Clinics and Nurses
SO JOURNAL OF SCHOOL NURSING
LA English
DT Article
DE quantitative research; communicable diseases; chronic diseases; asthma;
   immunizations; health; wellness
ID HEALTH CENTERS; SERVICES; BEHAVIORS; ACCESS
AB Access to school health clinics and nurses has been linked with improved student achievement and health. Unfortunately, no studies have examined how many students report using school clinics or nurses and for which services. This study addressed this gap with data from a nationally representative sample of 15- to 25-year-olds. Respondents who reported being in high school were provided a list of services and asked whether they had gone to a school nurse or clinic for any of the listed services. Nearly 90% reported having access to a school clinic or nurse. Among students with access, 65.6% reported using at least one service. Non-White students and younger students were more likely to report having access to a clinic or nurse. These results show many students have access to clinics or nurses and are using these services, although not uniformly for all services.
C1 [Harper, Christopher R.; Liddon, Nicole; Dunville, Richard] Ctr Dis Control & Prevent, Div Adolescent, Atlanta, GA 30329 USA.
   [Harper, Christopher R.; Liddon, Nicole; Dunville, Richard] Ctr Dis Control & Prevent, Sch Hlth, Atlanta, GA 30329 USA.
   [Habel, Melissa A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA.
RP Harper, CR (reprint author), Ctr Dis Control & Prevent, Div Adolescent, Atlanta, GA 30329 USA.; Harper, CR (reprint author), Ctr Dis Control & Prevent, Sch Hlth, Atlanta, GA 30329 USA.
EM xgj4@cdc.gov
NR 14
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1059-8405
EI 1546-8364
J9 J SCH NURS
JI J. Sch. Nurs.
PD OCT
PY 2016
VL 32
IS 5
BP 324
EP 328
DI 10.1177/1059840516652454
PG 5
WC Nursing
SC Nursing
GA DV6HQ
UT WOS:000383034600004
PM 27302959
ER

PT J
AU Miller, GF
   Coffield, E
   Leroy, Z
   Wallin, R
AF Miller, Gabrielle F.
   Coffield, Edward
   Leroy, Zanie
   Wallin, Robin
TI Prevalence and Costs of Five Chronic Conditions in Children
SO JOURNAL OF SCHOOL NURSING
LA English
DT Article
DE chronic diseases; diabetes; epilepsy; hypertension; food allergies;
   asthma
ID HEALTH-CARE UTILIZATION; SCHOOL-AGED CHILDREN; UNITED-STATES;
   RISK-FACTORS; NATIONAL PROFILE; CASE-MANAGEMENT; FOOD ALLERGY; ASTHMA;
   HYPERTENSION; OUTCOMES
AB The objective is to examine the prevalence and health-care costs associated with asthma, epilepsy, hypertension, food allergies, and diabetes in children aged 0-18 years. Prevalence was calculated using 2005-2012 Medical Expenditure Panel Survey (MEPS) data, a population-based, nationally representative sample. Using MEPS, two-part models estimated the cost of each condition for all children while controlling for sociodemographic categories. Prevalence rates varied by race and ethnicity across conditions. Females had higher prevalence of all chronic conditions, except epilepsy. An additional US$1,377.60-US$9,059.49 annually were spent on medical expenses for children aged 0-18 years, with asthma, diabetes, or epilepsy compared to children without these conditions. This is the first study to examine the costs and prevalence of chronic health conditions in children and adolescents using a single data set. Understanding the odds of having a condition by sociodemographic categories highlights disparities that can potentially inform school nurses on the best allocation of resources to serve students.
C1 [Miller, Gabrielle F.; Leroy, Zanie] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
   [Coffield, Edward] Hofstra Univ, Dept Hlth Profess, Hempstead, NY 11550 USA.
   [Wallin, Robin] Pkwy Sch, Chesterfield, MO USA.
RP Miller, GF (reprint author), Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-64, Atlanta, GA 30341 USA.
EM gferro@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 41
TC 1
Z9 1
U1 9
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1059-8405
EI 1546-8364
J9 J SCH NURS
JI J. Sch. Nurs.
PD OCT
PY 2016
VL 32
IS 5
BP 357
EP 364
DI 10.1177/1059840516641190
PG 8
WC Nursing
SC Nursing
GA DV6HQ
UT WOS:000383034600008
PM 27044668
ER

PT J
AU Zhou, B
   Meliopoulos, VA
   Wang, W
   Lin, XD
   Stucker, KM
   Halpin, RA
   Stockwell, TB
   Schultz-Cherry, S
   Wentworth, DE
AF Zhou, Bin
   Meliopoulos, Victoria A.
   Wang, Wei
   Lin, Xudong
   Stucker, Karla M.
   Halpin, Rebecca A.
   Stockwell, Timothy B.
   Schultz-Cherry, Stacey
   Wentworth, David E.
TI Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a
   Pathogenic Virus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TEMPERATURE-SENSITIVE PHENOTYPE; A VIRUS; REASSORTANT VIRUS;
   YOUNG-CHILDREN; GENETIC STABILITY; A/ANN ARBOR/6/60; WILD-TYPE; RELATIVE
   EFFICACY; IMMUNE-RESPONSE; CELL RESPONSES
AB The only licensed live attenuated influenza A virus vaccines (LAIVs) in the United States (FluMist) are created using internal protein-coding gene segments from the cold-adapted temperature-sensitive master donor virus A/Ann Arbor/6/1960 and HA/NA gene segments from circulating viruses. During serial passage of A/Ann Arbor/6/1960 at low temperatures to select the desired attenuating phenotypes, multiple cold-adaptive mutations and temperature-sensitive mutations arose. A substantial amount of scientific and clinical evidence has proven that FluMist is safe and effective. Nevertheless, no study has been conducted specifically to determine if the attenuating temperature-sensitive phenotype can revert and, if so, the types of substitutions that will emerge (i.e., compensatory substitutions versus reversion of existing attenuating mutations). Serial passage of the monovalent FluMist 2009 H1N1 pandemic vaccine at increasing temperatures in vitro generated a variant that replicated efficiently at higher temperatures. Sequencing of the variant identified seven nonsynonymous mutations, PB1-E51K, PB1-I171V, PA-N350K, PA-L366I, NP-N125Y, NP-V186I, and NS2-G63E. None occurred at positions previously reported to affect the temperature sensitivity of influenza A viruses. Synthetic genomics technology was used to synthesize the whole genome of the virus, and the roles of individual mutations were characterized by assessing their effects on RNA polymerase activity and virus replication kinetics at various temperatures. The revertant also regained virulence and caused significant disease in mice, with severity comparable to that caused by a wild-type 2009 H1N1 pandemic virus.
   IMPORTANCE
   The live attenuated influenza vaccine FluMist has been proven safe and effective and is widely used in the United States. The phenotype and genotype of the vaccine virus are believed to be very stable, and mutants that cause disease in animals or humans have never been reported. By propagating the virus under well-controlled laboratory conditions, we found that the FluMist vaccine backbone could regain virulence to cause severe disease in mice. The identification of the responsible substitutions and elucidation of the underlying mechanisms provide unique insights into the attenuation of influenza virus, which is important to basic research on vaccines, attenuation reversion, and replication. In addition, this study suggests that the safety of LAIVs should be closely monitored after mass vaccination and that novel strategies to continue to improve LAIV vaccine safety should be investigated.
C1 [Zhou, Bin; Wang, Wei; Lin, Xudong; Stucker, Karla M.; Halpin, Rebecca A.; Stockwell, Timothy B.; Wentworth, David E.] J Craig Venter Inst, Virol, Rockville, MD 20850 USA.
   [Meliopoulos, Victoria A.; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Zhou, Bin] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA.
   [Wentworth, David E.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA.
RP Zhou, B; Wentworth, DE (reprint author), J Craig Venter Inst, Virol, Rockville, MD 20850 USA.; Zhou, B (reprint author), NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA.; Wentworth, DE (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA.
EM bin.zhou@nyu.edu; dwentworth@cdc.gov
FU J. Craig Venter Institute; American Lebanese Syrian Associated Charities
   (ALSAC); HHS | NIH | National Institute of Allergy and Infectious
   Diseases (NIAID) [HHSN272201400006C]
FX This work, including the efforts of David E. Wentworth, was funded by J.
   Craig Venter Institute. This work, including the efforts of Stacey
   Schultz-Cherry, was funded by American Lebanese Syrian Associated
   Charities (ALSAC). This work, including the efforts of Stacey
   Schultz-Cherry, was funded by HHS | NIH | National Institute of Allergy
   and Infectious Diseases (NIAID) (HHSN272201400006C).
NR 55
TC 2
Z9 2
U1 7
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD OCT
PY 2016
VL 90
IS 19
BP 8454
EP 8463
DI 10.1128/JVI.00163-16
PG 10
WC Virology
SC Virology
GA DW6LH
UT WOS:000383761900007
PM 27440882
ER

PT J
AU McMillen, CM
   Beezhold, DH
   Blachere, FM
   Othumpangat, S
   Kashon, ML
   Noti, JD
AF McMillen, Cynthia M.
   Beezhold, Donald H.
   Blachere, Francoise M.
   Othumpangat, Sreekumar
   Kashon, Michael L.
   Noti, John D.
TI Inhibition of influenza A virus matrix and nonstructural gene expression
   using RNA interference
SO VIROLOGY
LA English
DT Article
DE Small interfering RNA (siRNA); Antivirals; Influenza virus; RNA
   interference (RNAi); Gene expression; Matrix protein 1 (M1); Matrix
   protein 2 (M2); Nonstructural protein 1 (NS1); Nonstructural protein 2
   (NS2)
ID NUCLEAR EXPORT; UNITED-STATES; STRANDED-RNA; PROTEIN; INFECTION;
   AMANTADINE; SIRNA; REPLICATION; RIMANTADINE; RESPONSES
AB Influenza antiviral drugs that use protein inhibitors can lose their efficacy as resistant strains emerge. As an alternative strategy, we investigated the use of small interfering RNA molecules (siRNAs) by characterizing three siRNAs (M747, M776 and M832) targeting the influenza matrix 2 gene and three (NS570, NS595 and NS615) targeting the nonstructural protein 1 and 2 genes. We also re-examined two previously reported siRNAs, M331 and M950, which target the matrix 1 and 2 genes. Treatment with M331-, M776-, M832-, and M950-siRNAs attenuated influenza titer. M776-siRNA treated cells had 29.8% less infectious virus than cells treated with the previously characterized siRNA, M950. NS570-, NS595- and NS615-siRNAs reduced nonstructural protein 1 and 2 expression and enhanced type I interferon expression by 50%. Combination siRNA treatment attenuated 20.9% more infectious virus than single siRNA treatment. Our results suggest a potential use for these siRNAs as an effective anti-influenza virus therapy. Published by Elsevier Inc.
C1 [McMillen, Cynthia M.; Beezhold, Donald H.; Blachere, Francoise M.; Othumpangat, Sreekumar; Kashon, Michael L.; Noti, John D.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S 4020, Morgantown, WV 26505 USA.
   [McMillen, Cynthia M.; Beezhold, Donald H.; Noti, John D.] West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA.
RP Noti, JD (reprint author), NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S 4020, Morgantown, WV 26505 USA.
EM jnoti@cdc.gov
NR 39
TC 1
Z9 1
U1 7
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD OCT
PY 2016
VL 497
BP 171
EP 184
DI 10.1016/j.virol.2016.07.019
PG 14
WC Virology
SC Virology
GA DW8RC
UT WOS:000383922200018
PM 27474950
ER

PT J
AU Blumberg, SJ
   Zablotsky, B
   Avila, RM
   Colpe, LJ
   Pringle, BA
   Kogan, MD
AF Blumberg, Stephen J.
   Zablotsky, Benjamin
   Avila, Rosa M.
   Colpe, Lisa J.
   Pringle, Beverly A.
   Kogan, Michael D.
TI Diagnosis lost: Differences between children who had and who currently
   have an autism spectrum disorder diagnosis
SO AUTISM
LA English
DT Article
DE autism spectrum disorder; diagnosis; epidemiology; national surveys
ID DOUBLY ROBUST ESTIMATION; CAUSAL INFERENCE; FOLLOW-UP; STABILITY;
   HISTORY; IDENTIFICATION; INTERVENTION; ADOLESCENTS; PREVALENCE; SYMPTOMS
AB Autism spectrum disorder diagnoses sometimes change due to misdiagnosis, maturation, or treatment. This study uses a probability-based national surveythe Survey of Pathways to Diagnosis and Servicesto compare currently diagnosed (n=1420) and previously diagnosed (n=187) children aged 6-17years based on retrospective parental reports of early concerns about their children's development, responses to those concerns by doctors and other healthcare providers, the type of provider who made the first autism spectrum disorder diagnosis, and the autism spectrum disorder subtype diagnoses received (if any). Propensity score matching was used to control for differences between the groups on children's current level of functioning and other current characteristics that may have been related to diagnosis loss. Approximately 13% of the children ever diagnosed with autism spectrum disorder were estimated to have lost the diagnosis, and parents of 74% of them believed it was changed due to new information. Previously diagnosed children were less likely to have parents with early concerns about verbal skills, nonverbal communication, learning, and unusual gestures or movements. They were also less likely to have been referred to and diagnosed by a specialist. Previously diagnosed children were less likely to have ever received a diagnosis of Asperger's disorder or autistic disorder.
C1 [Blumberg, Stephen J.; Zablotsky, Benjamin] Ctr Dis Control & Prevent, Hyattsville, MD USA.
   [Avila, Rosa M.] Univ Washington, Seattle, WA 98195 USA.
   [Colpe, Lisa J.; Pringle, Beverly A.] NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Kogan, Michael D.] Hlth Resources & Serv Adm, Rockville, MD USA.
RP Blumberg, SJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
EM sblumberg@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 49
TC 0
Z9 0
U1 18
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1362-3613
EI 1461-7005
J9 AUTISM
JI Autism
PD OCT
PY 2016
VL 20
IS 7
BP 783
EP 795
DI 10.1177/1362361315607724
PG 13
WC Psychology, Developmental
SC Psychology
GA DV5JQ
UT WOS:000382963700002
PM 26489772
ER

PT J
AU Johnson, MG
   Brown, S
   Archer, P
   Wendelboe, A
   Magzamen, S
   Bradley, KK
AF Johnson, Matthew G.
   Brown, Sheryll
   Archer, Pam
   Wendelboe, Aaron
   Magzamen, Sheryl
   Bradley, Kristy K.
TI Identifying heat-related deaths by using medical examiner and vital
   statistics data: Surveillance analysis and descriptive epidemiology
   Oklahoma, 1990-2011
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Heat; Mortality; Vital statistics; Medical examiner; Oklahoma
ID HIGH AMBIENT-TEMPERATURE; UNITED-STATES; CLIMATE-CHANGE; HUMAN HEALTH;
   MORTALITY; WAVE; DISEASE; CHICAGO; TRENDS; IMPACT
AB Objectives: Approximately 660 deaths occur annually in the United States associated with excess natural heat. A record heat wave in Oklahoma during 2011 generated increased interest concerning heat-related mortality among public health preparedness partners. We aimed to improve surveillance for heat-related mortality and better characterize heat-related deaths in Oklahoma during 1990-2011, and to enhance public health messaging during future heat emergencies.
   Methods: Heat-related deaths were identified by querying vital statistics (VS) and medical examiner (ME) data during 1990-2011. Case inclusion criteria were developed by using heat-related International Classification of Diseases codes, cause-of-death nomenclature, and ME investigation narrative. We calculated sensitivity and predictive value positive (PVP) for heat-related mortality surveillance by using VS and ME data and performed a descriptive analysis.
   Results: During the study period, 364 confirmed and probable heat-related deaths were identified when utilizing both data sets. ME reports had 87% sensitivity and 74% PVP; VS reports had 80% sensitivity and 52% PVP. Compared to Oklahoma's general population, decedents were disproportionately male (67% vs. 49%), aged >= 65 years (46% vs. 14%), and unmarried (78% vs. 47%). Higher rates of heat-related mortality were observed among Blacks. Of 95 decedents with available information, 91 (96%) did not use air conditioning.
   Conclusions: Linking ME and VS data sources together and using narrative description for case classification allows for improved case ascertainment and surveillance data quality. Males, Blacks, persons aged 65 years, unmarried persons, and those without air conditioning carry a disproportionate burden of the heat-related deaths in Oklahoma. Published by Elsevier Inc.
C1 [Johnson, Matthew G.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Johnson, Matthew G.] Oklahoma Dept Hlth, Acute Dis Serv, Oklahoma City, OK 73117 USA.
   [Brown, Sheryll; Archer, Pam] Oklahoma Dept Hlth, Injury Prevent Serv, Oklahoma City, OK 73117 USA.
   [Wendelboe, Aaron; Magzamen, Sheryl] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73104 USA.
   [Magzamen, Sheryl] Colorado State Univ, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA.
   [Bradley, Kristy K.] Oklahoma Dept Hlth, Off State Epidemiologist, Oklahoma City, OK 73117 USA.
RP Johnson, MG (reprint author), Duke Univ, Med Ctr, DUMC 102539,315 Trent Dr, Durham, NC 27710 USA.
EM mgjohnson33@gmail.com
NR 46
TC 0
Z9 0
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD OCT
PY 2016
VL 150
BP 30
EP 37
DI 10.1016/j.envres.2016.05.035
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DV4NU
UT WOS:000382903100005
PM 27236569
ER

PT J
AU Shoaff, JR
   Romano, ME
   Yolton, K
   Lanphear, BP
   Calafat, AM
   Braun, JM
AF Shoaff, Jessica R.
   Romano, Megan E.
   Yolton, Kimberly
   Lanphear, Bruce P.
   Calafat, Antonia M.
   Braun, Joseph M.
TI Prenatal phthalate exposure and infant size at birth and gestational
   duration
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Phthalate; Endocrine disrupting chemicals; Prenatal; Exposure; Birth
   outcomes
ID TANDEM MASS-SPECTROMETRY; BIS(2-ETHYLHEXYL) PHTHALATE; BISPHENOL-A;
   CHILDHOOD BEHAVIOR; CAUSAL-DIAGRAMS; SERUM COTININE; PRETERM BIRTH;
   PREGNANCY; URINARY; TOXICITY
AB Background: Phthalate exposure is widespread. Prior research suggests that prenatal phthalate exposure may influence birth size and gestational duration, but published results have been inconsistent. Objective: We quantified the relationship between maternal urinary phthalate concentrations and infant birth weight z-scores, length, head circumference, and gestational duration.
   Methods: In a cohort of 368 women from the HOME Study, based in Cincinnati, OH, we measured nine phthalate metabolites representing exposure to six parent phthalate diesters in urine collected at approximately 16 and 26 weeks gestation. Infant birth size and gestational duration were abstracted from medical records. We used multivariable linear regression to estimate covariate adjusted associations between urinary phthalate metabolite concentrations and infant outcomes.
   Results: In unadjusted models, we observed a negative association between monoethyl phthalate (MEP) and birth weight z-scores, while mono-3-carboxypropyl phthalate (MCPP) was positively associated with gestational duration. After covariate adjustment, phthalate metabolite concentrations were no longer associated with birth size or gestational duration.
   Conclusions: In this cohort, urinary phthalate metabolite concentrations during pregnancy were not associated with infant birth size or gestational duration. Additional research is needed to determine if exposures during earlier periods of fetal development are associated with infant health. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Shoaff, Jessica R.; Romano, Megan E.; Braun, Joseph M.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA.
   [Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.
   [Lanphear, Bruce P.] Simon Fraser Univ, Fac Hlth & Sci, Burnaby, BC V5A 1S6, Canada.
   [Lanphear, Bruce P.] BC Childrens & Womens Hosp, Child & Family Res Inst, Vancouver, BC, Canada.
   [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA.
RP Braun, JM (reprint author), Brown Univ, Sch Publ Hlth, Box G-S121-2, Providence, RI 02912 USA.
EM joseph_braun_l@brown.edu
RI Braun, Joseph/H-8649-2014
FU NIEHS, United States [R00 ES020346, R01 ES 024381, P01 ES11261, R01
   ES014575, R01 ES020349]
FX This work was supported by NIEHS, United States, Grants R00 ES020346,
   R01 ES 024381, P01 ES11261, R01 ES014575, and R01 ES020349. We
   acknowledge the technical assistance of M. Silva, E. Samandar, J. Preau,
   and J. Tao (Centers for Disease Control and Prevention, Atlanta, GA) in
   measuring the urinary concentrations of phthalate metabolites.
NR 43
TC 1
Z9 1
U1 7
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD OCT
PY 2016
VL 150
BP 52
EP 58
DI 10.1016/j.envres.2016.05.033
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DV4NU
UT WOS:000382903100008
PM 27236572
ER

PT J
AU Scinicariello, F
   Buser, MC
AF Scinicariello, Franco
   Buser, Melanie C.
TI Urinary antimony and leukocyte telomere length: An analysis of NHANES
   1999-2002
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Antimony; Leukocyte telomere length; NHANES; Heavy metals; Aging
ID TRIOXIDE-INDUCED APOPTOSIS; OXIDATIVE STRESS; CELLS; LEISHMANIASIS;
   TOXICITY; DISEASE; RESISTANCE; SYSTEM; DEATH
AB Telomeres are repetitive DNA sequences (TTAGGG) at the end of chromosomes. Cells with critically short telomeres enter replicative senescence and apoptosis. Several in vitro studies report that antimony causes cell apoptosis in human leukocyte cell lines. The goal of this analysis was to investigate whether there is an association between antimony exposure and leukocyte telomere length (LTL) among US adults aged 20 and older based on the National Health and Nutrition Examination Survey (NHANES) 1999-2002. We used multivariate linear regression to analyze the association of urinary antimony with LTL. LTL was log natural transformed and the results were re-transformed and presented as percent differences. After adjustment for potential confounders, individuals in the 3rd and 4th quartiles of urinary antimony had statistically significantly shorter LTL (-4.78%, 95% CI: -8.42,-0.90; and -6.11%, 95% CI: -11.04,-1.00, respectively) compared to the lowest referent quartile, with evidence of a dose-response relationship (p-value for trend =0.03). Shorter LTL with antimony was driven by middle aged (40-59 years) and older (60-85 years) adult groups. The association may be biologically plausible because of reported oxidative stress and apoptosis effects of antimony on blood cells, effects known to shorten telomere length. Published by Elsevier Inc.
C1 [Scinicariello, Franco; Buser, Melanie C.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA.
RP Scinicariello, F (reprint author), Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,MS F57, Atlanta, GA 30341 USA.
EM fes6@cdc.gov
NR 39
TC 0
Z9 0
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD OCT
PY 2016
VL 150
BP 513
EP 518
DI 10.1016/j.envres.2016.06.044
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DV4NU
UT WOS:000382903100061
PM 27423705
ER

PT J
AU Purpura, LJ
   Choi, MJ
   Rollin, PE
AF Purpura, Lawrence J.
   Choi, Mary J.
   Rollin, Pierre E.
TI Zika virus in semen: lessons from Ebola
SO LANCET INFECTIOUS DISEASES
LA English
DT Letter
C1 [Purpura, Lawrence J.; Choi, Mary J.; Rollin, Pierre E.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
RP Purpura, LJ (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM yxp0@cdc.gov
NR 7
TC 0
Z9 0
U1 17
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD OCT
PY 2016
VL 16
IS 10
BP 1107
EP 1108
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DW2JP
UT WOS:000383469000021
PM 27676341
ER

PT J
AU Otieno, L
   Oneko, M
   Otieno, W
   Abuodha, J
   Owino, E
   Odero, C
   Mendoza, YG
   Andagalu, B
   Awino, N
   Ivinson, K
   Heerwegh, D
   Otsyula, N
   Oziemkowska, M
   Usuf, EA
   Otieno, A
   Otieno, K
   Leboulleux, D
   Leach, A
   Oyieko, J
   Slutsker, L
   Lievens, M
   Cowden, J
   Lapierre, D
   Kariuki, S
   Ogutu, B
   Vekemans, J
   Hamel, MJ
AF Otieno, Lucas
   Oneko, Martina
   Otieno, Walter
   Abuodha, Joseph
   Owino, Emmanuel
   Odero, Chris
   Mendoza, Yolanda Guerra
   Andagalu, Ben
   Awino, Norbert
   Ivinson, Karen
   Heerwegh, Dirk
   Otsyula, Nekoye
   Oziemkowska, Maria
   Usuf, Effua Abigail
   Otieno, Allan
   Otieno, Kephas
   Leboulleux, Didier
   Leach, Amanda
   Oyieko, Janet
   Slutsker, Laurence
   Lievens, Marc
   Cowden, Jessica
   Lapierre, Didier
   Kariuki, Simon
   Ogutu, Bernhards
   Vekemans, Johan
   Hamel, Mary J.
TI Safety and immunogenicity of RTS, S/AS01 malaria vaccine in infants and
   children with WHO stage 1 or 2 HIV disease: a randomised, double-blind,
   controlled trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VACCINATION; CIRCUMSPOROZOITE
   PROTEIN; INFLUENZA VACCINATION; CANDIDATE VACCINE; IMMUNIZATION; AFRICA
AB Background Malaria remains a major global public health concern, especially in sub-Saharan Africa. The RTS, S/AS01 malaria candidate vaccine was reviewed by the European Medicines Agency and received a positive scientific opinion; WHO subsequently recommended pilot implementation in sub-Saharan African countries. Because malaria and HIV overlap geographically, HIV-infected children should be considered for RTS, S/AS01 vaccination. We therefore aimed to assess the safety of RTS, S/AS01 in HIV-infected children at two sites in western Kenya.
   Methods We did a randomised, double-blind, controlled trial at the clinical trial sites of the Kenya Medical Research Institute (KEMRI)-Walter Reed Army Institute of research in Kisumu and the KEMRI/US Centers for Disease Control and Prevention in Siaya. Eligible participants were infants and children aged from 6 weeks to 17 months with WHO stage 1 or 2 HIV disease (documented positive by DNA PCR), whether or not they were receiving antiretroviral therapy (ART). We randomly assigned participants (1: 1) to receive three doses of either RTS, S/AS01 or rabies vaccine (both 0.5 mL per dose by intramuscular injection), given once per month at 0, 1, and 2 months. We did the treatment allocation using a web-based central randomisation system stratified by age (6 weeks-4 months, 5-17 months), and by baseline CD4% (< 10, 10-14, 15-19, and >= 20). Data were obtained in an observer-blind manner, and the vaccine recipient, their parent or carer, the funder, and investigators responsible for the assessment of endpoints were all masked to treatment allocation (only staff responsible for the preparation and administration of the vaccines were aware of the assignment and these individuals played no other role in the study). We provided ART, even if the participants were not receiving ART before the study, and daily co-trimoxazole for prevention of opportunistic infections. The primary outcome was the occurrence of serious adverse events until 14 months after dose 1 of the vaccine, assessed in the intention-to-treat population. This trial was registered at ClinicalTrials.gov, number NCT01148459.
   Findings Between July 30, 2010, and May 24, 2013, we enrolled 200 children to our study and randomly assigned 99 to receive RTS, S/AS01 and 101 to receive rabies vaccine. 177 (89%) of the 200 children enrolled completed 14 months of follow-up. Serious adverse events were noted in 41 (41.4%, 95% CI 31.6-51.8) of 99 RTS, S/AS01 recipients and 37 (36.6%, 27.3-46.8) of 101 rabies-vaccine recipients (relative risk 1.1, 95% CI 0.8-1.6). 20 (20.2%, 95% CI 12.8-29.5) of 99 RTS, S/AS01 recipients and 12 (11.9%, 6.3-19.8) of 101 rabies-vaccine recipients had at least one serious adverse event within 30 days after vaccination, mainly pneumonia, febrile convulsions, and salmonella sepsis. Five (5.1%, 95% CI 1.7-11.4) of 99 RTS, S/AS01 recipients and four (4.0%, 1.1-9.8) of 101 rabies-vaccine recipients died, but no deaths were deemed related to vaccination. Mortality was associated with five cases of pneumonia (1% RTS, S/AS01 recipients vs 3% rabies-vaccine recipients), five cases of gastroenteritis (3% RTS, S/AS01 recipients vs 2% rabies-vaccine recipients), five cases of malnutrition (2% RTS, S/AS01 recipients vs 3% rabies-vaccine recipients), one case of sepsis (1% rabies-vaccine recipients), one case of Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case of tuberculosis (1% RTS, S/AS01 recipients).
   Interpretation RTS, S/AS01 was well tolerated when given to children with WHO clinical stage 1 or 2 HIV disease along with high antiretroviral and co-trimoxazole use. Children with HIV disease could be included in future RTS, S/AS01 vaccination programmes.
C1 [Otieno, Lucas; Otieno, Walter; Owino, Emmanuel; Andagalu, Ben; Otsyula, Nekoye; Otieno, Allan; Oyieko, Janet; Cowden, Jessica; Ogutu, Bernhards] Kenya Med Res Inst KEMRI Walter Reed Project, Kombewa, Kenya.
   [Oneko, Martina; Abuodha, Joseph; Odero, Chris; Awino, Norbert; Oziemkowska, Maria; Otieno, Kephas; Kariuki, Simon] KEMRI Ctr Dis Control & Prevent Res & Publ Hlth C, Kisumu, Kenya.
   [Slutsker, Laurence; Hamel, Mary J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA.
   [Mendoza, Yolanda Guerra; Heerwegh, Dirk; Usuf, Effua Abigail; Leach, Amanda; Lievens, Marc; Lapierre, Didier; Vekemans, Johan] GlaxoSmithKline Vaccines, Wavre, Belgium.
   [Ivinson, Karen; Leboulleux, Didier] PATH Malaria Vaccine Initiat, Washington, DC USA.
RP Otieno, L (reprint author), KEMRI Walter Reed Project, Kisumu 40100, Kenya.
EM Lucas.Tina@usamru-k.org
FU GlaxoSmithKline (GSK) Biologicals SA; PATH Malaria Vaccine Initiative
FX The trial was sponsored by GlaxoSmithKline (GSK) Biologicals SA and was
   funded by both GlaxoSmithKline Biologicals SA and the PATH Malaria
   Vaccine Initiative. GlaxoSmithKline Biologicals SA developed and
   manufactured the vaccine. We thank the following: the children and their
   families and communities who generously participated in this trial, the
   study team members at each site, staff of the health facilities in the
   study areas and the Jaramogi Oginga Odinga Teaching and Referral
   Hospital, Kisumu, Kenya, and the national and local government
   authorities for their guidance and support for the implementation of the
   trial; from KEMRI/CDC Research and Public Health Collaboration, Kisumu,
   Kenya: Jael Asewe, Grace Chumbe, Patrick Kachur, Vincent Muturi-Kioi,
   Christina Obiero, Brian Obunga, Cecilia Ochieng, John Vulule, the Kenyan
   Ministry of Health, the MOH staff at Siaya District Hospital, Ting
   Wang'i and Kogelo Health Centres, Ngiya Mission Hospital, the Siaya
   District Health Management Team, and the children and parents in Siaya;
   from the KEMRI Walter Reed Project, Kisumu, Kenya: Barrack Agutu,
   Consolata Appida, Carolyne Laboso, Irene Miruka, Jacob Nyariro, Dorothy
   Odera, George Odongo, Mary Omondi, Caroline Ongoro, Agnes Onyango,
   Lilian Otieno, Victorine Owira, Ruth Wasuna; and from GSK Vaccines,
   Belgium: Xavier Druart, Elodie Garric, Ioana Cristina Ilea, Sarah
   Liegeois, Thomas Moens, and Myriam Wilbaux (XPE Pharma and Science on
   behalf of GSK Vaccines) for editorial support and publication
   coordination. The opinions and assertions herein are the views of the
   authors and not those of KEMRI, the US Department of Defense, US Centers
   for Disease Control and Prevention, or the US Government.
NR 29
TC 2
Z9 2
U1 16
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD OCT
PY 2016
VL 16
IS 10
BP 1134
EP 1144
DI 10.1016/S1473-3099(16)30161-X
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA DW2JP
UT WOS:000383469000036
PM 27394191
ER

PT J
AU Fitchett, EJA
   Seale, AC
   Vergnano, S
   Sharland, M
   Heath, PT
   Saha, SK
   Agarwal, R
   Ayede, AI
   Bhutta, ZA
   Black, R
   Bojang, K
   Campbell, H
   Cousens, S
   Darmstadt, GL
   Madhi, SA
   Sobanjo-ter Meulen, A
   Modi, N
   Patterson, J
   Qazi, S
   Schrag, SJ
   Stoll, BJ
   Wall, SN
   Wammanda, RD
   Lawn, JE
AF Fitchett, Elizabeth J. A.
   Seale, Anna C.
   Vergnano, Stefania
   Sharland, Michael
   Heath, Paul T.
   Saha, Samir K.
   Agarwal, Ramesh
   Ayede, Adejumoke I.
   Bhutta, Zulfiqar A.
   Black, Robert
   Bojang, Kalifa
   Campbell, Harry
   Cousens, Simon
   Darmstadt, Gary L.
   Madhi, Shabir A.
   Sobanjo-ter Meulen, Ajoke
   Modi, Neena
   Patterson, Janna
   Qazi, Shamim
   Schrag, Stephanie J.
   Stoll, Barbara J.
   Wall, Stephen N.
   Wammanda, Robinson D.
   Lawn, Joy E.
CA SPRING Strengthening Publications
TI Strengthening the Reporting of Observational Studies in Epidemiology for
   Newborn Infection (STROBE-NI): an extension of the STROBE statement for
   neonatal infection research
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID INJECTABLE PROCAINE BENZYLPENICILLIN; SUB-SAHARAN AFRICA; SEVERE
   BACTERIAL-INFECTION; B STREPTOCOCCAL DISEASE; EQUIVALENCE TRIAL;
   CLINICAL SIGNS; YOUNG INFANTS; OPEN-LABEL; SYSTEMATIC ANALYSIS; RURAL
   BANGLADESH
AB Neonatal infections are estimated to account for a quarter of the 2.8 million annual neonatal deaths, as well as approximately 3% of all disability-adjusted life-years. Despite this burden, few data are available on incidence, aetiology, and outcomes, particularly regarding impairment. We aimed to develop guidelines for improved scientific reporting of observational neonatal infection studies, to increase comparability and to strengthen research in this area. This checklist, Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI), is an extension of the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement. STROBE-NI was developed following systematic reviews of published literature (1996-2015), compilation of more than 130 potential reporting recommendations, and circulation of a survey to relevant professionals worldwide, eliciting responses from 147 professionals from 37 countries. An international consensus meeting of 18 participants (with expertise in infectious diseases, neonatology, microbiology, epidemiology, and statistics) identified priority recommendations for reporting, additional to the STROBE statement. Implementation of these STROBE-NI recommendations, and linked checklist, aims to improve scientific reporting of neonatal infection studies, increasing data utility and allowing meta-analyses and pathogen-specific burden estimates to inform global policy and new interventions, including maternal vaccines.
C1 [Fitchett, Elizabeth J. A.; Seale, Anna C.; Cousens, Simon; Lawn, Joy E.] London Sch Hyg & Trop Med, MARCH Ctr, London, England.
   [Seale, Anna C.] UCL, Farr Inst Hlth Informat Res, London, England.
   [Vergnano, Stefania; Sharland, Michael; Heath, Paul T.] St Georges Univ London, Paediat Infect Dis Res Grp, London, England.
   [Saha, Samir K.] Dhaka Shishu Hosp, Dept Microbiol, Child Hlth Res Fdn, Dhaka, Bangladesh.
   [Agarwal, Ramesh] All India Inst Med Sci, Dept Pediat, New Delhi, India.
   [Ayede, Adejumoke I.] Univ Ibadan, Coll Med, Dept Paediat, Ibadan, Nigeria.
   [Ayede, Adejumoke I.] Univ Coll Hosp, Ibadan, Nigeria.
   [Bhutta, Zulfiqar A.] Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, Pakistan.
   [Bhutta, Zulfiqar A.] Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, Canada.
   [Black, Robert] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Int Programs, Baltimore, MD USA.
   [Bojang, Kalifa] MRC, Gambia Unit, Banjul, Gambia.
   [Campbell, Harry] Univ Edinburgh, Ctr Global Hlth Res, Edinburgh, Midlothian, Scotland.
   [Darmstadt, Gary L.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.
   [Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, DST NRF Vaccine Preventable Dis, Fac Hlth Sci, Johannesburg, South Africa.
   [Sobanjo-ter Meulen, Ajoke] Bill & Melinda Gates Fdn, Vaccines, Seattle, WA USA.
   [Modi, Neena] Royal Coll Paediat & Child Hlth, London, England.
   [Modi, Neena] Imperial Coll London, Sect Neonatal Med, Dept Med, London, England.
   [Patterson, Janna] Bill & Melinda Gates Fdn, Maternal Newborn & Child Hlth, Seattle, WA USA.
   [Qazi, Shamim] WHO, Dept Maternal Newborn Child & Adolescent Hlth, Geneva, Switzerland.
   [Schrag, Stephanie J.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA.
   [Stoll, Barbara J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
   [Stoll, Barbara J.] Childrens Healthcare Atlanta, Atlanta, GA USA.
   [Wall, Stephen N.] Save Children, Saving Newborn Lives, Washington, DC USA.
   [Wammanda, Robinson D.] Ahmadu Bello Univ, Teaching Hosp, Dept Paediat, Zaria, Nigeria.
RP Lawn, JE (reprint author), London Sch Hyg & Trop Med, MARCH Ctr, London, England.
EM joy.lawn@lshtm.ac.uk
FU Wellcome Trust; WHO; Bill & Melinda Gates Foundation
FX No specific funding was received for this work. Travel fellowships for
   experts attending the consensus meeting were provided by the Wellcome
   Trust, WHO, and the Bill & Melinda Gates Foundation through a grant to
   the Johns Hopkins Bloomberg School of Public Health. We thank the Royal
   Society of Medicine (Global Health Section) for hosting the expert
   consensus meeting and the members of the SPRING Group.
NR 59
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD OCT
PY 2016
VL 16
IS 10
BP E202
EP E213
DI 10.1016/S1473-3099(16)30082-2
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA DW2JP
UT WOS:000383469000001
PM 27633910
ER

PT J
AU Herrenkohl, TI
   Leeb, RT
   Higgins, D
AF Herrenkohl, Todd I.
   Leeb, Rebecca T.
   Higgins, Daryl
TI The Public Health Model of Child Maltreatment Prevention
SO TRAUMA VIOLENCE & ABUSE
LA English
DT Editorial Material
ID VIOLENCE; INTERSECTION; FRAMEWORK; EXPOSURE; ABUSE
C1 [Herrenkohl, Todd I.] Univ Washington, Social Work, Seattle, WA 98195 USA.
   [Herrenkohl, Todd I.] Univ Washington, Partnership 3DL, Seattle, WA 98195 USA.
   [Leeb, Rebecca T.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Higgins, Daryl] Australian Inst Family Studies, Res, Melbourne, Vic, Australia.
RP Herrenkohl, TI (reprint author), Univ Washington, 4101 15th Ave N, Seattle, WA 98105 USA.
EM tih@u.washington.edu
NR 15
TC 0
Z9 0
U1 5
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1524-8380
EI 1552-8324
J9 TRAUMA VIOLENCE ABUS
JI Trauma Violence Abus.
PD OCT
PY 2016
VL 17
IS 4
SI SI
BP 363
EP 365
DI 10.1177/1524838016661034
PG 3
WC Criminology & Penology; Family Studies; Social Work
SC Criminology & Penology; Family Studies; Social Work
GA DV5PH
UT WOS:000382979600001
PM 27580662
ER

PT J
AU Dodd, KE
   Mazurek, JM
AF Dodd, Katelynn E.
   Mazurek, Jacek M.
TI Agreement between current and active asthma classification methods,
   Asthma Call-back Survey, 2011-2012
SO JOURNAL OF ASTHMA
LA English
DT Article
DE Current asthma; active asthma; classification; agreement; BRFSS; ACBS
ID WORK-RELATED ASTHMA; FACTOR SURVEILLANCE SYSTEM; UNITED-STATES; ADULTS;
   PREVALENCE; VALIDATION; CARE; RESPONSIVENESS; QUESTIONNAIRE; DEFINITIONS
AB Objective: Various approaches have been developed to identify persons with asthma using survey data. To assess agreement between current and active asthma classifications, 2011-2012 Asthma Call-back Survey landline telephone household data from 38 states, District of Columbia, and Puerto Rico for adults aged 18years who have ever been told by a health professional they have asthma were analyzed. Methods: Respondents were classified to have current asthma if they reported still having asthma, and active asthma if they reported within the past year: 1) talking to a doctor about asthma, 2) taking asthma medication, or 3) having any symptoms of asthma. Agreement between classifications was assessed using the Kappa statistic. Results: Among adults ever told by a health professional they have asthma, an estimated 72% had current asthma and 75% had active asthma. Overall, 67% of individuals met classifications of both current and active asthma and 20% had neither current nor active asthma (Kappa = 0.68). The Kappa increased to 0.72 when talking to a doctor about asthma was removed from the active asthma classification. Conclusions: Results indicated substantial agreement between current and active asthma. Agreement was strengthened when talking to a doctor about asthma was removed from the active asthma classification.
C1 [Dodd, Katelynn E.; Mazurek, Jacek M.] NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent CDC, Morgantown, WV USA.
RP Dodd, KE (reprint author), NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS HG900, Morgantown, WV 26505 USA.
EM yla8@cdc.gov
FU Centers for Disease Control and Prevention (CDC) [3U36OE000002];
   Association of Schools and Programs of Public Health (ASPPH)
FX This publication was supported by Cooperative Agreement Number
   3U36OE000002 from the Centers for Disease Control and Prevention (CDC)
   and the Association of Schools and Programs of Public Health (ASPPH).
NR 42
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PD OCT
PY 2016
VL 53
IS 8
BP 808
EP 815
DI 10.3109/02770903.2016.1155221
PG 8
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA DU9ZU
UT WOS:000382577700005
PM 27050506
ER

PT J
AU Puckett, M
   Neri, A
   Underwood, JM
   Stewart, SL
AF Puckett, Mary
   Neri, Antonio
   Underwood, J. Michael
   Stewart, Sherri L.
TI Nutrition and Physical Activity Strategies for Cancer Prevention in
   Current National Comprehensive Cancer Control Program Plans
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE Comprehensive cancer control; Cancer prevention; Nutrition; Physical
   activity
ID UNITED-STATES; RISK-FACTORS; OBESITY; FOOD; GUIDELINES; HEALTH;
   MORTALITY; SURVIVORS; CHOICES
AB Obesity, diet and physical inactivity are risk factors for some cancers. Grantees of the National Comprehensive Cancer Control Program (NCCCP) in US states, tribes, and territories develop plans to coordinate funding and activities for cancer prevention and control. Including information and goals related to nutrition and physical activity (NPA) is a key opportunity for primary cancer prevention, but it is currently unclear to what extent NCCCP plans address these issues. We reviewed 69 NCCCP plans and searched for terms related to NPA. Plans were coded as (1) knowledge of NPA and cancer link; (2) goals to improve NPA behaviors; and (3) strategies to increase healthy NPA activities, environments, or systems changes. NPA content was consistently included in all cancer plans examined across all years. Only 4 (6 %) outlined only the relationship between NPA and cancer without goals or strategies. Fifty-nine plans (89 %) contained goals or strategies related to NPA, with 53 (82 %) including both. However, numbers of goals, strategies, and detail provided varied widely. All programs recognized the importance of NPA in cancer prevention. Most plans included NPA goals and strategies. Increasing the presence of NPA strategies that can be modified or adapted appropriately locally could help with more widespread implementation and measurement of NPA interventions.
C1 [Puckett, Mary; Neri, Antonio; Underwood, J. Michael; Stewart, Sherri L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Comprehens Canc Control Branch, 4770 Buford Highway,MS F-76, Atlanta, GA 30341 USA.
RP Puckett, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Comprehens Canc Control Branch, 4770 Buford Highway,MS F-76, Atlanta, GA 30341 USA.
EM xdg6@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 46
TC 0
Z9 0
U1 9
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
PD OCT
PY 2016
VL 41
IS 5
BP 1013
EP 1020
DI 10.1007/s10900-016-0184-8
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA DV1LH
UT WOS:000382682100015
PM 26994988
ER

PT J
AU Clarke, KEN
   Kraft, JM
   Wiener, JB
   Hatfield-Timajchy, K
   Kottke, M
   Sales, JM
   Goedken, P
   Kourtis, AP
AF Clarke, Kristie Elizabeth North
   Kraft, Joan Marie
   Wiener, Jeffrey B.
   Hatfield-Timajchy, Kendra
   Kottke, Melissa
   Sales, Jessica M.
   Goedken, Peggy
   Kourtis, Athena P.
TI Factors Associated with Contraceptive Use Differ between Younger and
   Older African-American Female Adolescents
SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY
LA English
DT Article
DE Contraception; Condoms; African American; Adolescent; Pregnancy;
   Sexually transmitted infection
ID WOMEN
AB Study Objective: To examine differences in factors associated with contraceptive use between younger and older adolescent age groups, which has not previously been well described.
   Design: Age group-specific analyses were performed on cross-sectional survey data to identify factors associated with any contraceptive use at last sex among younger (14- to 16-year-old) and older (17- to 19-year-old) sexually active African American female adolescents; interaction analyses were used to assess whether these associations differed by age.
   Setting: Adolescent reproductive health clinic in Atlanta, Georgia. Participants: Sexually active African American female adolescents 14-19 years of age. Interventions: No intervention tested; cross-sectional design.
   Main Outcome Measure: Self-reported contraceptive use during most recent vaginal sex with a male partner.
   Results: The prevalence of contraceptive use at last sex was identical in both groups; however, factors associated with contraceptive use differed according to age. The only factor associated with contraceptive use in both age groups was involvement in decisions about sexual health in the most recent relationship. Associations between factors and contraceptive use significantly differed according to age. History of sexually transmitted infection, age difference with partner, discussion of condoms with partner, and concurrent partners were important factors among younger adolescents; worry about pregnancy and discussion of birth control with partner were important among older adolescents.
   Conclusion: Factors associated with contraceptive use at last sex differ according to adolescent age; this should be considered when designing counseling and interventions for teens, as well as research.
C1 [Clarke, Kristie Elizabeth North; Kraft, Joan Marie; Wiener, Jeffrey B.; Hatfield-Timajchy, Kendra; Kourtis, Athena P.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
   [Kottke, Melissa; Goedken, Peggy] Emory Univ, Dept Gynecol & Obstet, Div Family Planning, Atlanta, GA 30322 USA.
   [Sales, Jessica M.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Clarke, KEN (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A04, Atlanta, GA 30329 USA.
EM vhz9@cdc.gov
FU US Centers for Disease Control and Prevention (CDC) [U48DP001909-01]
FX The study took place in Atlanta, Georgia and was supported by the US
   Centers for Disease Control and Prevention (CDC) through Cooperative
   Agreement U48DP001909-01. CDC staff were involved in the study design,
   analysis and interpretation of data, the writing of the report, and the
   decision to submit the report for publication. Kristie Elizabeth North
   Clarke wrote the first draft of the report and no honorarium, grant, or
   other form of payment was given to anyone to produce the manuscript.
   Everyone who contributed significantly to the work is listed as a
   coauthor. There are no other persons to acknowledge. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the official position of the CDC.
NR 11
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-3188
EI 1873-4332
J9 J PEDIATR ADOL GYNEC
JI J. Pediatr Adolesc. Gynecol.
PD OCT
PY 2016
VL 29
IS 5
BP 448
EP 453
DI 10.1016/j.jpag.2016.01.129
PG 6
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DV0EX
UT WOS:000382591900009
PM 26877099
ER

PT J
AU Parmer, J
   Baur, C
   Eroglu, D
   Lubell, K
   Prue, C
   Reynolds, B
   Weaver, J
AF Parmer, John
   Baur, Cynthia
   Eroglu, Dogan
   Lubell, Keri
   Prue, Christine
   Reynolds, Barbara
   Weaver, James
TI Crisis and Emergency Risk Messaging in Mass Media News Stories: Is the
   Public Getting the Information They Need to Protect Their Health?
SO HEALTH COMMUNICATION
LA English
DT Article
ID COMMUNICATION
AB The mass media provide an important channel for delivering crisis and emergency risk information to the public. We conducted a content analysis of 369 newspaper and television broadcast stories covering natural disaster and foodborne outbreak events and coded for seven best practices in crisis and emergency risk messaging. On average, slightly less than two (1.86) of the seven best practices were included in each story. The proportion of stories including individual best practices ranged from 4.6% for expressing empathy to 83.7% for explaining what is known about the event's impact to human health. Each of the other five best practices appeared in less than 25% of stories. These results suggest much of the risk messaging the public receives via mass media does not follow best practices for effective crisis and emergency communication, potentially compromising public understanding and actions in response to events.
C1 [Parmer, John; Baur, Cynthia; Eroglu, Dogan; Reynolds, Barbara; Weaver, James] Ctr Dis Control & Prevent, Off Associate Director Commun, 160 Clifton Rd, Atlanta, GA 30333 USA.
   [Lubell, Keri] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA.
   [Prue, Christine] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
RP Parmer, J (reprint author), Ctr Dis Control & Prevent, Off Associate Director Commun, 160 Clifton Rd, Atlanta, GA 30333 USA.
EM JParmer@cdc.gov
NR 32
TC 0
Z9 0
U1 13
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD OCT
PY 2016
VL 31
IS 10
BP 1215
EP 1222
DI 10.1080/10410236.2015.1049728
PG 8
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA DT2NQ
UT WOS:000381317400004
PM 26940247
ER

PT J
AU Violanti, JM
   Andrew, ME
   Mnatsakanova, A
   Hartley, TA
   Fekedulegn, D
   Burchfiel, CM
AF Violanti, John M.
   Andrew, Michael E.
   Mnatsakanova, Anna
   Hartley, Tara A.
   Fekedulegn, Desta
   Burchfiel, Cecil M.
TI Correlates of hopelessness in the high suicide risk police occupation
SO POLICE PRACTICE AND RESEARCH
LA English
DT Article
DE police; hopelessness; stress; posttraumatic stress; support; suicide
ID POSTTRAUMATIC-STRESS-DISORDER; NORWEGIAN POLICE; MODERATING ROLE; SOCIAL
   SUPPORT; MENTAL-HEALTH; OFFICERS; IDEATION; PREVALENCE; PREDICTORS;
   DEPRESSION
AB Police officers are chronically exposed to work stress. We examined specific stressors that may be associated with hopelessness, a possible risk factor for suicide in this high suicide risk population. The study included 378 officers (276 men and 102 women) with complete data. Analysis of variance was used to estimate mean levels of hopelessness scores as associated with stress, adjusted for age, gender, and race/ethnicity. Posttraumatic symptoms were tested as a modifier of the association between stress and hopelessness. Increasing stress of administrative practices and lack of support were significantly associated with increasing hopelessness among officers (p<.006 - hopelessness range: 1.64-2.65; and p<.001 - hopelessness range 1.60-2.80, respectively). Posttraumatic stress disorder (PTSD) symptoms significantly modified the association between lack of organizational support and hopelessness (p<.010) with significant association only among individuals with higher PTSD symptoms (p<.001). Results suggest that hopelessness is associated with specific stressors in police work, and this is modified by posttraumatic symptomatology.
C1 [Violanti, John M.] SUNY Buffalo, Univ Buffalo, Dept Social & Prevent Med Epidemiol & Environm Hl, Sch Publ Hlth & Hlth Profess, Buffalo, NY USA.
   [Andrew, Michael E.; Mnatsakanova, Anna; Hartley, Tara A.; Fekedulegn, Desta; Burchfiel, Cecil M.] Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Natl Inst Occupat Safety & Hlth, Morgantown, WV USA.
RP Violanti, JM (reprint author), SUNY Buffalo, Univ Buffalo, Dept Social & Prevent Med Epidemiol & Environm Hl, Sch Publ Hlth & Hlth Profess, Buffalo, NY USA.
EM violanti@buffalo.edu
FU National Institute for Occupational Safety and Health (NIOSH)
   [200-2003-01580]
FX This work was supported by the National Institute for Occupational
   Safety and Health (NIOSH), contract No. 200-2003-01580. The findings and
   conclusions in this article are those of the authors and do not
   necessarily represent the views of the National Institute for
   Occupational Safety and Health.
NR 65
TC 1
Z9 1
U1 9
U2 14
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1561-4263
EI 1477-271X
J9 POLICE PRACT RES
JI Police Pract. Res.
PD OCT
PY 2016
VL 17
IS 5
BP 408
EP 419
DI 10.1080/15614263.2015.1015125
PG 12
WC Criminology & Penology
SC Criminology & Penology
GA DR8LD
UT WOS:000380148500003
PM 26752981
ER

PT J
AU Stevens, AC
   Carroll, DD
   Courtney-Long, EA
   Zhang, QC
   Sloan, ML
   Griffin-Blake, S
   Peacock, G
AF Stevens, Alissa C.
   Carroll, Dianna D.
   Courtney-Long, Elizabeth A.
   Zhang, Qing C.
   Sloan, Michelle L.
   Griffin-Blake, Shannon
   Peacock, Georgina
TI Adults with One or More Functional Disabilities - United States,
   2011-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID HEALTH; EDUCATION
C1 [Stevens, Alissa C.; Carroll, Dianna D.; Courtney-Long, Elizabeth A.; Zhang, Qing C.; Sloan, Michelle L.; Griffin-Blake, Shannon; Peacock, Georgina] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
   [Carroll, Dianna D.] CDC, Commissioned Corps, US Publ Hlth Serv, Atlanta, GA 30333 USA.
RP Stevens, AC (reprint author), CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
EM astevens@cdc.gov
NR 10
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 30
PY 2016
VL 65
IS 38
BP 1021
EP 1025
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX9IK
UT WOS:000384706600001
PM 27684532
ER

PT J
AU Black, CL
   Yue, X
   Ball, SW
   Donahue, SMA
   Izrael, D
   de Perio, MA
   Laney, AS
   Williams, WW
   Lindley, MC
   Graitcer, SB
   Lu, PJ
   DiSogra, C
   Devlin, R
   Walker, DK
   Greby, SM
AF Black, Carla L.
   Yue, Xin
   Ball, Sarah W.
   Donahue, Sara M. A.
   Izrael, David
   de Perio, Marie A.
   Laney, A. Scott
   Williams, Walter W.
   Lindley, Megan C.
   Graitcer, Samuel B.
   Lu, Peng-Jun
   DiSogra, Charles
   Devlin, Rebecca
   Walker, Deborah K.
   Greby, Stacie M.
TI Influenza Vaccination Coverage Among Health Care Personnel-United
   States, 2015-16 Influenza Season
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; HOME STAFF; RESIDENTS; MORTALITY
C1 [Black, Carla L.; Williams, Walter W.; Lindley, Megan C.; Graitcer, Samuel B.; Lu, Peng-Jun; Greby, Stacie M.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Yue, Xin] Leidos, Reston, VA USA.
   [Ball, Sarah W.; Donahue, Sara M. A.; Izrael, David; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA.
   [de Perio, Marie A.] CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA.
   [Laney, A. Scott] CDC, Div Resp Hlth, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA.
   [DiSogra, Charles; Devlin, Rebecca] Abt SRBI, New York, NY USA.
RP Black, CL (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM cblack2@cdc.gov
NR 10
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 30
PY 2016
VL 65
IS 38
BP 1026
EP 1031
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX9IK
UT WOS:000384706600002
PM 27684642
ER

PT J
AU Likos, A
   Griffin, I
   Bingham, AM
   Stanek, D
   Fischer, M
   White, S
   Hamilton, J
   Eisenstein, L
   Atrubin, D
   Mulay, P
   Scott, B
   Jenkins, P
   Fernandez, D
   Rico, E
   Gillis, L
   Jean, R
   Cone, M
   Blackmore, C
   McAllister, J
   Vasquez, C
   Rivera, L
   Philip, C
AF Likos, Anna
   Griffin, Isabel
   Bingham, Andrea M.
   Stanek, Danielle
   Fischer, Marc
   White, Stephen
   Hamilton, Janet
   Eisenstein, Leah
   Atrubin, David
   Mulay, Prakash
   Scott, Blake
   Jenkins, Patrick
   Fernandez, Danielle
   Rico, Edhelene
   Gillis, Leah
   Jean, Reynald
   Cone, Marshall
   Blackmore, Carina
   McAllister, Janet
   Vasquez, Chalmers
   Rivera, Lillian
   Philip, Celeste
TI Local Mosquito-Borne Transmission of Zika Virus - Miami-Dade and Broward
   Counties, Florida, June-August 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID DENGUE; DISEASE
C1 [Likos, Anna; Griffin, Isabel; Bingham, Andrea M.; Stanek, Danielle; White, Stephen; Hamilton, Janet; Eisenstein, Leah; Atrubin, David; Mulay, Prakash; Scott, Blake; Jenkins, Patrick; Fernandez, Danielle; Rico, Edhelene; Gillis, Leah; Jean, Reynald; Cone, Marshall; Blackmore, Carina; Rivera, Lillian; Philip, Celeste] Florida Dept Hlth, Gainesville, FL 32641 USA.
   [Fischer, Marc; McAllister, Janet] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Vasquez, Chalmers] Miami Dade Cty Mosquito Control Dist, Miami, FL USA.
RP Likos, A (reprint author), Florida Dept Hlth, Gainesville, FL 32641 USA.
EM anna.likos@flhealth.gov
NR 10
TC 13
Z9 13
U1 11
U2 11
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 30
PY 2016
VL 65
IS 38
BP 1032
EP 1038
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX9IK
UT WOS:000384706600003
PM 27684886
ER

PT J
AU Fill, MMA
   Sweat, D
   Morrow, H
   Haushalter, A
   Martin, JC
   Zerwekh, T
   Chakraverty, T
   Kmet, J
   Morris, K
   Moore, K
   Kainer, M
   Murphree, R
   Dunn, JR
   Schaffner, W
   Jones, TF
AF Fill, Mary-Margaret A.
   Sweat, David
   Morrow, Helen
   Haushalter, Alisa
   Martin, Judy C.
   Zerwekh, Tyler
   Chakraverty, Tamal
   Kmet, Jennifer
   Morris, Kevin
   Moore, Kelly
   Kainer, Marion
   Murphree, Rendi
   Dunn, John R.
   Schaffner, William
   Jones, Timothy F.
TI Measles Outbreak of Unknown Source - Shelby County, Tennessee, April-May
   2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Fill, Mary-Margaret A.] CDC, Epidein Intelligence Serv, Atlanta, GA 30333 USA.
   [Fill, Mary-Margaret A.; Moore, Kelly; Kainer, Marion; Murphree, Rendi; Dunn, John R.; Jones, Timothy F.] Tennessee Dept Hlth, Div Communicable & Environm Dis & Emergency Prepa, Nashville, TN 37243 USA.
   [Sweat, David; Morrow, Helen; Haushalter, Alisa; Martin, Judy C.; Zerwekh, Tyler; Chakraverty, Tamal; Kmet, Jennifer] Shelby Cty Hlth Dept, Memphis, TN USA.
   [Murphree, Rendi] CDC, Off Publ Hlth Preparedness & Response, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA.
   [Morris, Kevin] West Tennessee Reg Hlth Dept, Jackson, TN USA.
   [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA.
RP Fill, MMA (reprint author), CDC, Epidein Intelligence Serv, Atlanta, GA 30333 USA.; Fill, MMA (reprint author), Tennessee Dept Hlth, Div Communicable & Environm Dis & Emergency Prepa, Nashville, TN 37243 USA.
EM mfill@cdc.gov
NR 5
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 30
PY 2016
VL 65
IS 38
BP 1039
EP 1040
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX9IK
UT WOS:000384706600004
PM 27685014
ER

PT J
AU Iliyasu, Z
   Verma, H
   Craig, KT
   Nwaze, E
   Ahmad-Shehu, A
   Jibir, BW
   Gwarzo, GD
   Gajida, AU
   Weldon, WC
   Oberste, MS
   Takane, M
   Mkanda, P
   Muhammad, AJG
   Sutter, RW
AF Iliyasu, Zubairu
   Verma, Harish
   Craig, Kehinde T.
   Nwaze, Eric
   Ahmad-Shehu, Amina
   Jibir, Binta Wudil
   Gwarzo, Garba Dayyabu
   Gajida, Auwalu U.
   Weldon, William C.
   Oberste, M. Steven
   Takane, Marina
   Mkanda, Pascal
   Muhammad, Ado J. G.
   Sutter, Roland W.
TI Poliovirus seroprevalence before and after interruption of poliovirus
   transmission in Kano State, Nigeria
SO VACCINE
LA English
DT Article
DE Poliomyelitis; Seroprevalence; Kano; Nigeria; Oral poliovirus vaccine
ID NORTHERN NIGERIA; ERADICATION; VACCINE; ANTIBODIES; OUTBREAK; PROGRESS
AB Introduction: In September 2015, Nigeria was removed from the list of polio-endemic countries after more than 12 months had passed since the detection of last wild poliovirus case in the country on 24 July 2014. We are presenting here a report of two polio seroprevalence surveys conducted in September 2013 and October 2014, respectively, in the Kano state of northern Nigeria.
   Methods: Health facility based seroprevalence surveys were undertaken at Murtala Mohammad Specialist Hospital, Kano. Parents or guardians of children aged 6-9 months, 36-47 months, 5-9 years and 10-14 years in 2013 and 6-9 months and 19-22 months (corresponding to 6-9 months range at the time of 2013 survey) in 2014 presenting to the outpatient department, were approached for participation, screened for eligibility and asked to provide informed consent. A questionnaire was administered and a blood sample collected for polio neutralization assay.
   Results: Among subjects aged 6-9 months in the 2013 survey, seroprevalence was 58% (95% confidence interval [CI] 51-66%) to poliovirus type 1, 42% (95% CI 34-50%) to poliovirus type 2, and 52% (95% CI 44-60%) to poliovirus type 3. Among children 36-47 months and older, seroprevalence was 85% or higher for all three serotypes. In 2014, seroprevalence in 6-9 month infants was 72% (95% CI 65-79%) for type 1, 59% (95% CI 52-66%) for type 2, and 65% (95% CI 57-72%) for type 3 and in 19-22 months, 80% (95% CI 74-85%), 57% (49-63%) and 78% (71-83%) respectively. Seroprevalence was positively associated with history of increasing oral poliovirus vaccine doses.
   Conclusions: There was significant improvement in seroprevalence in 2014 over the 2013 levels indicating a positive impact of recent programmatic interventions. However the continued low seroprevalence in 6-9 month age is a concern and calls for improved immunization efforts to sustain the polio-free Nigeria. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Iliyasu, Zubairu; Gajida, Auwalu U.] Aminu Kano Teaching Hosp, Dept Community Med, Kano, Nigeria.
   [Iliyasu, Zubairu; Gwarzo, Garba Dayyabu; Gajida, Auwalu U.] Bayero Univ, Kano, Nigeria.
   [Verma, Harish; Takane, Marina; Sutter, Roland W.] World Hlth Org, Geneva, Switzerland.
   [Craig, Kehinde T.; Mkanda, Pascal] World Hlth Org, Abuja, Nigeria.
   [Nwaze, Eric; Ahmad-Shehu, Amina; Muhammad, Ado J. G.] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
   [Jibir, Binta Wudil] Murtala Mohammed Specialist Hosp, Dept Pediat, Kano, Nigeria.
   [Gwarzo, Garba Dayyabu] Aminu Kano Teaching Hosp, Dept Pediat, Kano, Nigeria.
   [Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Verma, H (reprint author), World Hlth Org, Res Policy & Prod Dev, Polio Eradicat Dept, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM vermah@who.int
FU World Health Organization (Rotary International)
FX World Health Organization (using a Grant from Rotary International).
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2016
VL 34
IS 42
BP 5125
EP 5131
DI 10.1016/j.vaccine.2016.08.058
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DY0KW
UT WOS:000384786700011
PM 27591950
ER

PT J
AU Mercante, JW
   Morrison, SS
   Desai, HP
   Raphael, BH
   Winchell, JM
AF Mercante, Jeffrey W.
   Morrison, Shatavia S.
   Desai, Heta P.
   Raphael, Brian H.
   Winchell, Jonas M.
TI Genomic Analysis Reveals Novel Diversity among the 1976 Philadelphia
   Legionnaires' Disease Outbreak Isolates and Additional ST36 Strains
SO PLOS ONE
LA English
DT Article
ID LINKED-IMMUNOSORBENT-ASSAY; EUKARYOTIC-LIKE PROTEINS; OUTER-MEMBRANE
   PROTEIN; IV SECRETION SYSTEM; LEGIONELLA-PNEUMOPHILA; PHYLOGENETIC
   ANALYSIS; VIRULENCE SYSTEM; SEQUENCING DATA; IDENTIFICATION; GENE
AB Legionella pneumophila was first recognized as a cause of severe and potentially fatal pneumonia during a large-scale outbreak of Legionnaires' disease (LD) at a Pennsylvania veterans' convention in Philadelphia, 1976. The ensuing investigation and recovery of four clinical isolates launched the fields of Legionella epidemiology and scientific research. Only one of the original isolates, "Philadelphia-1", has been widely distributed or extensively studied. Here we describe the whole-genome sequencing (WGS), complete assembly, and comparative analysis of all Philadelphia LD strains recovered from that investigation, along with L. pneumophila isolates sharing the Philadelphia sequence type (ST36). Analyses revealed that the 1976 outbreak was due to multiple serogroup 1 strains within the same genetic lineage, differentiated by an actively mobilized, self-replicating episome that is shared with L. pneumophila str. Paris, and two large, horizontally-transferred genomic loci, among other polymorphisms. We also found a completely unassociated ST36 strain that displayed remarkable genetic similarity to the historical Philadelphia isolates. This similar strain implies the presence of a potential clonal population, and suggests important implications may exist for considering epidemiological context when interpreting phylogenetic relationships among outbreak-associated isolates. Additional extensive archival research identified the Philadelphia isolate associated with a non-Legionnaire case of "Broad Street pneumonia", and provided new historical and genetic insights into the 1976 epidemic. This retrospective analysis has underscored the utility of fully-assembled WGS data for Legionella outbreak investigations, highlighting the increased resolution that comes from longread sequencing and a sequence type-matched genomic data set.
C1 [Mercante, Jeffrey W.; Morrison, Shatavia S.; Desai, Heta P.; Raphael, Brian H.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Resp Dis Branch, Atlanta, GA 30329 USA.
RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Resp Dis Branch, Atlanta, GA 30329 USA.
EM jwinchell@cdc.gov
FU Office of Advanced Molecular Detection (CDC)
FX This study was supported, in part, by funds made available through the
   Office of Advanced Molecular Detection (CDC).; We would like to thank
   Mary Hilpertshauser at the David J. Sencer CDC Museum, Bill Nicholson in
   the CDC Rickettsial Zoonoses Branch, Steve Oberste in the CDC Polio and
   Picornovirus Laboratory Branch, Benjamin Metcalf in the CDC
   Streptococcus Laboratory, Vladimir Loparev in the CDC Biotechnology Core
   Facility, and especially Diane Wendt at the National Museum of American
   History, Smithsonian Institution. We also extend our deepest gratitude
   to Joe McDade for his encouragement as we conducted archival research
   and composed this manuscript. This study was supported, in part, by
   funds made available through the Office of Advanced Molecular Detection
   (CDC).
NR 114
TC 1
Z9 1
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 29
PY 2016
VL 11
IS 9
AR e0164074
DI 10.1371/journal.pone.0164074
PG 32
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DX4CV
UT WOS:000384328500147
PM 27684472
ER

PT J
AU Turinawe, K
   Vandebriel, G
   Lowrance, DW
   Uwinkindi, F
   Mutwa, P
   Boer, KR
   Mutembayire, G
   Tugizimana, D
   Nsanzimana, S
   Pevzner, E
   Howard, AA
   Gasana, M
AF Turinawe, Kenneth
   Vandebriel, Greet
   Lowrance, David W.
   Uwinkindi, Francois
   Mutwa, Philippe
   Boer, Kimberly R.
   Mutembayire, Grace
   Tugizimana, David
   Nsanzimana, Sabin
   Pevzner, Eric
   Howard, Andrea A.
   Gasana, Michel
TI Operating Characteristics of a Tuberculosis Screening Tool for People
   Living with HIV in Out-Patient HIV Care and Treatment Services, Rwanda
SO PLOS ONE
LA English
DT Article
ID RISK-FACTORS
AB Background
   The World Health Organization (WHO) 2010 guidelines for intensified tuberculosis (TB) case finding (ICF) among people living with HIV (PLHIV) includes a recommendation that PLHIV receive routine TB screening. Since 2005, the Rwandan Ministry of Health has been using a five-question screening tool. Our study objective was to assess the operating characteristics of the tool designed to identify PLHIV with presumptive TB as measured against a composite reference standard, including bacteriologically confirmed TB.
   Methods
   In a cross-sectional study, the TB screening tool was routinely administered at enrolment in outpatient HIV care and treatment services at seven public health facilities. From March to September 2011, study enrollees were examined for TB disease irrespective of TB screening outcome. The examination consisted of a chest radiograph (CXR), three sputum smears (SS), sputum culture (SC) and polymerase chain reaction line-probe assay (Hain test). PLHIV were classified as having "laboratory-confirmed TB" with positive results on SS for acid-fast bacilli, SC on Lowenstein-Jensen medium, or a Hain test.
   Results
   Overall, 1,767 patients were enrolled and screened of which; 1,017 (57.6%) were female, median age was 33 (IQR, 27-41), and median CD4(+) cell count was 385 (IQR, 229-563) cells/mm(3). Of the patients screened, 138 (7.8%) were diagnosed with TB of which; 125 (90.5%) were laboratory-confirmed pulmonary TB. Of 404 (22.9%) patients who screened positive and 1,363 (77.1%) who screened negative, 79 (19.5%) and 59 (4.3%), respectively, were diagnosed with TB. For laboratory-confirmed TB, the tool had a sensitivity of 54.4% (95% CI 45.3-63.3), specificity of 79.5% (95% CI 77.5-81.5), PPV of 16.8% and NPV of 95.8%.
   Conclusion
   TB prevalence among PLHIV newly enrolling into HIV care and treatment was 65 times greater than the overall population prevalence. However, the performance of the tool was poorer than the predicted performance of the WHO recommended TB screening questions.
C1 [Turinawe, Kenneth; Vandebriel, Greet] Columbia Univ, Mailman Sch Publ Hlth, ICAP, Kigali, Rwanda.
   [Lowrance, David W.; Mutwa, Philippe; Boer, Kimberly R.] US Ctr Dis Control & Prevent, Div Global HIV & TB, Kigali, Rwanda.
   [Uwinkindi, Francois; Mutembayire, Grace; Tugizimana, David; Nsanzimana, Sabin; Gasana, Michel] Inst HIV Dis Prevent & Care, Rwanda Biomed Ctr, Minist Hlth, Kigali, Rwanda.
   [Pevzner, Eric] US Ctr Dis Control & Prevent, Div Global HIV & TB, Global TB Branch, Atlanta, GA USA.
   [Howard, Andrea A.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10032 USA.
RP Vandebriel, G (reprint author), Columbia Univ, Mailman Sch Publ Hlth, ICAP, Kigali, Rwanda.
EM gv2124@cumc.columbia.edu
FU U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the
   U.S. Centers for Disease Control and Prevention [3U2GPS00161-05W1]
FX This evaluation was funded by the U.S. Presidents Emergency Plan for
   AIDS Relief (PEPFAR, www.pepfar.gov) through the U.S. Centers for
   Disease Control and Prevention under the terms of Cooperative Agreement
   Number 3U2GPS00161-05W1. AH is the grant recipient. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
NR 19
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 29
PY 2016
VL 11
IS 9
AR e0163462
DI 10.1371/journal.pone.0163462
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DX4CV
UT WOS:000384328500057
PM 27685783
ER

PT J
AU Streicker, DG
   Winternitz, JC
   Satterfield, DA
   Condori-Condori, RE
   Broos, A
   Tello, C
   Recuenco, S
   Velasco-Villa, A
   Altizer, S
   Valderrama, W
AF Streicker, Daniel G.
   Winternitz, Jamie C.
   Satterfield, Dara A.
   Condori-Condori, Rene Edgar
   Broos, Alice
   Tello, Carlos
   Recuenco, Sergio
   Velasco-Villa, Andres
   Altizer, Sonia
   Valderrama, William
TI Host-pathogen evolutionary signatures reveal dynamics and future
   invasions of vampire bat rabies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Desmodus; zoonotic disease; forecasting; sex bias; spatial dynamics
ID POPULATION-STRUCTURE; DESMODUS-ROTUNDUS; MITOCHONDRIAL-DNA;
   GENETIC-STRUCTURE; DISPERSAL; PHYLOGEOGRAPHY; ORGANIZATION; SEASONALITY;
   NUCLEAR; MARKERS
AB Anticipating how epidemics will spread across landscapes requires understanding host dispersal events that are notoriously difficult to measure. Here, we contrast host and virus genetic signatures to resolve the spatiotemporal dynamics underlying geographic expansions of vampire bat rabies virus (VBRV) in Peru. Phylogenetic analysis revealed recent viral spread between populations that, according to extreme geographic structure in maternally inherited host mitochondrial DNA, appeared completely isolated. In contrast, greater population connectivity in biparentally inherited nuclear microsatellites explained the historical limits of invasions, suggesting that dispersing male bats spread VBRV between genetically isolated female populations. Host nuclear DNA further indicated unanticipated gene flow through the Andes mountains connecting the VBRV-free Pacific coast to the VBRV-endemic Amazon rainforest. By combining Bayesian phylogeography with landscape resistance models, we projected invasion routes through northern Peru that were validated by real-time livestock rabies mortality data. The first outbreaks of VBRV on the Pacific coast of South America could occur by June 2020, which would have serious implications for agriculture, wildlife conservation, and human health. Our results show that combining host and pathogen genetic data can identify sex biases in pathogen spatial spread, which may be a widespread but under-appreciated phenomenon, and demonstrate that genetic forecasting can aid preparedness for impending viral invasions.
C1 [Streicker, Daniel G.] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland.
   [Streicker, Daniel G.; Broos, Alice] Univ Glasgow, MRC, Ctr Virus Res, Glasgow G61 1QH, Lanark, Scotland.
   [Streicker, Daniel G.; Winternitz, Jamie C.; Satterfield, Dara A.; Altizer, Sonia] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA.
   [Winternitz, Jamie C.] Acad Sci Czech Republic, Inst Vertebrate Biol, CS-60365 Brno, Czech Republic.
   [Winternitz, Jamie C.] Max Planck Inst Evolutionary Biol, Dept Evolutionary Ecol, D-24306 Plon, Germany.
   [Condori-Condori, Rene Edgar; Velasco-Villa, Andres] Ctr Dis Control & Prevent, Div High Consequence Pathogen & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA.
   [Tello, Carlos; Valderrama, William] Assoc Conservat & Dev Nat Resources, Lima 41, Peru.
   [Recuenco, Sergio] Minist Hlth Peru, Inst Nacl Salud, Lima 11, Peru.
   [Valderrama, William] SENASA Peru, Natl Serv Agr Hlth, Lima 12, Peru.
RP Streicker, DG (reprint author), Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland.; Streicker, DG (reprint author), Univ Glasgow, MRC, Ctr Virus Res, Glasgow G61 1QH, Lanark, Scotland.; Streicker, DG (reprint author), Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA.
EM daniel.streicker@glasgow.ac.uk
OI Streicker, Daniel/0000-0001-7475-2705; Recuenco-Cabrera,
   Sergio/0000-0002-8446-7411
FU National Science Foundation [DEB-1020966]; Pan American Health
   Organization; Sir Henry Dale Fellowship - Wellcome Trust
   [102507/Z/13/Z]; Sir Henry Dale Fellowship - Royal Society
   [102507/Z/13/Z]
FX We thank Heather Danaceau, Jennifer Towner, and Victoria Estacio for
   laboratory assistance and Roman Biek, Barbara Mable, and Mafalda Viana
   for comments on the manuscript. SENASA contributed surveillance data and
   livestock samples under an International Cooperative Agreement with the
   University of Georgia (30-11-2012). The Peruvian Government authorized
   collection, exportation, and use of genetic resources
   (RD-222-2009-AG-DGFFS-DGEFFS, 003851-AG-DGFFS,
   RD-273-2012-AG-DGFFS-DGEFFS, and RD-054-2016-SERFOR-DGGSPFFS). The
   University of Georgia Advanced Computing Resource Center provided
   computational resources. Funding was provided by National Science
   Foundation Grant DEB-1020966 (to D.G.S. and S.A.) and the Pan American
   Health Organization (W.V.). D.S. was funded by a Sir Henry Dale
   Fellowship, jointly funded by Wellcome Trust and Royal Society Grant
   102507/Z/13/Z. The findings and the conclusions in this report are those
   of the authors and do not necessarily represent the official position of
   the Centers for Disease Control and Prevention.
NR 40
TC 1
Z9 1
U1 25
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 27
PY 2016
VL 113
IS 39
BP 10926
EP 10931
DI 10.1073/pnas.1606587113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW9DD
UT WOS:000383954700049
PM 27621441
ER

PT J
AU Flegal, KM
   Ogden, CL
AF Flegal, Katherine M.
   Ogden, Cynthia L.
TI Use of Projection Analyses and Obesity Trends In Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Flegal, Katherine M.; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
EM kflegal@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 27
PY 2016
VL 316
IS 12
BP 1317
EP 1317
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW9EW
UT WOS:000383959800026
PM 27673313
ER

PT J
AU Johansson, MA
   Reich, NG
   Hota, A
   Brownstein, JS
   Santillana, M
AF Johansson, Michael A.
   Reich, Nicholas G.
   Hota, Aditi
   Brownstein, John S.
   Santillana, Mauricio
TI Evaluating the performance of infectious disease forecasts: A comparison
   of climate-driven and seasonal dengue forecasts for Mexico
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NINO-SOUTHERN-OSCILLATION; TIME-SERIES ANALYSIS; RIO-DE-JANEIRO;
   HEMORRHAGIC-FEVER; NORTHEASTERN THAILAND; VIRUS TRANSMISSION; TEMPORAL
   PATTERNS; AEDES-AEGYPTI; PREDICTION; MODEL
AB Dengue viruses, which infect millions of people per year worldwide, cause large epidemics that strain healthcare systems. Despite diverse efforts to develop forecasting tools including autoregressive time series, climate-driven statistical, and mechanistic biological models, little work has been done to understand the contribution of different components to improved prediction. We developed a framework to assess and compare dengue forecasts produced from different types of models and evaluated the performance of seasonal autoregressive models with and without climate variables for forecasting dengue incidence in Mexico. Climate data did not significantly improve the predictive power of seasonal autoregressive models. Short-term and seasonal autocorrelation were key to improving short-term and long-term forecasts, respectively. Seasonal autoregressive models captured a substantial amount of dengue variability, but better models are needed to improve dengue forecasting. This framework contributes to the sparse literature of infectious disease prediction model evaluation, using state-of-the-art validation techniques such as out-of-sample testing and comparison to an appropriate reference model.
C1 [Johansson, Michael A.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Dengue Branch, San Juan, PR 00920 USA.
   [Johansson, Michael A.] Harvard TH Chan Sch Publ Hlth, Ctr Communicable Dis Dynam, Boston, MA 02115 USA.
   [Reich, Nicholas G.] Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA.
   [Hota, Aditi; Brownstein, John S.; Santillana, Mauricio] Boston Childrens Hosp, Computat Hlth Informat Program, Boston, MA 02115 USA.
   [Brownstein, John S.; Santillana, Mauricio] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
   [Santillana, Mauricio] Harvard Univ, JA Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Johansson, MA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Dengue Branch, San Juan, PR 00920 USA.; Johansson, MA (reprint author), Harvard TH Chan Sch Publ Hlth, Ctr Communicable Dis Dynam, Boston, MA 02115 USA.; Santillana, M (reprint author), Boston Childrens Hosp, Computat Hlth Informat Program, Boston, MA 02115 USA.; Santillana, M (reprint author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; Santillana, M (reprint author), Harvard Univ, JA Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
EM eyq9@cdc.gov; msantill@g.harvard.edu
FU National Institute of General Medical Sciences at the National
   Institutes of Health [1U54GM088558]; National Institute of Allergy and
   Infectious Diseases at the National Institutes of Health [R21
   AI115173-01, R01 AI102939-01]; National Library of Medicine at the
   National Institutes of Health [R01 LM010812-04]
FX This work was supported by the National Institute of General Medical
   Sciences at the National Institutes of Health (Grant 1U54GM088558), the
   National Institute of Allergy and Infectious Diseases at the National
   Institutes of Health (Grants R21 AI115173-01 and R01 AI102939-01), and
   the National Library of Medicine at the National Institutes of Health
   (Grant R01 LM010812-04).
NR 63
TC 0
Z9 0
U1 6
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 26
PY 2016
VL 6
AR 33707
DI 10.1038/srep33707
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DX5IV
UT WOS:000384415600001
PM 27665707
ER

PT J
AU Bergen, G
   Stevens, MR
   Burns, ER
AF Bergen, Gwen
   Stevens, Mark R.
   Burns, Elizabeth R.
TI Falls and Fall Injuries Among Adults Aged >= 65 Years - United States,
   2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID OLDER-ADULTS; GENDER-DIFFERENCES; RISK-FACTORS; PREVENTION; HEALTH; CARE
C1 [Bergen, Gwen; Burns, Elizabeth R.] CDC, Div Unintent Injury, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Stevens, Mark R.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
RP Bergen, G (reprint author), CDC, Div Unintent Injury, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM gbergen@cdc.gov
NR 10
TC 4
Z9 4
U1 9
U2 9
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 23
PY 2016
VL 65
IS 37
BP 993
EP 998
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LW
UT WOS:000384275600001
ER

PT J
AU Linley, L
   An, Q
   Song, RG
   Valverde, E
   Oster, AM
   Qian, XN
   Hernandez, AL
AF Linley, Laurie
   An, Qian
   Song, Ruiguang
   Valverde, Eduardo
   Oster, Alexandra M.
   Qian, Xiaona
   Hernandez, Angela L.
TI HIV Testing Experience Before HIV Diagnosis Among Men Who Have Sex with
   Men-21 Jurisdictions, United States, 2007-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID RECOMMENDATIONS
C1 [Linley, Laurie; An, Qian; Song, Ruiguang; Valverde, Eduardo; Oster, Alexandra M.; Qian, Xiaona; Hernandez, Angela L.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA.
RP Linley, L (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA.
EM LLinley@cdc.gov
NR 9
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 23
PY 2016
VL 65
IS 37
BP 999
EP 1003
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LW
UT WOS:000384275600003
ER

PT J
AU DeGroote, NP
   Korhonen, LC
   Shouse, RL
   Valleroy, LA
   Bradley, H
AF DeGroote, Nicholas P.
   Korhonen, Lauren C.
   Shouse, R. Luke
   Valleroy, Linda A.
   Bradley, Heather
TI Unmet Needs for Ancillary Services Among Men Who Have Sex with Men and
   Who Are Receiving HIV Medical Care - United States, 2013-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID OUTCOMES
C1 [DeGroote, Nicholas P.; Korhonen, Lauren C.; Shouse, R. Luke; Valleroy, Linda A.; Bradley, Heather] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis, Atlanta, GA 30333 USA.
   [DeGroote, Nicholas P.; Korhonen, Lauren C.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
RP DeGroote, NP (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis, Atlanta, GA 30333 USA.; DeGroote, NP (reprint author), Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
EM ndegroote@cdc.gov
NR 9
TC 0
Z9 0
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 23
PY 2016
VL 65
IS 37
BP 1004
EP 1007
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LW
UT WOS:000384275600004
ER

PT J
AU Budd, A
   Blanton, L
   Kniss, K
   Smith, S
   Mustaquim, D
   Davlin, SL
   Kramer, N
   Flannery, B
   Fry, AM
   Grohskopf, LA
   Olsen, SJ
   Bresee, J
   Sessions, W
   Garten, R
   Xu, XY
   Abd Elal, AI
   Gubareva, L
   Barnes, J
   Wentworth, DE
   Burns, E
   Katz, J
   Jernigan, D
   Brammer, L
AF Budd, Alicia
   Blanton, Lenee
   Kniss, Krista
   Smith, Sophie
   Mustaquim, Desiree
   Davlin, Stacy L.
   Kramer, Natalie
   Flannery, Brendan
   Fry, Alicia M.
   Grohskopf, Lisa A.
   Olsen, Sonja J.
   Bresee, Joseph
   Sessions, Wendy
   Garten, Rebecca
   Xu, Xiyan
   Abd Elal, Anwar Isa
   Gubareva, Larisa
   Barnes, John
   Wentworth, David E.
   Burns, Erin
   Katz, Jacqueline
   Jernigan, Daniel
   Brammer, Lynnette
TI Update: Influenza Activity - United States and Worldwide, May
   22-September 10, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID HOSPITALIZATIONS; VACCINE
C1 [Budd, Alicia; Blanton, Lenee; Kniss, Krista; Smith, Sophie; Mustaquim, Desiree; Davlin, Stacy L.; Kramer, Natalie; Flannery, Brendan; Fry, Alicia M.; Grohskopf, Lisa A.; Olsen, Sonja J.; Bresee, Joseph; Sessions, Wendy; Garten, Rebecca; Xu, Xiyan; Abd Elal, Anwar Isa; Gubareva, Larisa; Barnes, John; Wentworth, David E.; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Budd, A (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM abudd@cdc.gov
NR 7
TC 0
Z9 0
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 23
PY 2016
VL 65
IS 37
BP 1008
EP 1014
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LW
UT WOS:000384275600005
ER

PT J
AU Yeung, KHT
   Tate, JE
   Chan, CC
   Chan, MCW
   Chan, PKS
   Poon, KH
   Siu, SLY
   Fung, GPG
   Ng, KL
   Chan, IMC
   Yu, PT
   Ng, CH
   Lau, YL
   Nelson, EAS
AF Yeung, Karene Hoi Ting
   Tate, Jacqueline E.
   Chan, Ching Ching
   Chan, Martin C. W.
   Chan, Paul K. S.
   Poon, Kin Hung
   Siu, Sylvia Luen Yee
   Fung, Genevieve Po Gee
   Ng, Kwok Leung
   Chan, Iris Mei Ching
   Yu, Pui Tak
   Ng, Chi Hang
   Lau, Yu Lung
   Nelson, E. Anthony S.
TI Rotavirus vaccine effectiveness in Hong Kong children
SO VACCINE
LA English
DT Article
DE Rotavirus; Gastroenteritis; Rotavirus vaccine; Vaccine effectiveness
ID US CHILDREN; GASTROENTERITIS HOSPITALIZATIONS; YOUNG-CHILDREN;
   UNITED-STATES; PENTAVALENT; EFFICACY; PREVENTION; DISEASE; SAFETY;
   POPULATION
AB Background: Rotavirus is a common infectious cause of childhood hospitalisation in Hong Kong. Rotavirus vaccines have been used in the private sector since licensure in 2006 but have not been incorporated in the government's universal Childhood Immunisation Programme. This study aimed to evaluate rotavirus vaccine effectiveness against hospitalisation.
   Methods: This case-control study was conducted in the 2014/2015 rotavirus season in six public hospitals. Hospitalised acute gastroenteritis patients meeting inclusion criteria were recruited and copies of their immunisation records were collected. Case-patients were defined as enrolled subjects with stool specimens obtained in the first 48 h of hospitalisation that tested positive for rotavirus, whereas control-patients were those with stool specimen obtained in the first 48 h of hospitalisation testing negative for rotavirus. Vaccine effectiveness for administration of at least one dose of either Rotarix((R)) (GlaxoSmithKline Biologicals) or RotaTeq((R)) (Merck Research Laboratories) was calculated as 1 minus the odds ratio for rotavirus vaccination history for case-patients versus control-patients.
   Results: Among the 525 eligible subjects recruited, immunisation records were seen in 404 (77%) subjects. 31% (162/525 and 126/404) tested positive for rotavirus. In the 404 subjects assessed for vaccine effectiveness, 2.4% and 24% received at least 1 dose of either rotavirus vaccine in case-and control-patients respectively. The unmatched vaccine effectiveness against hospitalisation for administration of at least one dose of either rotavirus vaccines was 92% (95% confidence interval [CI]: 75%, 98%). The matched analyses by age only and both age and admission date showed 96% (95% CI: 72%, 100%) and 89% (95% CI: 51%, 97%) protection against rotavirus hospitalisation respectively.
   Conclusions: Rotavirus vaccine is highly effective in preventing hospitalisation from rotavirus disease in young Hong Kong children. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Yeung, Karene Hoi Ting; Chan, Ching Ching; Nelson, E. Anthony S.] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.
   [Tate, Jacqueline E.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Chan, Martin C. W.; Chan, Paul K. S.] Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Poon, Kin Hung; Siu, Sylvia Luen Yee] Tuen Mun Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Fung, Genevieve Po Gee; Ng, Kwok Leung] United Christian Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Iris Mei Ching; Yu, Pui Tak] Kwong Wah Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.
   [Ng, Chi Hang] Queen Elizabeth Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.
   [Lau, Yu Lung] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
RP Nelson, EAS (reprint author), Chinese Univ Hong Kong, Dept Paediat, Prince Wales Hosp, 6-F Lui Che Woo Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM tony-nelson@cuhk.edu.hk
RI Chan, Martin C.W./B-3588-2009
OI Chan, Martin C.W./0000-0002-1568-1596
FU Research Grants Council General Research Fund [CUHK 14111514]
FX This work was supported by the Research Grants Council General Research
   Fund [CUHK 14111514].
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 22
PY 2016
VL 34
IS 41
BP 4935
EP 4942
DI 10.1016/j.vaccine.2016.08.047
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DY1LY
UT WOS:000384857700013
PM 27595446
ER

PT J
AU Nowalk, MP
   Lin, CJ
   Pavlik, VN
   Brown, AE
   Zhang, S
   Moehling, KK
   Raviotta, JM
   South-Paul, JE
   Hawk, M
   Ricci, EM
   Middleton, DB
   Patel, SA
   Ahmed, F
   Zimmerman, RK
AF Nowalk, Mary Patricia
   Lin, Chyongchiou J.
   Pavlik, Valory N.
   Brown, Anthony E.
   Zhang, Song
   Moehling, Krissy K.
   Raviotta, Jonathan M.
   South-Paul, Jeannette E.
   Hawk, Mary
   Ricci, Edmund M.
   Middleton, Donald B.
   Patel, Suchita A.
   Ahmed, Faruque
   Zimmerman, Richard K.
TI Using the 4 Pillars (TM) Practice Transformation Program to increase
   adult Tdap immunization in a randomized controlled cluster trial
SO VACCINE
LA English
DT Article
DE Tdap vaccine; Immunization; Adults; Pertussis; Tetanus
ID NONINFLUENZA VACCINATION COVERAGE; ACELLULAR PERTUSSIS-VACCINE;
   UNITED-STATES; DIPHTHERIA; TETANUS
AB Introduction: National adult Tdap vaccination rates are low, reinforcing the need to increase vaccination efforts in primary care offices. The 4 Pillars (TM) Practice Transformation Program is an evidence-based, step-by-step guide to improving primary care adult vaccination with an online implementation tracking dashboard. This study tested the effectiveness of an intervention to increase adult Tdap vaccination that included the 4 Pillars (TM) Program, provider education, and one-on-one coaching of practice-based immunization champions.
   Methods: 25 primary care practices participated in a randomized controlled cluster trial (RCCT) in Year 1 (6/1/2013-5/31/2014) and a pre-post study in Year 2 (6/1/2014-1/31/2015). Baseline year was 6/1/2012-5/31/2013, with data analyzed in 2016. Demographic and vaccination data were derived from de-identified electronic medical record (EMR) extractions. The primary outcomes were vaccination rates and percentage point (PP) changes/year.
   Results: The cohort consisted of 70,549 patients >= 18 years who were seen in the practices >= 1 time each year, with a baseline mean age = 55 years; 35% were men; 56% were non-white; 35% were Hispanic and 20% were on Medicare. Baseline vaccination rate averaged 35%. In the Year 1 RCCT, cumulative Tdap vaccination increased significantly in both intervention and control groups; in both cities, the percentage point increases in the intervention groups (7.7 PP in Pittsburgh and 9.9 PP in Houston) were significantly higher (P < 0.001) than in the control groups (6.4 PP in Pittsburgh and 7.6 PP in Houston). In the Year 2 pre-post study, in both cities, active intervention groups increased rates significantly more (6.2 PP for both) than maintenance groups (2.2 PP in Pittsburgh and 4.1 PP in Houston; P < 0.001).
   Conclusions: An intervention that includes the 4 Pillars (TM) Practice Transformation Program, staff education and coaching is effective for increasing adult Tdap immunization rates within primary care practices. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Nowalk, Mary Patricia; Lin, Chyongchiou J.; Zhang, Song; Moehling, Krissy K.; Raviotta, Jonathan M.; South-Paul, Jeannette E.; Middleton, Donald B.; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA USA.
   [Pavlik, Valory N.; Brown, Anthony E.; Zimmerman, Richard K.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA.
   [Hawk, Mary; Ricci, Edmund M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
   [Patel, Suchita A.; Ahmed, Faruque] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Brown, Anthony E.] Houston Methodist Primary Care Grp, Houston, TX USA.
RP Nowalk, MP (reprint author), Dept Family Med, 3518 5th Ave, Pittsburgh, PA 15261 USA.
EM tnowalk@pitt.edu
FU Centers for Disease Control and Prevention [U01IP000662]; National
   Institutes of Health [UL1RR024153, UL1TR000005]
FX This work was supported by the Centers for Disease Control and
   Prevention [Grant number U01IP000662] and the National Institutes of
   Health [Grant numbers UL1RR024153 and UL1TR000005].
NR 16
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 22
PY 2016
VL 34
IS 41
BP 5026
EP 5033
DI 10.1016/j.vaccine.2016.07.053
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DY1LY
UT WOS:000384857700026
PM 27576073
ER

PT J
AU Idoko, OT
   Hampton, LM
   Mboizi, RB
   Agbla, SC
   Wallace, AS
   Harris, JB
   Sowe, D
   Ehlman, DC
   Kampmann, B
   Ota, MO
   Hyde, TB
AF Idoko, Olubukola T.
   Hampton, Lee M.
   Mboizi, Robert B.
   Agbla, Schadrac C.
   Wallace, Aaron S.
   Harris, Jennifer B.
   Sowe, Dawda
   Ehlman, Daniel C.
   Kampmann, Beate
   Ota, Martin O.
   Hyde, Terri B.
TI Acceptance of multiple injectable vaccines in a single immunization
   visit in The Gambia pre and post introduction of inactivated polio
   vaccine
SO VACCINE
LA English
DT Article
DE Acceptance; Multiple injectable vaccines; Single visit; Healthcare
   providers; Caregivers; The Gambia
ID PARENTAL ATTITUDES; INJECTIONS; PROVIDER
AB Background: As the World Health Organization (WHO) currently recommends that children be protected against 11 different pathogens, it is becoming increasingly necessary to administer multiple injectable vaccines during a single immunization visit. In this study we assess Gambian healthcare providers' and infant caregivers' attitudes and practices related to the administration of multiple injectable vaccines to a child at a single immunization visit before and after the 2015 introduction of inactivated polio vaccine (IPV). IPV introduction increased the number of injectable vaccines recommended for the 4-month immunization visit from two to three in The Gambia.
   Methods: We conducted a cross-sectional questionnaire-based survey before and after the introduction of IPV at 4 months of age in a representative sample of all health facilities providing immunizations in The Gambia. Healthcare providers who administer vaccines at the selected health facilities and caregivers who brought infants for their 4 month immunization visit were surveyed.
   Findings: Prior to IPV introduction, 9.9% of healthcare providers and 35.7% of infant caregivers expressed concern about a child receiving more than 2 injections in a single visit. Nevertheless, 98.8% and 90.9% of infants received all required vaccinations for the visit before and after IPV introduction, respectively. The only reason why vaccines were not received was vaccine stock-outs. Infant caregivers generally agreed that vaccinators could be trusted to provide accurate information regarding the number of vaccines that a child needed.
   Conclusion: Healthcare providers and infant caregivers in this resource limited setting accepted an increase in the number of injectable vaccines administered at a single visit even though some expressed concerns about the increase. Published by Elsevier Ltd.
C1 [Idoko, Olubukola T.; Mboizi, Robert B.; Agbla, Schadrac C.; Kampmann, Beate] MRC Unit, Vaccines & Immun Theme, Banjul, Gambia.
   [Hampton, Lee M.; Wallace, Aaron S.; Harris, Jennifer B.; Ehlman, Daniel C.; Hyde, Terri B.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
   [Sowe, Dawda] Minist Hlth & Social Welf, Banjul, Gambia.
   [Kampmann, Beate] Imperial Coll London, Acad Dept Paediat, London, England.
   [Ota, Martin O.] WHO Reg Off Africa, Brazaville, Congo.
RP Idoko, OT (reprint author), MRC Unit, Vaccines & Immun Theme, Banjul, Gambia.
EM bukkyidoko@gmail.com
FU Centres for Disease Control by The medical Research Council Unit, The
   Gambia
FX Funds for the conduct of the study were received from the Centres for
   Disease Control by The medical Research Council Unit, The Gambia. The
   authors have no other conflicts of interest to declare.
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 22
PY 2016
VL 34
IS 41
BP 5034
EP 5039
DI 10.1016/j.vaccine.2016.07.021
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DY1LY
UT WOS:000384857700027
PM 27570237
ER

PT J
AU Lazar, M
   Abernathy, E
   Chen, M
   Icenogle, J
   Janta, D
   Stanescu, A
   Pistol, A
   Santibanez, S
   Mankertz, A
   Hubschen, JM
   Mihaescu, G
   Necula, G
   Lupulescu, E
AF Lazar, M.
   Abernathy, E.
   Chen, M.
   Icenogle, J.
   Janta, D.
   Stanescu, A.
   Pistol, A.
   Santibanez, S.
   Mankertz, A.
   Hubschen, J. M.
   Mihaescu, G.
   Necula, G.
   Lupulescu, E.
TI Epidemiological and molecular investigation of a rubella outbreak,
   Romania, 2011 to 2012
SO EUROSURVEILLANCE
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; VIRUS RNA; SURVEILLANCE; TESTS; TOOL; IGM
AB We describe a rubella outbreak that occurred in Romania between September 2011 and December 2012. During this period 24,627 rubella cases, 41.1% (n=10,134) of which female, were notified based on clinical criteria, and a total of 6,182 individuals were found serologically positive for IgM-specific rubella antibody. The median age of notified cases was 18 years (range: <1-65) and the most affected age group 15 to 19 years (n=16,245 cases). Of all notified cases, 24,067 cases (97.7%) reported no history of vaccination. Phylogenetic analysis of 19 sequences (739 nucleotides each), from 10 districts of the country revealed that the outbreak was caused by two distinct rubella virus strains of genotype 2B, which co-circulated with both temporal and geographical overlap. In addition to the 6,182 IgM-positive rubella cases, 28 cases of congenital rubella syndrome (CRS) were identified, including 11 neonatal deaths and one stillbirth. The outbreak underscores the need to encourage higher vaccination uptake in the population, particularly in women of reproductive age, and to strengthen epidemiological and laboratory investigations of suspected rubella cases. Genetic characterisation of wild-type rubella virus is an essential component to enhance surveillance and here we report rubella virus sequences from Romania.
C1 [Lazar, M.; Necula, G.; Lupulescu, E.] Natl Inst Res Dev Microbiol & Immunol Cantacuzino, Bucharest, Romania.
   [Abernathy, E.; Chen, M.; Icenogle, J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Janta, D.; Stanescu, A.; Pistol, A.] Natl Inst Publ Hlth, Natl Ctr Communicable Dis Surveillance & Control, Bucharest, Romania.
   [Santibanez, S.; Mankertz, A.] WHO EURO, Robert Koch Inst, Reg Reference Lab Measles & Rubella, Berlin, Germany.
   [Hubschen, J. M.] WHO EURO, Dept Infect & Immun, Reg Reference Lab Measles & Rubella, Luxembourg Inst Hlth Esch Sur Alzette, Luxembourg, Luxembourg.
   [Necula, G.] Horia Hulubei Natl Inst R&D Phys & Nucl Engn, Bucharest, Romania.
   [Mihaescu, G.] Univ Bucharest, Fac Biol, Dept Virol, Bucharest, Romania.
RP Lazar, M (reprint author), Natl Inst Res Dev Microbiol & Immunol Cantacuzino, Bucharest, Romania.
EM mlazar@cantacuzino.ro
OI Necula, Gheorghe/0000-0002-7647-4961
FU project 'Strengthening and expanding microbiological surveillance
   capacity in vaccine-preventable diseases'; CDC's rubella team, MMR and
   Herpesviruses Lab Branch
FX This research paper is made possible through the help and financial
   support from the project 'Strengthening and expanding microbiological
   surveillance capacity in vaccine-preventable diseases' (coordinated by
   Dr. Monica Straut) and CDC's rubella team, MMR and Herpesviruses Lab
   Branch coordinated by Dr William (Bill) Bellini. We thank Sorin Dinu,
   Emilia Dobre, Luiza Ustea and Nuti Enache for technical assistance. We
   are very grateful to all our colleagues from the Romanian local public
   health departments for sending specimens of suspected rubella cases.
NR 37
TC 0
Z9 0
U1 2
U2 2
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD SEP 22
PY 2016
VL 21
IS 38
BP 22
EP 32
AR 30345
DI 10.2807/1560-7917.ES.2016.21.38.30345
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA DX1SA
UT WOS:000384146100004
ER

PT J
AU Zimmerman, RK
   Balasubramani, GK
   Nowalk, MP
   Eng, H
   Urbanski, L
   Jackson, ML
   Jackson, LA
   McLean, HQ
   Belongia, EA
   Monto, AS
   Malosh, RE
   Gaglani, M
   Clipper, L
   Flannery, B
   Wisniewski, SR
AF Zimmerman, Richard K.
   Balasubramani, G. K.
   Nowalk, Mary Patricia
   Eng, Heather
   Urbanski, Leonard
   Jackson, Michael L.
   Jackson, Lisa A.
   McLean, Huong Q.
   Belongia, Edward A.
   Monto, Arnold S.
   Malosh, Ryan E.
   Gaglani, Manjusha
   Clipper, Lydia
   Flannery, Brendan
   Wisniewski, Stephen R.
TI Classification and Regression Tree (CART) analysis to predict influenza
   in primary care patients
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Clinical decision tools; Influenza; Recursive partitioning
ID CLINICAL DECISION RULE; TEST-NEGATIVE DESIGN; VACCINE EFFECTIVENESS;
   SEASONAL INFLUENZA; METAANALYSIS; DIAGNOSIS; VIRUS; COMPLICATIONS;
   OSELTAMIVIR; INFECTION
AB Background: The use of neuraminidase-inhibiting anti-viral medication to treat influenza is relatively infrequent. Rapid, cost-effective methods for diagnosing influenza are needed to enable appropriate prescribing. Multi-viral respiratory panels using reverse transcription polymerase chain reaction (PCR) assays to diagnose influenza are accurate but expensive and more time-consuming than low sensitivity rapid influenza tests. Influenza clinical decision algorithms are both rapid and inexpensive, but most are based on regression analyses that do not account for higher order interactions. This study used classification and regression trees (CART) modeling to estimate probabilities of influenza.
   Methods: Eligible enrollees >= 5 years old (n = 4,173) who presented at ambulatory centers for treatment of acute respiratory illness (<= 7 days) with cough or fever in 2011-2012, provided nasal and pharyngeal swabs for PCR testing for influenza, information on demographics, symptoms, personal characteristics and self-reported influenza vaccination status.
   Results: Antiviral medication was prescribed for just 15 % of those with PCR-confirmed influenza. An algorithm that included fever, cough, and fatigue had sensitivity of 84 %, specificity of 48 %, positive predictive value (PPV) of 23 % and negative predictive value (NPV) of 94 % for the development sample.
   Conclusions: The CART algorithm has good sensitivity and high NPV, but low PPV for identifying influenza among outpatients >= 5 years. Thus, it is good at identifying a group who do not need testing or antivirals and had fair to good predictive performance for influenza. Further testing of the algorithm in other influenza seasons would help to optimize decisions for lab testing or treatment.
C1 [Zimmerman, Richard K.; Balasubramani, G. K.; Nowalk, Mary Patricia; Eng, Heather; Wisniewski, Stephen R.] Univ Pittsburgh, Pittsburgh, PA USA.
   [McLean, Huong Q.; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA.
   [Flannery, Brendan] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Gaglani, Manjusha; Clipper, Lydia] Baylor Scott & White Hlth, Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA.
   [Jackson, Michael L.; Jackson, Lisa A.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA.
   [Monto, Arnold S.; Malosh, Ryan E.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Zimmerman, Richard K.] Univ Pittsburgh, Dept Family Med, 3518 5th Ave, Pittsburgh, PA USA.
   [Urbanski, Leonard] UPMC Urgent Care, Natrona Hts, PA USA.
RP Zimmerman, RK (reprint author), Univ Pittsburgh, Pittsburgh, PA USA.; Zimmerman, RK (reprint author), Univ Pittsburgh, Dept Family Med, 3518 5th Ave, Pittsburgh, PA USA.
EM zimmer@pitt.edu
FU Centers for Disease Control and Prevention; University of Michigan [U01
   IP000474]; Group Health Research Institute [U01 IP000466]; Marshfield
   Clinic Research Foundation [U01 IP000471]; University of Pittsburgh [U01
   IP000467]; Baylor Scott and White Health [U01 IP000473]; National
   Institutes of Health [UL1 RR024153, UL1TR000005]
FX This work was supported by the Centers for Disease Control and
   Prevention (author BF) through cooperative agreements with the
   University of Michigan (via grant U01 IP000474, authors ASM, REM), Group
   Health Research Institute (via grant U01 IP000466, authors MLJ, LAJ),
   Marshfield Clinic Research Foundation (via grant U01 IP000471, authors
   HQM, EAB), University of Pittsburgh (via grant U01 IP000467, authors
   RKZ, GKB, MPN, HE, LU, SRW), and Baylor Scott and White Health (via
   grant U01 IP000473, MG, LC).; At the University of Pittsburgh, the
   project was also supported by the National Institutes of Health through
   Grant Numbers UL1 RR024153 and UL1TR000005. It is subject to the NIH's
   Open Access Policy. The views expressed herein are those of those
   authors and not those of the funding agency.
NR 28
TC 0
Z9 0
U1 9
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD SEP 22
PY 2016
VL 16
AR 503
DI 10.1186/s12879-016-1839-x
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA DW5BV
UT WOS:000383658000001
PM 27659721
ER

PT J
AU Rainey, JJ
   Kenney, J
   Wilburn, B
   Putman, A
   Zheteyeva, Y
   O'Sullivan, M
AF Rainey, Jeanette J.
   Kenney, Jasmine
   Wilburn, Ben
   Putman, Ami
   Zheteyeva, Yenlik
   O'Sullivan, Megan
TI OnlineWork Force Analyzes Social Media to Identify Consequences of an
   Unplanned School Closure - Using Technology to Prepare for the Next
   Pandemic
SO PLOS ONE
LA English
DT Article
ID INFLUENZA-A H1N1; UNITED-STATES; SURVEILLANCE; TWITTER
AB Background
   During an influenza pandemic, the United States Centers for Disease Control and Prevention (CDC) may recommend school closures. These closures could have unintended consequences for students and their families. Publicly available social media could be analyzed to identify the consequences of an unplanned school closure.
   Methods
   As a proxy for an unplanned, pandemic-related school closure, we used the district-wide school closure due to the September 10 - 18, 2012 teachers' strike in Chicago, Illinois. We captured social media posts about the school closure using the Radian6 social media-monitoring platform. An online workforce from Amazon Mechanical Turk categorized each post into one of two groups. The first group included relevant posts that described the impact of the closure on students and their families. The second group included irrelevant posts that described the political aspects of the strike or topics unrelated to the school closure. All relevant posts were further categorized as expressing a positive, negative, or neutral sentiment. We analyzed patterns of relevant posts and sentiment over time and compared our findings to household surveys conducted after other unplanned school closures.
   Results
   We captured 4,546 social media posts about the district-wide school closure using our search criteria. Of these, 930 (20%) were categorized as relevant by the online workforce. Of the relevant posts, 619 (67%) expressed a negative sentiment, 51 (5%) expressed a positive sentiment, and 260 (28%) were neutral. The number of relevant posts, and especially those with a negative sentiment, peaked on day 1 of the strike. Negative sentiment expressed concerns about childcare, missed school lunches, and the lack of class time for students. This was consistent with findings from previously conducted household surveys.
   Conclusion
   Social media are publicly available and can readily provide information on the impact of an unplanned school closure on students and their families. Using social media to assess the impact of an unplanned school closure due to a public health event would be informative. An online workforce can effectively assist with the review process.
C1 [Rainey, Jeanette J.; Kenney, Jasmine; Putman, Ami; Zheteyeva, Yenlik; O'Sullivan, Megan] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30329 USA.
   [Wilburn, Ben] ORISE, Oak Ridge, TN USA.
RP Rainey, JJ (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30329 USA.
EM jkr7@cdc.gov
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2016
VL 11
IS 9
AR e0163207
DI 10.1371/journal.pone.0163207
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW8GK
UT WOS:000383892700041
PM 27655229
ER

PT J
AU Dorado, EJ
   Okoth, SA
   Montenegro, LM
   Diaz, G
   Barnwell, JW
   Udhayakumar, V
   Solano, CM
AF Jimena Dorado, Erika
   Okoth, Sheila Akinyi
   Madeline Montenegro, Lidia
   Diaz, Gustavo
   Barnwell, John W.
   Udhayakumar, Venkatachalam
   Murillo Solano, Claribel
TI Genetic Characterisation of Plasmodium falciparum Isolates with Deletion
   of the pfhrp2 and/or pfhrp3 Genes in Colombia: The Amazon Region, a
   Challenge for Malaria Diagnosis and Control
SO PLOS ONE
LA English
DT Article
ID HISTIDINE-RICH PROTEIN-2; MICROSATELLITE MARKERS; SEQUENCE VARIATION;
   TESTS; PARASITES; PERU; PERFORMANCE; ORIGIN
AB Most Plasmodium falciparum-detecting rapid diagnostic tests (RDTs) target histidine-rich protein 2 (PfHRP2). However, P. falciparum isolates with deletion of the pfhrp2 gene and its homolog gene, pfhrp3, have been detected. We carried out an extensive investigation on 365 P. falciparum dried blood samples collected from seven P. falciparum endemic sites in Colombia between 2003 and 2012 to genetically characterise and geographically map pfhrp2-and/or pfhrp3-negative P. falciparum parasites in the country. We found a high proportion of pfhrp2-negative parasites only in Amazonas (15/39; 38.5%), and these parasites were also pfhrp3-negative. These parasites were collected between 2008 and 2009 in Amazonas, while pfhrp3-negative parasites (157/365, 43%) were found in all the sites and from each of the sample collection years evaluated (2003 to 2012). We also found that all pfhrp2-and/or pfhrp3-negative parasites were also negative for one or both flanking genes. Six sub-population clusters were established with 93.3% (14/15) of the pfhrp2-negative parasites grouped in the same cluster and sharing the same haplotype. This haplotype corresponded with the genetic lineage B-V1, a multidrug resistant strain that caused two outbreaks reported in Peru between 2010 and 2013. We found this B-V1 lineage in the Colombian Amazon as early as 2006. Two new clonal lineages were identified in these parasites from Colombia: the genetic lineages E-V1 and F. PfHRP2 sequence analysis revealed high genetic diversity at the amino acid level, with 17 unique sequences identified among 53 PfHRP2 sequences analysed. The use of PfHRP2-based RDTs is not recommended in Amazonas because of the high proportion of parasites with pfhrp2 deletion (38.5%), and implementation of new strategies for malaria diagnosis and control in Amazonas must be prioritised. Moreover, studies to monitor and genetically characterise pfhrp2-negative P. falciparum parasites in the Americas are warranted, given the extensive human migration occurring in the region.
C1 [Jimena Dorado, Erika; Madeline Montenegro, Lidia; Diaz, Gustavo; Murillo Solano, Claribel] Ctr Int Entrenamiento & Invest Med CIDEIM, Malaria Res Grp, Cali, Valle, Colombia.
   [Okoth, Sheila Akinyi; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA.
   [Okoth, Sheila Akinyi] Atlanta Res & Educ Fdn, Decatur, GA USA.
RP Dorado, EJ; Solano, CM (reprint author), Ctr Int Entrenamiento & Invest Med CIDEIM, Malaria Res Grp, Cali, Valle, Colombia.
EM erika.dorado@gmail.com; claribel.murillo@gmail.com
FU Departamento Administrativo de Ciencia, Tecnologia e Innovacion de la
   Republica de Colombia, COLCIENCIAS [222951928929]
FX This study was funded by Departamento Administrativo de Ciencia,
   Tecnologia e Innovacion de la Republica de Colombia, COLCIENCIAS
   (www.colciencias.gov.co), Grant 222951928929. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; We would like to thank the patients who
   participated at each site studied. We thank the microscopists, the
   healthcare workers from the ColombianMalaria Project supported by The
   Global Fund Project, the Colombian National Institute of Health (INS),
   Hospital Divino Nino-Tumaco, Instituto Departamental de Salud de
   Narino-IDSN, Laboratorio de Salud Publica del Amazonas, Hospital San
   Sebastian de Uraba-Necocli, Hospital Nuestra Senora del Carmen-El Bagre,
   Laboratorio de Salud Publica del Choco-DASALUD and other institutions
   from our previous studies for their support in the collection of the
   samples. We thank Olga L. Murillo and Nancy E. Molina for their
   assistance in establishing the study sites in Antioquia, Choco, Cauca
   and Valle. We thank Alvaro M. Lasso, AngelicaMera, Katherine Navarro,
   Jonathan A. Mora, Paula Castaneda, Javier Martinez, Samanda Aponte,
   Catalina Alvarez, Cesar Restrepo andMelissa Rios for their assistance
   with the sample collection in Narino, Choco, Guaviare and Amazonas. We
   also thank Dragan Ljolje and LindsayMorton for their support in sample
   handling at the CDC in Atlanta, USA.
NR 39
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2016
VL 11
IS 9
AR e0163137
DI 10.1371/journal.pone.0163137
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5YN
UT WOS:000383723700037
PM 27636709
ER

PT J
AU Joseph, SJ
   Cox, D
   Wolff, B
   Morrison, SS
   Kozak-Muiznieks, NA
   Frace, M
   Didelot, X
   Castillo-Ramirez, S
   Winchell, J
   Read, TD
   Dean, D
AF Joseph, Sandeep J.
   Cox, Daniel
   Wolff, Bernard
   Morrison, Shatavia S.
   Kozak-Muiznieks, Natalia A.
   Frace, Michael
   Didelot, Xavier
   Castillo-Ramirez, Santiago
   Winchell, Jonas
   Read, Timothy D.
   Dean, Deborah
TI Dynamics of genome change among Legionella species
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; HORIZONTAL GENE-TRANSFER;
   LEGIONNAIRES-DISEASE; POPULATION-STRUCTURE; STAPHYLOCOCCUS-AUREUS;
   PHYLOGENETIC ANALYSIS; HIGH-THROUGHPUT; PONTIAC FEVER; PNEUMOPHILA;
   RECOMBINATION
AB Legionella species inhabit freshwater and soil ecosystems where they parasitize protozoa. L. pneumonphila (LP) serogroup-1 (Lp1) is the major cause of Legionnaires' Disease (LD), a life-threatening pulmonary infection that can spread systemically. The increased global frequency of LD caused by Lp and non-Lp species underscores the need to expand our knowledge of evolutionary forces underlying disease pathogenesis. Whole genome analyses of 43 strains, including all known Lp serogroups 1-17 and 17 emergent LD-causing Legionella species (of which 33 were sequenced in this study) in addition to 10 publicly available genomes, resolved the strains into four phylogenetic clades along host virulence demarcations. Clade-specific genes were distinct for genetic exchange and signal-transduction, indicating adaptation to specific cellular and/or environmental niches. CRISPR spacer comparisons hinted at larger pools of accessory DNA sequences in Lp than predicted by the pan-genome analyses. While recombination within Lp was frequent and has been reported previously, population structure analysis identified surprisingly few DNA admixture events between species. In summary, diverse Legionella LD-causing species share a conserved core-genome, are genetically isolated from each other, and selectively acquire genes with potential for enhanced virulence.
C1 [Joseph, Sandeep J.; Read, Timothy D.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
   [Cox, Daniel] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Wolff, Bernard; Morrison, Shatavia S.; Kozak-Muiznieks, Natalia A.; Frace, Michael; Winchell, Jonas] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
   [Didelot, Xavier] Imperial Coll, Dept Infect Dis Epidemiol, Norfolk Pl, London, England.
   [Castillo-Ramirez, Santiago] Univ Nacl Autonoma Mexico, Ctr Ciencias Genom, Programa Genom Evolut, Cuernavaca, Morelos, Mexico.
   [Read, Timothy D.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA.
   [Dean, Deborah] Dept Med, San Francisco, CA USA.
   [Dean, Deborah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Dean, Deborah] Univ Calif San Francisco, Dept Biomed Engn, San Francisco, CA 94143 USA.
   [Dean, Deborah] Univ Calif Berkeley, Dept Biomed Engn, Berkeley, CA 94720 USA.
   [Dean, Deborah] UCSF Benioff Childrens Hosp, Oakland Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA USA.
RP Dean, D (reprint author), Dept Med, San Francisco, CA USA.; Dean, D (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Dean, D (reprint author), Univ Calif San Francisco, Dept Biomed Engn, San Francisco, CA 94143 USA.; Dean, D (reprint author), Univ Calif Berkeley, Dept Biomed Engn, Berkeley, CA 94720 USA.; Dean, D (reprint author), UCSF Benioff Childrens Hosp, Oakland Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA USA.
EM ddean@chori.org
FU Public Health Service grant from the National Institutes of Health [R01
   AI098843]; Advanced Molecular Detection initiative of the CDC
FX Part of this work was presented as a Master's thesis at Emory University
   by D.C. We would like to thank Tracy Lamb and Joanna Goldberg for
   providing comments, and Dr. Jurgen H. Helbig for providing L.
   pneumonphila serogroup 16 and 17. This research was funded in part by
   Public Health Service grant from the National Institutes of Health R01
   AI098843 (to D.D.) and by the Advanced Molecular Detection initiative of
   the CDC (J.W.).
NR 72
TC 0
Z9 0
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 16
PY 2016
VL 6
DI 10.1038/srep33442
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW4WO
UT WOS:000383643900001
PM 27633769
ER

PT J
AU Silverman, B
   Chen, B
   Brener, N
   Kruger, J
   Krishna, N
   Renard, P
   Romero-Steiner, S
   Avchen, RN
AF Silverman, Brenda
   Chen, Brenda
   Brener, Nancy
   Kruger, Judy
   Krishna, Nevin
   Renard, Paul, Jr.
   Romero-Steiner, Sandra
   Avchen, Rachel Nonkin
TI School District Crisis Preparedness, Response, and Recovery Plans -
   United States, 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Editorial Material
ID HEALTH; CHILDREN
C1 [Silverman, Brenda; Chen, Brenda; Kruger, Judy; Krishna, Nevin; Renard, Paul, Jr.; Avchen, Rachel Nonkin] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
   [Brener, Nancy] CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Romero-Steiner, Sandra] CDC, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
RP Silverman, B (reprint author), CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
EM bsilverman@cdc.gov
NR 9
TC 0
Z9 0
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 949
EP 953
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100002
PM 27631951
ER

PT J
AU Watson, KB
   Carlson, SA
   Gunn, JP
   Galuska, DA
   O'Connor, A
   Greenlund, KJ
   Fulton, JE
AF Watson, Kathleen B.
   Carlson, Susan A.
   Gunn, Janelle P.
   Galuska, Deborah A.
   O'Connor, Ann
   Greenlund, Kurt J.
   Fulton, Janet E.
TI Physical Inactivity Among Adults Aged 50 Years and Older - United
   States, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Watson, Kathleen B.; Carlson, Susan A.; Gunn, Janelle P.; Galuska, Deborah A.; O'Connor, Ann; Fulton, Janet E.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Greenlund, Kurt J.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Watson, KB (reprint author), CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM KWatson@cdc.gov
NR 10
TC 0
Z9 0
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 954
EP 958
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100003
PM 27632143
ER

PT J
AU Whitfield, GP
   Ussery, EN
   Riordan, B
   Wendel, AM
AF Whitfield, Geoffrey P.
   Ussery, Emily N.
   Riordan, Brian
   Wendel, Arthur M.
TI Association Between User-Generated Commuting Data and
   Population-Representative Active Commuting Surveillance Data - Four
   Cities, 2014-2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Whitfield, Geoffrey P.; Ussery, Emily N.] CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
   [Riordan, Brian] Strava Inc, Hanover, NH USA.
   [Wendel, Arthur M.] Agcy Tox Subst & Dis Registry, Div Community Hlth Invest, Seattle, WA USA.
RP Whitfield, GP (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
EM GWhitfield@cdc.gov
NR 9
TC 0
Z9 0
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 959
EP 962
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100004
PM 27632357
ER

PT J
AU Purpura, LJ
   Soka, M
   Baller, A
   White, S
   Rogers, E
   Choi, MJ
   Mahmoud, N
   Wasunna, C
   Massaquoi, M
   Vanderende, K
   Kollie, J
   Dweh, S
   Bemah, P
   Christie, A
   Ladele, V
   Subah, O
   Pillai, S
   Mugisha, M
   Kpaka, J
   Nichol, S
   Stroher, U
   Abad, N
   Mettee-Zarecki, S
   Bailey, JA
   Rollin, P
   Marston, B
   Nyenswah, T
   Gasasira, A
   Knust, B
   Williams, D
AF Purpura, Lawrence J.
   Soka, Moses
   Baller, April
   White, Stephen
   Rogers, Emerson
   Choi, Mary J.
   Mahmoud, Nuha
   Wasunna, Christine
   Massaquoi, Moses
   Vanderende, Kristin
   Kollie, Jomah
   Dweh, Straker
   Bemah, Philip
   Christie, Athalia
   Ladele, Victor
   Subah, Onyekachi
   Pillai, Satish
   Mugisha, Margaret
   Kpaka, Jonathan
   Nichol, Stuart
   Stroher, Ute
   Abad, Neetu
   Mettee-Zarecki, Shauna
   Bailey, Jeff A.
   Rollin, Pierre
   Marston, Barbara
   Nyenswah, Tolbert
   Gasasira, Alex
   Knust, Barbara
   Williams, Desmond
TI Implementation of a National Semen Testing and Counseling Program for
   Male Ebola Survivors - Liberia, 2015-2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID SEXUAL TRANSMISSION; VIRUS
C1 [Purpura, Lawrence J.; Choi, Mary J.; Nichol, Stuart; Stroher, Ute; Rollin, Pierre; Knust, Barbara] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Purpura, Lawrence J.; Vanderende, Kristin] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Baller, April; Mahmoud, Nuha; Kollie, Jomah; Ladele, Victor; Mugisha, Margaret; Gasasira, Alex] WHO, Geneva, Switzerland.
   [White, Stephen; Wasunna, Christine; Dweh, Straker; Subah, Onyekachi; Kpaka, Jonathan; Bailey, Jeff A.] Acad Consortium Combating Ebola Liberia, Monrovia, Liberia.
   [Vanderende, Kristin] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Christie, Athalia] CDC, Off Director, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Pillai, Satish] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Abad, Neetu] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Mettee-Zarecki, Shauna] CDC, Ctr Global Hlth, Div Emergency Operat, Atlanta, GA 30333 USA.
   [Marston, Barbara; Williams, Desmond] CDC, Ctr Global Hlth, Div Global Hlth Protect & Secur, Atlanta, GA 30333 USA.
RP Purpura, LJ (reprint author), CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.; Purpura, LJ (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM yxp0@cdc.gov
NR 8
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 963
EP 966
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100005
PM 27632552
ER

PT J
AU Ritchey, M
   Chang, AP
   Powers, C
   Loustalot, F
   Schieb, L
   Ketcham, M
   Durthaler, J
   Hong, YL
AF Ritchey, Matthew
   Chang, Anping
   Powers, Christopher
   Loustalot, Fleetwood
   Schieb, Linda
   Ketcham, Michelle
   Durthaler, Jeffrey
   Hong, Yuling
TI Vital Signs: Disparities in Antihypertensive Medication Nonadherence
   Among Medicare Part D Beneficiaries - United States, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID BLOOD-PRESSURE CONTROL; OLDER-ADULTS; ADHERENCE; HYPERTENSION; DISEASE;
   IMPACT
AB Introduction: Nonadherence to taking prescribed antihypertensive medication (antihypertensive) regimens has been identified as a leading cause of poor blood pressure control among persons with hypertension and an important risk factor for adverse cardiovascular disease outcomes. CDC and the Centers for Medicare and Medicaid Services analyzed geographic, racial-ethnic, and other disparities in nonadherence to antihypertensives among Medicare Part D beneficiaries in 2014.
   Methods: Antihypertensive nonadherence, defined as a proportion of days a beneficiary was covered with antihypertensives of <80%, was assessed using prescription drug claims data among Medicare Advantage or Medicare fee-for-service beneficiaries aged >= 65 years with Medicare Part D coverage during 2014 (N = 18.5 million). Analyses were stratified by antihypertensive class, beneficiaries' state and county of residence, type of prescription drug plan, and treatment and demographic characteristics.
   Results: Overall, 26.3% (4.9 million) of Medicare Part D beneficiaries using antihypertensives were nonadherent to their regimen. Nonadherence differed by multiple factors, including medication class (range: 16.9% for angiotensin II receptor blockers to 28.9% for diuretics); race-ethnicity (24.3% for non-Hispanic whites, 26.3% for Asian/Pacific Islanders, 33.8% for Hispanics, 35.7% for blacks, and 38.8% for American Indians/Alaska Natives); and state of residence (range 18.7% for North Dakota to 33.7% for the District of Columbia). Considerable county-level variation in nonadherence was found; the highest nonadherence tended to occur in the southern United States (U.S. Census region nonadherence = 28.9% [South], 26.7% [West], 24.1% [Northeast], and 22.8% [Midwest])
   Conclusions and Implications for Public Health Practice: More than one in four Medicare Part D beneficiaries using antihypertensives were nonadherent to their regimen, and certain racial/ethnic groups, states, and geographic areas were at increased risk for nonadherence. These findings can help inform focused interventions among these groups, which might improve blood pressure control and cardiovascular disease outcomes.
C1 [Ritchey, Matthew; Chang, Anping; Loustalot, Fleetwood; Schieb, Linda; Durthaler, Jeffrey; Hong, Yuling] CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA.
   [Powers, Christopher] Ctr Medicare & Medicaid Serv, Off Enterprise Data & Analyt, Baltimore, MD USA.
   [Ketcham, Michelle] Ctr Medicare & Medicaid Serv, Medicare Drug Benefit & C&D Data Grp, Baltimore, MD USA.
RP Ritchey, M (reprint author), CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA.
EM MRitchey@cdc.gov
NR 23
TC 1
Z9 1
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 967
EP 976
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100006
PM 27632693
ER

PT J
AU Kline, KE
   Shover, J
   Kallen, AJ
   Lonsway, DR
   Watkins, S
   Miller, JR
AF Kline, Kelly E.
   Shover, Jordan
   Kallen, Alexander J.
   Lonsway, David R.
   Watkins, Sharon
   Miller, Jeffrey R.
TI Investigation of First Identified mcr-1 Gene in an Isolate from a US
   Patient - Pennsylvania, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID ESCHERICHIA-COLI
C1 [Kline, Kelly E.; Shover, Jordan; Watkins, Sharon; Miller, Jeffrey R.] Penn Dept Hlth, Harrisburg, PA 17108 USA.
   [Kline, Kelly E.] CDC, CSTE, Appl Epidemiol Fellowship Program, Atlanta, GA 30333 USA.
   [Kallen, Alexander J.; Lonsway, David R.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Miller, Jeffrey R.] CDC, Career Epidemiol Field Officer Program, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
RP Kline, KE (reprint author), Penn Dept Hlth, Harrisburg, PA 17108 USA.
EM c-kekline@pa.gov
NR 4
TC 2
Z9 2
U1 5
U2 5
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 977
EP 978
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100007
PM 27631164
ER

PT J
AU Vasquez, AM
   Montero, N
   Laughlin, M
   Dancy, E
   Melmed, R
   Sosa, L
   Watkins, LF
   Folster, JP
   Strockbine, N
   Moulton-Meissner, H
   Ansari, U
   Cartter, ML
   Walters, MS
AF Vasquez, Amber M.
   Montero, Noelisa
   Laughlin, Mark
   Dancy, Ehren
   Melmed, Russell
   Sosa, Lynn
   Watkins, Louise Francois
   Folster, Jason P.
   Strockbine, Nancy
   Moulton-Meissner, Heather
   Ansari, Uzma
   Cartter, Matthew L.
   Walters, Maroya Spalding
TI Investigation of Escherichia coli Harboring the mcr-1 Resistance Gene -
   Connecticut, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Vasquez, Amber M.; Laughlin, Mark] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Vasquez, Amber M.; Moulton-Meissner, Heather; Ansari, Uzma; Walters, Maroya Spalding] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Montero, Noelisa; Melmed, Russell; Sosa, Lynn; Cartter, Matthew L.] Connecticut Dept Publ Hlth, Hartford, CT USA.
   [Montero, Noelisa] CDC, CSTE, Appl Epidemiol Fellowship Program, Atlanta, GA 30333 USA.
   [Laughlin, Mark; Dancy, Ehren; Watkins, Louise Francois; Folster, Jason P.; Strockbine, Nancy] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Vasquez, AM (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Vasquez, AM (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM avasquez@cdc.gov
NR 7
TC 5
Z9 5
U1 7
U2 7
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 979
EP 980
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100008
PM 27631346
ER

PT J
AU Brent, C
   Dunn, A
   Savage, H
   Faraji, A
   Rubin, M
   Risk, I
   Garcia, W
   Cortese, M
   Novosad, S
   Krow-Lucal, ER
   Crain, J
   Hill, M
   Atkinson, A
   Peterson, D
   Christensen, K
   Dimond, M
   Staples, JE
   Nakashima, A
AF Brent, Carolyn
   Dunn, Angela
   Savage, Harry
   Faraji, Ary
   Rubin, Mike
   Risk, Ilene
   Garcia, Wendy
   Cortese, Margaret
   Novosad, Shannon
   Krow-Lucal, Elisabeth Raquel
   Crain, Jacqueline
   Hill, Mary
   Atkinson, Annette
   Peterson, Dallin
   Christensen, Kimberly
   Dimond, Melissa
   Staples, J. Erin
   Nakashima, Allyn
TI Preliminary Findings from an Investigation of Zika Virus Infection in a
   Patient with No Known Risk Factors - Utah, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Brent, Carolyn; Risk, Ilene; Hill, Mary] Salt Lake Cty Hlth Dept, Salt Lake City, UT 84190 USA.
   [Brent, Carolyn; Crain, Jacqueline] CDC, Publ Hlth Associates Program Off, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA.
   [Dunn, Angela; Crain, Jacqueline; Peterson, Dallin; Dimond, Melissa; Nakashima, Allyn] Utah Dept Hlth, Salt Lake City, UT USA.
   [Savage, Harry; Krow-Lucal, Elisabeth Raquel; Staples, J. Erin] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Faraji, Ary] Salt Lake City Mosquito Abatement Dist, Salt Lake City, UT USA.
   [Rubin, Mike] Univ Utah Hosp, Salt Lake City, UT USA.
   [Garcia, Wendy] Davis Cty Hlth Dept, Clearfield, UT USA.
   [Cortese, Margaret] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Novosad, Shannon] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Atkinson, Annette; Christensen, Kimberly] Utah Publ Hlth Lab, Taylorsville, UT USA.
RP Brent, C (reprint author), Salt Lake Cty Hlth Dept, Salt Lake City, UT 84190 USA.; Brent, C (reprint author), CDC, Publ Hlth Associates Program Off, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA.
EM cbrent@slco.org
NR 3
TC 2
Z9 2
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 981
EP 982
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100009
PM 27631467
ER

PT J
AU Walker, WL
   Lindsey, NP
   Lehman, JA
   Krow-Lucal, ER
   Rabe, IB
   Hills, SL
   Martin, SW
   Fischer, M
   Staples, JE
AF Walker, William L.
   Lindsey, Nicole P.
   Lehman, Jennifer A.
   Krow-Lucal, Elisabeth R.
   Rabe, Ingrid B.
   Hills, Susan L.
   Martin, Stacey W.
   Fischer, Marc
   Staples, J. Erin
TI Zika Virus Disease Cases-50 States and the District of Columbia, January
   1-July 31, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES
C1 [Walker, William L.; Krow-Lucal, Elisabeth R.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Walker, William L.; Lindsey, Nicole P.; Lehman, Jennifer A.; Krow-Lucal, Elisabeth R.; Rabe, Ingrid B.; Hills, Susan L.; Martin, Stacey W.; Fischer, Marc; Staples, J. Erin] CDC, Arboviral Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Staples, JE (reprint author), CDC, Arboviral Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM auv1@cdc.gov
NR 10
TC 8
Z9 8
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 16
PY 2016
VL 65
IS 36
BP 983
EP 986
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW1EP
UT WOS:000383386100010
PM 27631604
ER

PT J
AU Hunsperger, EA
   Munoz-Jordan, J
   Beltran, M
   Colon, C
   Carrion, J
   Vazquez, J
   Acosta, LN
   Medina-Izquierdo, JF
   Horiuchi, K
   Biggerstaff, BJ
   Margolis, HS
AF Hunsperger, Elizabeth A.
   Munoz-Jordan, Jorge
   Beltran, Manuela
   Colon, Candimar
   Carrion, Jessica
   Vazquez, Jesus
   Acosta, Luz Nereida
   Medina-Izquierdo, Juan F.
   Horiuchi, Kalanthe
   Biggerstaff, Brad J.
   Margolis, Harold S.
TI Performance of Dengue Diagnostic Tests in a Single-Specimen Diagnostic
   Algorithm
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE dengue virus; diagnostics; enzyme-linked immunoassay; dengue virus
   nonstructural protein 1 (NS1); NS1 antigen detection; anti-dengue virus
   IgM; dengue virus molecular diagnostics
ID LINKED IMMUNOSORBENT ASSAYS; NONSTRUCTURAL PROTEIN-1 ANTIGEN;
   TRANSCRIPTASE PCR ASSAY; VIRUS NS1 ANTIGEN; PUERTO-RICO; HUMAN SERUM;
   INFECTION; KINETICS; SEROTYPE; SAMPLES
AB Background. Anti-dengue virus (DENV) immunoglobulin M (IgM) seroconversion has been the reference standard for dengue diagnosis. However, paired specimens are rarely obtained, and the interval for this testing negates its usefulness in guiding clinical case management. The presence of DENV viremia and appearance of IgM during the febrile phase of dengue provides the framework for dengue laboratory diagnosis by using a single serum specimen.
   Methods. Archived paired serum specimens (n = 1234) from patients with laboratory-confirmed dengue from 2005 through 2011 were used to determine the diagnostic performance of real-time reverse transcription polymerase chain reaction (RT-PCR), for detection of DENV serotypes 1-4, and enzyme-linked immunosorbent assays (ELISAs), for detection of DENV nonstructural protein 1 (NS1) antigen and anti-DENV IgM.
   Results. During 1-3 days after illness onset, real-time RT-PCR and NS1 antigen testing detected 82%-69% and 90%-84% of cases, respectively, as viremia levels declined, while anti-DENV IgM ELISA detected 5%-41% of cases as antibody appeared. Over the 10-day period of the febrile phase of dengue, the cumulative effect of using these 3 types of tests in a diagnostic algorithm confirmed = 90% of dengue cases.
   Conclusions. The use of molecular or NS1 antigen tests to detect DENV and one to detect anti-DENV IgM in a single serum specimen collected during the first 10 days of illness accurately identified = 90% of dengue primary and secondary cases.
C1 [Hunsperger, Elizabeth A.; Munoz-Jordan, Jorge; Beltran, Manuela; Colon, Candimar; Carrion, Jessica; Vazquez, Jesus; Acosta, Luz Nereida; Medina-Izquierdo, Juan F.; Margolis, Harold S.] Ctr Dis Control & Prevent CDC, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA.
   [Horiuchi, Kalanthe; Biggerstaff, Brad J.] CDC, Off Director, Div Vector Borne Dis, Ft Collins, CO USA.
RP Hunsperger, EA (reprint author), 1324 Calle Canada, San Juan, PR 00920 USA.
EM enh4@cdc.gov
FU Centers for Disease Control and Prevention Dengue Branch, Division of
   Vector-Borne Diseases
FX This work was supported by the Centers for Disease Control and
   Prevention Dengue Branch, Division of Vector-Borne Diseases.
NR 32
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 15
PY 2016
VL 214
IS 6
BP 836
EP 844
DI 10.1093/infdis/jiw103
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DZ8RB
UT WOS:000386137400004
PM 26984143
ER

PT J
AU Buchacz, K
   Lau, B
   Jing, YZ
   Bosch, R
   Abraham, AG
   Gill, MJ
   Silverberg, MJ
   Goedert, JJ
   Sterling, TR
   Althoff, KN
   Martin, JN
   Burkholder, G
   Gandhi, N
   Samji, H
   Patel, P
   Rachlis, A
   Thorne, JE
   Napravnik, S
   Henry, K
   Mayor, A
   Gebo, K
   Gange, SJ
   Moore, RD
   Brooks, JT
AF Buchacz, Kate
   Lau, Bryan
   Jing, Yuezhou
   Bosch, Ronald
   Abraham, Alison G.
   Gill, M. John
   Silverberg, Michael J.
   Goedert, James J.
   Sterling, Timothy R.
   Althoff, Keri N.
   Martin, Jeffrey N.
   Burkholder, Greer
   Gandhi, Neel
   Samji, Hasina
   Patel, Pragna
   Rachlis, Anita
   Thorne, Jennifer E.
   Napravnik, Sonia
   Henry, Keith
   Mayor, Angel
   Gebo, Kelly
   Gange, Stephen J.
   Moore, Richard D.
   Brooks, John T.
CA IeDEA
TI Incidence of AIDS-Defining Opportunistic Infections in a Multicohort
   Analysis of HIV-infected Persons in the United States and Canada,
   2000-2010
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE AIDS-related opportunistic infections; HIV cohort studies; incidence;
   prophylaxis; combination antiretroviral therapy; CD4(+) T-lymphocyte
   count; epidemiology
ID COMBINATION ANTIRETROVIRAL THERAPY; RECONSTITUTION INFLAMMATORY
   SYNDROME; CD4 CELL COUNT; COHORT COLLABORATION; NONFATAL AIDS; VIRAL
   LOAD; MORTALITY; ERA; ILLNESSES; EVENTS
AB Background. There are few recent data on the rates of AIDS-defining opportunistic infections (OIs) among human immunodeficiency virus (HIV)-infected patients in care in the United States and Canada. Methods. We studiedHIV-infected participants in 16 cohorts in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) during 2000-2010. After excluding 16 737 (21%) with any AIDS-defining clinical events documented before NA-ACCORD enrollment, we analyzed incident OIs among the remaining 63 541 persons, most of whom received antiretroviral therapy during the observation. We calculated incidence rates per 100 person-years of observation (hereafter, "person-years") with 95% confidence intervals (CIs) for the first occurrence of any OI and select individual OIs during 2000-2003, 2004-2007, and 2008-2010. Results. A total of 63 541 persons contributed 261 573 person-years, of whom 5836 (9%) developed at least 1 OI. The incidence rate of any first OI decreased over the 3 observation periods, with 3.0 cases, 2.4 cases, and 1.5 cases per 100 person-years of observation during 2000-2003, 2004-2007, and 2008-2010, respectively (Ptrend<. 001); the rates of most individual OIs decreased as well. During 2008-2010, the leading OIs included Pneumocystis jiroveci pneumonia, esophageal candidiasis, and disseminated Mycobacterium avium complex or Mycobacterium kansasii infection. Conclusions. For HIV-infected persons in care during 2000-2010, rates of first OI were relatively low and generally declined over this time.
C1 [Buchacz, Kate; Patel, Pragna; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Lau, Bryan; Jing, Yuezhou; Abraham, Alison G.; Althoff, Keri N.; Samji, Hasina; Thorne, Jennifer E.; Gebo, Kelly; Gange, Stephen J.; Moore, Richard D.] Johns Hopkins Univ, Baltimore, MD USA.
   [Bosch, Ronald] Harvard Univ, Boston, MA 02115 USA.
   [Gill, M. John] Univ Calgary, Calgary, AB T2N 1N4, Canada.
   [Silverberg, Michael J.] Kaiser Permanente Northern Calif, Oakland, CA USA.
   [Goedert, James J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
   [Sterling, Timothy R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Burkholder, Greer] Univ Alabama Birmingham, Birmingham, AL USA.
   [Gandhi, Neel] Emory Univ, Atlanta, GA 30322 USA.
   [Samji, Hasina] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
   [Rachlis, Anita] Univ Toronto, Toronto, ON M5S 1A1, Canada.
   [Napravnik, Sonia] Univ North Carolina Chapel Hill, Chapel Hill, NC USA.
   [Henry, Keith] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
   [Mayor, Angel] Univ Cent Caribe, Bayamon, PR USA.
RP Buchacz, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E-45, Atlanta, GA 30329 USA.
EM acu7@cdc.gov
FU NIH [U01AI069918, F31DA037788, G12MD007583, K01AI093197, K23EY013707,
   K24DA000432, K24AI065298, KL2TR000421, M01RR000052, N02CP055504,
   P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050410,
   P30AI094189, P30AI110527, P30MH62246, 01AA016893]; CDC
   [CDC-200-2006-18797, CDC-200-2015-63931]; Agency for Healthcare Research
   and Quality [90047713]; Health Resources and Services Administration
   [90051652]; Canadian Institutes of Health Research [CBR-86906,
   CBR-94036, HCP-97105, TGF-96118]; Ontario Ministry of Health and Long
   Term Care; Government of Alberta, Canada; Intramural Research Program of
   the National Cancer Institute; THE NIH [R01CA165937, R01DA004334,
   R01DA011602, R01DA012568, R24AI067039, U01AA013566, U01AA020790,
   U01AI031834, U01AI034989, U01AI034993, U01AI034994, U01AI035004,
   U01AI035039, U01AI035040, U01AI035041, U01AI035042, U01AI037613,
   U01AI037984, U01AI038855, U01AI042590, U01AI068634]; A NIH [U01AI068636,
   U01AI069432, U01AI069434, U01AI103390, U01AI103397, U01AI103401,
   U01AI103408, U01DA036935, U01HD032632, U10EY008057, U10EY008052,
   U10EY008067, U24AA020794, U54MD007587, UL1RR024131, UL1TR000004,
   UL1TR000083, UL1TR000454, UM1AI035043, U01AI038858]
FX This work was supported by NIH (grants U01AI069918, F31DA037788,
   G12MD007583, K01AI093197, K23EY013707, K24DA000432, K24AI065298,
   KL2TR000421, M01RR000052, N02CP055504, P30AI027757, P30AI027763,
   P30AI027767, P30AI036219, P30AI050410, P30AI094189, P30AI110527,
   P30MH62246, 01AA016893, R01CA165937, R01DA004334, R01DA011602,
   R01DA012568, R24AI067039, U01AA013566, U01AA020790, U01AI031834,
   U01AI034989, U01AI034993, U01AI034994, U01AI035004, U01AI035039,
   U01AI035040, U01AI035041, U01AI035042, U01AI037613, U01AI037984,
   U01AI038855, U01AI038858, U01AI042590, U01AI068634, U01AI068636,
   U01AI069432, U01AI069434, U01AI103390, U01AI103397, U01AI103401,
   U01AI103408, U01DA036935, U01HD032632, U10EY008057, U10EY008052,
   U10EY008067, U24AA020794, U54MD007587, UL1RR024131, UL1TR000004,
   UL1TR000083, UL1TR000454, UM1AI035043, Z01CP010214 and Z01CP010176); the
   CDC (contract CDC-200-2006-18797 and CDC-200-2015-63931); the Agency for
   Healthcare Research and Quality (contract 90047713); the Health
   Resources and Services Administration (contract 90051652); Canadian
   Institutes of Health Research (grants CBR-86906, CBR-94036, HCP-97105
   and TGF-96118); Ontario Ministry of Health and Long Term Care; and the
   Government of Alberta, Canada. Additional support was provided by the
   Intramural Research Program of the National Cancer Institute.
NR 41
TC 2
Z9 2
U1 5
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 15
PY 2016
VL 214
IS 6
BP 862
EP 872
DI 10.1093/infdis/jiw085
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DZ8RB
UT WOS:000386137400007
PM 27559122
ER

PT J
AU Gieraltowski, L
   Higa, J
   Peralta, V
   Green, A
   Schwensohn, C
   Rosen, H
   Libby, T
   Kissler, B
   Marsden-Haug, N
   Booth, H
   Kimura, A
   Grass, J
   Bicknese, A
   Tolar, B
   Defibaugh-Chavez, S
   Williams, I
   Wise, M
AF Gieraltowski, Laura
   Higa, Jeffrey
   Peralta, Vi
   Green, Alice
   Schwensohn, Colin
   Rosen, Hilary
   Libby, Tanya
   Kissler, Bonnie
   Marsden-Haug, Nicola
   Booth, Hillary
   Kimura, Akiko
   Grass, Julian
   Bicknese, Amelia
   Tolar, Beth
   Defibaugh-Chavez, Stephanie
   Williams, Ian
   Wise, Matthew
CA Salmonella Heidelberg Invest Team
TI National Outbreak of Multidrug Resistant Salmonella Heidelberg
   Infections Linked to a Single Poultry Company
SO PLOS ONE
LA English
DT Article
ID ANTIMICROBIAL RESISTANCE; UNITED-STATES; FOOD ANIMALS; SEROTYPE
AB Importance
   This large outbreak of foodborne salmonellosis demonstrated the complexity of investigating outbreaks linked to poultry products. The outbreak also highlighted the importance of efforts to strengthen food safety policies related to Salmonella in chicken parts and has implications for future changes within the poultry industry.
   Objective
   To investigate a large multistate outbreak of multidrug resistant Salmonella Heidelberg infections.
   Design
   Epidemiologic and laboratory investigations of patients infected with the outbreak strains of Salmonella Heidelberg and traceback of possible food exposures.
   Setting
   United States. Outbreak period was March 1, 2013 through July 11, 2014
   Patients
   A case was defined as illness in a person infected with a laboratory-confirmed Salmonella Heidelberg with 1 of 7 outbreak pulsed-field gel electrophoresis (PFGE) XbaI patterns with illness onset from March 1, 2013 through July 11, 2014. A total of 634 case-patients were identified through passive surveillance; 200/528 (38%) were hospitalized, none died.
   Results
   Interviews were conducted with 435 case-patients: 371 (85%) reported eating any chicken in the 7 days before becoming ill. Of 273 case-patients interviewed with a focused questionnaire, 201 (74%) reported eating chicken prepared at home. Among case-patients with available brand information, 152 (87%) of 175 patients reported consuming Company A brand chicken. Antimicrobial susceptibility testing was completed on 69 clinical isolates collected from case-patients; 67% were drug resistant, including 24 isolates (35%) that were multidrug resistant. The source of Company A brand chicken consumed by case-patients was traced back to 3 California production establishments from which 6 of 7 outbreak strains were isolated.
   Conclusions
   Epidemiologic, laboratory, traceback, and environmental investigations conducted by local, state, and federal public health and regulatory officials indicated that consumption of Company A chicken was the cause of this outbreak. The outbreak involved multiple PFGE patterns, a variety of chicken products, and 3 production establishments, suggesting a reservoir for contamination upstream from the production establishments. Sources of bacteria and genes responsible for resistance, such as farms providing birds for slaughter or environmental reservoir on farms that raise chickens, might explain how multiple PFGE patterns were linked to chicken from 3 separate production establishments and many different poultry products.
C1 [Gieraltowski, Laura; Schwensohn, Colin; Grass, Julian; Bicknese, Amelia; Tolar, Beth; Williams, Ian; Wise, Matthew] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
   [Higa, Jeffrey; Peralta, Vi; Rosen, Hilary; Kimura, Akiko] Calif Dept Publ Hlth, Gardena, CA USA.
   [Higa, Jeffrey; Peralta, Vi; Rosen, Hilary; Kimura, Akiko] Calif Dept Publ Hlth, Richmond, CA USA.
   [Higa, Jeffrey; Peralta, Vi; Rosen, Hilary; Kimura, Akiko] Calif Dept Publ Hlth, Sacramento, CA USA.
   [Libby, Tanya] Calif Emerging Infect Program, Oakland, CA USA.
   [Marsden-Haug, Nicola] Washington State Dept Hlth, Olympia, WA USA.
   [Booth, Hillary] Oregon Publ Hlth Div, Portland, OR USA.
   [Green, Alice; Kissler, Bonnie; Defibaugh-Chavez, Stephanie] US Food Safety & Inspect Serv, Off Publ Hlth Sci, USDA, Washington, DC 20250 USA.
RP Gieraltowski, L (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
EM LGieraltowski@cdc.gov
NR 17
TC 2
Z9 2
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 15
PY 2016
VL 11
IS 9
AR e0162369
DI 10.1371/journal.pone.0162369
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5SJ
UT WOS:000383706900041
PM 27631492
ER

PT J
AU Kalou, MB
   Castro, A
   Watson, A
   Jost, H
   Clay, S
   Tun, Y
   Chen, C
   Karem, K
   Nkengasong, JN
   Ballard, R
   Parekh, B
AF Kalou, Mireille B.
   Castro, Arnold
   Watson, Amy
   Jost, Heather
   Clay, Stacy
   Tun, Ye
   Chen, Cheng
   Karem, Kevin
   Nkengasong, John N.
   Ballard, Ronald
   Parekh, Bharat
TI Laboratory evaluation of the Chembio Dual Path Platform HIV-Syphilis
   Assay
SO AFRICAN JOURNAL OF LABORATORY MEDICINE
LA English
DT Review
ID SEXUALLY-TRANSMITTED INFECTIONS; OF-CARE TEST; TREPONEMAL ANTIBODIES;
   CONGENITAL-SYPHILIS; COST-EFFECTIVENESS; TRANSMISSION; PREVENTION; CHINA
AB Background: Use of rapid diagnostic tests for HIV and syphilis has increased remarkably in the last decade. As new rapid diagnostic tests become available, there is a continuous need to assess their performance and operational characteristics prior to use in clinical settings.
   Objectives: In this study, we evaluated the performance of the Chembio Dual Path Platform (DPP (R)) HIV-Syphilis Assay to accurately diagnose HIV, syphilis, and HIV/syphilis co-infection.
   Method: In 2013, 990 serum samples from the Georgia Public Health Laboratory in Atlanta, Georgia, United States were characterised for HIV and syphilis and used to evaluate the platform. HIV reference testing combined third-generation Enzyme Immunoassay and Western Blot, whereas reference testing for syphilis was conducted by the Treponema pallidum passive particle agglutination method and the TrepSure assay. We assessed the sensitivity and specificity of the DPP assay on this panel by comparing results with the HIV and syphilis reference testing algorithms.
   Results: For HIV, sensitivity was 99.8% and specificity was 98.4%; for syphilis, sensitivity was 98.8% and specificity was 99.4%. Of the 348 co-infected sera, 344 (98.9%) were detected accurately by the DPP assay, but 11 specimens had false-positive results (9 HIV and 2 syphilis) due to weak reactivity.
   Conclusion: In this evaluation, the Chembio DPP HIV-Syphilis Assay had high sensitivity and specificity for detecting both HIV and treponemal antibodies. Our results indicate that this assay could have a significant impact on the simultaneous screening of HIV and syphilis using a single test device for high-risk populations or pregnant women needing timely care and treatment.
C1 [Kalou, Mireille B.; Watson, Amy; Clay, Stacy; Nkengasong, John N.; Parekh, Bharat] US Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA USA.
   [Castro, Arnold; Jost, Heather; Chen, Cheng; Karem, Kevin] US Ctr Dis Control & Prevent, Lab Reference & Res Branch, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Tun, Ye; Ballard, Ronald] US Ctr Dis Control & Prevent, Off Associate Director Lab Sci, Ctr Global Hlth, Atlanta, GA USA.
RP Kalou, MB (reprint author), US Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA USA.
EM chn7@cdc.gov
NR 36
TC 0
Z9 0
U1 3
U2 3
PU AOSIS
PI CAPE TOWN
PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH
   AFRICA
SN 2225-2002
EI 2225-2010
J9 AFR J LAB MED
JI Afr. J. Lab. Med.
PD SEP 15
PY 2016
VL 5
IS 1
AR a433
DI 10.4102/ajlm.v5i1.433
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DX3AA
UT WOS:000384243800002
ER

PT J
AU Galgiani, JN
   Ampel, NM
   Blair, JE
   Catanzaro, A
   Geertsma, F
   Hoover, SE
   Johnson, RH
   Kusne, S
   Lisse, J
   MacDonald, JD
   Meyerson, SL
   Raksin, PB
   Siever, J
   Stevens, DA
   Sunenshine, R
   Theodore, N
AF Galgiani, John N.
   Ampel, Neil M.
   Blair, Janis E.
   Catanzaro, Antonino
   Geertsma, Francesca
   Hoover, Susan E.
   Johnson, Royce H.
   Kusne, Shimon
   Lisse, Jeffrey
   MacDonald, Joel D.
   Meyerson, Shari L.
   Raksin, Patricia B.
   Siever, John
   Stevens, David A.
   Sunenshine, Rebecca
   Theodore, Nicholas
TI 2016 Infectious Diseases Society of America (IDSA) Clinical Practice
   Guideline for the Treatment of Coccidioidomycosis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE coccidioidomycosis; antifungal treatment; community acquired pneumonia;
   travel history; immunocompromised patients
ID GRADE
AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
   Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.
C1 [Galgiani, John N.] Univ Arizona, Valley Fever Ctr Excellence, Tucson, AZ USA.
   [Ampel, Neil M.] Univ Arizona, Div Infect Dis, Tucson, AZ USA.
   [Blair, Janis E.; Kusne, Shimon] Mayo Clin, Div Infect Dis, Scottsdale, AZ USA.
   [Catanzaro, Antonino] Univ Calif San Diego, Div Pulm & Crit Care, San Diego, CA 92103 USA.
   [Geertsma, Francesca] Stanford Univ, Sch Med, Dept Pediat, Infect Dis, Stanford, CA 94305 USA.
   [Hoover, Susan E.] Div Sanford Hlth, Sioux Falls, SD USA.
   [Johnson, Royce H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Kern Med Ctr, Bakersfield, CA USA.
   [Lisse, Jeffrey] Univ Arizona, Dept Rheumatol, Tucson, AZ USA.
   [MacDonald, Joel D.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA.
   [Meyerson, Shari L.] Northwestern Univ, Div Thorac Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Raksin, Patricia B.] John H Stroger Jr Hosp Cook Cty, Div Neurosurg, Chicago, IL USA.
   [Siever, John] Arizona Pulm Specialists Ltd, Phoenix, AZ USA.
   [Stevens, David A.] Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.
   [Sunenshine, Rebecca] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Phoenix, AZ USA.
   [Sunenshine, Rebecca] Barrow Neurol Inst, Maricopa Cty Dept Publ Hlth, Phoenix, AZ 85013 USA.
   [Theodore, Nicholas] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Galgiani, JN (reprint author), Univ Arizona, Coll Med, Valley Fever Ctr Excellence, POB 245215, Tucson, AZ 85724 USA.
EM spherule@u.arizona.edu
RI Hoover, Susan/F-8580-2015
FU Infectious Diseases Society of America (IDSA)
FX Support for these guidelines was provided by the Infectious Diseases
   Society of America (IDSA).
NR 5
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2016
VL 63
IS 6
BP 717
EP 722
DI 10.1093/cid/ciw538
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DW7UK
UT WOS:000383857500002
PM 27559032
ER

PT J
AU Sejvar, JJ
   Lopez, AS
   Cortese, MM
   Leshem, E
   Pastula, DM
   Miller, L
   Glaser, C
   Kambhampati, A
   Shioda, K
   Aliabadi, N
   Fischer, M
   Gregoricus, N
   Lanciotti, R
   Nix, WA
   Sakthivel, SK
   Schmid, DS
   Seward, JF
   Tong, SX
   Oberste, MS
   Pallansch, M
   Feikin, D
AF Sejvar, James J.
   Lopez, Adriana S.
   Cortese, Margaret M.
   Leshem, Eyal
   Pastula, Daniel M.
   Miller, Lisa
   Glaser, Carol
   Kambhampati, Anita
   Shioda, Kayoko
   Aliabadi, Negar
   Fischer, Marc
   Gregoricus, Nicole
   Lanciotti, Robert
   Nix, W. Allan
   Sakthivel, Senthilkumar K.
   Schmid, D. Scott
   Seward, Jane F.
   Tong, Suxiang
   Oberste, M. Steven
   Pallansch, Mark
   Feikin, Daniel
TI Acute Flaccid Myelitis in the United States, August-December 2014:
   Results of Nationwide Surveillance
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE acute flaccid myelitis; limb weakness; polio; enterovirus; surveillance
ID ENTEROVIRUS 71 INFECTION; SEMINESTED PCR AMPLIFICATION;
   OF-THE-LITERATURE; CEREBROSPINAL-FLUID; JAPANESE ENCEPHALITIS;
   NEUROMYELITIS-OPTICA; CLINICAL SPECIMENS; VIRUS-INFECTION; PARALYSIS;
   D68
AB Background. During late summer/fall 2014, pediatric cases of acute flaccid myelitis (AFM) occurred in the United States, coincident with a national outbreak of enterovirus D68 (EV-D68)-associated severe respiratory illness.
   Methods. Clinicians and health departments reported standardized clinical, epidemiologic, and radiologic information on AFM cases to the Centers for Disease Control and Prevention (CDC), and submitted biological samples for testing. Cases were <= 21 years old, with acute onset of limb weakness 1 August-31 December 2014 and spinal magnetic resonance imaging (MRI) showing lesions predominantly restricted to gray matter.
   Results. From August through December 2014, 120 AFM cases were reported from 34 states. Median age was 7.1 years (inter-quartile range, 4.8-12.1 years); 59% were male. Most experienced respiratory (81%) or febrile (64%) illness before limb weakness onset. MRI abnormalities were predominantly in the cervical spinal cord (103/118). All but 1 case was hospitalized; none died. Cerebrospinal fluid (CSF) pleocytosis (>5 white blood cells/mu L) was common (81%). At CDC, 1 CSF specimen was positive for EV-D68 and Epstein-Barr virus by real-time polymerase chain reaction, although the specimen had >3000 red blood cells/mu L. The most common virus detected in upper respiratory tract specimens was EV-D68 (from 20%, and 47% with specimen collected <= 7 days from respiratory illness/fever onset). Continued surveillance in 2015 identified 16 AFM cases reported from 13 states.
   Conclusions. Epidemiologic data suggest this AFM cluster was likely associated with the large outbreak of EV-D68-associated respiratory illness, although direct laboratory evidence linking AFM with EV-D68 remains inconclusive. Continued surveillance will help define the incidence, epidemiology, and etiology of AFM.
C1 [Sejvar, James J.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS A-30, Atlanta, GA 30329 USA.
   [Lopez, Adriana S.; Cortese, Margaret M.; Leshem, Eyal; Kambhampati, Anita; Shioda, Kayoko; Aliabadi, Negar; Gregoricus, Nicole; Nix, W. Allan; Sakthivel, Senthilkumar K.; Schmid, D. Scott; Seward, Jane F.; Tong, Suxiang; Oberste, M. Steven; Pallansch, Mark; Feikin, Daniel] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Pastula, Daniel M.; Fischer, Marc; Lanciotti, Robert] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA.
   [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Div Epidemiol, Denver, CO USA.
   [Glaser, Carol] Calif Dept Publ Hlth, Div Communicable Dis Control, Richmond, CA USA.
   [Kambhampati, Anita; Shioda, Kayoko] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
   [Glaser, Carol] Kaiser Permanente, Oakland Med Ctr, Dept Pediat, Oakland, CA USA.
RP Sejvar, JJ (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS A-30, Atlanta, GA 30329 USA.
EM zea3@cdc.gov
OI Leshem, Eyal/0000-0003-1267-6131
NR 53
TC 2
Z9 2
U1 4
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2016
VL 63
IS 6
BP 737
EP 745
DI 10.1093/cid/ciw372
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DW7UK
UT WOS:000383857500006
PM 27318332
ER

PT J
AU Galgiani, JN
   Ampel, NM
   Blair, JE
   Catanzaro, A
   Geertsma, F
   Hoover, SE
   Johnson, RH
   Kusne, S
   Lisse, J
   MacDonald, JD
   Meyerson, SL
   Raksin, PB
   Siever, J
   Stevens, DA
   Sunenshine, R
   Theodore, N
AF Galgiani, John N.
   Ampel, Neil M.
   Blair, Janis E.
   Catanzaro, Antonino
   Geertsma, Francesca
   Hoover, Susan E.
   Johnson, Royce H.
   Kusne, Shimon
   Lisse, Jeffrey
   MacDonald, Joel D.
   Meyerson, Shari L.
   Raksin, Patricia B.
   Siever, John
   Stevens, David A.
   Sunenshine, Rebecca
   Theodore, Nicholas
TI 2016 Infectious Diseases Society of America (IDSA) Clinical Practice
   Guideline for the Treatment of Coccidioidomycosis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE coccidioidomycosis; antifungal treatment; community acquired pneumonia;
   travel history; immunocompromised patients
ID PRIMARY PULMONARY COCCIDIOIDOMYCOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   SOLID-ORGAN TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; DELAYED-TYPE
   HYPERSENSITIVITY; LIPOSOMAL AMPHOTERICIN-B; HIV MEDICINE ASSOCIATION;
   NEEDLE-ASPIRATION BIOPSY; INSTITUTES-OF-HEALTH; THE-ART TREATMENT
AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
   Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.
C1 [Galgiani, John N.] Univ Arizona, Valley Fever Ctr Excellence, Tucson, AZ USA.
   [Ampel, Neil M.] Univ Arizona, Div Infect Dis, Tucson, AZ USA.
   [Blair, Janis E.; Kusne, Shimon] Mayo Clin, Div Infect Dis, Scottsdale, AZ USA.
   [Catanzaro, Antonino] Univ Calif San Diego, Div Pulm & Crit Care, San Diego, CA 92103 USA.
   [Geertsma, Francesca] Stanford Univ, Sch Med, Dept Pediat, Infect Dis, Stanford, CA 94305 USA.
   [Hoover, Susan E.] Div Sanford Hlth, Sioux Falls, SD USA.
   [Johnson, Royce H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Kern Med Ctr, Bakersfield, CA USA.
   [Lisse, Jeffrey] Univ Arizona, Dept Rheumatol, Tucson, AZ USA.
   [MacDonald, Joel D.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA.
   [Meyerson, Shari L.] Northwestern Univ, Div Thorac Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Raksin, Patricia B.] John H Stroger Jr Hosp Cook Cty, Div Neurosurg, Chicago, IL USA.
   [Siever, John] Arizona Pulm Specialists Ltd, Phoenix, AZ USA.
   [Stevens, David A.] Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.
   [Sunenshine, Rebecca] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Phoenix, AZ USA.
   [Sunenshine, Rebecca] Barrow Neurol Inst, Maricopa Cty Dept Publ Hlth, Phoenix, AZ 85013 USA.
   [Theodore, Nicholas] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Galgiani, JN (reprint author), Univ Arizona, Coll Med, Valley Fever Ctr Excellence, POB 245215, Tucson, AZ 85724 USA.
EM spherule@u.arizona.edu
RI Hoover, Susan/F-8580-2015
FU Infectious Diseases Society of America (IDSA)
FX Support for these guidelines was provided by the Infectious Diseases
   Society of America (IDSA).
NR 219
TC 4
Z9 4
U1 3
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2016
VL 63
IS 6
BP E112
EP E146
DI 10.1093/cid/ciw360
PG 35
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DW7UK
UT WOS:000383857500001
PM 27470238
ER

PT J
AU Wallace, RM
   Niezgoda, M
   Waggoner, EA
   Blanton, JD
   Radcliffe, RA
AF Wallace, Ryan M.
   Niezgoda, Michael
   Waggoner, Emily A.
   Blanton, Jesse Dean
   Radcliffe, Rachel A.
TI Serologic response in eight alpacas vaccinated by extralabel use of a
   large animal rabies vaccine during a public health response to a rabid
   alpaca in South Carolina
SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
LA English
DT Article
ID UNITED-STATES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE;
   RECOMMENDATIONS; SURVEILLANCE
AB CASE DESCRIPTION
   A female alpaca, kept at pasture with 12 other female alpacas, 2 crias, and 5 goats, was evaluated because of clinical signs of aggression.
   CLINICAL FINDINGS
   The clinical signs of aggression progressed to include biting at other animals as well as disorientation. Three days later, the alpaca was euthanized because of suspicion of rabies virus infection.
   TREATMENT AND OUTCOME
   No physical injuries were found at necropsy. Brain tissue specimens were confirmed positive for rabies on the basis of direct fluorescent antibody test results. Molecular typing identified the rabies virus variant as one that is enzootic in raccoons. The farm was placed under quarantine, restricting movement of animals on and off the property for 6 months. To prevent further rabies cases, 14 alpacas (12 adults and 2 crias) were vaccinated by extralabel use of a large animal rabies vaccine. Of the 14 vaccinated alpacas, 8 had paired serum samples obtained immediately before and 21 days after vaccination; all 8 alpacas had adequate serum antirabies antibody production in response to rabies vaccination. As a result of an adequate serologic response, the quarantine was reduced to 3 months. In the year after the index rabies case, no other animals on the farm developed rabies.
   CLINICAL RELEVANCE
   Extralabel use of rabies vaccines in camelids was used in the face of a public health investigation. This report provides an example of handling of a rabies case for future public health investigations, which will undoubtedly need to develop ad-hoc rabies vaccination recommendations on the basis of the unique characteristics of the event.
C1 [Wallace, Ryan M.; Niezgoda, Michael; Blanton, Jesse Dean] CDC, Poxvirus & Rabies Branch, Atlanta, GA 30307 USA.
   [Waggoner, Emily A.] Large Anim Vet Serv, 1602 Levis Smith Rd, Pendleton, SC 29670 USA.
   [Radcliffe, Rachel A.] South Carolina Dept Hlth & Environm Control, 2600 Bull St, Columbia, SC 29201 USA.
RP Wallace, RM (reprint author), CDC, Poxvirus & Rabies Branch, Atlanta, GA 30307 USA.
EM EUK5@cdc.gov
NR 10
TC 0
Z9 0
U1 5
U2 5
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA
SN 0003-1488
EI 1943-569X
J9 JAVMA-J AM VET MED A
JI JAVMA-J. Am. Vet. Med. Assoc.
PD SEP 15
PY 2016
VL 249
IS 6
BP 678
EP 681
PG 4
WC Veterinary Sciences
SC Veterinary Sciences
GA DU9JM
UT WOS:000382532900021
PM 27585106
ER

PT J
AU Yershova, K
   Yuan, JM
   Wang, RW
   Valentin, L
   Watson, C
   Gao, YT
   Hecht, SS
   Stepanov, I
AF Yershova, Katrina
   Yuan, Jian-Min
   Wang, Renwei
   Valentin, Liza
   Watson, Clifford
   Gao, Yu-Tang
   Hecht, Stephen S.
   Stepanov, Irina
TI Tobacco-specific N-nitrosamines and polycyclic aromatic hydrocarbons in
   cigarettes smoked by the participants of the Shanghai Cohort Study
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE TSNA; PAH; nicotine; nitrate; nitrite; tobacco; smoke
ID PHENANTHRENE METABOLITE RATIOS; TANDEM MASS-SPECTROMETRY; LUNG-CANCER
   DEVELOPMENT; US-BRAND CIGARETTES; MAINSTREAM SMOKE; URINARY LEVELS;
   TOXICANT EXPOSURE; CARCINOGENS; BIOMARKERS; PRODUCTS
AB Our recent studies on tobacco smoke carcinogen and toxicant biomarkers and cancer risk among male smokers in the Shanghai Cohort Study showed that exposure to tobacco-specific nitrosamines (TSNA) and polycyclic aromatic hydrocarbons (PAH) is prospectively associated with the risk of cancer. These findings support the hypothesis that the smokers' cancer risk is a function of the dose of select tobacco carcinogens and highlight the importance of understanding the factors that affect the intake of these carcinogens by smokers. Given that tobacco constituent exposures are driven, at least in part, by the levels of these constituents in cigarette smoke, we measured mainstream smoke TSNA and PAH levels in 43 Chinese cigarette brands that participants of the Shanghai Cohort Study reported to smoke. In all brands analyzed here, mainstream smoke levels of NNN and NNK, the two carcinogenic TSNA, were generally relatively low, averaging (+/- SD) 16.8(+/- 25.1) and 14.2(+/- 9.5) ng/cigarette, respectively. The levels of PAH were comparable to those found in U.S. cigarettes, averaging 15(+/- 9) ng/cigarette for benzo[a] pyrene, 119(+/- 66) ng/cigarette for phenanthrene and 37(+/- 19) ng/cigarette for pyrene. Our findings indicate that the generally low levels of NNN and NNK are most likely responsible for the relatively low levels of the corresponding biomarkers in the urine of the Shanghai Cohort Study participants as compared to those found in the U.S. smokers, supporting the role of the levels of these constituents in cigarette smoke in smokers' exposures. Our findings also suggest that, in addition to smoking, other sources contribute to Chinese smokers' exposure to PAH.
C1 [Yershova, Katrina; Hecht, Stephen S.; Stepanov, Irina] Univ Minnesota, Masonic Canc Ctr, 2231 6th St SE,Room 2-140 CCRB, Minneapolis, MN 55455 USA.
   [Yuan, Jian-Min; Wang, Renwei] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   [Yuan, Jian-Min] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
   [Valentin, Liza; Watson, Clifford] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Gao, Yu-Tang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
   [Stepanov, Irina] Univ Minnesota, Div Environm Hlth Sci, Minneapolis, MN USA.
RP Stepanov, I (reprint author), Univ Minnesota, Masonic Canc Ctr, 2231 6th St SE,Room 2-140 CCRB, Minneapolis, MN 55455 USA.
EM stepa011@umn.edu
FU NCI NIH HHS [R01 CA081301, R01 CA144034, P30 CA077598, R01 CA129534, R37
   CA081301, UM1 CA182876]
NR 39
TC 0
Z9 0
U1 26
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 15
PY 2016
VL 139
IS 6
BP 1261
EP 1269
DI 10.1002/ijc.30178
PG 9
WC Oncology
SC Oncology
GA DR5AO
UT WOS:000379915600010
PM 27163125
ER

PT J
AU Creanga, AA
   Odhiambo, GA
   Odera, B
   Odhiambo, FO
   Desai, M
   Goodwin, M
   Laserson, K
   Goldberg, H
AF Creanga, Andreea A.
   Odhiambo, George Awino
   Odera, Benjamin
   Odhiambo, Frank O.
   Desai, Meghna
   Goodwin, Mary
   Laserson, Kayla
   Goldberg, Howard
TI Pregnant Women's Intentions and Subsequent Behaviors Regarding Maternal
   and Neonatal Service Utilization: Results from a Cohort Study in Nyanza
   Province, Kenya
SO PLOS ONE
LA English
DT Article
ID FACILITY-BASED DELIVERY; OF-THE-LITERATURE; PLANNED BEHAVIOR;
   DEVELOPING-COUNTRIES; HOME DELIVERY; CARE; BARRIERS; HEALTH;
   METAANALYSIS; CHILDBIRTH
AB Higher use of maternal and neonatal health (MNH) services may reduce maternal and neonatal mortality in Kenya. This study aims to: 1) prospectively explore women's intentions to use MNH services (antenatal care, delivery in a facility, postnatal care, neonatal care) at < 20 and 30-35 weeks' gestation and their actual use of these services; 2) identify predictors of intention-behavior discordance among women with positive service use intentions; 3) examine associations between place of delivery, women's reasons for choosing it, and birthing experiences. We used data from a 2012-2013 population-based cohort of pregnant women in the Demographic Surveillance Site in Nyanza province, Kenya. Of 1,056 women completing the study (89.1% response rate), 948 had live-births and 22 stillbirths, and they represent our analytic sample. Logistic regression analysis identified predictors of intention-behavior discordance regarding delivery in a facility and use of postnatal and neonatal care. At < 20 and 30-35 weeks' gestation, most women intended to seek MNH services (>= 93.9% and >= 87.5%, respectively, for all services assessed). Actual service use was high for antenatal (98.1%) and neonatal (88.5%) care, but lower for delivery in a facility (76.9%) and postnatal care (51.8%). Woman's age > 35 and high-school education were significant predictors of intention-behavior discordance regarding delivery in a facility; several delivery-related factors were significantly associated with intention-behavior discordance regarding use of postnatal and neonatal care. Delivery facilities were chosen based on proximity to women's residence, affordability, and service quality; among women who delivered outside a health facility, 16.3% could not afford going to a facility. Good/very good birth experiences were reported by 93.6% of women who delivered in a facility and 32.6% of women who did not. We found higher MNH service utilization than previously documented in Nyanza province. Further increasing the number of facility deliveries and use of postnatal care may improve MNH in Kenya.
C1 [Creanga, Andreea A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.
   [Creanga, Andreea A.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Ctr Maternal & Newborn Hlth, Baltimore, MD 21205 USA.
   [Odhiambo, George Awino; Odera, Benjamin; Odhiambo, Frank O.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
   [Desai, Meghna; Laserson, Kayla] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA.
   [Goodwin, Mary; Goldberg, Howard] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   [Laserson, Kayla] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA.
RP Creanga, AA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.; Creanga, AA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Ctr Maternal & Newborn Hlth, Baltimore, MD 21205 USA.
EM acreanga@jhu.edu
FU US Centers for Disease Control and Prevention
FX The study was funded by the US Centers for Disease Control and
   Prevention; authors have received no funding to prepare the manuscript.
NR 41
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2016
VL 11
IS 9
AR e0162017
DI 10.1371/journal.pone.0162017
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5JR
UT WOS:000383681000013
PM 27622496
ER

PT J
AU N'gattia, AK
   Coulibaly, D
   Nzussouo, NT
   Kadjo, HA
   Cherif, D
   Traore, Y
   Kouakou, BK
   Kouassi, PD
   Ekra, KD
   Dagnan, NS
   Williams, T
   Tiembre, I
AF N'gattia, A. K.
   Coulibaly, D.
   Nzussouo, N. Talla
   Kadjo, H. A.
   Cherif, D.
   Traore, Y.
   Kouakou, B. K.
   Kouassi, P. D.
   Ekra, K. D.
   Dagnan, N. S.
   Williams, T.
   Tiembre, I.
TI Effects of climatological parameters in modeling and forecasting
   seasonal influenza transmission in Abidjan, Cote d'Ivoire
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Modeling; Influenza; Climatological parameters; Abidjan
ID RESPIRATORY-INFECTIONS; VIRUS; HUMIDITY; EPIDEMIOLOGY; SURVEILLANCE;
   TEMPERATE; SURVIVAL; REGIONS; TROPICS; AFRICA
AB Background: In temperate regions, influenza epidemics occur in the winter and correlate with certain climatological parameters. In African tropical regions, the effects of climatological parameters on influenza epidemics are not well defined. This study aims to identify and model the effects of climatological parameters on seasonal influenza activity in Abidjan, Cote d'Ivoire.
   Methods: We studied the effects of weekly rainfall, humidity, and temperature on laboratory-confirmed influenza cases in Abidjan from 2007 to 2010. We used the Box-Jenkins method with the autoregressive integrated moving average (ARIMA) process to create models using data from 2007-2010 and to assess the predictive value of best model on data from 2011 to 2012.
   Results: The weekly number of influenza cases showed significant cross-correlation with certain prior weeks for both rainfall, and relative humidity. The best fitting multivariate model (ARIMAX (2,0,0) _RF) included the number of influenza cases during 1-week and 2-weeks prior, and the rainfall during the current week and 5-weeks prior. The performance of this model showed an increase of > 3 % for Akaike Information Criterion (AIC) and 2.5 % for Bayesian Information Criterion (BIC) compared to the reference univariate ARIMA (2,0,0). The prediction of the weekly number of influenza cases during 2011-2012 with the best fitting multivariate model (ARIMAX (2,0,0) _RF), showed that the observed values were within the 95 % confidence interval of the predicted values during 97 of 104 weeks.
   Conclusion: Including rainfall increases the performances of fitted and predicted models. The timing of influenza in Abidjan can be partially explained by rainfall influence, in a setting with little change in temperature throughout the year. These findings can help clinicians to anticipate influenza cases during the rainy season by implementing preventive measures.
C1 [N'gattia, A. K.; Coulibaly, D.; Cherif, D.; Traore, Y.; Kouassi, P. D.; Ekra, K. D.; Dagnan, N. S.; Tiembre, I.] Inst Natl Hygiene Publ, Dept Epidemiol, BP 5 14, Abidjan, Cote Ivoire.
   [N'gattia, A. K.; Traore, Y.; Ekra, K. D.; Dagnan, N. S.; Tiembre, I.] Felix Houphouet Boigny Univ, Dept Publ Hlth & Community Med, Training & Res Unit Med Sci, BP 34, Abidjan, Cote Ivoire.
   [Nzussouo, N. Talla; Williams, T.] US Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Kadjo, H. A.; Kouakou, B. K.] Inst Pasteur, Dept Virol, Resp Dis, 01 BP 490, Abidjan 01, Cote Ivoire.
   [Kouassi, P. D.] Alassane Ouattara Univ, Dept Publ Hlth & Community Med, BP 5 18, Bouake, Cote Ivoire.
RP N'gattia, AK (reprint author), Inst Natl Hygiene Publ, Dept Epidemiol, BP 5 14, Abidjan, Cote Ivoire.; N'gattia, AK (reprint author), Felix Houphouet Boigny Univ, Dept Publ Hlth & Community Med, Training & Res Unit Med Sci, BP 34, Abidjan, Cote Ivoire.
EM jeanandersonk@yahoo.fr
FU CDC-Atlanta Influenza Division [5U51 IP000154, 5U51 IP000530]
FX The funding for this study was granted by CDC-Atlanta Influenza Division
   through two Cooperative Agreements (Grants Numbers: 5U51 IP000154; 5U51
   IP000530).
NR 25
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD SEP 13
PY 2016
VL 16
AR 972
DI 10.1186/s12889-016-3503-1
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV8ZD
UT WOS:000383228200003
PM 27624302
ER

PT J
AU McCarty, CL
   Nelson, L
   Eitniear, S
   Zgodzinski, E
   Zabala, A
   Billing, L
   DiOrio, M
AF McCarty, Carolyn L.
   Nelson, Leigh
   Eitniear, Samantha
   Zgodzinski, Eric
   Zabala, Amanda
   Billing, Laurie
   DiOrio, Mary
TI Community Needs Assessment After Microcystin Toxin Contamination of a
   Municipal Water Supply - Lucas County, Ohio, September 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [McCarty, Carolyn L.; Zabala, Amanda; Billing, Laurie] CDC, Div Sci Educ & Profess Dev, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [McCarty, Carolyn L.; Nelson, Leigh; DiOrio, Mary] Ohio Dept Hlth, Columbus, OH 43266 USA.
   [Eitniear, Samantha; Zgodzinski, Eric] Toledo Lucas Cty Hlth Dept, Toledo, OH USA.
RP Nelson, L (reprint author), Ohio Dept Hlth, Columbus, OH 43266 USA.
EM lanelson@columbus.gov
NR 8
TC 0
Z9 0
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 9
PY 2016
VL 65
IS 35
BP 925
EP 929
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW0DR
UT WOS:000383311600001
PM 27607896
ER

PT J
AU Sircar, AD
   Abanyie, F
   Blumberg, D
   Chin-Hong, P
   Coulter, KS
   Cunningham, D
   Huskins, WC
   Langelier, C
   Reid, M
   Scott, BJ
   Shirley, DA
   Babik, JM
   Belova, A
   Sapp, SGH
   McAuliffe, I
   Rivera, HN
   Yabsley, MJ
   Montgomery, SP
AF Sircar, Anita D.
   Abanyie, Francisca
   Blumberg, Dean
   Chin-Hong, Peter
   Coulter, Katrina S.
   Cunningham, Dennis
   Huskins, W. Charles
   Langelier, Charles
   Reid, Michael
   Scott, Brian J.
   Shirley, Debbie-Ann
   Babik, Jennifer M.
   Belova, Aleksandra
   Sapp, Sarah G. H.
   McAuliffe, Isabel
   Rivera, Hilda N.
   Yabsley, Michael J.
   Montgomery, Susan P.
TI Raccoon Roundworm Infection Associated with Central Nervous System
   Disease and Ocular Disease - Six States, 2013-2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID BAYLISASCARIASIS; ENCEPHALITIS
C1 [Sircar, Anita D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Sircar, Anita D.; Abanyie, Francisca; McAuliffe, Isabel; Rivera, Hilda N.; Montgomery, Susan P.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Blumberg, Dean; Belova, Aleksandra] Univ Calif Davis, Childrens Hosp, Sacramento, CA 95817 USA.
   [Chin-Hong, Peter; Langelier, Charles; Reid, Michael; Babik, Jennifer M.] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA.
   [Coulter, Katrina S.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
   [Cunningham, Dennis] Nationwide Childrens Hosp, Columbus, OH USA.
   [Huskins, W. Charles] Mayo Clin, Rochester, MN USA.
   [Scott, Brian J.] Lahey Hosp & Med Ctr, Dept Neurol, Burlington, MA USA.
   [Shirley, Debbie-Ann] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA.
   [Sapp, Sarah G. H.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.
   [Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Athens, GA 30602 USA.
RP Sircar, AD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Sircar, AD (reprint author), CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM ASircar@cdc.gov
FU NHLBI NIH HHS [K12 HL119997]
NR 9
TC 0
Z9 0
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 9
PY 2016
VL 65
IS 35
BP 930
EP 933
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW0DR
UT WOS:000383311600002
PM 27608169
ER

PT J
AU Hampton, LM
   Farrell, M
   Ramirez-Gonzalez, A
   Menning, L
   Shendale, S
   Lewis, I
   Rubin, J
   Garon, J
   Harris, J
   Hyde, T
   Wassilak, S
   Patel, M
   Nandy, R
   Chang-Blanc, D
AF Hampton, Lee M.
   Farrell, Margaret
   Ramirez-Gonzalez, Alejandro
   Menning, Lisa
   Shendale, Stephanie
   Lewis, Ian
   Rubin, Jennifer
   Garon, Julie
   Harris, Jennifer
   Hyde, Terri
   Wassilak, Steven
   Patel, Manish
   Nandy, Robin
   Chang-Blanc, Diana
CA Global Polio Eradication
TI Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of
   Inactivated Poliovirus Vaccine - Worldwide, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID ERADICATION; IMPLEMENTATION; PROGRESS; RISKS
C1 [Hampton, Lee M.; Harris, Jennifer; Hyde, Terri; Wassilak, Steven] CDC, Global Immunizat Div, Atlanta, GA 30333 USA.
   [Farrell, Margaret; Nandy, Robin] United Nations Childrens Fund, Programme Div, New York, NY USA.
   [Ramirez-Gonzalez, Alejandro; Menning, Lisa; Shendale, Stephanie; Chang-Blanc, Diana] WHO, Immunizat Vaccines & Biol Dept, Geneva, Switzerland.
   [Lewis, Ian; Rubin, Jennifer] United Nations Childrens Fund, Supply Div, New York, NY USA.
   [Garon, Julie] Emory Univ, Sch Med, Atlanta, GA USA.
   [Patel, Manish] Task Force Global Hlth, Decatur, GA USA.
RP Hampton, LM (reprint author), CDC, Global Immunizat Div, Atlanta, GA 30333 USA.
EM lhampton@cdc.gov
NR 9
TC 3
Z9 3
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 9
PY 2016
VL 65
IS 35
BP 934
EP 938
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW0DR
UT WOS:000383311600003
PM 27606675
ER

PT J
AU Nanduri, S
   Foo, C
   Ngo, V
   Jarashow, C
   Civen, R
   Schwartz, B
   Holguin, J
   Shearer, E
   Zahn, M
   Harriman, K
   Winter, K
   Kretz, C
   Chang, HY
   Meyer, S
   MacNeil, J
AF Nanduri, Srinivas
   Foo, Chelsea
   Van Ngo
   Jarashow, Claire
   Civen, Rachel
   Schwartz, Ben
   Holguin, John
   Shearer, Eric
   Zahn, Matt
   Harriman, Kathleen
   Winter, Kathleen
   Kretz, Cecilia
   Chang, How Yi
   Meyer, Sarah
   MacNeil, Jessica
TI Outbreak of Serogroup C Meningococcal Disease Primarily Affecting Men
   Who Have Sex with Men - Southern California, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Nanduri, Srinivas; Jarashow, Claire] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Nanduri, Srinivas; Kretz, Cecilia; Chang, How Yi; Meyer, Sarah; MacNeil, Jessica] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Foo, Chelsea; Van Ngo; Jarashow, Claire; Civen, Rachel; Schwartz, Ben] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
   [Holguin, John] Long Beach Dept Hlth & Human Serv, Long Beach, CA USA.
   [Shearer, Eric; Zahn, Matt] Orange Cty Hlth Care Agcy, Santa Ana, CA USA.
   [Harriman, Kathleen; Winter, Kathleen] Calif Dept Publ Hlth, Sacramento, CA USA.
RP MacNeil, J (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM jmacneil@cdc.gov
NR 7
TC 0
Z9 0
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 9
PY 2016
VL 65
IS 35
BP 939
EP 940
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW0DR
UT WOS:000383311600004
PM 27606798
ER

PT J
AU Goers, M
   Ope, MO
   Samuels, A
   Gitu, N
   Akandwanaho, S
   Nabwami, G
   Nyoka, R
   Cetron, MS
   Dalal, W
   Conroy, AL
   Cantey, P
   John, C
   Naoum, M
   Weinberg, M
   Marano, N
   Stauffer, W
AF Goers, Matthew
   Ope, Maurice O.
   Samuels, Aaron
   Gitu, Natalia
   Akandwanaho, Saul
   Nabwami, Gladys
   Nyoka, Raymond
   Cetron, Martin S.
   Dalal, Warren
   Conroy, Andrea L.
   Cantey, Paul
   John, Chandy
   Naoum, Marwan
   Weinberg, Michelle
   Marano, Nina
   Stauffer, William
TI Splenomegaly of Unknown Etiology in Congolese Refugees Applying for
   Resettlement to the United States - Uganda, 2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Goers, Matthew; Stauffer, William] Univ Minnesota, Minneapolis, MN USA.
   [Ope, Maurice O.; Nyoka, Raymond] CDC, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, Nairobi, Kenya.
   [Samuels, Aaron] CDC, Malaria Branch, Div Parasit Dis & Malaria, Kisumu, Kenya.
   [Gitu, Natalia; Akandwanaho, Saul; Nabwami, Gladys] Int Org Migrat, Kampala, Uganda.
   [Cetron, Martin S.; Weinberg, Michelle; Marano, Nina; Stauffer, William] CDC, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
   [Dalal, Warren] Int Org Migrat, Nairobi, Kenya.
   [Conroy, Andrea L.; John, Chandy] Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA.
   [Cantey, Paul] CDC, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Marano, N (reprint author), CDC, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
EM nmarano@cdc.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 9
PY 2016
VL 65
IS 35
BP 943
EP 944
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW0DR
UT WOS:000383311600006
PM 27607133
ER

PT J
AU Chen, WW
   Messonnier, M
   Zhou, FJ
AF Chen, Weiwei
   Messonnier, Mark
   Zhou, Fangjun
TI Trends in childhood vaccine purchase costs in the US public sector:
   1996-2014
SO VACCINE
LA English
DT Article
DE Childhood vaccine purchase costs; Price variation; Vaccine
   recommendations
AB While vaccination remains as one of the most cost-effective preventive strategies, the cost of fully immunizing a child has grown considerably over the last few decades. This study examines trends in non influenza childhood vaccine purchase costs in the public sector from 1996 to 2014. Non-influenza vaccine purchase cost per child for children aged 0 through 18 years was calculated based on public-sector purchase prices. Purchase cost changes were then decomposed into changes attributable to recommendation updates and changes attributable to price variation. The study analyzed the growth rate of combination vaccine prices separately and compared these prices with the sum of prices of component vaccines. It is found that the average annual growth rate of non-influenza vaccine purchase cost per child during 19962014 was 12.6%. The growth rate attributable to price changes was 1.0% on average. Combination vaccine prices showed greater variation. The study concludes that vaccine price variation was one but a minor reason for purchase cost changes. Recommendation updates, particularly the introduction of new vaccines, played a much larger role in raising the purchase costs. If the 12.6% annual growth rate found during 1996-2014 in the study continues to apply, the purchase costs of childhood vaccines may more than double by 2020. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Chen, Weiwei; Messonnier, Mark; Zhou, Fangjun] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,A-19, Atlanta, GA 30329 USA.
RP Chen, WW (reprint author), Florida Int Univ, 11200 SW 8th St AHC5, Miami, FL 33199 USA.
EM wechen@flu.edu
OI Chen, Weiwei/0000-0002-2162-0941
NR 10
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 7
PY 2016
VL 34
IS 39
BP 4706
EP 4711
DI 10.1016/j.vaccine.2016.08.012
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DV9XL
UT WOS:000383295400012
PM 27522176
ER

PT J
AU Shepard, SS
   Meno, S
   Bahl, J
   Wilson, MM
   Barnes, J
   Neuhaus, E
AF Shepard, Samuel S.
   Meno, Sarah
   Bahl, Justin
   Wilson, Malania M.
   Barnes, John
   Neuhaus, Elizabeth
TI Viral deep sequencing needs an adaptive approach: IRMA, the iterative
   refinement meta-assembler
SO BMC GENOMICS
LA English
DT Article
DE Deep sequencing; NGS; Influenza; Ebola; Surveillance; High throughput;
   Public health
ID ERROR-CORRECTION; HIGH-THROUGHPUT; ALIGNMENT; POPULATIONS
AB Background: Deep sequencing makes it possible to observe low-frequency viral variants and sub-populations with greater accuracy and sensitivity than ever before. Existing platforms can be used to multiplex a large number of samples; however, analysis of the resulting data is complex and involves separating barcoded samples and various read manipulation processes ending in final assembly. Many assembly tools were designed with larger genomes and higher fidelity polymerases in mind and do not perform well with reads derived from highly variable viral genomes. Reference-based assemblers may leave gaps in viral assemblies while de novo assemblers may struggle to assemble unique genomes.
   Results: The IRMA (iterative refinement meta-assembler) pipeline solves the problem of viral variation by the iterative optimization of read gathering and assembly. As with all reference-based assembly, reads are included in assembly when they match consensus template sets; however, IRMA provides for on-the-fly reference editing, correction, and optional elongation without the need for additional reference selection. This increases both read depth and breadth. IRMA also focuses on quality control, error correction, indel reporting, variant calling and variant phasing. In fact, IRMA's ability to detect and phase minor variants is one of its most distinguishing features. We have built modules for influenza and ebolavirus. We demonstrate usage and provide calibration data from mixture experiments. Methods for variant calling, phasing, and error estimation/correction have been redesigned to meet the needs of viral genomic sequencing.
   Conclusion: IRMA provides a robust next-generation sequencing assembly solution that is adapted to the needs and characteristics of viral genomes. The software solves issues related to the genetic diversity of viruses while providing customized variant calling, phasing, and quality control. IRMA is freely available for non-commercial use on Linux and Mac OS X and has been parallelized for high-throughput computing.
C1 [Shepard, Samuel S.; Meno, Sarah; Wilson, Malania M.; Barnes, John; Neuhaus, Elizabeth] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Bahl, Justin] Univ Texas Sch Publ Hlth, Ctr Infect Dis, Houston, TX USA.
   [Wilson, Malania M.] Battelle Mem Res Inst, 1600 Clifton Rd, Atlanta, GA 30329 USA.
RP Shepard, SS; Neuhaus, E (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA.
EM vfn4@cdc.gov; ebn9@cdc.gov
FU Centers for Disease Control and Prevention; National Institutes of
   Health, Centers of Excellence for Influenza Research and Surveillance
   program [NIAID HHSN272201400006C]
FX This article is supported in part by the Centers for Disease Control and
   Prevention. Justin Bahl is supported by funds from National Institutes
   of Health, Centers of Excellence for Influenza Research and Surveillance
   program (NIAID HHSN272201400006C).
NR 41
TC 2
Z9 2
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD SEP 5
PY 2016
VL 17
AR 708
DI 10.1186/s12864-016-3030-6
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DW2JR
UT WOS:000383469200004
PM 27595578
ER

PT J
AU Azofeifa, A
   Mattson, ME
   Schauer, G
   McAfee, T
   Grant, A
   Lyerla, R
AF Azofeifa, Alejandro
   Mattson, Margaret E.
   Schauer, Gillian
   McAfee, Tim
   Grant, Althea
   Lyerla, Rob
TI National Estimates of Marijuana Use and Related Indicators - National
   Survey on Drug Use and Health, United States, 2002-2014
SO MMWR SURVEILLANCE SUMMARIES
LA English
DT Article
ID PERCEIVED RISK; CANNABIS USE; DISORDERS
AB Problem/Condition: In the United States, marijuana is the most commonly used illicit drug. In 2013, 7.5% (19.8 million) of the U.S. population aged >= 12 years reported using marijuana during the preceding month. Because of certain state-level policies that have legalized marijuana for medical or recreational use, population-based data on marijuana use and other related indicators are needed to help monitor behavioral health changes in the United States.
   Period Covered: 2002-2014.
   Description of System: The National Survey on Drug Use and Health (NSDUH) is a national-and state-level survey of a representative sample of the civilian, noninstitutionalized U.S. population aged >= 1.2. years. NSDUH collects information about the use of illicit drugs, alcohol, and tobacco; initiation of substance use; frequency of substance use; substance dependence and abuse; perception of substance harm risk or no risk; and other related behavioral health indicators. This report describes national trends for selected marijuana use and related indicators, including prevalence of marijuana use; initiation; perception of harm risk, approval, and attitudes; perception of availability and mode of acquisition; dependence and abuse; and perception of legal penalty for marijuana possession.
   Results: In 2014, a total of 2.5 million persons aged >= 1.2 years had used marijuana for the first time during the preceding 12 months, an average, of approximately 7,000 new users each day. During 2002-2014, the prevalence of marijuana use during the past month, past year, and daily or almost daily increased among persons aged 18 years, but not among those aged 12-17 years. Among persons aged 12 years, the prevalence of perceived great risk from smoking marijuana once or twice a week and once a month decreased and the prevalence of perceived no risk increased. The prevalence of past year marijuana dependence and abuse decreased, except among persons aged years. Among persons aged >= 12 years, the percentage reporting that marijuana was fairly easy or very easy to obtain increased. The percentage of persons aged 12 reporting the mode of acquisition of marijuana was buying it and growing it increased versus getting it for free and sharing it. The percentage of persons aged >= 12 years reporting that the perceived maximum legal penalty for the possession of an ounce or less of marijuana in their state is a fine and no penalty increased versus probation, community service, possible prison sentence, and mandatory prison sentence.
   Interpretation: Since 2002, marijuana use in the United States has increased among persons aged 18 years, but not among those aged 12-17 years. A decrease in the perception of great risk from smoking marijuana combined with increases in the perception of availability (i.e., fairly easy or very easy to obtain marijuana) and fewer punitive legal penalties (e.g., no penalty) for the possession of marijuana for personal use might play a role in increased use among adults.
   Public Health Action: National-and state-level data can help federal, state, and local public health officials develop targeted prevention activities to reduce youth initiation of marijuana use, prevent marijuana dependence and abuse, and prevent adverse health effects. As state-level laws on medical and recreational marijuana use change, modifications might be needed to national-and state-level surveys and more timely and comprehensive surveillance systems might be necessary to provide these data. Marijuana use in younger age groups is a particular public health concern, and changing the perception of harm risk from smoking marijuana is needed.
C1 [Azofeifa, Alejandro; Mattson, Margaret E.; Lyerla, Rob] Subst Abuse & Mental Hlth Serv Adm, Div Evaluat Anal & Qual, Ctr Behav Hlth Stat & Qual, Rockville, MD 20857 USA.
   [Schauer, Gillian] CDC, Battelle Mem Inst, Publ Hlth Ctr Tobacco Res, Off Smoking & Hlth,Natl Ctr Chron Dis Prevent & H, Atlanta, GA 30333 USA.
   [McAfee, Tim] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Grant, Althea] CDC, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA.
RP Azofeifa, A (reprint author), Subst Abuse & Mental Hlth Serv Adm, Div Evaluat Anal & Qual, Ctr Behav Hlth Stat & Qual, Rockville, MD 20857 USA.
EM Alejandro.Azofeifa@samhsa.hhs.gov
NR 20
TC 3
Z9 3
U1 11
U2 11
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-8636
J9 MMWR SURVEILL SUMM
JI MMWR Surv. Summ.
PD SEP 2
PY 2016
VL 65
IS 11
BP 1
EP COVER3
PG 25
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA1AN
UT WOS:000386320800001
PM 27584586
ER

PT J
AU Watson, J
   Carlile, J
   Dunn, A
   Evans, M
   Fratto, E
   Hartsell, J
   Meinor, L
   Mietchen, M
   Nakashima, A
AF Watson, Joanna
   Carlile, Jerry
   Dunn, Angela
   Evans, Megan
   Fratto, Erin
   Hartsell, Joel
   Meinor, Lynn
   Mietchen, Matthew
   Nakashima, Allyn
TI Increased Gonorrhea Cases - Utah, 2009-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Editorial Material
C1 [Watson, Joanna; Dunn, Angela] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Watson, Joanna; Carlile, Jerry; Dunn, Angela; Evans, Megan; Fratto, Erin; Hartsell, Joel; Meinor, Lynn; Mietchen, Matthew; Nakashima, Allyn] Utah Dept Hlth, Salt Lake City, UT 84116 USA.
RP Watson, J (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Watson, J (reprint author), Utah Dept Hlth, Salt Lake City, UT 84116 USA.
EM wgq6@cdc.gov
OI Watson, Joanna/0000-0002-2532-2423
NR 8
TC 0
Z9 0
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 889
EP 893
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700001
PM 27583786
ER

PT J
AU David-Ferdon, C
   Crosby, AE
   Caine, ED
   Hindman, J
   Reed, J
   Iskander, J
AF David-Ferdon, Corinne
   Crosby, Alex E.
   Caine, Eric D.
   Hindman, Jarrod
   Reed, Jerry
   Iskander, John
TI CDC Grand Rounds: Preventing Suicide Through a Comprehensive Public
   Health Approach
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID PROGRAM
C1 [David-Ferdon, Corinne; Crosby, Alex E.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Caine, Eric D.; Reed, Jerry] Univ Rochester, Med Ctr, Injury Control Res Ctr Suicide Prevent, Rochester, NY 14627 USA.
   [Hindman, Jarrod] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
   [Reed, Jerry] Suicide Prevent Resource Ctr, Boston, MA USA.
   [Reed, Jerry] Educ Dev Ctr, Boston, MA USA.
   [Iskander, John] CDC, Off Director, Atlanta, GA 30333 USA.
RP David-Ferdon, C (reprint author), CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM cferdon@cdc.gov
NR 13
TC 0
Z9 0
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 894
EP 897
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700002
PM 27584004
ER

PT J
AU D'Angelo, D
   Ahluwalia, IB
   Pun, E
   Yin, S
   Palipudi, K
   Mbulo, T
AF D'Angelo, Denise
   Ahluwalia, Indu B.
   Pun, Eugene
   Yin, Shaoman
   Palipudi, Krishna
   Mbulo, Tazarous
TI Current Cigarette Smoking, Access, and Purchases from Retail Outlets
   Among Students Aged 13-15 Years - Global Youth Tobacco Survey, 45
   Countries, 2013 and 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID MINORS
C1 [D'Angelo, Denise; Ahluwalia, Indu B.; Pun, Eugene; Palipudi, Krishna; Mbulo, Tazarous] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Yin, Shaoman] CDC Fdn, Atlanta, GA USA.
RP D'Angelo, D (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM DDAngelo@cdc.gov
NR 10
TC 0
Z9 0
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 898
EP 901
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700003
PM 27584595
ER

PT J
AU Lopez, AS
   Zhang, J
   Marin, M
AF Lopez, Adriana S.
   Zhang, John
   Marin, Mona
TI Epidemiology of Varicella During the 2-Dose Varicella Vaccination
   Program - United States, 2005-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID SURVEILLANCE; IMPACT
C1 [Lopez, Adriana S.; Zhang, John; Marin, Mona] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Lopez, AS (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM alopez@cdc.gov
NR 10
TC 1
Z9 1
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 902
EP 905
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700004
PM 27584717
ER

PT J
AU Elbadawi, LI
   Borlaug, G
   Gundlach, KM
   Monson, T
   Warshauer, D
   Walters, MS
   Kallen, A
   Gulvik, CA
   Davis, JP
AF Elbadawi, Lina I.
   Borlaug, Gwen
   Gundlach, Kristin M.
   Monson, Timothy
   Warshauer, David
   Walters, Maroya S.
   Kallen, Alexander
   Gulvik, Christopher A.
   Davis, Jeffrey P.
TI Carbapenem-Resistant Enterobacteriaceae Transmission in Health Care
   Facilities - Wisconsin, February-May 2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Elbadawi, Lina I.] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [Elbadawi, Lina I.; Borlaug, Gwen; Davis, Jeffrey P.] Bur Communicable Dis, Wisconsin Div Publ Hlth, Madison, WI 53703 USA.
   [Gundlach, Kristin M.; Monson, Timothy; Warshauer, David] CDC, Wisconsin State Lab Hyg, Atlanta, GA 30333 USA.
   [Walters, Maroya S.; Kallen, Alexander; Gulvik, Christopher A.] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Elbadawi, LI (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.; Elbadawi, LI (reprint author), Bur Communicable Dis, Wisconsin Div Publ Hlth, Madison, WI 53703 USA.
EM lelbadawi@cdc.gov
NR 9
TC 0
Z9 0
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 906
EP 909
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700005
PM 27584864
ER

PT J
AU Dirlikov, E
   Major, CG
   Mayshack, M
   Medina, N
   Matos, D
   Ryff, KR
   Torres-Aponte, J
   Alkis, R
   Munoz-Jordan, J
   Colon-Sanchez, C
   Salinas, JL
   Pastula, DM
   Garcia, M
   Segarra, MO
   Malave, G
   Thomas, DL
   Rodriguez-Vega, GM
   Luciano, CA
   Sejvar, J
   Sharp, TM
   Rivera-Garcia, B
AF Dirlikov, Emilio
   Major, Chelsea G.
   Mayshack, Marrielle
   Medina, Nicole
   Matos, Desiree
   Ryff, Kyle R.
   Torres-Aponte, Jomil
   Alkis, Rebecca
   Munoz-Jordan, Jorge
   Colon-Sanchez, Candimar
   Salinas, Jorge L.
   Pastula, Daniel M.
   Garcia, Myriam
   Segarra, Marangely Olivero
   Malave, Graciela
   Thomas, Dana L.
   Rodriguez-Vega, Gloria M.
   Luciano, Carlos A.
   Sejvar, James
   Sharp, Tyler M.
   Rivera-Garcia, Brenda
TI Guillain-Barre Syndrome During Ongoing Zika Virus Transmission - Puerto
   Rico, January 1-July 31, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Dirlikov, Emilio; Mayshack, Marrielle; Ryff, Kyle R.; Torres-Aponte, Jomil; Rivera-Garcia, Brenda] Puerto Rico Dept Hlth, Off Epidemiol & Res, San Juan, PR 00927 USA.
   [Dirlikov, Emilio; Salinas, Jorge L.] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [Major, Chelsea G.; Medina, Nicole; Matos, Desiree; Munoz-Jordan, Jorge; Colon-Sanchez, Candimar; Pastula, Daniel M.; Sharp, Tyler M.] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Major, Chelsea G.; Mayshack, Marrielle] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA.
   [Alkis, Rebecca] Emory Univ, Atlanta, GA 30322 USA.
   [Pastula, Daniel M.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA.
   [Pastula, Daniel M.] Univ Colorado, Div Infect Dis, Denver, CO 80202 USA.
   [Garcia, Myriam; Segarra, Marangely Olivero; Malave, Graciela] Puerto Rico Dept Hlth, Biol & Chem Emergencies Lab, Off Publ Hlth Preparedness & Response, San Juan, PR USA.
   [Garcia, Myriam; Segarra, Marangely Olivero; Malave, Graciela] Puerto Rico Dept Hlth, Publ Hlth Lab, San Juan, PR USA.
   [Thomas, Dana L.] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
   [Rodriguez-Vega, Gloria M.] HIMA San Pablo, Caguas, PR USA.
   [Luciano, Carlos A.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Sejvar, James] CDC, Off Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Dirlikov, E (reprint author), Puerto Rico Dept Hlth, Off Epidemiol & Res, San Juan, PR 00927 USA.; Dirlikov, E (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
EM GBS@salud.pr.gov
NR 10
TC 8
Z9 8
U1 64
U2 64
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 910
EP 914
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700006
PM 27584942
ER

PT J
AU Brooks, RB
   Carlos, MP
   Myers, RA
   White, MG
   Bobo-Lenoci, T
   Aplan, D
   Blythe, D
   Feldman, KA
AF Brooks, Richard B.
   Carlos, Maria Paz
   Myers, Robert A.
   White, Mary Grace
   Bobo-Lenoci, Tanya
   Aplan, Debra
   Blythe, David
   Feldman, Katherine A.
TI Likely Sexual Transmission of Zika Virus from a Man with No Symptoms of
   Infection - Maryland, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UPDATE INTERIM GUIDANCE; UNITED-STATES; EPIDEMIC
C1 [Brooks, Richard B.] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [Brooks, Richard B.; Blythe, David; Feldman, Katherine A.] Maryland Dept Hlth & Mental Hyg, Prevent & Hlth Promot Adm, Baltimore, MD 21201 USA.
   [Carlos, Maria Paz; Myers, Robert A.] Maryland Dept Hlth & Mental Hyg, Labs Adm, Baltimore, MD 21201 USA.
   [White, Mary Grace; Bobo-Lenoci, Tanya] Baltimore City Dept Hlth, Baltimore, MD USA.
   [Aplan, Debra] Montgomery Cty Dept Hlth & Human Serv, Rockville, MD USA.
RP Brooks, RB (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.; Brooks, RB (reprint author), Maryland Dept Hlth & Mental Hyg, Prevent & Hlth Promot Adm, Baltimore, MD 21201 USA.
EM richard.brooks@maryland.gov
NR 6
TC 10
Z9 10
U1 18
U2 18
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 915
EP 916
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700007
PM 27585037
ER

PT J
AU de Voux, A
   Kent, JB
   Macomber, K
   Krzanowski, K
   Jackson, D
   Starr, T
   Johnson, S
   Richmond, D
   Crane, LR
   Cohn, J
   Finch, C
   McFadden, J
   Pillay, A
   Chen, C
   Anderson, L
   Kersh, EN
AF de Voux, Alex
   Kent, James B.
   Macomber, Kathryn
   Krzanowski, Karen
   Jackson, Dawn
   Starr, Tayneata
   Johnson, Sandra
   Richmond, Deborah
   Crane, Lawrence R.
   Cohn, Jonathan
   Finch, Christopher
   McFadden, Jevon
   Pillay, Allan
   Chen, Cheng
   Anderson, Laurie
   Kersh, Ellen N.
TI Cluster of Lymphogranuloma Venereum Cases Among Men Who Have Sex with
   Men - Michigan, August 2015-April 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [de Voux, Alex] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [de Voux, Alex; Pillay, Allan; Chen, Cheng; Anderson, Laurie; Kersh, Ellen N.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Kent, James B.; Macomber, Kathryn] Michigan Dept Hlth Human Serv, Div Communicable Dis, Detroit, MI USA.
   [Krzanowski, Karen; Jackson, Dawn; Starr, Tayneata; Johnson, Sandra] Michigan Dept Hlth Human Serv, Div HIV & STD Programs, Detroit, MI USA.
   [Richmond, Deborah; Crane, Lawrence R.; Cohn, Jonathan; Finch, Christopher] Wayne State Univ, Sch Med, Detroit, MI USA.
   [McFadden, Jevon] CDC, Career Epidemiol Field Officer Program, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
RP de Voux, A (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.; de Voux, A (reprint author), CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM AdeVoux@cdc.gov
NR 6
TC 1
Z9 1
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD SEP 2
PY 2016
VL 65
IS 34
BP 920
EP 921
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV4NQ
UT WOS:000382902700009
PM 27583686
ER

PT J
AU Joyner, C
   Moreno, A
   Meyer, EVS
   Cabrera-Mora, M
   Kissinger, JC
   Barnwell, JW
   Galinski, MR
AF Joyner, Chester
   Moreno, Alberto
   Meyer, Esmeralda V. S.
   Cabrera-Mora, Monica
   Kissinger, Jessica C.
   Barnwell, John W.
   Galinski, Mary R.
CA MaHPIC Consortium
TI Plasmodium cynomolgi infections in rhesus macaques display clinical and
   parasitological features pertinent to modelling vivax malaria pathology
   and relapse infections
SO MALARIA JOURNAL
LA English
DT Article
DE Plasmodium vivax; Host-pathogen interactions; Malaria; Non-human
   primates; Rhesus; Anaemia; Thrombocytopaenia; Systems biology; Animal
   models
ID CAVEOLA-VESICLE COMPLEXES; UNINFECTED ERYTHROCYTES; FALCIPARUM-MALARIA;
   PRIMATE MALARIA; TERTIAN MALARIA; SCHUFFNERS DOTS; MACACA-MULATTA;
   IN-VITRO; ANEMIA; THROMBOCYTOPENIA
AB Background: Plasmodium vivax infections in humans or in new world monkeys pose research challenges that necessitate the use of alternative model systems. Plasmodium cynomolgi is a closely related species that shares genetic and biological characteristics with P. vivax, including relapses. Here, the haematological dynamics and clinical presentation of sporozoite-initiated P. cynomolgi infections in Macaca mulatta (rhesus macaques) are evaluated over a 100-day period.
   Methods: Five M. mulatta were inoculated with 2000 P. cynomolgi B strain sporozoites. Parasitological and haematological data were collected daily to study the clinical presentations of primary infections and relapses. Peripheral blood and bone marrow aspirates were collected at specific time points during infection for future and retrospective systems biology analyses.
   Results: Patent infections were observed between days 10 and 12, and the acute, primary infection consisted of parasitaemias ranging from 269,962 to 1,214,842 parasites/mu l (4.42-19.5 % parasitaemia). All animals presented with anaemia, ranging from moderate (7-10 g/dl) to severe (<7 g/dl), based on peripheral haemoglobin concentrations. Minimum haemoglobin levels coincided with the clearance of parasites and peripheral reticulocytosis was evident at this time. Mild thrombocytopaenia (<150,000 platelets/mu l) was observed in all animals, but unlike haemoglobin, platelets were lowest whenever peripheral parasitaemia peaked. The animals' conditions were classified as non-severe, severe or lethal (in one case) based upon their clinical presentation. The lethal phenotype presented uniquely with an exceptionally high parasitaemia (19.5 %) and lack of a modest reticulocyte release, which was observed in the other animals prior to acute manifestations. One or two relapses were observed in the four surviving animals, and these were characterized by significantly lower parasitaemias and minimal changes in clinical parameters compared to pre-infection values.
   Conclusions: Rhesus macaque infections initiated by P. cynomolgi B strain sporozoites recapitulated pathology of human malaria, including anaemia and thrombocytopaenia, with inter-individual differences in disease severity. Importantly, this study provides an in-depth assessment of clinical and parasitological data, and shows that unlike the
C1 [Joyner, Chester; Moreno, Alberto; Meyer, Esmeralda V. S.; Cabrera-Mora, Monica; Galinski, Mary R.] Emory Univ, Yerkes Natl Primate Res Ctr, Int Ctr Malaria Res Educ & Dev, Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.
   [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA USA.
   [Moreno, Alberto; Galinski, Mary R.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Kissinger, Jessica C.] Univ Georgia, Dept Genet, Ctr Trop & Emerging Global Dis, Inst Bioinformat, Athens, GA 30602 USA.
   [Joyner, Chester; Moreno, Alberto; Meyer, Esmeralda V. S.; Cabrera-Mora, Monica; Kissinger, Jessica C.; Barnwell, John W.; Galinski, Mary R.] Malaria Host Pathogen Interact Ctr, Atlanta, GA USA.
RP Galinski, MR (reprint author), Emory Univ, Yerkes Natl Primate Res Ctr, Int Ctr Malaria Res Educ & Dev, Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.; Galinski, MR (reprint author), Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.; Galinski, MR (reprint author), Malaria Host Pathogen Interact Ctr, Atlanta, GA USA.
EM mary.galinski@emory.edu
OI Kissinger, Jessica/0000-0002-6413-1101
FU US National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services
   [HHSN272201200031C]; Office of Research Infrastructure Programs/OD
   [P51OD011132]
FX This project was funded in part by Federal funds from the US National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human Services under contract #
   HHSN272201200031C (PI: Mary Galinski), which supports the Malaria
   Host-Pathogen Interaction Center (MaHPIC), as well as the Office of
   Research Infrastructure Programs/OD P51OD011132.
NR 77
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 2
PY 2016
VL 15
AR 451
DI 10.1186/s12936-016-1480-6
PG 18
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU9KU
UT WOS:000382536800003
PM 27590312
ER

PT J
AU Sambhara, D
   Hill, C
   Hart, L
   Chen, JF
   Scott, IU
   Pantanelli, S
AF Sambhara, Deepak
   Hill, Christopher
   Hart, Lisa
   Chen, Jufu
   Scott, Ingrid U.
   Pantanelli, Seth
TI Effect of Applanation Tonometry on Keratometry Measurements Obtained
   with IOLMaster and Galilei Dual-Scheimpflug Analyzer
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY MAY 01-05, 2016
CL Seattle, WA
SP Assoc Res Vis & Ophthalmol
C1 [Sambhara, Deepak; Hill, Christopher; Hart, Lisa; Scott, Ingrid U.; Pantanelli, Seth] Penn State Hershey Med Ctr, Penn State Hershey Eye Ctr, Hershey, PA USA.
   [Chen, Jufu] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2016
VL 57
IS 12
MA 922
PG 2
WC Ophthalmology
SC Ophthalmology
GA EK8LA
UT WOS:000394174002335
ER

PT J
AU Chandrasekar, E
   Song, S
   Johnson, M
   Harris, AM
   Kaufman, GI
   Freedman, D
   Quinn, MT
   Kim, KE
AF Chandrasekar, Edwin
   Song, Sharon
   Johnson, Matthew
   Harris, Aaron M.
   Kaufman, Gary I.
   Freedman, David
   Quinn, Michael T.
   Kim, Karen E.
TI A Novel Strategy to Increase Identification of African-Born People With
   Chronic Hepatitis B Virus Infection in the Chicago Metropolitan Area,
   2012-2014
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID HEALTH; COMMUNITY; CARE; IMMIGRANTS; DISEASES; ACCESS; MODEL
AB Introduction
   Most research on hepatitis B virus (HBV) infection in the United States is limited to Asian populations, despite an equally high prevalence among African immigrants. The purpose of this study was to determine testing and detection rates of HBV infection among African-born people residing in the Chicago metropolitan area.
   Methods
   A hepatitis education and prevention program was developed in collaboration with academic, clinical, and community partners for immigrant and refugee populations at risk for HBV infection. Community health workers implemented chain referral sampling, a novel strategy for recruiting hard-to-reach participants, targeting African-born participants. Participants were tested in both clinical and nonclinical settings. To assess infection status, blood samples were obtained for hepatitis B surface antigen (HBsAg), core antibody, and surface antibody testing. Demographic information was collected on age, sex, health insurance status, country of origin, and years residing in the United States. Participants were notified of testing results, and HBsAg-positive participants were referred for follow-up medical care.
   Results
   Of 1,000 African-born people who received education, 445 (45%) agreed to participate in HBV screening. There were 386 (87%) participants tested in clinical and 59 (13%) tested in nonclinical sites. Compared with participants who were tested in clinical settings, participants tested in nonclinical settings were older, were less likely to have health insurance, and had lived in the United States longer (P <.005 for each). Of these, most were from the Democratic Republic of the Congo (14%), Nigeria (13%), Ghana (11%), Somalia (11%), or Ethiopia (10%). There were 35 (8%) HBsAg-positive people, 37% had evidence of past infection, and 29% were immune.
   Conclusions
   Chain referral sampling identified many at-risk African-born people with chronic HBV infection. The large proportion of HBsAg-positive people in this sample reinforces the need for health promotion programs that are culturally appropriate and community-driven.
C1 [Chandrasekar, Edwin; Song, Sharon; Johnson, Matthew] Asian Hlth Coalit, 180 West Washington St,Off 1000, Chicago, IL 60602 USA.
   [Harris, Aaron M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA.
   [Kaufman, Gary I.] Mt Sinai Hosp, Sinai Hlth Syst, Touhy Hlth Ctr, Chicago, IL USA.
   [Freedman, David] Heartland Hlth Ctr, Chicago, IL USA.
   [Quinn, Michael T.; Kim, Karen E.] Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA.
   [Quinn, Michael T.; Kim, Karen E.] Univ Chicago, Off Community Engagement & Canc Dispar, Chicago, IL 60637 USA.
RP Chandrasekar, E (reprint author), Asian Hlth Coalit, 180 West Washington St,Off 1000, Chicago, IL 60602 USA.
EM edwin@asianhealth.org
FU Centers for Disease Control and Prevention [5U51PS004616, PS003816-01];
   African Community United Methodist Church; Heartland Health Centers;
   Mount Sinai Hospital Touhy Health Clinic; United African Organization;
   Illinois Department of Public Health
FX Education, outreach, and participant recruitment for this study were
   made possible through funding from the Illinois Department of Public
   Health and private foundations. The screening and link-age-to-care
   activities were supported by cooperative grants from the Centers for
   Disease Control and Prevention nos. 5U51PS004616 and PS003816-01. We are
   grateful to the following organizations for their partnerships: African
   Community United Methodist Church, Heartland Health Centers, Mount Sinai
   Hospital Touhy Health Clinic, United African Organization, and other
   community agencies. We also appreciate the University of Chicago's
   institutional review board for providing ethical review of the project.
NR 26
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD SEP
PY 2016
VL 13
AR 160162
DI 10.5888/pcd13.160162
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JN
UT WOS:000393108500002
ER

PT J
AU King, RJ
   Garrett, N
   Kriseman, J
   Crum, M
   Rafalski, EM
   Sweat, D
   Frazier, R
   Schearer, S
   Cutts, T
AF King, Raymond J.
   Garrett, Nedra
   Kriseman, Jeffrey
   Crum, Melvin
   Rafalski, Edward M.
   Sweat, David
   Frazier, Renee
   Schearer, Sue
   Cutts, Teresa
TI A Community Health Record: Improving Health Through Multisector
   Collaboration, Information Sharing, and Technology
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID STRATEGIES; DISEASE
AB We present a framework for developing a community health record to bring stakeholders, information, and technology together to collectively improve the health of a community. It is both social and technical in nature and presents an iterative and participatory process for achieving multisector collaboration and information sharing. It proposes a methodology and infrastructure for bringing multisector stakeholders and their information together to inform, target, monitor, and evaluate community health initiatives. The community health record is defined as both the proposed framework and a tool or system for integrating and transforming multisector data into actionable information. It is informed by the electronic health record, personal health record, and County Health Ranking systems but differs in its social complexity, communal ownership, and provision of information to multisector partners at scales ranging from address to zip code.
C1 [King, Raymond J.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
   [Garrett, Nedra] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
   [Kriseman, Jeffrey] State Tennessee, Nashville, TN USA.
   [Crum, Melvin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
   [Rafalski, Edward M.] BayCare Hlth Syst, Clearwater, FL USA.
   [Sweat, David] Shelby Cty Hlth Dept, Memphis, TN USA.
   [Frazier, Renee] Common Table Hlth Alliance, Memphis, TN USA.
   [Rafalski, Edward M.; Schearer, Sue; Cutts, Teresa] Methodist Le Bonheur Healthcare, Memphis, TN USA.
   [Cutts, Teresa] Wake Forest Sch Med, Winston Salem, NC USA.
   [King, Raymond J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP King, RJ (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM rjking@cdc.gov
FU Division of Heart Disease and Stroke Prevention (DHDSP) at the CDC; CDC
   Innovation Fund; CDC Public Health Informatics Fellowship Program;
   Public Health Informatics Institute
FX Funding for this research was provided by the Division of Heart Disease
   and Stroke Prevention (DHDSP) at the CDC and CDC Innovation Fund. The
   authors are grateful for the insight and editorial feedback provided by
   Sam Posner, CDC. We gratefully acknowledge Michele Casper and Fleetwood
   Loustalot of DHDSP for their project support and guidance and review of
   the manuscript. We are immensely grateful for the contributions and hard
   work provided by members of the Community Health Record team: Pradeep
   Podila and Leon Cistrunk from Methodist Le Bonheur Healthcare, Jennifer
   Kmet and Lilian Ogari from the Shelby County Health Department, and
   Lilly Rowland and Derrick Boswell (formerly) at the Tennessee Department
   of Health. The authors appreciate the expert advice and support provided
   by Mary George, DHDSP; the CDC Public Health Informatics Fellowship
   Program (Herman Tolentino, Laura Franzke, and Sridhar Papagari); and the
   Public Health Informatics Institute (Dave Ross, Bill Brand, and Debra
   Bara). We are grateful for the support and leadership of Robert Merritt,
   DHDSP, and Lori Ferranti, Tennessee Department of Health. The authors
   are thankful for the expert advice and development of the community
   health record prototype by the Web-Based Analysis and Visualization
   Environment Organization (Georges Grinstein, Joss Stubblefield, and Pat
   Stickney). We thank Zachary Welch, formerly at Deloitte, for his design
   of the user interface; Aly Goodman, CDC, for input on Figure 2; and
   Natalie Wilkins, Karin Mack and Paul Siegel, CDC, for their editorial
   feedback. Dr. King is also affiliated with IHRC, Inc, Atlanta, Georgia.
   The findings and conclusions in this report are those of the authors and
   do not necessarily represent the official position of the Centers for
   Disease Control and Prevention.
NR 31
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD SEP
PY 2016
VL 13
AR 160101
DI 10.5888/pcd13.160101
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JN
UT WOS:000393108500006
ER

PT J
AU Meador, A
   Lang, JE
   Davis, WD
   Jones-Jack, NH
   Mukhtar, Q
   Lu, H
   Acharya, SD
   Molloy, ME
AF Meador, Amy
   Lang, Jason E.
   Davis, Whitney D.
   Jones-Jack, Nkenge H.
   Mukhtar, Qaiser
   Lu, Hua
   Acharya, Sushama D.
   Molloy, Meg E.
TI Comparing 2 National Organization-Level Workplace Health Promotion and
   Improvement Tools, 2013-2015
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID PROGRAMS; WORKSITE; INTERVENTIONS; DISEASE
AB Creating healthy workplaces is becoming more common. Half of employers that have more than 50 employees offer some type of workplace health promotion program. Few employers implement comprehensive evidence-based interventions that reach all employees and achieve desired health and cost outcomes. A few organization-level assessment and benchmarking tools have emerged to help employers evaluate the comprehensiveness and rigor of their health promotion offerings. Even fewer tools exist that combine assessment with technical assistance and guidance to implement evidence-based practices. Our descriptive analysis compares 2 such tools, the Centers for Disease Control and Prevention's Worksite Health ScoreCard and Prevention Partners' WorkHealthy America, and presents data from both to describe workplace health promotion practices across the United States. These tools are reaching employers of all types (N = 1,797), and many employers are using a comprehensive approach (85% of those using WorkHealthy America and 45% of those using the ScoreCard), increasing program effectiveness and impact.
C1 [Meador, Amy; Davis, Whitney D.; Molloy, Meg E.] Prevent Partners, 88 Vilcom Ctr Dr,Ste 110, Chapel Hill, NC 27514 USA.
   [Lang, Jason E.; Mukhtar, Qaiser; Lu, Hua] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   [Jones-Jack, Nkenge H.] Carter Consulting Inc, Atlanta, GA USA.
   [Acharya, Sushama D.] CDC Fdn, Atlanta, GA USA.
RP Meador, A (reprint author), Prevent Partners, 88 Vilcom Ctr Dr,Ste 110, Chapel Hill, NC 27514 USA.
EM amy@forprevention.org
NR 19
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD SEP
PY 2016
VL 13
AR 160164
DI 10.5888/pcd13.160164
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JN
UT WOS:000393108500020
ER

PT J
AU Persoskie, A
   Donaldson, EA
   King, BA
AF Persoskie, Alexander
   Donaldson, Elisabeth A.
   King, Brian A.
TI Ever-Use and Curiosity About Cigarettes, Cigars, Smokeless Tobacco, and
   Electronic Cigarettes Among US Middle and High School Students,
   2012-2014
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID YOUNG-ADULTS; SMOKING INITIATION; UNITED-STATES; EXPOSURE; YOUTH;
   EXPERIMENTATION; SUSCEPTIBILITY; DISPARITIES; REASONS; HEALTH
AB Introduction
   Among young people, curiosity about tobacco products is a primary reason for tobacco experimentation and is a risk factor for future use. We examined whether curiosity about and ever-use of tobacco products among US middle and high school students changed from 2012 to 2014.
   Methods
   Data came from the 2012 and 2014 National Youth Tobacco Surveys, nationally representative surveys of US students in grades 6 through 12. For cigarettes, cigars, smokeless tobacco, and e-cigarettes (2014 only), students were classified as ever-users or neverusers of each product. Among never-users, curiosity about using each product was assessed by asking participants if they had "definitely," "probably," "probably not," or "definitely not" been curious about using the product.
   Results
   From 2012 to 2014, there were declines in ever-use of cigarettes (26% to 22%; P=.005) and cigars (21% to 18%; P =.003) overall and among students who were Hispanic (cigarettes, P=.001; cigars, P=.001) or black (cigarettes, P =.004; cigars, P=.01). The proportion of never-users reporting they were " definitely not" curious increased for cigarettes (51% to 54%; P=.01) and cigars (60% to 63%; P=.03). Ever-use and curiosity about smokeless to bacco did not change significantly from 2012 to 2014. In 2014, the proportion of young people who were "definitely" or "probably" curious never-users of each product was as follows: cigarettes, 11.4%; e-cigarettes, 10.8%; cigars, 10.3%; and smokeless tobacco, 4.4%.
   Conclusion
   The proportion of US students who are never users and are not curious about cigarettes and cigars increased. However, many young people remain curious about tobacco products, including ecigarettes. Understanding factors driving curiosity can inform tobacco use prevention for youth.
C1 [Persoskie, Alexander] Bldg 71,Room G335,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
   [Donaldson, Elisabeth A.] US FDA, Off Sci, Ctr Tobacco Prod, Silver Spring, MD USA.
   [King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Persoskie, A (reprint author), Bldg 71,Room G335,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM alexander.persoskie@fda.hhs.gov
FU Food and Drug Administration's Center for Tobacco Products
FX Publication of this article was supported by the Food and Drug
   Administration's Center for Tobacco Products.
NR 36
TC 1
Z9 1
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD SEP
PY 2016
VL 13
AR 160151
DI 10.5888/pcd13.160151
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JN
UT WOS:000393108500018
ER

PT J
AU Shaw, KM
   Theis, KA
   Self-Brown, S
   Roblin, DW
   Barker, L
AF Shaw, Kate M.
   Theis, Kristina A.
   Self-Brown, Shannon
   Roblin, Douglas W.
   Barker, Lawrence
TI Chronic Disease Disparities by County Economic Status and Metropolitan
   Classification, Behavioral Risk Factor Surveillance System, 2013
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID SELF-RATED HEALTH; INCOME INEQUALITY; UNITED-STATES; US; NEIGHBORHOOD;
   ENVIRONMENTS; MORTALITY; OBESITY
AB Introduction
   Racial/ethnic disparities have been studied extensively. However, the combined influence of geographic location and economic status on specific health outcomes is less well studied. This study's objective was to examine 1) the disparity in chronic disease prevalence in the United States by county economic status and metropolitan classification and 2) the social gradient by economic status. The association of hypertension, arthritis, and poor health with county economic status was also explored.
   Methods
   We used 2013 Behavioral Risk Factor Surveillance System data. County economic status was categorized by using data on unemployment, poverty, and per capita market income. While controlling for sociodemographics and other covariates, we used multivariable logistic regression to evaluate the relationship between economic status and hypertension, arthritis, and self-rated health.
   Results
   Prevalence of hypertension, arthritis, and poor health in the poorest counties was 9%, 13%, and 15% higher, respectively, than in the most affluent counties. After we controlled for covariates, poor counties still had a higher prevalence of the studied conditions.
   Conclusion
   We found that residents of poor counties had a higher prevalence of poor health outcomes than affluent counties, even after we controlled for known risk factors. Further, the prevalence of poor health outcomes decreased as county economics improved. Findings suggest that poor counties would benefit from targeted public health interventions, better access to health care services, and improved food and built environments.
C1 [Shaw, Kate M.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E28, Chamblee, GA 30329 USA.
   [Theis, Kristina A.; Barker, Lawrence] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Shaw, Kate M.; Self-Brown, Shannon; Roblin, Douglas W.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA.
RP Shaw, KM (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E28, Chamblee, GA 30329 USA.
EM kmshaw@cdc.gov
NR 25
TC 1
Z9 1
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD SEP
PY 2016
VL 13
AR 160088
DI 10.5888/pcd13.160088
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JN
UT WOS:000393108500003
ER

PT J
AU Whitfield, GP
   Wendel, AM
   Auchincloss, AH
AF Whitfield, Geoffrey P.
   Wendel, Arthur M.
   Auchincloss, Amy H.
TI Ecological Analysis of Parking Prices and Active Commuting in US Cities,
   2009
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID PHYSICAL-ACTIVITY; BUILT ENVIRONMENT; ADULTS; TRAVEL
AB We conducted an ecological study to determine whether parking prices are associated with active commuting across US cities. We obtained parking prices for 107 US cities from the Drexel University Central Business District Public Parking Survey, obtained city prevalence of walking and bicycling to work from the American Community Survey, and used weighted least squares linear regression to explore associations between parking prices and active commuting. After adjusting for several covariates, walking to work was 3.1% higher for every additional dollar charged for off-street daily parking, but only among more densely populated cities, and no such association was detected for bicycling to work. These preliminary results hint at the potential for parking policies to influence commuting mode choice, a link that city planners and public health officials could consider when evaluating parking policies and active transportation behaviors.
C1 [Whitfield, Geoffrey P.; Wendel, Arthur M.] Ctr Dis Control & Prevent, Hlth Community Design Initiat, 4770 Buford Hwy NE,MS F-58, Atlanta, GA 30341 USA.
   [Auchincloss, Amy H.] Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Whitfield, GP (reprint author), Ctr Dis Control & Prevent, Hlth Community Design Initiat, 4770 Buford Hwy NE,MS F-58, Atlanta, GA 30341 USA.
EM xdh5@cdc.gov
NR 11
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD SEP
PY 2016
VL 13
AR 160097
DI 10.5888/pcd13.160097
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JN
UT WOS:000393108500007
ER

PT J
AU Kiefer, M
   Rodriguez-Guzman, J
   Watson, J
   de Joode, BV
   Mergler, D
   da Silva, AS
AF Kiefer, Max
   Rodriguez-Guzman, Julietta
   Watson, Joanna
   de Joode, Berna van Wendel
   Mergler, Donna
   da Silva, Agnes Soares
TI Worker health and safety and climate change in the Americas: issues and
   research needs
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA English
DT Article
DE Climate change; occupational risks; occupational exposure; working
   environment; Central America; Americas
ID OCCUPATIONAL HEAT-STRESS; MESOAMERICAN NEPHROPATHY; KIDNEY-FUNCTION;
   NATURAL DISASTERS; UNITED-STATES; AIR-QUALITY; DISEASE; PRODUCTIVITY;
   ADAPTATION; SALVADOR
AB This report summarizes and discusses current knowledge on the impact that climate change can have on occupational safety and health (OSH), with a particular focus on the Americas. Worker safety and health issues are presented on topics related to specific stressors (e.g., temperature extremes), climate associated impacts (e.g., ice melt in the Arctic), and a health condition associated with climate change (chronic kidney disease of non-traditional etiology). The article discusses research needs, including hazards, surveillance, and risk assessment activities to better characterize and understand how OSH may be associated with climate change events. Also discussed are the actions that OSH professionals can take to ensure worker health and safety in the face of climate change.
C1 [Kiefer, Max; Watson, Joanna] NIOSH, US Ctr Dis Control & Prevent, Western States Div, Atlanta, GA 30329 USA.
   [Rodriguez-Guzman, Julietta; da Silva, Agnes Soares] Pan Amer Hlth Org, Washington, DC USA.
   [de Joode, Berna van Wendel] Univ Nacl, Cent Amer Inst Studies Tox Subst, Heredia, Costa Rica.
   [Mergler, Donna] Univ Quebec Montreal, Ctr Interdisciplinary Res Hlth Well Being Environ, Montreal, PQ, Canada.
RP Kiefer, M (reprint author), NIOSH, US Ctr Dis Control & Prevent, Western States Div, Atlanta, GA 30329 USA.
EM myk3@cdc.gov
OI Watson, Joanna/0000-0002-2532-2423
FU Intramural CDC HHS [CC999999]
NR 56
TC 0
Z9 0
U1 0
U2 0
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PD SEP
PY 2016
VL 40
IS 3
BP 192
EP 197
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ4UD
UT WOS:000393211500008
PM 27991978
ER

PT J
AU Lee, EK
   Nakaya, HI
   Yuan, F
   Querec, TD
   Burel, G
   Pietz, FH
   Benecke, BA
   Pulendran, B
AF Lee, Eva K.
   Nakaya, Helder I.
   Yuan, Fan
   Querec, Troy D.
   Burel, Greg
   Pietz, Ferdinand H.
   Benecke, Bernard A.
   Pulendran, Bali
TI Machine Learning for Predicting Vaccine Immunogenicity
SO INTERFACES
LA English
DT Article
DE machine learning; multiple-group classification; vaccine immunogenicity
   prediction; influenza; yellow fever; malaria; health security;
   prophylactic medical countermeasures; hypothesis generation; vaccine
   design for emerging infections
ID PROTEIN-KINASE-IV; CPG ISLAND METHYLATION; YELLOW-FEVER VACCINE;
   INFLUENZA VACCINATION; SEASONAL INFLUENZA; SYSTEMS BIOLOGY; DENDRITIC
   CELLS; SENSOR GCN2; IMMUNITY; RESPONSES
AB ability to predict how different individuals will respond to vaccination and to understand what best protects individuals from infection greatly facilitates developing next-generation vaccines. It facilitates both the rapid design and evaluation of new and emerging vaccines and identifies individuals unlikely to be protected by vaccine. We describe a general-purpose machine-learning framework, DAMIP, for discovering gene signatures that can predict vaccine immunity and efficacy. DAMIP is a multiple-group, concurrent classifier that offers unique features not present in other models: a nonlinear data transformation to manage the curse of dimensionality and noise; a reserved-judgment region that handles fuzzy entities; and constraints on the allowed percentage of misclassifications.
   Using DAMIP, implemented results for yellow fever demonstrated that, for the first time, a vaccine's ability to immunize a patient could be successfully predicted (with accuracy of greater than 90 percent) within one week after vaccination. A gene identified by DAMIP, EIF2AK4, decrypted a seven-decade-old mystery of vaccination. Results for flu vaccine demonstrated DAMIP's applicability to both live-attenuated and inactivated vaccines. Results in a malaria study enabled targeted delivery to individual patients.
   Our project's methods and findings permit highlighting and probabilistically prioritizing hypothesis design to enhance biological discovery. Moreover, they guide the rapid development of better vaccines to fight emerging infections, and improve monitoring for poor responses in the elderly, infants, or others with weakened immune systems. In addition, the project's work should help with universal flu-vaccine design.
C1 [Lee, Eva K.; Yuan, Fan] NSF Whitaker Ctr Operat Res Med & HealthCare, Atlanta, GA 30332 USA.
   [Lee, Eva K.; Yuan, Fan] NSF I UCRC Ctr Hlth Org Transformat, Atlanta, GA 30332 USA.
   [Lee, Eva K.; Yuan, Fan] Georgia Inst Technol, Ind & Syst Engn & Comp Sci, Atlanta, GA 30332 USA.
   [Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil.
   [Nakaya, Helder I.; Pulendran, Bali] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30329 USA.
   [Querec, Troy D.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Atlanta, GA 30322 USA.
   [Burel, Greg; Pietz, Ferdinand H.] Ctr Dis Control & Prevent, Strateg Natl Stockpile, Atlanta, GA 30322 USA.
   [Benecke, Bernard A.] Ctr Dis Control & Prevent, Global Dis Detect & Emergency Response, Atlanta, GA 30322 USA.
   [Pulendran, Bali] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30329 USA.
RP Lee, EK (reprint author), NSF Whitaker Ctr Operat Res Med & HealthCare, Atlanta, GA 30332 USA.; Lee, EK (reprint author), NSF I UCRC Ctr Hlth Org Transformat, Atlanta, GA 30332 USA.; Lee, EK (reprint author), Georgia Inst Technol, Ind & Syst Engn & Comp Sci, Atlanta, GA 30332 USA.
EM eva.lee@gatech.edu; hnakaya@gmail.com
RI Nakaya, Helder/A-1397-2010; CEPID, CRID/J-2644-2015
OI Nakaya, Helder/0000-0001-5297-9108; 
FU National Science Foundation [0832390, 1361532, 1516074]; National
   Institutes of Health [U19 AI 057266, U19 AI090023-01]; Centers for
   Disease Control and Prevention [200-2011-38339]
FX The work is partially supported by grants from the National Science
   Foundation [Grants 0832390, 1361532, 1516074], National Institutes of
   Health [Grants U19 AI 057266, U19 AI090023-01], and Centers for Disease
   Control and Prevention [Grant no. 200-2011-38339]. The findings and
   conclusions in this paper are those of the authors and do not
   necessarily represent the official position of the funding agencies.
NR 59
TC 0
Z9 0
U1 4
U2 4
PU INFORMS
PI CATONSVILLE
PA 5521 RESEARCH PARK DR, SUITE 200, CATONSVILLE, MD 21228 USA
SN 0092-2102
EI 1526-551X
J9 INTERFACES
JI Interfaces
PD SEP-OCT
PY 2016
VL 46
IS 5
SI SI
BP 368
EP 389
DI 10.1287/inte.2016.0862
PG 22
WC Management; Operations Research & Management Science
SC Business & Economics; Operations Research & Management Science
GA EF3XU
UT WOS:000390259300002
ER

PT J
AU Sahl, JW
   Pearson, T
   Okinaka, R
   Schupp, JM
   Gillece, JD
   Heaton, H
   Birdsell, D
   Hepp, C
   Fofanov, V
   Noseda, R
   Fasanella, A
   Hoffmaster, A
   Wagner, DM
   Keim, P
AF Sahl, Jason W.
   Pearson, Talima
   Okinaka, Richard
   Schupp, James M.
   Gillece, John D.
   Heaton, Hannah
   Birdsell, Dawn
   Hepp, Crystal
   Fofanov, Viacheslav
   Noseda, Ramon
   Fasanella, Antonio
   Hoffmaster, Alex
   Wagner, David M.
   Keim, Paul
TI A Bacillus anthracis Genome Sequence from the Sverdlovsk 1979 Autopsy
   Specimens
SO MBIO
LA English
DT Article
ID OUTBREAK; RESISTANCE; ALGORITHM; DISCOVERY; INFECTION; FRAMEWORK;
   STRAINS; VACCINE; CEREUS; TISSUE
AB Anthrax is a zoonotic disease that occurs naturally in wild and domestic animals but has been used by both state-sponsored programs and terrorists as a biological weapon. A Soviet industrial production facility in Sverdlovsk, USSR, proved deficient in 1979 when a plume of spores was accidentally released and resulted in one of the largest known human anthrax outbreaks. In order to understand this outbreak and others, we generated a Bacillus anthracis population genetic database based upon whole-genome analysis to identify all single-nucleotide polymorphisms (SNPs) across a reference genome. Phylogenetic analysis has defined three major clades (A, B, and C), B and C being relatively rare compared to A. The A clade has numerous subclades, including a major polytomy named the trans-Eurasian (TEA) group. The TEA radiation is a dominant evolutionary feature of B. anthracis, with many contemporary populations having resulted from a large spatial dispersal of spores from a single source. Two autopsy specimens from the Sverdlovsk outbreak were deep sequenced to produce draft B. anthracis genomes. This allowed the phylogenetic placement of the Sverdlovsk strain into a clade with two Asian live vaccine strains, including the Russian Tsiankovskii strain. The genome was examined for evidence of drug resistance manipulation or other genetic engineering, but none was found. The Soviet Sverdlovsk strain genome is consistent with a wild-type strain from Russia that had no evidence of genetic manipulation during its industrial production. This work provides insights into the world's largest biological weapons program and provides an extensive B. anthracis phylogenetic reference.
   IMPORTANCE The 1979 Russian anthrax outbreak resulted from an industrial accident at the Soviet anthrax spore production facility in the city of Sverdlovsk. Deep genomic sequencing of two autopsy specimens generated a draft genome and phylogenetic placement of the Soviet Sverdlovsk anthrax strain. While it is known that Soviet scientists had genetically manipulated Bacillus anthracis with the potential to evade vaccine prophylaxis and antibiotic therapeutics, there was no genomic evidence of this from the Sverdlovsk production strain genome. The whole-genome SNP genotype of the Sverdlovsk strain was used to precisely identify it and its close relatives in the context of an extensive global B. anthracis strain collection. This genomic identity can now be used for forensic tracking of this weapons material on a global scale and for future anthrax investigations.
C1 [Sahl, Jason W.; Pearson, Talima; Okinaka, Richard; Birdsell, Dawn; Hepp, Crystal; Fofanov, Viacheslav; Wagner, David M.; Keim, Paul] No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA.
   [Schupp, James M.; Gillece, John D.; Heaton, Hannah; Keim, Paul] Translat Genom Res Inst, Div Pathogen Genom, Flagstaff, AZ USA.
   [Hepp, Crystal; Fofanov, Viacheslav] No Arizona Univ, Sch Informat Comp & Cyber Syst, Flagstaff, AZ 86011 USA.
   [Noseda, Ramon] Lab Azul, Buenos Aires, DF, Argentina.
   [Fasanella, Antonio] Ist Zooprofilatt Sperimentale Puglia & Basilicata, Foggia, Italy.
   [Hoffmaster, Alex] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Keim, P (reprint author), No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA.; Keim, P (reprint author), Translat Genom Res Inst, Div Pathogen Genom, Flagstaff, AZ USA.
EM Paul.Keim@nau.edu
FU U.S. Department of Homeland Security (DHS) [HSHQDC-15-C-B0068]
FX This work, including the efforts of Paul Stephen Keim, was funded by
   U.S. Department of Homeland Security (DHS) (HSHQDC-15-C-B0068).
NR 56
TC 0
Z9 0
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2016
VL 7
IS 5
AR e01501-16
DI 10.1128/mBio.01501-16
PG 8
WC Microbiology
SC Microbiology
GA EF2CU
UT WOS:000390132900061
ER

PT J
AU McDermott, PF
   Tyson, GH
   Kabera, C
   Chen, YS
   Li, C
   Folster, JP
   Ayers, SL
   Lam, C
   Tate, HP
   Zhao, SH
AF McDermott, Patrick F.
   Tyson, Gregory H.
   Kabera, Claudine
   Chen, Yuansha
   Li, Cong
   Folster, Jason P.
   Ayers, Sherry L.
   Lam, Claudia
   Tate, Heather P.
   Zhao, Shaohua
TI Whole-Genome Sequencing for Detecting Antimicrobial Resistance in
   Nontyphoidal Salmonella
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ESCHERICHIA-COLI; QUINOLONE RESISTANCE; UNITED-STATES; BETA-LACTAMASE;
   PARC GENES; ENTERICA; ANIMALS; FOOD; SURVEILLANCE; HUMANS
AB Laboratory-based in vitro antimicrobial susceptibility testing is the foundation for guiding anti-infective therapy and monitoring antimicrobial resistance trends. We used whole-genome sequencing (WGS) technology to identify known antimicrobial resistance determinants among strains of nontyphoidal Salmonella and correlated these with susceptibility phenotypes to evaluate the utility of WGS for antimicrobial resistance surveillance. Six hundred forty Salmonella of 43 different serotypes were selected from among retail meat and human clinical isolates that were tested for susceptibility to 14 antimicrobials using broth microdilution. The MIC for each drug was used to categorize isolates as susceptible or resistant based on Clinical and Laboratory Standards Institute clinical breakpoints or National Antimicrobial Resistance Monitoring System (NARMS) consensus interpretive criteria. Each isolate was subjected to whole-genome shotgun sequencing, and resistance genes were identified from assembled sequences. A total of 65 unique resistance genes, plus mutations in two structural resistance loci, were identified. There were more unique resistance genes (n = 59) in the 104 human isolates than in the 536 retail meat isolates (n = 36). Overall, resistance genotypes and phenotypes correlated in 99.0% of cases. Correlations approached 100% for most classes of antibiotics but were lower for aminoglycosides and beta-lactams. We report the first finding of extended-spectrum beta-lactamases (ESBLs) (bla(CTX-M1) and bla(SHV2a)) in retail meat isolates of Salmonella in the United States. Whole-genome sequencing is an effective tool for predicting antibiotic resistance in nontyphoidal Salmonella, although the use of more appropriate surveillance breakpoints and increased knowledge of new resistance alleles will further improve correlations.
C1 [McDermott, Patrick F.; Tyson, Gregory H.; Kabera, Claudine; Chen, Yuansha; Li, Cong; Ayers, Sherry L.; Lam, Claudia; Tate, Heather P.; Zhao, Shaohua] US FDA, Ctr Vet Med, Div Anim & Food Microbiol, Res Off, Laurel, MD 20708 USA.
   [Folster, Jason P.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
RP McDermott, PF (reprint author), US FDA, Ctr Vet Med, Div Anim & Food Microbiol, Res Off, Laurel, MD 20708 USA.
EM Patrick.McDermott@fda.hhs.gov
FU U.S. Food and Drug Administration
FX This work was supported by the U.S. Food and Drug Administration with
   internal funds as part of routine work.
NR 34
TC 2
Z9 2
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2016
VL 60
IS 9
BP 5515
EP 5520
DI 10.1128/AAC.01030-16
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA ED7OH
UT WOS:000389055400048
PM 27381390
ER

PT J
AU Roux, AVD
   Mujahid, MS
   Hirsch, JA
   Moore, K
   Moore, LV
AF Roux, Ana V. Diez
   Mujahid, Mahasin S.
   Hirsch, Jana A.
   Moore, Kari
   Moore, Latetia V.
TI The Impact of Neighborhoods on CV Risk
SO Global Heart
LA English
DT Review
ID CARDIOVASCULAR-DISEASE RISK; AMERICAN-HEART-ASSOCIATION; LEUKOCYTE
   TELOMERE LENGTH; TYPE-2 DIABETES-MELLITUS; LOCAL FOOD ENVIRONMENT;
   POLICE-RECORDED CRIME; BODY-MASS INDEX; PHYSICAL-ACTIVITY;
   ATHEROSCLEROSIS MESA; LONGITUDINAL ASSOCIATIONS
AB Cardiovascular disease (CVD) continues to be the leading cause of death and a major source of health disparities in the Unites States and globally. Efforts to reduce CVD risk and eliminate cardiovascular health disparities have increasingly emphasized the importance of the social determinants of health. Neighborhood environments have emerged as a possible target for prevention and policy efforts. Hence there is a need to better understand the role of neighborhood environments in shaping cardiovascular risk. The MESA (Multi-Ethnic Study of Atherosclerosis) Neighborhood Study provided a unique opportunity to build a comprehensive place-based resource for investigations of associations between specific features of neighborhood physical and social environments and cardiovascular risk factors and outcomes. This review summarizes the approaches used to characterize residential neighborhood environments in the MESA cohort, provides an overview of key findings to date, and discusses challenges and opportunities in neighborhood health effects research. Results to date suggest that neighborhood physical and social environments are related to behavioral and biomedical risk factors for CVD and that cardiovascular prevention efforts may benefit from taking neighborhood context into account.
C1 [Roux, Ana V. Diez] Drexel Univ, Dept Epidemiol & Biostat, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.
   [Roux, Ana V. Diez; Moore, Kari] Drexel Univ, Urban Hlth Collaborat, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.
   [Mujahid, Mahasin S.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA.
   [Hirsch, Jana A.] Univ North Carolina Chapel Hill, Carolina Populat Ctr, Chapel Hill, NC USA.
   [Moore, Latetia V.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Roux, AVD (reprint author), Drexel Univ, Dept Epidemiol & Biostat, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.; Roux, AVD (reprint author), Drexel Univ, Urban Hlth Collaborat, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.
EM avd37@drexel.edu
NR 97
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2211-8160
EI 2211-8179
J9 GLOB HEART
JI Glob. Heart
PD SEP
PY 2016
VL 11
IS 3
BP 353
EP 363
DI 10.1016/j.gheart.2016.08.002
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ED9WY
UT WOS:000389225400010
ER

PT J
AU Zachariah, P
   Whittier, S
   Reed, C
   LaRussa, P
   Larson, EL
   Vargas, CY
   Saiman, L
   Stockwell, MS
AF Zachariah, Philip
   Whittier, Susan
   Reed, Carrie
   LaRussa, Philip
   Larson, Elaine L.
   Vargas, Celibell Y.
   Saiman, Lisa
   Stockwell, Melissa S.
TI Community -and hospital laboratory-based surveillance for respiratory
   viruses
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE Influenza; surveillance; viruses
ID INFLUENZA-LIKE ILLNESS; ELECTRONIC SURVEILLANCE; B VIRUS; INFECTION;
   CHILDREN
AB Traditional surveillance for respiratory viruses relies on symptom detection and laboratory detection during medically attended encounters for acute respiratory infection/influenza-like illness (ARI/ILI). Ecological momentary reporting using text messages is a novel method for surveillance. This study compares respiratory viral activity detected through longitudinal community-based surveillance using text message responses for sample acquisition and testing to respiratory viral activity obtained from hospital laboratory data from the same community. We demonstrate a significant correlation between community-and hospital laboratory-based surveillance for most respiratory viruses, although the relative proportions of viruses detected in the community and hospital differed significantly.
C1 [Zachariah, Philip; Whittier, Susan; LaRussa, Philip; Larson, Elaine L.; Vargas, Celibell Y.; Saiman, Lisa; Stockwell, Melissa S.] Columbia Univ, Med Ctr, 622 West 168th St,VC4-417, New York, NY 10032 USA.
   [Whittier, Susan; Saiman, Lisa; Stockwell, Melissa S.] New York Presbyterian Hosp, New York, NY USA.
   [Reed, Carrie] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Zachariah, P (reprint author), Columbia Univ, Med Ctr, Dept Pediat, 622 West 168th St,VC4-417, New York, NY 10032 USA.
EM pz2177@cumc.columbia.edu
FU Centers for Disease for Control and Prevention [U01 IP000618]
FX This study was supported by a grant from the Centers for Disease for
   Control and Prevention, U01 IP000618 - MOSAIC Mobile Surveillance for
   ARI/ILI in the Community.
NR 11
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD SEP
PY 2016
VL 10
IS 5
BP 361
EP 366
DI 10.1111/irv.12387
PG 6
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA ED3MV
UT WOS:000388754100002
PM 26987664
ER

PT J
AU Jones, AH
   Ampofo, W
   Akuffo, R
   Doman, B
   Duplessis, C
   Amankwa, JA
   Sarpong, C
   Sagoe, K
   Agbenohevi, P
   Puplampu, N
   Armah, G
   Koram, KA
   Nyarko, EO
   Bel-Nono, S
   Dueger, EL
AF Jones, Alexander H.
   Ampofo, William
   Akuffo, Richard
   Doman, Brooke
   Duplessis, Christopher
   Amankwa, Joseph A.
   Sarpong, Charity
   Sagoe, Ken
   Agbenohevi, Prince
   Puplampu, Naiki
   Armah, George
   Koram, Kwadwo A.
   Nyarko, Edward O.
   Bel-Nono, Samuel
   Dueger, Erica L.
TI Sentinel surveillance for influenza among severe acute respiratory
   infection and acute febrile illness inpatients at three hospitals in
   Ghana
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE Ghana; human; influenza; sentinel surveillance
ID VIROLOGICAL SURVEILLANCE; EMERGENCY-DEPARTMENT; SENEGAL; AFRICA;
   CHILDREN; VIRUSES
AB Background Influenza epidemiology in Africa is generally not well understood. Using syndrome definitions to screen patients for laboratory confirmation of infection is an established means to effectively conduct influenza surveillance.
   Methods To compare influenza-related epidemiologic data, from October 2010 through March 2013, we enrolled hospitalized severe acute respiratory infection (SARI; fever with respiratory symptoms) and acute febrile illness (AFI; fever without respiratory or other localizing symptoms) patients from three referral hospitals in Ghana. Demographic and epidemiologic data were obtained from enrolled patients after which nasopharyngeal and oropharyngeal swabs were collected, and processed by molecular methods for the presence of influenza viruses.
   Results Of 730 SARI patients, 59 (8%) were influenza positive; of 543 AFI patients, 34 (6%) were positive for influenza. Both SARI and AFI surveillance yielded influenza A(H3N2) (3% versus 1%), A (H1N1) pdm09 (2% versus 1%), and influenza B (3% versus 4%) in similar proportions. Data from both syndromes show year-round influenza transmission but with increased caseloads associated with the rainy seasons.
   Conclusions As an appreciable percentage of influenza cases (37%) presented without defined respiratory symptoms, and thus met the AFI but not the SARI definition, it is important to consider broader screening criteria (i.e., AFI) to identify all laboratory-confirmed influenza. The identified influenza transmission seasonality has important implications for the timing of related public health interventions.
C1 [Jones, Alexander H.] US Naval Med Res Unit 3, Global Dis Detect & Response Program, PSC 452 Box 5000, Cairo, Egypt.
   [Ampofo, William] Natl Influenza Ctr, Noguchi Mem Inst Med Res, Accra, Ghana.
   [Akuffo, Richard; Doman, Brooke] US Naval Med Res Unit 3 Ghana Detachment, Global Dis Detect & Response Program, Accra, Ghana.
   [Duplessis, Christopher; Puplampu, Naiki] US Naval Med Res Unit 3 Ghana Detachment, Accra, Ghana.
   [Amankwa, Joseph A.; Sarpong, Charity] Ghana Hlth Serv, Accra, Ghana.
   [Sagoe, Ken] Tamale Teaching Hosp, Tamale, Ghana.
   [Agbenohevi, Prince; Nyarko, Edward O.; Bel-Nono, Samuel] 37 Mil Hosp, Accra, Ghana.
   [Armah, George; Koram, Kwadwo A.] Noguchi Mem Inst Med Res, Accra, Ghana.
   [Dueger, Erica L.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Dueger, Erica L.] US Naval Med Res Unit 3, Cairo, Egypt.
RP Jones, AH (reprint author), US Naval Med Res Unit 3, Global Dis Detect & Response Program, PSC 452 Box 5000, Cairo, Egypt.
EM jonesahj@yahoo.com
FU U.S. Centers for Disease Control and Prevention [908]; Global Emerging
   Infections Surveillance and Response System (GEIS) Operations, a
   division of the Armed Forces Health Surveillance Center (AFHSC)
   [C0236_10_N3]
FX This work was supported by the U.S. Centers for Disease Control and
   Prevention [Protocol #908] and the Global Emerging Infections
   Surveillance and Response System (GEIS) [Grant: C0236_10_N3] Operations,
   a division of the Armed Forces Health Surveillance Center (AFHSC).
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD SEP
PY 2016
VL 10
IS 5
BP 367
EP 374
DI 10.1111/irv.12397
PG 8
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA ED3MV
UT WOS:000388754100003
PM 27239956
ER

PT J
AU Emukule, GO
   Mott, JA
   Spreeuwenberg, P
   Viboud, C
   Commanday, A
   Muthoka, P
   Munywoki, PK
   Nokes, DJ
   van Der Velden, K
   Paget, JW
AF Emukule, Gideon O.
   Mott, Joshua A.
   Spreeuwenberg, Peter
   Viboud, Cecile
   Commanday, Alexander
   Muthoka, Philip
   Munywoki, Patrick K.
   Nokes, David J.
   van der Velden, Koos
   Paget, John W.
TI Influenza activity in Kenya, 2007-2013: timing, association with
   climatic factors, and implications for vaccination campaigns
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE Humidity; influenza; Kenya; respiratory; seasonality; vaccination
ID SEASONALITY; CHILDREN; TROPICS; VIRUS
AB Background Information on the timing of influenza circulation remains scarce in Tropical regions of Africa.
   Objectives We assessed the relationship between influenza activity and several meteorological factors (temperature, specific humidity, precipitation) and characterized the timing of influenza circulation and its implications to vaccination strategies in Kenya.
   Methods We analyzed virologically confirmed influenza data for outpatient influenza-like illness (ILI), hospitalized for severe acute respiratory infections (SARI), and cases of severe pneumonia over the period 2007-2013. Using logistic and negative binomial regression methods, we assessed the independent association between climatic variables (lagged up to 4 weeks) and influenza activity.
   Results There were multiple influenza epidemics occurring each year and lasting a median duration of 2-4 months. On average, there were two epidemics occurring each year in most of the regions in Kenya, with the first epidemic occurring between the months of February and March and the second one between July and November. Specific humidity was independently and negatively associated with influenza activity. Combinations of low temperature (<18 degrees C) and low specific humidity (<11 g/kg) were significantly associated with increased influenza activity.
   Conclusions Our study broadens understanding of the relationships between seasonal influenza activity and meteorological factors in the Kenyan context. While rainfall is frequently thought to be associated with influenza circulation in the tropics, the present findings suggest low humidity is more important in Kenya. If annual vaccination were a component of a vaccination strategy in Kenya, the months of April to June are proposed as optimal for associated campaigns.
C1 [Emukule, Gideon O.; Mott, Joshua A.] Ctr Dis Control & Prevent, Kenya Country Off, Nairobi, Kenya.
   [Emukule, Gideon O.; van der Velden, Koos; Paget, John W.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands.
   [Mott, Joshua A.; Commanday, Alexander] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Mott, Joshua A.] US PHS, Rockville, MD USA.
   [Spreeuwenberg, Peter; Paget, John W.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands.
   [Viboud, Cecile] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Muthoka, Philip] Govt Kenya, Minist Hlth, Nairobi, Kenya.
   [Munywoki, Patrick K.; Nokes, David J.] Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
   [Nokes, David J.] Univ Warwick, Sch Life Sci, Coventry, W Midlands, England.
RP Emukule, GO (reprint author), Mbagathi Rd,Off Mbagathi Way,POB 606, Nairobi, Kenya.
EM uyr9@cdc.gov
FU KEMRI; U.S. CDC research collaboration; Wellcome Trust, UK
FX This study was supported through The KEMRI and U.S. CDC research
   collaboration and The Wellcome Trust, UK. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD SEP
PY 2016
VL 10
IS 5
BP 375
EP 385
DI 10.1111/irv.12393
PG 11
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA ED3MV
UT WOS:000388754100004
PM 27100128
ER

PT J
AU Lindsley, WG
   Blachere, FM
   Beezhold, DH
   Thewlis, RE
   Noorbakhsh, B
   Othumpangat, S
   Goldsmith, WT
   McMillen, CM
   Andrew, ME
   Burrell, CN
   Noti, JD
AF Lindsley, William G.
   Blachere, Francoise M.
   Beezhold, Donald H.
   Thewlis, Robert E.
   Noorbakhsh, Bahar
   Othumpangat, Sreekumar
   Goldsmith, William T.
   McMillen, Cynthia M.
   Andrew, Michael E.
   Burrell, Carmen N.
   Noti, John D.
TI Viable influenza A virus in airborne particles expelled during coughs
   versus exhalations
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE Aerosols; air microbiology; airborne transmission; cough; infectious
   disease transmission; influenza
ID AEROSOL TRANSMISSION; SIZE DISTRIBUTIONS; EXHALED-BREATH; EXPOSURE; CARE
AB Background To prepare for a possible influenza pandemic, a better understanding of the potential for the airborne transmission of influenza from person to person is needed.
   Objectives The objective of this study was to directly compare the generation of aerosol particles containing viable influenza virus during coughs and exhalations.
   Methods Sixty-one adult volunteer outpatients with influenza-like symptoms were asked to cough and exhale three times into a spirometer. Aerosol particles produced during coughing and exhalation were collected into liquid media using aerosol samplers. The samples were tested for the presence of viable influenza virus using a viral replication assay (VRA).
   Results Fifty-three test subjects tested positive for influenza A virus. Of these, 28 (53%) produced aerosol particles containing viable influenza A virus during coughing, and 22 (42%) produced aerosols with viable virus during exhalation. Thirteen subjects had both cough aerosol and exhalation aerosol samples that contained viable virus, 15 had positive cough aerosol samples but negative exhalation samples, and 9 had positive exhalation samples but negative cough samples.
   Conclusions Viable influenza A virus was detected more often in cough aerosol particles than in exhalation aerosol particles, but the difference was not large. Because individuals breathe much more often than they cough, these results suggest that breathing may generate more airborne infectious material than coughing over time. However, both respiratory activities could be important in airborne influenza transmission. Our results are also consistent with the theory that much of the aerosol containing viable influenza originates deep in the lungs.
C1 [Lindsley, William G.; Blachere, Francoise M.; Beezhold, Donald H.; Thewlis, Robert E.; Noorbakhsh, Bahar; Othumpangat, Sreekumar; Goldsmith, William T.; McMillen, Cynthia M.; Andrew, Michael E.; Noti, John D.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S 4020, Morgantown, WV 26505 USA.
   [Burrell, Carmen N.] West Virginia Univ, Dept Emergency Med, Morgantown, WV USA.
RP Lindsley, WG (reprint author), NIOSH, 1095 Willowdale Rd,M-S 4020, Morgantown, WV 26505 USA.
EM wlindsley@cdc.gov
FU Centers for Disease Control and Prevention
FX We would like to thank the volunteers who participated in this study and
   the staff of West Virginia University Medicine Student Health Services
   for their cheerful cooperation and assistance. This work was funded by
   the Centers for Disease Control and Prevention. The authors have no
   competing interests to declare. The findings and conclusions in this
   report are those of the authors and do not necessarily represent the
   official position of the Centers for Disease Control and Prevention.
NR 42
TC 1
Z9 1
U1 7
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD SEP
PY 2016
VL 10
IS 5
BP 404
EP 413
DI 10.1111/irv.12390
PG 10
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA ED3MV
UT WOS:000388754100007
PM 26991074
ER

PT J
AU Wong, KK
   Cohen, AL
   Norris, SA
   Martinson, NA
   von Mollendorf, C
   Tempia, S
   Walaza, S
   Madhi, SA
   McMorrow, ML
   Variava, E
   Motlhaoleng, KM
   Cohen, C
AF Wong, Karen K.
   Cohen, Adam L.
   Norris, Shane A.
   Martinson, Neil A.
   von Mollendorf, Claire
   Tempia, Stefano
   Walaza, Sibongile
   Madhi, Shabir A.
   McMorrow, Meredith L.
   Variava, Ebrahim
   Motlhaoleng, Katlego M.
   Cohen, Cheryl
TI Knowledge, attitudes, and practices about influenza illness and
   vaccination: a cross-sectional survey in two South African communities
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE Influenza; South Africa; survey; vaccination
ID PANDEMIC INFLUENZA; CHILDREN; MORTALITY; VACCINES; IMMUNIZATION; VIRUS
AB Background Understanding knowledge and sentiment toward influenza and vaccination is important for effective health messages and prevention strategies. We aimed to characterize knowledge, attitudes, and practices surrounding influenza illness and vaccination in two South African communities and explore reasons for vaccine hesitancy.
   Methods Household primary caregivers in Soweto and Klerksdorp townships were interviewed about knowledge of influenza and intention to receive an influenza vaccine using a structured questionnaire. Factors associated with unwillingness to receive vaccine were explored using multivariable regression.
   Results We interviewed representatives of 973 households in Soweto and 1,442 in Klerksdorp. Most respondents in Soweto (692, 71%) and Klerksdorp (1247, 87%) thought weather or cold caused influenza. While most would get a free influenza vaccine, those unwilling to receive vaccine had concerns about efficacy (Soweto: 19%; Klerksdorp: 19%) and safety (Soweto: 17%; Klerksdorp: 10%). In Soweto, females (aRR 2.0, 95% CI 1.3-3.2) and those with higher household income (aRR 1.8, 95% CI 1.2-2.7) were less willing to receive vaccine. In Klerksdorp, more educated respondents (aRR 1.6, 95% CI 1.1-2.4) were less willing to receive vaccine; households reporting an HIV-positive member were more willing to receive vaccine (aRR 0.3, 95% CI 0.1-0.8).
   Conclusions Although findings suggest most community participants were amenable to influenza vaccination, knowledge gaps were present. Emphasizing the importance of influenza as a health problem and addressing vaccine safety and efficacy concerns may improve uptake. Populations less amenable to vaccination, including those with higher education and income, may benefit from targeted messaging efforts.
C1 [Wong, Karen K.; Cohen, Adam L.; Tempia, Stefano; McMorrow, Meredith L.] Ctr Dis Control, Atlanta, GA 30333 USA.
   [Wong, Karen K.; Cohen, Adam L.; McMorrow, Meredith L.] US PHS, Atlanta, GA USA.
   [Norris, Shane A.; von Mollendorf, Claire; Madhi, Shabir A.; Variava, Ebrahim; Cohen, Cheryl] Univ Witwatersrand, Johannesburg, South Africa.
   [Martinson, Neil A.] Univ Witwatersrand, MRC Dev Pathways Hlth Res Unit, Johannesburg, South Africa.
   [Martinson, Neil A.] Johns Hopkins Univ, Baltimore, MD USA.
   [von Mollendorf, Claire; Tempia, Stefano; Walaza, Sibongile; Madhi, Shabir A.; Cohen, Cheryl] Natl Inst Communicable Dis, Johannesburg, South Africa.
   [Variava, Ebrahim; Motlhaoleng, Katlego M.] Klerksdorp Tshepong Hosp Complex, Klerksdorp, South Africa.
RP Wong, KK (reprint author), Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM kwong@cdc.gov
FU US Centers for Disease Control and Prevention, USA [5U19/GH000622];
   National Institute for Communicable Diseases, South Africa
FX This work was supported by the US Centers for Disease Control and
   Prevention, USA (Cooperative Agreement Number 5U19/GH000622), and the
   National Institute for Communicable Diseases, South Africa. We thank the
   following individuals for their contributions to this work: Rhulani
   Mkansi, Limakatso Lebina, Seema Jain, Marc-Alain Widdowson, Anne von
   Gottberg, Samantha Iyaloo, Philip Sahr, Makatisane Papo, Karen Keddy,
   Jocelyn Moyes, Adrienne Shapiro, and Jill Murray.
NR 25
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD SEP
PY 2016
VL 10
IS 5
BP 421
EP 428
DI 10.1111/irv.12388
PG 8
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA ED3MV
UT WOS:000388754100009
PM 26987756
ER

PT J
AU Smith, CR
   Gillespie, GL
   Brown, KC
   Grubb, PL
AF Smith, Carolyn R.
   Gillespie, Gordon Lee
   Brown, Kathryn C.
   Grubb, Paula L.
TI Seeing Students Squirm: Nursing Students' Experiences of Bullying
   Behaviors During Clinical Rotations
SO JOURNAL OF NURSING EDUCATION
LA English
DT Article
ID EDUCATION; VIOLENCE; PRODUCTIVITY
AB Background: Bullying remains a troubling problem in the nursing profession. Nursing students may encounter bullying behavior in clinical settings. However, they may not be adequately prepared to recognize and handle bullying behavior when it occurs. This study's purpose was to gain a greater understanding of nursing students' experiences of bullying behaviors in the clinical setting. Method: Using a descriptive qualitative approach, eight focus groups were held with 56 undergraduate baccalaureate nursing students from four college campuses. Focus group data were coded and analyzed for themes. Results: Four categories were identified: Bullying Behaviors, Rationale for Bullying, Response to Bullying, and Recommendations to Address Bullying. Each category and its corresponding themes are presented. Conclusion: Interventions for nurse educators to address the bullying of nursing students in clinical settings are presented.
C1 [Smith, Carolyn R.; Gillespie, Gordon Lee] Univ Cincinnati, Coll Nursing, POB 210038, Cincinnati, OH 45221 USA.
   [Brown, Kathryn C.] Christ Hosp, Hlth Network, Comprehens Med, Div Director Patient Care Serv, Cincinnati, OH 45219 USA.
   [Grubb, Paula L.] Ctr Res Dis Prevent, NIOSH, Cincinnati, OH USA.
RP Smith, CR (reprint author), Univ Cincinnati, Coll Nursing, POB 210038, Cincinnati, OH 45221 USA.
EM Carolyn.Smith@uc.edu
FU Centers for Disease Control and Prevention-National Institute for
   Occupational Safety and Health (CDC-NIOSH) [200-2013-M-57090]
FX This research study was funded by contract No. 200-2013-M-57090 from the
   Centers for Disease Control and Prevention-National Institute for
   Occupational Safety and Health (CDC-NIOSH), awarded to Dr. Gillespie.
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official view of the CDC-NIOSH.
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0148-4834
EI 1938-2421
J9 J NURS EDUC
JI J. Nurs. Educ.
PD SEP
PY 2016
VL 55
IS 9
BP 505
EP 513
DI 10.3928/01484834-20160816-04
PG 9
WC Nursing
SC Nursing
GA ED8TA
UT WOS:000389142600004
PM 27560118
ER

PT J
AU Caldwell, GG
   Zack, MM
   Mumma, MT
   Falk, H
   Heath, CW
   Till, JE
   Chen, H
   Boice, JD
AF Caldwell, Glyn G.
   Zack, Matthew M.
   Mumma, Michael T.
   Falk, Henry
   Heath, Clark W.
   Till, John E.
   Chen, Heidi
   Boice, John D.
TI Mortality among military participants at the 1957 PLUMBBOB nuclear
   weapons test series and from leukemia among participants at the SMOKY
   test
SO JOURNAL OF RADIOLOGICAL PROTECTION
LA English
DT Article
DE atomic veterans; SMOKY; leukemia; nuclear weapons tests; Nevada test
   site; epidemiology; PLUMBBOB
ID CASE-COHORT; FOLLOW-UP; CANCER INCIDENCE; WORKER; UK
AB Health effects following low doses of ionizing radiation are uncertain. Military veterans at the Nevada test site (NTS) during the SMOKY atmospheric nuclear weapons test in 1957 were reported to be at increased risk for leukemia in 1979, but this increase was not evaluated with respect to radiation dose. The SMOKY test was one of 30 tests in 1957 within the PLUMBBOB test series. These early studies led to public laws where atomic veterans could qualify for compensation for presumptive radiogenic diseases.
   A retrospective cohort study was conducted of 12219 veterans at the PLUMBBOB test series, including 3020 at the SMOKY nuclear test. Mortality follow-up was through 2010 and observed causes of death were compared with expected causes based on general population rates. Radiation dose to red bone marrow was based on individual dose reconstructions, and Cox proportional hazards models were used to evaluate dose response for all leukemias other than chronic lymphocytic leukemia (non-CLL leukemia).
   Vital status was determined for 95.3% of the 12 219 veterans. The dose to red bone marrow was low (mean 3.2 mGy, maximum 500 mGy). Military participants at the PLUMBBOB nuclear test series remained relatively healthy after 53 years and died at a lower rate than the general population. In contrast, and in comparison with national rates, the SMOKY participants showed significant increases in all causes of death, respiratory cancer, leukemia, nephritis and nephrosis, and accidents, possibly related in part to lifestyle factors common to enlisted men who made up 81% of the SMOKY cohort.
   Compared with national rates, a statistically significant excess of nonCLL leukemia was observed among SMOKY participants (Standardized Mortality Ratio = 1.89, 95% 1.24-2.75, n = 27) but not among PLUMBBOB participants after excluding SMOKY (SMR = 0.87, 95% 0.64-1.51, n = 47). Leukemia risk, initially reported to be significantly increased among SMOKY participants, remained elevated, but this risk diminished over time. Despite an intense dose reconstruction, the risk for leukemia was not found to increase with increasing levels of radiation dose to the red bone marrow. Based on a linear model, the estimated excess relative risk per mGy is -0.05 (95% CI -0.14, 0.04). An explanation for the observed excess of leukemia remains unresolved but conceivably could be related to chance due to small numbers, subtle biases in the study design and/or high tobacco use among enlisted men. Larger studies should elucidate further the possible relationship between fallout radiation, leukemia and cancer among atomic veterans.
C1 [Caldwell, Glyn G.] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY USA.
   [Zack, Matthew M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA USA.
   [Mumma, Michael T.] Int Epidemiol Inst, Rockville, MD USA.
   [Falk, Henry] Ctr Dis Control, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA.
   [Till, John E.] Risk Assessment Corp, Neeses, SC USA.
   [Chen, Heidi; Boice, John D.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.
RP Boice, JD (reprint author), Natl Council Radiat Protect & Measurements, 7910 Woodmont Ave Suite 400, Bethesda, MD 20814 USA.
EM john.boice@vanderbilt.edu
FU National Cancer Institute [U01 CA137026]; U.S. Department of Energy
   [DE-SC0008944]; U.S. Nuclear Regulatory Commission; U.S. Environmental
   Protection Agency; National Aeronautics and Space Administration;
   Vanderbilt-Ingram Cancer Center [404-357-9682]
FX This research was supported in part by contracts and grants from the
   National Cancer Institute (Grant No. U01 CA137026); the U.S. Department
   of Energy (Grant No. DE-SC0008944 awarded to the National Council on
   Radiation Protection and Measurements), which included interagency
   support from the U.S. Nuclear Regulatory Commission, the U.S.
   Environmental Protection Agency and the National Aeronautics and Space
   Administration; and a Discovery Grant from the Vanderbilt-Ingram Cancer
   Center (Center No. 404-357-9682).
NR 37
TC 2
Z9 2
U1 2
U2 2
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0952-4746
EI 1361-6498
J9 J RADIOL PROT
JI J. Radiol. Prot.
PD SEP
PY 2016
VL 36
IS 3
BP 474
EP 489
DI 10.1088/0952-4746/36/3/474
PG 16
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
   Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
GA EE6IB
UT WOS:000389712100008
PM 27355245
ER

PT J
AU Tong, VT
   Farr, SL
   Bombard, J
   D'Angelo, D
   Ko, JY
   England, LJ
AF Tong, Van T.
   Farr, Sherry L.
   Bombard, Jennifer
   D'Angelo, Denise
   Ko, Jean Y.
   England, Lucinda J.
TI Smoking Before and During Pregnancy Among Women Reporting Depression or
   Anxiety
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID ASSESSMENT MONITORING-SYSTEM; UNITED-STATES; NONPREGNANT WOMEN;
   CIGARETTE-SMOKING; MEDICAID COVERAGE; REPRODUCTIVE AGE; POSTPARTUM
   WOMEN; CESSATION; DEPENDENCE; PRAMS
AB OBJECTIVE: To describe prepregnancy smoking, prenatal smoking, and prenatal cessation among women reporting and not reporting depression or anxiety.
   METHODS: We analyzed cross-sectional data from the 2009-2011 Pregnancy Risk Assessment Monitoring System, a population-based survey of women with live births (N=34,633). Smoking status was defined as self-reported prepregnancy smoking (during the 3 months before pregnancy), prenatal smoking (during the last 3 months of pregnancy), and prenatal cessation (no smoking by the last 3 months among prepregnancy smokers). Depression and anxiety status was self-reported of having either condition or both during the 3 months before pregnancy. We compared smoking prevalence by self-reported depression and anxiety status using chi(2) tests and adjusted prevalence ratios.
   RESULTS: Overall, 16.9% of women in our sample reported depression, anxiety, or both during the 3 months before pregnancy. Compared with those who did not report, women who reported depression or anxiety had significantly higher prepregnancy (46.7% compared with 22.5%, P<.01) and prenatal smoking (27.5% compared with 10.5%, P<.01). A lower proportion of prepregnancy smokers who reported depression or anxiety quit smoking by the last 3 months of pregnancy than those who did not report (41.4% compared with 53.8%, P<.01). In adjusted analyses, women reporting depression or anxiety were 1.5 and 1.7 times more likely to smoke prepregnancy and prenatally, respectively, and less likely to quit smoking (adjusted prevalence ratio 0.86, 95% confidence interval 0.80-0.92).
   CONCLUSION: Women who reported depression, anxiety, or both were more likely to smoke before and during pregnancy and less likely to quit smoking during the prenatal period. Screening recommendations for perinatal depression and anxiety provide an opportunity to identify a subpopulation of women who may have a higher prevalence of smoking and to provide effective tobacco cessation interventions and mental health care.
C1 [Tong, Van T.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE,MS F74, Atlanta, GA 30341 USA.
   Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE,MS F74, Atlanta, GA 30341 USA.
EM vtong@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 33
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD SEP
PY 2016
VL 128
IS 3
BP 562
EP 570
DI 10.1097/AOG.0000000000001595
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX6VQ
UT WOS:000384523200025
PM 27500342
ER

PT J
AU Harris, JB
   Badiane, O
   Lam, E
   Nicholson, J
   Ba, IO
   Diallo, A
   Fall, A
   Masresha, BG
   Goodson, JL
AF Harris, Jennifer B.
   Badiane, Ousseynou
   Lam, Eugene
   Nicholson, Jennifer
   Ba, Ibrahim Oumar
   Diallo, Aliou
   Fall, Amadou
   Masresha, Balcha G.
   Goodson, James L.
TI Application of the World Health Organization Programmatic Assessment
   Tool for Risk of Measles Virus Transmission-Lessons Learned from a
   Measles Outbreak in Senegal
SO RISK ANALYSIS
LA English
DT Article
DE Measles; risk assessment; Senegal
AB The World Health Organization (WHO) African Region set a goal for regional measles elimination by 2020; however, regional measles incidence was 125/1,000,000 in 2012. To support elimination efforts, the WHO and U.S. Centers for Disease Control and Prevention developed a tool to assess performance of measles control activities and identify high-risk areas at the subnational level. The tool uses routinely collected data to generate district-level risk scores across four categories: population immunity, surveillance quality, program performance, and threat assessment. To pilot test this tool, we used retrospective data from 2006 to 2008 to identify high-risk districts in Senegal; results were compared with measles case-based surveillance data from 2009 when Senegal experienced a large measles outbreak. Seventeen (25%) of 69 districts in Senegal were classified as high or very high risk. The tool highlighted how each of the four categories contributed to the total risk scores for high or very high risk districts. Measles case-based surveillance reported 986 cases during 2009, including 368 laboratory-confirmed, 540 epidemiologically linked, and 78 clinically compatible cases. The seven districts with the highest numbers of laboratory-confirmed or epidemiologically linked cases were within the capital region of Dakar. All except one of these seven districts were estimated to be high or very high risk, suggesting that districts identified as high risk by the tool have the potential for measles outbreaks. Prospective use of this tool is recommended to help immunization and surveillance program managers identify high-risk areas in which to strengthen specific programmatic weaknesses and mitigate risk for potential measles outbreaks.
C1 [Harris, Jennifer B.; Lam, Eugene; Nicholson, Jennifer; Goodson, James L.] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Global Immunizat Div, 1600 Clifton Rd,MS A-04, Atlanta, GA 30329 USA.
   [Harris, Jennifer B.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Off Publ Hlth Sci Serv, Atlanta, GA USA.
   [Badiane, Ousseynou; Ba, Ibrahim Oumar] Minist Sante & Act Social, Direct Prevent, Dakar, Senegal.
   [Diallo, Aliou] WHO, Country Off Senegal, Dakar, Senegal.
   [Fall, Amadou; Masresha, Balcha G.] WHO, Reg Off Afr, Brazzaville, Congo.
RP Harris, JB (reprint author), Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Global Immunizat Div, 1600 Clifton Rd,MS A-04, Atlanta, GA 30329 USA.
EM xdd4@cdc.gov
FU World Health Organization [001]
NR 6
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4332
EI 1539-6924
J9 RISK ANAL
JI Risk Anal.
PD SEP
PY 2016
VL 36
IS 9
SI SI
BP 1708
EP 1717
DI 10.1111/risa.12431
PG 10
WC Public, Environmental & Occupational Health; Mathematics,
   Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
   Methods In Social Sciences
GA ED6RK
UT WOS:000388983300004
PM 26094651
ER

PT J
AU Croft, JB
   Lu, H
   Zhang, XY
   Holt, JB
AF Croft, Janet B.
   Lu, Hua
   Zhang, Xingyou
   Holt, James B.
TI Geographic Accessibility of Pulmonologists for Adults With COPD United
   States, 2013
SO CHEST
LA English
DT Article
DE COPD; epidemiology; geographic variation; pulmonologist
ID OBSTRUCTIVE PULMONARY-DISEASE; FACTOR SURVEILLANCE SYSTEM; SMALL-AREA
   ESTIMATION; PRIMARY-CARE; HEALTH-CARE; SPATIAL ACCESSIBILITY; MULTILEVEL
   REGRESSION; POPULATION; PHYSICIANS; POSTSTRATIFICATION
AB BACKGROUND: Geographic clusters in prevalence and hospitalizations for COPD have been identified at national, state, and county levels. The study objective is to identify county-level geographic accessibility to pulmonologists for adults with COPD.
   METHODS: Service locations of 12,392 practicing pulmonologists and 248,160 primary care physicians were identified from the 2013 National Provider Identifier Registry and weighted by census block-level populations within a series of circular distance buffer zones. Model-based county-level population counts of US adults >= 18 years of age with COPD were estimated from the 2013 Behavioral Risk Factor Surveillance System. The percentages of all estimated adults with potential access to at least one provider type and the county-level ratio of adults with COPD per pulmonologist were estimated for selected distances.
   RESULTS: Most US adults (100% in urbanized areas, 99.5% in urban clusters, and 91.7% in rural areas) had geographic access to a primary care physician within a 10-mile buffer distance; almost all (>= 99.9%) had access to a primary care physician within 50 miles. At least one pulmonologist within 10 miles was available for 97.5% of US adults living in urbanized areas, but only for 38.3% in urban clusters and 34.5% in rural areas. When distance increased to 50 miles, at least one pulmonologist was available for 100% in urbanized areas, 93.2% in urban clusters, and 95.2% in rural areas. County-level ratios of adults with COPD per pulmonologist varied greatly across the United States, with residents in many counties in the Midwest having no pulmonologist within 50 miles.
   CONCLUSIONS: County-level geographic variations in pulmonologist access for adults with COPD suggest that those adults with limited access will have to depend on care from primary care physicians.
C1 [Croft, Janet B.; Lu, Hua; Zhang, Xingyou; Holt, James B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Croft, JB (reprint author), Ctr Dis Control & Prevent, 4770 Buford HWY NE,MS-F78, Atlanta, GA 30341 USA.
EM jbc0@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 36
TC 0
Z9 0
U1 2
U2 2
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD SEP
PY 2016
VL 150
IS 3
BP 544
EP 553
DI 10.1016/j.chest.2016.05.014
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DW3HH
UT WOS:000383532200020
PM 27221645
ER

PT J
AU Davis, KC
   Shafer, PR
   Rodes, R
   Kim, A
   Hansen, H
   Patel, D
   Coln, C
   Beistle, D
AF Davis, Kevin C.
   Shafer, Paul R.
   Rodes, Robert
   Kim, Annice
   Hansen, Heather
   Patel, Deesha
   Coln, Caryn
   Beistle, Diane
TI Does Digital Video Advertising Increase Population-Level Reach of
   Multimedia Campaigns? Evidence From the 2013 Tips From Former Smokers
   Campaign
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE social marketing; smoking; health campaigns; digital advertising;
   television advertising
ID SMOKING-CESSATION; TOBACCO CONTROL; INTERNET; RECRUITMENT; EXPOSURE;
   ACCURACY; PROGRAM; TESTS
AB Background: Federal and state public health agencies in the United States are increasingly using digital advertising and social media to promote messages from broader multimedia campaigns. However, little evidence exists on population-level campaign awareness and relative cost efficiencies of digital advertising in the context of a comprehensive public health education campaign.
   Objective: Our objective was to compare the impact of increased doses of digital video and television advertising from the 2013 Tips From Former Smokers (Tips) campaign on overall campaign awareness at the population level. We also compared the relative cost efficiencies across these media platforms.
   Methods: We used data from a large national online survey of approximately 15,000 US smokers conducted in 2013 immediately after the conclusion of the 2013 Tips campaign. These data were used to compare the effects of variation in media dose of digital video and television advertising on population-level awareness of the Tips campaign. We implemented higher doses of digital video among selected media markets and randomly selected other markets to receive similar higher doses of television ads. Multivariate logistic regressions estimated the odds of overall campaign awareness via digital or television format as a function of higher-dose media in each market area. All statistical tests used the .05 threshold for statistical significance and the .10 level for marginal nonsignificance. We used adjusted advertising costs for the additional doses of digital and television advertising to compare the cost efficiencies of digital and television advertising on the basis of costs per percentage point of population awareness generated.
   Results: Higher-dose digital video advertising was associated with 94% increased odds of awareness of any ad online relative to standard-dose markets (P<.001). Higher-dose digital advertising was associated with a marginally nonsignificant increase (46%) in overall campaign awareness regardless of media format (P=.09). Higher-dose television advertising was associated with 81% increased odds of overall ad awareness regardless of media format (P<.001). Increased doses of television advertising were also associated with significantly higher odds of awareness of any ad on television (P<.001) and online (P=.04). The adjusted cost of each additional percentage point of population-level reach generated by higher doses of advertising was approximately US $440,000 for digital advertising and US $1 million for television advertising.
   Conclusions: Television advertising generated relatively higher levels of overall campaign awareness. However, digital video was relatively more cost efficient for generating awareness. These results suggest that digital video may be used as a cost-efficient complement to traditional advertising modes (eg, television), but digital video should not replace television given the relatively smaller audience size of digital video viewers.
C1 [Davis, Kevin C.; Shafer, Paul R.; Kim, Annice; Hansen, Heather] RTI Int, Ctr Hlth Policy Sci & Tobacco Res, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
   [Shafer, Paul R.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA.
   [Rodes, Robert; Patel, Deesha; Beistle, Diane] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA.
   [Coln, Caryn] Northrop Grumman Informat Syst, Atlanta, GA USA.
RP Davis, KC (reprint author), RTI Int, Ctr Hlth Policy Sci & Tobacco Res, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
EM kcdavis@rti.org
FU Centers for Disease Control and Prevention; RTI International
FX This work was funded by the Centers for Disease Control and Prevention
   under a contract with RTI International. KD designed the study and led
   drafting of the manuscript. PS assisted in drafting the manuscript and
   conducted the analysis. AK, HH, and DP provided feedback on the
   manuscript. RR and DB assisted in the implementation of the media buy
   and provided feedback on the manuscript. CC assisted with implementation
   of digital advertising and provided feedback on the manuscript.
NR 27
TC 0
Z9 0
U1 9
U2 9
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD SEP
PY 2016
VL 18
IS 9
AR e235
DI 10.2196/jmir.5683
PG 11
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA EC9WU
UT WOS:000388495800025
PM 27627853
ER

PT J
AU Hillis, S
   Mercy, J
   Saul, J
   Gleckel, J
   Abad, N
   Kress, H
AF Hillis, Susan
   Mercy, James
   Saul, Janet
   Gleckel, Jessie
   Abad, Neetu
   Kress, Howard
TI THRIVES: Using the best evidence to prevent violence against children
SO JOURNAL OF PUBLIC HEALTH POLICY
LA English
DT Review
DE violence against children; global; child maltreatment; child sexual
   abuse; prevention programs
ID RANDOMIZED CONTROLLED-TRIAL; INTIMATE PARTNER VIOLENCE; MIDDLE-INCOME
   COUNTRIES; PROGRAM; SCHOOL; EMPOWERMENT; RISK; INTERVENTION; FAMILIES;
   BEHAVIOR
AB More than 1 billion children - half the children in the world - are victims of violence every year. As part of the Post-2015 sustainable development agenda, the UN has issued a global call-to-action: to eliminate violence against children. Essential to preventing violence against children is guidance to countries on using the best available evidence to address this problem. THRIVES provides this evidence. It represents a framework of complementary strategies that, taken together, have potential to achieve and sustain efforts to prevent violence against children. These strategies, which span health, social services, education, and justice sectors, include Training in parenting, Household economic strengthening, Reduced violence through legislative protection, Improved services, Values and norms that protect children, Education and life skills, and Surveillance and evaluation. For each THRIVES area, we review evidence for effectiveness and identify programmatic or policy examples. This framework will facilitate commitments to effective, sustainable, and scalable action.
C1 [Hillis, Susan] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Mercy, James; Kress, Howard] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA.
   [Saul, Janet; Gleckel, Jessie] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
   [Abad, Neetu] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA.
RP Hillis, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM shillis@cdc.gov; jmercy@cdc.gov; jsaul@cdc.gov; jgleckel@cdc.gov;
   vjx3@cdc.gov; hkress@cdc.gov
NR 41
TC 0
Z9 0
U1 1
U2 1
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 0197-5897
EI 1745-655X
J9 J PUBLIC HEALTH POL
JI J. Public Health Policy
PD SEP
PY 2016
VL 37
SU 1
BP S51
EP S65
DI 10.1057/s41271-016-0003-6
PG 15
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA EC4QW
UT WOS:000388119500004
PM 27638242
ER

PT J
AU Pownall, HJ
   Schwartz, AV
   Bray, GA
   Berkowitz, RI
   Lewis, CE
   Boyko, EJ
   Jakicic, JM
   Chen, HY
   Heshka, S
   Gregg, EW
   Johnson, KC
AF Pownall, Henry J.
   Schwartz, Anne V.
   Bray, George A.
   Berkowitz, Robert I.
   Lewis, Cora E.
   Boyko, Edward J.
   Jakicic, John M.
   Chen, Haiying
   Heshka, Stanley
   Gregg, Edward W.
   Johnson, Karen C.
CA Look AHEAD Res Grp
TI Changes in Regional Body Composition over 8 Years in a Randomized
   Lifestyle Trial: The Look AHEAD Study
SO OBESITY
LA English
DT Article
ID MUSCLE STRENGTH; OLDER-ADULTS; OBESITY; INTERVENTION; WOMEN; MASS; MEN
AB Objective: To test the hypothesis that an 8-year intensive lifestyle intervention (ILI) suppresses aging-dependent changes in regional lean mass (LM) and fat mass (FM) among people with overweight/obesity and type 2 diabetes.
   Methods: Regional body composition was measured by dual-energy X-ray absorptiometry within a subset of 1,019 volunteers (45-75 years old) in the Look AHEAD study randomized to ILI or diabetes support and education (DSE). The ILI goal was to achieve and maintain >= 7% weight loss through increased physical activity and reduced caloric intake.
   Results: Over 8 years, the DSE group exhibited a linear loss of LM and FM. During year 1, the ILI group lost LM and FM. Between years 1 and 8, the ILI group regained most FM in all regions; regional LM converged with that of the DSE group; the percent of LM loss was greater for the leg than for the trunk. Among both groups, regional LM and FM change was proportional to the size of the region, trunk>leg>arm.
   Conclusions: Aging-dependent LM losses, particularly in the leg region, were not suppressed by ILI. The long-term consequences of rapid LM and FM loss and subsequent regain mostly as fat are unknown.
C1 [Pownall, Henry J.] Houston Methodist Res Inst, Dept Cardiol, Houston, TX 77030 USA.
   [Pownall, Henry J.] Baylor Coll Med, Houston, TX 77030 USA.
   [Schwartz, Anne V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Bray, George A.] LSU, Dept Clin Obes & Metab, Pennington Biomed Res Ctr, Baton Rouge, LA USA.
   [Berkowitz, Robert I.] Univ Penn, Sch Med, Dept Child & Adolescent Psychiat & Behav Sci, Philadelphia, PA 19104 USA.
   [Lewis, Cora E.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA.
   [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Dept Internal Med, Seattle, WA USA.
   [Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA.
   [Jakicic, John M.] Univ Pittsburgh, Dept Hlth & Phys Act, Pittsburgh, PA USA.
   [Chen, Haiying] Wake Forest Sch Med, Dept Biostat, Winston Salem, NC USA.
   [Heshka, Stanley] St Lukes Roosevelt Hosp, Inst Human Nutr, New York, NY 10025 USA.
   [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
   [Johnson, Karen C.] Univ Tennessee, Dept Prevent Med, Memphis, TN USA.
RP Pownall, HJ (reprint author), Houston Methodist Res Inst, Dept Cardiol, Houston, TX 77030 USA.; Pownall, HJ (reprint author), Baylor Coll Med, Houston, TX 77030 USA.
EM hjpownall@houstonmethodist.org
FU NIH; NIDDK [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151,
   DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008,
   DK57135, DK56992]; NHLBI; National Institute of Nursing Research;
   National Center on Minority Health and Health Disparities; NIH Office of
   Research on Women's Health; Centers for Disease Control and Prevention;
   NIDDK; Johns Hopkins Bayview General Clinical Research Center (GCRC)
   [M01RR02719]; Massachusetts General Hospital Mallinckrodt GCRC;
   Massachusetts Institute of Technology GCRC [M01RR01066]; University of
   Colorado Health Sciences GCRC [M01RR00051]; Clinical Nutrition Research
   Unit [P30 DK48520]; University of Tennessee at Memphis GCRC
   [M01RR0021140]; University of Pittsburgh GCRC [M01RR000056]; Clinical
   Translational Research Center [UL1 RR 024153]; NIH [DK 046204]; VA Puget
   Sound Health Care System Medical Research Service, Department of
   Veterans Affairs; Frederic C. Bartter GCRC [M01RR01346]
FX NIH cooperative agreements with NIDDK: DK57136, DK57149, DK56990,
   DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154,
   DK57178, DK57219, DK57008, DK57135, and DK56992 and by NHLBI; National
   Institute of Nursing Research; National Center on Minority Health and
   Health Disparities; NIH Office of Research on Women's Health; and
   Centers for Disease Control and Prevention. Other support was from the
   Intramural Research Program of NIDDK. Other support was from Johns
   Hopkins Bayview General Clinical Research Center (GCRC; M01RR02719);
   Massachusetts General Hospital Mallinckrodt GCRC and Massachusetts
   Institute of Technology GCRC (M01RR01066); University of Colorado Health
   Sciences GCRC (M01RR00051) and Clinical Nutrition Research Unit (P30
   DK48520); University of Tennessee at Memphis GCRC (M01RR0021140);
   University of Pittsburgh GCRC (M01RR000056), the Clinical Translational
   Research Center (UL1 RR 024153), and NIH grant (DK 046204); VA Puget
   Sound Health Care System Medical Research Service, Department of
   Veterans Affairs; and Frederic C. Bartter GCRC (M01RR01346).
   Contributions to Look AHEAD were from FedEx Corporation; Health
   Management Resources; LifeScan, Inc., a Johnson & Johnson Company;
   OPTIFAST (R) (Nestle HealthCare Nutrition) Inc.; Hoffmann-La Roche Inc.;
   Abbott Nutrition; and Slim-Fast Brand (Unilever North America).
NR 29
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD SEP
PY 2016
VL 24
IS 9
BP 1899
EP 1905
DI 10.1002/oby.21577
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EC6VW
UT WOS:000388275800013
PM 27465756
ER

PT J
AU Durkin, MS
   Benedict, RE
   Christensen, D
   Dubois, LA
   Fitzgerald, RT
   Kirby, RS
   Maenner, MJ
   Braun, KV
   Wingate, MS
   Yeargin-Allsopp, M
AF Durkin, Maureen S.
   Benedict, Ruth E.
   Christensen, Deborah
   Dubois, Lindsay A.
   Fitzgerald, Robert T.
   Kirby, Russell S.
   Maenner, Matthew J.
   Braun, Kim Van Naarden
   Wingate, Martha S.
   Yeargin-Allsopp, Marshalyn
TI Prevalence of Cerebral Palsy among 8-Year-Old Children in 2010 and
   Preliminary Evidence of Trends in Its Relationship to Low Birthweight
SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY
LA English
DT Article
DE cerebral palsy; birth weight; epidemiology prevalence; public health
   surveillance
ID GROSS MOTOR FUNCTION; RACIAL-DISPARITIES; UNITED-STATES; INFANTS;
   AUTISM; RISK
AB Background: The public health objective for cerebral palsy (CP) in the United States is to reduce the percentage of children with CP who were born low birthweight (LBW, <2500 g) by 10% between 2006 and 2020. This study reports the prevalence of CP in a constant surveillance area for the years 2006, 2008, and 2010 and describes initial progress towards the CP public health objective.
   Methods: Data on children with CP at age 8 years were ascertained by the Autism and Developmental Disabilities Monitoring (ADDM) Network, a population-based surveillance system that monitored CP in four areas of the United States.
   Results: CP prevalence in 2010 was 2.9 per 1000 [95% confidence interval (CI) 2.6, 3.2], down from 3.5 (95% CI 3.2, 3.9) in the same surveillance area in 2006. Among CP cases with no documented postneonatal aetiology, 49.1% (95% CI 42.9, 55.2) were born LBW in 2010 compared with 54.3% (95% CI 48.4, 60.1) in 2006. In 2010, 28.1% (95% CI 22.9, 30.4) were born very low birthweight (VLBW, <1500 g) compared with 35.4% (95% CI 30.0, 41.2) in 2006. The relative risks for associations between CP and both LBW and VLBW also declined, though not significantly, during the study period.
   Conclusions: Declines in the associations between CP and LBW categories may have contributed to declines during the study period in both the prevalence of CP and the percentage of children with CP who were born LBW or VLBW. Ongoing monitoring of these trends is warranted.
C1 [Durkin, Maureen S.; Dubois, Lindsay A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA.
   [Durkin, Maureen S.; Benedict, Ruth E.; Dubois, Lindsay A.] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.
   [Durkin, Maureen S.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA.
   [Benedict, Ruth E.] Univ Wisconsin, Dept Kinesiol, Madison, WI USA.
   [Christensen, Deborah; Maenner, Matthew J.; Braun, Kim Van Naarden; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Fitzgerald, Robert T.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
   [Kirby, Russell S.] Univ S Florida, Dept Community & Family Hlth, Coll Publ Hlth, Tampa, FL USA.
   [Wingate, Martha S.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA.
RP Durkin, MS (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA.
EM mdurkin@wisc.edu
FU CDC Cooperative Agreements [UR3/CCU523235, UR3/DD000078, UR3/DD000677];
   University of Wisconsin-Madison; National Institute of Child Health and
   Human Development [P30HD03352]
FX Funding for this work was provided by CDC Cooperative Agreements
   UR3/CCU523235, UR3/DD000078, and UR3/DD000677, and by the University of
   Wisconsin-Madison and the National Institute of Child Health and Human
   Development Grant P30HD03352. We are grateful to the many staff,
   scientists, and clinicians that have contributed to the Autism and
   Developmental Disabilities Monitoring (ADDM) Network project.
NR 32
TC 1
Z9 1
U1 4
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-5022
EI 1365-3016
J9 PAEDIATR PERINAT EP
JI Paediatr. Perinat. Epidemiol.
PD SEP
PY 2016
VL 30
IS 5
BP 496
EP 510
DI 10.1111/ppe.12299
PG 15
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
GA EC9IM
UT WOS:000388458300009
PM 27215680
ER

PT J
AU Gounder, PP
   Bulkow, LR
   McMahon, BJ
AF Gounder, P. P.
   Bulkow, L. R.
   McMahon, B. J.
TI Letter: hepatitis B surface seroclearance does reduce the risk of
   hepatocellular carcinoma - authors' reply
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Letter
ID GENOTYPE; ANTIGEN
C1 [Gounder, P. P.; Bulkow, L. R.; McMahon, B. J.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 30329 USA.
   [McMahon, B. J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA.
RP Gounder, PP (reprint author), Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 30329 USA.
EM iym4@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD SEP
PY 2016
VL 44
IS 6
BP 650
EP 651
DI 10.1111/apt.13730
PG 3
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA DW4QM
UT WOS:000383628100017
PM 27511139
ER

PT J
AU Heller, DS
   Tellier, R
   Pabbaraju, K
   Wong, S
   Faye-Petersen, OM
   Muehlenbachs, A
   Goldsmith, C
   Denison, A
   Zaki, SR
AF Heller, Debra S.
   Tellier, Raymond
   Pabbaraju, Kanti
   Wong, Sallene
   Faye-Petersen, Ona M.
   Muehlenbachs, Atis
   Goldsmith, Cynthia
   Denison, Amy
   Zaki, Sherif R.
TI Placental Massive Perivillous Fibrinoid Deposition Associated with
   Coxsackievirus A16-Report of a Case, and Review of the Literature
SO PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
LA English
DT Review
DE Coxsackievirus A16 infection; hand-footmouth disease; intrauterine fetal
   death; massive placental perivillous fibrinoid deposition
ID VIRUS-INFECTION; ENTEROVIRUS; FETAL; PATHOLOGY; TISSUE
AB Massive placental perivillous fibrinoid deposition in the placenta is thought to be an immune-related condition associated with poor perinatal outcomes, including growth restriction and intrauterine fetal demise, with a high risk of recurrence. Rare cases have been associated with Coxsackievirus infection. We present such a case and review the literature.
C1 [Heller, Debra S.] Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, UH E158,185 South Orange Ave, Newark, NJ 07103 USA.
   [Tellier, Raymond; Pabbaraju, Kanti; Wong, Sallene] Prov Lab Publ Hlth, Calgary, AB, Canada.
   [Tellier, Raymond] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.
   [Faye-Petersen, Ona M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Muehlenbachs, Atis; Goldsmith, Cynthia; Denison, Amy; Zaki, Sherif R.] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, NCEZID, Atlanta, GA 30333 USA.
RP Heller, DS (reprint author), Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, UH E158,185 South Orange Ave, Newark, NJ 07103 USA.
EM hellerds@njms.rutgers.edu
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA
SN 1093-5266
EI 1615-5742
J9 PEDIATR DEVEL PATHOL
JI Pediatr. Dev. Pathol.
PD SEP-OCT
PY 2016
VL 19
IS 5
BP 421
EP 423
DI 10.2350/15-10-1726-CR.1
PG 3
WC Pathology; Pediatrics
SC Pathology; Pediatrics
GA EC3ED
UT WOS:000388007200009
PM 26555408
ER

PT J
AU Li, CS
   Ansari, A
   Etherington, G
   Jourdain, JR
   Kukhta, B
   Kurihara, O
   Lopez, MA
   Menetrier, F
   dos Reis, AA
   Solomon, S
   Zhang, JF
   Carr, Z
AF Li, Chunsheng
   Ansari, Armin
   Etherington, George
   Jourdain, Jean-Rene
   Kukhta, Boris
   Kurihara, Osamu
   Lopez, Maria Antonia
   Menetrier, Florence
   dos Reis, Arlene Alves
   Solomon, Stephen
   Zhang, Jiangfeng
   Carr, Zhanat
TI Managing Internal Radiation Contamination Following an Emergency:
   Identification of Gaps and Priorities
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article; Proceedings Paper
CT 14th Coordination and Planning Meeting of the
   World-Health-Organization's
   Radiation-Emergency-Medical-Preparedness-and-Assistance-Network
   (WHO-REMPAN) - Radiation Emergency Medical Preparedness and Assistance
   Network
CY MAY 07-09, 2014
CL Wuerzburg, GERMANY
SP World Hlth Org, Radiat Emergency Med Preparedness & Assistance Network
ID NUCLEAR-POWER-PLANT; DECORPORATION THERAPY; FUKUSHIMA; ACCIDENT; CS-137;
   DTPA
AB Following a radiological or nuclear emergency, first responders and the public may become internally contaminated with radioactive materials, as demonstrated during the GoiA cent nia, Chernobyl and Fukushima accidents. Timely monitoring of the affected populations for potential internal contamination, assessment of radiation dose and the provision of necessary medical treatment are required to minimize the health risks from the contamination. This paper summarizes the guidelines and tools that have been developed, and identifies the gaps and priorities for future projects.
C1 [Li, Chunsheng] Hlth Canada, Ottawa, ON, Canada.
   [Ansari, Armin] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Etherington, George] Publ Hlth England, Chilton, England.
   [Jourdain, Jean-Rene] Inst Radioprotect & Surete Nucl, Fontenay Aux Roses, France.
   [Kukhta, Boris] Burnasyan Fed Med Biophys Ctr Fed Med, Biol Agcy, Moscow, Russia.
   [Kurihara, Osamu] Natl Inst Radiol Sci, Chiba, Japan.
   [Lopez, Maria Antonia] Ctr Invest Energet Medioambientales & Tecnol, Madrid, Spain.
   [Menetrier, Florence] Commissariat Energie Atom & Energies Alternat, Fontenay Aux Roses, France.
   [dos Reis, Arlene Alves] Inst Radioprotecao & Dosimetria, Rio De Janeiro, Brazil.
   [Solomon, Stephen] Australian Radiat Protect & Nucl Safety Agcy, Melbourne, Vic, Australia.
   [Zhang, Jiangfeng] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Carr, Zhanat] WHO, Geneva, Switzerland.
RP Li, CS (reprint author), Hlth Canada, Ottawa, ON, Canada.
EM li.chunsheng@hc-sc.gc.ca
RI Kukhta, Boris/B-1497-2017; 
OI Reis, Arlene/0000-0002-6387-6769
NR 52
TC 0
Z9 0
U1 3
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD SEP
PY 2016
VL 171
IS 1
BP 78
EP 84
DI 10.1093/rpd/ncw199
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
   Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
GA EC1NG
UT WOS:000387872100016
PM 27521210
ER

PT J
AU Barrera, R
AF Barrera, Roberto
TI Recommendations for the surveillance of Aedes aegypti
SO BIOMEDICA
LA Spanish
DT Review
DE Aedes aegypti; disease vector; dengue; chikungunya virus; zika virus
   infection
ID CONTAINER-BREEDING MOSQUITOS; NORTH QUEENSLAND AUSTRALIA; AUTOCIDAL
   GRAVID OVITRAP; DIPTERA-CULICIDAE; PUERTO-RICO; CULEX-QUINQUEFASCIATUS;
   DENGUE CONTROL; STEGOMYIA-AEGYPTI; STICKY OVITRAPS; VECTOR CONTROL
AB Diseases caused by arboviruses transmitted by Aedes aegypti, such as dengue, chikungunya and Zika, continue to rise in annual incidence and geographic expansion. A key limitation for achieving control of A. aegypti has been the lack of effective tools for monitoring its population, and thus determine what control measures actually work. Surveillance of A. aegypti has been based mainly on immature indexes, but they bear little relation to the number of mosquito females, which are the ones capable of transmitting the viruses.
   The recent development of sampling techniques for adults of this vector species promises to facilitate surveillance and control activities. In this review, we present the various monitoring techniques for this mosquito, along with a discussion of their usefulness, and recommendations for improved entomological surveillance.
C1 [Barrera, Roberto] Ctr Dis Control & Prevent CDC, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA.
RP Barrera, R (reprint author), Ctr Dis Control & Prevent CDC, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA.
EM rbarrera@cdc.gov
NR 64
TC 1
Z9 1
U1 3
U2 3
PU INST NACIONAL SALUD
PI BOGOTA D C
PA AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C,
   00000, COLOMBIA
SN 0120-4157
J9 BIOMEDICA
JI Biomedica
PD SEP
PY 2016
VL 36
IS 3
BP 454
EP 462
DI 10.7705/biomedica.v36i3.2892
PG 9
WC Tropical Medicine
SC Tropical Medicine
GA EB6GD
UT WOS:000387478800015
PM 27869394
ER

PT J
AU Acevedo, V
   Amador, M
   Felix, G
   Barrera, R
AF Acevedo, Veronica
   Amador, Manuel
   Felix, Gilberto
   Barrera, Roberto
TI OPERATIONAL ASPECTS OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION
   AUTOCIDAL GRAVID OVITRAP
SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION
LA English
DT Article
DE Aedes aegypti; dengue; mosquito traps; Puerto Rico; vector control
ID CONTAINER-BREEDING MOSQUITOS; AEDES-AEGYPTI; LETHAL OVITRAP;
   DIPTERA-CULICIDAE; DENGUE VECTORS; BRAZIL; TRAP; SURVEILLANCE;
   ALBOPICTUS
AB Dengue viruses cause hundreds of millions of infections every year in tropical and subtropical countries. Unfortunately, there is not a single universal vector control method capable of suppressing Aedes aegypti (L.) populations. Amongst novel control tools or approaches are various types of traps targeting gravid females or their eggs. Here, we provide details of the operational use of the Centers for Disease Control and Prevention autocidal gravid ovitrap (CDC-AGO trap) for the surveillance and control of Ae. aegypti. Adult mosquitoes were monitored every week in 2 isolated neighborhoods treated with 3 AGO traps per house in 85% of houses and in 2 reference neighborhoods without control traps. Between March 2013 and April 2015 we serviced the AGO traps 14 times in each community (every 2 months). Common trap problems were absent or broken trap tops (1-1.5%), flooded (0.1-0.7%) or dry (0.5-1.3%) traps, and missing (0.3-0.8%) or vandalized (0.5-1.4%) traps. Most traps kept a volume of infusion between 45% and 97% of their original volume (10 liters). Nontarget organisms captured in AGO traps were mostly small flies, and to a lesser extent ants, cockroaches, grasshoppers, butterflies, dragonflies, and lizards. Trap coverage ranged between 83% and 87% of houses in both communities throughout the study. We interpret such high levels of trap retention over time as an expression of acceptance by the community.
C1 [Acevedo, Veronica; Amador, Manuel; Felix, Gilberto; Barrera, Roberto] Ctr Dis Control & Prevent, Dengue Branch, Entomol & Ecol Act, 1324 Calle Canada, San Juan, PR 00920 USA.
RP Acevedo, V (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Entomol & Ecol Act, 1324 Calle Canada, San Juan, PR 00920 USA.
NR 24
TC 0
Z9 0
U1 3
U2 3
PU AMER MOSQUITO CONTROL ASSOC
PI MOUNT LAUREL
PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA
SN 8756-971X
EI 1943-6270
J9 J AM MOSQUITO CONTR
JI J. Am. Mosq. Control Assoc.
PD SEP
PY 2016
VL 32
IS 3
BP 254
EP 257
PG 4
WC Entomology
SC Entomology
GA EB6YC
UT WOS:000387530500015
PM 27802402
ER

PT J
AU Itoh, M
   Arguin, PM
AF Itoh, Megumi
   Arguin, Paul M.
TI A conversation about chemoprophylaxis
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Editorial Material
ID MEFLOQUINE
C1 [Itoh, Megumi; Arguin, Paul M.] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA.
RP Arguin, PM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA.
EM pma0@cdc.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD SEP-OCT
PY 2016
VL 14
IS 5
BP 434
EP 435
DI 10.1016/j.tmaid.2016.07.007
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA EA8BW
UT WOS:000386861300003
PM 27471174
ER

PT J
AU Cherry, CC
   Beer, KD
   Fulton, C
   Wong, D
   Buttke, D
   Staples, JE
   Ellis, EM
AF Cherry, Cara C.
   Beer, Karlyn D.
   Fulton, Corey
   Wong, David
   Buttke, Danielle
   Staples, J. Erin
   Ellis, Esther M.
TI Knowledge and use of prevention measures for chikungunya virus among
   visitors - Virgin Islands National Park, 2015
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Article
DE Chikungunya virus; Health knowledge, attitudes, practice; Travel;
   Preventive measures; United States Virgin Islands
ID INTERNATIONAL TRAVELERS; WESTERN-HEMISPHERE; DISEASES; AMERICA;
   ATTITUDES; BEHAVIOR; SPREADS; AIRPORT
AB Background: In June 2014, the mosquito-borne chikungunya virus (CHIKV) emerged in the U.S. Virgin Islands (USVI), a location where tourists comprise the majority of the population during peak season (January April). Limited information is available concerning visitors' CHIKV awareness and prevention measures.
   Methods: We surveyed a convenience sample of Virgin Islands National Park visitors aged >= 18 years. Respondents completed a questionnaire assessing CHIKV knowledge, attitudes, and practices; health information-seeking practices; and demographics.
   Results: Of 783 persons contacted, 443 (57%) completed the survey. Fewer than half (208/441 [47%]) were aware of CHIKV. During trip preparation, 28% of respondents (126/443) investigated USVI-specific health concerns. Compared with persons unaware of CHIKV, CHIKV-aware persons were more likely to apply insect repellent (134/207 [65%] versus 111/231 [48%]; p < 0.001), wear long-sleeves and long pants (84/203 [41%] versus 57/227 [25%]; p < 0.001), and wear insect repellent-treated clothing (36/204 [18%] versus 22/227 [10%]; p = 0.02).
   Conclusions: The majority of visitors surveyed did not research destination-related health concerns and were unaware of CHIKV. However, CHIKV awareness was associated with using multiple prevention measures to reduce disease risk. These findings underscore the importance of providing tourists with disease education upon destination arrival. Published by Elsevier Ltd.
C1 [Cherry, Cara C.; Beer, Karlyn D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ and Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
   [Cherry, Cara C.; Buttke, Danielle] Natl Pk Serv, Off Publ Hlth, 1201 Oakridge Dr, Ft Collins, CO USA.
   [Cherry, Cara C.; Buttke, Danielle] Natl Pk Serv, Wildlife Hlth Branch, Biol Resources Div, 1201 Oakridge Dr, Ft Collins, CO USA.
   [Beer, Karlyn D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE CDC, Atlanta, GA USA.
   [Fulton, Corey] Ctr Dis Control & Prevent, Epidemiol Elect Program, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE, Atlanta, GA USA.
   [Fulton, Corey; Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO USA.
   [Wong, David] Natl Pk Serv, Off Publ Hlth, 4030 Mackland Ave NE, Albuquerque, NM USA.
   [Ellis, Esther M.] Virgin Islands Dept Hlth, 3500 Estate Richmond Christiansted, St Croix, VI 00820 USA.
RP Cherry, CC (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ and Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM ccherry@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD SEP-OCT
PY 2016
VL 14
IS 5
BP 475
EP 480
DI 10.1016/j.tmaid.2016.08.011
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA EA8BW
UT WOS:000386861300010
PM 27597388
ER

PT J
AU Knauf, S
   Raphael, J
   Mitja, O
   Lejora, IAV
   Chuma, IS
   Batamuzi, EK
   Keyyu, JD
   Fyumagwa, R
   Luert, S
   Godornes, C
   Liu, H
   Schwarz, C
   Smajs, D
   Grange, P
   Zinner, D
   Roos, C
   Lukehart, SA
AF Knauf, Sascha
   Raphael, Jane
   Mitja, Oriol
   Lejora, Inyasi A. V.
   Chuma, Idrissa S.
   Batamuzi, Emmanuel K.
   Keyyu, Julius D.
   Fyumagwa, Robert
   Lueert, Simone
   Godornes, Charmie
   Liu, Hsi
   Schwarz, Christiane
   Smajs, David
   Grange, Philippe
   Zinner, Dietmar
   Roos, Christian
   Lukehart, Sheila A.
TI Isolation of Treponema DNA from Necrophagous Flies in a Natural
   Ecosystem
SO EBIOMEDICINE
LA English
DT Article
DE Treponema pallidum; Dipteria; Yaws; Nonhuman primates; Transmission
ID YAWS; PALLIDUM; TRANSMISSION; SYPHILIS; INFECTION; SEQUENCE; TRACHOMA;
   DISEASE; TESTS
AB Background: Recently, the World Health Organization launched a campaign to eradicate the tropical disease yaws, caused by the bacterium Treponema pallidum subsp. pertenue; however, for decades researchers have questioned whether flies act as a vector for the pathogen that could facilitate transmission.
   Methods: A total of 207 fly specimens were trapped in areas of Africa in which T. pallidum-induced skin ulcerations are common in wild baboons; 88 flies from Tarangire National Park and 119 from Lake Manyara National Park in Tanzania were analyzed by PCR for the presence of T. pallidum DNA.
   Findings: We report that in the two study areas, T. pallidum DNA was found in 17-24% of wild-caught flies of the order Diptera. Treponemal DNA sequences obtained from many of the flies match sequences derived from nearby baboon T. pallidum strains, and one of the fly species with an especially high prevalence of T. pallidum DNA, Musca sorbens, has previously been shown to transmit yaws in an experimental setting.
   Interpretation: Our results raise the possibility that flies play a role in yaws transmission; further research is warranted, given how important understanding transmission is for the eradication of this disfiguring disease. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Knauf, Sascha; Lueert, Simone] Leibniz Inst Primate Res, German Primate Ctr, Pathol Unit, Work Grp Neglected Trop Dis, Kellnerweg 4, D-37077 Gottingen, Germany.
   [Raphael, Jane; Lejora, Inyasi A. V.; Chuma, Idrissa S.] Tanzania Natl Pk, Ecol Monitoring Dept, POB 3134, Arusha, Tanzania.
   [Mitja, Oriol] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res, ISGlobal, Barcelona, Spain.
   [Batamuzi, Emmanuel K.] Sokoine Univ Agr, Fac Vet Med, Dept Surg & Theriogenol, POB 3020, Morogoro, Tanzania.
   [Keyyu, Julius D.; Fyumagwa, Robert] Tanzania Wildlife Res Inst, POB 661, Arusha, Tanzania.
   [Lueert, Simone; Schwarz, Christiane; Roos, Christian] Leibniz Inst Primate Res, German Primate Ctr, Primate Genet Lab, Kellnerweg 4, D-37077 Gottingen, Germany.
   [Godornes, Charmie; Lukehart, Sheila A.] Univ Washington, Harborview Med Ctr, Dept Med, 325 Ninth Ave, Seattle, WA 98104 USA.
   [Liu, Hsi] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Smajs, David] Masaryk Univ, Fac Med, Dept Biol, Kamenice 5, Brno 62500, Czech Republic.
   [Grange, Philippe] Ctr Natl Reference Syphilis, Lab Dermatol, F-75014 Paris, France.
   [Zinner, Dietmar] German Primate Ctr, Cognit Ethol Lab, Kellnerweg 4, D-37077 Gottingen, Germany.
   [Roos, Christian] Leibniz Inst Primate Res, German Primate Ctr, Gene Bank Primates, Gottingen, Germany.
RP Knauf, S (reprint author), Leibniz Inst Primate Res, German Primate Ctr, Pathol Unit, Work Grp Neglected Trop Dis, Kellnerweg 4, D-37077 Gottingen, Germany.
EM sknauf@dpz.eu
RI Knauf, Sascha/F-1661-2017; 
OI Knauf, Sascha/0000-0001-5744-4946; Mitja, Oriol/0000-0003-3266-8868
NR 36
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD SEP
PY 2016
VL 11
BP 85
EP 90
DI 10.1016/j.ebiom.2016.07.033
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA8II
UT WOS:000386878100021
PM 27488881
ER

PT J
AU Mendola, P
   Gilboa, SM
AF Mendola, Pauline
   Gilboa, Suzanne M.
TI Reporting of birth defects in SART CORS: time to rely on data linkage
SO FERTILITY AND STERILITY
LA English
DT Editorial Material
C1 [Mendola, Pauline] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Rockville, MD 20847 USA.
   [Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
RP Mendola, P (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Rockville, MD 20847 USA.
OI Mendola, Pauline/0000-0001-5330-2844
FU Intramural CDC HHS [CC999999]
NR 5
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP 1
PY 2016
VL 106
IS 3
BP 554
EP 555
DI 10.1016/j.fertnstert.2016.06.020
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA EA4GT
UT WOS:000386569800013
PM 27343954
ER

PT J
AU Dhalwani, NN
   Boulet, SL
   Kissin, DM
   Zhang, YJ
   McKane, P
   Bailey, MA
   Hood, ME
   Tata, LJ
AF Dhalwani, Nafeesa N.
   Boulet, Sheree L.
   Kissin, Dmitry M.
   Zhang, Yujia
   McKane, Patricia
   Bailey, Marie A.
   Hood, Maria-Elena
   Tata, Laila J.
TI Assisted reproductive technology and perinatal outcomes: conventional
   versus discordant-sibling design
SO FERTILITY AND STERILITY
LA English
DT Article
DE Assisted reproductive technology; low birth weight; preterm birth; small
   for gestational age; discordant-sibling design
ID GESTATIONAL-AGE; UNITED-STATES; RISK-FACTORS; DIAGNOSIS; TRENDS; GROWTH
AB Objective: To compare risks of adverse perinatal outcomes between assisted reproductive technology (ART) and naturally conceived singleton births using a dual design approach.
   Design: Discordant-sibling and conventional cross-sectional general population comparison.
   Setting: Not applicable.
   Patient(s): All singleton live births, conceived naturally or via ART.
   Intervention(s): None.
   Main Outcome Measure(s): Birth weight, gestational age, low birth weight, preterm delivery, small for gestational age (SGA), low Apgar score.
   Result(s): A total of 32,762 (0.8%) of 3,896,242 singleton live births in the three states were conceived via ART. In 6,458 sibling pairs, ART-conceived singletons were 33 g lighter (adjusted beta- -33.40, 95% confidence interval [CI], -48.60, -18.21) and born half a day sooner (beta - -0.58, 95% CI, -1.02, -0.14) than singletons conceived naturally. The absolute risk of low birth weight and preterm birth was 6.8% and 9.7%, respectively, in the ART group and 4.9% and 7.9%, respectively, in the non-ART group. The odds of low birth weight were 33% higher (adjusted odds ratio [aOR] = 1.33; 95% CI, 1.13, 1.56) and 20% higher for preterm birth (aOR = 1.20; 95% CI, 1.07, 1.34). The odds of SGA and low Apgar score were not significantly different in both groups (aOR = 1.22; 95% CI, 0.88, 1.68; and aOR = 0.75; 95% CI, 0.54, 1.05, respectively). Results of conventional analyses were similar, although the magnitude of risk was higher for preterm birth (aOR, 1.51; 95% CI 1.46, 1.56).
   Conclusion(s): Despite some inflated risks in the general population comparison, ART remained associated with an increased likelihood of low birth weight and preterm birth when underlying maternal factors were kept constant using discordant-sibling comparison. (C) 2016 by American Society for Reproductive Medicine.
C1 [Dhalwani, Nafeesa N.; Boulet, Sheree L.; Kissin, Dmitry M.; Zhang, Yujia] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
   [Dhalwani, Nafeesa N.; Tata, Laila J.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham, England.
   [Dhalwani, Nafeesa N.] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Gwendolen Rd, Leicester LE5 4PW, Leics, England.
   [McKane, Patricia] Michigan Dept Hlth & Human Serv, Lansing, MI USA.
   [Bailey, Marie A.] Florida Dept Hlth, Tallahassee, FL USA.
   [Hood, Maria-Elena] Massachusetts Dept Publ Hlth, Boston, MA USA.
RP Dhalwani, NN (reprint author), Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Gwendolen Rd, Leicester LE5 4PW, Leics, England.
EM nnd2@le.ac.uk
OI Tata, Laila/0000-0002-6404-8658
FU Building Experience and Skills Travel Scholarship - Graduate School,
   University of Nottingham; National Institute for Health Research (NIHR)
   Collaboration for Leadership in Applied Health Research and Care-East
   Midlands (NIHR CLAHRC-EM); Leicester Clinical Trials Unit; NIHR
   Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical
   Research Unit
FX Supported by the Building Experience and Skills Travel Scholarship
   awarded by the Graduate School, University of Nottingham for the
   duration of the research project (to N.N.D.); the National Institute for
   Health Research (NIHR) Collaboration for Leadership in Applied Health
   Research and Care-East Midlands (NIHR CLAHRC-EM; to N.N.D.); the
   Leicester Clinical Trials Unit (to N.N.D.); and the NIHR
   Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical
   Research Unit, which is a partnership among University Hospitals of
   Leicester National Health Service (NHS) Trust, Loughborough University,
   and the University of Leicester (to N.N.D.).
NR 24
TC 1
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP 1
PY 2016
VL 106
IS 3
BP 710
EP +
DI 10.1016/j.fertnstert.2016.04.038
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA EA4GT
UT WOS:000386569800037
PM 27187051
ER

PT J
AU Moir, W
   Zeig-Owens, R
   Daniels, RD
   Hall, CB
   Webber, MP
   Jaber, N
   Yiin, JH
   Schwartz, T
   Liu, XX
   Vossbrinck, M
   Kelly, K
   Prezant, DJ
AF Moir, William
   Zeig-Owens, Rachel
   Daniels, Robert D.
   Hall, Charles B.
   Webber, Mayris P.
   Jaber, Nadia
   Yiin, James H.
   Schwartz, Theresa
   Liu, Xiaoxue
   Vossbrinck, Madeline
   Kelly, Kerry
   Prezant, David J.
TI Post-9/11 Cancer Incidence in World Trade Center-Exposed New York City
   Firefighters as Compared to a Pooled Cohort of Firefighters From San
   Francisco, Chicago, and Philadelphia (9/11/2001-2009)
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE World Trade Center (WTC); firefighters; cancer; environmental disaster;
   epidemiology
ID OCCUPATIONAL ASBESTOS EXPOSURE; POLYCYCLIC AROMATIC-HYDROCARBONS;
   POLYCHLORINATED-BIPHENYLS; PROSTATE-CANCER; CENTER DISASTER; RISK;
   METAANALYSIS; MORTALITY; WORKERS; HEALTH
AB Background We previously reported a modest excess of cancer in World Trade Center (WTC)-exposed firefighters versus the general population. This study aimed to separate the potential carcinogenic effects of firefighting and WTC exposure by comparing to a cohort of non-WTC-exposed firefighters.
   Methods Relative rates (RRs) for all cancers combined and individual cancer subtypes from 9/11/2001 to 12/31/2009 were modeled using Poisson regression comparing 11,457 WTC-exposed firefighters to 8,220 urban non-WTC-exposed firefighters.
   Results Compared with non-WTC-exposed firefighters, there was no difference in the RR of all cancers combined for WTC-exposed firefighters (RR = 0.96, 95% CI: 0.83-1.12). Thyroid cancer was significantly elevated (RR = 3.82, 95% CI: 1.07-20.81) from 2001 to 2009; this was attenuated (RR = 3.43, 95% CI: 0.94-18.94) and non-significant when controlling for possible surveillance bias. Prostate cancer was elevated during the latter half (2005-2009; RR = 1.38, 95% CI: 1.01-1.88).
   Conclusions Further follow-up is needed to assess the relationship between WTC exposure and cancers with longer latency periods. (C) 2016 Wiley Periodicals, Inc.
C1 [Moir, William; Zeig-Owens, Rachel; Schwartz, Theresa; Liu, Xiaoxue; Vossbrinck, Madeline] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA.
   [Moir, William; Zeig-Owens, Rachel; Webber, Mayris P.; Jaber, Nadia; Schwartz, Theresa; Liu, Xiaoxue; Vossbrinck, Madeline; Kelly, Kerry; Prezant, David J.] Fire Dept City New York, Bur Hlth Serv, 9 Metrotech Ctr 5E-63-K, Brooklyn, NY 11201 USA.
   [Daniels, Robert D.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA.
   [Hall, Charles B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Div Biostat, Bronx, NY 10467 USA.
   [Webber, Mayris P.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Yiin, James H.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
   [Prezant, David J.] Montefiore Med Ctr, Div Pulm Med, 111 E 210th St, Bronx, NY 10467 USA.
RP Zeig-Owens, R (reprint author), Fire Dept City New York, Bur Hlth Serv, 9 Metrotech Ctr 5E-63-K, Brooklyn, NY 11201 USA.
EM rachel.zeig-owens@fdny.nyc.gov
FU National Institute for Occupational Safety and Health [1UO1OH0710728,
   200-2011-39378]
FX The work was supported by the grant sponsor: National Institute for
   Occupational Safety and Health; grant number: 1UO1OH0710728 and contract
   number: 200-2011-39378.
NR 42
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-3586
EI 1097-0274
J9 AM J IND MED
JI Am. J. Ind. Med.
PD SEP
PY 2016
VL 59
IS 9
BP 722
EP 730
DI 10.1002/ajim.22635
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DZ7KT
UT WOS:000386045000003
PM 27582474
ER

PT J
AU Mann, MN
   Neufeld, BH
   Hawker, MJ
   Pegalajar-Jurado, A
   Paricio, LN
   Reynolds, MM
   Fisher, ER
AF Mann, Michelle N.
   Neufeld, Bella H.
   Hawker, Morgan J.
   Pegalajar-Jurado, Adoracion
   Paricio, Lindsey N.
   Reynolds, Melissa M.
   Fisher, Ellen R.
TI Plasma-modified nitric oxide-releasing polymer films exhibit
   time-delayed 8-log reduction in growth of bacteria
SO BIOINTERPHASES
LA English
DT Article
ID POLY(VINYL CHLORIDE) FILMS; CONTROLLED DRUG-RELEASE; MEDICAL-GRADE PVC;
   SURFACE MODIFICATION; SILICA NANOPARTICLES; PROTEIN ADSORPTION;
   HYDROPHILIC MODIFICATION; ACINETOBACTER-BAUMANNII; ANTIBACTERIAL
   SURFACES; STAPHYLOCOCCUS-AUREUS
AB Tygon (R) and other poly( vinyl chloride)-derived polymers are frequently used for tubing in blood transfusions, hemodialysis, and other extracorporeal circuit applications. These materials, however, tend to promote bacterial proliferation which contributes to the high risk of infection associated with device use. Antibacterial agents, such as nitric oxide donors, can be incorporated into these materials to eliminate bacteria before they can proliferate. The release of the antimicrobial agent from the device, however, is challenging to control and sustain on timescales relevant to blood transport procedures. Surface modification techniques can be employed to address challenges with controlled drug release. Here, surface modification using H2O (v) plasma is explored as a potential method to improve the biocompatibility of biomedical polymers, namely, to tune the nitric oxide-releasing capabilities from Tygon films. Film properties are evaluated pre- and post-treatment by contact angle goniometry, x-ray photoelectron spectroscopy, and optical profilometry. H2O ( v) plasma treatment significantly enhances the wettability of the nitric-oxide releasing films, doubles film oxygen content, and maintains surface roughness. Using the kill rate method, the authors determine both treated and untreated films cause an 8 log reduction in the population of both Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus. Notably, however, H2O ( v) plasma treatment delays the kill rate of treated films by 24 h, yet antibacterial efficacy is not diminished. Results of nitric oxide release, measured via chemiluminescent detection, are also reported and correlated to the observed kill rate behavior. Overall, the observed delay in biocidal agent release caused by our treatment indicates that plasma surface modification is an important route toward achieving controlled drug release from polymeric biomedical devices. (C) 2016 American Vacuum Society.
C1 [Mann, Michelle N.; Neufeld, Bella H.; Hawker, Morgan J.; Pegalajar-Jurado, Adoracion; Paricio, Lindsey N.; Reynolds, Melissa M.; Fisher, Ellen R.] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
   [Reynolds, Melissa M.] Colorado State Univ, Sch Biomed Engn, Ft Collins, CO 80523 USA.
   [Reynolds, Melissa M.] Colorado State Univ, Dept Chem & Biol Engn, Ft Collins, CO 80523 USA.
   [Pegalajar-Jurado, Adoracion] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Fisher, ER (reprint author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
EM Ellen.Fisher@colostate.edu
FU Colorado State University; Department of Defense Congressionally
   Directed Medical Research Program (DOD-CDMRP); National Science
   Foundation; Dreyfus Foundation via Camille and Henry Dreyfus Foundation
   Postdoctoral Program in Environmental Chemistry; Boettcher Foundation's
   Webb-Waring Biomedical Research Program
FX The authors gratefully acknowledge funding received from the Vice
   President for Research at Colorado State University (Catalyst for
   Innovative Partnerships), the Department of Defense Congressionally
   Directed Medical Research Program (DOD-CDMRP), and the National Science
   Foundation. A.P.J. also thanks the Dreyfus Foundation for support via
   the Camille and Henry Dreyfus Foundation Postdoctoral Program in
   Environmental Chemistry. The authors thank Patrick McCurdy of the CSU
   Chemistry Central Instrument Facility for XPS and Scott Noblitt and
   Charles Henry's research group at CSU for profilometry technical
   support. This research, and L.N.P., in particular, was supported by
   funds from the Boettcher Foundation's Webb-Waring Biomedical Research
   Program.
NR 80
TC 0
Z9 0
U1 11
U2 11
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1934-8630
EI 1559-4106
J9 BIOINTERPHASES
JI Biointerphases
PD SEP
PY 2016
VL 11
IS 3
AR 031005
DI 10.1116/1.4959105
PG 11
WC Biophysics; Materials Science, Biomaterials
SC Biophysics; Materials Science
GA EA4MF
UT WOS:000386586100006
PM 27440395
ER

PT J
AU Papp, JR
   Lawrence, K
   Sharpe, S
   Mueller, J
   Kirkcaldy, RD
AF Papp, John R.
   Lawrence, Kenneth
   Sharpe, Samera
   Mueller, John
   Kirkcaldy, Robert D.
TI In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is
   inhibited by ETX0914, a novel spiropyrimidinetrione
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Neisseria gonorrhoeae; Gonorrhoea; Antimicrobial susceptibility; Novel
   drug
ID SUSCEPTIBILITY; AZD0914; CEPHALOSPORINS
AB Antimicrobial resistance in Neisseria gonorrhoeae has severely limited the number of treatment options, and the emergence of extended-spectrum cephalosporin resistance threatens the effectiveness of the last remaining recommended treatment regimen. This study assessed the in vitro susceptibility of N. gonorrhoeae to ETX0914, a novel spiropyrimidinetrione that inhibits DNA biosynthesis. In vitro activity was determined by agar dilution against 100 N. gonorrhoeae isolates collected from men presenting with urethritis in the USA during 2012-2013 through the Gonococcal Isolate Surveillance Project. The minimum inhibitory concentration (MIC) that inhibited growth in 50% (MIC50) and 90% (MIC90) of isolates was calculated for each antimicrobial agent. ETX0914 demonstrated a high level of antimicrobial activity against N. gonorrhoeae, including isolates with decreased susceptibility or resistance to currently available agents. The ability of ETX0914 to inhibit the growth of N. gonorrhoeae was similar to ceftriaxone, which is currently recommended in combination with azithromycin to treat gonorrhoea. The data presented in this study strongly suggest that ETX0914 should be evaluated in a clinical trial for the treatment of N. gonorrhoeae. Published by Elsevier B.V.
C1 [Papp, John R.; Sharpe, Samera; Kirkcaldy, Robert D.] US Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Lawrence, Kenneth; Mueller, John] Entasis Therapeut, 35 Gatehouse Dr Suite E0, Waltham, MA 02451 USA.
RP Papp, JR (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A-12, Atlanta, GA 30333 USA.
EM jwp6@cdc.gov
FU Entasis Therapeutics (Waltham, MA); US Centers for Disease Control and
   Prevention (CDC) [NCHHSTP-V147666-0]
FX Funding: This study was funded by Entasis Therapeutics (Waltham, MA) and
   the US Centers for Disease Control and Prevention (CDC) under the
   Material Transfer Agreement NCHHSTP-V147666-0.
NR 19
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD SEP
PY 2016
VL 48
IS 3
BP 328
EP 330
DI 10.1016/j.ijantimicag.2016.05.018
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA DZ7CQ
UT WOS:000386022000016
PM 27499432
ER

PT J
AU Dominguez, SR
   Anderson, LJ
   Kotter, CV
   Littlehorn, CA
   Arms, LE
   Dowell, E
   Todd, JK
   Frank, DN
AF Dominguez, Samuel R.
   Anderson, Lydia J.
   Kotter, Cassandra V.
   Littlehorn, Cynthia A.
   Arms, Lesley E.
   Dowell, Elaine
   Todd, James K.
   Frank, Daniel N.
TI Comparison of Whole-Genome Sequencing and Molecular-Epidemiological
   Techniques for Clostridium difficile Strain Typing
SO JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
LA English
DT Article
DE Clostridium difficile; next generation sequencing; outbreak
   investigation; pediatrics
ID PHYLOGENETIC TREES; OUTBREAK; TRANSMISSION; MRSA
AB We analyzed in parallel 27 pediatric Clostridium difficile isolates by repetitive sequence-based polymerase chain reaction (RepPCR), pulsed-field gel electrophoresis (PFGE), and whole-genome next-generation sequencing. Next-generation sequencing distinguished 3 groups of isolates that were indistinguishable by RepPCR and 1 isolate that clustered in the same PFGE group as other isolates.
C1 [Dominguez, Samuel R.; Todd, James K.] Univ Colorado, Sch Med, Dept Pediat Infect Dis, Aurora, CO USA.
   [Dominguez, Samuel R.; Todd, James K.] Childrens Hosp Colorado, Dept Epidemiol, Aurora, CO USA.
   [Kotter, Cassandra V.; Frank, Daniel N.] Univ Colorado, Sch Med, Dept Adult Infect Dis, Aurora, CO USA.
   [Littlehorn, Cynthia A.; Arms, Lesley E.; Dowell, Elaine] Childrens Hosp Colorado, Dept Pathol & Lab Med, Aurora, CO USA.
   [Anderson, Lydia J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Dominguez, SR (reprint author), Childrens Hosp Colorado, Sect Pediat Infect Dis, B055,13123 E 16th Ave, Aurora, CO 80045 USA.
EM samuel.dominguez@childrenscolorado.org
NR 13
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048-7193
EI 2048-7207
J9 J PEDIATR INFECT DIS
JI J. Pediatr. Infect. Dis. Soc.
PD SEP
PY 2016
VL 5
IS 3
BP 329
EP 332
DI 10.1093/jpids/piv020
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DZ8RH
UT WOS:000386138100016
PM 26407257
ER

PT J
AU Prill, MM
   Iwane, MK
   Little, D
   Gerber, SI
AF Prill, Mila M.
   Iwane, Marika K.
   Little, Delmar
   Gerber, Susan I.
TI Investigation of Respiratory Syncytial Virus-Associated Deaths Among US
   Children Aged < 2 Years, 2004-2007
SO JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
LA English
DT Article
DE deaths; RSV; United States
ID YOUNG-CHILDREN; UNITED-STATES; MORTALITY; INFANTS; COHORT
AB We validated the respiratory syncytial virus-coded deaths of children aged <2 years in 2004-2007 using national/ state death data and medical records. There were 48 deaths in 4 states, and hospital records for 32 of them were available; 26 of those 32 (81%) had a laboratory finding of respiratory syncytial virus, and 21 of those 26 (81%) had a potential high-risk condition, most commonly preterm birth (35%).
C1 [Prill, Mila M.; Iwane, Marika K.; Gerber, Susan I.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA.
   [Little, Delmar] Georgia Dept Publ Hlth, Acute Dis Epidemiol Sect, Atlanta, GA USA.
RP Prill, MM (reprint author), Ctr Dis Control & Prevent, NCIRD, DVD, Epidemiol Branch, 1600 Clifton Rd,NE,MS A-34, Atlanta, GA 30333 USA.
EM mprill@cdc.gov
NR 10
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048-7193
EI 2048-7207
J9 J PEDIATR INFECT DIS
JI J. Pediatr. Infect. Dis. Soc.
PD SEP
PY 2016
VL 5
IS 3
BP 333
EP 336
DI 10.1093/jpids/piv006
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DZ8RH
UT WOS:000386138100017
PM 27534673
ER

PT J
AU Wong, VK
   Holt, KE
   Okoro, C
   Baker, S
   Pickard, DJ
   Marks, F
   Page, AJ
   Olanipekun, G
   Munir, H
   Alter, R
   Fey, PD
   Feasey, NA
   Weill, FX
   Le Hello, S
   Hart, PJ
   Kariuki, S
   Breiman, RF
   Gordon, MA
   Heyderman, RS
   Jacobs, J
   Lunguya, O
   Msefula, C
   MacLennan, CA
   Keddy, KH
   Smith, AM
   Onsare, RS
   De Pinna, E
   Nair, S
   Amos, B
   Dougan, G
   Obaro, S
AF Wong, Vanessa K.
   Holt, Kathryn E.
   Okoro, Chinyere
   Baker, Stephen
   Pickard, Derek J.
   Marks, Florian
   Page, Andrew J.
   Olanipekun, Grace
   Munir, Huda
   Alter, Roxanne
   Fey, Paul D.
   Feasey, Nicholas A.
   Weill, Francois-Xavier
   Le Hello, Simon
   Hart, Peter J.
   Kariuki, Samuel
   Breiman, Robert F.
   Gordon, Melita A.
   Heyderman, Robert S.
   Jacobs, Jan
   Lunguya, Octavie
   Msefula, Chisomo
   MacLennan, Calman A.
   Keddy, Karen H.
   Smith, Anthony M.
   Onsare, Robert S.
   De Pinna, Elizabeth
   Nair, Satheesh
   Amos, Ben
   Dougan, Gordon
   Obaro, Stephen
CA Int Typhoid Consortium
TI Molecular Surveillance Identifies Multiple Transmissions of Typhoid in
   West Africa
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID COMMUNITY-ACQUIRED BACTEREMIA; RESISTANT SALMONELLA-ENTERICA;
   ANTIBIOTIC-RESISTANCE; INTERACTIVE TREE; CHILDREN; MUTATIONS; SEQUENCE;
   FEVER; PREVALENCE; ANNOTATION
AB Background
   The burden of typhoid in sub-Saharan African (SSA) countries has been difficult to estimate, in part, due to suboptimal laboratory diagnostics. However, surveillance blood cultures at two sites in Nigeria have identified typhoid associated with Salmonella enterica serovar Typhi (S. Typhi) as an important cause of bacteremia in children.
   Methods
   A total of 128 S. Typhi isolates from these studies in Nigeria were whole-genome sequenced, and the resulting data was used to place these Nigerian isolates into a worldwide context based on their phylogeny and carriage of molecular determinants of antibiotic resistance.
   Results
   Several distinct S. Typhi genotypes were identified in Nigeria that were related to other clusters of S. Typhi isolates from north, west and central regions of Africa. The rapidly expanding S. Typhi clade 4.3.1 (H58) previously associated with multiple antimicrobial resistances in Asia and in east, central and southern Africa, was not detected in this study. However, antimicrobial resistance was common amongst the Nigerian isolates and was associated with several plasmids, including the IncHI1 plasmid commonly associated with S. Typhi.
   Conclusions
   These data indicate that typhoid in Nigeria was established through multiple independent introductions into the country, with evidence of regional spread. MDR typhoid appears to be evolving independently of the haplotype H58 found in other typhoid endemic countries. This study highlights an urgent need for routine surveillance to monitor the epidemiology of typhoid and evolution of antimicrobial resistance within the bacterial population as a means to facilitate public health interventions to reduce the substantial morbidity and mortality of typhoid.
C1 [Wong, Vanessa K.; Okoro, Chinyere; Pickard, Derek J.; Page, Andrew J.; Kariuki, Samuel; MacLennan, Calman A.; Dougan, Gordon] Wellcome Trust Sanger Inst, Cambridge, England.
   [Wong, Vanessa K.; Okoro, Chinyere] Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Addenbrookes Hosp, Cambridge, England.
   [Holt, Kathryn E.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic, Australia.
   [Holt, Kathryn E.] Univ Melbourne, Ctr Syst Genom, Parkville, Vic, Australia.
   [Baker, Stephen] Univ Oxford, Hosp Trop Dis, Wellcome Trust Major Overseas Programme, Clin Res Unit, Ho Chi Minh City, Vietnam.
   [Baker, Stephen] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
   [Baker, Stephen] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England.
   [Marks, Florian] Int Vaccine Inst, Dept Epidemiol, Seoul, South Korea.
   [Olanipekun, Grace] Int Fdn Infect Dis Nigeria, Abuja, Nigeria.
   [Munir, Huda] Aminu Kano Teaching Hosp, Dept Med Microbiol, Kano, Nigeria.
   [Alter, Roxanne; Fey, Paul D.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA.
   [Feasey, Nicholas A.] Univ Liverpool Liverpool Sch Trop Med, Pembroke Pl, Liverpool, Merseyside, England.
   [Weill, Francois-Xavier; Le Hello, Simon] Inst Pasteur, Unite Bacteries Pathogenes Enter, Paris, France.
   [Hart, Peter J.; MacLennan, Calman A.] Univ Birmingham, Inst Biomed Res, Sch Immun & Infect, Coll Med & Dent Sci, Birmingham, W Midlands, England.
   [Hart, Peter J.] St Georges Univ London, London, England.
   [Kariuki, Samuel; Breiman, Robert F.; Onsare, Robert S.] Kenya Med Res Inst KEMRI, Nairobi, Kenya.
   [Breiman, Robert F.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Breiman, Robert F.] Emory Global Hlth Inst, Atlanta, GA USA.
   [Gordon, Melita A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England.
   [Gordon, Melita A.; Heyderman, Robert S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Heyderman, Robert S.; Msefula, Chisomo] UCL, Div Infect & Immun, London, England.
   [Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium.
   [Jacobs, Jan] Univ Leuven, KU Leuven, Dept Microbiol & Immunol, Leuven, Belgium.
   [Lunguya, Octavie] Natl Inst Biomed Res, Kinshasa, DEM REP CONGO.
   [Lunguya, Octavie] Univ Hosp Kinshasa, Kinshasa, DEM REP CONGO.
   [Msefula, Chisomo] Univ Malawi, Dept Microbiol, Coll Med, Blantyre, Malawi.
   [MacLennan, Calman A.] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England.
   [Keddy, Karen H.; Smith, Anthony M.] Univ Witwatersrand, Natl Inst Communicable Dis, Ctr Enter Dis, Div Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Keddy, Karen H.; Smith, Anthony M.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [De Pinna, Elizabeth; Nair, Satheesh] Publ Hlth England, Salmonella Reference Serv, London, England.
   [Amos, Ben] St Augustines Hosp, Muheza, Tanzania.
   [Obaro, Stephen] Univ Nebraska Med Ctr, Div Pediat Infect Dis, Omaha, NE USA.
   [Obaro, Stephen] Univ Abuja Teaching Hosp, Gwagwalada, Nigeria.
   [Obaro, Stephen] Bingham Univ, Karu, Nassarawa State, Nigeria.
RP Wong, VK (reprint author), Wellcome Trust Sanger Inst, Cambridge, England.; Wong, VK (reprint author), Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Addenbrookes Hosp, Cambridge, England.
EM vw1@sanger.ac.uk
OI Nair, Satheesh/0000-0002-7297-1485; Hatta,
   Mochammad/0000-0002-8456-4203; Dufour, Muriel/0000-0003-3638-4918;
   Watson, Conall/0000-0002-2469-791X
FU Wellcome Trust [098051, WT092152MA, 101113/Z/13/Z, 100087/Z/12/Z]; NHMRC
   of Australia [1061409]; Victorian Life Sciences Computation Initiative
   (VLSCI) [VR0082]; Clinical Research Fellowship from GlaxoSmithKline; UK
   Medical Research Council; IP; Institut de Veille Sanitaire; French
   Government "Investissement d'Avenir" program [ANR-10-LABX-62-IBEID];
   Society in Science; Branco Weiss Fellowship; antibiotic resistance
   surveillance project in DR Congo; Belgian Directorate General of
   Development Cooperation [2.01]; Institute of Tropical Medicine, Antwerp,
   Belgium [2.01]; Bill & Melinda Gates Foundation; NIH [R01 AI099525-02];
   Royal Society; National Institute Of Allergy And Infectious Diseases
   (NIAID) of the National Institutes of Health [R01AI097493]
FX This work was supported by a number of organizations. The Wellcome Trust
   Sanger Institute authors were funded by Wellcome Trust Award 098051; NAF
   was supported by the Wellcome Trust Research Fellowship WT092152MA. NAF,
   RSH and this work were supported by a strategic award from the Wellcome
   Trust for the MLW Clinical Research Programme (101113/Z/13/Z). KEH was
   supported by the NHMRC of Australia (fellowship #1061409) and the
   Victorian Life Sciences Computation Initiative (VLSCI) (grant #VR0082).
   CAM was supported by a Clinical Research Fellowship from GlaxoSmithKline
   and PJH by a UK Medical Research Council PhD studentship. This work
   forms part of an EU FP7 Marie Curie Actions Industry Academia
   Partnerships and Pathways (IAPP) Consortium Programme, entitled
   GENDRIVAX (Genome-driven vaccine development for bacterial infections),
   involving the Wellcome Trust Sanger Institute, KEMRI Nairobi and
   Novartis Vaccines Institute for Global Health. The Institut Pasteur (IP)
   authors were funded by the IP, the Institut de Veille Sanitaire, and by
   the French Government "Investissement d'Avenir" program (Integrative
   Biology of Emerging Infectious Diseases" Laboratory of Excellence, grant
   no. ANR-10-LABX-62-IBEID). CO was supported by Society in Science, The
   Branco Weiss Fellowship, administered by the ETH Zurich. JJ was
   supported by the antibiotic resistance surveillance project in DR Congo,
   funded by Project 2.01 of the Third Framework Agreement between the
   Belgian Directorate General of Development Cooperation and the Institute
   of Tropical Medicine, Antwerp, Belgium. FM was supported by a research
   grant from the Bill & Melinda Gates Foundation. The findings and
   conclusions contained within this publication are those of the authors
   and do not necessarily reflect positions or policies of the Bill &
   Melinda Gates Foundation. SK was supported by the NIH Grant Number R01
   AI099525-02. SB is a Sir Henry Dale Fellow, jointly funded by the
   Wellcome Trust and the Royal Society (100087/Z/12/Z). SO was supported
   by the National Institute Of Allergy And Infectious Diseases (NIAID) of
   the National Institutes of Health (#R01AI097493). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
NR 37
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD SEP
PY 2016
VL 10
IS 9
AR e0004781
DI 10.1371/journal.pntd.0004781
PG 22
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DZ1UZ
UT WOS:000385627900002
ER

PT J
AU Reynolds, M
   Gates, E
   Hummelbrunner, R
   Marra, M
   Williams, B
AF Reynolds, Martin
   Gates, Emily
   Hummelbrunner, Richard
   Marra, Mita
   Williams, Bob
TI Towards Systemic Evaluation
SO SYSTEMS RESEARCH AND BEHAVIORAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 59th Annual Conference of the
   International-Society-for-the-Systems-Sciences (ISSS)
CY AUG 02-07, 2015
CL Berlin, GERMANY
SP Int Soc Syst Sci
DE bricolage; complexity science; developmental evaluation; systemic
   evaluation; systems thinking
ID COMPLEX; EQUITY
AB Problems of conventional evaluation models can be understood as an impoverished conversation' between realities (of non-linearity, indeterminate attributes, and ever-changing context), and models of evaluating such realities. Meanwhile, ideas of systems thinking and complexity sciencegrouped here under the acronym STCSstruggle to gain currency in the big E' world of institutionalized evaluation. Four evaluation practitioners familiar with evaluation tools associated with STCS offer perspectives on issues regarding mainstream uptake of STCS in the big E' world. The perspectives collectively suggest three features of practicing systemic evaluation: (i) developing value in conversing between bounded values (evaluations) and unbounded reality (evaluand), with humility; (ii) developing response-ability with evaluand stakeholders based on reflexivity, with empathy; and (iii) developing adaptive rather than mere contingent use(fulness) of STCS tools' as part of evaluation praxis, with inevitable fallibility and an orientation towards bricolage (adaptive use). The features hint towards systemic evaluation as core to a reconfigured notion of developmental evaluation. Copyright (c) 2016 John Wiley & Sons, Ltd.
C1 [Reynolds, Martin] Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   [Gates, Emily] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
   [Hummelbrunner, Richard] OAR Regionalberatung Consultancy, Graz, Austria.
   [Marra, Mita] Univ Salerno, Dept Polit Social & Media Sci, Fisciano, SA, Italy.
RP Reynolds, M (reprint author), Open Univ, Milton Keynes MK7 6AA, Bucks, England.
EM martin.reynolds@open.ac.uk
NR 56
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1092-7026
EI 1099-1743
J9 SYST RES BEHAV SCI
JI Syst. Res. Behav. Sci.
PD SEP-OCT
PY 2016
VL 33
IS 5
SI SI
BP 662
EP 673
DI 10.1002/sres.2423
PG 12
WC Management; Social Sciences, Interdisciplinary
SC Business & Economics; Social Sciences - Other Topics
GA DW5HG
UT WOS:000383673800006
ER

PT J
AU Mansfield, KL
   Banyard, AC
   Fooks, AR
   Franka, R
   Isloor, S
   Rahman, A
AF Mansfield, Karen L.
   Banyard, Ashley C.
   Fooks, Anthony R.
   Franka, Richard
   Isloor, Shrikrishna
   Rahman, Abdul
TI Supporting rabies control in India
SO VETERINARY RECORD
LA English
DT News Item
C1 [Mansfield, Karen L.; Banyard, Ashley C.; Fooks, Anthony R.] Anim & Plant Hlth Agcy Weybridge, Wildlife Zoonoses & Vector Borne Dis Res Grp, Woodham Lane, Surrey KT15 3NB, England.
   [Franka, Richard] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Isloor, Shrikrishna; Rahman, Abdul] Anim & Fisheries Sci Univ, Vet Coll, Rabies Lab, Karnataka Vet, Bangalore, Karnataka, India.
   [Mansfield, Karen L.; Fooks, Anthony R.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L3 5TQ, Merseyside, England.
   [Fooks, Anthony R.] Univ London, St Georges Hosp, Sch Med, Inst Infect & Immun, London SW17 0RE, England.
RP Fooks, AR (reprint author), Anim & Plant Hlth Agcy Weybridge, Wildlife Zoonoses & Vector Borne Dis Res Grp, Woodham Lane, Surrey KT15 3NB, England.; Fooks, AR (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool L3 5TQ, Merseyside, England.; Fooks, AR (reprint author), Univ London, St Georges Hosp, Sch Med, Inst Infect & Immun, London SW17 0RE, England.
EM Tony.Fooks@apha.gsi.gov.uk
RI Mansfield, Karen/D-8399-2011; APHA, Staff publications/E-6082-2010
NR 7
TC 0
Z9 0
U1 3
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0042-4900
EI 2042-7670
J9 VET REC
JI Vet. Rec.
PD SEP
PY 2016
VL 179
IS 12
BP 296
EP U19
DI 10.1136/vr.i4687
PG 2
WC Veterinary Sciences
SC Veterinary Sciences
GA DZ6ER
UT WOS:000385954900012
PM 27660350
ER

PT J
AU Voas, RB
   Tippetts, AS
   Bergen, G
   Grosz, M
   Marques, P
AF Voas, Robert B.
   Tippetts, A. Scott
   Bergen, Gwen
   Grosz, Milton
   Marques, Paul
TI Mandating Treatment Based on Interlock Performance: Evidence for
   Effectiveness
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Impaired Driving; AUD Treatment; Interlocks; Multiple DUI Offenders; DUI
   Recidivism
ID ALCOHOL IGNITION INTERLOCK; DUI; BIOMARKERS; OFFENDERS
AB Background: Vehicle alcohol ignition interlocks reduce alcohol-impaired driving recidivism while installed, but recidivism reduction does not continue after removal. It has been suggested that integrating alcohol use disorder (AUD) treatment with interlock programs might extend the effectiveness of interlocks in reducing recidivism beyond their removal. This study evaluated the first implementation of a Florida policy mandating AUD treatment for driving under the influence (DUI) offenders on interlocks. Treatment was required when the offender accumulated 3 violations (defined as 2 "lockouts" within 4 hours; a lockout occurs when the device prevents a drinking driver from starting the vehicle).
   Methods: Cox regression was used to compare alcohol-impaired driving recidivism during the 48 months following the interlock removal between 2 groups: (i) 640 multiple DUI offenders who received AUD treatment while interlocks were installed; and (ii) 806 matched offenders not mandated to treatment while interlocks were installed.
   Results: The ignition interlock plus treatment group experienced 32% lower recidivism, 95% confidence interval [ 9, 49], following the removal of the interlock during the 12 to 48 months in which they were compared with the nontreatment group. We estimated that this decline in recidivism would have prevented 41 rearrests, 13 crashes, and almost 9 injuries in crashes involving the 640 treated offenders over the period following interlock removal.
   Conclusions: This study provides strong support for the inclusion of AUD treatment for offenders in interlock programs based on the number of times they are "locked out." The offenders required to attend treatment demonstrated a one-third lower DUI recidivism following their time on the interlock compared to similar untreated offenders.
C1 [Voas, Robert B.; Tippetts, A. Scott; Marques, Paul] Pacific Inst Res & Evaluat, Calverton, MD USA.
   [Bergen, Gwen] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA USA.
   [Grosz, Milton] Florida Dept Highway Safety & Motor Vehicles, Tallahassee, FL USA.
RP Voas, RB (reprint author), Pacific Inst Res & Evaluat, Calverton Ctr, 11720 Beltsville Dr,Suite 900, Calverton, MD 20705 USA.
EM voas@pire.org
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD SEP
PY 2016
VL 40
IS 9
DI 10.1111/acer.13149
PG 8
WC Substance Abuse
SC Substance Abuse
GA DZ0TQ
UT WOS:000385553000016
PM 27427288
ER

PT J
AU Borst, A
   Beckman, M
   Reyes, N
   Thames, E
   Saber, I
   Byrne, K
   Ortel, T
AF Borst, Alexandra
   Beckman, Michele
   Reyes, Nimia
   Thames, Elizabeth
   Saber, Ibrahim
   Byrne, Kristin
   Ortel, Thomas
TI INCIDENCE OF PEDIATRIC VENOUS THROMBOEMBOLISM IN DURHAM COUNTY, NORTH
   CAROLINA
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Borst, Alexandra; Thames, Elizabeth; Saber, Ibrahim; Byrne, Kristin; Ortel, Thomas] Duke Univ, Med Ctr, Durham, NC USA.
   [Beckman, Michele; Reyes, Nimia] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA T34
BP E378
EP E378
PG 1
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100043
ER

PT J
AU McCumber, M
   Wendelboe, AM
   Campbell, J
   Ding, K
   Bratzler, D
   Beckman, M
   Reyes, N
   Raskob, GE
AF McCumber, Micah
   Wendelboe, Aaron M.
   Campbell, Janis
   Ding, Kai
   Bratzler, Dale
   Beckman, Michele
   Reyes, Nimia
   Raskob, Gary E.
TI DIFFERENCES BETWEEN ACTIVE AND PASSIVE SURVEILLANCE OF VENOUS
   THROMBOEMBOLISM IN OKLAHOMA COUNTY, 2012-2013
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [McCumber, Micah; Wendelboe, Aaron M.; Campbell, Janis; Ding, Kai; Bratzler, Dale; Raskob, Gary E.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK USA.
   [Beckman, Michele; Reyes, Nimia] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA T71
BP E395
EP E395
PG 1
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100078
ER

PT J
AU Miller, CH
   Adcock, DM
AF Miller, Connie H.
   Adcock, Dorothy M.
TI THE NEED FOR STANDARDIZATION OF FACTOR INHIBITOR ASSAYS
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Miller, Connie H.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Adcock, Dorothy M.] Colorado Coagulat, Lab Corp Amer Holdings, Englewood, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA F59
BP E424
EP E424
PG 1
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100136
ER

PT J
AU Miller, CH
   Boylan, B
AF Miller, Connie H.
   Boylan, Brian
CA HIRS Investigators
TI LIMIT OF DETECTION OF THE NIJMEGEN-BETHESDA ASSAY FOR FACTOR VIII
   INHIBITORS
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Miller, Connie H.; Boylan, Brian; HIRS Investigators] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA F36
BP E412
EP E413
PG 2
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100114
ER

PT J
AU Pai, M
   Key, N
   Skinner, M
   Curtis, R
   Feinstein, M
   Kessler, C
   Lane, S
   Makris, M
   Riker, E
   Santesso, N
   Soucie, JM
   Yeung, C
   Iorio, A
   Schunemann, H
AF Pai, Menaka
   Key, Nigel
   Skinner, Mark
   Curtis, Randall
   Feinstein, Marla
   Kessler, Craig
   Lane, Shannon
   Makris, Michael
   Riker, Ellen
   Santesso, Nancy
   Soucie, J. Michael
   Yeung, Cindy
   Iorio, Alfonso
   Schunemann, Holger
TI NHF-MCMASTER GUIDELINE ON CARE MODELS FOR HEMOPHILIA MANAGEMENT
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Pai, Menaka; Iorio, Alfonso] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Key, Nigel] Univ N Carolina, Chapel Hill, NC USA.
   [Skinner, Mark] Inst Policy Adv Ltd, Washington, DC USA.
   [Kessler, Craig] Georgetown Univ, Washington, DC USA.
   [Curtis, Randall] Factor VIII Comp, Berkeley, CA USA.
   [Pai, Menaka] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   [Feinstein, Marla] Natl Hemophilia Fdn, New York, NY USA.
   [Riker, Ellen] CRD Associates, Washington, DC USA.
   [Santesso, Nancy; Yeung, Cindy; Iorio, Alfonso; Schunemann, Holger] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
   [Lane, Shannon] McMaster Univ, McMaster Ctr Transfus Res, Hamilton, ON, Canada.
   [Soucie, J. Michael] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA.
   [Makris, Michael] Univ Sheffield, Sheffield, S Yorkshire, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA F69
BP E428
EP E429
PG 2
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100146
ER

PT J
AU Payne, AB
   Ghaji, N
   Mehal, JM
   Holman, RC
   Soucie, JM
   Hooper, WC
AF Payne, Amanda B.
   Ghaji, Nafisa
   Mehal, Jason M.
   Holman, Robert C.
   Soucie, J. Michael
   Hooper, W. Craig
TI MORTALITY TRENDS AND CAUSES OF DEATH IN PERSONS WITH HEMOPHILIA, UNITED
   STATES, 1999-2010
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Payne, Amanda B.; Ghaji, Nafisa; Soucie, J. Michael; Hooper, W. Craig] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Mehal, Jason M.; Holman, Robert C.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA F38
BP E413
EP E414
PG 2
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100116
ER

PT J
AU Sidonio, RF
   Barry, V
   Byams, V
   Debaun, M
   Lollar, J
AF Sidonio, Robert F., Jr.
   Barry, Vaughn
   Byams, Vanessa
   Debaun, Michael
   Lollar, John
CA HTC Network
TI REPORTED BLEEDING AMONG FEMALES WITH FVIII OR FIX DEFICIENCY AND TYPE 1
   VON WILLEBRAND DISEASE: RESULTS FROM THE FEMALE UDC
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Sidonio, Robert F., Jr.; Barry, Vaughn; Lollar, John] Emory Univ, Atlanta, GA 30322 USA.
   [Byams, Vanessa; HTC Network] CDC, Div Blood Disorders, Atlanta, GA 30333 USA.
   [Debaun, Michael] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA F50
BP E420
EP E420
PG 1
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100128
ER

PT J
AU Tobase, P
   Lane, H
   Siddiqi, AEA
   Soucie, JM
   Ingram-Rich, R
   Ward, RS
AF Tobase, Patricia
   Lane, Heidi
   Siddiqi, Azfar-E-Alam
   Soucie, J. Michael
   Ingram-Rich, Robina
   Ward, R. Scott
CA Hemophilia Treatment Ctr Network
TI RISK FACTORS ASSOCIATED WITH INVASIVE ORTHOPEDIC INTERVENTIONS IN MALES
   WITH HEMOPHILIA ENROLLED IN THE UNIVERSAL DATA COLLECTION (UDC) PROGRAM
   FROM 2000-2010.
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Tobase, Patricia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Lane, Heidi] Primary Childrens Med Ctr, Intermt Hemophilia Thrombosis Ctr, Salt Lake City, UT USA.
   [Siddiqi, Azfar-E-Alam; Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA.
   [Ingram-Rich, Robina] Oregon Hlth & Sci Univ, Hemophilia, Portland, OR 97201 USA.
   [Ward, R. Scott] Univ Utah, Coll Hlth, Dept Phys Therapy, Salt Lake City, UT USA.
   [Hemophilia Treatment Ctr Network] Hemophilia Treatment Ctr Network Study, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2016
VL 91
IS 9
MA F51
BP E420
EP E421
PG 2
WC Hematology
SC Hematology
GA DY6LT
UT WOS:000385237100129
ER

PT J
AU Dong, J
   Ma, Q
AF Dong, Jie
   Ma, Qiang
TI In vivo activation of a T helper 2-driven innate immune response in lung
   fibrosis induced by multi-walled carbon nanotubes
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Multi-walled carbon nanotubes; Th2-type response; Pulmonary fibrosis;
   IL-4; IL-13
ID PULMONARY TOXICITY; FIBROTIC DISEASE; VITRO TOXICITY; MECHANISMS;
   INFLAMMATION; MICE; MESOTHELIOMA; INHALATION
AB Pulmonary exposure to certain forms of carbon nanotubes (CNT) induces fibrosing lesions in the lungs that manifest an acute inflammation followed by chronic interstitial fibrosis. The mechanism of CNT-induced fibrogenesis is largely unknown. The biphasic development with drastically distinct pathologic manifestations suggests a junction of acute-to-chronic transition. Here we analyzed the molecular pathways and regulators underlying the pathologic development of CNT-induced lung fibrosis. Mice were exposed to multi-walled CNT (MWCNT; XNRI MWNT-7, Mitsui; 40 mu g) by pharyngeal aspiration for 7 days along with vehicle and carbonaceous controls. Genome-wide microarray analyses of the lungs identified a range of differentially expressed genes that potentially function in the acute-to-chronic transition through pathways involving immune and inflammatory regulation, responses to stress and extracellular stimuli, and cell migration and adhesion. In particular, a T helper 2 (Th2)-driven innate immune response was significantly enriched. We then demonstrated that MWCNT induced the expression of Th2 cytokines interleukin (IL)-4 and IL-13, and a panel of signature downstream genes, such as Il4i1, Chia, and Ccl11/Eotaxin, time dependently. Induction of Th2 cytokines took place in CD4+ T lymphocytes indicating activation of Th2 cells. Furthermore, induction involved activation of a Th2 cell-specific signaling pathway through phosphorylation of STAT6 and up-regulation of GATA-3 to mediate the transcription of Th2 target genes. Our study uncovers activation of a Th2-driven immune/inflammatory response during pulmonary fibrosis development induced by MWCNT. The findings provide novel insights into the molecular events that control the transition from an acute inflammatory response to chronic fibrosis through Th2 functions in CNT-exposed lungs.
C1 [Dong, Jie; Ma, Qiang] Ctr Dis Control & Prevent, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,NIOSH, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.
RP Ma, Q (reprint author), Ctr Dis Control & Prevent, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,NIOSH, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.
EM qam1@cdc.gov
FU National Institute for Occupational Safety and Health, Health Effects
   Laboratory Division; National Institute for Occupational Safety and
   Health, Nanotechnology Research Center
FX This work was funded to QM by National Institute for Occupational Safety
   and Health, Health Effects Laboratory Division and Nanotechnology
   Research Center.
NR 30
TC 4
Z9 4
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD SEP
PY 2016
VL 90
IS 9
BP 2231
EP 2248
DI 10.1007/s00204-016-1711-1
PG 18
WC Toxicology
SC Toxicology
GA DZ2DR
UT WOS:000385653000012
PM 27106021
ER

PT J
AU van Beek, J
   de Graaf, M
   Xia, M
   Jiang, X
   Vinje, J
   Beersma, M
   de Bruin, E
   van de Vijver, D
   Holwerda, M
   van Houten, M
   Buisman, AM
   van Binnendijk, R
   Osterhaus, ADME
   van der Klis, F
   Vennema, H
   Koopmans, MPG
AF van Beek, Janko
   de Graaf, Miranda
   Xia, Ming
   Jiang, Xi
   Vinje, Jan
   Beersma, Mathias
   de Bruin, Erwin
   van de Vijver, David
   Holwerda, Melle
   van Houten, Marlies
   Buisman, Annemarie M.
   van Binnendijk, Rob
   Osterhaus, Albert D. M. E.
   van der Klis, Fiona
   Vennema, Harry
   Koopmans, Marion P. G.
TI Comparison of norovirus genogroup I, II and IV seroprevalence among
   children in the Netherlands, 1963, 1983 and 2006
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID VIRUS-LIKE PARTICLES; PROTEIN MICROARRAY; INFLUENZA-VIRUSES;
   IMMUNE-RESPONSES; CAPSID PROTEINS; GASTROENTERITIS; ANTIBODIES;
   INFECTION; POPULATION; PREVALENCE
AB Noroviruses are a major cause of acute gastroenteritis worldwide and are a genetically diverse group of viruses. Since 2002, an increasing number of norovirus outbreaks have been reported globally, but it is not clear whether this increase has been caused by a higher awareness or reflects the emergence of new genogroup II genotype 4 (GII.4) variants. The hypothesis that norovirus prevalence has increased post-2002 and is related to the emergence of GII.4 is tested in this study. Sera collected from children aged <5 years of three Dutch cross-sectional population based cohorts in 1963, 1983 and 2006/2007 (n = 143, n = 130 and n = 376, respectively) were tested for specific serum IgG by protein array using antigens to GII.4 and a range of other antigens representing norovirus GI, GII and GIV genotypes. The protein array was validated by paired sera of norovirus infected patients and supernatants of B-cell cultures with single epitope specificity. Evidence for norovirus infection was found to be common among Dutch children in each cohort, but the prevalence towards different genotypes changed over time. At the genogroup level, GI seroprevalence decreased significantly between 1963 and 2006/2007, while a significant increase of GII and, in particular, specific antibodies of the genotype GII.4 was detected in the 2006/2007 cohort. There were no children with only GII.4 antibodies in the 1963 cohort. This study shows that the high GII.4 norovirus incidence in very young children is a recent phenomenon. These findings are of importance for vaccine development and trials that are currently focusing mostly on GII.4 viruses.
C1 [van Beek, Janko; Beersma, Mathias; de Bruin, Erwin; van de Vijver, David; Osterhaus, Albert D. M. E.; Koopmans, Marion P. G.] Erasmus MC, Dept Virosci, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.
   [van Beek, Janko; de Graaf, Miranda; de Bruin, Erwin; Holwerda, Melle; Buisman, Annemarie M.; van Binnendijk, Rob; van der Klis, Fiona; Vennema, Harry; Koopmans, Marion P. G.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Res Diagnost & Screening, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
   [Xia, Ming; Jiang, Xi] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [van Houten, Marlies] Spaarne Hosp Hoofddorp, Dept Pediat, Hoofddorp, Netherlands.
RP Koopmans, MPG (reprint author), Erasmus MC, Dept Virosci, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.; Koopmans, MPG (reprint author), Natl Inst Publ Hlth & Environm, Ctr Infect Dis Res Diagnost & Screening, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
EM m.koopmans@erasmusmc.nl
FU EU H2020 grant COMPARE [643476]; Virgo Consortium - Dutch government
   [FES0908]
FX We thank Ilse Zutt, Hinke ten Hulscher and Gert-Jan Godeke for excellent
   technical laboratory support. This study was supported by the EU H2020
   grant COMPARE under grant agreement number 643476 and the Virgo
   Consortium, funded by the Dutch government, project number FES0908. The
   findings and conclusions in this article are those of the authors and do
   not necessarily represent the official position of the Centers for
   Disease Control and Prevention (CDC) or the institutions with which the
   authors are affiliated.
NR 34
TC 1
Z9 1
U1 2
U2 2
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 2016
VL 97
BP 2255
EP 2264
DI 10.1099/jgv.0.000533
PN 9
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA DY7EF
UT WOS:000385291700022
PM 27365054
ER

PT J
AU Karandikar, UC
   Crawford, SE
   Ajami, NJ
   Murakami, K
   Kou, BJ
   Ettayebi, K
   Papanicolaou, GA
   Jongwutiwes, U
   Perales, MA
   Shia, JR
   Mercer, D
   Finegold, MJ
   Vinje, J
   Atmar, RL
   Estes, MK
AF Karandikar, Umesh C.
   Crawford, Sue E.
   Ajami, Nadim J.
   Murakami, Kosuke
   Kou, Baijun
   Ettayebi, Khalil
   Papanicolaou, Genovefa A.
   Jongwutiwes, Ubonvan
   Perales, Miguel-Angel
   Shia, Jinru
   Mercer, David
   Finegold, Milton J.
   Vinje, Jan
   Atmar, Robert L.
   Estes, Mary K.
TI Detection of human norovirus in intestinal biopsies from
   immunocompromised transplant patients
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID INFECTIOUS NONBACTERIAL GASTROENTERITIS; STEM-CELL TRANSPLANTATION;
   EPITHELIAL-CELLS; NORWALK VIRUS; UNITED-STATES; HAWAII AGENT;
   HISTOPATHOLOGY; RECIPIENTS; FAILURE; LESION
AB Human noroviruses (HuNoVs) can often cause chronic infections in solid organ and haematopoietic stem cell transplant (HSCT) patients. Based on histopathological changes observed during HuNoV infections, the intestine is the presumed site of virus replication in patients; however, the cell types infected by HuNoVs remain unknown. The objective of this study was to characterize histopathological changes during HuNoV infection and to determine the cell types that may be permissive for HuNoV replication in transplant patients. We analysed biopsies from HuNoV-infected and non-infected (control) transplant patients to assess histopathological changes in conjunction with detection of HuNoV antigens to identify the infected cell types. HuNoV infection in immunocompromised patients was associated with histopathological changes such as disorganization and flattening of the intestinal epithelium. The HuNoV major capsid protein, VP1, was detected in all segments of the small intestine, in areas of biopsies that showed histopathological changes. Specifically, VP1 was detected in enterocytes, macrophages, T cells and dendritic cells. HuNoV replication was investigated by detecting the non-structural proteins, RdRp and VPg. We detected RdRp and VPg along with VP1 in duodenal and jejunal enterocytes. These results provide critical insights into histological changes due to HuNoV infection in immunocompromised patients and propose human enterocytes as a physiologically relevant cell type for HuNoV cultivation.
C1 [Karandikar, Umesh C.; Crawford, Sue E.; Ajami, Nadim J.; Murakami, Kosuke; Kou, Baijun; Ettayebi, Khalil; Atmar, Robert L.; Estes, Mary K.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Papanicolaou, Genovefa A.; Jongwutiwes, Ubonvan] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis & Adult Bone Marrow Transplant Serv, New York, NY 10065 USA.
   [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA.
   [Perales, Miguel-Angel] Weill Cornell Med Coll, New York, NY USA.
   [Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
   [Mercer, David] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68198 USA.
   [Finegold, Milton J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Finegold, Milton J.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
   [Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
   [Atmar, Robert L.; Estes, Mary K.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Estes, MK (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.; Estes, MK (reprint author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
EM mestes@bcm.edu
FU Public Health Service [NIH P01 AI057788, NIH P30 DK56338, P30 CA125123];
   Agriculture and Food Research Initiative competitive grant from the USDA
   National Institute of Food and Agriculture [2011-68003-30395]; John S.
   Dunn Research Foundation; Texas Medical Center Digestive Diseases Center
   [P30 DK-56338]
FX Authors would like to thank Sasirekha Ramani (Dept MVM, BCM) for her
   critical reading of the manuscript and Pamela Parsons (Cellular and
   Molecular Morphology Core) for her technical assistance. This research
   was funded in part by Public Health Service grants NIH P01 AI057788, NIH
   P30 DK56338 and P30 CA125123; by Agriculture and Food Research
   Initiative competitive grant 2011-68003-30395 from the USDA National
   Institute of Food and Agriculture and by the John S. Dunn Research
   Foundation. Sectioning and Imaging in the Cellular Molecular Morphology
   Core was supported by P30 DK-56338, which funds the Texas Medical Center
   Digestive Diseases Center. The findings and conclusions in this article
   are those of the authors and do not necessarily represent the official
   position of the Centers for Disease Control and Prevention.
NR 38
TC 2
Z9 2
U1 3
U2 3
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 2016
VL 97
BP 2291
EP 2300
DI 10.1099/jgv.0.000545
PN 9
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA DY7EF
UT WOS:000385291700025
PM 27412790
ER

PT J
AU Laprise, JF
   Markowitz, LE
   Chesson, HW
   Drolet, M
   Brisson, M
AF Laprise, Jean-Francois
   Markowitz, Lauri E.
   Chesson, Harrell W.
   Drolet, Melanie
   Brisson, Marc
TI Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine
   Schedules in the United States: A Cost-effectiveness Analysis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE human papillomavirus (HPV); HPV vaccination; cost-effectiveness;
   transmission-dynamic modeling
ID HPV VACCINE; LONG-TERM; IMMUNOGENICITY; ADOLESCENTS; EFFICACY; COVERAGE;
   SAFETY; WOMEN
AB A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model to compare the population-level effectiveness and cost-effectiveness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States. Our model predicts that if 2 doses of 9-valent vaccine protect for a parts per thousand yen20 years, the additional benefits of a 3-dose schedule are small as compared to those of 2-dose schedules, and 2-dose schedules are likely much more cost-efficient than 3-dose schedules.
C1 [Laprise, Jean-Francois; Drolet, Melanie; Brisson, Marc] Univ Laval, CHU Quebec, Ctr Rech, Axe Sante Populat & Prat Optimales Sante, Quebec City, PQ, Canada.
   [Markowitz, Lauri E.; Chesson, Harrell W.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Brisson, Marc] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada.
   [Brisson, Marc] Imperial Coll, Dept Infect Dis Epidemiol, London, England.
RP Brisson, M (reprint author), Univ Laval, CHU Quebec, Axe Sante Populat & Prat Optimales Sante, Hop St Sacrement, 1050 Chemin St Foy, Quebec City, PQ G1S 4L8, Canada.
EM marc.brisson@uresp.ulaval.ca
FU CDC [00HCVJDC-2014-77287]; Canada Research Chairs program; Canadian
   Institutes of Health Research [FDN-143283]
FX This work was supported by the CDC (contract 00HCVJDC-2014-77287), the
   Canada Research Chairs program (support to M. B.), and the Canadian
   Institutes of Health Research (Foundation scheme grant FDN-143283).
NR 15
TC 5
Z9 5
U1 3
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2016
VL 214
IS 5
BP 685
EP 688
DI 10.1093/infdis/jiw227
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DY7YY
UT WOS:000385346400005
PM 27234416
ER

PT J
AU Meites, E
   Gorbach, PM
   Gratzer, B
   Panicker, G
   Steinau, M
   Collins, T
   Parrish, A
   Randel, C
   McGrath, M
   Carrasco, S
   Moore, J
   Zaidi, A
   Braxton, J
   Kerndt, PR
   Unger, ER
   Crosby, RA
   Markowitz, LE
AF Meites, Elissa
   Gorbach, Pamina M.
   Gratzer, Beau
   Panicker, Gitika
   Steinau, Martin
   Collins, Tom
   Parrish, Adam
   Randel, Cody
   McGrath, Mark
   Carrasco, Steven
   Moore, Janell
   Zaidi, Akbar
   Braxton, Jim
   Kerndt, Peter R.
   Unger, Elizabeth R.
   Crosby, Richard A.
   Markowitz, Lauri E.
TI Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual,
   and Other Men Who Have Sex With Men-United States, 2012-2014
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE epidemiological monitoring; homosexuality; male; papillomavirus
   infections; papillomavirus vaccines
ID HIV-INFECTED MSM; QUADRIVALENT HPV VACCINE; COST-EFFECTIVENESS;
   IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RISK-FACTORS; PREVALENCE;
   PROGRAMS; CANCER; RECOMMENDATIONS
AB Background. Gay, bisexual, and other men who have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommended for US males, including MSM through age 26 years. We assessed evidence of HPV among vaccine- eligible MSM and transgender women to monitor vaccine impact.
   Methods.aEuro integral During 2012-2014, MSM aged 18-26 years at select clinics completed a computer-assisted self-interview regarding sexual behavior, human immunodeficiency virus (HIV) status, and vaccinations. Self-collected anal swab and oral rinse specimens were tested for HPV DNA (37 types) by L1 consensus polymerase chain reaction; serum was tested for HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assay.
   Results.aEuro integral Among 922 vaccine-eligible participants, the mean age was 23 years, and the mean number of lifetime sex partners was 37. Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%, yet only 8.5% had evidence of exposure to all quadrivalent vaccine types. In multivariate analysis, HPV prevalence varied significantly (P < .05) by HIV status, sexual orientation, and lifetime number of sex partners, but not by race/ethnicity.
   Discussions.aEuro integral Most young MSM lacked evidence of current or past infection with all vaccine-type HPV types, suggesting that they could benefit from vaccination. The impact of vaccination among MSM may be assessed by monitoring HPV prevalence, including in self-collected specimens.
C1 [Meites, Elissa; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30329 USA.
   [Panicker, Gitika; Steinau, Martin; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Zaidi, Akbar; Braxton, Jim] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Gorbach, Pamina M.; McGrath, Mark; Carrasco, Steven; Moore, Janell; Kerndt, Peter R.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
   [Gratzer, Beau; Randel, Cody] Howard Brown Hlth, Chicago, IL USA.
   [Collins, Tom; Parrish, Adam; Crosby, Richard A.] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA.
RP Meites, E (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30329 USA.
EM emeites@cdc.gov
OI Meites, Elissa/0000-0002-0077-2591
FU CDC
FX This work was supported by the CDC.
NR 50
TC 0
Z9 0
U1 7
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2016
VL 214
IS 5
BP 689
EP 696
DI 10.1093/infdis/jiw232
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DY7YY
UT WOS:000385346400006
PM 27296847
ER

PT J
AU Assiri, AM
   Midgley, CM
   Abedi, GR
   Bin Saeed, A
   Almasri, MM
   Lu, XY
   Al-Abdely, HM
   Abdalla, O
   Mohammed, M
   Algarni, HS
   Alhakeem, RF
   Sakthivel, SK
   Nooh, R
   Alshayab, Z
   Alessa, M
   Srinivasamoorthy, G
   AlQahtani, SY
   Kheyami, A
   HajOmar, WH
   Banaser, TM
   Esmaeel, A
   Hall, AJ
   Curns, AT
   Tamin, A
   Alsharef, AA
   Erdman, D
   Watson, JT
   Gerber, SI
AF Assiri, Abdullah M.
   Midgley, Claire M.
   Abedi, Glen R.
   Bin Saeed, Abdulaziz
   Almasri, Malak M.
   Lu, Xiaoyan
   Al-Abdely, Hail M.
   Abdalla, Osman
   Mohammed, Mutaz
   Algarni, Homoud S.
   Alhakeem, Raafat F.
   Sakthivel, Senthilkumar K.
   Nooh, Randa
   Alshayab, Zainab
   Alessa, Mohammad
   Srinivasamoorthy, Ganesh
   AlQahtani, Saeed Yahya
   Kheyami, Ali
   HajOmar, Waleed Husein
   Banaser, Talib M.
   Esmaeel, Ahmad
   Hall, Aron J.
   Curns, Aaron T.
   Tamin, Azaibi
   Alsharef, Ali Abraheem
   Erdman, Dean
   Watson, John T.
   Gerber, Susan I.
TI Epidemiology of a Novel Recombinant Middle East Respiratory Syndrome
   Coronavirus in Humans in Saudi Arabia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Middle East respiratory syndrome; MERS; coronavirus; MERS epidemiology;
   MERS transmission; MERS phylogeny; recombinant; Saudi Arabia
ID DROMEDARY CAMELS; MERS CORONAVIRUS; FAMILY CLUSTER; TRANSMISSION;
   INFECTIONS; EMERGENCE; OUTBREAK; COV; EVOLUTION; GENOTYPE
AB Background. Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory illness in humans. Fundamental questions about circulating viruses and transmission routes remain.
   Methods.aEuro integral We assessed routinely collected epidemiologic data for MERS-CoV cases reported in Saudi Arabia during 1 January-30 June 2015 and conducted a more detailed investigation of cases reported during February 2015. Available respiratory specimens were obtained for sequencing.
   Results.aEuro integral During the study period, 216 MERS-CoV cases were reported. Full genome (n = 17) or spike gene sequences (n = 82) were obtained from 99 individuals. Most sequences (72 of 99 [73%]) formed a discrete, novel recombinant subclade (NRC-2015), which was detected in 6 regions and became predominant by June 2015. No clinical differences were noted between clades. Among 87 cases reported during February 2015, 13 had no recognized risks for secondary acquisition; 12 of these 13 also denied camel contact. Most viruses (8 of 9) from these 13 individuals belonged to NRC-2015.
   Discussions.aEuro integral Our findings document the spread and eventual predominance of NRC-2015 in humans in Saudi Arabia during the first half of 2015. Our identification of cases without recognized risk factors but with similar virus sequences indicates the need for better understanding of risk factors for MERS-CoV transmission.
C1 [Assiri, Abdullah M.; Bin Saeed, Abdulaziz; Almasri, Malak M.; Al-Abdely, Hail M.; Abdalla, Osman; Mohammed, Mutaz; Algarni, Homoud S.; Alhakeem, Raafat F.; Nooh, Randa; Alshayab, Zainab; Alessa, Mohammad; AlQahtani, Saeed Yahya; Kheyami, Ali; HajOmar, Waleed Husein; Banaser, Talib M.; Esmaeel, Ahmad; Alsharef, Ali Abraheem] King Saud Med City, Minist Hlth, Riyadh, Saudi Arabia.
   [Bin Saeed, Abdulaziz] King Saud Med City, Dept Family & Community Med, Riyadh, Saudi Arabia.
   [Nooh, Randa; Alshayab, Zainab; Alessa, Mohammad] Minist Hlth, Field Epidemiol Training Program, Riyadh, Saudi Arabia.
   [Midgley, Claire M.; Abedi, Glen R.; Lu, Xiaoyan; Sakthivel, Senthilkumar K.; Srinivasamoorthy, Ganesh; Hall, Aron J.; Curns, Aaron T.; Tamin, Azaibi; Erdman, Dean; Watson, John T.; Gerber, Susan I.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Midgley, Claire M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.
RP Midgley, CM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM ydk5@cdc.gov
FU Saudi Arabia Ministry of Health; CDC
FX This work was supported by the Saudi Arabia Ministry of Health and the
   CDC as part of an emergency response.
NR 42
TC 3
Z9 3
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2016
VL 214
IS 5
BP 712
EP 721
DI 10.1093/infdis/jiw236
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DY7YY
UT WOS:000385346400009
PM 27302191
ER

PT J
AU Bowen, MD
   Mijatovic-Rustempasic, S
   Esona, MD
   Teel, EN
   Gautam, R
   Sturgeon, M
   Azimi, PH
   Baker, CJ
   Bernstein, DI
   Boom, JA
   Chappell, J
   Donauer, S
   Edwards, KM
   Englund, JA
   Halasa, NB
   Harrison, CJ
   Johnston, SH
   Klein, EJ
   McNeal, MM
   Moffatt, ME
   Rench, MA
   Sahni, LC
   Selvarangan, R
   Staat, MA
   Szilagyi, PG
   Weinberg, GA
   Wikswo, ME
   Parashar, UD
   Payne, DC
AF Bowen, Michael D.
   Mijatovic-Rustempasic, Slavica
   Esona, Mathew D.
   Teel, Elizabeth N.
   Gautam, Rashi
   Sturgeon, Michele
   Azimi, Parvin H.
   Baker, Carol J.
   Bernstein, David I.
   Boom, Julie A.
   Chappell, James
   Donauer, Stephanie
   Edwards, Kathryn M.
   Englund, Janet A.
   Halasa, Natasha B.
   Harrison, Christopher J.
   Johnston, Samantha H.
   Klein, Eileen J.
   McNeal, Monica M.
   Moffatt, Mary E.
   Rench, Marcia A.
   Sahni, Leila C.
   Selvarangan, Rangaraj
   Staat, Mary A.
   Szilagyi, Peter G.
   Weinberg, Geoffrey A.
   Wikswo, Mary E.
   Parashar, Umesh D.
   Payne, Daniel C.
TI Rotavirus Strain Trends During the Postlicensure Vaccine Era: United
   States, 2008-2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE rotavirus; genotype; prevalence; surveillance; vaccine
ID REASSORTANT ROTAVIRUS; CHILDREN; GASTROENTERITIS; SURVEILLANCE;
   GENOTYPES; ROTATEQ; DIVERSITY; DISEASE; PENTAVALENT; PREVALENCE
AB Background. Group A rotaviruses (RVA) are a significant cause of pediatric gastroenteritis worldwide. The New Vaccine Surveillance Network (NVSN) has conducted active surveillance for RVA at pediatric hospitals and emergency departments at 3- 7 geographically diverse sites in the United States since 2006.
   Methods.aEuro integral Over 6 consecutive years, from 2008 to 2013, 1523 samples from NVSN sites that were tested positive by a Rotaclone enzyme immunoassay were submitted to the Centers for Disease Control and Prevention for genotyping.
   Results.aEuro integral In the 2009, 2010, and 2011 seasons, genotype G3P[8] was the predominant genotype throughout the network, with a 46%-84% prevalence. In the 2012 season, G12P[8] replaced G3P[8] as the most common genotype, with a 70% prevalence, and this trend persisted in 2013 (68.0% prevalence). Vaccine (RotaTeq; Rotarix) strains were detected in 0.6%-3.4% of genotyped samples each season. Uncommon and unusual strains (eg, G8P[4], G3P[24], G2P[8], G3P[4], G3P[6], G24P[14], G4P[6], and G9P[4]) were detected sporadically over the study period. Year, study site, and race were found to be significant predictors of genotype.
   Conclusions.aEuro integral Continued active surveillance is needed to monitor RVA genotypes in the United States and to detect potential changes since vaccine licensure.
C1 [Bowen, Michael D.; Mijatovic-Rustempasic, Slavica; Esona, Mathew D.; Teel, Elizabeth N.; Gautam, Rashi; Sturgeon, Michele; Wikswo, Mary E.; Parashar, Umesh D.; Payne, Daniel C.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop G-04, Atlanta, GA 30329 USA.
   [Azimi, Parvin H.; Johnston, Samantha H.] UCSF Benioff Childrens Hosp Oakland, Oakland, CA USA.
   [Szilagyi, Peter G.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
   [Baker, Carol J.; Boom, Julie A.; Rench, Marcia A.; Sahni, Leila C.] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Baker, Carol J.; Boom, Julie A.; Rench, Marcia A.] Baylor Coll Med, Houston, TX 77030 USA.
   [Bernstein, David I.; Donauer, Stephanie; McNeal, Monica M.; Staat, Mary A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Chappell, James; Edwards, Kathryn M.; Halasa, Natasha B.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Englund, Janet A.; Klein, Eileen J.] Seattle Childrens Hosp, Washington, DC USA.
   [Harrison, Christopher J.; Moffatt, Mary E.; Selvarangan, Rangaraj] Childrens Mercy Hosp & Clin, Kansas City, MO USA.
   [Weinberg, Geoffrey A.] Univ Rochester, Sch Med & Dent, New York, NY USA.
RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop G-04, Atlanta, GA 30329 USA.
EM mkb6@cdc.gov
FU CDC
FX This work was supported by the CDC.
NR 45
TC 1
Z9 1
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2016
VL 214
IS 5
BP 732
EP 738
DI 10.1093/infdis/jiw233
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DY7YY
UT WOS:000385346400011
PM 27302190
ER

PT J
AU Lee, S
   Nguyen, MT
   Currier, MG
   Jenkins, JB
   Strobert, EA
   Kajon, AE
   Madan-Lala, R
   Bochkov, YA
   Gern, JE
   Roy, K
   Lu, XY
   Erdman, DD
   Spearman, P
   Moore, ML
AF Lee, Sujin
   Minh Trang Nguyen
   Currier, Michael G.
   Jenkins, Joe B.
   Strobert, Elizabeth A.
   Kajon, Adriana E.
   Madan-Lala, Ranjna
   Bochkov, Yury A.
   Gern, James E.
   Roy, Krishnendu
   Lu, Xiaoyan
   Erdman, Dean D.
   Spearman, Paul
   Moore, Martin L.
TI A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in
   rhesus macaques
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PNEUMONIA REQUIRING HOSPITALIZATION; RESPIRATORY-TRACT INFECTIONS;
   NEUTRALIZING ANTIBODY; ILLNESS; RESPONSES; STRATEGIES; GENOTYPE;
   CHILDREN; ADULTS
AB As the predominant aetiological agent of the common cold, human rhinovirus (HRV) is the leading cause of human infectious disease. Early studies showed that a monovalent formalin-inactivated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with protection. However, co-circulation of many HRV types discouraged further vaccine efforts. Here, we test the hypothesis that increasing virus input titres in polyvalent inactivated HRV vaccine may result in broad nAb responses. We show that serum nAb against many rhinovirus types can be induced by polyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant. Using formulations up to 25-valent in mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantity of input antigens, and valency was not a major factor for potency or breadth of the response. Thus, we have generated a vaccine capable of inducing nAb responses to numerous and diverse HRV types.
C1 [Lee, Sujin; Minh Trang Nguyen; Currier, Michael G.; Spearman, Paul; Moore, Martin L.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
   [Lee, Sujin; Minh Trang Nguyen; Currier, Michael G.; Spearman, Paul; Moore, Martin L.] Childrens Healthcare Atlanta, Atlanta, GA 30322 USA.
   [Jenkins, Joe B.; Strobert, Elizabeth A.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
   [Kajon, Adriana E.] Lovelace Resp Res Inst, Program Infect Dis, Albuquerque, NM 87108 USA.
   [Madan-Lala, Ranjna; Roy, Krishnendu] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
   [Bochkov, Yury A.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA.
   [Gern, James E.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA.
   [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
RP Moore, ML (reprint author), Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.; Moore, ML (reprint author), Childrens Healthcare Atlanta, Atlanta, GA 30322 USA.
EM martin.moore@emory.edu
OI Bochkov, Yury/0000-0003-2618-4496
FU Emory + Children's Center for Childhood Infections and Vaccines (CCIV);
   Department of Health and Human Services, National Institutes of Health
   [1R01AI087798, 1U19AI095227]
FX We are indebted to the Yerkes veterinary personnel for providing
   technical assistance. We thank the Children's Healthcare of Atlanta and
   Emory University Pediatrics Biostatistics Core for assistance with
   statistical analyses. We thank Max Cooper (Emory University) and Joshy
   Jacob (Emory University) for helpful discussions. This study was
   supported by a pilot grant from the Emory + Children's Center for
   Childhood Infections and Vaccines (CCIV) to M.L.M and in part by
   Department of Health and Human Services, National Institutes of Health
   grants 1R01AI087798 and 1U19AI095227 to M.L.M. This work is dedicated to
   'A.R.'.
NR 38
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP
PY 2016
VL 7
AR 12838
DI 10.1038/ncomms12838
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DY8FA
UT WOS:000385363000006
PM 27653379
ER

PT J
AU Wang, S
   Wang, S
   Luo, YF
   Xiao, LH
   Luo, XN
   Gao, SH
   Dou, YX
   Zhang, HK
   Guo, AJ
   Meng, QS
   Hou, JL
   Zhang, B
   Zhang, SH
   Yang, M
   Meng, XL
   Mei, HL
   Li, H
   He, ZL
   Zhu, XL
   Tan, XY
   Zhu, XQ
   Yu, J
   Cai, JP
   Zhu, G
   Hu, SN
   Cai, XP
AF Wang, Shuai
   Wang, Sen
   Luo, Yingfeng
   Xiao, Lihua
   Luo, Xuenong
   Gao, Shenghan
   Dou, Yongxi
   Zhang, Huangkai
   Guo, Aijiang
   Meng, Qingshu
   Hou, Junling
   Zhang, Bing
   Zhang, Shaohua
   Yang, Meng
   Meng, Xuelian
   Mei, Hailiang
   Li, Hui
   He, Zilong
   Zhu, Xueliang
   Tan, Xinyu
   Zhu, Xing-quan
   Yu, Jun
   Cai, Jianping
   Zhu, Guan
   Hu, Songnian
   Cai, Xuepeng
TI Comparative genomics reveals adaptive evolution of Asian tapeworm in
   switching to a new intermediate host
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ECHINOCOCCUS-GRANULOSUS; TAENIA-ASIATICA; MAXIMUM-LIKELIHOOD; GENE
   DUPLICATION; MODERN HUMANS; ANTIGEN-B; ALIGNMENT; PARASITE; SEQUENCE;
   ORIGINS
AB Taenia saginata, Taenia solium and Taenia asiatica (beef, pork and Asian tapeworms, respectively) are parasitic flatworms of major public health and food safety importance. Among them, T. asiatica is a newly recognized species that split from T. saginata via an intermediate host switch similar to 1.14 Myr ago. Here we report the 169- and 168-Mb draft genomes of T. saginata and T. asiatica. Comparative analysis reveals that high rates of gene duplications and functional diversifications might have partially driven the divergence between T. asiatica and T. saginata. We observe accelerated evolutionary rates, adaptive evolutions in homeostasis regulation, tegument maintenance and lipid uptakes, and differential/specialized gene family expansions in T. asiatica that may favour its hepatotropism in the new intermediate host. We also identify potential targets for developing diagnostic or intervention tools against human tapeworms. These data provide new insights into the evolution of Taenia parasites, particularly the recent speciation of T. asiatica.
C1 [Wang, Shuai; Luo, Xuenong; Dou, Yongxi; Guo, Aijiang; Hou, Junling; Zhang, Shaohua; Meng, Xuelian; Li, Hui; Zhu, Xueliang; Zhu, Xing-quan; Cai, Jianping; Cai, Xuepeng] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Key Lab Vet Parasitol Gansu Prov, State Key Lab Vet Etiol Biol, Lanzhou 730046, Gansu, Peoples R China.
   [Wang, Sen; Luo, Yingfeng; Gao, Shenghan; Zhang, Huangkai; Meng, Qingshu; Zhang, Bing; Yang, Meng; Mei, Hailiang; He, Zilong; Tan, Xinyu; Yu, Jun; Hu, Songnian] Chinese Acad Sci, CAS Key Lab Genome Sci & Informat, Beijing Inst Genom, Beijing 100101, Peoples R China.
   [Wang, Sen; Zhang, Huangkai] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA.
   [Zhang, Bing] Chinese Acad Sci, Core Genom Facil, Beijing Inst Genom, Beijing 100101, Peoples R China.
   [Zhu, Guan] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.
RP Cai, XP (reprint author), Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Key Lab Vet Parasitol Gansu Prov, State Key Lab Vet Etiol Biol, Lanzhou 730046, Gansu, Peoples R China.; Hu, SN (reprint author), Chinese Acad Sci, CAS Key Lab Genome Sci & Informat, Beijing Inst Genom, Beijing 100101, Peoples R China.; Zhu, G (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.
EM gzhu@cvm.tamu.edu; husn@big.ac.cn; caixuepeng@caas.cn
FU National Key Basic Research Program (973 Program) of China
   [2015CB150300]; International Science & Technology Cooperation Program
   of China' [2013DFA31840]; State Key Laboratory of Veterinary Etiological
   Biology of Lanzhou Veterinary Research Institute, Chinese Academy of
   Agricultural Sciences
FX We thank H. Li from Dali University for providing parasite material; Y.
   Liu, M. Sun, W. Li, J. Yang and S. Li from Beijing Institute of
   Genomics, Chinese Academy of Sciences for preparing genomic DNA,
   constructing libraries and generating raw sequencing reads; and Y. Zheng
   for helpful discussions. This work was funded by the 'National Key Basic
   Research Program (973 Program) of China' (grant no. 2015CB150300),
   'International Science & Technology Cooperation Program of China' (grant
   no. 2013DFA31840) and State Key Laboratory of Veterinary Etiological
   Biology of Lanzhou Veterinary Research Institute, Chinese Academy of
   Agricultural Sciences.
NR 70
TC 1
Z9 1
U1 8
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP
PY 2016
VL 7
AR 12845
DI 10.1038/ncomms12845
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DY8FA
UT WOS:000385363000013
PM 27653464
ER

PT J
AU Pazo, DY
   Moliere, F
   Sampson, MM
   Reese, CM
   Agnew-Heard, KA
   Walters, MJ
   Holman, MR
   Blount, BC
   Watson, CH
   Chambers, DM
AF Pazo, Daniel Y.
   Moliere, Fallon
   Sampson, Maureen M.
   Reese, Christopher M.
   Agnew-Heard, Kimberly A.
   Walters, Matthew J.
   Holman, Matthew R.
   Blount, Benjamin C.
   Watson, Clifford H.
   Chambers, David M.
TI Mainstream Smoke Levels of Volatile Organic Compounds in 50 US Domestic
   Cigarette Brands Smoked With the ISO and Canadian Intense Protocols
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID TOBACCO-SPECIFIC NITROSAMINES; COMMERCIAL CIGARETTES; BENZENE; MARKET
AB A significant portion of the increased risk of cancer and respiratory disease from exposure to cigarette smoke is attributed to volatile organic compounds (VOCs). In this study, 21 VOCs were quantified in mainstream cigarette smoke from 50U.S. domestic brand varieties that included high market share brands and 2 Kentucky research cigarettes (3R4F and 1R5F).
   Mainstream smoke was generated under ISO 3308 and Canadian Intense (CI) smoking protocols with linear smoking machines with a gas sampling bag collection followed by solid phase microextraction/gas chromatography/mass spectrometry (SPME/GC/MS) analysis.
   For both protocols, mainstream smoke VOC amounts among the different brand varieties were strongly correlated between the majority of the analytes. Overall, Pearson correlation (r) ranged from 0.68 to 0.99 for ISO and 0.36 to 0.95 for CI. However, monoaromatic compounds were found to increase disproportionately compared to unsaturated, nitro, and carbonyl compounds under the CI smoking protocol where filter ventilation is blocked.
   Overall, machine generated "vapor phase" amounts (A mu g/cigarette) are primarily attributed to smoking protocol (e.g., blocking of vent holes, puff volume, and puff duration) and filter ventilation. A possible cause for the disproportionate increase in monoaromatic compounds could be increased pyrolysis under low oxygen conditions associated with the CI protocol.
   This is the most comprehensive assessment of volatile organic compounds (VOCs) in cigarette smoke to date, encompassing 21 toxic VOCs, 50 different cigarette brand varieties, and 2 different machine smoking protocols (ISO and CI). For most analytes relative proportions remain consistent among U.S. cigarette brand varieties regardless of smoking protocol, however the CI smoking protocol did cause up to a factor of 6 increase in the proportion of monoaromatic compounds. This study serves as a basis to assess VOC exposure as cigarette smoke is a principle source of overall population-level VOC exposure in the United States.
C1 [Pazo, Daniel Y.; Moliere, Fallon; Sampson, Maureen M.; Reese, Christopher M.; Blount, Benjamin C.; Watson, Clifford H.; Chambers, David M.] US Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, 4770 Buford Highway,F-47, Atlanta, GA 30341 USA.
   [Agnew-Heard, Kimberly A.; Walters, Matthew J.; Holman, Matthew R.] US FDA, Off Sci, Ctr Tobacco Prod, Rockville, MD 20857 USA.
RP Chambers, DM (reprint author), US Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, 4770 Buford Highway,F-47, Atlanta, GA 30341 USA.
EM mzz7@cdc.gov
FU U.S. Food and Drug Administration Center for Tobacco Products [IAA:
   224-10-9022]
FX This study was funded by an interagency agreement (IAA) by the U.S. Food
   and Drug Administration Center for Tobacco Products (IAA: 224-10-9022).
NR 27
TC 1
Z9 1
U1 4
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD SEP
PY 2016
VL 18
IS 9
BP 1886
EP 1894
DI 10.1093/ntr/ntw118
PG 9
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA DZ1WE
UT WOS:000385631500012
PM 27113015
ER

PT J
AU Carias, AM
   Allen, SA
   Fought, AJ
   Halavaty, KK
   Anderson, MR
   Jimenez, ML
   McRaven, MD
   Gioia, CJ
   Henning, TR
   Kersh, EN
   Smith, JM
   Pereira, LE
   Butler, K
   McNicholl, SJM
   Hendry, RM
   Kiser, PF
   Veazey, RS
   Hope, TJ
AF Carias, Ann M.
   Allen, Shannon A.
   Fought, Angela J.
   Halavaty, Katarina Kotnik
   Anderson, Meegan R.
   Jimenez, Maria L.
   McRaven, Michael D.
   Gioia, Casey J.
   Henning, Tara R.
   Kersh, Ellen N.
   Smith, James M.
   Pereira, Lara E.
   Butler, Katherine
   McNicholl, S. Janet M.
   Hendry, R. Michael
   Kiser, Patrick F.
   Veazey, Ronald S.
   Hope, Thomas J.
TI Increases in Endogenous or Exogenous Progestins Promote Virus-Target
   Cell Interactions within the Non-human Primate Female Reproductive Tract
SO PLOS PATHOGENS
LA English
DT Article
ID DEPOT-MEDROXYPROGESTERONE ACETATE; HORMONAL CONTRACEPTIVE USE; HUMAN
   CERVICOVAGINAL MUCUS; NORMAL RHESUS MACAQUES; MENSTRUAL-CYCLE; HIV
   ACQUISITION; PIGTAIL MACAQUES; VAGINAL EPITHELIUM; SUSCEPTIBILITY
   FACTORS; LUTEAL-PHASE
AB Currently, there are mounting data suggesting that HIV-1 acquisition in women can be affected by the use of certain hormonal contraceptives. However, in non-human primate models, endogenous or exogenous progestin-dominant states are shown to increase acquisition. To gain mechanistic insights into this increased acquisition, we studied how mucosal barrier function and CD4+ T-cell and CD68+ macrophage density and localization changed in the presence of natural progestins or after injection with high-dose DMPA. The presence of natural or injected progestins increased virus penetration of the columnar epithelium and the infiltration of susceptible cells into a thinned squamous epithelium of the vaginal vault, increasing the likelihood of potential virus interactions with target cells. These data suggest that increasing either endogenous or exogenous progestin can alter female reproductive tract barrier properties and provide plausible mechanisms for increased HIV-1 acquisition risk in the presence of increased progestin levels.
C1 [Carias, Ann M.; Allen, Shannon A.; Halavaty, Katarina Kotnik; Anderson, Meegan R.; Jimenez, Maria L.; McRaven, Michael D.; Gioia, Casey J.; Kiser, Patrick F.; Hope, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.
   [Fought, Angela J.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Henning, Tara R.; Kersh, Ellen N.; Smith, James M.; Pereira, Lara E.; Butler, Katherine; McNicholl, S. Janet M.; Hendry, R. Michael] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Veazey, Ronald S.] Tulane Univ, Sch Med, Tulane Natl Primate Res Ctr, Covington, LA USA.
RP Hope, TJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.
EM thope@northwestern.edu
FU National Institute of Health [U19AI03461, R33 AI094584, RO1 AI094595]
FX These studies were partially supported by National Institute of Health
   grants U19AI03461 (TJH), R33 AI094584 (TJH) and RO1 AI094595 (TJH). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
NR 56
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2016
VL 12
IS 9
AR e1005885
DI 10.1371/journal.ppat.1005885
PG 21
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA DZ1TB
UT WOS:000385621900047
PM 27658293
ER

PT J
AU Chung, KW
   Basavaraju, SV
   Mu, Y
   van Santen, KL
   Haass, KA
   Henry, R
   Berger, J
   Kuehnert, MJ
AF Chung, Koo-Whang
   Basavaraju, Sridhar V.
   Mu, Yi
   van Santen, Katharina L.
   Haass, Kathryn A.
   Henry, Richard
   Berger, James
   Kuehnert, Matthew J.
TI Declining blood collection and utilization in the United States
SO TRANSFUSION
LA English
DT Article
ID BYPASS GRAFT-SURGERY; MULTIPLE IMPUTATION; CELL TRANSFUSION; PRODUCT
   TRANSFUSION; MANAGEMENT; COMPONENTS; OUTCOMES; DEMAND
AB BACKGROUND: The Department of Health and Human Services National Blood Collection and Utilization Survey (NBCUS) has been conducted biennially since 1997. Data are used to estimate national blood collection and utilization.
   STUDY DESIGN AND METHODS: The 2013 Department of Health and Human Services NBCUS is a cross-sectional survey of all US blood collection centers and hospitals as listed in the 2012 American Hospital Association Annual Survey database that perform at least 100 inpatient surgical procedures annually. The study objective was to estimate, with 95% confidence intervals (CIs), the number of blood and blood components collected and transfused in the United States.
   RESULTS: In 2013, a total of 14,237,000 whole blood and apheresis red blood cell (RBC) units (95% CI, 13,639,000-14,835,000) were collected with 13,395,000 available for transfusion. Of these, 13,180,000 (95% CI, 12,389,000-13,972,000) whole blood and RBC units were transfused. This represented a 4.4% decline in the number of transfused units compared to 2011. Outdated (i.e., expired without being transfused) whole blood and RBC units declined by 17.3%. Apheresis (2,318,000; 95% CI, 2,154,000-2,482,000) and whole blood-derived platelet (PLT; 130,000; 95% CI, 23,000-237,000) distribution declined in 2013. Total PLT transfusions increased in 2013 (2,281,000) in comparison to 2011 (2,169,000). Total plasma units distributed (4,338,000) and transfused (3,624,000) declined.
   CONCLUSION: Both blood collection and utilization have declined, but the gap between collection and utilization is narrowing. As collections decline further and hospitals decrease transfusions and manage products more efficiently, the decline in surplus inventory may be a concern for disaster preparedness or other unexpected utilization needs.
C1 [Chung, Koo-Whang; Basavaraju, Sridhar V.; Haass, Kathryn A.; Kuehnert, Matthew J.] US Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Atlanta, GA USA.
   [Mu, Yi; van Santen, Katharina L.] US Ctr Dis Control & Prevent, Surveillance Branch, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [van Santen, Katharina L.] CACI Inc, Publ Hlth & Surveillance, Healthcare Solut Grp, Arlington, VA USA.
   [Haass, Kathryn A.] Northrop Grumman Corp, Hlth Div, Atlanta, GA USA.
   [Henry, Richard; Berger, James] US Dept HHS, Off HIV AIDS & Infect Dis Policy, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
RP Kuehnert, MJ (reprint author), US Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, 1600 Clifton Rd NE,MS A07, Atlanta, GA 30333 USA.
EM mgk8@cdc.gov
NR 46
TC 6
Z9 6
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2016
VL 56
IS 9
BP 2184
EP 2192
DI 10.1111/trf.13644
PG 9
WC Hematology
SC Hematology
GA DZ4OL
UT WOS:000385837900006
PM 27174734
ER

PT J
AU Graves, MC
   Harris, JR
   Hannon, PA
   Hammerback, K
   Parrish, AT
   Ahmed, F
   Zhou, C
   Allen, CL
AF Graves, Meredith C.
   Harris, Jeffrey R.
   Hannon, Peggy A.
   Hammerback, Kristen
   Parrish, Amanda T.
   Ahmed, Faruque
   Zhou, Chuan
   Allen, Claire L.
TI Promoting Influenza Vaccination to Restaurant Employees
SO AMERICAN JOURNAL OF HEALTH PROMOTION
LA English
DT Article
DE Influenza; Vaccination; Immunization; Workplace; Employee; Promotion;
   Prevention Research
AB Purpose. To evaluate an evidence-based workplace approach to increasing adult influenza vaccination levels applied in the restaurant setting
   Design. We implemented an intervention and conducted a pre/post analysis to determine effect on vaccination.
   Setting. Eleven Seattle-area restaurants.
   Subjects. Restaurants with 25+ employees speaking English or Spanish and over 18 years.
   Intervention. Restaurants received influenza vaccination promotion materials, assistance arranging on-site vaccination events, and free influenza vaccinations for employees.
   Measures. Pre/post employee surveys of vaccination status with direct observation and employer interviews to evaluate implementation.
   Analysis. We conducted descriptive analysis of employee survey data and performed qualitative analysis of implementation data. To assess intervention effect, we used a mixed-effects logistic regression model with a restaurant-specific random effect.
   Results. Vaccination levels increased from 26% to 46% (adjusted odds ratio 2.33, 95% confidence interval 1.69, 3.22), with 428 employees surveyed pre intervention, 305 surveyed postintervention, and response rates of 73% and 55%, respectively. The intervention was effective across subgroups, but there were restaurant-level differences.
   Conclusion. An access-based workplace intervention can increase influenza vaccination levels in restaurant employees, but restaurant-level factors may influence success.
C1 [Graves, Meredith C.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Harris, Jeffrey R.; Hannon, Peggy A.; Hammerback, Kristen; Parrish, Amanda T.; Zhou, Chuan; Allen, Claire L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Harris, Jeffrey R.; Hannon, Peggy A.; Hammerback, Kristen; Parrish, Amanda T.; Allen, Claire L.] Hlth Promot Res Ctr, 1107 45th Ave NE,Suite 200, Seattle, WA 98105 USA.
   [Ahmed, Faruque] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA.
   [Zhou, Chuan] Seattle Childrens Res Inst, Seattle, WA USA.
RP Harris, JR (reprint author), Hlth Promot Res Ctr, 1107 45th Ave NE,Suite 200, Seattle, WA 98105 USA.
EM jh7@uw.edu
NR 7
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0890-1171
EI 2168-6602
J9 AM J HEALTH PROMOT
JI Am. J. Health Promot.
PD SEP
PY 2016
VL 30
IS 7
BP 498
EP 500
DI 10.4278/ajhp.131216-ARB-643
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY0VG
UT WOS:000384813700002
PM 26305606
ER

PT J
AU Kumar, G
   Jim-Martin, S
   Piltch, E
   Onufrak, S
   McNeil, C
   Adams, L
   Williams, N
   Blanck, HM
   Curley, L
AF Kumar, Gayathri
   Jim-Martin, Sonlatsa
   Piltch, Emily
   Onufrak, Stephen
   McNeil, Carrie
   Adams, Laura
   Williams, Nancy
   Blanck, Heidi M.
   Curley, Larry
TI Healthful Nutrition of Foods in Navajo Nation Stores: Availability and
   Pricing
SO AMERICAN JOURNAL OF HEALTH PROMOTION
LA English
DT Article
DE Navajo; Native American; American Indian; Food Environment; Nutrition
   Environment; Healthy Food Access; Healthy Food Availability; Healthy
   Food Pricing; Nutrition; Prevention Research
ID BODY-MASS INDEX; ATHEROSCLEROSIS RISK; AMERICAN; ACCESS; CHILDREN;
   OBESITY; COMMUNITIES; ENVIRONMENT; INFANTS; PROGRAM
AB Purpose. Low availability and affordability of healthier foods in food stores on the Navajo Nation (NN) may be a community-level risk factor for the high prevalence of obesity among the Navajo people. This study assessed the availability and pricing of foods and beverages in supermarkets and convenience stores throughout the NN.
   Design. Descriptive study design using the Nutrition Environment Measurement Survey in Stores audit tool.
   Setting. Supermarkets (n = 13) and convenience stores (n = 50) on NN and border-town supermarkets (n = 9).
   Subjects. Not applicable.
   Measures. Availability and pricing of healthy and less-healthy foods.
   Analysis. Descriptive and chi(2) analyses.
   Results. Navajo convenience stores offered fewer healthier food options compared to Navajo supermarkets. In Navajo convenience stores, 100% whole grain products, reduced-fat cheese, lean meats, reduced-fat chips, and fat-free or light hot dogs were available in fewer stores than their corresponding less-healthy versions (all with p < .05). In both Navajo supermarkets and convenience stores, 100% whole wheat bread, lean cold cuts, and reduced-fat cheese were all more expensive per unit than their corresponding less-healthy versions (all with p < .05).
   Conclusions. According to this study, healthier foods are not as readily available in Navajo convenience stores as they are in Navajo supermarkets. Improving access to and affordability of healthier foods in reservation stores of all sizes may support healthy eating among Navajo residents.
C1 [Kumar, Gayathri; McNeil, Carrie; Adams, Laura] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS E-92, Atlanta, GA 30333 USA.
   [Onufrak, Stephen; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
   [Jim-Martin, Sonlatsa; Curley, Larry] Navajo Div Hlth, Window Rock, AZ USA.
   [Piltch, Emily] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
RP Kumar, G (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS E-92, Atlanta, GA 30333 USA.
EM wiz3@cdc.gov
NR 47
TC 0
Z9 0
U1 10
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0890-1171
EI 2168-6602
J9 AM J HEALTH PROMOT
JI Am. J. Health Promot.
PD SEP
PY 2016
VL 30
IS 7
BP 501
EP 510
DI 10.4278/ajhp.140821-QUAN-422
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY0VG
UT WOS:000384813700003
PM 26305604
ER

PT J
AU Dynes, M
   Rosenthal, M
   Hulland, E
   Hardy, C
   Torre, L
   Tomczyk, B
AF Dynes, Michelle
   Rosenthal, Mariana
   Hulland, Erin
   Hardy, Colleen
   Torre, Lisandro
   Tomczyk, Barbara
TI Handheld solar light use, durability, and retention among women and
   girls in internally displaced persons camps in Haiti-2013-2014
SO INTERNATIONAL JOURNAL OF DISASTER RISK REDUCTION
LA English
DT Article
DE Disasters; Haiti; Solar lights; Gender based violence
ID VIOLENCE
AB During conflict and disasters, women and girls are at increased risk of gender based violence. International humanitarian guidelines call for the distribution of individual lighting to meet women and girls' basic needs and to reduce risk of violence; however, little evidence exists to support these guidelines. This paper presents an evaluation of handheld solar light use, retention, and durability among women and girls living in two internally displaced persons camps in Port-au-Prince, Haiti. Data was gathered prospectively via five household surveys from August 2013 to April 2014; a total of 754 females participated in the study. Women reported going outside at night more frequently at the end of the study than at the beginning. The handheld solar lights were the most common source of lighting at endline, whereas candle and gas lamp use declined significantly over time. Results from a Life-Table survival analysis estimated that households had an 83% probability of still owning a functioning light after seven months. Given the frequent use, acceptable durability, and retention of the lights, donors and humanitarian organizations should consider supporting light distribution to women and girls in internally displaced persons camps to help meet their basic needs. Published by Elsevier Ltd.
C1 [Dynes, Michelle] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Rosenthal, Mariana] Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Rosenthal, Mariana; Tomczyk, Barbara] Idaho Dept Hlth & Welf, 3402 Franklin Rd, Caldwell, ID 83605 USA.
   [Hulland, Erin; Hardy, Colleen; Torre, Lisandro] Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30329 USA.
RP Dynes, M (reprint author), 4770 Buford Hwy NE, Atlanta, GA 30341 USA.
EM mdynes@cdc.gov
FU United States Agency for International Development Office of Foreign
   Disaster Assistance (OFDA); CDC [3UE2EH000611-04S1]; US Department of
   Energy; CDC
FX This evaluation would not have been possible without the collaborative
   efforts of numerous individuals from the International Rescue Committee
   (IRC) Women's Protection and Empowerment Technical Team, CDC Atlanta,
   IRC and CDC country offices in Haiti, and the women and girls who
   participated in the interviews. Funding was provided by United States
   Agency for International Development Office of Foreign Disaster
   Assistance (OFDA) and CDC (3UE2EH000611-04S1). This research was also
   supported in part by an appointment to the Research Participation
   Program at the CDC administered by the Oak Ridge Institute for Science
   and Education through an interagency agreement between the US Department
   of Energy and the CDC. The authors also wish to thank Leora Ward and
   Kathryn Falb, IRC, for comments on the final paper.
NR 45
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212-4209
J9 INT J DISAST RISK RE
JI Int. J. Disaster Risk Reduct.
PD SEP
PY 2016
VL 18
BP 162
EP 170
DI 10.1016/j.ijdrr.2016.04.016
PG 9
WC Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences;
   Water Resources
SC Geology; Meteorology & Atmospheric Sciences; Water Resources
GA DY1EK
UT WOS:000384837500017
PM 27482509
ER

PT J
AU Kruger, J
   Jama, A
   Kegler, M
   Marynak, K
   King, B
AF Kruger, Judy
   Jama, Amal
   Kegler, Michelle
   Marynak, Kristy
   King, Brian
TI National and State-Specific Attitudes toward Smoke-Free Parks among US
   Adults
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE parks; smoke-free; secondhand smoke; state; national; attitudes
ID NEW-YORK-CITY; SECONDHAND SMOKE; TOBACCO-SMOKE; UNITED-STATES;
   BEHAVIORAL IMPACT; FREE POLICIES; EXPOSURE; BEACHES; PERCEPTIONS;
   RESTAURANTS
AB Outdoor places, such as parks, remain a source of secondhand smoke (SHS) exposure. We assessed attitudes toward smoke-free parks among U.S. adults. Data came from the 2009-2010 National Adult Tobacco Survey, a landline and cellular telephone survey of noninstitutionalized adults aged 18 in the 50 U.S. states and D.C. Descriptive statistics and logistic regression were used to assess the prevalence and sociodemographic correlates of attitudes toward smoke-free parks, overall and by current tobacco use. Overall, 38.5% of adults reported favorable attitudes toward complete smoke-free parks; prevalence ranged from 29.2% in Kentucky to 48.2% in Maine. Prevalence of favorable attitudes toward smoke-free parks was higher among nonusers of tobacco (44.6%) and noncombustible-only users (30.0%) than any combustible users (21.3%). The adjusted odds of having a favorable attitude were higher among: women; Hispanics and Black non-Hispanics, American Indian and Alaska Native non-Hispanics, and other non-Hispanics; those with an unspecified sexual orientation; and those with children aged 17 in the household, relative to each characteristics respective referent group. Odds were lower among: any combustible tobacco and noncombustible-only tobacco users; adults aged 45-64; and those with some college or an undergraduate degree. Opportunities exist to educate the public about the benefits of smoke-free outdoor environments.
C1 [Kruger, Judy; Marynak, Kristy; King, Brian] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30306 USA.
   [Jama, Amal] DB Consulting Grp, Atlanta, GA 30329 USA.
   [Kegler, Michelle] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Kruger, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30306 USA.
EM jkruger@cdc.gov; vuj3@cdc.gov; mkegler@emory.edu; vhy4@cdc.gov;
   iyn3@cdc.gov
FU National Cancer Institute under the State and Community Tobacco Control
   Initiative [UO1-CA154282]
FX No funding, direct or indirect, for CDC authors. Michelle Kegler funded
   by the National Cancer Institute under the State and Community Tobacco
   Control Initiative, Grant Number UO1-CA154282. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the official position of the Centers for Disease
   Control and Prevention.
NR 39
TC 0
Z9 0
U1 3
U2 3
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2016
VL 13
IS 9
AR 864
DI 10.3390/ijerph13090864
PG 16
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DX9EG
UT WOS:000384695800028
ER

PT J
AU Eisen, L
   Eisen, RJ
AF Eisen, Lars
   Eisen, Rebecca J.
TI Critical Evaluation of the Linkage Between Tick-Based Risk Measures and
   the Occurrence of Lyme Disease Cases
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Borrelia burgdorferi; Ixodes scapularis; blacklegged tick; Lyme disease
ID AMBLYOMMA-AMERICANUM ACARI; IXODES-SCAPULARIS ACARI;
   BORRELIA-BURGDORFERI TRANSMISSION; GEOGRAPHIC INFORMATION-SYSTEMS;
   ERYTHEMA CHRONICUM MIGRANS; CONTINENTAL UNITED-STATES; SOUTHERN
   NEW-YORK; DAMMINI ACARI; ENDEMIC AREA; SAMPLING METHODS
AB The nymphal stage of the blacklegged tick, Ixodes scapularis Say, is considered the primary vector to humans in the eastern United States of the Lyme disease spirochete Borrelia burgdorferi sensu stricto. The abundance of infected host-seeking nymphs is commonly used to estimate the fundamental risk of human exposure to B. burgdorferi, for the purpose of environmental risk assessment and as an outcome measure when evaluating environmentally based tick or pathogen control methods. However, as this tick-based risk measure does not consider the likelihoods of either human encounters with infected ticks or tick bites resulting in pathogen transmission, its linkage to the occurrence of Lyme disease cases is worth evaluating. In this Forum article, we describe different tick-based risk measures, discuss their strengths and weaknesses, and review the evidence for their capacity to predict the occurrence of Lyme disease cases. We conclude that: 1) the linkage between abundance of host-seeking B. burgdorferi-infected nymphs and Lyme disease occurrence is strong at community or county scales but weak at the fine spatial scale of residential properties where most human exposures to infected nymphs occur in Northeast, 2) the combined use of risk measures based on infected nymphs collected from the environment and ticks collected from humans is preferable to either one of these risk measures used singly when assessing the efficacy of environmentally based tick or pathogen control methods aiming to reduce the risk of human exposure to B. burgdorferi, 3) there is a need for improved risk assessment methodology for residential properties that accounts for both the abundance of infected nymphs and the likelihood of human-tick contact, and 4) we need to better understand how specific human activities conducted in defined residential microhabitats relate to risk for nymphal exposures and bites.
C1 [Eisen, Lars; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
RP Eisen, L (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
EM evp4@cdc.gov; dyn2@cdc.gov
NR 119
TC 0
Z9 0
U1 10
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2016
VL 53
IS 5
BP 1050
EP 1062
DI 10.1093/jme/tjw092
PG 13
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DW5SV
UT WOS:000383708100008
ER

PT J
AU Eisen, L
   Dolan, MC
AF Eisen, Lars
   Dolan, Marc C.
TI Evidence for Personal Protective Measures to Reduce Human Contact With
   Blacklegged Ticks and for Environmentally Based Control Methods to
   Suppress Host-Seeking Blacklegged Ticks and Reduce Infection with Lyme
   Disease Spirochetes in Tick Vectors and Rodent Reservoirs
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Review
DE Borrelia burgdorferi; Ixodes scapularis; blacklegged tick; Lyme disease;
   risk management
ID IXODES-SCAPULARIS ACARI; AMBLYOMMA-AMERICANUM ACARI; WHITE-TAILED DEER;
   F52 HYPOCREALES CLAVICIPITACEAE; BLACK-LEGGED TICK; SOUTHERN NEW-YORK;
   LONE-STAR TICKS; HUNTERELLUS-HOOKERI HYMENOPTERA; TOPICAL TREATMENT
   DEVICES; FUNGI BEAUVERIA-BASSIANA
AB In the 1980s, the blacklegged tick, Ixodes scapularis Say, and rodents were recognized as the principal vector and reservoir hosts of the Lyme disease spirochete Borrelia burgdorferi in the eastern United States, and deer were incriminated as principal hosts for I. scapularis adults. These realizations led to pioneering studies aiming to reduce the risk for transmission of B. burgdorferi to humans by attacking host-seeking ticks with acaricides, interrupting the enzootic transmission cycle by killing immatures infesting rodent reservoirs by means of acaricide-treated nesting material, or reducing deer abundance to suppress tick numbers. We review the progress over the past three decades in the fields of: 1) prevention of human-tick contact with repellents and permethrin-treated clothing, and 2) suppression of I. scapularis and disruption of enzootic B. burgdorferi transmission with environmentally based control methods. Personal protective measures include synthetic and natural product-based repellents that can be applied to skin and clothing, permethrin sprays for clothing and gear, and permethrin-treated clothing. A wide variety of approaches and products to suppress I. scapularis or disrupt enzootic B. burgdorferi transmission have emerged and been evaluated in field trials. Application of synthetic chemical acaricides is a robust method to suppress host-seeking I. scapularis ticks within a treated area for at least 6-8 wk. Natural product-based acaricides or entomopathogenic fungi have emerged as alternatives to kill host-seeking ticks for homeowners who are unwilling to use synthetic chemical acaricides. However, as compared with synthetic chemical acaricides, these approaches appear less robust in terms of both their killing efficacy and persistence. Use of rodent-targeted topical acaricides represents an alternative for homeowners opposed to open distribution of acaricides to the ground and vegetation on their properties. This host-targeted approach also provides the benefit of the intervention impacting the entire rodent home range. Rodent-targeted oral vaccines against B. burgdorferi and a rodent-targeted antibiotic bait have been evaluated in laboratory and field trials but are not yet commercially available. Targeting of deer-via deer reduction or treatment of deer with topical acaricides-can provide area-wide suppression of host-seeking I. scapularis. These two deer-targeted approaches combine great potential for protection that impacts the entire landscape with severe problems relating to public acceptance or implementation logistics. Integrated use of two or more methods has unfortunately been evaluated in very few published studies, but additional field evaluations of integrated tick and pathogen strategies are underway.
C1 [Eisen, Lars; Dolan, Marc C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
RP Eisen, L (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
EM evp4@cdc.gov; mcd4@cdc.gov
NR 213
TC 0
Z9 0
U1 15
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2016
VL 53
IS 5
BP 1063
EP 1092
DI 10.1093/jme/tjw103
PG 30
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DW5SV
UT WOS:000383708100009
ER

PT J
AU Hahn, MB
   Eisen, RJ
   Eisen, L
   Boegler, KA
   Moore, CG
   McAllister, J
   Savage, HM
   Mutebi, JP
AF Hahn, Micah B.
   Eisen, Rebecca J.
   Eisen, Lars
   Boegler, Karen A.
   Moore, Chester G.
   McAllister, Janet
   Savage, Harry M.
   Mutebi, John-Paul
TI Reported Distribution of Aedes (Stegomyia) aegypti and Aedes (Stegomyia)
   albopictus in the United States, 1995-2016 (Diptera: Culicidae)
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Aedes aegypti; Aedes albopictus; surveillance; distribution; United
   States
ID YELLOW-FEVER; TEMPORAL PATTERNS; GEOGRAPHIC RANGE; DENGUE; FLORIDA;
   MOSQUITOS; AMERICA; DISEASE; SPREAD; VIRUS
AB Aedes (Stegomyia)aegypti (L.) andAedes (Stegomyia)albopictus (Skuse) transmit arboviruses that are increasing threats to human health in the Americas, particularly dengue, chikungunya, and Zika viruses. Epidemics of the associated arboviral diseases have been limited to South and Central America, Mexico, and the Caribbean in the Western Hemisphere, with only minor localized outbreaks in the United States. Nevertheless, accurate and up-to-date information for the geographical ranges ofAe. aegypti andAe. albopictus in the United States is urgently needed to guide surveillance and enhance control capacity for these mosquitoes. We compiled county records for presence ofAe. aegypti andAe. albopictus in the United States from 1995-2016, presented here in map format. Records were derived from the Centers for Disease Control and Prevention ArboNET database, VectorMap, the published literature, and a survey of mosquito control agencies, university researchers, and state and local health departments. Between January 1995 and March 2016, 183 counties from 26 states and the District of Columbia reported occurrence ofAe. aegypti, and 1,241 counties from 40 states and the District of Columbia reported occurrence ofAe. albopictus. During the same time period,Ae. aegypti was collected in 3 or more years from 94 counties from 14 states and the District of Columbia, andAe. albopictus was collected during 3 or more years from 514 counties in 34 states and the District of Columbia. Our findings underscore the need for systematic surveillance ofAe. aegypti andAe. albopictus in the United States and delineate areas with risk for the transmission of these introduced arboviruses.
C1 [Hahn, Micah B.; Eisen, Rebecca J.; Eisen, Lars; Boegler, Karen A.; McAllister, Janet; Savage, Harry M.; Mutebi, John-Paul] Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
   [Moore, Chester G.] Colorado State Univ, Dept Microbiol Immunol & Pathol, 3195 Rampart Rd, Ft Collins, CO 80523 USA.
RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM xht1@cdc.gov; dyn2@cdc.gov; hms1@cdc.gov; kje5@cdc.gov;
   Chester.Moore@ColoState.edu; evp4@cdc.gov; jvm6@cdc.gov; grv0@cdc.gov
NR 45
TC 2
Z9 2
U1 12
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2016
VL 53
IS 5
BP 1169
EP 1175
DI 10.1093/jme/tjw072
PG 7
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DW5SV
UT WOS:000383708100020
ER

PT J
AU Hahn, MB
   Jarnevich, CS
   Monaghan, AJ
   Eisen, RJ
AF Hahn, Micah B.
   Jarnevich, Catherine S.
   Monaghan, Andrew J.
   Eisen, Rebecca J.
TI Modeling the Geographic Distribution of Ixodes scapularis and Ixodes
   pacificus (Acari: Ixodidae) in the Contiguous United States
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Lyme disease; bioclimatic modeling; habitat suitability; Ixodes
   scapularis; Ixodes pacificus
ID BLACKLEGGED TICK ACARI; CLIMATE-BASED MODEL; HUMAN LYME-DISEASE;
   BORRELIA-BURGDORFERI; SPECIES DISTRIBUTIONS; RELATIVE-HUMIDITY; WINTER
   ACTIVITY; LIFE-CYCLE; DENSITY; DEER
AB In addition to serving as vectors of several other human pathogens, the black-legged tick, Ixodes scapularis Say, and western black-legged tick, Ixodes pacificus Cooley and Kohls, are the primary vectors of the spirochete (Borrelia burgdorferi) that causes Lyme disease, the most common vector-borne disease in the United States. Over the past two decades, the geographic range of I. pacificus has changed modestly while, in contrast, the I. scapularis range has expanded substantially, which likely contributes to the concurrent expansion in the distribution of human Lyme disease cases in the Northeastern, North-Central and Mid-Atlantic states. Identifying counties that contain suitable habitat for these ticks that have not yet reported established vector populations can aid in targeting limited vector surveillance resources to areas where tick invasion and potential human risk are likely to occur. We used county-level vector distribution information and ensemble modeling to map the potential distribution of I. scapularis and ZI. pacificus in the contiguous United States as a function of climate, elevation, and forest cover. Results show that I. pacificus is currently present within much of the range classified by our model as suitable for establishment. In contrast, environmental conditions are suitable for I. scapularis to continue expanding its range into northwestern Minnesota, central and northern Michigan, within the Ohio River Valley, and inland from the southeastern and Gulf coasts. Overall, our ensemble models show suitable habitat for I. scapularis in 441 eastern counties and for I. pacificus in 11 western counties where surveillance records have not yet supported classification of the counties as established.
C1 [Hahn, Micah B.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
   [Jarnevich, Catherine S.] US Geol Survey, 2150 Ctr Ave,Bldg C, Ft Collins, CO 80526 USA.
   [Monaghan, Andrew J.] Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.
RP Hahn, MB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM mhahn@cdc.gov; jarnevichc@usgs.gov; monaghan@ucar.edu; dyn2@cdc.gov
FU National Science Foundation
FX The National Center for Atmospheric Research is sponsored by the
   National Science Foundation. Any use of trade, firm, or product names is
   for descriptive purposes only and does not imply endorsement by the U.S.
   Government.
NR 76
TC 0
Z9 0
U1 23
U2 23
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2016
VL 53
IS 5
BP 1176
EP 1191
DI 10.1093/jme/tjw076
PG 16
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DW5SV
UT WOS:000383708100021
ER

PT J
AU Del Rio-Galvan, SL
   Flores, AE
   Barrera, R
   Lopez-Monroy, B
   Felix, G
   Amador, M
   Ponce-Garcia, G
AF Del Rio-Galvan, Samanta L.
   Flores, Adriana E.
   Barrera, Roberto
   Lopez-Monroy, Beatriz
   Felix, Gilberto
   Amador, Manuel
   Ponce-Garcia, Gustavo
TI Susceptibility to Temephos and Spinosad in Aedes aegypti (Diptera:
   Culicidae) From Puerto Rico
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE temephos; spinosad; Aedes aegypti; larvicide
ID INSECTICIDE RESISTANCE; MOSQUITO LARVAE; AMERICAN COUNTRIES; FIELD
   POPULATIONS; CROSS-RESISTANCE; MECHANISMS; VECTOR; MICROASSAY;
   ALBOPICTUS; VENEZUELA
AB We examined the susceptibility to temephos and spinosad (Natular EC) of eight Aedes aegypti (L.) populations from Puerto Rico, following WHO method (WHO 2005). Enzyme activity was measured for alpha- and beta-esterases, multiple function oxidases, glutathione-s-transferases, and insensitive acetylcholinesterase and was tested for correlation with the susceptibility level. The results showed that larval populations from Puerto Rico obtained during 2014 were found to be susceptible to both larvicides, with low (resistance factor) RRLC50 values (< 5 fold) and altered and incipiently altered enzyme expression for all populations, except the insensitive acetylcholinesterase enzyme, where only the population of Ponce showed overexpression (53.3%) above the threshold established with the New Orleans susceptible strain. We recommend the use of both larvicides for mosquito control in the study area and encourage further susceptibility monitoring.
C1 [Del Rio-Galvan, Samanta L.; Flores, Adriana E.; Lopez-Monroy, Beatriz; Ponce-Garcia, Gustavo] Univ Autonoma Nuevo Leon, Fac Ciencias Biol, San Nicolas De Los Garza 66455, NL, Mexico.
   [Barrera, Roberto; Felix, Gilberto; Amador, Manuel] Ctr Dis Control & Prevent, Entomol & Ecol Act, Dengue Branch, San Juan, PR USA.
RP Del Rio-Galvan, SL (reprint author), Univ Autonoma Nuevo Leon, Fac Ciencias Biol, San Nicolas De Los Garza 66455, NL, Mexico.
EM samdel-riog@hotmail.com; adrflores@gmail.com; amz9@cdc.gov;
   betygenesis@hotmail.com; ckn5@cdc.gov; maa4@cdc.gov;
   gponcealfa@gmail.com
OI Flores, Adriana E./0000-0001-8554-8865; Ponce-Garcia,
   Gustavo/0000-0003-0654-006X
FU Laboratorio de Entomologia Medica, Facultad de Ciencias Biologicas,
   UANL, Mexico
FX We thank Selene M. Gutierrez-Rodriguez who helped performing larvicide
   bioassays. The study was funded by the Laboratorio de Entomologia
   Medica, Facultad de Ciencias Biologicas, UANL, Mexico.
NR 57
TC 0
Z9 0
U1 39
U2 39
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2016
VL 53
IS 5
BP 1211
EP 1217
DI 10.1093/jme/tjw090
PG 7
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DW5SV
UT WOS:000383708100025
ER

PT J
AU Godsey, MS
   Savage, HM
   Burkhalter, KL
   Bosco-Lauth, AM
   Delorey, MJ
AF Godsey, Marvin S., Jr.
   Savage, Harry M.
   Burkhalter, Kristen L.
   Bosco-Lauth, Angela M.
   Delorey, Mark J.
TI Transmission of Heartland Virus (Bunyaviridae: Phlebovirus) by
   Experimentally Infected Amblyomma americanum (Acari: Ixodidae)
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Amblyomma americanum; Heartland virus; Phlebovirus; vertical
   transmission; transstadial transmission
ID TRANS-OVARIAL TRANSMISSION; TICK-BORNE PHLEBOVIRUSES; IXODES-SCAPULARIS
   LARVAE; GENUS PHLEBOVIRUS; SEASONAL ACTIVITY; FEVER VIRUS; SAND FLIES;
   MISSOURI; WATER; ABUNDANCE
AB Heartland virus (HRTV; Bunyaviridae: Phlebovirus) is a recently described cause of human illness in the United States. After field studies conducted in 2012 implicated Amblyomma americanum (L.) as a vector of HRTV, we initiated experiments to assess the vector competence of A. americanum. Larval and nymphal ticks were immersed in high-titered suspensions of HRTV, and then tested for virus at various intervals postimmersion. In a later trial larval ticks were immersed in HRTV, followed by engorgement on a rabbit. A subset of postmolt nymphs was tested for HRTV to document transstadial transmission. Putatively infected nymphs were cofed with uninfected colony larvae to assess nonviremic transmission. In another trial, nymphs were fed on a rabbit and allowed to molt to the adult stage. Male and female ticks fed and mated upon a rabbit, and females were allowed to oviposit. Male and spent female ticks were tested for HRTV, and offspring of infected females were tested to assess vertical transmission. Infection rates of a parts per thousand currency sign50% were observed in immersed larvae and nymphs tested at intervals following immersion. Transstadial transmission from larvae to nymphs and then to adults was documented. HRTV was detected in a pool of nymphs molted from uninfected larvae cofed with infected nymphs. Vertical transmission of HRTV was observed in progeny of infected females. Infected females took longer to oviposit and produced fewer offspring. Serologic conversions (without viremia) in rabbits fed upon by immersed larvae or transstadially infected ticks indicate horizontal transmission of HRTV.
C1 [Godsey, Marvin S., Jr.; Savage, Harry M.; Burkhalter, Kristen L.; Bosco-Lauth, Angela M.; Delorey, Mark J.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Godsey, MS (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
EM MGodsey@cdc.gov; hms1@cdc.gov; ktb3@cdc.gov; vue6@cdc.gov; esy7@cdc.gov
FU Division of Vector-Borne Diseases of the Centers for Disease Control and
   Prevention
FX We wish to thank Dr. Michael Levin, Lindsay Killmaster, and Lauren
   Schumacher, Rickettsial Zoonosis Branch, CDC, Atlanta, GA, for training
   in tick colonization techniques, and for provision of larval ticks used
   in the experiments. We also acknowledge Dr. Michael Levin for critically
   reviewing an earlier version of the manuscript and suggesting useful
   changes. We thank Jason Velez, CDC, Fort Collins, CO, for preparation of
   cells, and John Liddell, Andrea Sherman, and Ashley Waller of the CDC
   animal care staff. The use of rabbits was authorized under CDC-Fort
   Collins Institutional Animal Care and Use Committee Protocol numbers
   13-001 and 13-006. This study was supported by the Division of
   Vector-Borne Diseases of the Centers for Disease Control and Prevention.
NR 36
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2016
VL 53
IS 5
BP 1226
EP 1233
DI 10.1093/jme/tjw080
PG 8
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DW5SV
UT WOS:000383708100027
ER

PT J
AU Fu, Y
   Zhang, Z
   Sheehan, J
   Avnir, Y
   Ridenour, C
   Sachnik, T
   Sun, JS
   Hossain, MJ
   Chen, LM
   Zhu, Q
   Donis, RO
   Marasco, WA
AF Fu, Ying
   Zhang, Zhen
   Sheehan, Jared
   Avnir, Yuval
   Ridenour, Callie
   Sachnik, Thomas
   Sun, Jiusong
   Hossain, M. Jaber
   Chen, Li-Mei
   Zhu, Quan
   Donis, Ruben O.
   Marasco, Wayne A.
TI A broadly neutralizing anti-influenza antibody reveals ongoing capacity
   of haemagglutinin-specific memory B cells to evolve
SO NATURE COMMUNICATIONS
LA English
DT Article
ID INFLUENZA-A VIRUS; STALK-SPECIFIC ANTIBODIES; HUMAN MONOCLONAL-ANTIBODY;
   LIVED PLASMA-CELLS; IN-VIVO; SOMATIC HYPERMUTATION; RECEPTOR-BINDING;
   EVOLUTION; ANTIGEN; VACCINE
AB Understanding the natural evolution and structural changes involved in broadly neutralizing antibody (bnAb) development holds great promise for improving the design of prophylactic influenza vaccines. Here we report an haemagglutinin (HA) stem-directed bnAb, 3I14, isolated from human memory B cells, that utilizes a heavy chain encoded by the IGHV3-30 germline gene. MAb 3I14 binds and neutralizes groups 1 and 2 influenza A viruses and protects mice from lethal challenge. Analysis of VH and VL germline back-mutants reveals binding to H3 and H1 but not H5, which supports the critical role of somatic hypermutation in broadening the bnAb response. Moreover, a single VLD94N mutation improves the affinity of 3I14 to H5 by nearly 10-fold. These data provide evidence that memory B cell evolution can expand the HA subtype specificity. Our results further suggest that establishing an optimized memory B cell pool should be an aim of 'universal' influenza vaccine strategies.
C1 [Fu, Ying; Zhang, Zhen; Sheehan, Jared; Avnir, Yuval; Sachnik, Thomas; Sun, Jiusong; Zhu, Quan; Marasco, Wayne A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & Virol, 450 Brookline Ave, Boston, MA 02115 USA.
   [Ridenour, Callie; Hossain, M. Jaber; Chen, Li-Mei; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Road Mail Stop G-16, Atlanta, GA 30333 USA.
RP Marasco, WA (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & Virol, 450 Brookline Ave, Boston, MA 02115 USA.
EM wayne_marasco@dfci.harvard.edu
FU National Institutes of Health (NIAID) [U01-AI074518]
FX We thank Drs De-Kuan Chang and Xian-Chun Tang for technical support.
   This work was supported by National Institutes of Health (NIAID
   U01-AI074518) to W.A.M. The findings and conclusions in this report are
   those of the authors and do not necessarily represent the views of the
   Centers for Disease Control and Prevention or the Agency for Toxic
   Substances and Disease Registry.
NR 54
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP
PY 2016
VL 7
AR 12780
DI 10.1038/ncomms12780
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DY6RU
UT WOS:000385256500010
PM 27619409
ER

PT J
AU Donauer, S
   Altaye, M
   Xu, YY
   Sucharew, H
   Succop, P
   Calafat, AM
   Khoury, JC
   Lanphear, B
   Yolton, K
AF Donauer, Stephanie
   Altaye, Mekibib
   Xu, Yingying
   Sucharew, Heidi
   Succop, Paul
   Calafat, Antonia M.
   Khoury, Jane C.
   Lanphear, Bruce
   Yolton, Kimberly
TI An Observational Study to Evaluate Associations Between Low-Level
   Gestational Exposure to Organophosphate Pesticides and Cognition During
   Early Childhood
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article; Proceedings Paper
CT Prenatal Programming and Toxicity Conference
CY OCT 27, 2014
CL Boston, MA
DE cognition; gestation; organophosphate pesticides; pregnancy; prenatal
   exposures
ID MEXICAN-AMERICAN CHILDREN; PRENATAL EXPOSURE; NEURODEVELOPMENT;
   CHLORPYRIFOS; METABOLITES; SCORES; IMPACT; COHORT
AB Prenatal exposure to organophosphate pesticides, which is ubiquitous, may be detrimental to neurological development. We examined 327 mother/infant pairs in Cincinnati, Ohio, between 2003 and 2006 to determine associations between prenatal exposure to organophosphate pesticides and neurodevelopment. Twice during pregnancy urinary concentrations of 6 common dialkylphosphates, nonspecific metabolites of organophosphate pesticides, were measured. Aggregate concentrations of diethylphosphates, dimethylphosphates, and total dialkylphosphates were calculated. Bayley Scales of Infant Development, Second Edition-Mental and Psychomotor Developmental indices were administered at ages 1, 2, and 3 years, the Clinical Evaluation of Language Fundamentals-Preschool, Second Edition, at age 4, and theWechsler Preschool and Primary Scale of Intelligence, Third Edition, at age 5. Mothers with higher urinary total dialkylphosphate concentrations reported higher levels of socioeconomic status and increased fresh fruit and vegetable intake. We found no associations between prenatal exposure to organophosphate pesticides and cognition at 1-5 years of age. In our cohort, exposure to organophosphate pesticides during pregnancy was not associated with cognition during early childhood. It is possible that a higher socioeconomic status and healthier diet may protect the fetus from potential adverse associations with gestational organophosphate pesticide exposure, or that dietary exposure to the metabolites is innocuous and not an ideal measure of exposure to the parent compound.
C1 [Donauer, Stephanie; Xu, Yingying; Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Div Gen & Community Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Altaye, Mekibib; Sucharew, Heidi; Khoury, Jane C.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA.
   [Succop, Paul] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA.
   [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
   [Lanphear, Bruce] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada.
RP Donauer, S (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Gen & Community Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM stephanie.donauer@cchmc.org
FU NIEHS NIH HHS [R01 ES015517]
NR 30
TC 0
Z9 0
U1 6
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2016
VL 184
IS 5
BP 410
EP 418
DI 10.1093/aje/kwv447
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX8OX
UT WOS:000384649500008
PM 27539379
ER

PT J
AU Linton, SL
   Cooper, HLF
   Kelley, ME
   Karnes, CC
   Ross, Z
   Wolfe, ME
   Chen, YT
   Friedman, SR
   Des Jarlais, D
   Semaan, S
   Tempalski, B
   Sionean, C
   DiNenno, E
   Wejnert, C
   Paz-Bailey, G
AF Linton, Sabriya L.
   Cooper, Hannah L. F.
   Kelley, Mary E.
   Karnes, Conny C.
   Ross, Zev
   Wolfe, Mary E.
   Chen, Yen-Tyng
   Friedman, Samuel R.
   Des Jarlais, Don
   Semaan, Salaam
   Tempalski, Barbara
   Sionean, Catlainn
   DiNenno, Elizabeth
   Wejnert, Cyprian
   Paz-Bailey, Gabriela
CA Natl HIV Behav Surveillance Study
TI Associations of place characteristics with HIV and HCV risk behaviors
   among racial/ethnic groups of people who inject drugs in the United
   States
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE HIV; HCV; Injection drug use; Condom use; PWID; Housing; Drug treatment
ID NEW-YORK-CITY; RACIAL RESIDENTIAL SEGREGATION; C VIRUS-INFECTIONS;
   SYRINGE EXCHANGE PROGRAMS; US METROPOLITAN-AREAS; SURVEILLANCE SYSTEM;
   STERILE SYRINGES; SAN-FRANCISCO; SEXUAL RISK; LONGITUDINAL ANALYSIS
AB Purpose: Investigate whether characteristics of geographic areas are associated with condomless sex and injection-related risk behavior among racial/ethnic groups of people who inject drugs (PWID) in the United States.
   Methods: PWID were recruited from 19 metropolitan statistical areas for 2009 National HIV Behavioral Surveillance. Administrative data described ZIP codes, counties, and metropolitan statistical areas where PWID lived. Multilevel models, stratified by racial/ethnic groups, were used to assess relationships of place-based characteristics to condomless sex and injection-related risk behavior (sharing injection equipment).
   Results: Among black PWID, living in the South (vs. Northeast) was associated with injection-related risk behavior (adjusted odds ratio [AOR] = 2.24, 95% confidence interval [CI] = 1.21-4.17; P =.011), and living in counties with higher percentages of unaffordable rental housing was associated with condomless sex (AOR = 1.02, 95% CI = 1.00-1.04; P =.046). Among white PWID, living in ZIP codes with greater access to drug treatment was negatively associated with condomless sex (AOR = 0.93, 95% CI = 0.88-1.00; P =.038).
   Conclusions: Policies that increase access to affordable housing and drug treatment may make environments more conducive to safe sexual behaviors among black and white PWID. Future research designed to longitudinally explore the association between residence in the south and injection-related risk behavior might identify specific place-based features that sustain patterns of injection-related risk behavior. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Linton, Sabriya L.; Cooper, Hannah L. F.; Kelley, Mary E.; Karnes, Conny C.; Wolfe, Mary E.; Chen, Yen-Tyng] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Ross, Zev] ZevRoss Spatial Anal, Ithaca, NY USA.
   [Friedman, Samuel R.; Tempalski, Barbara] Natl Dev & Res Inst, Inst Infect Dis Res, New York, NY USA.
   [Des Jarlais, Don] Mt Sinai Beth Israel, Baron Edmond de Rothschild Chem Dependency Inst, New York, NY USA.
   [Semaan, Salaam; Sionean, Catlainn; DiNenno, Elizabeth; Wejnert, Cyprian; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Linton, SL (reprint author), 1518 Clifton Rd NE,Room 552, Atlanta, GA 30322 USA.
EM sabriya.linton@emory.edu
FU National Institutes of Health: "Place Characteristics & Disparities in
   HIV in IDUS: A Multilevel Analysis of NHBS" [DA035101]; Emory Center for
   AIDS Research [P30 AI050409]; Centers for Disease Control and
   Prevention; National HIV Behavioral Surveillance System Study Group:
   Atlanta, GA; National HIV Behavioral Surveillance System Study Group:
   Baltimore, MD; National HIV Behavioral Surveillance System Study Group:
   Boston, MA; National HIV Behavioral Surveillance System Study Group:
   Chicago, IL; National HIV Behavioral Surveillance System Study Group:
   Dallas, TX; National HIV Behavioral Surveillance System Study Group:
   Denver, CO; National HIV Behavioral Surveillance System Study Group:
   Detroit, MI; National HIV Behavioral Surveillance System Study Group:
   Houston, TX; National HIV Behavioral Surveillance System Study Group:
   Los Angeles, CA; National HIV Behavioral Surveillance System Study
   Group: Miami, FL; National HIV Behavioral Surveillance System Study
   Group: Nassau-Suffolk, NY; National HIV Behavioral Surveillance System
   Study Group: New Orleans, LA; National HIV Behavioral Surveillance
   System Study Group: New York City, NY; National HIV Behavioral
   Surveillance System Study Group: Newark, NJ; National HIV Behavioral
   Surveillance System Study Group: Philadelphia, PA; National HIV
   Behavioral Surveillance System Study Group: San Diego, CA; National HIV
   Behavioral Surveillance System Study Group: San Francisco, CA; National
   HIV Behavioral Surveillance System Study Group: San Juan, PR; National
   HIV Behavioral Surveillance System Study Group: Seattle, WA; National
   HIV Behavioral Surveillance System Study Group: St Louis, MO; National
   HIV Behavioral Surveillance System Study Group: Washington, DC
FX This research was supported by two grants from the National Institutes
   of Health: "Place Characteristics & Disparities in HIV in IDUS: A
   Multilevel Analysis of NHBS" (DA035101; Cooper, PI) and the Emory Center
   for AIDS Research (P30 AI050409; Curran, PI). It was also supported by
   the Centers for Disease Control and Prevention and the National HIV
   Behavioral Surveillance System Study Group: Atlanta, GA: Jennifer
   Taussig, Shacara Johnson, Jeff Todd; Baltimore, MD: Colin Flynn,
   Danielle German; Boston, MA: Debbie Isenberg, Maura Driscoll, Elizabeth
   Hurwitz; Chicago, IL: Nikhil Prachand, Nanette Benbow; Dallas, TX:
   Sharon Melville, Richard Yeager, Jim Dyer, Alicia Novoa; Denver, CO:
   Mark Thrun, Alia Al-Tayyib; Detroit, MI: Emily Higgins, Eve Mokotoff,
   Vivian Griffin; Houston, TX: Aaron Sayegh, Jan Risser, Hafeez Rehman;
   Los Angeles, CA: Trista Bingham, Ekow Kwa Sey; Miami, FL: Lisa Metsch,
   David Forrest, Dano Beck, Gabriel Cardenas; Nassau-Suffolk, NY: Chris
   Nemeth, Lou Smith, Carol-Ann Watson; New Orleans, LA: William T.
   Robinson, DeAnn Gruber, Narquis Barak; New York City, NY: Alan Neaigus,
   Samuel Jenness, Travis Wendel, Camila Gelpi-Acosta, Holly Hagan; Newark,
   NJ: Henry Godette, Barbara Bolden, Sally D'Errico; Philadelphia, PA:
   Kathleen A. Brady, Althea Kirkland, Mark Shpaner; San Diego, CA: Vanessa
   Miguelino-Keasling, Al Velasco; San Francisco, CA: H. Fisher Raymond;
   San Juan, PR: Sandra Miranda De Leo'n, Yadira Rolo'n-Colo'n; Seattle,
   WA: Maria Courogen, Hanne Thiede, Richard Burt; St Louis, MO: Michael
   Herbert, Yelena Friedberg, Dale Wrigley, Jacob Fisher; Washington, DC:
   Marie Sansone, Tiffany West-Ojo, Manya Magnus, Irene Kuo; Behavioral
   Surveillance Team.
NR 91
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
EI 1873-2585
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD SEP
PY 2016
VL 26
IS 9
BP 619
EP 630
DI 10.1016/j.annepidem.2016.07.012
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX8HN
UT WOS:000384628800004
PM 27576908
ER

PT J
AU Crume, TL
   Hamman, RF
   Isom, S
   Talton, J
   Divers, J
   Mayer-Davis, EJ
   Zhong, VW
   Liese, AD
   Saydah, S
   Standiford, DA
   Lawrence, JM
   Pihoker, C
   Dabelea, D
AF Crume, Tessa L.
   Hamman, Richard F.
   Isom, Scott
   Talton, Jennifer
   Divers, Jasmin
   Mayer-Davis, Elizabeth J.
   Zhong, Victor W.
   Liese, Angela D.
   Saydah, Sharon
   Standiford, Debra A.
   Lawrence, Jean M.
   Pihoker, Catherine
   Dabelea, Dana
CA SEARCH Diabet Youth Study Grp
TI Factors influencing time to case registration for youth with type 1 and
   type 2 diabetes: SEARCH for Diabetes in Youth Study
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE Surveillance; Case ascertainment; Diabetes in youth; Type 1 diabetes;
   Type 2 diabetes
ID ADOLESCENTS; PREVALENCE; MELLITUS; CHILDHOOD; CHILDREN
AB Purpose: The development of a sustainable pediatric diabetes surveillance system for the United States requires a better understanding of issues related to case ascertainment.
   Methods: Using the SEARCH for Diabetes in Youth registry, we examined whether time from diabetes diagnosis to case registration differed by diabetes type, patient demographics, and the type of provider reporting the case to the study. Plots for time from diagnosis to registration were developed, and differences by key variables were examined using the log-rank test.
   Results: Compared with time to registration for type 1 cases, it took 2.6 (95% confidence interval [CI], 2.5-2.6) times longer to register 50% of type 2 diabetes cases, and 2.3 (95% CI, 2.0-2.5) times longer to register 90% of type 2 cases. For type 1 diabetes cases, a longer time to registration was associated with older age, minority race/ethnicity, and cases, where the referring provider was not an endocrinologist. For type 2 diabetes cases, older age, non-Hispanic white race/ethnicity, and cases reported by providers other than an endocrinologist took longer to identify and register.
   Conclusions: These findings highlight the need for continued childhood diabetes surveillance to identify future trends and influences on changes in prevalence and incidence. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Crume, Tessa L.; Hamman, Richard F.; Dabelea, Dana] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus,13001 East 17th Ave,Box B119, Aurora, CO 80045 USA.
   [Isom, Scott; Talton, Jennifer; Divers, Jasmin] Wake Forest Sch Med, Med Ctr Blvd, Winston Salem, NC USA.
   [Mayer-Davis, Elizabeth J.; Zhong, Victor W.] Univ North Carolina Chapel Hill, Sch Publ Hlth, Chapel Hill, NC USA.
   [Mayer-Davis, Elizabeth J.; Zhong, Victor W.] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA.
   [Liese, Angela D.] Univ South Carolina, Dept Epidemiol & Biostat, Columbia, SC USA.
   [Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Hyattsville, MD USA.
   [Standiford, Debra A.] Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH USA.
   [Lawrence, Jean M.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA.
   [Pihoker, Catherine] Univ Washington, Childrens Hosp, Dept Pediat Endocrinol, Seattle, WA 98195 USA.
   [Pihoker, Catherine] Univ Washington, Reg Med Ctr, Seattle, WA 98195 USA.
RP Crume, TL (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus,13001 East 17th Ave,Box B119, Aurora, CO 80045 USA.
EM Tessa.Crume@ucdenver.edu
FU Centers for Disease Control and Prevention [00097, DP-05-069,
   DP-10-001]; National Institute of Diabetes and Digestive and Kidney
   Diseases; General Clinical Research Centers (GCRC) at the South Carolina
   Clinical & Translational Research (SCTR) Institute; General Clinical
   Research Centers (GCRC) at the Medical University of South Carolina
   (NIH/NCRR) [UL1RR029882]; Children's Hospital and Regional Medical
   Center [M01RR00037]; Colorado Pediatric General Clinical Research Center
   [M01 RR00069]; Barbara Davis Center at the University of Colorado at
   Denver (DERC NIH) [P30DK57516]; National Center for Research Resources;
   National Center for Advancing Translational Sciences, National
   Institutes of Health [8 UL1 TR000077]; Children with Medical Handicaps
   program; Kaiser Permanente Southern California [U48/CCU919219, U01
   DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3,
   U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256,
   U01 DP000245]; Children's Hospital Medical Center [U48/CCU519239, U01
   DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill
   [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington
   School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake
   Forest University School of Medicine [U48/CCU919219, U01 DP000250,
   200-2010-35171]
FX Grants and financial support: SEARCH for Diabetes in Youth is funded by
   the Centers for Disease Control and Prevention (PA numbers 00097,
   DP-05-069, and DP-10-001) and supported by the National Institute of
   Diabetes and Digestive and Kidney Diseases.; Additional acknowledgments:
   The authors wish to acknowledge the involvement of General Clinical
   Research Centers (GCRC) at the South Carolina Clinical & Translational
   Research (SCTR) Institute, at the Medical University of South Carolina
   (NIH/NCRR Grant number UL1RR029882); Children's Hospital and Regional
   Medical Center (Grant Number M01RR00037); Colorado Pediatric General
   Clinical Research Center (Grant Number M01 RR00069) and the Barbara
   Davis Center at the University of Colorado at Denver (DERC NIH
   P30DK57516); and the National Center for Research Resources and the
   National Center for Advancing Translational Sciences, National
   Institutes of Health, through Grant 8 UL1 TR000077; and the Children
   with Medical Handicaps program managed by the Ohio Department of
   Health.; Members of study group: Site Contract Numbers: Kaiser
   Permanente Southern California (U48/CCU919219, U01 DP000246, and
   U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01
   DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256
   and U01 DP000245), Children's Hospital Medical Center (Cincinnati)
   (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North
   Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and
   U18DP002708-01), University of Washington School of Medicine
   (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), Wake Forest
   University School of Medicine (U48/CCU919219, U01 DP000250, and
   200-2010-35171).
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
EI 1873-2585
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD SEP
PY 2016
VL 26
IS 9
BP 631
EP 637
DI 10.1016/j.annepidem.2016.07.014
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX8HN
UT WOS:000384628800005
PM 27664849
ER

PT J
AU Dawood, FS
   Jara, J
   Gonzalez, R
   Castillo, JM
   De Leon, T
   Estripeaut, D
   Luciani, K
   Brizuela, YS
   Barahona, A
   Cazares, RA
   Lawson, AM
   Rodriguez, M
   de Viana, D
   Franco, D
   Castillo, M
   Fry, AM
   Gubareva, L
   Tamura, D
   Hughes, M
   Gargiullo, P
   Clara, W
   Azziz-Baumgartner, E
   Widdowson, MA
AF Dawood, Fatimah S.
   Jara, Jorge
   Gonzalez, Rosalba
   Miguel Castillo, Juan
   De Leon, Tirza
   Estripeaut, Dora
   Luciani, Kathia
   Sujey Brizuela, Yarisa
   Barahona, Alfredo
   Antonio Cazares, Rafael
   Lawson, Aracelis M.
   Rodriguez, Mariana
   de Viana, Dinora
   Franco, Danilo
   Castillo, Marlene
   Fry, Alicia M.
   Gubareva, Larisa
   Tamura, Daisuke
   Hughes, Michael
   Gargiullo, Paul
   Clara, Wilfrido
   Azziz-Baumgartner, Eduardo
   Widdowson, Marc-Alain
TI A randomized, double-blind, placebo-controlled trial evaluating the
   safety of early oseltamivir treatment among children 0-9 years of age
   hospitalized with influenza in El Salvador and Panama
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Oseltamivir; Influenza; Human; Antiviral agents; Children; Hospitalized
ID CRITICALLY-ILL CHILDREN; NEURAMINIDASE INHIBITORS; SEASONAL INFLUENZA;
   INFECTION; BURDEN; ILLNESS
AB Background: Oseltamivir reduces symptom duration among children with uncomplicated influenza, but few data exist on treatment efficacy and tolerability among hospitalized children, particularly among infants aged <1 year. We evaluated tolerability and efficacy of oseltamivir treatment of children aged 0-9 years hospitalized with influenza.
   Methods: We conducted a double-blind, randomized, placebo-controlled trial at tertiary care hospitals in El Salvador and Panama. Primary outcomes were length of hospitalization and increased work of breathing. Children were eligible if hospitalized <7 days after symptom onset with cough or sore throat plus tachypnea. Children were randomized 1:1 to receive oseltamivir or placebo; had swabs collected at enrollment for influenza RT-PCR testing; were assessed at enrollment and every 12 h for work of breathing; and were followed for adverse events through 7 days after discharge. Analyses were intention-to-treat.
   Results: Overall, 683 children were randomized (oseltamivir, n = 341, placebo n = 342). Fifty-three percent were aged <1 year and 30 had influenza (oseltamivir, n = 19; placebo, n = 11). The study was terminated early after enrollment of 21% of the sample size due to lower than anticipated participant accrual. Using Kaplan-Meier analysis, there was no significant difference in median length of hospitalization (3 days, IQR 2-4 vs. 5 days, IQR 3-7, p = 0.22) and increased work of breathing (36 h, IQR 24-72 vs. 9611, IQR 13-108, p = 0.14) between oseltamivir versus placebo recipients. There was no difference in adverse events between groups.
   Conclusion: Oseltamivir treatment was well tolerated among hospitalized children, including among infants aged <1 year. Published by Elsevier B.V.
C1 [Dawood, Fatimah S.; Fry, Alicia M.; Gubareva, Larisa; Tamura, Daisuke; Hughes, Michael; Gargiullo, Paul; Azziz-Baumgartner, Eduardo; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, CDC, Atlanta, GA USA.
   [Jara, Jorge] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala.
   [Gonzalez, Rosalba; Franco, Danilo; Castillo, Marlene] Gorgas Mem Inst Hlth Studies, Panama City, Panama.
   [Miguel Castillo, Juan; de Viana, Dinora] Hosp San Juan Dios, Santa Ana, El Salvador.
   [De Leon, Tirza; Barahona, Alfredo] Hosp Materno Infantil Jose Domingo De Obaldia, David, Panama.
   [Estripeaut, Dora; Rodriguez, Mariana] Hosp Del Nino, Panama City, Panama.
   [Luciani, Kathia; Lawson, Aracelis M.] Hosp Especialidades Pediat Omar Torrijos, Panama City, Panama.
   [Sujey Brizuela, Yarisa; Antonio Cazares, Rafael] Hosp San Juan Dios, San Miguel, El Salvador.
   [Clara, Wilfrido] CDC Cent Amer Reg Off, San Salvador, El Salvador.
RP Dawood, FS (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS A-32, Atlanta, GA 30329 USA.
EM fdawood@cdc.gov
FU US Centers for Disease Control and Prevention [RFA-GH-13-00102CONT14];
   Universidad del Valle de Guatemala
FX This study was funded by the US Centers for Disease Control and
   Prevention through Cooperative Agreement number RFA-GH-13-00102CONT14
   with the Universidad del Valle de Guatemala.
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD SEP
PY 2016
VL 133
BP 85
EP 94
DI 10.1016/j.antiviral.2016.07.007
PG 10
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA DY1LJ
UT WOS:000384856200010
PM 27451343
ER

PT J
AU Ezeanolue, EE
   Nwizu, C
   Greene, GS
   Amusu, O
   Chukwuka, C
   Ndembi, N
   Smith, RM
   Chiller, T
   Pharr, J
   Kozel, TR
AF Ezeanolue, Echezona E.
   Nwizu, Chidi
   Greene, Gregory S.
   Amusu, Olatilewa
   Chukwuka, Chinwe
   Ndembi, Nicaise
   Smith, Rachel M.
   Chiller, Tom
   Pharr, Jennifer
   Kozel, Thomas R.
TI Geographical Variation in Prevalence of Cryptococcal Antigenemia Among
   HIV-Infected, Treatment-Naive Patients in Nigeria: A Multicenter
   Cross-Sectional Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE AIDS; cryptococcal antigen; cryptococcal meningitis; retrospective
   cross-sectional study; sub-Saharan Africa; Nigeria
ID ACTIVE SURVEILLANCE; NEOFORMANS; MENINGITIS; BURDEN
AB Objective:Worldwide, HIV-associated cryptococcal meningitis affects approximately 1 million persons and causes 600,000 deaths each year mostly in sub-Saharan Africa. Limited data exist on cryptococcal meningitis and antigenemia in Nigeria, and most studies are geographically restricted. We determined the prevalence of cryptococcal antigenemia (CrAg) among HIV-infected, treatment-naive individuals in Nigeria.Design/Methods:This was a retrospective, cross-sectional study across 4 geographic regions in Nigeria. We performed CrAg testing using a lateral flow immunoassay on archived whole-blood samples collected from HIV-infected participants at US President's Emergency Plan for AIDS Relief (PEPFAR)-supported sites selected to represent the major geographical and ethnic diversity in Nigeria. Eligible samples were collected from consenting patients (>15 years) naive to antiretroviral therapy with CD4(+) count less than 200 cells per cubic millimeter and were stored in an -80 degrees C freezer.Results:A total of 2752 stored blood samples were retrospectively screened for CrAg. Most of the samples were from participants aged 30-44 years (57.6%), and 1570 (57.1%) were from women. The prevalence of CrAg positivity in specimens with CD4 <200 cells per cubic millimeter was 2.3% (95% confidence interval: 1.8% to 3.0%) and varied significantly across the 4 regions (P < 0.001). At 4.4% (3.2% to 5.9%), the South East contained the highest prevalence.Conclusions:The significant regional variation in CrAg prevalence found in Nigeria should be taken into consideration as plans are made to integrate routine screening into clinical care for HIV-infected patients.
C1 [Ezeanolue, Echezona E.; Pharr, Jennifer] Univ Nevada, Sch Community Hlth Sci, Global Hlth Initiat, Las Vegas, NV 89154 USA.
   [Ezeanolue, Echezona E.] Univ Nevada, Sch Med, Dept Pediat, Las Vegas, NV 89154 USA.
   [Nwizu, Chidi] Nigeria CCCRN, Ctr Clin Care & Clin Res, Abuja, Nigeria.
   [Greene, Gregory S.; Smith, Rachel M.; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA.
   [Amusu, Olatilewa] Nigerian Army Reference Hosp, Lagos, Nigeria.
   [Chukwuka, Chinwe] Univ Nigeria Enugu Campus, Dept Med, Coll Med, Enugu, Nigeria.
   [Ndembi, Nicaise] Inst Human Virol Nigeria, Abuja, Nigeria.
   [Kozel, Thomas R.] Univ Nevada, Sch Med, Dept Microbiol & Immunol, Reno, NV 89557 USA.
RP Ezeanolue, EE (reprint author), Univ Nevada, Sch Community Hlth Sci, UNLV Global Hlth Initiat, 4505 S Maryland Pkwy,Box 454009, Las Vegas, NV 89154 USA.
EM echezona.ezeanolue@unlv.edu
FU Clinton Health Access Initiative (CHAI); Centre for Clinical Care and
   Clinical Research, Nigeria (CCCRN); University of Nevada School of
   Medicine; Public Health Service Grants from the National Institutes of
   Health [AI014209, AI093365, HD075050]
FX Supported by the Clinton Health Access Initiative (CHAI). Additional
   support for this study was provided by the Centre for Clinical Care and
   Clinical Research, Nigeria (CCCRN), the University of Nevada School of
   Medicine, and Public Health Service Grants AI014209 and AI093365 and
   HD075050 from the National Institutes of Health. The funding agencies
   played no role in the study conception, design, data collection, data
   analysis, data interpretation, or writing of the report.
NR 23
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2016
VL 73
IS 1
BP 117
EP 121
DI 10.1097/QAI.0000000000001048
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DW3SQ
UT WOS:000383563500018
PM 27144527
ER

PT J
AU Tong, X
   Chu, EK
   Fang, J
   Wall, HK
   Ayala, C
AF Tong, Xin
   Chu, Elizabeth K.
   Fang, Jing
   Wall, Hilary K.
   Ayala, Carma
TI Nonadherence to Antihypertensive Medication Among Hypertensive Adults in
   the United StatesHealthStyles, 2010
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID BLOOD-PRESSURE CONTROL; DEPRESSIVE SYMPTOMS; ADHERENCE; DISEASE; HEALTH;
   CARE; BARRIERS; TRIAL; INTERVENTIONS; ASSOCIATION
AB Nonadherence, or not taking medications as prescribed, to antihypertensive medications has been associated with uncontrolled hypertension. The authors analyzed data from HealthStyles 2010 to assess medication nonadherence among adults with hypertension. The overall prevalence of hypertension was 27.4% and the prevalence of nonadherence was 30.5% among hypertensive adult respondents. Nonadherence rates were highest among younger adults (aged 18-44 years), Hispanics, those who reported lowest annual income (<$25,000), and those who reported depression. The most common reason stated for nonadherence was I cannot afford the medication (35.1%). A multivariate logistic regression model showed age, race, and household income to be associated with nonadherence. These findings suggest that certain subgroups are more likely to report barriers to adherence. Interventions to support the management of hypertension should consider the identification of certain at-risk subgroups and utilize community and clinical evidenced-based resources to improve long-term control.
C1 [Tong, Xin; Chu, Elizabeth K.; Fang, Jing; Wall, Hilary K.; Ayala, Carma] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS-F77, Atlanta, GA 30341 USA.
RP Tong, X (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS-F77, Atlanta, GA 30341 USA.
EM xtong@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 41
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD SEP
PY 2016
VL 18
IS 9
BP 892
EP 900
DI 10.1111/jch.12786
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DX9WF
UT WOS:000384747000011
PM 26841710
ER

PT J
AU McCarty, CL
   Karwowski, MP
   Basler, C
   Erme, M
   Kippes, C
   Quinn, K
   de Fijter, S
   DiOrio, M
   Braden, C
   Knust, B
   Santibanez, S
AF McCarty, Carolyn L.
   Karwowski, Mateusz P.
   Basler, Colin
   Erme, Marguerite
   Kippes, Chris
   Quinn, Kim
   de Fijter, Sietske
   DiOrio, Mary
   Braden, Christopher
   Knust, Barbara
   Santibanez, Scott
TI Identifying and Addressing the Daily Needs of Contacts of an Ebola
   Patient During Investigation, Monitoring, and Movement Restriction, Ohio
SO PUBLIC HEALTH REPORTS
LA English
DT Editorial Material
ID UNITED-STATES; PARTNERSHIPS; QUARANTINE; EXPERIENCE; COMMUNITY; SARS
C1 [McCarty, Carolyn L.; Karwowski, Mateusz P.; Basler, Colin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.
   [McCarty, Carolyn L.; Quinn, Kim; de Fijter, Sietske; DiOrio, Mary] Ohio Dept Hlth, 246 N High St, Columbus, OH 43215 USA.
   [Karwowski, Mateusz P.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Atlanta, GA USA.
   [Basler, Colin; Braden, Christopher] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
   [Erme, Marguerite] Summit Cty Publ Hlth, Akron, OH USA.
   [Kippes, Chris] Cuyahoga Cty Board Hlth, Parma, OH USA.
   [Knust, Barbara] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA.
   [Santibanez, Scott] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA.
RP de Fijter, S (reprint author), Ohio Dept Hlth, 246 N High St, Columbus, OH 43215 USA.
EM sietske.defijter@odh.ohio.gov
NR 14
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0033-3549
EI 1468-2877
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD SEP-OCT
PY 2016
VL 131
IS 5
BP 661
EP 665
DI 10.1177/0033354916660087
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LT
UT WOS:000384275300003
PM 28123205
ER

PT J
AU Santibanez, S
   Polgreen, PM
   Beekmann, SE
   Cairns, C
   Filice, GA
   Layton, M
   Hughes, JM
AF Santibanez, Scott
   Polgreen, Philip M.
   Beekmann, Susan E.
   Cairns, Catherine
   Filice, Gregory A.
   Layton, Marcelle
   Hughes, James M.
TI Communication Between Infectious Disease Physicians and US State and
   Local Public Health Agencies: Strengths, Challenges, and Opportunities
SO PUBLIC HEALTH REPORTS
LA English
DT Article
DE emerging infectious diseases; communications; mobile smartphone
   applications
ID UNITED-STATES
AB Strong working relationships between infectious disease (ID) physicians and public health have resulted in the early detection of emerging infectious threats. From May 6 through June 5, 2015, we surveyed ID physicians in the Infectious Diseases Society of America's Emerging Infections Network about communications with public health. A total of 688 of 1491 (46%) members completed the survey, 624 (91%) of whom knew how to reach their health department directly for an urgent issue. Only 38 (6%) described communications with their health department as poor. Interest in newer technologies (eg, mobile smartphone applications) showed mixed results. Interest in a smartphone application differed significantly by years of ID experience, with 8 I of 146 (55%) respondents with <5 years of ID experience, 172 of 359 (48%) respondents with 5 to 24 years of ID experience, and 6 I of 183 (33%) respondents with >25 years of ID experience in favor of a smartphone application (P<.001). As more physicians adopt newer communication technologies, health departments should be prepared to incorporate these tools to communicate with ID physicians.
C1 [Santibanez, Scott] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, 1600 Clifton Rd NE,MS-C18, Atlanta, GA 30333 USA.
   [Santibanez, Scott] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Polgreen, Philip M.] Univ Iowa, Emerging Infect Network, Iowa City, IA USA.
   [Beekmann, Susan E.; Cairns, Catherine] Assoc State & Terr Hlth Officials, Arlington, VA USA.
   [Filice, Gregory A.] Vet Affairs Med Ctr Med Serv, Infect Dis Sect, Minneapolis, MN USA.
   [Filice, Gregory A.] Univ Minnesota, Dept Med, Div Infect Dis, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Layton, Marcelle] New York City Dept Hlth & Mental Hyg, New York, NY USA.
   [Layton, Marcelle] Council State & Terr Epidemiologists, Atlanta, GA USA.
   [Hughes, James M.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
RP Santibanez, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, 1600 Clifton Rd NE,MS-C18, Atlanta, GA 30333 USA.
EM zqg5@cdc.gov
FU Centers for Disease Control and Prevention (CDC) [1U50CK000187]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This
   publication was supported by cooperative agreement #1U50CK000187 from
   the Centers for Disease Control and Prevention (CDC). Its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official views of CDC.
NR 11
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0033-3549
EI 1468-2877
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD SEP-OCT
PY 2016
VL 131
IS 5
BP 666
EP 670
DI 10.1177/0033354916660083
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LT
UT WOS:000384275300004
PM 28123206
ER

PT J
AU Walker, TY
   Smith, EA
   Fenton, N
   Lazaroff, JE
   Dusek, C
   Fineis, P
   Crowley, SA
   Benson, R
   Veselsky, SL
   Murphy, TV
AF Walker, Tanja Y.
   Smith, Emily A.
   Fenton, Nancy
   Lazaroff, Julie E.
   Dusek, Cristina
   Fineis, Patrick
   Crowley, Susan A.
   Benson, Ruthie
   Veselsky, Steven L.
   Murphy, Trudy V.
TI Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5
   US Public Health Jurisdictions, 2008-2012
SO PUBLIC HEALTH REPORTS
LA English
DT Article
DE hepatitis B; pregnancy; women
ID PERINATAL TRANSMISSION; ANTIVIRAL THERAPY; PREVENTION; MANAGEMENT;
   INTERVENTION; PREVALENCE; STRATEGIES; GUIDELINES; STATES
AB Objective. We estimated the prevalence of hepatitis B surface antigen (HBsAg), a serologic marker of active hepatitis B virus (HBV) infection, among pregnant women, and estimated the proportion HBsAg-positive pregnant women who had received additional recommended testing.
   Methods. From 2008 through 2012, Perinatal Hepatitis B Prevention Programs (PHBPPs) in Florida, Michigan, Minnesota, New York City, and Texas prospectively collected data on demographic characteristics of HBsAg-positive pregnant women. We estimated the prevalence of HBsAg positivity among pregnant women by demographic characteristics using natality data. PHBPPs (excluding Texas) collected additional recommended testing (for hepatitis B e antigen [HBeAg] and/or HBV deoxyribonucleic acid [DNA]) among HBsAg-positive pregnant women to measure levels of viremia.
   Results. During the study period, 15,205 HBsAg-positive women were case-managed. The median age of HBsAg-positive women was 29 years; prenatal HBsAg screening was at a median of 27 weeks pre-delivery. Of 15,205 HBsAg-positive women, 11,293 (74.3%) were foreign-born. In four PHBPPs with 14,098 pregnancies among 12,214 HBsAg-positive women, HBeAg and/or HBV DNA testing was documented for 2,794 (19.8%) pregnancies. The estimated prevalence of HBsAg positivity among pregnant women was 0.38% (17,023 of 4,468,773). HBsAg prevalence was highest among foreign-born women from most regions in Asia (2.0% to 8.7%; with the exception of South Asia, 0.4%) and Africa (3.4%).
   Conclusion. One-fifth of HBsAg-positive pregnant women had documentation for HBeAg and/or HBV DNA, and about one-third reported receiving care for HBV infection during a case-managed pregnancy. Greater emphasis is needed on prenatal evaluation for HBV liver disease care and treatment among pregnant women with HBV infection.
C1 [Walker, Tanja Y.; Smith, Emily A.; Veselsky, Steven L.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30333 USA.
   [Fenton, Nancy] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA.
   [Lazaroff, Julie E.] Bur Immunizat, New York City Dept Hlth & Mental Hyg, Perinatal Hepatitis Prevent Unit B, New York, NY USA.
   [Dusek, Cristina] Florida Dept Hlth, Div Dis Control, Tallahassee, FL USA.
   [Fineis, Patrick] Michigan Dept Community Hlth, Div Immunizat, Lansing, MI USA.
   [Crowley, Susan A.] Minnesota Dept Hlth, Hepatitis Unit, Cross Cutting Sect, Infect Dis Epidemiol Prevent & Control, St Paul, MN USA.
   [Benson, Ruthie] Texas Dept State Hlth Serv, ACE Unit, Immunizat Branch, Austin, TX USA.
RP Walker, TY (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30333 USA.
EM tywalker@cdc.gov
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0033-3549
EI 1468-2877
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD SEP-OCT
PY 2016
VL 131
IS 5
BP 685
EP 694
DI 10.1177/0033354916663183
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3LT
UT WOS:000384275300007
PM 28123209
ER

PT J
AU Scott, C
   Cavanaugh, JS
   Pratt, R
   Silk, BJ
   LoBue, P
   Moonan, PK
AF Scott, Colleen
   Cavanaugh, Joseph S.
   Pratt, Robert
   Silk, Benjamin J.
   LoBue, Philip
   Moonan, Patrick K.
TI Human Tuberculosis Caused by Mycobacterium bovis in the United States,
   2006-2013
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Mycobacterium bovis; tuberculosis; epidemiology; trends
ID TO-PERSON TRANSMISSION; MEXICO BORDER; RISK-FACTORS; RESISTANT
   TUBERCULOSIS; EPIDEMIOLOGY; CALIFORNIA; DISEASE; IDENTIFICATION;
   CHILDREN
AB Background. Using genotyping techniques that have differentiated Mycobacterium bovis from Mycobacterium tuberculosis since 2005, we review the epidemiology of human tuberculosis caused by M. bovis in the United States and validate previous findings nationally.
   Methods. All tuberculosis cases with a genotyped M. tuberculosis complex isolate reported during 2006-2013 in the United States were eligible for analysis. We used binomial regression to identify characteristics independently associated with M. bovis disease using adjusted prevalence ratios (aPRs) and corresponding 95% confidence intervals (CIs).
   Results. During 2006-2013, the annual percentages of tuberculosis cases attributable to M. bovis remained consistent nationally (range, 1.3%-1.6%) among all tuberculosis cases (N = 59 273). Compared with adults 25-44 years of age, infants aged 0-4 years (aPR, 1.9 [95% CI, 1.4-2.8]) and children aged 5-14 years (aPR, 4.0 [95% CI, 3.1-5.3]) had higher prevalences of M. bovis disease. Patients who were foreign-born (aPR, 1.4 [95% CI, 1.2-1.7]), Hispanic (aPR, 3.9 [95% CI, 3.0-5.0]), female (aPR, 1.4 [95% CI, 1.3-1.6]), and resided in US-Mexico border counties (aPR, 2.0 [95% CI, 1.7-2.4]) also had higher M. bovis prevalences. Exclusively extrapulmonary disease (aPR, 3.7 [95% CI, 3.3-4.2]) or disease that was both pulmonary and extrapulmonary (aPR, 2.4 [95% CI, 2.1-2.9]) were associated with a higher prevalence of M. bovis disease.
   Conclusions. Children, foreign-born persons, Hispanics, and females are disproportionately affected by M. bovis, which was independently associated with extrapulmonary disease. Targeted prevention efforts aimed at Hispanic mothers and caregivers are warranted.
C1 [Scott, Colleen] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Atlanta, GA USA.
   [Scott, Colleen; Cavanaugh, Joseph S.; Moonan, Patrick K.] Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA USA.
   [Pratt, Robert; Silk, Benjamin J.; LoBue, Philip] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
RP Scott, C (reprint author), Ctr Dis Control & Prevent, Div Global HIV & TB, Global TB Branch, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA.
EM ibk9@cdc.gov
FU Centers for Disease Control and Prevention (CDC)
FX This project was supported by the Centers for Disease Control and
   Prevention (CDC). All authors from this publication are employed by the
   CDC.
NR 40
TC 3
Z9 3
U1 4
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2016
VL 63
IS 5
BP 594
EP 601
DI 10.1093/cid/ciw371
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DW7TZ
UT WOS:000383856300005
PM 27298329
ER

PT J
AU Marks, M
   Yin, YP
   Chen, XS
   Castro, A
   Causer, L
   Guy, R
   Wangnapi, R
   Mitja, O
   Aziz, A
   Castro, R
   Pereira, FDM
   Taleo, F
   Guinard, J
   Belec, L
   Tun, Y
   Bottomley, C
   Ballard, RC
   Mabey, DCW
AF Marks, Michael
   Yin, Yue-Ping
   Chen, Xiang-Sheng
   Castro, Arnold
   Causer, Louise
   Guy, Rebecca
   Wangnapi, Regina
   Mitja, Oriol
   Aziz, Abdul
   Castro, Rita
   Martins Pereira, Filomena da Luz
   Taleo, Fasihah
   Guinard, Jerome
   Belec, Laurent
   Tun, Ye
   Bottomley, Christian
   Ballard, Ronald C.
   Mabey, David C. W.
TI Metaanalysis of the Performance of a Combined Treponemal and
   Nontreponemal Rapid Diagnostic Test for Syphilis and Yaws
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE syphilis; yaws; sexually transmitted infections; point-of-care test;
   metaanalysis
ID OF-CARE TEST; ANTIBODIES; INFECTION; PALLIDUM; MALARIA; EPIDEMIOLOGY;
   PREGNANCY; TANZANIA; PATIENT
AB Background. The human treponematoses are important causes of disease. Mother-to-child transmission of syphilis remains a major cause of stillbirth and neonatal death. There are also almost 100 000 cases of endemic treponemal disease reported annually, predominantly yaws. Rapid diagnostic tests (RDTs) would improve access to screening for these diseases. Most RDTs cannot distinguish current and previous infection. The Dual Path Platform (DPP) Syphilis Screen & Confirm test includes both a treponemal (T1) and nontreponemal (T2) component and may improve the accuracy of diagnosis.
   Methods. We conducted a metaanalysis of published and unpublished evaluations of the DPP-RDT for the diagnosis of syphilis and yaws. We calculated the sensitivity, specificity, and overall agreement of the test compared with reference laboratory tests.
   Results. Nine evaluations, including 7267 tests, were included. Sensitivity was higher in patients with higher titer rapid plasma reagin (>= 1:16) for both the T1 (98.2% vs 90.1%, P < .0001) and the T2 component (98.2% vs 80.6%, P < .0001). Overall agreement between the DPP test and reference serology was 85.2% (84.4%-86.1%). Agreement was highest for high-titer active infection and lowest for past infection.
   Conclusions. The RDT has good sensitivity and specificity of the treponemal and nontreponemal components both in cases of suspected syphilis and yaws, although the sensitivity is decreased at lower antibody titers.
C1 [Marks, Michael; Mabey, David C. W.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Clin Res Dept, London, England.
   [Marks, Michael; Mabey, David C. W.] Univ Coll London Hosp NHS Trust, Hosp Trop Dis, London, England.
   [Yin, Yue-Ping; Chen, Xiang-Sheng] China Ctr Dis Control & Prevent, Natl Ctr STD Control, Beijing, Peoples R China.
   [Yin, Yue-Ping; Chen, Xiang-Sheng] Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China.
   [Yin, Yue-Ping; Chen, Xiang-Sheng] Hosp Skin Dis, Nanjing, Jiangsu, Peoples R China.
   [Castro, Arnold] Ctr Dis Control & Prevent, Lab Reference, Div STD Prevent, Atlanta, GA USA.
   [Castro, Arnold] Ctr Dis Control & Prevent, Res Branch, Div STD Prevent, Atlanta, GA USA.
   [Causer, Louise; Guy, Rebecca] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Wangnapi, Regina] Papua New Guinea Inst Med Res, Goroka, Eastern Highlan, Papua N Guinea.
   [Mitja, Oriol] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth, Barcelona Ctr Int Hlth Res, E-08007 Barcelona, Spain.
   [Mitja, Oriol] Int SOS, Lihir Med Ctr, Newcrest Mining, Lihir Island, Papua N Guinea.
   [Aziz, Abdul] Ghana Hlth Serv, Accra, Ghana.
   [Castro, Rita; Martins Pereira, Filomena da Luz] Inst Higiene & Med Trop, Unidade Microbiol Med, Lisbon, Portugal.
   [Taleo, Fasihah] Minist Hlth, Port Vila, Vanuatu.
   [Guinard, Jerome] Ctr Hosp Reg Orleans, Lab Microbiol, Orleans, France.
   [Belec, Laurent] Hop Europeen Georges Pompidou, AP HP, Lab Microbiol, Paris, France.
   [Belec, Laurent] Univ Paris 05, Sorbonne Paris Cite, Fac Med Paris Descartes, Paris, France.
   [Tun, Ye; Ballard, Ronald C.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA.
   [Bottomley, Christian] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
RP Marks, M (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England.
EM michael.marks@lshtm.ac.uk
OI Marks, Michael/0000-0002-7585-4743; Mitja, Oriol/0000-0003-3266-8868
FU Wellcome Trust [WT102807]
FX Chembio donated test kits used in some of the original publications.
   They had no role in any stage of this metaanalysis. M. M. is supported
   by a Wellcome Trust Clinical Research Fellowship (WT102807).
NR 25
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2016
VL 63
IS 5
BP 627
EP 633
DI 10.1093/cid/ciw348
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DW7TZ
UT WOS:000383856300010
PM 27217216
ER

PT J
AU Hoots, BE
   Finlayson, T
   Nerlander, L
   Paz-Bailey, G
AF Hoots, Brooke E.
   Finlayson, Teresa
   Nerlander, Lina
   Paz-Bailey, Gabriela
CA Natl HIV Behav Surveillance Study
TI Willingness to Take, Use of, and Indications for Pre-exposure
   Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; pre-exposure prophylaxis; PrEP; MSM; United States
ID UNITED-STATES; HIV RISK; WHITE MEN; PREVENTION; DISPARITIES; BEHAVIORS;
   BLACK; SURVEILLANCE; METAANALYSIS; INFECTION
AB Background. Pre-exposure prophylaxis (PrEP) is an effective prevention tool for people at substantial risk of acquiring human immunodeficiency virus (HIV). To monitor the current state of PrEP use among men who have sex with men (MSM), we report on willingness to use PrEP and PrEP utilization. To assess whether the MSM subpopulations at highest risk for infection have indications for PrEP according to the 2014 clinical guidelines, we estimated indications for PrEP for MSM by demographics.
   Methods. We analyzed data from the 2014 cycle of the National HIV Behavioral Surveillance (NHBS) system among MSM who tested HIV negative in NHBS and were currently sexually active. Adjusted prevalence ratios and 95% confidence intervals were estimated from log-linked Poisson regression with generalized estimating equations to explore differences in willingness to take PrEP, PrEP use, and indications for PrEP.
   Results. Whereas over half of MSM said they were willing to take PrEP, only about 4% reported using PrEP. There was no difference in willingness to take PrEP between black and white MSM. PrEP use was higher among white compared with black MSM and among those with greater education and income levels. Young, black MSM were less likely to have indications for PrEP compared with young MSM of other races/ethnicities.
   Conclusions. Young, black MSM, despite being at high risk of HIV acquisition, may not have indications for PrEP under the current guidelines. Clinicians may need to consider other factors besides risk behaviors such as HIV incidence and prevalence in subgroups of their communities when considering prescribing PrEP.
C1 [Hoots, Brooke E.; Finlayson, Teresa; Nerlander, Lina; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Nerlander, Lina] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
RP Hoots, BE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30329 USA.
EM bhoots@cdc.gov
FU NHBS by the CDC [PS11-001]
FX This work was supported by funding of NHBS by the CDC (PS11-001).
NR 20
TC 4
Z9 4
U1 7
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2016
VL 63
IS 5
BP 672
EP 677
DI 10.1093/cid/ciw367
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DW7TZ
UT WOS:000383856300018
PM 27282710
ER

PT J
AU Kobau, R
   Cui, WJ
   Zack, MM
AF Kobau, Rosemarie
   Cui, Wanjun
   Zack, Matthew M.
TI More than 40% of those not taking antiseizure medication with recent
   seizures reported that epilepsy or its treatment interfered with their
   recent activities, 2010 and 2013 US National Health Interview Surveys
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Activity limitation; Adults; Epilepsy; Seizures; National Health
   Interview Survey
AB From the combined 2010 and 2013 National Health Interview Surveys, we estimated US national age standardized prevalence of adults with active epilepsy who reported that a nervous system/sensory organ condition caused a limitation (e.g., walking; memory; or physical, mental, or emotional problems) and, separately, that epilepsy interfered with their activities (e.g., working, schooling, or socializing) during the 30 days preceding the survey. Sixty-one percent of adults who took antiseizure medication and had recent seizures and 51% of those who took medication and had no seizures reported having limitations caused by a nervous system/sensory organ condition. Sixty-two percent of adults who took antiseizure medication and had recent seizures and 20% of those who took medication and had no seizures reported that epilepsy or its treatment interfered with their recent activities. Forty-one percent of those who did not take medication and had recent seizures also reported that epilepsy interfered with their activities. To reduce activity limitations in people with epilepsy, health and social service providers can ensure that adequate policies and practices that promote access to high quality care and social participation are in effect in organizations and communities. Published by Elsevier Inc.
C1 [Kobau, Rosemarie; Cui, Wanjun; Zack, Matthew M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Epilepsy Program, 4770 Buford Highway NE,MS F-78, Atlanta, GA 30341 USA.
RP Cui, WJ (reprint author), Epilepsy Program, Div Populat Hlth, 4770 Buford Highway NE,MS F-78, Atlanta, GA 30341 USA.
NR 11
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD SEP
PY 2016
VL 62
BP 129
EP 131
DI 10.1016/j.yebeh.2016.06.013
PG 3
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DX5AP
UT WOS:000384392500022
PM 27459033
ER

PT J
AU Kroner, BL
   Fahimi, M
   Gaillard, WD
   Kenyon, A
   Thurman, DJ
AF Kroner, Barbara L.
   Fahimi, Mansour
   Gaillard, William D.
   Kenyon, Anne
   Thurman, David J.
TI Epilepsy or seizure disorder? The effect of cultural and socioeconomic
   factors on self-reported prevalence
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Seizure disorder; Prevalence; Race; Self-report; Cultural bias; Stigma
ID UNITED-STATES; ADULTS; SURVEILLANCE; VALIDATION; COMMUNITY
AB Self-reported epilepsy may be influenced by culture, knowledge, and beliefs. We screened 6420 residents of the District of Columbia (DC) for epilepsy to investigate whether socio-demographics were associated with whether they reported their diagnosis as epilepsy or as seizure disorder. Lifetime and active prevalence rates were 0.54% and 0.21%, respectively for 'epilepsy' and 1.30% and 0.70%, respectively for 'seizure disorder'. Seizure disorder was reported significantly more often than epilepsy among blacks, females, respondents 50 years, those with lower level education, respondents who lived alone and in low income neighborhoods, and those who resided in DC for at least five years. Clinicians should assure that patients and caregivers understand that epilepsy is synonymous with seizure disorder and other culturally appropriate terms, in order to optimize compliance with treatment, disease management instructions, and utilization of other resources targeted at persons with epilepsy. Furthermore, education and awareness campaigns aimed at improving access-to-care, reducing stigma, and increasing awareness of adverse events, such as SUDEP, should include a more diverse definition of epilepsy in their messages. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Kroner, Barbara L.] RTI Int, Biostat & Epidemiol Div, 6110 Execut Blvd, Rockville, MD 20852 USA.
   [Fahimi, Mansour] LLC Mkt & Data Sci, GfK Custom Res, Wayne, PA USA.
   [Gaillard, William D.] Childrens Natl Hlth Syst, Div Epilepsy & Neurophysiol, 111 Michigan Ave NW, Washington, DC 20010 USA.
   [Kenyon, Anne] RTI Int, Survey Res Div, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
   [Thurman, David J.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Thurman, David J.] Emory Clin, Sch Med, 540 Asbury Circle, Atlanta, GA 30322 USA.
RP Kroner, BL (reprint author), RTI Int, 6110 Execut Blvd, Rockville, MD 20852 USA.
EM byk@rti.org; mansour.fahimi@gfk.com; wgaillar@childrensnational.org;
   aek@rti.org; david.j.thurman@emory.edu
FU Centers for Disease Control and Prevention (CDC) through the Association
   for Prevention Teaching and Research (APTR) [5U50CD300860, TS-1389]
FX This work was supported by the Centers for Disease Control and
   Prevention (CDC) through the Association for Prevention Teaching and
   Research (APTR) [Cooperative Agreement, No. 5U50CD300860, Project
   TS-1389]. The findings and conclusions in this paper are those of the
   authors and do not necessarily represent the views of the CDC or the
   APTR.
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD SEP
PY 2016
VL 62
BP 214
EP 217
DI 10.1016/j.yebeh.2016.07.013
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DX5AP
UT WOS:000384392500038
PM 27494358
ER

PT J
AU Santibanez, S
   Polgreen, PM
   Beekmann, SE
   Rupp, ME
   Del Rio, C
AF Santibanez, Scott
   Polgreen, Philip M.
   Beekmann, Susan E.
   Rupp, Mark E.
   Del Rio, Carlos
TI Infectious Disease Physicians' Perceptions About Ebola Preparedness
   Early in the US Response: A Qualitative Analysis and Lessons for the
   Future
SO HEALTH SECURITY
LA English
DT Article
ID PUBLIC-HEALTH; VIRUS DISEASE
AB On September 30, 2014, the first US patient with Ebola virus disease was diagnosed. Hospitals and healthcare systems identified many complex issues that needed to be addressed to prepare for possible future outbreaks. Here we summarize themes identified in free text responses from a query of infectious disease physicians from the Infectious Disease Society of America's (IDSA) Emerging Infections Network (EIN) early in the domestic Ebola response and place them into the context of biopreparedness for possible future events. We queried infectious disease physician members of the EIN from October 21-November 11, 2014, about their institutions' experience with Ebola preparedness at that time. Of 1,566 EIN physicians, 869 replied to this query, and 318 provided 448 write-in comments in response to the question, What gaps have been identified in order for facilities to safely care for suspected Ebola patients? or in a section for general comments. Six themes emerged from the responses: the unique challenges faced by small community hospitals (87 comments), the burden placed on infectious disease and infection control staff (61), ethical questions and planning for vulnerable populations (40), misinformation and stigma (29), financial issues faced by response staff (27), and long-term sustainability (16). This qualitative analysis provides insights into early thinking about challenges in preparing for Ebola and other emerging infections in the United States. The themes identified here should be considered during local, state, and national planning.
C1 [Santibanez, Scott] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, CDC, Atlanta, GA USA.
   [Polgreen, Philip M.] Univ Iowa, Coll Publ Hlth, Emerging Infect Network, Carver Coll Med, Iowa City, IA USA.
   [Beekmann, Susan E.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
   [Rupp, Mark E.] Univ Nebraska Med Ctr, Div Infect Dis, Internal Med, Omaha, NE USA.
   [Del Rio, Carlos] Emory Univ, Sch Med, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA USA.
   [Del Rio, Carlos] Emory Univ, Sch Med, Div Infect Dis, Med, Atlanta, GA USA.
RP Santibanez, S (reprint author), CAPT US Publ Hlth Serv, 1600 Clifton Rd MS C18, Atlanta, GA 30333 USA.; Santibanez, S (reprint author), CDC, Div Preparedness & Emerging Infect, Sci, 1600 Clifton Rd MS C18, Atlanta, GA 30333 USA.
EM zqg5@cdc.gov
RI del Rio, Carlos/B-3763-2012
OI del Rio, Carlos/0000-0002-0153-3517
NR 12
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2326-5094
EI 2326-5108
J9 HEALTH SECUR
JI Health Secur.
PD SEP-OCT
PY 2016
VL 14
IS 5
BP 345
EP 350
DI 10.1089/hs.2016.0038
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX7BU
UT WOS:000384541800007
PM 27584854
ER

PT J
AU Ramage, JG
   Prentice, KW
   DePalma, L
   Venkateswaran, KS
   Chivukula, S
   Chapman, C
   Bell, M
   Datta, S
   Singh, A
   Hoffmaster, A
   Sarwar, J
   Parameswaran, N
   Joshi, M
   Thirunavkkarasu, N
   Krishnan, V
   Morse, S
   Avila, JR
   Sharma, S
   Estacio, PL
   Stanker, L
   Hodge, DR
   Pillai, SP
AF Ramage, Jason G.
   Prentice, Kristin W.
   DePalma, Lindsay
   Venkateswaran, Kodumudi S.
   Chivukula, Sruti
   Chapman, Carol
   Bell, Melissa
   Datta, Shomik
   Singh, Ajay
   Hoffmaster, Alex
   Sarwar, Jawad
   Parameswaran, Nishanth
   Joshi, Mrinmayi
   Thirunavkkarasu, Nagarajan
   Krishnan, Viswanathan
   Morse, Stephen
   Avila, Julie R.
   Sharma, Shashi
   Estacio, Peter L.
   Stanker, Larry
   Hodge, David R.
   Pillai, Segaran P.
TI Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow
   Assay for the Presumptive Identification of Bacillus anthracis Spores in
   Suspicious White Powders and Environmental Samples
SO HEALTH SECURITY
LA English
DT Article
ID INHALATIONAL ANTHRAX; INFECTION; IMMUNOASSAY; AGENTS; THURINGIENSIS;
   PERFORMANCE; ANTIGEN; CEREUS
AB We conducted a comprehensive, multiphase laboratory evaluation of the Anthrax BioThreat Alert((R)) test strip, a lateral flow immunoassay (LFA) for the rapid detection of Bacillus anthracis spores. The study, conducted at 2 sites, evaluated this assay for the detection of spores from the Ames and Sterne strains of B. anthracis, as well as those from an additional 22 strains. Phylogenetic near neighbors, environmental background organisms, white powders, and environmental samples were also tested. The Anthrax LFA demonstrated a limit of detection of about 10(6) spores/mL (ca. 1.5x10(5) spores/assay). In this study, overall sensitivity of the LFA was 99.3%, and the specificity was 98.6%. The results indicated that the specificity, sensitivity, limit of detection, dynamic range, and repeatability of the assay support its use in the field for the purpose of qualitatively evaluating suspicious white powders and environmental samples for the presumptive presence of B. anthracis spores.
C1 [Ramage, Jason G.] BAI Inc, Washington, DC USA.
   [Prentice, Kristin W.] Sci Technol Directorate, DHS, Washington, DC USA.
   [DePalma, Lindsay; Chivukula, Sruti] Booz Allen Hamilton, Mclean, VA USA.
   [Venkateswaran, Kodumudi S.; Sarwar, Jawad; Parameswaran, Nishanth; Joshi, Mrinmayi] Omni Array Biotechnol, Rockville, MD USA.
   [Chivukula, Sruti] DHS, Washington, DC USA.
   [Chapman, Carol] Geneva Fdn, Silver Spring, MD USA.
   [Chapman, Carol] Naval Med Res Ctr, Silver Spring, MD USA.
   [Bell, Melissa; Hoffmaster, Alex] Ctr Dis Control & Prevent, CDC, Bacterial Special Pathogens Branch, Atlanta, GA USA.
   [Datta, Shomik] Vorsight, Washington, DC USA.
   [Singh, Ajay] Laulima Govt Solut, Aberdeen Proving Ground, MD USA.
   [Singh, Ajay] USAMRICD Neurobiol Toxicol Branch, Analyt Toxicol Div, Aberdeen Proving Ground, MD USA.
   [Thirunavkkarasu, Nagarajan] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA.
   [Sharma, Shashi] US FDA, Select Agents & Environm Pathogens, Mol Methods & Subtyping Branch, Ctr Food Safety & Appl Nutr, College Pk, MD USA.
   [Krishnan, Viswanathan] Calif State Univ Fresno, Phys Chem, Fresno, CA 93740 USA.
   [Morse, Stephen] CDC, Div Select Agents & Toxins, Atlanta, GA USA.
   [Avila, Julie R.] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA USA.
   [Estacio, Peter L.] Lawrence Berkeley Natl Lab, Hlth Serv, Berkeley, CA USA.
   [Stanker, Larry] USDA ARS, Foodborne Toxin Detect & Prevent Unit, Albany, CA USA.
   [Hodge, David R.] DHS S&T Chem & Biol Def Div, Washington, DC USA.
   [Pillai, Segaran P.] US FDA, Off Lab Sci & Safety, Silver Spring, MD 20993 USA.
RP Pillai, SP (reprint author), US FDA, Off Lab Sci & Safety, Silver Spring, MD 20993 USA.
EM Segaran.Pillai@fda.hhs.gov
FU Department of Homeland Security (DHS) Science and Technology Directorate
   (S&T) Homeland Security Research Projects Agency [HSHQDC-12-C-00071]
FX The authors wish to acknowledge the important contributions to this
   manuscript of Dr. Douglas L. Anders, Hazardous Materials Response Unit,
   Federal Bureau of Investigation Laboratory, Quantico, Virginia, and Dr.
   Sally Hojvat, Center for Devices and Radiological Health, Food and Drug
   Administration, Silver Spring, Maryland, for subject matter expert
   advice and consultation. We express our thanks and appreciation for
   their assistance in the preparation and execution of this project. This
   work was funded by Department of Homeland Security (DHS) Science and
   Technology Directorate (S&T) Homeland Security Research Projects Agency,
   Contract #HSHQDC-12-C-00071. The views expressed here are those of the
   authors and do not necessarily represent the position of DHS.
NR 54
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2326-5094
EI 2326-5108
J9 HEALTH SECUR
JI Health Secur.
PD SEP-OCT
PY 2016
VL 14
IS 5
BP 351
EP 365
DI 10.1089/hs.2016.0041
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX7BU
UT WOS:000384541800008
PM 27661796
ER

PT J
AU Palella, FJ
   Armon, C
   Chmiel, JS
   Brooks, JT
   Hart, R
   Lichtenstein, K
   Novak, RM
   Yangco, B
   Wood, K
   Durham, M
   Buchacz, K
AF Palella, F. J., Jr.
   Armon, C.
   Chmiel, J. S.
   Brooks, J. T.
   Hart, R.
   Lichtenstein, K.
   Novak, R. M.
   Yangco, B.
   Wood, K.
   Durham, M.
   Buchacz, K.
CA HOPS Investigators
TI CD4 cell count at initiation of ART, long-term likelihood of achieving
   CD4 > 750 cells/mm(3) and mortality risk
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID COMBINATION ANTIRETROVIRAL THERAPY; HIV-INFECTED INDIVIDUALS;
   CLINICAL-OUTCOMES; SURVIVAL; DEATH; AIDS; COHORT; HAART; TIME; ERA
AB We sought to evaluate associations between CD4 at ART initiation (AI), achieving CD4 > 750 cells/mm(3) (CD4 > 750), long-term immunological recovery and survival.
   This was a prospective observational cohort study. We analysed data from ART-naive patients seen in 1996-2012 and followed a parts per thousand yen3 years after AI. We used Kaplan-Meier (KM) methods and log-rank tests to compare time to achieving CD4 > 750 by CD4 at AI (CD4-AI); and Cox regression models and generalized estimating equations to identify factors associated with achieving CD4 > 750 and mortality risk.
   Of 1327 patients, followed for a median of 7.9 years, > 85% received ART for a parts per thousand yen75% of follow-up time; 64 died. KM estimates evaluating likelihood of CD4 > 750 during 5 years of follow-up, stratified by CD4-AI < 50, 50-199, 200-349, 350-499 and 500-750, were 20%, 25%, 56%, 80% and 87%, respectively (log-rank PaEuroS < aEuroS0.001). In adjusted models, CD4-AI a parts per thousand yen200 (versus CD4-AI < 200) was associated with achievement of CD4 > 750 [adjusted HR (aHR)aEuroS=aEuroS4.77]. Blacks were less likely than whites to achieve CD4 > 750 (33% versus 49%, aHRaEuroS=aEuroS0.77). Mortality rates decreased with increasing CD4-AI (PaEuroS=aEuroS0.004 across CD4 strata for AIDS causes and PaEuroS=aEuroS0.009 for non-AIDS death causes). Among decedents with CD4-AI a parts per thousand yen50, 56% of deaths were due to non-AIDS causes.
   Higher CD4-AI resulted in greater long-term CD4 gains, likelihood of achieving CD4 > 750, longer survival and decreased mortality regardless of cause. Over 80% of persons with CD4-AI a parts per thousand yen350 achieved CD4 > 750 by 4 years while 75% of persons with CD4-AI < 200 did not. These data confirm the hazards of delayed AI and support early AI.
C1 [Palella, F. J., Jr.; Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Armon, C.; Hart, R.; Wood, K.] Cerner Corp, Kansas City, MO USA.
   [Brooks, J. T.; Durham, M.; Buchacz, K.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Lichtenstein, K.] Eisenhower Med Ctr, Rancho Mirage, CA USA.
   [Novak, R. M.] Univ Illinois, Dept Med, Chicago, IL USA.
   [Yangco, B.] Infect Dis Res Inst, Tampa, FL USA.
RP Palella, FJ (reprint author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
EM f-palella@northwestern.edu
FU Centers for Disease Control and Prevention [200-2001-00133,
   200-2006-18797, 200-2011-41872, 200-2015-63931]
FX Funding was provided by the Centers for Disease Control and Prevention
   (contract numbers 200-2001-00133, 200-2006-18797, 200-2011-41872 and
   200-2015-63931).
NR 22
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD SEP
PY 2016
VL 71
IS 9
BP 2654
EP 2662
DI 10.1093/jac/dkw196
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA DW8NB
UT WOS:000383911600042
PM 27330061
ER

PT J
AU Yang, HO
   Haldeman, S
   Lu, ML
   Baker, D
AF Yang, Haiou
   Haldeman, Scott
   Lu, Ming-Lun
   Baker, Dean
TI Low Back Pain Prevalence and Related Workplace Psychosocial Risk
   Factors: A Study Using Data From the 2010 National Health Interview
   Survey
SO JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS
LA English
DT Article
DE Low Back Pain; Demographic Analysis; Workplace; Behavior; Psychology;
   Epidemiology
ID PERCEIVED JOB INSECURITY; WORK-FAMILY CONFLICT; PATIENT-CARE WORKERS;
   MUSCULOSKELETAL DISORDERS; UNITED-STATES; PROSPECTIVE COHORT; NECK PAIN;
   OCCUPATIONAL EXPOSURES; CARDIOVASCULAR-DISEASE; REPRESENTATIVE SAMPLE
AB Objectives: The objectives of this study were to estimate prevalence of low back pain, to investigate associations between low back pain and a set of emerging workplace risk factors, and to identify worker groups with an increased vulnerability for low back pain in the United States.
   Methods: The data used for this cross-sectional study came from the 2010 National Health Interview Survey, which was designed to collect data on health conditions and related risk factors from the US civilian population. The variance estimation method was used to compute weighted data for prevalence of low back pain. Multivariable logistic regression analyses stratified by sex and age were performed to determine the odds ratios (ORs) and the 95% confidence interval (CI) for low back pain. The examined work-related psychosocial risk factors included work-family imbalance, exposure to a hostile work environment, and job insecurity. Work hours, occupation, and other work organizational factors (nonstandard work arrangements and alternative shifts) were also examined.
   Results: The prevalence of self-reported low back pain in the previous 3 months among workers in the United States was 25.7% in 2010. Female or older workers were at increased risk of experiencing low back pain. We found significant associations between low back pain and a set of psychosocial factors, including work-family imbalance (OR 1.27, CI 1.15-1.41), exposure to hostile work (OR 1.39, CI 1.25-1.55), and job insecurity (OR 1.44, CI 1.241.67), while controlling for demographic characteristics and other health-related factors. Older workers who had nonstandard work arrangements were more likely to report low back pain. Women who worked 41 to 45 hours per week and younger workers who worked > 60 hours per week had an increased risk for low back pain. Workers from several occupation groups, including male health care practitioners, female and younger health care support workers, and female farming, fishing, and forestry workers, had an increased risk of low back pain.
   Conclusions: This study linked low back pain to work-family imbalance, exposure to a hostile work environment, job insecurity, long work hours, and certain occupation groups. These factors should be considered by employers, policymakers, and health care practitioners who are concerned about the impact of low back pain in workers.
C1 [Yang, Haiou; Baker, Dean] Univ Calif Irvine, Ctr Occupat & Environm Hlth, Irvine, CA USA.
   [Haldeman, Scott] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA.
   [Haldeman, Scott] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
   [Lu, Ming-Lun] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA.
RP Yang, HO (reprint author), Univ Calif Irvine, Ctr Occupat & Environm Hlth, Theory 100, Suite 100, Irvine, CA 92617 USA.
EM hyang@uci.edu
NR 117
TC 1
Z9 1
U1 15
U2 15
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-4754
J9 J MANIP PHYSIOL THER
JI J. Manip. Physiol. Ther.
PD SEP
PY 2016
VL 39
IS 7
BP 459
EP 472
DI 10.1016/j.jmpt.2016.07.004
PG 14
WC Health Care Sciences & Services; Integrative & Complementary Medicine;
   Rehabilitation
SC Health Care Sciences & Services; Integrative & Complementary Medicine;
   Rehabilitation
GA DX1NC
UT WOS:000384133100001
PM 27568831
ER

PT J
AU Gu, JK
   Charles, LE
   Andrew, ME
   Ma, CC
   Hartley, TA
   Violanti, JM
   Burchfiel, CM
AF Gu, Ja K.
   Charles, Luenda E.
   Andrew, Michael E.
   Ma, Claudia C.
   Hartley, Tara A.
   Violanti, John M.
   Burchfiel, Cecil M.
TI Prevalence of work-site injuries and relationship between obesity and
   injury among US workers: NHIS 2004-2012
SO JOURNAL OF SAFETY RESEARCH
LA English
DT Article
DE Occupational incident; Overweight; Obese; Body mass index; United States
ID BODY-MASS INDEX; POLICE OFFICERS; BACK INJURY; SHIFT WORK; RISK; ADULTS;
   ABSENTEEISM; HEALTH; COMPENSATION; ASSOCIATION
AB Introduction: Studies have reported associations between obesity and injury in a single occupation or industry. Our study estimated the prevalence of work-site injuries and investigated the association between obesity and work-site injury in a nationally representative sample of U.S. workers. Methods: Self-reported weight, height, and injuries within the previous three months were collected annually for U.S. workers in the National Health Interview Survey (NHIS) from 2004-2012. Participants were categorized as normal weight (BMI: 18.5-24.9 kg/m(2)), overweight (BMI: 25.0-29.9), obese I (BMI: 30.0-34.9), and obese II (BMI: 35+). The prevalence of injury and prevalence ratios from fitted logistic regression models was used to assess relationships between obesity and injury after adjusting for covariates. Sampling weights were incorporated using SUDAAN software. Results: During the 9-year study period from 2004 to 2012, 1120 workers (78 workers per 10,000) experienced a work-related injury during the previous three months. The anatomical sites with the highest prevalence of injury were-the back (143/10,000 +/- 12), fingers (11.5 +/- 1.3), and knees (7.1 +/- 0.8). The most common types of injuries were sprains/strains/twists (41.5% of all injuries), cuts (20.0%), and fractures (11.8%). Compared to normal weight workers, overweight and obese workers were more likely to experience work-site injuries [overweight: PR = 1.25 (95% CI = 1.04-1.52); obese I: 1.41 (1.14-1.74); obese II: 1.68 (1.32-2.14)]. These injuries were more likely to affect the lower extremities [overweight: PR = 1.48, (95% CI = 1.03-2.13); obese I: 1.70 (1.13-2.55); obese II: 2.91 (1.91-4.41)] and were more likely to be due to sprains/strains/twists [overweight: PR = 1.73 (95% CI=1.29-231); obese I: PR = 224 (1.64-3.06); obese II: PR = 2.95 (2.04-4.26)]. Conclusions: Among NHIS participants, overweight and obese workers were 25% to 68% more likely to experience injuries than normal weight workers. Practical applications: Weight reduction policies and management programs may be effectively targeted towards overweight and obese groups to prevent or reduce work-site injuries. National Safety Council and Elsevier Ltd. All rights reserved.
C1 [Gu, Ja K.; Charles, Luenda E.; Andrew, Michael E.; Ma, Claudia C.; Hartley, Tara A.; Burchfiel, Cecil M.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Health, Hlth Effects Lab Div, Biostat & Epidemiol Branch, Morgantown, WV USA.
   [Violanti, John M.] Univ Buffalo, State Univ New York, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA.
RP Gu, JK (reprint author), Natl Inst Occupat Safety & Hlth, HELD BEB, Mailstop L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA.
EM jgu@cdc.gov; lcharles@cdc.gov; mandrew@cdc.gov; claudiama@cdc.gov;
   thartley@cdc.gov; violanti@buffalo.edu; cburchfiel@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 43
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-4375
EI 1879-1247
J9 J SAFETY RES
JI J. Saf. Res.
PD SEP
PY 2016
VL 58
BP 21
EP 30
DI 10.1016/j.jsr.2016.06.001
PG 10
WC Ergonomics; Public, Environmental & Occupational Health; Social
   Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
   Sciences - Other Topics; Transportation
GA DW8VR
UT WOS:000383934100003
PM 27620931
ER

PT J
AU Burns, ER
   Stevens, JA
   Lee, R
AF Burns, Elizabeth R.
   Stevens, Judy A.
   Lee, Robin
TI The direct costs of fatal and non-fatal falls among older adults -
   United States
SO JOURNAL OF SAFETY RESEARCH
LA English
DT Article
DE Fall; Older people; Costs; Hospital care; STEADI
ID MEDICAL-CARE; INJURIES; PREVENTION; POPULATION; COMMUNITY; GROWTH
AB Introduction: This study sought to estimate the incidence, average cost, and total direct medical costs for fatal and non-fatal fall injuries in hospital, ED, and out-patient settings among U.S. adults aged 65 or older in 2012, by sex and age group and to report total direct medical costs for falls inflated to 2015 dollars. Method: Incidence data came from the 2012 National Vital Statistics System, 2012 Healthcare Cost and Utilization Project-Nationwide Inpatient Sample, 2012 Health Care Utilization Program National Emergency Department Sample, and 2007 Medical Expenditure Panel Survey. Costs for fatal falls were derived from the Centers for Disease Control and Prevention's Web-based Injury Statistics Query and Reporting System; costs for non-fatal falls were based on claims from the 1998/1999 Medicare fee-for-service 5% Standard Analytical Files. Costs were inflated to 2015 estimates using the health care component of the Personal Consumption Expenditure index. Results: In 2012, there were 24,190 fatal and 3.2 million medically treated non-fatal fall related injuries. Direct medical costs totaled $616.5 million for fatal and $30.3 billion for non-fatal injuries in 2012 and rose to $637.5 million and $31.3 billion, respectively, in 2015. Fall incidence as well as total cost increased with age and were higher among women. Conclusion: Medically treated falls among older adults, especially among older women, are associated with substantial economic costs. Practical application: Widely implementing evidence-based interventions for fall prevention is essential to decrease the incidence and healthcare costs associated with these injuries. National Safety Council and Elsevier Ltd. All rights reserved.
C1 [Burns, Elizabeth R.; Stevens, Judy A.; Lee, Robin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA.
RP Burns, ER (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA.
EM ync7@cdc.gov
NR 30
TC 1
Z9 1
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-4375
EI 1879-1247
J9 J SAFETY RES
JI J. Saf. Res.
PD SEP
PY 2016
VL 58
BP 99
EP 103
DI 10.1016/j.jsr.2016.05.001
PG 5
WC Ergonomics; Public, Environmental & Occupational Health; Social
   Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
   Sciences - Other Topics; Transportation
GA DW8VR
UT WOS:000383934100011
PM 27620939
ER

PT J
AU Easterling, KW
   Mack, KA
   Jones, CM
AF Easterling, Keith W.
   Mack, Karin A.
   Jones, Christopher M.
TI Location of fatal prescription opioid-related deaths in 12 states,
   2008-2010: Implications for prevention programs
SO JOURNAL OF SAFETY RESEARCH
LA English
DT Article
DE Drug Abuse Warning Network (DAWN); Mortality; Overdose; Opioid; Heroin
ID OVERDOSE PREVENTION; HEROIN OVERDOSE; SAN-FRANCISCO; UNITED-STATES;
   DRUG-USERS; NALOXONE; INTERVENTION
AB Introduction: Prescription opioid pain reliever overdose is a major public health issue in the United States. To characterize the location of drug-related deaths, we examined fatal prescription opioid and illicit drug related deaths reported in 12 states. Methods: Data are from the Substance Abuse and Mental Health Services Administration's Drug Abuse Warning Network (DAWN). Medical examiners or coroners in 12 states (MA, MD, ME, NH, NM, OK, OR, RI, UT, VA, VT, WV) reported details of state-wide drug-related mortality during 2008-2010. DAWN data included location and manner of death, age, race, and drugs involved. Deaths were coded into three categories: prescription opioid-related, illicit drug-related, and cases that involved both a prescription opioid and an illicit drug. Results: During a 3-year period, there were 14,091 opioid or illicit drug related deaths in 12 states. More than half of the prescription opioid-related deaths in all states, except Maryland, occurred at home, rather than in public or in a health care facility. Although it was still the predominant category, lower percentages of illicit drug-related deaths occurred at home. Conclusion: Prescription opioid overdoses have increased substantially, and the location of the person at the time of death can have important public health implications for interventions. Practical applications: This paper highlights that bystander support can be a critical lifesaving factor in drug related deaths but may be more likely for illicit drug-related deaths than for prescription opioid-related deaths. National Safety Council and Elsevier Ltd. All rights reserved.
C1 [Easterling, Keith W.] Emory Univ, Sch Med, Dept Pharmacol, 1462 Clifton Rd,Ste 304G, Atlanta, GA 30322 USA.
   [Mack, Karin A.] Ctr Dis Control & Prevent CDC, NCIPC, Atlanta, GA USA.
   [Jones, Christopher M.] US Dept Hlth & Human Serv, Off Assistant Secretary Planning & Evaluat, Washington, DC USA.
RP Easterling, KW (reprint author), Emory Univ, Sch Med, Dept Pharmacol, 1462 Clifton Rd,Ste 304G, Atlanta, GA 30322 USA.
EM Keith.Easterling@emory.edu
FU Intramural CDC HHS [CC999999]
NR 23
TC 1
Z9 1
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-4375
EI 1879-1247
J9 J SAFETY RES
JI J. Saf. Res.
PD SEP
PY 2016
VL 58
BP 105
EP 109
DI 10.1016/j.jsr.2016.07.004
PG 5
WC Ergonomics; Public, Environmental & Occupational Health; Social
   Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
   Sciences - Other Topics; Transportation
GA DW8VR
UT WOS:000383934100012
PM 27620940
ER

PT J
AU Zotti, ME
   Ellington, SR
   Perez, M
AF Zotti, Marianne E.
   Ellington, Sascha R.
   Perez, Mirna
TI CDC Online Course: Reproductive Health in Emergency Preparedness and
   Response
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID UNITED-STATES; POSTPARTUM WOMEN; COMPETENCE SET; INFANTS
AB In an emergency, the needs of women of reproductive age, particularly pregnant and postpartum women, introduce unique challenges for public health and clinical care. Incorporating reproductive health issues and considerations into emergency preparedness and response is a relatively new field. In recent years, several resources and tools specific to reproductive health have been developed. However, there is still a need for training about the effects of emergencies on women of reproductive age. In an effort to train medical and public health professionals about these topics, the CDC Division of Reproductive Health developed Reproductive Health in Emergency Preparedness and Response, an online course that is available across the United States.
C1 [Zotti, Marianne E.; Ellington, Sascha R.; Perez, Mirna] Ctr Dis Control & Prevent CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, DRH, Atlanta, GA USA.
RP Ellington, SR (reprint author), Centers Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA.
EM sellington@cdc.gov
NR 21
TC 1
Z9 1
U1 3
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD SEP
PY 2016
VL 25
IS 9
BP 861
EP 864
DI 10.1089/jwh.2016.5993
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA DW9YP
UT WOS:000384019000003
PM 27631300
ER

PT J
AU Coker, TR
   Elliott, MN
   Toomey, SL
   Schwebel, DC
   Cuccaro, P
   Emery, ST
   Davies, SL
   Visser, SN
   Schuster, MA
AF Coker, Tumaini R.
   Elliott, Marc N.
   Toomey, Sara L.
   Schwebel, David C.
   Cuccaro, Paula
   Emery, Susan Tortolero
   Davies, Susan L.
   Visser, Susanna N.
   Schuster, Mark A.
TI Racial and Ethnic Disparities in ADHD Diagnosis and Treatment
SO PEDIATRICS
LA English
DT Article
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; FAMILY-CENTERED CARE;
   SCHOOL-AGE-CHILDREN; US CHILDREN; HEALTH-CARE; UNITED-STATES;
   RACIAL/ETHNIC DISPARITIES; INSURANCE STATUS; NATIONAL SAMPLE; SERVICES
AB OBJECTIVES: We examined racial/ethnic disparities in attention-deficit/hyperactivity disorder (ADHD) diagnosis and medication use and determined whether medication disparities were more likely due to underdiagnosis or undertreatment of African-American and Latino children, or overdiagnosis or overtreatment of white children.
   METHODS: We used a population-based, multisite sample of 4297 children and parents surveyed over 3 waves (fifth, seventh, and 10th grades). Multivariate logistic regression examined disparities in parent-reported ADHD diagnosis and medication use in the following analyses: (1) using the total sample; (2) limited to children with an ADHD diagnosis or symptoms; and (3) limited to children without a diagnosis or symptoms.
   RESULTS: Across all waves, African-American and Latino children, compared with white children, had lower odds of having an ADHD diagnosis and of taking ADHD medication, controlling for sociodemographics, ADHD symptoms, and other potential comorbid mental health symptoms. Among children with an ADHD diagnosis or symptoms, African-American children had lower odds of medication use at fifth, seventh, and 10th grades, and Latino children had lower odds at fifth and 10th grades. Among children who had neither ADHD symptoms nor ADHD diagnosis by fifth grade (and thus would not likely meet ADHD diagnostic criteria at any age), medication use did not vary by race/ethnicity in adjusted analysis.
   CONCLUSIONS: Racial/ethnic disparities in parent-reported medication use for ADHD are robust, persisting from fifth grade to 10th grade. These findings suggest that disparities may be more likely related to underdiagnosis and undertreatment of African-American and Latino children as opposed to overdiagnosis or overtreatment of white children.
C1 [Coker, Tumaini R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Mattel Childrens Hosp, Los Angeles, CA 90095 USA.
   [Coker, Tumaini R.; Elliott, Marc N.; Schuster, Mark A.] RAND Corp, Santa Monica, CA USA.
   [Toomey, Sara L.] Harvard Med Sch, Div Gen Pediat, Boston Childrens Hosp, Boston, MA USA.
   [Toomey, Sara L.] Harvard Med Sch, Dept Pediat, Boston, MA USA.
   [Schwebel, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA.
   [Cuccaro, Paula; Emery, Susan Tortolero] Univ Alabama Birmingham, Dept Hlth Behav, Birmingham, AL 35294 USA.
   [Davies, Susan L.] Univ Texas Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX USA.
   [Visser, Susanna N.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Coker, TR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, 10833 Le Conte Ave,Room 12-436, Los Angeles, CA 90095 USA.
EM tcoker@mednet.ucla.edu
FU Centers for Disease Control and Prevention, Prevention Research Centers
   [CCU409679, CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056,
   U19DP002663, U19DP002664, U19DP002665]
FX The Healthy Passages Study was funded by the Centers for Disease Control
   and Prevention, Prevention Research Centers (Cooperative Agreements
   CCU409679, CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056,
   U19DP002663, U19DP002664, and U19DP002665). The findings and conclusions
   in this report are those of the authors and do not necessarily represent
   the official position of the Centers for Disease Control and Prevention.
NR 37
TC 0
Z9 0
U1 10
U2 10
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD SEP
PY 2016
VL 138
IS 3
AR e20160407
DI 10.1542/peds.2016-0407
PG 9
WC Pediatrics
SC Pediatrics
GA DW9SE
UT WOS:000384002100024
ER

PT J
AU Tate, JE
   Yen, C
   Steiner, CA
   Cortese, MM
   Parashar, UD
AF Tate, Jacqueline E.
   Yen, Catherine
   Steiner, Claudia A.
   Cortese, Margaret M.
   Parashar, Umesh D.
TI Intussusception Rates Before and After the Introduction of Rotavirus
   Vaccine
SO PEDIATRICS
LA English
DT Article
ID IMMUNIZATION PRACTICES ACIP; US INFANTS; ADVISORY-COMMITTEE;
   UNITED-STATES; GASTROENTERITIS; CHILDREN; SAFETY; RISK; PENTAVALENT;
   HOSPITALIZATIONS
AB BACKGROUND: Recent US studies have identified a small increased risk of intussusception after rotavirus vaccination, mainly after the first dose. We examined trends in intussusception hospitalizations before (2000-2005) and after (2007-2013) rotavirus vaccine introduction to assess whether this observed temporal risk translates into more hospitalized cases at the population level.
   METHODS: Intussusception hospitalizations in children <12 months of age were abstracted from the State Inpatient Database maintained by the Healthcare Cost and Utilization Project for 26 states that provided data from 2000 to 2013. Rates were calculated using bridged-race postcensal population estimates. Trends were analyzed by age groups (6-14 weeks, 15-24 weeks, and 25-34 weeks) based on the recommended ages for vaccine administration as well as 8-11 weeks when the majority of first doses are given. Rate ratios were calculated by using Poisson regression.
   RESULTS: No consistent change in intussusception hospitalization rates was observed among all children <12 months of age and among children 15 to 24 weeks and 25 to 34 weeks of age. The intussusception hospitalization rate for children aged 8 to 11 weeks was significantly elevated by 46% to 101% (range: 16.7-22.9 per 100 000) in all postvaccine years except 2011 and 2013 compared with the prevaccine baseline (11.7 per 100 000).
   CONCLUSIONS: The increase in the intussusception hospitalization rate in children 8 to 11 weeks when the majority of first doses of vaccine are given is consistent with recent US postlicensure studies. Given the magnitude of declines in rotavirus disease compared with this small increase in intussusception, the benefits of rotavirus vaccination outweigh the increase risk of intussusception.
C1 [Tate, Jacqueline E.; Yen, Catherine; Cortese, Margaret M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA.
   [Steiner, Claudia A.] Agcy Healthcare Res & Qual, Ctr Delivery Org & Markets, Rockville, MD USA.
RP Tate, JE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS-A34, Atlanta, GA 30333 USA.
EM jqt8@cdc.gov
NR 22
TC 1
Z9 1
U1 1
U2 1
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD SEP
PY 2016
VL 138
IS 3
AR e20161082
DI 10.1542/peds.2016-1082
PG 7
WC Pediatrics
SC Pediatrics
GA DW9SE
UT WOS:000384002100044
ER

PT J
AU Blevins, J
   Benn, C
   Thurman, S
AF Blevins, John
   Benn, Christoph
   Thurman, Sandra
TI Reflections on HIV-Related Experiences of Two Global Funding Mechanisms
   Supporting Religious Health Providers
SO REVIEW OF FAITH & INTERNATIONAL AFFAIRS
LA English
DT Article
C1 [Blevins, John] Emory Univ, Interfaith Hlth Program, Atlanta, GA 30322 USA.
   [Benn, Christoph] Global Fund fight AIDS TB & Malaria, External Relat, Geneva, Switzerland.
   [Benn, Christoph] Global Fund, Founding Board, Geneva, Switzerland.
   [Thurman, Sandra] Off US Global AIDS Coordinator & Global Diplomacy, Atlanta, GA USA.
   [Thurman, Sandra] Off Natl AIDS Policy, Atlanta, GA USA.
   [Thurman, Sandra] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Blevins, J (reprint author), Emory Univ, Interfaith Hlth Program, Atlanta, GA 30322 USA.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1557-0274
EI 1931-7743
J9 REV FAITH INT AFF
JI Rev. Faith Int. Aff.
PD FAL
PY 2016
VL 14
IS 3
SI SI
BP 110
EP 117
DI 10.1080/15570274.2016.1215815
PG 8
WC Religion
SC Religion
GA DX3YY
UT WOS:000384315000013
ER

PT J
AU Grosse, SD
AF Grosse, Scott D.
TI Cost-of-illness models for venous thromboembolism: One size does not fit
   all
SO THROMBOSIS RESEARCH
LA English
DT Letter
DE Venous thromboembolism; Cost-of-illness analysis; Health economics;
   Indirect costs; United States
ID CANCER
C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA.
RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA.
EM sgrosse@cdc.gov
OI Grosse, Scott/0000-0003-1078-6855
FU Intramural CDC HHS [CC999999]
NR 10
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD SEP
PY 2016
VL 145
BP 65
EP 66
DI 10.1016/j.thromres.2016.07.018
PG 2
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DX0QS
UT WOS:000384069800012
PM 27494774
ER

PT J
AU Gammon, DG
   Loomis, BR
   Dench, DL
   King, BA
   Fulmer, EB
   Rogers, T
AF Gammon, Doris G.
   Loomis, Brett R.
   Dench, Daniel L.
   King, Brian A.
   Fulmer, Erika B.
   Rogers, Todd
TI Effect of price changes in little cigars and cigarettes on little cigar
   sales: USA, Q4 2011-Q4 2013
SO TOBACCO CONTROL
LA English
DT Article
DE Economics; Taxation; Public policy; Non-cigarette tobacco products;
   Price
ID UNITED-STATES; SMOKING; DISEASE; ADULTS; IMPACT; MEN
AB Introduction Little cigars are comparable to cigarettes in terms of shape, size, filters and packaging. Disproportionate tobacco excise taxes, which directly affect purchase price, may lead consumers to substitute cigarettes with less expensive little cigars. This study estimated the effects of little cigar and cigarette prices on little cigar sales.
   Methods Sales data from a customised retail scanner database were used to model a log-log equation to infer own-price and cross-price elasticity of demand for little cigars relative to little cigar and cigarette prices, respectively, from quarter 4 of 2011 to quarter 4 of 2013. Data were available for convenience stores (C-stores) (n=29 states); food, drug and mass merchandisers (FDMs) (n=44 states); and C-stores and FDMs combined (n=27 states). The dependent variable was per capita little cigar pack sales, and key independent variables were the price index for little cigars and cigarettes.
   Results A 10% increase in little cigar price was associated with a 25% (p<0.01) decrease in little cigar sales in C-stores alone, and a 31.7% (p<0.01) decrease in C-stores and FDMs combined. A 10% increase in cigarette price was associated with a 21.5% (p<0.05) increase in little cigar sales in C-stores, and a 27.3% (p<0.01) increase in C-stores and FDMs combined.
   Conclusions Our results suggest that US cigarette smokers are avoiding the high cost of cigarettes by switching to lower priced little cigars. Increasing and equalising prices among comparable products, like cigarettes and little cigars, may motivate cost-conscious smokers to quit.
C1 [Gammon, Doris G.; Loomis, Brett R.; Dench, Daniel L.; Rogers, Todd] RTI Int, Publ Hlth Res Div, 3040 E Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.
   [King, Brian A.; Fulmer, Erika B.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Gammon, DG (reprint author), RTI Int, Publ Hlth Res Div, 3040 E Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.
EM dgammon@rti.org
OI Gammon, Doris/0000-0002-5879-7986
FU Centers for Disease Control and Prevention, Office on Smoking and Health
FX Support was provided by the Centers for Disease Control and Prevention,
   Office on Smoking and Health.
NR 32
TC 2
Z9 2
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
EI 1468-3318
J9 TOB CONTROL
JI Tob. Control
PD SEP
PY 2016
VL 25
IS 5
BP 538
EP 544
DI 10.1136/tobaccocontrol-2015-052343
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX4CJ
UT WOS:000384326900015
PM 26357952
ER

PT J
AU Seth, P
   Figueroa, A
   Wang, GS
AF Seth, Puja
   Figueroa, Argelia
   Wang, Guoshen
TI Centers for Disease Control and Prevention-Funded Human Immunodeficiency
   Virus Testing, Positivity, and Service Delivery among Newly Diagnosed
   Women in 61 Health Department Jurisdictions, United States, 2014
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID INTIMATE PARTNER VIOLENCE; AFRICAN-AMERICAN WOMEN; ANTIRETROVIRAL
   THERAPY; FEMALE ADOLESCENTS; SEXUAL-BEHAVIORS; HIV-INFECTION; SUBSTANCE
   USE; CARE; RISK; INTERSECTION
AB Background: More than 1.2 million persons are living with human immunodeficiency virus (HIV) in the United States; at the end of 2011, 23% of them were women. Minority women are disproportionately affected by HIV, and new infections are higher among older women. HIV testing and service delivery among women funded by the U.S. Centers for Disease Control and Prevention (CDC) is examined.
   Methods: Data were submitted by 61 health department jurisdictions. HIV testing, HIV-positive tests, new HIV diagnoses among women, and linkage and referral services among newly diagnosed women are described. Differences across demographic characteristics for HIV diagnoses, linkage, and referral services were assessed. Diagnoses were identified as new when women who tested HIV positive were not found to be reported previously in the jurisdiction's HIV surveillance system; when jurisdictions could not verify prior test results in their surveillance systems, new diagnoses were identified by self-report.
   Results: Of CDC-funded testing events in 2014, 1,484,902 (48.7%) were among women, and they accounted for 19.5% of all HIV-positive testing events. Among women tested, 0.4% were HIV positive, and 0.1% had new HIV diagnoses. Women aged 40 and older and Black women were more likely to test HIV positive (0.7% and 0.5%, respectively). Among newly diagnosed women, 62.8% were linked within any timeframe, 57.1% were linked within 90 days, 74.1% were referred to partner services, 57.5% were interviewed for partner services, and 55.5% were referred to HIV risk reduction services.
   Conclusions: Among all women receiving CDC-funded HIV testing, Black women and older women were more likely to have HIV-positive tests and new diagnoses. Although women overall may not be at the highest risk for HIV, Black women in this sample are disproportionately affected. Additionally, linkage, referral, and interview services for women need improvement. Targeted testing approaches may ensure effective test-and-treat strategies for women. Published by Elsevier Inc. on behalf of Jacobs Institute of Women's Health.
C1 [Seth, Puja; Figueroa, Argelia; Wang, Guoshen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA.
   [Seth, Puja] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA.
   [Figueroa, Argelia] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1825 Century Ctr Blvd,MS E-28, Atlanta, GA 30345 USA.
RP Seth, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA.; Seth, P (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA.
EM pseth@cdc.gov
NR 29
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2016
VL 26
IS 5
BP 496
EP 503
DI 10.1016/j.whi.2016.05.011
PG 8
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA DX1TT
UT WOS:000384150600004
PM 27424776
ER

PT J
AU Novosad, SA
   Vasquez, AM
   Nambiar, A
   Arduino, MJ
   Christensen, E
   Moulton-Meissner, H
   Keckler, MS
   Miller, J
   Perz, JF
   Lockhart, SR
   Chiller, T
   Gould, C
   Sehulster, L
   Brandt, ME
   Weber, JT
   Halpin, AL
   Mody, RK
AF Novosad, S. A.
   Vasquez, A. M.
   Nambiar, A.
   Arduino, M. J.
   Christensen, E.
   Moulton-Meissner, H.
   Keckler, M. S.
   Miller, J.
   Perz, J. F.
   Lockhart, S. R.
   Chiller, T.
   Gould, C.
   Sehulster, L.
   Brandt, M. E.
   Weber, J. T.
   Halpin, A. L.
   Mody, R. K.
TI Notes From the Field: Probable Mucormycosis Among Adult Solid Organ
   Transplant Recipients at an Acute Care Hospital Pennsylvania, 2014-2015
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Editorial Material
ID SURVEILLANCE NETWORK TRANSNET; INVASIVE FUNGAL-INFECTIONS; OUTBREAKS
C1 [Novosad, S. A.; Vasquez, A. M.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Novosad, S. A.; Vasquez, A. M.; Arduino, M. J.; Moulton-Meissner, H.; Keckler, M. S.; Perz, J. F.; Gould, C.; Sehulster, L.; Weber, J. T.; Halpin, A. L.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Nambiar, A.] Penn Dept Hlth, Harrisburg, PA 17108 USA.
   [Christensen, E.] Univ Utah, Sch Med, Salt Lake City, UT USA.
   [Keckler, M. S.] CDC, Lab Leadership Serv, Atlanta, GA 30333 USA.
   [Miller, J.] Penn Dept Hlth, CDC Career Epidemiol Field, Harrisburg, PA 17108 USA.
   [Lockhart, S. R.; Chiller, T.; Brandt, M. E.; Mody, R. K.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Novosad, SA (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Novosad, SA (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM snovosad@cdc.gov
NR 7
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2016
VL 16
IS 9
BP 2758
EP 2759
DI 10.1111/ajt.13990
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA DW6PZ
UT WOS:000383774700032
PM 27575726
ER

PT J
AU Mirkovic, KR
   Perrine, CG
   Scanlon, KS
AF Mirkovic, Kelsey R.
   Perrine, Cria G.
   Scanlon, Kelley S.
TI Paid Maternity Leave and Breastfeeding Outcomes
SO BIRTH-ISSUES IN PERINATAL CARE
LA English
DT Article
DE breastfeeding; employment; initiation
ID UNITED-STATES; OCCUPATIONAL CHARACTERISTICS; WORK STATUS; DURATION;
   EMPLOYMENT; MOTHERS; INITIATION; RECALL; WOMEN; TIME
AB Background: Despite the benefits of breastfeeding, rates in the United States are low. Shorter maternity leave is associated with lower initiation and shorter durations of breastfeeding; however, little is known about how paid maternity leave may influence breastfeeding rates. Methods: We used data from the 2006-2010 U.S. National Survey of Family Growth on the most recent birth to employed women who delivered a child within the previous 5 years. Separate multivariable logistic regression models were used to describe the associations between paid leave duration (0, 1-5, 6-11, >= 12 weeks, maternity leave not taken) and three outcomes: 1) breastfeeding initiation, 2) 6-month duration, and 3) 6-month duration among initiators. Results: Twenty-eight percent of prenatally employed women received no paid leave. Women who received 12 or more weeks of paid leave were more likely to initiate breastfeeding compared to women with no paid leave (87.3% vs 66.7%, adjusted odds ratio [aOR] 2.83 [95% confidence interval {CI} 1.23-6.48]). Similarly, women with 12 or more weeks of paid leave were more likely to breastfeed at 6 months, compared to women with no paid leave (24.9% vs 50.1%, aOR 2.26 [95% CI 1.20-4.26]). Among women who initiated breastfeeding, having received 12 or more weeks' paid leave increased the odds of breastfeeding for 6 or more months; however, the association was not statistically significant in the adjusted model (aOR 1.81 [95% CI 0.93-3.52]). Conclusions: Employed women who received 12 or more weeks of paid maternity leave were more likely to initiate breastfeeding and be breastfeeding their child at 6 months than those without paid leave. (BIRTH 43:3 September 2016)
C1 [Mirkovic, Kelsey R.] Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, Atlanta, GA USA.
   [Mirkovic, Kelsey R.; Perrine, Cria G.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
RP Mirkovic, KR (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Publ Hlth Sci Serv, 4770 Buford Hwy NE,Mailstop F-77, Atlanta, GA 30341 USA.
EM kmirkovic@cdc.gov
NR 30
TC 0
Z9 0
U1 11
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-7659
EI 1523-536X
J9 BIRTH-ISS PERINAT C
JI Birth-Issue Perinat. Care
PD SEP
PY 2016
VL 43
IS 3
BP 233
EP 239
DI 10.1111/birt.12230
PG 7
WC Nursing; Obstetrics & Gynecology; Pediatrics
SC Nursing; Obstetrics & Gynecology; Pediatrics
GA DW0RM
UT WOS:000383349400007
PM 26991788
ER

PT J
AU Can, O
   Blount, B
   Valentin-Blasini, L
   Erdemgil, Y
   Uzunoglu, D
   Aksoy, M
   Coskun, A
   Serteser, M
   Unsal, I
   Ozpinar, A
AF Can, Ozge
   Blount, Ben
   Valentin-Blasini, Liza
   Erdemgil, Yigit
   Uzunoglu, Deniz
   Aksoy, Murat
   Coskun, Abdurrahman
   Serteser, Mustafa
   Unsal, Ibrahim
   Ozpinar, Aysel
TI Perchlorate Exposure Through Water and Milk in Istanbul
SO BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY
LA English
DT Article
DE Perchlorate; Nitrate; Iodide; Water; Milk
ID IODINE-DEFICIENCY DISORDERS; DRINKING-WATER; UNITED-STATES; DAIRY MILK;
   TAP WATER; NITRATE; TURKEY; JAPAN; FEED; CHLORIDE
AB Perchlorate is a chemical pollutant that inhibits iodide uptake and may possibly impair thyroid function. Our previous study found widespread perchlorate exposure in non-pregnant, non-lactating, healthy women residing in Istanbul. The aim of this study is to assess the relative amounts of perchlorate exposure attributable to consumption of municipal water, bottled water and boxed milk available in Istanbul. Only trace levels of perchlorate were found in treated municipal water (58 % detectable, mean = 0.13 A mu g/L, maximum = 0.75 A mu g/L) and bottled water (7.4 % detectable, mean = < LOD, maximum = 0.19 A mu g/L). Conversely, all 30 boxed milk samples contained measurable levels of perchlorate (mean = 4.53 A mu g/L; maximum = 6.21 A mu g/L). Median perchlorate exposure attributable to water and milk (0.007 A mu g/kg/day) is small compared both to the reference dose (0.7 A mu g/kg/day) and to total perchlorate exposure (0.13 A mu g/kg/day) in Istanbul. Therefore, additional studies are needed to identify the major sources of perchlorate exposure in Istanbul.
C1 [Can, Ozge] Acibadem Univ, Dept Med Engn, Istanbul, Turkey.
   [Blount, Ben; Valentin-Blasini, Liza] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Erdemgil, Yigit; Uzunoglu, Deniz; Aksoy, Murat; Coskun, Abdurrahman; Serteser, Mustafa; Unsal, Ibrahim; Ozpinar, Aysel] Acibadem Univ, Sch Med, Dept Med Biochem, Kayisdagi Caddesi 32, Istanbul, Turkey.
RP Ozpinar, A (reprint author), Acibadem Univ, Sch Med, Dept Med Biochem, Kayisdagi Caddesi 32, Istanbul, Turkey.
EM aysel.ozpinar@acibadem.edu.tr
RI Serteser, Mustafa/F-9130-2015; Coskun, Abdurrahman/C-3906-2015; Ozpinar,
   Aysel/D-5150-2016
OI Serteser, Mustafa/0000-0001-7868-7613; Coskun,
   Abdurrahman/0000-0002-1273-0604; Ozpinar, Aysel/0000-0002-7399-4929
NR 52
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0007-4861
EI 1432-0800
J9 B ENVIRON CONTAM TOX
JI Bull. Environ. Contam. Toxicol.
PD SEP
PY 2016
VL 97
IS 3
BP 439
EP 445
DI 10.1007/s00128-016-1889-1
PG 7
WC Environmental Sciences; Toxicology
SC Environmental Sciences & Ecology; Toxicology
GA DU3YQ
UT WOS:000382149000023
PM 27435977
ER

PT J
AU Lockridge, O
   Norgren, RB
   Johnson, RC
   Blake, TA
AF Lockridge, Oksana
   Norgren, Robert B., Jr.
   Johnson, Rudolph C.
   Blake, Thomas A.
TI Naturally Occurring Genetic Variants of Human Acetylcholinesterase and
   Butyrylcholinesterase and Their Potential Impact on the Risk of Toxicity
   from Cholinesterase Inhibitors
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Review
ID HUMAN-SERUM CHOLINESTERASE; MASS-SPECTROMETRY; KNOCKOUT MOUSE; TOKYO
   SUBWAY; ERYTHROCYTE ACETYLCHOLINESTERASE; ORGANOPHOSPHATE TOXICITY;
   RETROSPECTIVE DETECTION; PLASMA CHOLINESTERASE; METHYLPHOSPHONIC ACID;
   ANTI-CHOLINESTERASES
AB Acetylcholinesterase (AChE) is the physiologically important target for organophosphorus toxicants (OP) including nerve agents and pesticides. Butyrylcholinesterase (BChE) in blood serves as a bioscavenger that protects AChE in nerve synapses from inhibition by OP. Mass spectrometry methods can detect exposure to OP by measuring adducts on the active site serine of plasma BChE. Genetic variants of human AChE and BChE do exist, but loss of function mutations have been identified only in the BCHE gene. The most common AChE variant, His353Asn (H322N), also known as the Yt blood group antigen, has normal AChE activity. The most common BChE variant, Ala567Thr (A539T) or the K-variant in honor of Werner Kalow, has 33% reduced plasma BChE activity. The genetic variant most frequently associated with prolonged response to muscle relaxants, Asp98Gly (D70G) or atypical BChE, has reduced activity and reduced enzyme concentration. Early studies in young, healthy males, performed at a time when it was legal to test nerve agents in humans, showed that individuals responded differently to the same low dose of sarin with toxic symptoms ranging in severity from minimal to moderate. Additionally, animal studies indicated that BChE protects from toxicants that have a higher reactivity with AChE than with BChE (e.g., nerve agents) but not from toxicants that have a higher reactivity with BChE than with AChE (e.g., OP pesticides). As a corollary, we hypothesize that individuals with genetic variants of BChE may be at increased risk of toxicity from nerve agents but not from OP pesticides.
C1 [Lockridge, Oksana] Univ Nebraska Med Ctr, Eppley Inst, 42nd & Emile, Omaha, NE 68198 USA.
   [Norgren, Robert B., Jr.] Univ Nebraska Med Ctr, Genet Cell Biol & Anat, Omaha, NE 68198 USA.
   [Johnson, Rudolph C.; Blake, Thomas A.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F44, Chamblee, GA 30341 USA.
RP Lockridge, O (reprint author), Univ Nebraska Med Ctr, Eppley Inst, 42nd & Emile, Omaha, NE 68198 USA.
EM olockrid@unmc.edu
OI Blake, Thomas/0000-0001-8536-9998
FU DLS/NCEH/CDC [200-2015-87939]; Centers for Disease Control and
   Prevention; Office of Public Health Preparedness and Response; Defense
   Threat Reduction Agency [11-005-12430]; National Institutes of Health
   [R21OD019930]
FX This work was supported by DLS/NCEH/CDC contract 200-2015-87939 (to
   O.L.), Centers for Disease Control and Prevention, Office of Public
   Health Preparedness and Response, and Defense Threat Reduction Agency
   (11-005-12430) (to T.A.B. and R.C.J.), and National Institutes of Health
   R21OD019930 (to R.B.N.).
NR 97
TC 1
Z9 1
U1 13
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
EI 1520-5010
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD SEP
PY 2016
VL 29
IS 9
BP 1381
EP 1392
DI 10.1021/acs.chemrestox.6b00228
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA DW6CF
UT WOS:000383733300003
PM 27551784
ER

PT J
AU Gong, QH
   Zhang, P
   Wang, JP
   An, YL
   Gregg, EW
   Li, H
   Zhang, B
   Shuai, Y
   Yang, WY
   Chen, YY
   Liu, SQ
   Engelgau, MM
   Hu, YH
   Bennett, PH
   Li, GW
AF Gong, Qiuhong
   Zhang, Ping
   Wang, Jinping
   An, Yali
   Gregg, Edward W.
   Li, Hui
   Zhang, Bo
   Shuai, Ying
   Yang, Wenying
   Chen, Yanyan
   Liu, Shuqian
   Engelgau, Michael M.
   Hu, Yinghua
   Bennett, Peter H.
   Li, Guangwei
TI Changes in Mortality in People With IGT Before and After the Onset of
   Diabetes During the 23-Year Follow-up of the Da Qing Diabetes Prevention
   Study
SO DIABETES CARE
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; ALL-CAUSE MORTALITY; CARDIOVASCULAR
   MORTALITY; FASTING GLUCOSE; LIFE-STYLE; RISK; MELLITUS; POPULATION;
   DISEASE; DEATH
AB OBJECTIVE
   People with impaired glucose tolerance (IGT) have increased risk of mortality and a high risk of progression to diabetes, but the extent that the excess mortality is associated with IGT per se or is the result of subsequent diabetes is unclear.
   RESEARCH DESIGN AND METHODS
   We compared mortality before and after the development of diabetes among 542 persons with IGT initially who participated in a 6-year lifestyle diabetes prevention trial and were followed-up from 1986 to 2009.
   RESULTS
   During the 23-year follow-up, 174 (32.1%) died, with an overall death rate of 15.9/1,000 person-years. The majority of deaths (74.7%; 130 of 174) occurred after progression to type 2 diabetes, with age-adjusted death rates of 11.1/1,000 person-years (95% CI 8.2-12.0) before and 19.4/1,000 person-years (95% CI 11.9-23.3) after the development of type 2 diabetes. The cumulative mortality was 37.8% (95% CI 33.1-42.2%) in participants who developed type 2 diabetes during first 10 years of follow-up, 28.6% (95% CI 21.6-35.0%) in those who progressed to type 2 diabetes in 10-20 years, and 13.9% (95% CI 7.0-20.3%) in those who did not develop to type 2 diabetes within 20 years. Time-dependent multivariate Cox proportional hazards analyses, with adjustment for baseline age, sex, intervention, and other potential confounding risk factors, showed that the development of type 2 diabetes was associated with a 73% higher risk of death (hazard ratio 1.73 [95% CI 1.18-2.52]).
   CONCLUSIONS
   As elsewhere, IGT is associated with increased risk of mortality in China, but much of this excess risk is attributable to the development of type 2 diabetes.
C1 [Gong, Qiuhong; An, Yali; Chen, Yanyan; Li, Guangwei] Chinese Acad Med Sci, Fuwai Hosp, Dept Endocrinol, Beijing, Peoples R China.
   [Zhang, Ping; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.
   [Wang, Jinping; Li, Hui; Hu, Yinghua] Da Qing First Hosp, Dept Cardiol, Da Qing, Peoples R China.
   [Zhang, Bo; Shuai, Ying; Yang, Wenying; Li, Guangwei] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China.
   [Liu, Shuqian] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Hlth Management & Policy, New Orleans, LA USA.
   [Engelgau, Michael M.] NHLBI, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USA.
   [Bennett, Peter H.] NIDDK, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA.
RP Li, GW (reprint author), Chinese Acad Med Sci, Fuwai Hosp, Dept Endocrinol, Beijing, Peoples R China.; Zhang, P (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.; Li, GW (reprint author), China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China.
EM pzhang@cdc.gov; guangwei_li@medmail.com.cn
FU National Center for Chronic Disease Prevention and Health Promotion
   through CDC/WHO [U58/CCU424123-01-02]; China-Japan Friendship Hospital
FX This study was supported by the National Center for Chronic Disease
   Prevention and Health Promotion through CDC/WHO Cooperative Agreement
   No. U58/CCU424123-01-02 and by the China-Japan Friendship Hospital.
NR 27
TC 1
Z9 1
U1 2
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD SEP
PY 2016
VL 39
IS 9
BP 1550
EP 1555
DI 10.2337/dc16-0429
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DW5DT
UT WOS:000383663000023
PM 27411697
ER

PT J
AU Bruce, MG
   Newbrough, D
   Bruden, D
   Hurlburt, D
   Morris, J
   Reasonover, A
   Sacco, F
   Hennessy, T
   Kejka, J
   McMahon, B
AF Bruce, M. G.
   Newbrough, D.
   Bruden, D.
   Hurlburt, D.
   Morris, J.
   Reasonover, A.
   Sacco, F.
   Hennessy, T.
   Kejka, J.
   McMahon, B.
TI Antimicrobial resistance and treatment outcome for Helicobacter pylori
   infections in Alaska
SO HELICOBACTER
LA English
DT Meeting Abstract
CT 29th International Workshop on Helicobacter and Microbiota in
   Inflammation and Cancer
CY SEP 15-17, 2016
CL Magdeburg, GERMANY
C1 [Bruce, M. G.; Bruden, D.; Hurlburt, D.; Morris, J.; Reasonover, A.; Hennessy, T.] CDC, Anchorage, AK USA.
   [Newbrough, D.; Sacco, F.; McMahon, B.] Alaska Native Med Ctr, Anchorage, AK USA.
   [Kejka, J.] Yukon Kuskokwim Hlth Corp, Bethel, AK USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-4389
EI 1523-5378
J9 HELICOBACTER
JI Helicobacter
PD SEP
PY 2016
VL 21
SU 1
SI SI
MA W3.6
BP 83
EP 84
PG 2
WC Gastroenterology & Hepatology; Microbiology
SC Gastroenterology & Hepatology; Microbiology
GA DW3BR
UT WOS:000383517600042
ER

PT J
AU Tirkkonen, J
   Taubel, M
   Hirvonen, MR
   Leppanen, H
   Lindsley, WG
   Chen, BT
   Hyvarinen, A
   Huttunen, K
AF Tirkkonen, Jenni
   Taubel, Martin
   Hirvonen, Maija-Riitta
   Leppanen, Hanna
   Lindsley, William G.
   Chen, Bean T.
   Hyvarinen, Anne
   Huttunen, Kati
TI Evaluation of sampling methods for toxicological testing of indoor air
   particulate matter
SO INHALATION TOXICOLOGY
LA English
DT Article
DE Indoor air; in vitro; moisture damage; particulate matter; sampling;
   toxicity testing
ID MOISTURE-DAMAGED BUILDINGS; IN-HOUSE DUST; MICROBIAL EXPOSURE;
   DETERMINANTS; ENDOTOXIN; ERGOSTEROL; PARTICLES; COLLECTOR; PROJECT;
   HITEA
AB There is a need for toxicity tests capable of recognizing indoor environments with compromised air quality, especially in the context of moisture damage. One of the key issues is sampling, which should both provide meaningful material for analyses and fulfill requirements imposed by practitioners using toxicity tests for health risk assessment. We aimed to evaluate different existing methods of sampling indoor particulate matter (PM) to develop a suitable sampling strategy for a toxicological assay. During three sampling campaigns in moisture-damaged and non-damaged school buildings, we evaluated one passive and three active sampling methods: the Settled Dust Box (SDB), the Button Aerosol Sampler, the Harvard Impactor and the National Institute for Occupational Safety and Health (NIOSH) Bioaerosol Cyclone Sampler. Mouse RAW264.7 macrophages were exposed to particle suspensions and cell metabolic activity (CMA), production of nitric oxide (NO) and tumor necrosis factor (TNF) were determined after 24h of exposure. The repeatability of the toxicological analyses was very good for all tested sampler types. Variability within the schools was found to be high especially between different classrooms in the moisture-damaged school. Passively collected settled dust and PM collected actively with the NIOSH Sampler (Stage 1) caused a clear response in exposed cells. The results suggested the higher relative immunotoxicological activity of dust from the moisture-damaged school. The NIOSH Sampler is a promising candidate for the collection of size-fractionated PM to be used in toxicity testing. The applicability of such sampling strategy in grading moisture damage severity in buildings needs to be developed further in a larger cohort of buildings.
C1 [Tirkkonen, Jenni; Taubel, Martin; Hirvonen, Maija-Riitta; Leppanen, Hanna; Huttunen, Kati] Univ Eastern Finland, Dept Environm Sci, Kuopio, Finland.
   [Taubel, Martin; Hirvonen, Maija-Riitta; Leppanen, Hanna; Hyvarinen, Anne] Natl Inst Hlth & Welf, Dept Hlth Protect, Living Environm & Hlth Unit, Kuopio, Finland.
   [Lindsley, William G.; Chen, Bean T.] Ctr Dis Control & Prevent, NIOSH, Morgantown, WV USA.
RP Tirkkonen, J (reprint author), Univ Eastern Finland, Dept Environm Sci, Inhalat Toxicol Lab, POB 1627, FI-70211 Kuopio, Finland.
EM jenni.tirkkonen@uef.fi
FU Tekes - the Finnish Funding Agency for Innovation, New knowledge and
   business from research ideas - HOVAVART (Homevaurion vakavuuden
   arviointi toksisuustestin avulla) [2285733-9]; Tekes - the Finnish
   Funding Agency for Innovation, New knowledge and business from research
   ideas - HOVAVART (Homevaurion vakavuuden arviointi toksisuustestin
   avulla) Grant [2285733-9]; Finnish Work Environment Fund Grant [115283]
FX This work was supported by Tekes - the Finnish Funding Agency for
   Innovation, New knowledge and business from research ideas - HOVAVART
   (Homevaurion vakavuuden arviointi toksisuustestin avulla) Grant
   agreement no. 2285733-9. Professor Maija-Riitta Hirvonen, Drs Martin
   Taubel and Kati Huttunen as well as doctoral students Jenni Tirkkonen
   and Hanna Leppanen reported funding from Tekes - the Finnish Funding
   Agency for Innovation, New knowledge and business from research ideas -
   HOVAVART (Homevaurion vakavuuden arviointi toksisuustestin avulla) Grant
   agreement no. 2285733-9. Dr Bean T Chen has U.S. Patent Nos. 8,205,511 &
   7,370,543 issued. Drs Anne Hyvarinen and William G Lindsley reported no
   declarations of interest. Doctoral student Jenni Tirkkonen was also
   funded by The Finnish Work Environment Fund Grant agreement no. 115283.
NR 22
TC 1
Z9 1
U1 16
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0895-8378
EI 1091-7691
J9 INHAL TOXICOL
JI Inhal. Toxicol.
PD SEP
PY 2016
VL 28
IS 11
BP 500
EP 507
DI 10.1080/08958378.2016.1210702
PG 8
WC Toxicology
SC Toxicology
GA DW1XM
UT WOS:000383436900003
PM 27569522
ER

PT J
AU Cooper, CP
   Gelb, CA
   Chu, J
AF Cooper, Crystale Purvis
   Gelb, Cynthia A.
   Chu, Jennifer
TI Gynecologic Cancer Information on YouTube: Will Women Watch
   Advertisements to Learn More?
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article
DE Advertisements; Gynecologic cancer; YouTube; Internet
ID PORTRAYAL; DISEASE
AB The quality and accuracy of health content posted on YouTube varies widely. To increase dissemination of evidence-based gynecologic cancer information to US YouTube users, the Centers for Disease Control and Prevention (CDC) sponsored two types of advertisements: (1) pre-roll videos that users had to watch for at least 5 s before seeing a video they selected and (2) keyword-targeted listings that appeared in search results when users entered terms related to gynecologic cancer. From July 2012 to November 2013, pre-roll videos were shown 9.2 million times, viewed (watched longer than the mandatory 5 s) 1.6 million times (17.6 %), and cost $0.09 per view. Keyword-targeted listings were displayed 15.3 million times, viewed (activated by users) 59,766 times (0.4 %), and cost $0.31 per view. CDC videos in advertisements played completely in 17.0 % of pre-roll video views and 44.4 % of keyword-targeted listing views. Advertisements on YouTube can disseminate evidence-based cancer information broadly with minimal cost.
C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, 9566 N Placita Roca Bronce, Tucson, AZ 85704 USA.
   [Gelb, Cynthia A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA.
   [Chu, Jennifer] Ogilvy Washington, Washington, DC USA.
RP Gelb, CA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA.
EM crystale_cooper@comcast.net; cgelb@cdc.gov
FU Centers for Disease Control and Prevention
FX This study was funded by the Centers for Disease Control and Prevention.
   However, the findings and conclusions in this paper are those of the
   authors and do not necessarily represent the official position of the
   Centers for Disease Control and Prevention.
NR 13
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-8195
EI 1543-0154
J9 J CANCER EDUC
JI J. Cancer Educ.
PD SEP
PY 2016
VL 31
IS 3
BP 602
EP 604
DI 10.1007/s13187-015-0830-3
PG 3
WC Oncology; Education, Scientific Disciplines; Public, Environmental &
   Occupational Health
SC Oncology; Education & Educational Research; Public, Environmental &
   Occupational Health
GA DU1UA
UT WOS:000381993900028
PM 25877466
ER

PT J
AU Wong-McClure, R
   Gregg, EW
   Barcelo, A
   Sanabria-Lopez, L
   Lee, K
   Abarca-Gomez, L
   Cervantes-Loaiza, M
   Luman, ET
AF Wong-McClure, Roy
   Gregg, Edward W.
   Barcelo, Alberto
   Sanabria-Lopez, Laura
   Lee, Kahye
   Abarca-Gomez, Leandra
   Cervantes-Loaiza, Marvin
   Luman, Elizabeth T.
TI Prevalence of diabetes and impaired fasting glucose in Costa Rica: Costa
   Rican National Cardiovascular Risk Factors Survey, 2010
SO JOURNAL OF DIABETES
LA English
DT Article
DE diabetes mellitus type 2; health survey; prediabetes; prevalence
ID POPULATION; ADULTS
AB BackgroundThe projected rising prevalence of diabetes and impaired fasting glucose (IFG) in developing countries warrants careful monitoring. The aim of this study was to present the results of the Costa Rican National Cardiovascular Risk Factors Surveillance System, which provides the first national estimates of diabetes and IFG prevalence among adults in Costa Rica.
   MethodsA cross-sectional survey of 3653 non-institutionalized adults aged 20years (87.8% response rate) following the World Health Organization STEPwise approach was built on a probabilistic sample of the non-institutionalized population during 2010. Known diabetes was defined as self-reported diagnosis, the use of insulin, or hypoglycemic oral treatment as consequence of diabetes during at least the previous 2weeks before the survey. Unknown diabetes was defined no self-reported diabetes but with venous blood concentrations of fasting glucose >125mg/dL determined by laboratory testing. Impaired fasting glucose was defined as fasting glucose between 100 and 125mg/dL among those without diabetes. The prevalence of diabetes and IFG prevalence was estimated according gender, body mass index (BMI), waist circumference (WC), educational level, and physical activity level.
   ResultsOverall diabetes prevalence was 10.8% (9.5% known and 1.3% unknown diabetes) and IFG prevalence was 16.5%. The prevalence of known diabetes was higher among women >65years compared with men of the same age group. Both known and unknown diabetes were significantly associated with higher BMI, increased WC, and low education level (P=0.01).
   ConclusionsThe prevalence of diabetes and IFG in Costa Rica is comparable to that in developed countries and indicates an urgent need for effective preventive interventions.
C1 [Wong-McClure, Roy; Sanabria-Lopez, Laura; Lee, Kahye; Abarca-Gomez, Leandra; Cervantes-Loaiza, Marvin] Caja Costarricense Seguro Social, Off Epidemiol & Surveillance, San Jose, Costa Rica.
   [Gregg, Edward W.] US Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Atlanta, GA USA.
   [Luman, Elizabeth T.] US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
   [Barcelo, Alberto] Pan Amer Hlth Org, Chron Dis, Washington, DC USA.
RP Wong-McClure, R (reprint author), Caja Costarricense Seguro Social, Epidemiol Off & Surveillance, Genaro Valverde Bldg,Second Ave, San Jose, Costa Rica.
EM rwong@ccss.sa.cr
FU Caja Costarricense de Seguro Social
FX Special thanks to Guiselle Arguello (Costa Rican Census and Statistics
   National Institute (INEC), San Jose, Costa Rica) for help with revision
   of the weights survey and sample results adjustment, to the health
   technician assistant of the Caja Costarricense de Seguro Social, the
   survey coordinators, and everyone who contributed to this project. The
   investigation was funded by Caja Costarricense de Seguro Social, which
   is the public healthcare provider of the Costa Rican Government.
NR 26
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1753-0393
EI 1753-0407
J9 J DIABETES
JI J. Diabetes
PD SEP
PY 2016
VL 8
IS 5
BP 686
EP 692
DI 10.1111/1753-0407.12348
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DW1GH
UT WOS:000383390500012
PM 26516694
ER

PT J
AU Coyle, C
   Wheelhouse, N
   Jacques, M
   Longbottom, D
   Svoboda, P
   Pohl, J
   Duncan, WC
   Rae, MT
   Barlow, PG
AF Coyle, Christopher
   Wheelhouse, Nick
   Jacques, Maxime
   Longbottom, David
   Svoboda, Pavel
   Pohl, Jan
   Duncan, W. Colin
   Rae, Michael T.
   Barlow, Peter G.
TI Ovine trophoblasts express cathelicidin host defence peptide in response
   to infection
SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
DE Chlamydia-related organisms; Waddlia; Cathelicidin; Defensin;
   Antimicrobial peptide; Trophoblast
ID ANTIMICROBIAL PEPTIDE; IN-VITRO; 1,25-DIHYDROXYVITAMIN D-3; NATURAL
   ANTIMICROBIALS; DENDRITIC CELLS; CUTTING EDGE; ABORTION; WADDLIA; GENE;
   ANTIBACTERIAL
AB Cationic host defence peptides (CHDP; also known as antimicrobial peptides) are key components of the immune response in the female reproductive tract. The role of the placental trophoblast in ovine host defence remains poorly understood. This study characterises expression of genes for cathelicidin and defensin peptides in primary ovine placental tissues, the ovine trophoblast cell line (AH-1) and in response to the TLR-4 ligand LPS, the abortifacient organism Waddlia chondrophila and 1 alpha,25-dihydroxyvitamin D-3.
   Using RT-PCR, expression of the CHDP SMAP-29, sBD-1 and sBD-2 was assessed in the AH-1 cell line in response to LPS, 1 alpha,25-dihydroxyvitamin D-3 exposure (a known stimulator of cathelicidin gene expression), or W. chondrophila infection. Expression of cathelicidin in the trophoblast compartment of the ovine placenta and in the ovine trophoblast cell line (AH-1) was also established. AH-1 cells did not upregulate expression of CHDP in response to LPS, but sBD-1 and sBD-2 expression was significantly increased in response to W. chondrophila infection. SMAP-29 expression was not altered by in vitro exposure to 1 alpha,25-dihydroxyvitamin D-3.
   This study demonstrates that the ovine trophoblast expresses cathelicidins, but does not upregulate expression of CHDP in response to LPS. Ovine trophoblasts are shown to differentially regulate expression of CHDP and lack a demonstrable vitamin D-mediated cathelicidin response. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Coyle, Christopher; Jacques, Maxime; Rae, Michael T.; Barlow, Peter G.] Edinburgh Napier Univ, Sch Life Sport & Social Sci, Sighthill Campus, Edinburgh EH11 4BN, Midlothian, Scotland.
   [Wheelhouse, Nick; Longbottom, David] Moredun Res Inst, Pentlands Sci Pk, Edinburgh EH26 0PZ, Midlothian, Scotland.
   [Svoboda, Pavel; Pohl, Jan] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Div Sci Resources, Atlanta, GA 30333 USA.
   [Duncan, W. Colin] Univ Edinburgh, Queens Med Res Inst, MRC Ctr Reprod Hlth, Edinburgh EH16 4TJ, Midlothian, Scotland.
RP Barlow, PG (reprint author), Edinburgh Napier Univ, Sch Life Sport & Social Sci, Sighthill Campus, Edinburgh EH11 4BN, Midlothian, Scotland.
EM p.barlow@napier.ac.uk
OI Wheelhouse, Nick/0000-0002-2803-0055; Barlow, Peter/0000-0002-6516-9312
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-0378
J9 J REPROD IMMUNOL
JI J. Reprod. Immunol.
PD SEP
PY 2016
VL 117
BP 10
EP 16
DI 10.1016/j.jri.2016.06.006
PG 7
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA DW7FV
UT WOS:000383817500003
PM 27348190
ER

PT J
AU Sejvar, J
   Styczinski, A
   Malta, J
   Leal, P
   Lanzieri, T
   Krow-Lucal, E
   Nobrega, M
   Percio, J
   Vargas, A
   Carvalho, M
   Miranda, R
   Lentini, N
   Barbosa, A
   Coelho, G
   Badaro, R
   Maierovitch, C
AF Sejvar, J.
   Styczinski, A.
   Malta, J.
   Leal, P.
   Lanzieri, T.
   Krow-Lucal, E.
   Nobrega, M.
   Percio, J.
   Vargas, A.
   Carvalho, M.
   Miranda, R.
   Lentini, N.
   Barbosa, A.
   Coelho, G.
   Badaro, R.
   Maierovitch, C.
TI INVESTIGATION OF GUILLAIN-BARRE SYNDROME OUTBREAK - BAHIA STATE, BRAZIL,
   2016
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Inflammatory Neuropathy Consortium and GBS 100 Centenary Symposium and
   Ceilidh
CY JUN 21-24, 2016
CL Univ Glasgow, Glasgow, SCOTLAND
SP Baxalta, CSL Behring, Grifols, Kedrion S p A, GBS CIDP Fdn Int, Guillain Barre Associated Inflammatory Neuropathies, LFB Biomedicaments, Octapharma, TEVA
HO Univ Glasgow
C1 [Sejvar, J.; Styczinski, A.; Lanzieri, T.; Krow-Lucal, E.; Carvalho, M.; Miranda, R.; Lentini, N.; Barbosa, A.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
   [Malta, J.; Nobrega, M.; Percio, J.; Vargas, A.] EPISUS, Brasilia, DF, Brazil.
   [Leal, P.; Coelho, G.; Maierovitch, C.] Brazil Minist Hlth MOH, Brasilia, DF, Brazil.
   [Badaro, R.] Dept Hlth, Bahia, Bahia State, Argentina.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD SEP
PY 2016
VL 21
IS 3
BP 208
EP 208
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DW7TY
UT WOS:000383856200145
ER

PT J
AU Faul, M
   Xu, LK
   Sasser, SM
AF Faul, Mark
   Xu, Likang
   Sasser, Scott M.
TI HOSPITALIZED TRAUMATIC BRAIN INJURY: LOW TRAUMA CENTER UTILIZATION AND
   HIGH INTERFACILITY TRANSFERS AMONG OLDER ADULTS
SO PREHOSPITAL EMERGENCY CARE
LA English
DT Article
DE TBI; Traumatic Brain Injury; Field triage; Brain Trauma Foundation
   Guidelines; Field Triage Guidelines; ambulance; transport; older adults;
   children
ID UNITED-STATES; LEVEL I; DIRECT TRANSPORT; MAJOR TRAUMA; OUTCOMES;
   GUIDELINES; MORTALITY; IMPACT; POPULATION; TRENDS
AB Objective: Guidelines suggest that Traumatic Brain Injury (TBI) related hospitalizations are best treated at Level I or II trauma centers because of continuous neurosurgical care in these settings. This population-based study examines TBI hospitalization treatment paths by age groups. Methods: Trauma center utilization and transfers by age groups were captured by examining the total number of TBI hospitalizations from National Inpatient Sample (NIS) and the number of TBI hospitalizations and transfers in the Trauma Data Bank National Sample Population (NTDB-NSP). TBI cases were defined using diagnostic codes. Results: Of the 351,555 TBI related hospitalizations in 2012, 47.9% (n = 168,317) were directly treated in a Level I or II trauma center, and an additional 20.3% (n = 71,286) were transferred to a Level I or II trauma center. The portion of the population treated at a trauma center (68.2%) was significantly lower than the portion of the U.S. population who has access to a major trauma center (90%). Further, nearly half of all transfers to a Level I or II trauma center were adults aged 55 and older (p < 0.001) and that 20.2% of pediatric patients arrive by non-ambulatory means. Conclusion: Utilization of trauma center resources for hospitalized TBIs may be low considering the established lower mortality rate associated with treatment at Level I or II trauma centers. The higher transfer rate for older adults may suggest rapid decline amid an unrecognized initial need for a trauma center care. A better understanding of hospital destination decision making is needed for patients with TBI.
C1 [Faul, Mark] Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA.
   Greenville Hlth Syst, Dept Emergency Med, Greenville, SC USA.
RP Faul, M (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA.
EM mfaul@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 42
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1090-3127
EI 1545-0066
J9 PREHOSP EMERG CARE
JI Prehosp. Emerg. Care
PD SEP-OCT
PY 2016
VL 20
IS 5
BP 594
EP 600
DI 10.3109/10903127.2016.1149651
PG 7
WC Emergency Medicine; Public, Environmental & Occupational Health
SC Emergency Medicine; Public, Environmental & Occupational Health
GA DW8OI
UT WOS:000383915000007
PM 26986195
ER

PT J
AU Caceres, VM
   Cardoso, P
   Sidibe, S
   Lambert, S
   Lopez, A
   Pedalino, B
   Guibert, DJH
AF Caceres, V. M.
   Cardoso, P.
   Sidibe, S.
   Lambert, S.
   Lopez, A.
   Pedalino, B.
   Guibert, D. J. Herrera
TI Daily zero-reporting for suspect Ebola using short message service (SMS)
   in Guinea-Bissau
SO PUBLIC HEALTH
LA English
DT Article
DE Surveillance; SMS; Ebola
ID VIRUS DISEASE; OUTBREAK; SYSTEM
AB Objective: Intensified surveillance will be vital in the elimination phase to verify Ebola-free status and mitigate potential reemergence of the disease in West Africa. Zero-reporting from high-risk districts is a key strategy for surveillance. Our objective was to implement a Pilot investigation to assess the feasibility of using short message service (SMS) texting for daily reporting of Ebola cases under investigation (CUI) in Guinea-Bissau in the context of an ongoing emergency-response training program known as Surveillance Training for Ebola Preparedness (STEP).
   Study design: Prospective cohort (pilot investigation)
   Methods: The reporting period for the SMS pilot was January 24 March 24, 2015. STEP was conducted for two sequential groups during January 19 March 27, 2015 in Bissau, Guinea-Bissau. Training on SMS daily reporting occurred over one hour during the first week of didactic training of each group. Fourteen participants (nine from the first group and five from the second), including one surveillance officer from each of the 13 regions in Guinea-Bissau and one from the national laboratory, were selected as reporters, receiving a simple cell phone for sending SMS indicating the number of CUI for Ebola. The WHO suspect Ebola case definition was used initially and then modified on day 32 of the pilot. The text message was sent to the WiFi-connected smartphone at the Instituto Nacional Satade Publica (INASA). The smartphone utilised an SMS-gateway application (Ushahidi SMSsync Android App) to upload the data to the Magpi cloud application.
   Results: The average daily reporting from the first group was 7.7 of 9 (86%) and for the second group was 4.1 of 5 (82%). For the two groups combined, the reporting rate was 85%. Among the 14 reporters the median reporting rate was 85% (range 36%-100%). No cases meeting the definition for an Ebola CUI were reported during the 60 days.
   Conclusions: Real-time, SMS-based, daily zero-reporting can be implemented in a rapid, simple way in a low resource country. We believe that the high compliance rates were due to the simplicity and familiarity of SMS and heightened sensitivity that resulted from STEP to the importance of zero-reporting in the midst of an Ebola epidemic in neighbouring countries. This model could be useful for rapid scale-up and implementation of alert systems in other outbreaks and public health emergencies. Published by Elsevier Ltd on behalf of The Royal Society for Public Health.
C1 [Caceres, V. M.; Lambert, S.; Lopez, A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Cardoso, P.] Inst Nacl Saude Publ, Bissau, Guinea Bissau.
   [Sidibe, S.] CDC Fdn, Atlanta, GA USA.
   [Pedalino, B.; Guibert, D. J. Herrera] Taskforce Global Hlth, TEPHINET, Decatur, GA USA.
RP Caceres, VM (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, Mailstop K-72,1600 Clifton Rd, Atlanta, GA 30329 USA.
FU CDC Foundation; TEPHINET
FX This investigation was supported financially through the CDC Foundation
   and TEPHINET.
NR 11
TC 0
Z9 0
U1 4
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD SEP
PY 2016
VL 138
BP 69
EP 73
DI 10.1016/j.puhe.2016.03.006
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW7JN
UT WOS:000383827100010
PM 27106280
ER

PT J
AU Fernandez, MI
   Hosek, SG
   Hotton, AL
   Gaylord, SE
   Hernandez, N
   Alfonso, SV
   Joseph, H
AF Fernandez, M. Isabel
   Hosek, Sybil G.
   Hotton, Anna L.
   Gaylord, Sanford E.
   Hernandez, Nilda
   Alfonso, Sarah V.
   Joseph, Heather
TI A Randomized Controlled Trial of POWER: An Internet-Based HIV Prevention
   Intervention for Black Bisexual Men
SO AIDS AND BEHAVIOR
LA English
DT Article
DE BMSMW; HIV prevention; Interventions; Sexual behavior
ID TRANSMISSION RISK; SEXUAL TRANSMISSION; HIDDEN POPULATIONS; PHYSICAL
   HEALTH; UNITED-STATES; WOMEN; GAY; BEHAVIOR; PROPHYLAXIS; STRATEGIES
AB POWER is a theory-based, on-line HIV prevention intervention developed specifically for Black men who have sex with men and women (BMSMW), an understudied group significantly impacted by HIV. To test its efficacy, we recruited 224 BMSMW using chain referral methods and randomly assigned 108 to POWER and 103 to a health information comparison condition. Three months after the intervention, participants assigned to POWER had lower odds of reporting any condomless vaginal or condomless anal intercourse (CVAI) compared to those in the comparison group (aOR = 0.49; 95 % CI 0.25-0.98; p = 0.044). The intervention was associated with significantly lower odds of condomless anal intercourse with male partners (aOR = 0.55; 95 % CI 0.34-0.91; p = 0.020) but not with female partners and serodiscordant sex with male partners but not with female partners. Future studies are needed to replicate these findings in larger and more diverse samples of BMSMW and to understand the underlying mechanisms through which intervention efficacy was achieved.
C1 [Fernandez, M. Isabel; Hernandez, Nilda; Alfonso, Sarah V.] Nova Southeastern Univ, Coll Osteopath Med, Behav Hlth Promot Program, 2000 S Dixie Highway,Suite 108, Miami, FL 33133 USA.
   [Hosek, Sybil G.] John H Stroger Jr Hosp Cook Cty, Dept Psychiat, Chicago, IL USA.
   [Hotton, Anna L.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA.
   [Gaylord, Sanford E.] US Dept HHS, Reg Resource Network Program, Chicago, IL USA.
   [Joseph, Heather] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Fernandez, MI (reprint author), Nova Southeastern Univ, Coll Osteopath Med, Behav Hlth Promot Program, 2000 S Dixie Highway,Suite 108, Miami, FL 33133 USA.
EM mariafer@nova.edu
NR 31
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD SEP
PY 2016
VL 20
IS 9
BP 1951
EP 1960
DI 10.1007/s10461-016-1403-0
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DU1SZ
UT WOS:000381990800011
PM 27085548
ER

PT J
AU Seth, P
   Raiford, J
   DiClemente, RJ
AF Seth, Puja
   Raiford, Jerris
   DiClemente, Ralph J.
TI Factors Associated with HIV Testing among African American Female
   Adolescents in Juvenile Detention Centers
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Youth; Incarcerated; Testing; Risky sexual behavior; STIs
ID INCARCERATED ADOLESCENTS; RISK; INTERVENTION
AB Little is known about sexual and psychosocial factors associated with HIV testing among detained African American female adolescents-an understudied group at risk for HIV.
   188 detained African American female adolescents completed assessments on HIV testing, sexual risk behaviors, and psychosocial factors.
   Unprotected vaginal sex, history of STI-positivity or pregnancy, higher STI knowledge, and lower partner availability were associated with a higher likelihood of ever being tested for HIV.
   HIV testing is the gateway to important services for high-risk HIV-positive and HIV-negative adolescents. More research is needed to address barriers and to inform programmatic changes to increase testing among youth.
C1 [Seth, Puja; Raiford, Jerris] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
   [DiClemente, Ralph J.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
   [DiClemente, Ralph J.] Ctr AIDS Res Prevent Sci Core, Atlanta, GA USA.
   [Seth, Puja] Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30329 USA.
RP Seth, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.; Seth, P (reprint author), Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30329 USA.
EM pseth@cdc.gov
FU Centers for Disease Control and Prevention [5 UR6 PS000679]
FX This study was supported by the Centers for Disease Control and
   Prevention, cooperative agreement 5 UR6 PS000679.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD SEP
PY 2016
VL 20
IS 9
BP 2010
EP 2013
DI 10.1007/s10461-016-1310-4
PG 4
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DU1SZ
UT WOS:000381990800016
PM 26869185
ER

PT J
AU Bachanas, P
   Kidder, D
   Medley, A
   Pals, SL
   Carpenter, D
   Howard, A
   Antelman, G
   DeLuca, N
   Muhenje, O
   Sheriff, M
   Somi, G
   Katuta, F
   Cherutich, P
   Moore, J
AF Bachanas, Pamela
   Kidder, Daniel
   Medley, Amy
   Pals, Sherri L.
   Carpenter, Deborah
   Howard, Andrea
   Antelman, Gretchen
   DeLuca, Nicolas
   Muhenje, Odylia
   Sheriff, Muhsin
   Somi, Geoffrey
   Katuta, Frieda
   Cherutich, Peter
   Moore, Janet
TI Delivering Prevention Interventions to People Living with HIV in
   Clinical Care Settings: Results of a Cluster Randomized Trial in Kenya,
   Namibia, and Tanzania
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Sub-Saharan Africa; HIV prevention; People living with HIV
ID SOUTH-AFRICA; ALCOHOL-USE; BEHAVIORS; COUNTRIES
AB We conducted a group randomized trial to assess the feasibility and effectiveness of a multi-component, clinic-based HIV prevention intervention for HIV-positive patients attending clinical care in Namibia, Kenya, and Tanzania. Eighteen HIV care and treatment clinics (six per country) were randomly assigned to intervention or control arms. Approximately 200 sexually active clients from each clinic were enrolled and interviewed at baseline and 6- and 12-months post-intervention. Mixed model logistic regression with random effects for clinic and participant was used to assess the effectiveness of the intervention. Of 3522 HIV-positive patients enrolled, 3034 (86 %) completed a 12-month follow-up interview. Intervention participants were significantly more likely to report receiving provider-delivered messages on disclosure, partner testing, family planning, alcohol reduction, and consistent condom use compared to participants in comparison clinics. Participants in intervention clinics were less likely to report unprotected sex in the past 2 weeks (OR = 0.56, 95 % CI 0.32, 0.99) compared to participants in comparison clinics. In Tanzania, a higher percentage of participants in intervention clinics (17 %) reported using a highly effective method of contraception compared to participants in comparison clinics (10 %, OR = 2.25, 95 % CI 1.24, 4.10). This effect was not observed in Kenya or Namibia. HIV prevention services are feasible to implement as part of routine care and are associated with a self-reported decrease in unprotected sex. Further operational research is needed to identify strategies to address common operational challenges including staff turnover and large patient volumes.
C1 [Bachanas, Pamela; Kidder, Daniel; Medley, Amy; Pals, Sherri L.; Moore, Janet] US Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd,MS E04, Atlanta, GA 30333 USA.
   [Carpenter, Deborah] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Dar Es Salaam, Tanzania.
   [Howard, Andrea] Columbia Univ, ICAP, New York, NY USA.
   [Antelman, Gretchen] Columbia Univ, ICAP Tanzania, Dar Es Salaam, Tanzania.
   [DeLuca, Nicolas] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Windhoek, Namibia.
   [Muhenje, Odylia] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Nairobi, Kenya.
   [Sheriff, Muhsin] Columbia Univ, ICAP Kenya, Nairobi, Kenya.
   [Somi, Geoffrey] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania.
   [Katuta, Frieda] Minist Hlth & Social Serv, Windhoek, Namibia.
   [Cherutich, Peter] Natl AIDS STD Control Programme NASCOP, Nairobi, Kenya.
RP Bachanas, P (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd,MS E04, Atlanta, GA 30333 USA.
EM pbachanas@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 22
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD SEP
PY 2016
VL 20
IS 9
BP 2110
EP 2118
DI 10.1007/s10461-016-1349-2
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DU1SZ
UT WOS:000381990800026
PM 26995678
ER

PT J
AU Alemnji, G
   Guevara, G
   Parris, K
   Kalou, M
   Behel, S
   Parekh, B
   Nkengasong, J
   Albalak, R
AF Alemnji, George
   Guevara, Giselle
   Parris, Keith
   Kalou, Mireille
   Behel, Stephanie
   Parekh, Bharat
   Nkengasong, John
   Albalak, Rachel
TI Improving the Quality of and Access to HIV Rapid Testing in the
   Caribbean Region: Program Implementation, Outcomes, and Recommendations
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID DEVELOPING-COUNTRIES; LAY COUNSELORS; JAMAICA; CARE
AB In 2008, HIV rapid testing (HIV RT) was only minimally used in the Caribbean region. Collaboration with countries and international partners since then has resulted in greater availability and use of HIV RT services. Surveys were conducted in 2012 and 2014 among 11 selected Caribbean countries to inform stakeholders of progress made since 2008 and to identify strategies to further improve access and uptake of high-quality HIV RT in community- and facility-based settings in support of the UNAIDS 90-90-90 targets. Key accomplishments during this period include (1) presence of in-country national HIV RT algorithms, (2) use of the dried tube specimen (DTS) as an external quality assessment (EQA) program, (3) use of standardized logbooks for data collection and monitoring, and (4) use of oral fluid for HIV RT, particularly for key population surveys. Although progress has been made since 2008 to increase access and improve the quality of HIV RT among countries in the Caribbean, some work remains to be done. This includes the development of new policies and implementation of existing ones, task shifting, quality and access to testing, testing strategies, and integration of HIV RT into HIV Testing Services.
C1 [Alemnji, George; Guevara, Giselle; Parris, Keith; Albalak, Rachel] Ctr Dis Control & Prevent CDC, Caribbean Reg Off, Div Global HIV & TB, Bridgetown, Barbados.
   [Kalou, Mireille; Parekh, Bharat; Nkengasong, John] Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Int Lab Branch, Atlanta, GA USA.
   [Behel, Stephanie] Ctr Dis Control & Prevent CDC, HIV Prevent Branch, Div Global HIV & TB, Atlanta, GA USA.
RP Alemnji, G (reprint author), Ctr Dis Control & Prevent CDC, Caribbean Reg Off, Div Global HIV & TB, Bridgetown, Barbados.
EM ikv3@cdc.gov
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers
   for Disease Control and Prevention (CDC)
FX This research has been supported by the President's Emergency Plan for
   AIDS Relief (PEPFAR) through the Centers for Disease Control and
   Prevention (CDC). The authors would also like to acknowledge staff from
   various Ministries of Health in the region who participated in this
   survey.
NR 37
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2016
VL 32
IS 9
BP 879
EP 884
DI 10.1089/aid.2015.0353
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DV9SY
UT WOS:000383283400008
PM 27170101
ER

PT J
AU Cleveland, JL
   Gray, SK
   Harte, JA
   Robison, VA
   Moorman, AC
   Gooch, BF
AF Cleveland, Jennifer L.
   Gray, Shellie Kolavic
   Harte, Jennifer A.
   Robison, Valerie A.
   Moorman, Anne C.
   Gooch, Barbara F.
TI Transmission of blood-borne pathogens in US dental health care settings
   2016 update
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Infection control; infection prevention; dentistry; blood-borne
   pathogens; hepatitis B virus; hepatitis C virus; human immunodeficiency
   virus; health care-associated infection; standard precautions
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; B-VIRUS;
   ROOM-TEMPERATURE; GUIDELINES; INFECTION; RECOMMENDATIONS; MANAGEMENT;
   PERSONNEL
AB Background. During the past decade, investigators have reported transmissions of blood-borne pathogens (BBPs) in dental settings. In this article, the authors describe these transmissions and examine the lapses in infection prevention on the basis of available information.
   Methods. The authors reviewed the literature from 2003 through 2015 to identify reports of the transmission of BBPs in dental settings and related lapses in infection prevention efforts, as well as to identify reports of known or suspected health care-associated BBP infections submitted by state health departments to the Centers for Disease Control and Prevention.
   Results. The authors identified 3 published reports whose investigators described the transmission of hepatitis B virus and hepatitis C virus. In 2 of these reports, the investigators described single-transmission events (from 1 patient to another) in outpatient oral surgery practices. The authors of the third report described the possible transmission of hepatitis B virus to 3 patients and 2 dental health care personnel in a large temporary dental clinic. The authors identified lapses in infection prevention practices that occurred during 2 of the investigations; however, the investigators were not always able to link a specific lapse to a transmission event. Examples of lapses included the failure to heat-sterilize handpieces between patients, a lack of training for volunteers on BBPs, and the use of a combination of unsafe injection practices.
   Conclusions. The authors found that reports describing the transmission of BBPs in dental settings since 2003 were rare. Failure to adhere to Centers for Disease Control and Prevention recommendations for infection control in dental settings likely led to disease transmission in these cases.
   Practical Implications. The existence of these reports emphasizes the need to improve dental health care personnel's understanding of the basic principles and implementation of standard precautions through the use of checklists, policies, and practices.
C1 [Cleveland, Jennifer L.; Robison, Valerie A.; Gooch, Barbara F.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-80,4770 Buford Hwy, Atlanta, GA 30341 USA.
   [Gray, Shellie Kolavic; Harte, Jennifer A.] Carter Consulting, Atlanta, GA USA.
   [Harte, Jennifer A.] US Air Force, Washington, DC 20330 USA.
   [Moorman, Anne C.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Robison, VA (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-80,4770 Buford Hwy, Atlanta, GA 30341 USA.
EM VRobison@cdc.gov
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD SEP
PY 2016
VL 24
IS 9
BP 729
EP 738
DI 10.1016/j.adaj.2016.03.020
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DV2OE
UT WOS:000382759200013
ER

PT J
AU Jeyarajah, J
   Elam-Evans, LD
   Stokley, S
   Smith, PJ
   Singleton, JA
AF Jeyarajah, Jenny
   Elam-Evans, Laurie D.
   Stokley, Shannon
   Smith, Philip J.
   Singleton, James A.
TI Human Papillomavirus Vaccination Coverage Among Girls Before 13 Years: A
   Birth Year Cohort Analysis of the National Immunization Survey-Teen,
   2008-2013
SO CLINICAL PEDIATRICS
LA English
DT Article
DE human papillomavirus; trends in vaccination coverage; missed
   opportunity; achievable coverage; birth year cohort; adolescent
   vaccination; vaccination coverage
ID HPV VACCINATION; ADVISORY-COMMITTEE; ADOLESCENT GIRLS; RECOMMENDATIONS;
   OPPORTUNITIES; HEALTH; STATES; EPIDEMIOLOGY; DELIVERY; VACCINES
AB Routine human papillomavirus (HPV) vaccination is recommended at 11 or 12 years by the Advisory Committee on Immunization Practices. National Immunization Survey-Teen data were analyzed to evaluate, among girls, coverage with one or more doses of HPV vaccination, missed opportunities for HPV vaccination, and potential achievable coverage before 13 years. Results were stratified by birth year cohorts. HPV vaccination coverage before 13 years (1 HPV dose) increased from 28.4% for girls born in 1995 to 46.8% for girls born in 2000. Among girls born during 1999-2000 who had not received HPV vaccination before 13 years (57.2%), 80.1% had at least 1 missed opportunity to receive HPV vaccination before 13 years. Opportunities to vaccinate for HPV at age 11 to 12 years are missed. Strategies are needed to decrease these missed opportunities for HPV vaccination. This can be facilitated by the administration of all vaccines recommended for adolescents at the same visit.
C1 [Jeyarajah, Jenny] Carter Consulting, Atlanta, GA USA.
   [Jeyarajah, Jenny; Elam-Evans, Laurie D.; Stokley, Shannon; Smith, Philip J.; Singleton, James A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mail Stop A-19, Atlanta, GA 30333 USA.
RP Jeyarajah, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mail Stop A-19, Atlanta, GA 30333 USA.
EM uxz1@cdc.gov
NR 29
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0009-9228
EI 1938-2707
J9 CLIN PEDIATR
JI Clin. Pediatr.
PD SEP
PY 2016
VL 55
IS 10
BP 904
EP 914
DI 10.1177/0009922815616245
PG 11
WC Pediatrics
SC Pediatrics
GA DV5BM
UT WOS:000382940500002
PM 26603581
ER

PT J
AU Namulanda, G
   Maisonet, M
   Taylor, E
   Flanders, WD
   Olson, D
   Sjodin, A
   Qualters, JR
   Vena, J
   Northstone, K
   Naeher, L
AF Namulanda, Gonza
   Maisonet, Mildred
   Taylor, Ethel
   Flanders, W. Dana
   Olson, David
   Sjodin, Andreas
   Qualters, Judith R.
   Vena, John
   Northstone, Kate
   Naeher, Luke
TI In utero exposure to organochlorine pesticides and early menarche in the
   Avon Longitudinal Study of Parents and Children
SO ENVIRONMENT INTERNATIONAL
LA English
DT Article
DE ALSPAC; Endocrine disrupting compounds; Organochlorine pesticides;
   Puberty; Menarche
ID POLYBROMINATED DIPHENYL ETHERS; CONTEMPORARY BRITISH COHORT;
   POLYCHLORINATED-BIPHENYLS; PUBERTAL DEVELOPMENT; SECULAR TRENDS;
   BREAST-CANCER; HUMAN-SERUM; AGE; CHEMICALS; HEALTH
AB Introduction: Epidemiologic data supporting the role of organochlorine pesticides in pubertal development are limited.
   Methods: Using a nested case-control design, serum collected during pregnancy from mothers of 218 girls who reported menarche before 11.5 years of age (cases) and 230 girls who reported menarche at or after 11.5 years of age (controls) was analyzed for 9 organochlorines and metabolites. We analyzed the association between in utero organochlorine concentrations and early menarche using multivariate logistic regression controlling for mother's age at menarche, or mother's prenatal BMI.
   Results: We did not observe an association between in utero exposure to HCB, beta-HCH, p,p'-DDT,p,p'-DDE, oxychlordane or trans-nonachlor and early menarche.
   Conclusions: This study is the first to examine the association between in utero exposure to HCB, beta-HCH, T-HCH, oxychlordane or trans-nonachlor and early menarche. In utero exposure to organochlorine pesticides does not appear to have a role in the timing of menarche in this study. Published by Elsevier Ltd
C1 [Namulanda, Gonza; Taylor, Ethel; Flanders, W. Dana; Olson, David; Qualters, Judith R.; Naeher, Luke] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA.
   [Namulanda, Gonza; Naeher, Luke] Univ Georgia, Coll Publ Hlth, 105 Spear Rd, Athens, GA 30602 USA.
   [Maisonet, Mildred] East Tennessee State Univ, Coll Publ Hlth, POB 70259, Johnson City, TN 37614 USA.
   [Flanders, W. Dana] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Sjodin, Andreas] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-17, Atlanta, GA 30341 USA.
   [Vena, John] Med Univ South Carolina, Dept Publ Hlth Sci, 135 Cannon St Suite 303,MSC 835, Charleston, SC 29425 USA.
   [Northstone, Kate] Univ Bristol, Sch Social & Community Med, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England.
RP Namulanda, G (reprint author), 4770 Buford Hwy NE,MS F-60, Atlanta, GA 30341 USA.
EM fos0@cdc.gov
RI Northstone, Kate/A-8165-2011
OI Northstone, Kate/0000-0002-0602-1983
FU Wellcome Trust [102215/2/13/2]; University of Bristol; Centers for
   Disease Control and Prevention
FX We are extremely grateful to all the families who took part in this
   study, the midwives for their help in recruiting them, and the whole
   ALSPAC team, which includes interviewers, computer and laboratory
   technicians, clerical workers, research scientists, volunteers,
   managers, receptionists and nurses. The UK Medical Research Council and
   the Wellcome Trust (Grant ref.: 102215/2/13/2) and the University of
   Bristol provide core support for ALSPAC. This work was specifically
   funded by Centers for Disease Control and Prevention. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the views of the Centers for Disease Control and
   Prevention.
NR 42
TC 0
Z9 0
U1 6
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-4120
EI 1873-6750
J9 ENVIRON INT
JI Environ. Int.
PD SEP
PY 2016
VL 94
BP 467
EP 472
DI 10.1016/j.envint.2016.06.001
PG 6
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA DU6QF
UT WOS:000382339000050
PM 27297227
ER

PT J
AU Weiner, LM
   Webb, AK
   Walters, MS
   Dudeck, MA
   Kallen, AJ
AF Weiner, Lindsey M.
   Webb, Amy K.
   Walters, Maroya S.
   Dudeck, Margaret A.
   Kallen, Alexander J.
TI Policies for Controlling Multidrug-Resistant Organisms in US Healthcare
   Facilities Reporting to the National Healthcare Safety Network, 2014
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID CONTACT PRECAUTIONS; STAPHYLOCOCCUS-AUREUS; EPIDEMIOLOGY; ENTEROCOCCUS
AB We examined reported policies for the control of common multidrug-resistant organisms (MDROs) in US healthcare facilities using data from the National Healthcare Safety Network Annual Facility Survey. Policies for the use of Contact Precautions were commonly reported. Chlorhexidine bathing for preventing MDRO transmission was also common among acute care hospitals.
C1 [Weiner, Lindsey M.; Webb, Amy K.; Walters, Maroya S.; Dudeck, Margaret A.; Kallen, Alexander J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
RP Weiner, LM (reprint author), 1600 Clifton Rd,MS A24, Atlanta, GA 30329 USA.
EM Lweiner@cdc.gov
FU Division of Healthcare Quality Promotion, Centers for Disease Control
   and Prevention
FX The NHSN surveillance system is supported by the Division of Healthcare
   Quality Promotion, Centers for Disease Control and Prevention.
NR 10
TC 1
Z9 1
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD SEP
PY 2016
VL 37
IS 9
BP 1105
EP 1108
DI 10.1017/ice.2016.139
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DV4LJ
UT WOS:000382896800015
PM 27350394
ER

PT J
AU Allen-Bridson, K
   Pollock, D
AF Allen-Bridson, Katherine
   Pollock, Daniel
TI Response to "Potential Misclassification of Urinary Tract Related
   Bacteremia Upon Applying the 2015 Catheter-Associated Urinary Tract
   Infection Surveillance Definition From the National Healthcare Safety
   Network"
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Letter
C1 [Allen-Bridson, Katherine; Pollock, Daniel] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Allen-Bridson, K (reprint author), 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA.
EM Fsa6@cdc.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD SEP
PY 2016
VL 37
IS 9
BP 1121
EP 1121
DI 10.1017/ice.2016.142
PG 1
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DV4LJ
UT WOS:000382896800021
PM 27420639
ER

PT J
AU Huang, YLA
   Hutchinson, AB
   Hollis, ND
   Sansom, SL
AF Huang, Ya-Lin A.
   Hutchinson, Angela B.
   Hollis, NaTasha D.
   Sansom, Stephanie L.
TI Notification following new positive HIV test results
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV testing; receipt of test result; notification; rapid test;
   conventional test
ID PREVENTION; STRATEGIES; TRANSMISSION; METAANALYSIS; EPIDEMIC; BEHAVIOR
AB Client notification of a new HIV diagnosis is critical for timely access to treatment and reduction in behaviours associated with HIV infection. It is also an important input in HIV transmission and disease progression models. We used national, Centers for Disease Control and Prevention-funded HIV testing events data collected through the National HIV Prevention Program Monitoring and Evaluation system to update estimates of the proportion of newly identified HIV-positives notified of their status. We compared estimates from 2008 to 2010 across test technologies, settings, and HIV risk groups. In 2010, notification following a positive rapid test was 99.6% compared with 99.3% in 2008. Notification following a positive conventional test was 81.5% in 2010 compared with 80.8% in 2008. To realise the full promise of early HIV diagnosis and treatment for the prevention of additional HIV cases, efforts to ensure prompt notification following a new HIV diagnosis will be crucial.
C1 [Huang, Ya-Lin A.; Hutchinson, Angela B.; Hollis, NaTasha D.; Sansom, Stephanie L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mail Stop E-48, Atlanta, GA 30329 USA.
RP Huang, YLA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mail Stop E-48, Atlanta, GA 30329 USA.
EM yhuang@cdc.gov
NR 19
TC 1
Z9 1
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD SEP
PY 2016
VL 27
IS 10
BP 868
EP 872
DI 10.1177/0956462415598090
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DV4YN
UT WOS:000382931900007
PM 26378191
ER

PT J
AU Martin, SB
   Schauer, ES
   Blum, DH
   Kremer, PA
   Bahnfleth, WP
   Freihaut, JD
AF Martin, Stephen B., Jr.
   Schauer, Elizabeth S.
   Blum, David H.
   Kremer, Paul A.
   Bahnfleth, William P.
   Freihaut, James D.
TI A new dual-collimation batch reactor for determination of ultraviolet
   inactivation rate constants for microorganisms in aqueous suspensions
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Ultraviolet; Inactivation rate constant; Collimated-beam reactor;
   Germicidal; k-Value; Bacillus subtilis
ID BACILLUS-SUBTILIS SPORES; BEAM TESTING PROTOCOL; UV DISINFECTION;
   CHEMICAL ACTINOMETER; RADIATION; NELLOR,MARGARET; CHEN,CHING,LIN;
   VALIDATION; BACTERIA; KUO,JEFF
AB We developed, characterized, and tested a new dual-collimation aqueous UV reactor to improve the accuracy and consistency of aqueous k-value determinations. This new system is unique because it collimates UV energy from a single lamp in two opposite directions. The design provides two distinct advantages over traditional single-collimation systems: 1) real-time UV dose (fluence) determination; and 2) simple actinometric determination of a reactor factor that relates measured irradiance levels to actual irradiance levels experienced by the microbial suspension. This reactor factor replaces three of the four typical correction factors required for single-collimation reactors. Using this dual -collimation reactor, Bacillus subtilis spores demonstrated inactivation following the classic multi-hit model with k = 0.1471 cm(2)/mj (with 95% confidence bounds of 0.1426 to 0.1516). Published by Elsevier B.V.
C1 [Martin, Stephen B., Jr.; Schauer, Elizabeth S.] NIOSH, Ctr Dis Control & Prevent, Resp Hlth Div, Field Studies Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.
   [Martin, Stephen B., Jr.; Kremer, Paul A.; Bahnfleth, William P.; Freihaut, James D.] Penn State Univ, Coll Engn, Dept Architectural Engn, Indoor Environm Ctr, 104 Engn Unit A, University Pk, PA 16802 USA.
   [Blum, David H.] MIT, Dept Architecture, Bldg Technol Lab, 77 Massachusetts Ave,Room 5-418, Cambridge, MA 02139 USA.
RP Martin, SB (reprint author), NIOSH, Ctr Dis Control & Prevent, Resp Hlth Div, Field Studies Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.
EM SMartin1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 27
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD SEP
PY 2016
VL 162
BP 674
EP 680
DI 10.1016/j.jphotobiol.2016.07.028
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DV5XK
UT WOS:000383003800080
PM 27498232
ER

PT J
AU Cleveland, JL
   Gray, SK
   Harte, JA
   Robison, VA
   Moorman, AC
   Gooch, BF
AF Cleveland, Jennifer L.
   Gray, Shellie Kolavic
   Harte, Jennifer A.
   Robison, Valerie A.
   Moorman, Anne C.
   Gooch, Barbara F.
TI Transmission of blood-borne pathogens in US dental health care settings
   2016 update
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article
DE Infection control; infection prevention; dentistry; blood-borne
   pathogens; hepatitis B virus; hepatitis C virus; human immunodeficiency
   virus; health care-associated infection; standard precautions
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; B-VIRUS;
   ROOM-TEMPERATURE; GUIDELINES; INFECTION; RECOMMENDATIONS; MANAGEMENT;
   PERSONNEL
AB Background. During the past decade, investigators have reported transmissions of blood-borne pathogens (BBPs) in dental settings. In this article, the authors describe these transmissions and examine the lapses in infection prevention on the basis of available information.
   Methods. The authors reviewed the literature from 2003 through 2015 to identify reports of the transmission of BBPs in dental settings and related lapses in infection prevention efforts, as well as to identify reports of known or suspected health care-associated BBP infections submitted by state health departments to the Centers for Disease Control and Prevention.
   Results. The authors identified 3 published reports whose investigators described the transmission of hepatitis B virus and hepatitis C virus. In 2 of these reports, the investigators described single-transmission events (from 1 patient to another) in outpatient oral surgery practices. The authors of the third report described the possible transmission of hepatitis B virus to 3 patients and 2 dental health care personnel in a large temporary dental clinic. The authors identified lapses in infection prevention practices that occurred during 2 of the investigations; however, the investigators were not always able to link a specific lapse to a transmission event. Examples of lapses included the failure to heat-sterilize handpieces between patients, a lack of training for volunteers on BBPs, and the use of a combination of unsafe injection practices.
   Conclusions. The authors found that reports describing the transmission of BBPs in dental settings since 2003 were rare. Failure to adhere to Centers for Disease Control and Prevention recommendations for infection control in dental settings likely led to disease transmission in these cases.
C1 [Cleveland, Jennifer L.; Robison, Valerie A.; Gooch, Barbara F.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-80,4770 Buford Hwy, Atlanta, GA 30341 USA.
   [Gray, Shellie Kolavic; Harte, Jennifer A.] Carter Consulting, Atlanta, GA USA.
   [Harte, Jennifer A.] US Air Force, Randolph Air Force Base, TX USA.
   [Moorman, Anne C.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Robison, VA (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-80,4770 Buford Hwy, Atlanta, GA 30341 USA.
EM VRobison@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 50
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD SEP
PY 2016
VL 147
IS 9
BP 729
EP 738
DI 10.1016/j.adaj.2016.03.020
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DV2NH
UT WOS:000382756800013
PM 27233680
ER

PT J
AU Johnston, EO
   Sharma, AJ
   Abe, K
AF Johnston, Emily O.
   Sharma, Andrea J.
   Abe, Karon
TI Association Between Maternal Multivitamin Use and Preterm Birth in 24
   States, Pregnancy Risk Assessment Monitoring System, 2009-2010
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE PRAMS; Pregnancy; Preterm birth; Vitamins
ID GESTATIONAL-AGE BIRTHS; SUPPLEMENT USE; UNITED-STATES; OUTCOMES; WOMEN;
   NUTRITION; EPIDEMIOLOGY; MORTALITY; RATES
AB Objectives The study objective was to examine the prevalence of maternal multivitamin use and associations with preterm birth (< 37 weeks gestation) in the United States. We additionally examined whether associations differed by race/ethnicity. Methods Using the Pregnancy Risk Assessment Monitoring System, we analyzed 2009-2010 data among women aged aeyen18 years with a singleton live birth who completed questions on multivitamin use 1 month prior to pregnancy (24 states; n = 57,348) or in the last 3 months of pregnancy (3 states, n = 5095). Results In the month prior to pregnancy, multivitamin use aeyen4 times/week continued to remain low (36.8 %). In the last 3 months of pregnancy, 79.6 % of women reported using multivitamins aeyen4 times/week. Adjusting for confounders, multivitamin use 1-3 times/week or aeyen4 times/week prior to pregnancy was not associated with preterm birth overall. Though there was no evidence of dose response, any multivitamin use in the last 3 months of pregnancy was associated with a significant reduction in preterm birth among non-Hispanic black women. Conclusions for Practice Multivitamin use during pregnancy may help reduce preterm birth, particularly among populations with the highest burden, though further investigations are warranted.
C1 [Johnston, Emily O.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA.
   [Sharma, Andrea J.; Abe, Karon] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA.
   [Abe, Karon] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-64, Atlanta, GA 30333 USA.
RP Johnston, EO (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA.
EM EOJohnston@cdc.gov
OI Sharma, Andrea/0000-0003-0385-0011
FU Intramural CDC HHS [CC999999]
NR 35
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD SEP
PY 2016
VL 20
IS 9
BP 1825
EP 1834
DI 10.1007/s10995-016-1985-1
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV2MG
UT WOS:000382754100008
PM 27209294
ER

PT J
AU Sinha, A
   Russell, LB
   Tomczyk, S
   Verani, JR
   Schrag, SJ
   Berkley, JA
   Mohammed, M
   Sigauque, B
   Kim, SY
AF Sinha, Anushua
   Russell, Louise B.
   Tomczyk, Sara
   Verani, Jennifer R.
   Schrag, Stephanie J.
   Berkley, James A.
   Mohammed, Musa
   Sigauque, Betuel
   Kim, Sun-Young
CA GBS Vaccine Cost-Effectiveness
TI Disease Burden of Group B Streptococcus Among Infants in Sub-Saharan
   Africa A Systematic Literature Review and Meta-analysis
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Review
DE Africa; group B streptococcus; neonatal sepsis; neonatal meningitis;
   global health; meta-analysis
ID PREGNANT-WOMEN; SOUTH-AFRICA; RISK-FACTORS; NEONATAL SEPTICEMIA;
   COLONIZATION; INFECTION; MALAWI; BABIES; EPIDEMIOLOGY; METAANALYSIS
AB Background: Group B streptococcus (GBS) is a leading neonatal sepsis pathogen globally. Investment in GBS disease prevention, such as maternal vaccination, requires evidence of disease burden, particularly in high infant mortality regions like sub-Saharan Africa. We aimed to provide such evidence by conducting a systematic literature review and meta-analysis to estimate maternal colonization proportion, GBS disease incidence and GBS serotype distribution.
   Methods: MEDLINE, MEDLINE in process and Cochrane Library were searched for studies published during 1990-2014, pertaining to sub-Saharan Africa. Eligible studies were used to estimate the proportion of pregnant women colonized with GBS, early-onset GBS disease incidence, late-onset GBS disease incidence and respective serotype distributions. Random effects meta-analysis was conducted to estimate weighted means and confidence intervals (CIs).
   Results: We identified 17 studies of colonization, 9 of disease incidence, and 6 of serotype distribution meeting inclusion criteria. 21.8% (95% CI: 18.3, 25.5) of expectant women were colonized with GBS. The incidence of early-onset GBS disease was 1.3 per 1000 births (95% CI: 0.81, 1.9), that of late-onset GBS disease 0.73 per 1000 births (95% CI: 0.48, 1.0). The most common disease-causing serotype was 3, followed by 1a. Serotypes 1b, 2 and 5 were next most common in frequency.
   Conclusion: Despite methodological factors leading to underestimation, GBS disease incidence appears high in sub-Saharan Africa. A small number of GBS serotypes cause almost all disease. GBS disease burden in sub-Saharan Africa suggests that safe, effective and affordable GBS disease prevention is needed.
C1 [Sinha, Anushua] Rutgers Sch Publ Hlth, Dept Hlth Syst & Policy, Newark, NJ USA.
   [Russell, Louise B.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA.
   [Tomczyk, Sara; Verani, Jennifer R.; Schrag, Stephanie J.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Infect Dis, Atlanta, GA USA.
   [Berkley, James A.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Berkley, James A.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England.
   [Mohammed, Musa] Hawassa Univ, Coll Med & Hlth Sci, Hawassa, Ethiopia.
   [Sigauque, Betuel] CISM, Maputo, Mozambique.
   [Kim, Sun-Young] Univ Texas San Antonio, Sch Publ Hlth, Div Management Policy & Community Hlth, San Antonio, TX USA.
RP Sinha, A (reprint author), Rutgers State Univ, Dept Hlth Syst & Policy, Rutgers Sch Publ Hlth, MSB F506,185 South Orange Ave, Newark, NJ 07101 USA.
EM anushua.sinha@rutgers.edu
FU Novartis Vaccines and Diagnostics, Inc.; Bill and Melinda Gates
   Foundation [OPP1105076]
FX N.H., R.S.H. and S.A.M. have received funding for a GBS vaccine trial
   from Novartis Vaccines and Diagnostics, Inc. S.A.M. has received
   honoraria for advisory board participation from Pfizer, Inc. This study
   was supported by award OPP1105076 from the Bill and Melinda Gates
   Foundation.
NR 41
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD SEP
PY 2016
VL 35
IS 9
BP 933
EP 942
DI 10.1097/INF.0000000000001233
PG 10
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DU5NP
UT WOS:000382258800004
PM 27213263
ER

PT J
AU Dixon, LB
   Breck, A
   Khan, LK
AF Dixon, L. Beth
   Breck, Andrew
   Khan, Laura Kettel
TI Comparison of children's food and beverage intakes with national
   recommendations in New York City child-care centres
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Dietary guidelines; Child care; Nutrition; Child nutrition
ID YOUNG-CHILDREN; PHYSICAL-ACTIVITY; NUTRIENT INTAKE; DIETARY-INTAKE;
   NUTRITION; BENCHMARKS; PREVENTION; PROVIDERS; SETTINGS; PARENTS
AB Objective The present study compared foods and beverages provided to and consumed by children at child-care centres in New York City (NYC) with national nutrition recommendations.
   Design The study used survey, observational and centre record data collected from child-care centres. Food and beverage intakes from two days of observation and amounts of energy and nutrients were estimated using the US National Cancer Institute's Automated Self-Administered 24 h Recall system.
   Setting Meal and snack time at 108 child-care centres in low-income communities in NYC.
   Subjects Children aged 3-4 years old in classrooms selected by the directors of the participating child-care centres.
   Results Foods and beverages provided to and consumed by children (n 630) met >50 % of the Dietary Reference Intake (DRI) for most nutrients. Intakes of fibre and vitamins D and E were <30 % of the DRI. Foods and beverages provided >50 % of the recommended average daily intake amounts for total grains, fruits and fruit juices, and dairy, but <50 % of the recommended amounts for whole grains, protein foods and vegetables. Intake of oils was below the allowance for energy levels, but foods and beverages with solid fats and added sugars exceeded the limits by 68 %.
   Conclusions Providing more whole grains, vegetables and low-fat dairy and fewer foods with solid fats and added sugars may improve children's diet quality when at child-care centres. Centre staff may need training, resources and strategies in order to meet the nutrition recommendations.
C1 [Dixon, L. Beth] Syracuse Univ, Dept Publ Hlth Food Studies & Nutr, 415 Sims Bldg,26 Ostrom Ave, Syracuse, NY 13078 USA.
   [Breck, Andrew] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
   [Breck, Andrew] NYU, Wagner Sch Publ Serv, Dept Publ Adm, New York, NY 10016 USA.
   [Khan, Laura Kettel] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA.
RP Dixon, LB (reprint author), Syracuse Univ, Dept Publ Hlth Food Studies & Nutr, 415 Sims Bldg,26 Ostrom Ave, Syracuse, NY 13078 USA.
EM lbdixon@syr.edu
FU Robert Wood Johnson Foundation [65425]
FX This project was funded by a grant from the Robert Wood Johnson
   Foundation (number 65425) to the National Foundation for the CDC.
NR 34
TC 0
Z9 0
U1 5
U2 5
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD SEP
PY 2016
VL 19
IS 13
BP 2451
EP 2457
DI 10.1017/S1368980016001129
PG 7
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA DV4IK
UT WOS:000382889000019
PM 27280552
ER

PT J
AU Felix, SE
   Mack, KA
   Jones, CM
AF Felix, Sausan El Burai
   Mack, Karin A.
   Jones, Christopher M.
TI Trends in the Distribution of Opioids in Puerto Rico, 1999-2013
SO PUERTO RICO HEALTH SCIENCES JOURNAL
LA English
DT Article
DE Prescription drugs; Overdose
ID UNITED-STATES
AB Objective: Limited information has been published about opioid prescribing practices in Puerto Rico. The objective of this study was to create baseline trends of opioids distributed over a period of fourteen years in Puerto Rico.
   Methods: We examined data from the U.S. Drug Enforcement Administration's Automation of Reports and Consolidated Orders System (ARCOS) for the period 1999-2013. ARCOS data reflects the amount of controlled substances legally dispensed. Analyses include the distribution of opioids (in morphine milligram equivalent kg per 10,000 persons) by year and entity (pharmacy, hospital, practitioner).
   Results: The distribution of four drugs (fentanyl, hydromorphone, methadone, oxycodone) increased over 100% between 1999 and 2013. The distribution of two drugs (hydrocodone and meperidine) declined between 1999 and 2013. Oxycodone distribution grew from 0.13 MME kg grams per 10,000 persons in 1999 to 0.29 MME kg in 2013.
   Conclusion: ARCOS data showed that the overall amount of opioid pain relievers distributed in Puerto Rico increased by 68% between 1999 and 2013. Currently, prescription opioid pain reliever overdose deaths in Puerto Rico do not appear to be skyrocketing as they are in the mainland U.S. However, the ongoing problem with prescription opioid pain reliever overdoses in certain areas should serve as a warning to monitor consumption of opioid pain relievers, as well as changes in prescription drug abuse, overdoses, and deaths.
C1 [Felix, Sausan El Burai] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA.
   [Mack, Karin A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat, 4770 Buford Hwy NE F62, Atlanta, GA 30341 USA.
   [Jones, Christopher M.] Food & Drug Adm, Off Commissioner, Off Publ Hlth Strategy & Anal, Silver Spring, MD USA.
RP Mack, KA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat, 4770 Buford Hwy NE F62, Atlanta, GA 30341 USA.
EM kmack@cdc.gov
NR 14
TC 0
Z9 0
U1 0
U2 0
PU UNIV PUERTO RICO MEDICAL SCIENCES CAMPUS
PI SAN JUAN
PA OFFICE DEAN ACADEMIC AFFAIRS BOX 365067, SAN JUAN, PR 00936-5067 USA
SN 0738-0658
J9 P R HEALTH SCI J
JI P. R. Health Sci. J.
PD SEP
PY 2016
VL 35
IS 3
BP 165
EP 169
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV3XV
UT WOS:000382859700007
ER

PT J
AU Robbins, CL
   Gavin, L
   Zapata, LB
   Carter, MW
   Lachance, C
   Mautone-Smith, N
   Moskosky, SB
AF Robbins, Cheryl L.
   Gavin, Loretta
   Zapata, Lauren B.
   Carter, Marion W.
   Lachance, Christina
   Mautone-Smith, Nancy
   Moskosky, Susan B.
TI Preconception Care in Publicly Funded US Clinics That Provide Family
   Planning Services
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID UNITED-STATES; HEALTH-CARE; RECOMMENDATIONS
AB Introduction: Federal recommendations for providing quality family planning services were published in 2014 and included preconception care (PCC). This paper aims to describe the prevalence of PCC delivery among publicly funded clinics, prior to the recommendations.
   Methods: Prevalence of providing occasional or frequent PCC in the last 3 months and having written protocols for recommended PCC screenings were estimated in 2015 using survey data collected from a nationally representative sample of publicly funded clinic administrators (2013-2014, N = 1,615). Analyses included examination of differential distributions of outcomes by clinic characteristics (p<0.05) and multivariable regression.
   Results: Prevalence of occasional or frequent PCC delivery was 81% for women and 38% for men. The percentage of clinics with written protocols for specific PCC screenings ranged from 74% to 88% (women) and 66% to 83% (men). Prevalence of having written protocols for all PCC screenings was 29% for women and 22% for men. Characteristics negatively associated with having written protocols for all PCC screenings for women and men (respectively) were as follows: not receiving Title X funding (adjusted prevalence ratio [APR] = 0.6, 95% CI = 0.50, 0.76; APR = 0.6, 95% CI = 0.47, 0.77) and being a community health center (APR = 0.5, 95% CI = 0.37, 0.72; APR = 0.5, 95% CI = 0.30, 0.67); health department (APR = 0.7, 95% CI = 0.61, 0.87; APR = 0.6, 95% CI = 0.49, 0.76); or hospital/other (APR = 0.6, 95% CI = 0.50, 0.79; APR = 0.6, 95% CI = 0.43, 0.75) (versus Planned Parenthood).
   Conclusions: Provision of PCC appears to differ by clinic characteristics and by interpretation of the phrase "preconception care," suggesting opportunities for education and Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Robbins, Cheryl L.; Zapata, Lauren B.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Gavin, Loretta; Lachance, Christina; Mautone-Smith, Nancy; Moskosky, Susan B.] US DHHS, Off Populat Affairs, Rockville, MD USA.
   [Carter, Marion W.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Robbins, CL (reprint author), CDC, 4770 Buford Highway NE,Mailstop F-74, Atlanta, GA 30341 USA.
EM ggf9@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 14
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD SEP
PY 2016
VL 51
IS 3
BP 336
EP 343
DI 10.1016/j.amepre.2016.02.013
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DU6CC
UT WOS:000382299700011
PM 27020317
ER

PT J
AU Lau, DT
   McCaig, LF
   Hing, E
AF Lau, Denys T.
   McCaig, Linda F.
   Hing, Esther
TI Toward a More Complete Picture of Outpatient, Office-Based Health Care
   in the US
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID NURSE-PRACTITIONERS; PHYSICIAN ASSISTANTS; SERVICES; CENTERS; STATES
AB The healthcare system in the U.S., particularly outpatient, office-based care, has been shifting toward service delivery by advanced practice providers, particularly nurse practitioners (NPs) and physician assistants (PAs). The National Ambulatory Medical Care Survey (NAMCS), conducted by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention, is the leading source of nationally representative data on care delivered by office-based physicians. This paper first describes NAMCS, then discusses key NAMCS expansion efforts, and finally presents major findings from two exploratory studies that assess the feasibility of collecting data from NPs and PAs as sampled providers in NAMCS. The first NAMCS expansion effort began in 2006 when the NAMCS sample was expanded to include community health centers and started collecting and disseminating data on physicians, NPs, PAs, and nurse midwives in these settings. Then, in 2013, NCHS included workforce questions in NAMCS on the composition and clinical tasks of all healthcare staff in physician offices. Finally, in 2013-2014, NCHS conducted two exploratory studies and found that collecting data from NPs and PAs as sampled providers in NAMCS is feasible. However, modifications to the current NAMCS procedures may be necessary, for example, changing recruitment strategies, visit sampling procedures, and physician-centric survey items. Collectively, these NCHS initiatives are important for healthcare research, practice, and policy communities in their efforts toward providing a more complete picture of the changing outpatient, office-based workforce, team-based care approach, and service utilization in the U.S. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Lau, Denys T.; McCaig, Linda F.; Hing, Esther] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA.
   [Lau, Denys T.] George Washington Univ, Sch Publ Hlth, Dept Prevent & Community Hlth, Milken Inst, Washington, DC USA.
   [Lau, Denys T.] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Coll Pharm, Chicago, IL USA.
RP Lau, DT (reprint author), 3311 Toledo Rd, Hyattsville, MD 20782 USA.
EM dlau1@cdc.gov
FU U.S. DHHS, Assistant Secretary for Planning and Evaluation
FX The National Ambulatory Medical Care Survey (NAMCS) Workforce Items and
   the NAMCS Nurse Practitioner and Physician Assistant Pilot Studies were
   made possible with funding via an Interagency Agreement from the U.S.
   DHHS, Assistant Secretary for Planning and Evaluation. The authors thank
   Drs. James Cawley and Ellen Kurtzman of George Washington University for
   their insightful comments on an earlier version of this paper.
NR 26
TC 2
Z9 2
U1 5
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD SEP
PY 2016
VL 51
IS 3
BP 403
EP 409
DI 10.1016/j.amepre.2016.02.028
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DU6CC
UT WOS:000382299700018
PM 27079637
ER

PT J
AU Schiffer, JM
   McNeil, MM
   Quinn, CP
AF Schiffer, Jarad M.
   McNeil, Michael M.
   Quinn, Conrad P.
TI Recent developments in the understanding and use of anthrax vaccine
   adsorbed: achieving more with less
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE Anthrax; vaccines; BioThrax; Bacillus anthracis; antibody formation;
   post-exposure prophylaxis; pre-exposure prophylaxis; humans; nonhuman
   primate; correlates of protection
ID CELLULAR IMMUNE-RESPONSES; SERUM PROGESTERONE LEVELS; REPORTING SYSTEM
   VAERS; HUMAN CLINICAL-TRIAL; BODY-MASS INDEX; QUALITY-OF-LIFE; CPG 7909
   AV7909; BACILLUS-ANTHRACIS; ADVERSE EVENTS; PROTECTIVE ANTIGEN
AB Anthrax Vaccine Adsorbed (AVA, BioThrax) is the only Food and Drug Administration (FDA) approved vaccine for the prevention of anthrax in humans. Recent improvements in pre-exposure prophylaxis (PrEP) use of AVA include intramuscular (IM) administration and simplification of the priming series to three doses over 6months. Administration IM markedly reduced the frequency, severity and duration of injection site reactions. Refinement of animal models for inhalation anthrax, identification of immune correlates of protection and cross-species modeling have created opportunities for reductions in the PrEP booster schedule and were pivotal in FDA approval of a post-exposure prophylaxis (PEP) indication. Clinical and nonclinical studies of accelerated PEP schedules and divided doses may provide prospects for shortening the PEP antimicrobial treatment period. These data may assist in determining feasibility of expanded coverage in a large-scale emergency when vaccine demand may exceed availability. Enhancements to the AVA formulation may broaden the vaccine's PEP application.
C1 [Schiffer, Jarad M.] Ctr Dis Control & Prevent CDC, MPIR Lab, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis,Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [McNeil, Michael M.] Natl Ctr Emerging & Zoonot Infect Dis, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA.
   [Quinn, Conrad P.] Ctr Dis Control & Prevent CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Quinn, CP (reprint author), Ctr Dis Control & Prevent CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM cquinn@cdc.gov
NR 83
TC 1
Z9 1
U1 8
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD SEP
PY 2016
VL 15
IS 9
SI SI
BP 1151
EP 1162
DI 10.1586/14760584.2016.1162104
PG 12
WC Immunology
SC Immunology
GA DV2TX
UT WOS:000382775700010
PM 26942655
ER

PT J
AU Landgraf, KM
   Kakkar, R
   Meigs, M
   Jankauskas, PT
   Huong, PTT
   Nga, NV
   Thai, ND
   Tung, DT
   Hoa, NT
   Bond, KB
AF Landgraf, Kenneth M.
   Kakkar, Reshma
   Meigs, Michelle
   Jankauskas, Paul T.
   Phan Thi Thu Huong
   Nguyen Viet Nga
   Nguyen Duy Thai
   Duong Thanh Tung
   Nguyen Thi Hoa
   Bond, Kyle B.
TI Open-source LIMS in Vietnam: The path toward sustainability and host
   country ownership
SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
LA English
DT Article
DE Laboratory; Information systems; Open source; OSS; FLOSS;
   Sustainability; Health; Resource-constrained; Medical informatics;
   Development; LIMS; LIS; PEPFAR
ID HEALTH INFORMATION-SYSTEMS; OPEN-SOURCE SOFTWARE; CARE; IMPLEMENTATION;
   EXPERIENCE; MANAGEMENT
AB Objective: The objectives of this case report are as follows: to describe the process of establishing a national laboratory information management system (LIMS) program for clinical and public health laboratories in Vietnam; to evaluate the outcomes and lessons learned; and to present a model for sustainability based on the program outcomes that could be applied to diverse laboratory programs.
   Methods: This case report comprises a review of program documentation and records, including planning and budgetary records of the donor, monthly reports from the implementer, direct observation, and ad-hoc field reports from technical advisors and governmental agencies. Additional data on program efficacy and user acceptance were collected from routine monitoring of laboratory policies and operational practices.
   Results: LIMS software was implemented at 38 hospital, public health and HIV testing laboratories in Vietnam. This LIMS was accepted by users and program managers as a useful tool to support laboratory processes. Implementation cost per laboratory and average duration of deployment decreased over time, and project stakeholders initiated transition of financing (from the donor to local institutions) and of system maintenance functions (from the implementer to governmental and site-level staff). Collaboration between the implementer in Vietnam and the global LIMS user community was strongly established, and knowledge was successfully transferred to staff within Vietnam.
   Conclusion: Implementing open-sourced LIMS with local development and support was a feasible approach towards establishing a sustainable laboratory informatics program that met the needs of health laboratories in Vietnam. Further effort to institutionalize IT support capacity within key government agencies is ongoing. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Landgraf, Kenneth M.] QED Grp LLC, Ctr Dis Control & Prevent, Hanoi, Vietnam.
   [Kakkar, Reshma; Meigs, Michelle; Jankauskas, Paul T.] Assoc Publ Hlth Labs, Silver Spring, MD USA.
   [Phan Thi Thu Huong; Nguyen Viet Nga] Vietnam Agcy HIV Aids Control, Hanoi, Vietnam.
   [Nguyen Duy Thai] VAAC US CDC Project, Hanoi, Vietnam.
   [Duong Thanh Tung] Ho Chi Minh City Aids Comm, Ho Chi Minh City, Vietnam.
   [Nguyen Thi Hoa; Bond, Kyle B.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Landgraf, KM (reprint author), 2 Ngo Quyen St, Hanoi, Vietnam.
EM yci8@cdc.gov
OI Landgraf, Kenneth/0000-0001-5462-0561
FU President's Emergency Plan for AIDS Relief (PEFPAR) through the Centers
   for Disease Control and Prevention (CDC) [U2GGH001097]; OpenELIS
   foundation
FX The authors would like to thank the following organizations and
   individuals for their valuable contributions to the project: the staff
   at the Vietnam Administration for AIDS Control; Pham Hai Phong from
   HCMC-PAC, for his significant efforts supporting OpenELIS sites in HCMC;
   Sherrie Staley and Lucy Maryogo-Robinson from the Association of Public
   Health Laboratories, for their valuable program management support; the
   Minnesota Public Health Laboratory, for supporting the training of LIMS
   implementers in Vietnam; Global CyberSoft, the LIMS implementer in
   Vietnam, particularly Huy Van Doan, An Cao Dai, and Tien Dang Han; the
   OpenELIS foundation, for their continuous collaboration and support; Jan
   Flowers and the University of Washington for their support in developing
   and introducing the LIMS Policy & Adoption Analysis; Sheryl Lyss,
   Associate Director for Science, and Thomas Rush, Laboratory Advisor, at
   the U.S. Centers for Disease Control and Prevention-Vietnam, for the
   many valuable discussions regarding this report; and the laboratorians
   in each of the OpenELIS sites in Vietnam, for their constant commitment
   to laboratory strengthening. This project has been supported by the
   President's Emergency Plan for AIDS Relief (PEFPAR) through the Centers
   for Disease Control and Prevention (CDC) under the terms of cooperative
   agreement # U2GGH001097.
NR 39
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1386-5056
EI 1872-8243
J9 INT J MED INFORM
JI Int. J. Med. Inform.
PD SEP
PY 2016
VL 93
BP 92
EP 102
DI 10.1016/j.ijmedinf.2016.06.010
PG 11
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA DT6JY
UT WOS:000381591700012
PM 27435952
ER

PT J
AU Erdely, A
   Dahm, MM
   Schubauer-Berigan, MK
   Chen, BT
   Antonini, JM
   Hoover, MD
AF Erdely, Aaron
   Dahm, Matthew M.
   Schubauer-Berigan, Mary K.
   Chen, Bean T.
   Antonini, James M.
   Hoover, Mark D.
TI Bridging the gap between exposure assessment and inhalation toxicology:
   Some insights from the carbon nanotube experience
SO JOURNAL OF AEROSOL SCIENCE
LA English
DT Article
DE Exposure assessment; Inhalation; Carbon nanotube; Toxicology;
   Nanomaterial; Epidemiology
ID INTRATRACHEAL INSTILLATION; SECONDARY MANUFACTURERS; PULMONARY TOXICITY;
   NANOFIBER PRIMARY; LUNG; MICE; NANOMATERIALS; RESPONSES; WORKERS; RATS
AB The early incorporation of exposure assessment can be invaluable to help design, prioritize, and interpret toxicological studies or outcomes. The sum total of the exposure assessment findings combined with preliminary toxicology results allows for exposure informed toxicological study design and the findings can then be integrated, together with available epidemiologic data, to provide health effect relevance. With regard to engineered nanomaterial inhalation toxicology in particular, a single type of material (e.g. carbon nanotube, graphene) can have a vast array of physicochemical characteristics resulting in the potential for varying toxicities. To compound the matter, the methodologies necessary to establish a material adequate for in vivo exposure testing raises questions on the applicability of the outcomes. From insights gained from evaluating carbon nanotubes, we recommend the following integrated approach involving exposure informed hazard assessment and hazard-informed exposure assessment especially for materials as diverse as engineered nanomaterials: 1) market-informed identification of potential hazards and potentially exposed populations, 2) initial toxicity screening to drive prioritized assessments of exposure, 3) development of exposure assessment-informed chronic and sub-chronic in vivo studies, and 4) conduct of exposure- and hazard-informed epidemiological studies. Published by Elsevier Ltd.
C1 [Erdely, Aaron; Chen, Bean T.; Antonini, James M.] NIOSH, Hlth Effects Lab Div, HELD, PPRB, 1095 Willowdale Rd,MS-2015, Morgantown, WV 26505 USA.
   [Dahm, Matthew M.; Schubauer-Berigan, Mary K.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
   [Hoover, Mark D.] NIOSH, Resp Hlth Div, Morgantown, WV 26505 USA.
RP Erdely, A (reprint author), NIOSH, Hlth Effects Lab Div, HELD, PPRB, 1095 Willowdale Rd,MS-2015, Morgantown, WV 26505 USA.
EM efi4@cdc.gov
FU Nanotechnology Research Center of the National Institute for
   Occupational Safety and Health
FX This work was funded by the Nanotechnology Research Center of the
   National Institute for Occupational Safety and Health
NR 34
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021-8502
EI 1879-1964
J9 J AEROSOL SCI
JI J. Aerosol. Sci.
PD SEP
PY 2016
VL 99
SI SI
BP 157
EP 162
DI 10.1016/j.jaerosci.2016.03.005
PG 6
WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences;
   Meteorology & Atmospheric Sciences
SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric
   Sciences
GA DT6JE
UT WOS:000381589700017
PM 27546900
ER

PT J
AU Wheaton, AG
   Pleasants, RA
   Croft, JB
   Croft, JB
   Ohar, JA
   Heidari, K
   Mannino, DM
   Liu, Y
   Strange, C
AF Wheaton, Anne G.
   Pleasants, Roy A.
   Croft, Janet B.
   Croft, Janet B.
   Ohar, Jill A.
   Heidari, Khosrow
   Mannino, David M.
   Liu, Yong
   Strange, Charlie
TI Gender and asthma-chronic obstructive pulmonary disease overlap syndrome
SO JOURNAL OF ASTHMA
LA English
DT Article
DE Respiratory symptoms; health status; obstructive lung disease;
   comorbidities; health survey; tobacco history
ID RESPIRATORY SYMPTOMS; LUNG-FUNCTION; COPD-ASTHMA; FOLLOW-UP;
   POPULATION-SAMPLE; INCREASED RISK; UNITED-STATES; WEIGHT-GAIN; HEALTH;
   ADULTS
AB Objective: To assess relationships between obstructive lung diseases, respiratory symptoms, and comorbidities by gender. Methods: Data from 12594 adult respondents to the 2012 South Carolina Behavioral Risk Factor Surveillance System telephone survey were used. Five categories of chronic obstructive airway disease (OAD) were defined: former asthma only, current asthma only, chronic obstructive pulmonary disease (COPD) only, asthma-COPD overlap syndrome (ACOS), and none. Associations of these categories with respiratory symptoms (frequent productive cough, shortness of breath, and impaired physical activities due to breathing problems), overall health, and comorbidities were assessed using multivariable logistic regression for men and women. Results: Overall, 16.2% of men and 18.7% of women reported a physician diagnosis of COPD and/or asthma. Former asthma only was higher among men than women (4.9% vs. 3.2%, t-test p = 0.008). Current asthma only was more prevalent among women than men (7.2% vs. 4.7%, p < 0.001), as was ACOS (4.0% vs. 2.2%, p < 0.001). Having COPD only did not differ between women (4.3%) and men (4.4%). Adults with ACOS were most likely to report the 3 respiratory symptoms. COPD only and ACOS were associated with higher likelihoods of poor health and most comorbidities for men and women. Current asthma only was also associated with these outcomes among women, but not among men. Conclusions: In this large population-based sample, women were more likely than men to report ACOS and current asthma, but not COPD alone. Gender differences were evident between the OAD groups in sociodemographic characteristics, respiratory symptoms, and comorbidities, as well as overall health.
C1 [Wheaton, Anne G.; Croft, Janet B.; Liu, Yong] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F 78, Atlanta, GA 30341 USA.
   [Pleasants, Roy A.] Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Durham, NC USA.
   [Ohar, Jill A.] Wake Forest Univ, Sect Pulm Crit Care Allergy & Immunol Dis, Sch Med, Winston Salem, NC 27109 USA.
   [Heidari, Khosrow] South Carolina Dept Hlth & Environm Control, Chron Dis Epidemiol Off, Columbia, SC USA.
   [Mannino, David M.] Univ Kentucky, Div Pulm Crit Care & Sleep Med, Pulm Epidemiol Res Lab, Lexington, KY USA.
   [Strange, Charlie] Med Univ South Carolina, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC USA.
RP Wheaton, AG (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F 78, Atlanta, GA 30341 USA.
EM awheaton@cdc.gov
OI Mannino, David/0000-0003-3646-7828
FU GlaxoSmithKline; AstraZeneca; Boehringer Ingelheim; Genentech;
   GlaxoSmithKline plc; Novartis Pharmaceuticals; Pfizer Inc.; AstraZeneca
   PLC; Forest Laboratories Inc.; Merck; Sunovion; Sunovion, and Amgen
FX Dr. Pleasants reports grants from GlaxoSmithKline, AstraZeneca,
   Boehringer Ingelheim, and Genentech during the conduct of the study. Dr.
   Ohar reports personal fees from Novartis, AstraZeneca, Boehringer
   Ingelheim, and CSL Behring, outside the submitted work. Dr. Mannino has
   received honoraria/consulting fees and served on speaker bureaus for
   GlaxoSmithKline plc, Novartis Pharmaceuticals, Pfizer Inc., Boehringer
   Ingelheim, AstraZeneca PLC, Forest Laboratories Inc., Merck, Sunovion,
   and Amgen. Furthermore, he has received royalties from Up-to-Date and is
   on the Board of Directors of the COPD Foundation. He has also served as
   an expert witness on the health effects of tobacco use. Dr. Strange
   reports personal fees from AstraZeneca outside the submitted work. Other
   authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the article. The findings and
   conclusions in this article are those of the authors and do not
   necessarily represent the official position of the Centers for Disease
   Control and Prevention.
NR 48
TC 2
Z9 2
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PD SEP
PY 2016
VL 53
IS 7
BP 720
EP 731
DI 10.3109/02770903.2016.1154072
PG 12
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA DT2GJ
UT WOS:000381298500009
PM 27043854
ER

PT J
AU Kambhampati, A
   Shioda, K
   Gould, LH
   Sharp, D
   Brown, LG
   Parashar, UD
   Hall, AJ
AF Kambhampati, Anita
   Shioda, Kayoko
   Gould, L. Hannah
   Sharp, Donald
   Brown, Laura G.
   Parashar, Umesh D.
   Hall, Aron J.
TI A State-by-State Assessment of Food Service Regulations for Prevention
   of Norovirus Outbreaks
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
DE Food service; Norovirus; Prevention; Regulation; Retail food code
ID UNITED-STATES; ACUTE GASTROENTERITIS; NORWALK VIRUS; HANDLER;
   CONTAMINATION; TRANSMISSION
AB Noroviruses are the leading cause of foodborne disease in the United States. Foodborne transmission of norovirus is often associated with contamination of food during preparation by an infected food worker. The U.S. Food and Drug Administration's Food Code provides model food safety regulations for preventing transmission of foodborne disease in restaurants; however, adoption of specific provisions is at the discretion of state and local governments. We analyzed the food service regulations of all 50 states and the District of Columbia (i.e., 51 states) to describe differences in adoption of norovirus-related Food Code provisions into state food service regulations. We then assessed potential correlations between adoption of these regulations and characteristics of foodborne norovirus outbreaks reported to the National Outbreak Reporting System from 2009 through 2014. Of the 51 states assessed, all (100%) required food workers to wash their hands, and 39 (76%) prohibited bare-hand contact with ready-to-eat food. Thirty states (59%) required exclusion of staff with vomiting and diarrhea until 24 h after cessation of symptoms. Provisions requiring a certified food protection manager (CFPM) and a response plan for contamination events (i.e., vomiting) were least commonly adopted; 26 states (51%) required a CFPM, and 8 (16%) required a response plan. Although not statistically significant, states that adopted the provisions prohibiting bare-hand contact (0.45 versus 0.74, P = 0.07), requiring a CFPM (0.38 versus 0.75, P = 0.09), and excluding ill staff for >= 24 h after symptom resolution (0.44 versus 0.73, P = 0.24) each reported fewer foodborne norovirus outbreaks per million person-years than did those states without these provisions. Adoption and compliance with federal recommended food service regulations may decrease the incidence of foodborne norovirus outbreaks.
C1 [Kambhampati, Anita; Shioda, Kayoko; Parashar, Umesh D.; Hall, Aron J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Gould, L. Hannah; Sharp, Donald] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Brown, Laura G.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
   [Kambhampati, Anita; Shioda, Kayoko] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37830 USA.
RP Kambhampati, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.; Kambhampati, A (reprint author), Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37830 USA.
EM wyc4@cdc.gov
FU U.S. Department of Energy; CDC; Agriculture and Food Research Initiative
   Competitive Grant from U.S. Department of Agriculture, National
   Institute of Food and Agriculture [2011-68003-30395]
FX This research was supported in part by appointments to the Research
   Participation Program at the Centers for Disease Control and Prevention
   (A.K. and K.S.) administered by the Oak Ridge Institute for Science and
   Education through an interagency agreement between the U.S. Department
   of Energy and the CDC. This work was also supported in part by
   Agriculture and Food Research Initiative Competitive Grant
   2011-68003-30395 from the U.S. Department of Agriculture, National
   Institute of Food and Agriculture. The findings and conclusions in this
   report are those of the authors and do not necessarily represent the
   official position of the CDC.
NR 31
TC 0
Z9 0
U1 5
U2 5
PU INT ASSOC FOOD PROTECTION
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA
SN 0362-028X
EI 1944-9097
J9 J FOOD PROTECT
JI J. Food Prot.
PD SEP
PY 2016
VL 79
IS 9
BP 1527
EP 1536
DI 10.4315/0362-028X.JFP-16-088
PG 10
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA DV3DP
UT WOS:000382801500008
PM 28221948
ER

PT J
AU Radke, TJ
   Brown, LG
   Hoover, ER
   Faw, BV
   Reimann, D
   Wong, MR
   Nicholas, D
   Barkley, J
   Ripley, D
AF Radke, Taylor J.
   Brown, Laura G.
   Hoover, E. Rickamer
   Faw, Brenda V.
   Reimann, David
   Wong, Melissa R.
   Nicholas, David
   Barkley, Jonathan
   Ripley, Danny
TI Food Allergy Knowledge and Attitudes of Restaurant Managers and Staff:
   An EHS-Net Study
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
DE Food allergies; Food allergy attitudes; Food allergy knowledge; Food
   safety; Restaurants
ID PERSONNEL
AB Dining outside of the home can be difficult for persons with food allergies who must rely on restaurant staff to properly prepare allergen-free meals. The purpose of this study was to understand and identify factors associated with food allergy knowledge and attitudes among restaurant managers, food workers, and servers. This study was conducted by the Environmental Health Specialists Network (EHS-Net), a collaborative forum of federal, state, and local environmental health specialists working to understand the environmental factors associated with food safety issues. EHS-Net personnel collected data from 278 randomly selected restaurants through interviews with restaurant managers, food workers, and servers. Results indicated that managers, food workers, and servers were generally knowledgeable and had positive attitudes about accommodating customers' food allergies. However, we identified important gaps, such as more than 10% of managers and staff believed that a person with a food allergy can safely consume a small amount of that allergen. Managers and staff also had lower confidence in their restaurant's ability to properly respond to a food allergy emergency. The knowledge and attitudes of all groups were higher at restaurants that had a specific person to answer food allergy questions and requests or a plan for answering questions from food allergic customers. However, food allergy training was not associated with knowledge in any of the groups but was associated with manager and server attitudes. Based on these findings, we encourage restaurants to be proactive by training staff about food allergies and creating plans and procedures to reduce the risk of a customer having a food allergic reaction.
C1 [Radke, Taylor J.; Brown, Laura G.; Hoover, E. Rickamer] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway,Mailstop F58, Atlanta, GA 30341 USA.
   [Faw, Brenda V.] Calif Dept Publ Hlth, Sacramento, CA 95899 USA.
   [Reimann, David] Minnesota Dept Hlth, Mankato, MN 56001 USA.
   [Wong, Melissa R.] New York City Dept Hlth & Mental Hyg, New York, NY 11101 USA.
   [Nicholas, David] New York State Dept Hlth, Albany, NY 12237 USA.
   [Barkley, Jonathan] Rhode Isl Dept Hlth, Providence, RI 02908 USA.
   [Ripley, Danny] Metro Nashville Davidson Cty Publ Hlth Dept, Nashville, TN 37209 USA.
RP Radke, TJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway,Mailstop F58, Atlanta, GA 30341 USA.
EM tradke@cdc.gov
FU CDC [CDC-RFA-EH05-013]
FX We thank the restaurant managers, workers, and servers who participated
   in this study and the EHS-Net staff who assisted with study design and
   data collection. This publication is based on data collected and
   provided by CDC EHS-Net, which is supported by a CDC grant award funded
   under CDC-RFA-EH05-013. The findings and conclusions in this report are
   those of the authors and do not necessarily represent the views of CDC
   or the Agency for Toxic Substances and Disease Registry.
NR 12
TC 0
Z9 0
U1 9
U2 9
PU INT ASSOC FOOD PROTECTION
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA
SN 0362-028X
EI 1944-9097
J9 J FOOD PROTECT
JI J. Food Prot.
PD SEP
PY 2016
VL 79
IS 9
BP 1588
EP 1598
DI 10.4315/0362-028X.JFP-16-085
PG 11
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA DV3DP
UT WOS:000382801500015
PM 28221943
ER

PT J
AU Yucesoy, B
   Talzhanov, Y
   Barmada, MM
   Johnson, VJ
   Kashon, ML
   Baron, E
   Wilson, NW
   Frye, B
   Wang, W
   Fluharty, K
   Gharib, R
   Meade, J
   Germolec, D
   Luster, MI
   Nedorost, S
AF Yucesoy, Berran
   Talzhanov, Yerkebulan
   Barmada, M. Michael
   Johnson, Victor J.
   Kashon, Michael L.
   Baron, Elma
   Wilson, Nevin W.
   Frye, Bonnie
   Wang, Wei
   Fluharty, Kara
   Gharib, Rola
   Meade, Jean
   Germolec, Dori
   Luster, Michael I.
   Nedorost, Susan
TI Association of MHC region SNPs with irritant susceptibility in
   healthcare workers
SO JOURNAL OF IMMUNOTOXICOLOGY
LA English
DT Article
DE Genetics; healthcare workers; irritant contact dermatitis; MHC
ID TRIM FAMILY PROTEINS; PATCH TEST REACTIONS; CONTACT-DERMATITIS; HAND
   ECZEMA; BENZALKONIUM CHLORIDE; PREVALENCE; GENE; POPULATION; TOOL;
   POLYMORPHISMS
AB Irritant contact dermatitis is the most common work-related skin disease, especially affecting workers in wet-work occupations. This study was conducted to investigate the association between single nucleotide polymorphisms (SNPs) within the major histocompatibility complex (MHC) and skin irritant response in a group of healthcare workers. 585 volunteer healthcare workers were genotyped for MHC SNPs and patch tested with three different irritants: sodium lauryl sulfate (SLS), sodium hydroxide (NaOH) and benzalkonium chloride (BKC). Genotyping was performed using Illumina Goldengate MHC panels. A number of SNPs within the MHC Class I (OR2B3, TRIM31, TRIM10, TRIM40 and IER3), Class II (HLA-DPA1, HLA-DPB1) and Class III (C2) genes were associated (p<0.001) with skin response to tested irritants in different genetic models. Linkage disequilibrium patterns and functional annotations identified two SNPs in the TRIM40 (rs1573298) and HLA-DPB1 (rs9277554) genes, with a potential impact on gene regulation. In addition, SNPs in PSMB9 (rs10046277 and ITPR3 (rs499384) were associated with hand dermatitis. The results are of interest as they demonstrate that genetic variations in inflammation-related genes within the MHC can influence chemical-induced skin irritation and may explain the connection between inflamed skin and propensity to subsequent allergic contact sensitization.
C1 [Yucesoy, Berran; Kashon, Michael L.; Frye, Bonnie; Wang, Wei; Fluharty, Kara] NIOSH, Hlth Effects Lab Div, CDC, Morgantown, WV USA.
   [Talzhanov, Yerkebulan; Barmada, M. Michael] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Johnson, Victor J.] BRT, Morrisville, NC USA.
   [Baron, Elma; Nedorost, Susan] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
   [Wilson, Nevin W.] Univ Nevada, Sch Med, Dept Pediat, Reno, NV 89557 USA.
   [Gharib, Rola] West Virginia Univ, Sch Med, Dept Dermatol, Morgantown, WV USA.
   [Meade, Jean] NIOSH, Off Director, CDC, Morgantown, WV USA.
   [Germolec, Dori] NIEHS, Toxicol Branch, DNTP, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Luster, Michael I.] West Virginia Univ, Sch Publ Hlth, Morgantown, WV USA.
RP Yucesoy, B (reprint author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA.
EM berranyucesoy@gmail.com
FU NIOSH [AES12007001-1-0-6]; NIEHS [AES12007001-1-0-6]
FX This study was supported in part by an inter-agency agreement between
   NIOSH and NIEHS (AES12007001-1-0-6) as a collaborative National
   Toxicology Program research activity.
NR 39
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1547-691X
EI 1547-6901
J9 J IMMUNOTOXICOL
JI J. Immunotoxicol.
PD SEP
PY 2016
VL 13
IS 5
BP 738
EP 744
DI 10.3109/1547691X.2016.1173135
PG 7
WC Toxicology
SC Toxicology
GA DU9NF
UT WOS:000382543800013
PM 27258892
ER

PT J
AU Nicholson, MR
   Van Horn, GT
   Tang, YW
   Vinje, J
   Payne, DC
   Edwards, KM
   Chappell, JD
AF Nicholson, Maribeth R.
   Van Horn, Gerald T.
   Tang, Yi-Wei
   Vinje, Jan
   Payne, Daniel C.
   Edwards, Kathryn M.
   Chappell, James D.
TI Using Multiplex Molecular Testing to Determine the Etiology of Acute
   Gastroenteritis in Children
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID CLOSTRIDIUM-DIFFICILE INFECTION; ENTERIC BACTERIAL PANEL; UNITED-STATES;
   HOSPITALIZED CHILDREN; PEDIATRIC-PATIENTS; STOOL SPECIMENS;
   COLONIZATION; ROTAVIRUS; DISEASE; ASSAY
AB Objective To detect the etiologic agents of acute gastroenteritis (AGE) in children using broad molecular-based techniques, and compare clinical presentations among etiologies.
   Study design This was a prospective population-based surveillance study of children aged <6 years with AGE conducted between 2008 and 2011 as part of the New Vaccine Surveillance Network. Stools from patients and healthy controls were tested for 21 gastrointestinal pathogens using the analyte-specific reagent Gastrointestinal Pathogen Panel and an additional reverse transcription real-time polymerase chain reaction assay for sapovirus and astrovirus.
   Results Of the 216 stool samples from patients with AGE, 152 (70.4%) tested positive for a pathogen, with norovirus genogroup II (n = 78; 36.1%) and Clostridium difficile (n = 35; 16.2%) the most common pathogens detected. Forty-nine patients (22.7%) tested positive for more than 1 pathogen, including 25 (71%) with a C difficile detection. There were no significant clinical differences among the patients with no pathogen detected, those with a single pathogen detected, and those with >= 2 pathogens detected.
   Conclusion Using a broad molecular testing approach, high rates of enteropathogens were detected in children with AGE, dominated by norovirus genogroup II and C difficile. Coinfections were common but had no identifiable impact on clinical manifestations. As routine diagnostics of AGE progressively evolve toward nucleic acid-based pathogen detection, ongoing systematic studies are needed to better analyze the clinical significance of results.
C1 [Nicholson, Maribeth R.] Vanderbilt Univ, Sch Med, Div Pediat Gastroenterol Hepatol & Nutr, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Van Horn, Gerald T.] Amer Esoter Labs, Dept Microbiol, Memphis, TN USA.
   [Tang, Yi-Wei] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, Dept Lab Med,Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Vinje, Jan; Payne, Daniel C.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
   [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Div Pediat Infect Dis, Vanderbilt Vaccine Res Program, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.
RP Nicholson, MR (reprint author), Monroe Carell Jr Childrens Hosp Vanderbilt, Div Pediat Gastroenterol Hepatol & Nutr, 2200 Childrens Way, Nashville, TN 37232 USA.
EM maribeth.r.nicholson@vanderbilt.edu
FU Luminex Molecular Diagnostics; Luminex Corporation
FX Supported by Luminex Molecular Diagnostics (J.C.). Specimens were
   obtained through a cooperative agreement between Vanderbilt University
   and the US Centers for Disease Control and Prevention (CDC) as part of
   the New Vaccine Surveillance Network. Luminex Corporation provided the
   reagents and supplies necessary to perform specimen testing, as well as
   funds supporting the statistical analysis of study data. The findings
   and conclusions in this article are those of the authors and do not
   necessarily represent the official position of the CDC. Names of
   specific vendors, manufacturers, or products are included for public
   health and informational purposes; inclusion does not imply endorsement
   of the vendors, manufacturers, or products by the CDC or the US
   Department of Health and Human Services. J.C. has served as a consultant
   to Luminex Molecular Diagnostics on the xTAG Gastrointestinal Pathogen
   Panel, and currently collaborates with Luminex Corporation in the
   evaluation of new technology for the diagnosis of C difficile infection.
   The other authors declare no conflicts of interest.
NR 34
TC 1
Z9 1
U1 4
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD SEP
PY 2016
VL 176
BP 50
EP +
DI 10.1016/j.jpeds.2016.05.068
PG 9
WC Pediatrics
SC Pediatrics
GA DU5NM
UT WOS:000382258500010
PM 27329497
ER

PT J
AU Hwang, SS
   Smith, RA
   Barfield, WD
   Smith, VC
   McCormick, MC
   Williams, MA
AF Hwang, S. S.
   Smith, R. A.
   Barfield, W. D.
   Smith, V. C.
   McCormick, M. C.
   Williams, M. A.
TI Supine sleep positioning in preterm and term infants after hospital
   discharge from 2000 to 2011
SO JOURNAL OF PERINATOLOGY
LA English
DT Article
ID INTENSIVE-CARE-UNIT; DEATH-SYNDROME; RECOMMENDATIONS; TRENDS; STATES;
   SIDS
AB OBJECTIVE: Supine sleep positioning (SSP) has been shown to reduce the risk of sudden infant cleat!) syndrome (SIDS) and preterm infants are at higher risk for SIDS. Population-based estimates of SSP are lacking for the preterm population. The objectives of this study are: (1) compare the prevalence of SSP after hospital discharge for preterm and term infants in the United States; and (2) assess racial/ethnic disparities in SSP for preterm and term infants. STUDY
   DESIGN: We analyzed the 2000 to 2011 data from the Pregnancy Risk Assessment Monitoring System of Centers for Disease Control and Prevention from 35 states. We measured prevalence of SSP by preterm and term gestational age (GA) categories. We calculated adjusted prevalence ratios (APR) to evaluate the likelihood of SSP for each GA category compared with term infants and the likelihood of SSP for non-Hispanic black (NHB) and Hispanic infants compared with non-Hispanic white (NHW) infants.
   RESULTS: Prevalence of SSP varied by GA: <= 27, 59.7%; 28 0/7 to 33 6/7, 63.7%; 34 0/7 to 36 6/7 (late preterm), 63.6%; and 37 0/7 to 42 6/7 (term) weeks, 66.8% (P < 0.001). In the adjusted analyses, late preterm infants were slightly less likely to be placed in SSP compared with term infants (APR: 0.96, confidence interval: 0.95 to 0.98). There were racial/ethnic disparities in SSP for all GA categories when NHB and Hispanic infants were compared with NHW infants.
   CONCLUSIONS: All infants had suboptimal adherence to SSP indicating a continued need to better engage families about SSP. Parents of late preterm infants and families of NHB and Hispanic infants will also require greater attention given their decreased likelihood of SSP.
C1 [Hwang, S. S.] Childrens Hosp Colorado, Sect Neonatol, Dept Pediat, 13121 E 17th St,Mailstop 8402, Aurora, CO 80045 USA.
   [Hwang, S. S.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA.
   [Smith, R. A.; Barfield, W. D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
   [Smith, V. C.; McCormick, M. C.] Harvard Med Sch, Dept Pediat, Boston, MA USA.
   [Smith, V. C.; McCormick, M. C.] Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA.
   [McCormick, M. C.; Williams, M. A.] Harvard Sch Publ Hlth, Boston, MA USA.
RP Hwang, SS (reprint author), Childrens Hosp Colorado, Sect Neonatol, Dept Pediat, 13121 E 17th St,Mailstop 8402, Aurora, CO 80045 USA.
EM Sunah.hwang@childrenscolorado.org
NR 19
TC 0
Z9 0
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0743-8346
EI 1476-5543
J9 J PERINATOL
JI J. Perinatol.
PD SEP
PY 2016
VL 36
IS 9
BP 787
EP 793
DI 10.1038/jp.2016.80
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DU4LC
UT WOS:000382183100020
PM 27171759
ER

PT J
AU Dill, JA
   Camus, AC
   Leary, JH
   Di Giallonardo, F
   Holmes, EC
   Ng, TFF
AF Dill, Jennifer A.
   Camus, Alvin C.
   Leary, John H.
   Di Giallonardo, Francesca
   Holmes, Edward C.
   Ng, Terry Fei Fan
TI Distinct Viral Lineages from Fish and Amphibians Reveal the Complex
   Evolutionary History of Hepadnaviruses
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HEPATITIS-B-VIRUS; ARGININE-RICH DOMAIN; HEPATOCELLULAR-CARCINOMA;
   GENETIC DIVERSITY; CRYSTAL-STRUCTURE; UNITED-STATES; CORE PROTEIN; X
   PROTEIN; SEQUENCE; GENOME
AB Hepadnaviruses (hepatitis B viruses [HBVs]) are the only animal viruses that replicate their DNA by reverse transcription of an RNA intermediate. Until recently, the known host range of hepadnaviruses was limited to mammals and birds. We obtained and analyzed the first amphibian HBV genome, as well as several prototype fish HBVs, which allow the first comprehensive comparative genomic analysis of hepadnaviruses from four classes of vertebrates. Bluegill hepadnavirus (BGHBV) was characterized from in-house viral metagenomic sequencing. The African cichlid hepadnavirus (ACHBV) and the Tibetan frog hepadnavirus (TFHBV) were discovered using in silico analyses of the whole-genome shotgun and transcriptome shotgun assembly databases. Residues in the hydrophobic base of the capsid (core) proteins, designated motifs I, II, and III, are highly conserved, suggesting that structural constraints for proper capsid folding are key to capsid protein evolution. Surface proteins in all vertebrate HBVs contain similar predicted membrane topologies, characterized by three transmembrane domains. Most striking was the fact that BGHBV, ACHBV, and the previously described white sucker hepadnavirus did not form a fish-specific monophyletic group in the phylogenetic analysis of all three hepadnaviral genes. Notably, BGHBV was more closely related to the mammalian hepadnaviruses, indicating that cross-species transmission events have played a major role in viral evolution. Evidence of cross-species transmission was also observed with TFHBV. Hence, these data indicate that the evolutionary history of the hepadnaviruses is more complex than previously realized and combines both virus-host codivergence over millions of years and host species jumping.
   IMPORTANCE
   Hepadnaviruses are responsible for significant disease in humans (hepatitis B virus) and have been reported from a diverse range of vertebrates as both exogenous and endogenous viruses. We report the full-length genome of a novel hepadnavirus from a fish and the first hepadnavirus genome from an amphibian. The novel fish hepadnavirus, sampled from bluegills, was more closely related to mammalian hepadnaviruses than to other fish viruses. This phylogenetic pattern reveals that, although hepadnaviruses have likely been associated with vertebrates for hundreds of millions of years, they have also been characterized by species jumping across wide phylogenetic distances.
C1 [Dill, Jennifer A.; Camus, Alvin C.; Leary, John H.; Ng, Terry Fei Fan] Univ Georgia, Dept Pathol, Athens, GA 30602 USA.
   [Di Giallonardo, Francesca; Holmes, Edward C.] Univ Sydney, Sch Life & Environm Sci, Marie Bashir Inst Infect Dis & Biosecur, Charles Perkins Ctr, Sydney, NSW, Australia.
   [Di Giallonardo, Francesca; Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
   [Ng, Terry Fei Fan] CDC, Div Viral Dis, NCIRD, Atlanta, GA 30333 USA.
RP Ng, TFF (reprint author), Univ Georgia, Dept Pathol, Athens, GA 30602 USA.; Ng, TFF (reprint author), CDC, Div Viral Dis, NCIRD, Atlanta, GA 30333 USA.
EM ylz9@cdc.gov
OI Holmes, Edward/0000-0001-9596-3552; Ng, Terry Fei
   Fan/0000-0002-4815-8697
FU NHMRC Australia Fellowship [AF30]
FX E.C.H. is funded by an NHMRC Australia Fellowship (AF30).
NR 60
TC 2
Z9 2
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2016
VL 90
IS 17
BP 7920
EP 7933
DI 10.1128/JVI.00832-16
PG 14
WC Virology
SC Virology
GA DU6EM
UT WOS:000382306800028
PM 27334580
ER

PT J
AU DiPiazza, A
   Richards, K
   Batarse, F
   Lockard, L
   Zeng, H
   Garca-Sastre, A
   Albrecht, RA
   Sant, AJ
AF DiPiazza, Anthony
   Richards, Katherine
   Batarse, Frances
   Lockard, Laura
   Zeng, Hui
   Garca-Sastre, Adolfo
   Albrecht, Randy A.
   Sant, Andrea J.
TI Flow Cytometric and Cytokine ELISpot Approaches To Characterize the
   Cell-Mediated Immune Response in Ferrets following Influenza Virus
   Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CD4 T-CELLS; A VIRUS; B-CELL; SEASONAL INFLUENZA; ANTIBODY-RESPONSES;
   LETHAL INFLUENZA; DENDRITIC CELLS; RESPIRATORY VIRUS; FOLLICULAR HELPER;
   ANIMAL-MODELS
AB Influenza virus infections represent a significant socioeconomic and public health burden worldwide. Although ferrets are considered by many to be ideal for modeling human responses to influenza infection and vaccination, efforts to understand the cellular immune response have been severely hampered by a paucity of standardized procedures and reagents. In this study, we developed flow cytometric and T cell enzyme-linked immunosorbent spot (ELISpot) approaches to characterize the leukocyte composition and antigen-specific T cell response within key lymphoid tissues following influenza virus infection in ferrets. Through a newly designed and implemented set of serological reagents, we used multiparameter flow cytometry to directly quantify the frequency of CD4(+) and CD8(+) T cells, Ig(+) B cells, CD11b(+) myeloid-derived cells, and major histocompatibility complex (MHC) class II-positive antigen-presenting cells (APCs) both prior to and after intranasal infection with A/California/04/09 (H1N1). We found that the leukocyte composition was altered at 10 days postinfection, with notable gains in the frequency of T cells and myeloid cells within the draining lymph node. Furthermore, these studies revealed that the antigen specificity of influenza virus-reactive CD4 and CD8 T cells was very broad, with recognition of the viral HA, NA, M1, NS1, and NP proteins, and that total reactivity to influenza virus postinfection represented approximately 0.1% of the circulating peripheral blood mononuclear cells (PBMC). Finally, we observed distinct patterns of reactivity between individual animals, suggesting heterogeneity at the MHC locus in ferrets within commercial populations, a finding of considerable interest in efforts to move the ferret model forward for influenza vaccine and challenge studies.
   IMPORTANCE
   Ferrets are an ideal animal model to study transmission, diseases, and vaccine efficacies of respiratory viruses because of their close anatomical and physiological resemblances to humans. However, a lack of reagents has limited our understanding of the cell-mediated immune response following infection and vaccination. In this study, we used cross-reactive and ferret-specific antibodies to study the leukocyte composition and antigen-specific CD4 and CD8 T cell responses following influenza A/California/04/09 (H1N1) virus infection. These studies revealed strikingly distinct patterns of reactivity between CD4 and CD8 T cells, which were overlaid with differences in protein-specific responses between individual animals. Our results provide a first, in-depth look at the T cell repertoire in response to influenza infection and suggest that there is considerable heterogeneity at the MHC locus, which is akin to that in humans and an area of intense research interest.
C1 [DiPiazza, Anthony; Richards, Katherine; Batarse, Frances; Lockard, Laura; Sant, Andrea J.] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA.
   [Zeng, Hui] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Garca-Sastre, Adolfo; Albrecht, Randy A.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Garca-Sastre, Adolfo; Albrecht, Randy A.] Icahn Sch Med, Global Hlth & Emerging Pathogens Inst, New York, NY USA.
   [Garca-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
RP Sant, AJ (reprint author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA.
EM andrea_sant@urmc.rochester.edu
OI Garcia-Sastre, Adolfo/0000-0002-6551-1827
FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases
   (NIAID) [T32AI007285, HHSN272201300005C, HHSN272201400008C, P01AI097092]
FX This work, including the efforts of Anthony Thomas DiPiazza, was funded
   by HHS vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) (T32AI007285). This work, including the
   efforts of Andrea J. Sant and John J. Treanor, was funded by HHS
   vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) (HHSN272201300005C). This work, including
   the efforts of Randy A. Albrecht and Adolfo Garcia-Sastre, was funded by
   HHS vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) under grant number HHSN272201400008C. This
   work, including the efforts of Adolfo Garcia-Sastre, was funded by HHS
   vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) (P01AI097092).
NR 86
TC 2
Z9 2
U1 3
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2016
VL 90
IS 17
BP 7991
EP 8004
DI 10.1128/JVI.01001-16
PG 14
WC Virology
SC Virology
GA DU6EM
UT WOS:000382306800034
PM 27356897
ER

PT J
AU Deaton, MK
   Dzimianski, JV
   Daczkowski, CM
   Whitney, GK
   Mank, NJ
   Parham, MM
   Bergeron, E
   Pegan, SD
AF Deaton, M. K.
   Dzimianski, J. V.
   Daczkowski, C. M.
   Whitney, G. K.
   Mank, N. J.
   Parham, M. M.
   Bergeron, E.
   Pegan, S. D.
TI Biochemical and Structural Insights into the Preference of Nairoviral
   DeISGylases for Interferon-Stimulated Gene Product 15 Originating from
   Certain Species
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CONGO HEMORRHAGIC-FEVER; PAPAIN-LIKE PROTEASE; ERVE VIRUS; ISG15
   CONJUGATION; VIRAL RESISTANCE; UBIQUITIN; DOMAIN; DEUBIQUITINASE;
   BUNYAVIRIDAE; SPECIFICITY
AB The regulation of the interferon type I (IFN-I) response has been shown to rely on posttranslational modification by ubiquitin (Ub) and Ub-like interferon-stimulated gene product 15 (ISG15) to stabilize, or activate, a variety of IFN-I signaling and downstream effector proteins. Unlike Ub, which is almost perfectly conserved among eukaryotes, ISG15 is highly divergent, even among mammals. Since zoonotic viruses rely on viral proteins to recognize, or cleave, ISG15 conjugates in order to evade, or suppress, innate immunity, the impact of ISG15 biodiversity on deISGylating proteases of the ovarian tumor family (vOTU) from nairoviruses was evaluated. The enzymatic activities of vOTUs originating from the Crimean-Congo hemorrhagic fever virus, Erve virus, and Nairobi sheep disease virus were tested against ISG15s from humans, mice, shrews, sheep, bats, and camels, which are mammalian species known to be infected by nairoviruses. This along with investigation of binding by isothermal titration calorimetry illustrated significant differences in the abilities of nairovirus deISGylases to accommodate certain species of ISG15. To investigate the molecular underpinnings of species preferences of these vOTUs, a structure was determined to 2.5 angstrom for a complex of Erve virus vOTU protease and a mouse IS15 domain. This structure revealed the molecular basis of Erve virus vOTU's preference for ISG15 over Ub and the first structural insight into a nonhuman ISG15. This structure also revealed key interactions, or lack thereof, surrounding three amino acids that may drive a viral deISgylase to prefer an ISG15 from one species over that of another.
   IMPORTANCE
   Viral ovarian tumor domain proteases (vOTUs) are one of the two principal classes of viral proteases observed to reverse posttranslational modification of host proteins by ubiquitin and interferon-stimulated gene product 15 (ISG15), subsequently facilitating downregulation of IFN-I signaling pathways. Unlike the case with ubiquitin, the amino acid sequences of ISG15s from various species are notably divergent. We illustrate that vOTUs have clear preferences for ISG15s from certain species. In addition, these observations are related to the molecular insights acquired via the first X-ray structure of the vOTU from the Erve nairovirus in complex with the first structurally resolved nonhuman ISG15. This information implicates certain amino acids that drive the preference of vOTUs for ISG15s from certain species.
C1 [Deaton, M. K.; Dzimianski, J. V.; Daczkowski, C. M.; Whitney, G. K.; Mank, N. J.; Parham, M. M.; Pegan, S. D.] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
   [Bergeron, E.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA.
RP Pegan, SD (reprint author), Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
EM spegan@uga.edu
OI Bergeron, Eric/0000-0003-3398-8628
FU HHS \ National Institutes of Health (NIH) [R01AI109008]; U.S. Department
   of Agriculture (USDA) [58-5030-5-034]
FX This work, including the efforts of Eric Bergeron and Scott D. Pegan,
   was funded by HHS vertical bar National Institutes of Health (NIH)
   (R01AI109008). This work, including the efforts of Scott D. Pegan, was
   funded by U.S. Department of Agriculture (USDA) (58-5030-5-034).
NR 48
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2016
VL 90
IS 18
BP 8314
EP 8327
DI 10.1128/JVI.00975-16
PG 14
WC Virology
SC Virology
GA DU6HD
UT WOS:000382314100024
PM 27412597
ER

PT J
AU Feigin, VL
   Norrving, B
   George, MG
   Foltz, JL
   Roth, GA
   Mensah, GA
AF Feigin, Valery L.
   Norrving, Bo
   George, Mary G.
   Foltz, Jennifer L.
   Roth, Gregory A.
   Mensah, George A.
TI Prevention of stroke: a strategic global imperative
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID RANDOMIZED-CONTROLLED-TRIAL; CARDIOVASCULAR-DISEASE PREVENTION;
   COMPARATIVE RISK-ASSESSMENT; AMERICAN-HEART-ASSOCIATION; LOW-INCOME
   COUNTRIES; HEALTHY LIFE-STYLE; SMARTPHONE APPLICATION;
   ATRIAL-FIBRILLATION; MOBILE PHONE; SYSTEMATIC ANALYSIS
AB The increasing global stroke burden strongly suggests that currently implemented primary stroke prevention strategies are not sufficiently effective, and new primary prevention strategies with larger effect sizes are needed. Here, we review the latest stroke epidemiology literature, with an emphasis on the recently published Global Burden of Disease 2013 Study estimates; highlight the problems with current primary stroke and cardiovascular disease (CVD) prevention strategies; and outline new developments in primary stroke and CVD prevention. We also suggest key priorities for the future, including comprehensive prevention strategies that target people at all levels of CVD risk; implementation of an integrated approach to promote healthy behaviours and reduce health disparities; capitalizing on information technology to advance prevention approaches and techniques; and incorporation of culturally appropriate education about healthy lifestyles into standard education curricula early in life. Given the already immense and fast-increasing burden of stroke and other major noncommunicable diseases (NCDs), which threatens worldwide sustainability, governments of all countries should develop and implement an emergency action plan addressing the primary prevention of NCDs, possibly including taxation strategies to tackle unhealthy behaviours that increase the risk of stroke and other NCDs.
C1 [Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Sch Rehabil & Occupat Studies, Sch Publ Hlth & Psychosocial Studies,Fac Hlth & E, North Shore Campus,AA254,90 Akoranga Dr, Auckland 1142, New Zealand.
   [Norrving, Bo] Lund Univ, Dept Clin Sci, Neurol, Paradisgatan 2, Lund, Sweden.
   [George, Mary G.; Foltz, Jennifer L.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 600 Clifton Rd, Atlanta, GA 30333 USA.
   [Roth, Gregory A.] Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.
   [Roth, Gregory A.] Univ Washington, Sch Med, Div Cardiol, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.
   [Mensah, George A.] NHLBI, CTRIS, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Mensah, George A.] NHLBI, Div Cardiovasc Sci, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Feigin, VL (reprint author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Sch Rehabil & Occupat Studies, Sch Publ Hlth & Psychosocial Studies,Fac Hlth & E, North Shore Campus,AA254,90 Akoranga Dr, Auckland 1142, New Zealand.
EM valery.feigin@aut.ac.nz
FU Health Council of New Zealand; Brain Research New Zealand Centre of
   Research Excellence; "Ageing Well" Programme of the National Science
   Challenge; Ministry of Business, Innovation and Employment of New
   Zealand; US National Institute on Ageing and Medtronic Philanthropy
FX V.L.F. was partly funded by the Health Council of New Zealand, the Brain
   Research New Zealand Centre of Research Excellence, the "Ageing Well"
   Programme of the National Science Challenge, and the Ministry of
   Business, Innovation and Employment of New Zealand. G.A.R. has grant
   funding from the US National Institute on Ageing and Medtronic
   Philanthropy. We would like to thank Barbara Bowman at the Centers for
   Disease Control and Prevention for her valuable comments on early
   version of the manuscript. The views expressed in this article are those
   of the authors and do not necessarily represent the views of the
   National Heart, Lung, and Blood Institute; NIH; Centers for Disease
   Control and Prevention; or the U.S. Department of Health and Human
   Services.
NR 175
TC 5
Z9 5
U1 11
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
EI 1759-4766
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD SEP
PY 2016
VL 12
IS 9
BP 501
EP 512
DI 10.1038/nrneurol.2016.107
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU2BW
UT WOS:000382017000004
PM 27448185
ER

PT J
AU Moss, AS
   Murphy, LB
   Helmick, CG
   Schwartz, TA
   Barbour, KE
   Renner, JB
   Kalsbeek, W
   Jordan, JM
AF Moss, A. S.
   Murphy, L. B.
   Helmick, C. G.
   Schwartz, T. A.
   Barbour, K. E.
   Renner, J. B.
   Kalsbeek, W.
   Jordan, J. M.
TI Annual incidence rates of hip symptoms and three hip OA outcomes from a
   US population-based cohort study: the Johnston County Osteoarthritis
   Project
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Hip osteoarthritis; Hip symptoms; Race; Socioeconomic status; Incidence
   rates
ID BODY-MASS INDEX; KNEE OSTEOARTHRITIS; AFRICAN-AMERICANS; UNITED-STATES;
   RISK-FACTORS; ACETABULAR DYSPLASIA; SUBSEQUENT KNEE; JOINT INJURY;
   WEIGHT-GAIN; HAND
AB Objective: Estimate annual incidence rates (IRs) of hip symptoms and three osteoarthritis (OA) outcomes (radiographic, symptomatic, and severe radiographic) overall and by race, sociodemographic characteristics, and hip OA risk factors.
   Design: Analyze baseline (1991-1997) and first follow-up (1999-2003) data (n = 1446) from the Johnston County Osteoarthritis Project, a population-based, prospective study of adults >= 45 years in North Carolina. Hip symptoms were pain, aching, and/ or stiffness on most days, or groin pain. Radiographic and severe radiographic OA were KellgreneLawrence (KL) grades >= 2 and >= 3, respectively. Symptomatic OA was radiographic OA with symptoms in the same hip. Sociodemographics were age, gender, race, highest attained education, and annual household income. Hip OA risk factors were self-reported body mass index (BMI) at age 18 years, clinically measured BMI at baseline, and history of hip injury.
   Results: Annual IRs (median = 5.5 years follow-up) were 37, 23, 13, and 2.9 per 1000 person-years for hip symptoms, and radiographic, symptomatic, and severe radiographic hip OA, respectively. We found low IRs of radiographic and symptomatic hip OA among African Americans and high IRs of hip symptoms among the obese and the very poor. Across outcomes, IRs were highest for those with hip injury.
   Conclusion: No prior studies have reported IRs of hip symptoms; IRs of radiographic and severe radiographic hip OA were similar to, and the IR of symptomatic hip OA was higher than, previous estimates. Prevention efforts should target low socioeconomic status (SES) populations and obese adults; interventions for hip OA and hip symptoms are imperative for those with hip injuries. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
C1 [Moss, A. S.] Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA.
   [Murphy, L. B.; Helmick, C. G.; Barbour, K. E.] Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Highway NE,Mailstop F78, Atlanta, GA 30341 USA.
   [Schwartz, T. A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
   [Renner, J. B.] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA.
   [Renner, J. B.] Univ N Carolina, Dept Allied Hlth Sci, Chapel Hill, NC USA.
   [Kalsbeek, W.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Carolina Survey Res Lab, Chapel Hill, NC USA.
   [Jordan, J. M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA.
RP Murphy, LB (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Arthrit Program, 4770 Buford Highway NE,Mailstop F78, Atlanta, GA 30341 USA.
EM lmurphy1@cdc.gov
FU Centers for Disease Control (CDC) and Prevention/Association of Schools
   of Public Health [S043, S1734, S3486]; NIAMS Multipurpose Arthritis and
   Musculoskeletal Disease Center grant [5-P60-AR30701]; NIAMS
   Multidisciplinary Clinical Research Center [-5 P60 AR49465,
   P60-AR064166]; National Association of Chronic Disease Directors
   [117-1400-5]
FX The Johnston County Osteoarthritis Project is supported in part by
   cooperative agreements S043, S1734, and S3486 from the Centers for
   Disease Control (CDC) and Prevention/Association of Schools of Public
   Health; the NIAMS Multipurpose Arthritis and Musculoskeletal Disease
   Center grant 5-P60-AR30701; and the NIAMS Multidisciplinary Clinical
   Research Center grants -5 P60 AR49465 and P60-AR064166. A.S. Moss' work
   was made possible by a contract with the National Association of Chronic
   Disease Directors (contract no. 117-1400-5).
NR 46
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
EI 1522-9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD SEP
PY 2016
VL 24
IS 9
BP 1518
EP 1527
DI 10.1016/j.joca.2016.04.012
PG 10
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA DU5PY
UT WOS:000382265000004
PM 27109873
ER

PT J
AU Kendrick, K
   Brown, V
   Lords, C
   Matthias, J
   Henning, I
   Blackmore, C
   Likos, A
AF Kendrick, Katherine
   Brown, Veronica
   Lords, Caleb
   Matthias, James
   Henning, Ian
   Blackmore, Carina
   Likos, Anna
TI Full House: A Retrospective Analysis of High Sexually Transmitted
   Infection Prevalence among Adult Film Actors at a Singular Residence
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID PREEXPOSURE PROPHYLAXIS; PHARYNGEAL GONORRHEA; LOS-ANGELES; INDUSTRY;
   MEN; SEX; HIV; PERFORMERS; HEALTH; PREVENTION
AB Background: During a routine human immunodeficiency virus (HIV) investigation, Florida Department of Health staff identified a house (house A) in which over 150 individuals had resided at least briefly. Further investigation revealed that house A is used by the producer of a small adult film production company to board his actors. This report describes sexually transmitted infection (STI) prevalence among male actors in gay adult films residing in a common Florida residence.
   Methods: LexisNexis Accurint was used to identify house A residents since October 2002 when the producer arrived. Information on STIs and interview data were obtained from Florida's STI surveillance system. An infection was considered to be associated with residence in house A if the date of diagnosis occurred 6 months before an individual's residence start date through 6 months after his residence end date.
   Results: Excluding the producer, 150 men resided in house A starting from September 2003 to July 2015. Forty-six individuals had a reported case of HIV, syphilis, gonorrhea, and/or chlamydia with 92 infections total. Forty-two (46%) infections among 24 men were considered associated with residence in house A.
   Conclusions: LexisNexis Accurint was a useful tool for identifying house A residents, a highly mobile and highly sexually active population. There is a high prevalence of STIs among residents, but it is unclear where transmission is occurring. Settings like house A are good candidates for HIV pre-exposure prophylaxis and active STI screenings and may be an opportunity for public health officials to intervene in high-risk groups to reduce STI rates in the community.
C1 [Kendrick, Katherine; Brown, Veronica; Lords, Caleb; Matthias, James; Henning, Ian; Blackmore, Carina; Likos, Anna] Florida Dept Hlth, 4052 Bald Cypress Way,Bin A12, Tallahassee, FL 32399 USA.
   [Kendrick, Katherine] CDC, CSTE Appl Epidemiol Fellowship Program, Atlanta, GA 30333 USA.
RP Kendrick, K (reprint author), Florida Dept Hlth, 4052 Bald Cypress Way,Bin A12, Tallahassee, FL 32399 USA.
EM KatieLynnKendrick@gmail.com
FU Centers for Disease Control and Prevention (CDC) [1U38OT000143-03];
   Improving Sexually Transmitted Disease Programs through Assessment,
   Assurance, Policy Development, and Prevention Strategies (STD AAPPS Part
   A) grant [5H25PS004342]
FX This study/report was supported in part by an appointment to the Applied
   Epidemiology Fellowship Program administered by the Council of State and
   Territorial Epidemiologists (CSTE) and funded by the Centers for Disease
   Control and Prevention (CDC) Cooperative Agreement Number
   1U38OT000143-03. This study was also supported by the Improving Sexually
   Transmitted Disease Programs through Assessment, Assurance, Policy
   Development, and Prevention Strategies (STD AAPPS Part A) grant, grant
   number 5H25PS004342.
NR 22
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD SEP
PY 2016
VL 43
IS 9
BP 556
EP 559
DI 10.1097/OLQ.0000000000000483
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DU5KO
UT WOS:000382250800005
PM 27513381
ER

PT J
AU Coleman, R
   Lemire, SW
   Bragg, W
   Garrett, A
   Ojeda-Torres, G
   Hamelin, E
   Johnson, RC
   Thomas, J
AF Coleman, Rebecca
   Lemire, Sharon W.
   Bragg, William
   Garrett, Alaine
   Ojeda-Torres, Geovannie
   Hamelin, Elizabeth
   Johnson, Rudolph C.
   Thomas, Jerry
TI Development and validation of a high-throughput online solid phase
   extraction - Liquid chromatography - Tandem mass spectrometry method for
   the detection of tetrodotoxin in human urine
SO TOXICON
LA English
DT Article
DE Tetrodotoxin; Online SPE; HILIC; Marine toxins; Paralytic
ID LC-MS/MS; PLASMA; ANALOGS; TAIWAN; SERUM; IDENTIFICATION; NEOSAXITOXIN;
   SAXITOXIN
AB Tetrodotoxin (TTX) is an extremely potent paralytic toxin responsible for yearly illness and death around the world. A clinical measurement is necessary to confirm exposure because symptoms of TTX intoxication cannot be distinguished from other paralytic toxins. Our group has developed an online solid phase extraction hydrophilic interaction liquid chromatography (HILIC) method for the analysis of TTX in human urine with tandem mass spectrometry. The reportable range for the method was 2.80 - 249 ng/mL in urine with precision and accuracy within 15% as determined for all quality control samples. No isotopically-labeled internal standard is available for TTX; thus a surrogate internal standard, voglibose, was investigated to compensate for matrix effects and ionization suppression. However, upon evaluation, voglibose was ineffective for this purpose. This new online method rapidly identifies TTX, facilitating the work of public health authorities and providing support to monitoring programs worldwide. Published by Elsevier Ltd.
C1 [Coleman, Rebecca; Lemire, Sharon W.; Bragg, William; Hamelin, Elizabeth; Johnson, Rudolph C.; Thomas, Jerry] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA.
   [Garrett, Alaine] Natl Biodef Anal & Countermeasures Ctr, Ft Detrick, MD 21702 USA.
   [Ojeda-Torres, Geovannie] Ctr Dis Control & Prevent, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA.
RP Hamelin, E (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA.
EM eph3@cdc.gov
NR 37
TC 1
Z9 1
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP 1
PY 2016
VL 119
BP 64
EP 71
DI 10.1016/j.toxicon.2016.05.009
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA DT5OK
UT WOS:000381532300008
PM 27212629
ER

PT J
AU Farhat, MR
   Sultana, R
   Iartchouk, O
   Bozeman, S
   Galagan, J
   Sisk, P
   Stolte, C
   Nebenzahl-Guimaraes, H
   Jacobson, K
   Sloutsky, A
   Kaur, D
   Posey, J
   Kreiswirth, BN
   Kurepina, N
   Rigouts, L
   Streicher, EM
   Victor, TC
   Warren, RM
   van Soolingen, D
   Murray, M
AF Farhat, Maha R.
   Sultana, Razvan
   Iartchouk, Oleg
   Bozeman, Sam
   Galagan, James
   Sisk, Peter
   Stolte, Christian
   Nebenzahl-Guimaraes, Hanna
   Jacobson, Karen
   Sloutsky, Alexander
   Kaur, Devinder
   Posey, James
   Kreiswirth, Barry N.
   Kurepina, Natalia
   Rigouts, Leen
   Streicher, Elizabeth M.
   Victor, Tommie C.
   Warren, Robin M.
   van Soolingen, Dick
   Murray, Megan
TI Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis
   and Their Diagnostic Value
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE multidrug-resistant tuberculosis; molecular diagnostics; sensitivity and
   specificity
ID GENOTYPE MTBDRSL TEST; ANTIBIOTIC-RESISTANCE; COMPLEX STRAINS;
   EPIDEMIOLOGY; PYRAZINAMIDE; MUTATIONS; 2ND-LINE; TOOL; FLUOROQUINOLONES;
   CLASSIFICATION
AB Rationale: The development of molecular diagnostics that detect both the presence of Mycobacterium tuberculosis in clinical samples and drug resistance-conferring mutations promises to revolutionize patient care and interrupt transmission by ensuring early diagnosis. However, these tools require the identification of genetic determinants of resistance to the full range of antituberculosis drugs.
   Objectives: To determine the optimal molecular approach needed, we sought to create a comprehensive catalog of resistance mutations and assess their sensitivity and specificity in diagnosing drug resistance.
   Methods: We developed and validated molecular inversion probes for DNA capture and deep sequencing of 28 drug-resistance loci in M. tuberculosis. We used the probes for targeted sequencing of a geographically diverse set of 1,397 clinical M. tuberculosis isolates with known drug resistance phenotypes. We identified a minimal set of mutations to predict resistance to first- and second-line antituberculosis drugs and validated our predictions in an independent dataset. We constructed and piloted a web-based database that provides public access to the sequence data and predidtion tool.
   Measurements and Main Results: The predicted resistance to rifampicin and isoniazid exceeded 90% sensitivity and specificity but was lower for other drugs. The number of mutations needed to diagnose resistance is large, and for the 13 drugs studied it was 238 across 18 genetic loci.
   Conclusions: These data suggest that a comprehensive M. tuberculosis drug resistance diagnostic will need to allow for a high dimension of mutation detection. They also support the hypothesis that currently unknown genetic determinants, potentially discoverable by whole-genome sequencing, encode resistance to second-line tuberculosis drugs.
C1 [Farhat, Maha R.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
   [Farhat, Maha R.; Sloutsky, Alexander; Murray, Megan] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA.
   [Sultana, Razvan] Queen Mary Univ, Genom England, London, England.
   [Iartchouk, Oleg] Novartis Inst Biomed Res, Cambridge, MA USA.
   [Bozeman, Sam] Abt Associates Inc, Boston, MA USA.
   [Galagan, James] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
   [Galagan, James] Boston Univ, Dept Microbiol, Boston, MA 02215 USA.
   [Galagan, James] Boston Univ, Bioinformat Program, Boston, MA 02215 USA.
   [Sisk, Peter] Gen9 Inc, Cambridge, MA USA.
   [Stolte, Christian] CSIRO, N Ryde, NSW, Australia.
   [Nebenzahl-Guimaraes, Hanna] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands.
   [Nebenzahl-Guimaraes, Hanna; van Soolingen, Dick] Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, Nijmegen, Netherlands.
   [Nebenzahl-Guimaraes, Hanna; van Soolingen, Dick] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands.
   [Nebenzahl-Guimaraes, Hanna; van Soolingen, Dick] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, Braga, Portugal.
   [Nebenzahl-Guimaraes, Hanna] PT Govt Associate Lab, Life & Hlth Sci Res Inst 3Bs, Braga, Portugal.
   [Jacobson, Karen] Boston Univ, Sch Med, Sect Infect Dis, Boston, MA 02118 USA.
   [Jacobson, Karen; Streicher, Elizabeth M.; Victor, Tommie C.; Warren, Robin M.] Univ Stellenbosch, Fac Med & Hlth Sci, SAMRC Ctr TB Res, DST NRF Ctr Excellence Biomed TB Res,Div Mol Biol, Tygerberg, South Africa.
   [Sloutsky, Alexander; Kaur, Devinder] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.
   [Posey, James] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Kreiswirth, Barry N.; Kurepina, Natalia] Rutgers State Univ, Publ Hlth Res Inst, TB Ctr, Newark, NJ USA.
   [Rigouts, Leen] Inst Trop Med, Mycobacteriol, Antwerp, Belgium.
   [Rigouts, Leen] Univ Antwerp, Biomed Sci, Antwerp, Belgium.
   [Murray, Megan] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Farhat, MR (reprint author), 55 Fruit St,Bldg 148, Boston, MA 02114 USA.
EM mrfarhat@partners.org
OI Jacobson, Karen/0000-0003-4239-3685
FU NIAID NIH HHS [U19 AI076217, U19 AI109755]; NIEHS NIH HHS [K01 ES026835]
NR 49
TC 11
Z9 11
U1 5
U2 12
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP 1
PY 2016
VL 194
IS 5
BP 621
EP 630
DI 10.1164/rccm.201510-2091OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DU7SY
UT WOS:000382416100018
PM 26910495
ER

PT J
AU Reider, L
   Beck, T
   Alley, D
   Miller, R
   Shardell, M
   Schumacher, J
   Magaziner, J
   Cawthon, PM
   Barbour, KE
   Cauley, JA
   Harris, T
AF Reider, Lisa
   Beck, Thomas
   Alley, Dawn
   Miller, Ram
   Shardell, Michelle
   Schumacher, John
   Magaziner, Jay
   Cawthon, Peggy M.
   Barbour, Kamil E.
   Cauley, Jane A.
   Harris, Tamara
CA Hlth ABC Study
TI Evaluating the relationship between muscle and bone modeling response in
   older adults
SO BONE
LA English
DT Article
DE Femoral stress; Bone modeling response; Muscle
ID PROXIMAL FEMUR GEOMETRY; HIP FRACTURE; FEMORAL-NECK; CORTICAL BONE; AGE;
   STRENGTH; RISK; DENSITY; HEALTH; WOMEN
AB Bone modeling, the process that continually adjusts bone strength in response to prevalent muscle-loading forces throughout an individual's lifespan, may play an important role in bone fragility with age. Femoral stress, an index of bone modeling response, can be estimated using measurements of DXA derived bone geometry and loading information incorporated into an engineering model. Assuming that individuals have adapted to habitual muscle loading forces, greater stresses indicate a diminished response and a weaker bone. The purpose of this paper was to evaluate the associations of lean mass and muscle strength with the femoral stress measure generated from the engineering model and to examine the extent to which lean mass and muscle strength account for variation in femoral stress among 2539 healthy older adults participating in the Health ABC study using linear regression. Mean femoral stress was higher in women (9.51, SD = 1.85 Mpa) than in men (8.02, SD = 1.43 Mpa). Percent lean mass explained more of the variation in femoral stress than did knee strength adjusted for body size (R-2 = 0.187 vs. 0.055 in men; R-2 = 0237 vs. 0.095 in women). In models adjusted for potential confounders, for every percent increase in lean mass, mean femoral stress was 0.121 Mpa lower (95% CI: 0.138, 0.104; p < 0.001) in men and 0.139 Mpa lower (95% CI: 0.158, 0.121; p < 0.001) in women. The inverse association of femoral stress with lean mass and with knee strength did not differ by category of BMI. Results from this study provide insight into bone modeling differences as measured by femoral stress among older men and women and indicate that lean mass may capture elements of bone's response to load. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Reider, Lisa] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Beck, Thomas] Beck Radiol Innovat Inc, Catonsville, MD USA.
   [Alley, Dawn] Ctr Medicare & Medicaid Serv, Ctr Medicare & Medicaid Innovat, Baltimore, MD USA.
   [Miller, Ram] Novartis Inst Biomed Res, Cambridge, MA USA.
   [Miller, Ram] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD USA.
   [Shardell, Michelle] NIA, Longitudinal Study Sect, Bethesda, MD USA.
   [Schumacher, John] Univ Maryland Baltimore Cty, Dept Sociol & Anthropol, Baltimore, MD USA.
   [Magaziner, Jay] Univ Maryland, Sch Med, Baltimore, MD USA.
   [Cawthon, Peggy M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Cawthon, Peggy M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
   [Barbour, Kamil E.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
   [Harris, Tamara] NIA, Lab Epidemiol & Populat Sci, Intramural Res Program, Bethesda, MD USA.
RP Reider, L (reprint author), 415 N Washington St,Room 351, Baltimore, MD 21231 USA.
EM lsemani1@jhu.edu
FU  [P30 AG028747];  [R37 AG009901]
FX Magaziner: During the past year Jay Magaziner consulted with or served
   on advisory boards for: Ammonett; Novartis; Regeneron; Sanofi; Viking;
   partially supported by grants P30 AG028747; R37 AG009901.
NR 33
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD SEP
PY 2016
VL 90
BP 152
EP 158
DI 10.1016/j.bone.2016.06.012
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DT1MK
UT WOS:000381246600019
PM 27352990
ER

PT J
AU Sudhindra, P
   Wang, GQ
   Schriefer, ME
   McKenna, D
   Jian, ZG
   Krause, PJ
   Marques, AR
   Wormser, GP
AF Sudhindra, Praveen
   Wang, Guiqing
   Schriefer, Martin E.
   McKenna, Donna
   Jian Zhuge
   Krause, Peter J.
   Marques, Adriana R.
   Wormser, Gary P.
TI Insights into Borrelia miyamotoi infection from an untreated case
   demonstrating relapsing fever, monocytosis and a positive C6 Lyme
   serology
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Borrelia; Borrelia Miyamotoi; Lyme disease; C6 serology; Monocytosis;
   Relapsing fever
ID UNITED-STATES; DISEASE; MENINGOENCEPHALITIS; BURGDORFERI; SYPHILIS;
   VECTOR; EUROPE; JAPAN; ASSAY
AB We describe a patient from the United States with PCR- and serology-confirmed Borrelia miyamotoi infection who recovered without antibiotics. Our findings suggest that B. miyamotoi infection may cause relapsing fever, blood monocytosis and antibody reactivity to the C6 peptide. Further studies are required to better define the spectrum of clinical and laboratory findings for this emerging tick-transmitted infection. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sudhindra, Praveen; Wormser, Gary P.] New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA.
   [Wang, Guiqing; Jian Zhuge] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA.
   [Wang, Guiqing; Jian Zhuge] Westchester Med Ctr, Dept Pathol & Clin Labs, Valhalla, NY 10595 USA.
   [Schriefer, Martin E.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
   [Krause, Peter J.] Yale Univ, Yale Sch Publ Hlth, New Haven, CT USA.
   [Krause, Peter J.] Yale Univ, Yale Sch Med, New Haven, CT USA.
   [Marques, Adriana R.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Wormser, GP (reprint author), New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA.
EM gwormser@nymc.edu
FU Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health
FX The authors thank Denise Cooper, Carol Scavarda, Julia Singer, Sophia
   Less, Artemio Zavalla, Lisa Giarratano, Chris Sexton, Adam Replogle,
   Luke Kingly and Cecilia Dumouchel for their assistance. This work was
   supported in part by the Intramural Research Program of the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health (ARM).
NR 26
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD SEP
PY 2016
VL 86
IS 1
BP 93
EP 96
DI 10.1016/j.diagmicrobio.2016.06.015
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA DU7TB
UT WOS:000382416400020
PM 27412815
ER

PT J
AU Besera, GT
   Cox, S
   Malotte, CK
   Rietmeijer, CA
   Klausner, JD
   O'Donnell, L
   Margolis, AD
   Warner, L
AF Besera, Ghenet T.
   Cox, Shanna
   Malotte, C. Kevin
   Rietmeijer, Cornelis A.
   Klausner, Jeffrey D.
   O'Donnell, Lydia
   Margolis, Andrew D.
   Warner, Lee
TI Assessing Patient Exposure to a Video-Based Intervention in STD Clinic
   Waiting Rooms: Findings From the Safe in the City Trial
SO HEALTH PROMOTION PRACTICE
LA English
DT Article
DE STD clinic; STD prevention; video intervention; health communication;
   intervention exposure
ID RANDOMIZED CONTROLLED-TRIAL; SEXUAL RISK REDUCTION; EDUCATION;
   INFECTIONS; KNOWLEDGE; BEHAVIOR; COST
AB Safe in the City, a video intervention for clinic waiting rooms, was previously shown to reduce sexually transmitted disease (STD) incidence. However, little is known about patients' recall of exposure to the intervention. Using data from a nested study of patients attending clinics during the trial, we assessed whether participants recalled Safe in the City, and, if so, how the intervention affected subsequent attitudes and behaviors. Analyses were restricted to responses to a 3-month follow-up questionnaire among participants who were exposed to the video (n = 708). Impact was measured as participants' reports of the video's effect on behaviors and attitudes. Associations were evaluated using multivariable logistic regression. Of participants who were exposed, 685 (97%) recalled viewing the video, and 68% recalled all three vignettes. After watching the video, participants felt more positive about condoms (69%) and comfortable acquiring condoms (56%), were reminded of important information about STDs and condoms (90%), and tried to apply what they learned to their lives (59%). Compared with those who recalled viewing one or two vignettes, participants who recalled viewing all three vignettes reported more positive attitudes toward condoms and peer/provider communication. These findings demonstrate that a low-resource video intervention for waiting rooms can provide sufficient exposure to positively influence STD-related attitudes/behaviors.
C1 [Besera, Ghenet T.; Cox, Shanna; Margolis, Andrew D.; Warner, Lee] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Malotte, C. Kevin] Calif State Univ Long Beach, Long Beach, CA 90840 USA.
   [Rietmeijer, Cornelis A.] Rietmeijer Consulting LLC, Denver, CO USA.
   [Klausner, Jeffrey D.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [O'Donnell, Lydia] Educ Dev Ctr Inc, Waltham, MA USA.
RP Besera, GT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Mailstop F74,4770 Buford Highway, Atlanta, GA 30341 USA.
EM xwi5@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 21
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1524-8399
EI 1552-6372
J9 HEALTH PROMOT PRACT
JI Health Promot. Pract.
PD SEP
PY 2016
VL 17
IS 5
BP 731
EP 738
DI 10.1177/1524839916631537
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU9NB
UT WOS:000382543300013
PM 27091608
ER

PT J
AU Garbers, S
   Friedman, A
   Martinez, O
   Scheinmann, R
   Bermudez, D
   Silva, M
   Silverman, J
   Chiasson, MA
AF Garbers, Samantha
   Friedman, Allison
   Martinez, Omar
   Scheinmann, Roberta
   Bermudez, Dayana
   Silva, Manel
   Silverman, Jen
   Chiasson, Mary Ann
TI Adapting the Get Yourself Tested Campaign to Reach Black and Latino
   Sexual-Minority Youth
SO HEALTH PROMOTION PRACTICE
LA English
DT Article
DE sexually transmitted diseases; prevention and control; social marketing;
   health communication; sexual health; health promotion; LGBT; minority
   health; focus groups
ID UNITED-STATES; CHLAMYDIA-TRACHOMATIS; QUALITATIVE-ANALYSIS;
   YOUNG-ADULTS; HEALTH; STD; PREVENTION; SERVICES; MEN; INFECTIONS
AB Background. Culturally appropriate efforts are needed to increase sexually transmitted disease (STD) testing and care among Black and Latino sexual-minority youth, who are at high risk for STDs. Get Yourself Tested, a national testing campaign, has demonstrated success among youth, but it has yet to be assessed for relevance or impact among this population. Method. This effort included (1) formative and materials-testing research through focus groups; (2) adaptation of existing Get Yourself Tested campaign materials to be more inclusive of Black and Latino sexual-minority youth; (3) a 3-month campaign in four venues of New York City, promoting STD testing at events and through mobile testing and online and social media platforms; (4) process evaluation of outreach activities; and (5) an outcome evaluation of testing at select campaign venues, using a preexperimental design. Results. During the 3-month campaign period, the number of STD tests conducted at select campaign venues increased from a comparable 3-month baseline period. Although testing uptake through mobile vans remained low in absolute numbers, the van drew a high-prevalence sample, with positivity rates of 26.9% for chlamydia and 11.5% for gonorrhea. This article documents the process and lessons learned from adapting and implementing a local campaign for Black and Latino sexual-minority youth.
C1 [Garbers, Samantha] Columbia Univ, New York, NY USA.
   [Friedman, Allison] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Martinez, Omar] Temple Univ, Philadelphia, PA 19122 USA.
   [Scheinmann, Roberta; Bermudez, Dayana; Chiasson, Mary Ann] Publ Hlth Solut, New York, NY USA.
   [Silva, Manel; Silverman, Jen] Callen Lorde Community Hlth Ctr, New York, NY USA.
RP Garbers, S (reprint author), Columbia Univ, Heilbrunn Dept Populat & Family Hlth, Mailman Sch Publ Hlth, 60 Haven Ave,Room 2D, New York, NY 10032 USA.
EM svg2108@cumc.columbia.edu
FU NIMH NIH HHS [P30 MH043520, T32 MH019139]
NR 35
TC 0
Z9 0
U1 6
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1524-8399
EI 1552-6372
J9 HEALTH PROMOT PRACT
JI Health Promot. Pract.
PD SEP
PY 2016
VL 17
IS 5
BP 739
EP 750
DI 10.1177/1524839916647329
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU9NB
UT WOS:000382543300014
PM 27225216
ER

PT J
AU Courtenay-Quirk, C
   Selenic, D
   Lahuerta, M
   Kassa, G
   Murrman, M
   Bock, N
AF Courtenay-Quirk, Cari
   Selenic, Dejana
   Lahuerta, Maria
   Kassa, Getachew
   Murrman, Marita
   Bock, Naomi
TI Development of an Intervention to Increase Occupational Postexposure
   Prophylaxis in Sub-Saharan Africa
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE HIV prevention; infection control; needlestick injuries; occupational
   injuries; postexposure prophylaxis
ID HEALTH-CARE WORKERS; INJURIES; RISK
C1 [Courtenay-Quirk, Cari] Ctr Dis Control & Prevent CDC, HIV Prevent Branch, Div Global HIV AIDS & TB, Atlanta, GA 30333 USA.
   [Selenic, Dejana; Bock, Naomi] CDC, HIV Prevent Branch, Div Global HIV AIDS & TB, Atlanta, GA 30333 USA.
   [Lahuerta, Maria] Columbia Univ, ICAP, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
   [Kassa, Getachew] ICAP, Freetown, Sierra Leone.
   [Murrman, Marita] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA.
RP Courtenay-Quirk, C (reprint author), Ctr Dis Control & Prevent CDC, HIV Prevent Branch, Div Global HIV AIDS & TB, Atlanta, GA 30333 USA.
EM ccourtenayquirk@cdc.gov
FU President's Emergency Plan for AIDS Relief through the CDC, through the
   Global Epidemiology and Strategic Information Support (GESIS) [CDC ESIS
   200-2011-37935]
FX This project was funded through the President's Emergency Plan for AIDS
   Relief through the CDC, through the Global Epidemiology and Strategic
   Information Support (GESIS; grant number CDC ESIS 200-2011-37935). The
   findings and conclusions in this report are those of the authors and do
   not necessarily represent the official position of the CDC. The authors
   acknowledge the following members of Pathways to PEP Study Team: Megan
   Affrunti, Gretchen Antelman, Batya Elul, Goodluck Mwakitosha, Padmaja
   Patnaik, and Morgan Sakala (ICAP-Columbia University, Mailman School of
   Public Health, New York, USA); Sridhar V. Basavaraju and Yang Liu
   (Division of Global HIV/AIDS and Tuberculosis, CDC, Atlanta, Georgia,
   USA), Tendani Gaolathe and Garegole Letang (Botswana Harvard AIDS
   Institute Partnership, Gaborone, Botswana), Joseph Hokororo (Ministry of
   Health and Social Welfare, Dar es Salaam, Tanzania), Esther Masebe
   (Ministry of Health Zambia, Lusaka, Zambia), Nelson Kiama Mwaniki
   (Ministry of Health Botswana, Gaborone, Botswana), and Fatma Soud (CDC
   Zambia, Lusaka), Koku Kazaura (CDC Tanzania, Dar es Salaam), and Sarah
   Gaolekwe (CDC Botswana, Gaborone).
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD SEP-OCT
PY 2016
VL 27
IS 5
BP 727
EP 730
DI 10.1016/j.jana.2016.06.004
PG 4
WC Nursing
SC Nursing
GA DS5VQ
UT WOS:000380851500019
PM 27425796
ER

PT J
AU Plante, JA
   Torres, M
   Huang, CYH
   Beasley, DWC
AF Plante, Jessica A.
   Torres, Maricela
   Huang, Claire Y. -H.
   Beasley, David W. C.
TI Plasticity of a critical antigenic determinant in the West Nile virus
   NY99 envelope protein domain III
SO VIROLOGY
LA English
DT Article
DE West nile virus; Flavivirus; Envelope; Domain III
ID HUMANIZED MONOCLONAL-ANTIBODY; MOLECULAR EVOLUTION; LINEAGE 2;
   NEUTRALIZING EPITOPES; CRYSTAL-STRUCTURE; LETHAL INFECTION;
   UNITED-STATES; NS4B PROTEIN; FEVER VIRUS; BINDING
AB West Nile virus (WNV) is a mosquito-borne flavivirus that causes febrile illness, encephalitis, and occasionally death in humans. The envelope protein is the main component of the WNV virion surface, and domain III of the envelope protein (EIII) is both a putative receptor binding domain and a target of highly specific, potently neutralizing antibodies. Envelope E-332 (E-332) is known to have naturally occurring variation and to be a key determinant of neutralization for anti-EIII antibodies. A panel of viruses containing all possible amino acid substitutions at E-332 was constructed. E-332 was found to be highly tolerant of mutation, and almost all of these changes had large impacts on antigenicity of EIII but only limited effects on growth or virulence phenotypes. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Plante, Jessica A.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Plante, Jessica A.; Beasley, David W. C.] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA.
   [Torres, Maricela; Beasley, David W. C.] Univ Texas Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Huang, Claire Y. -H.] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
   [Beasley, David W. C.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Plante, Jessica A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
RP Beasley, DWC (reprint author), Univ Texas Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.
EM japlante@email.unc.edu
FU UTMB's Institute for Human Infections and Immunity; Biodefense Training
   Program (NIH) [T32-AI060549]; Sealy Center for Vaccine Development
FX This work was supported by funding from UTMB's Institute for Human
   Infections and Immunity to DWCB. JAP was supported by pre-doctoral
   fellowships from the Biodefense Training Program (NIH grant
   T32-AI060549) and the Sealy Center for Vaccine Development.
NR 59
TC 0
Z9 0
U1 2
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD SEP
PY 2016
VL 496
BP 97
EP 105
DI 10.1016/j.virol.2016.05.024
PG 9
WC Virology
SC Virology
GA DT1IU
UT WOS:000381235700012
PM 27284640
ER

PT J
AU Jaramillo, L
   Smithee, S
   Tracy, S
   Chapman, NM
AF Jaramillo, L.
   Smithee, S.
   Tracy, S.
   Chapman, N. M.
TI Domain I of the 5' non-translated genomic region in coxsackievirus B3
   RNA is not required for productive replication
SO VIROLOGY
LA English
DT Article
DE Coxsackievirus; Enterovirus; 5' terminal deletion; Cloverleaf; Domain I;
   RNA structure
ID POLIOVIRUS RNA; VIRAL-RNA; DELETIONS; PROTEIN; SEQUENCE; CULTURES; END
AB Domain I is a cloverleaf-like secondary structure at the 5' termini of all enterovirus genomes, comprising part of a cis-acting replication element essential for efficient enteroviral replication. 5' genomic terminal deletions up to as much as 55% of domain I can occur without lethality following coxsackie B virus infections. We report here that the entire CVB structural domain I can be deleted without lethality. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Jaramillo, L.; Smithee, S.; Tracy, S.; Chapman, N. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
   [Jaramillo, L.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Smithee, S.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
RP Chapman, NM (reprint author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
EM nchapman@unmc.edu
FU Juvenile Diabetes Research Foundation; nPOD-V; University of Nebraska
   Medical Center
FX This work was supported in part by funds from the Juvenile Diabetes
   Research Foundation and nPOD-V (N.M.C.) and represents research
   performed in part by L.J. for the Master's degree. S.S. was supported by
   a graduate student fellowship from University of Nebraska Medical
   Center.
NR 22
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD SEP
PY 2016
VL 496
BP 127
EP 130
DI 10.1016/j.virol.2016.05.021
PG 4
WC Virology
SC Virology
GA DT1IU
UT WOS:000381235700015
PM 27289561
ER

PT J
AU Albarino, CG
   Guerrero, LW
   Chakrabarti, AK
   Kainulainen, MH
   Whitmer, SLM
   Welch, SR
   Nichol, ST
AF Albarino, Cesar G.
   Guerrero, Lisa Wiggleton
   Chakrabarti, Ayan K.
   Kainulainen, Markus H.
   Whitmer, Shannon L. M.
   Welch, Stephen R.
   Nichol, Stuart T.
TI Virus fitness differences observed between two naturally occurring
   isolates of Ebola virus Makona variant using a reverse genetics approach
SO VIROLOGY
LA English
DT Article
DE Ebola virus; West Africa outbreak; Makona variant; Recombinant virus;
   Reverse genetics
ID MARBURG HEMORRHAGIC-FEVER; SUBTYPE RESTON VIRUS; UNITED-STATES;
   WEST-AFRICA; SIERRA-LEONE; TRANSCRIPTION; REPLICATION; DISEASE; VP30;
   EVOLUTION
AB During the large outbreak of Ebola virus disease that occurred in Western Africa from late 2013 to early 2016, several hundred Ebola virus (EBOV) genomes have been sequenced and the virus genetic drift analyzed. In a previous report, we described an efficient reverse genetics system designed to generate recombinant EBOV based on a Makona variant isolate obtained in 2014. Using this system, we characterized the replication and fitness of 2 isolates of the Makona variant. These virus isolates are nearly identical at the genetic level, but have single amino acid differences in the VP30 and L proteins. The potential effects of these differences were tested using minigenomes and recombinant viruses. The results obtained with this approach are consistent with the role of VP30 and L as components of the EBOV RNA replication machinery. Moreover, the 2 isolates exhibited clear fitness differences in competitive growth assays. Published by Elsevier Inc.
C1 [Albarino, Cesar G.; Guerrero, Lisa Wiggleton; Chakrabarti, Ayan K.; Kainulainen, Markus H.; Whitmer, Shannon L. M.; Welch, Stephen R.; Nichol, Stuart T.] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA.
RP Albarino, CG (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA.
EM calbarino@cdc.gov
NR 37
TC 4
Z9 4
U1 3
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD SEP
PY 2016
VL 496
BP 237
EP 243
DI 10.1016/j.virol.2016.06.011
PG 7
WC Virology
SC Virology
GA DT1IU
UT WOS:000381235700027
PM 27366976
ER

PT J
AU Beer, L
   Mattson, CL
   Shouse, RL
   Prejean, J
AF Beer, Linda
   Mattson, Christine L.
   Shouse, R. Luke
   Prejean, Joseph
TI Receipt of clinical and prevention services, clinical outcomes, and
   sexual risk behaviors among HIV-infected young adults in care in the
   United States
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE HIV; youth; young adults; antiretroviral therapy; viral load; health
   status disparities
ID ANTIRETROVIRAL THERAPY; YOUTH; ADHERENCE
AB We describe receipt of clinical and prevention services, clinical outcomes, and sexual risk behaviors among young adult HIV patients in the United States during 2009-2013, using a sample designed to produce nationally representative estimates. Compared with older HIV patients, proportionately more young adults received provider-delivered prevention services and reported sexual risk behaviors. Young adults had similar care patterns as older HIV patients, but were less likely to have or adhere to an antiretroviral therapy prescription and achieve viral suppression. These estimates establish a national baseline from which to monitor changes in clinical outcomes and transmission behaviors among young HIV-infected adults.
C1 [Beer, Linda; Mattson, Christine L.; Shouse, R. Luke; Prejean, Joseph] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA.
RP Beer, L (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA.
EM lbeer@cdc.gov
FU Centers for Disease Control and Prevention
FX Funding for the Medical Monitoring Project is provided by the Centers
   for Disease Control and Prevention.
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD SEP
PY 2016
VL 28
IS 9
BP 1166
EP 1170
DI 10.1080/09540121.2016.1160028
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA DS8GU
UT WOS:000381022300014
PM 27011102
ER

PT J
AU Sigakis, MJG
   Leffert, LR
   Mirzakhani, H
   Sharawi, N
   Rajala, B
   Callaghan, WM
   Kuklina, EV
   Creanga, AA
   Mhyre, JM
   Bateman, BT
AF Sigakis, Matthew J. G.
   Leffert, Lisa R.
   Mirzakhani, Hooman
   Sharawi, Nadir
   Rajala, Baskar
   Callaghan, William M.
   Kuklina, Elena V.
   Creanga, Andreea A.
   Mhyre, Jill M.
   Bateman, Brian T.
TI The Validity of Discharge Billing Codes Reflecting Severe Maternal
   Morbidity
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID UNITED-STATES; ADMINISTRATIVE DATA; ACCURACY; IDENTIFICATION;
   VALIDATION; DIAGNOSES; MORTALITY; DATABASE; MISS
AB BACKGROUND: Discharge diagnoses are used to track national trends and patterns of maternal morbidity. There are few data regarding the validity of the International Classification of Diseases (ICD) codes used for this purpose. The goal of our study was to try to better understand the validity of administrative data being used to monitor and assess trends in morbidity.
   METHODS: Hospital stay billing records were queried to identify all delivery admissions at the Massachusetts General Hospital for the time period 2001 to 2011 and the University of Michigan Health System for the time period 2005 to 2011. From this, we identified patients with ICD-9-Clinical Modification (CM) diagnosis and procedure codes indicative of severe maternal morbidity. Each patient was classified with 1 of 18 different medical/obstetric categories (conditions or procedures) based on the ICD-9-CM code that was recorded. Within each category, 20 patients from each institution were selected at random, and the corresponding medical charts were reviewed to determine whether the ICD-9-CM code was assigned correctly. The percentage of correct codes for each of 18 preselected clinical categories was calculated yielding a positive predictive value (PPV) and 99% confidence interval (CI).
   RESULTS: The overall number of correctly assigned ICD-9-CM codes, or PPV, was 218 of 255 (86%; CI, 79%-90%) and 154 of 188 (82%; CI, 74%-88%) at Massachusetts General Hospital and University of Michigan Health System, respectively (combined PPV, 372/443 [84%; CI, 79-88%]). Codes within 4 categories (Hysterectomy, Pulmonary edema, Disorders of fluid, electrolyte and acid-base balance, and Sepsis) had a 99% lower confidence limit >= 75%. Codes within 8 additional categories demonstrated a 99% lower confidence limit between 74% and 50% (Acute respiratory distress, Ventilation, Other complications of obstetric surgery, Disorders of coagulation, Cardiomonitoring, Acute renal failure, Thromboembolism, and Shock). Codes within 6 clinical categories demonstrated a 99% lower confidence limit <50% (Puerperal cerebrovascular disorders, Conversion of cardiac rhythm, Acute heart failure [includes arrest and fibrillation], Eclampsia, Neurotrauma, and Severe anesthesia complications).
   CONCLUSIONS: ICD-9-CM codes capturing severe maternal morbidity during delivery hospitalization demonstrate a range of PPVs. The PPV was high when objective supportive evidence, such as laboratory values or procedure documentation supported the ICD-9-CM code. The PPV was low when greater judgment, interpretation, and synthesis of the clinical data (signs and symptoms) was required to support a code, such as with the category Severe anesthesia complications. As a result, these codes should be used for administrative research with more caution compared with codes primarily defined by objective data.
C1 [Sigakis, Matthew J. G.; Sharawi, Nadir; Rajala, Baskar] Univ Michigan, Sch Med, Dept Anesthesiol, 1H247 UH,SPC 5048,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Leffert, Lisa R.; Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Div Obstet Anesthesia, Boston, MA 02114 USA.
   [Mirzakhani, Hooman] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
   [Callaghan, William M.; Creanga, Andreea A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
   [Kuklina, Elena V.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Heart Dis & Stroke Prevent, Atlanta, GA USA.
   [Mhyre, Jill M.] Univ Arkansas Med Sci, Dept Anesthesiol, Little Rock, AR 72205 USA.
RP Sigakis, MJG (reprint author), Univ Michigan, Sch Med, Dept Anesthesiol, 1H247 UH,SPC 5048,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM msigakis@med.umich.edu
OI Mirzakhani, Hooman/0000-0002-2290-4436
NR 28
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 2016
VL 123
IS 3
BP 731
EP 738
DI 10.1213/ANE.0000000000001436
PG 8
WC Anesthesiology
SC Anesthesiology
GA DT9RA
UT WOS:000381838800025
PM 27387839
ER

PT J
AU Norton, BL
   Southern, WN
   Steinman, M
   Smith, BD
   Deluca, J
   Rosner, Z
   Litwin, AH
AF Norton, Brianna L.
   Southern, William N.
   Steinman, Meredith
   Smith, Bryce D.
   Deluca, Joseph
   Rosner, Zachary
   Litwin, Alain H.
TI No Differences in Achieving Hepatitis C Virus Care Milestones Between
   Patients Identified by Birth Cohort or Risk-Based Screening
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Population; Therapy; Antiviral Agent; Patient Management; Cascade of
   Care
ID UNITED-STATES; INFECTION; PREVALENCE; MORTALITY
AB BACKGROUND & AIMS: National hepatitis C virus (HCV) screening guidelines recommended 1-time testing of persons born between 1945 and 1965.
   METHODS: We performed a retrospective study to compare care milestones achieved by HCV-infected patients identified by birth cohort versus risk-based screens.
   RESULTS: We determined the proportions of patients newly identified with HCV infection who met care milestones (viral load, referral to and evaluation by a specialist, offer of treatment, initiation of treatment, and sustained viral response) and the time it took to reach them. We found no differences in HCV care milestones for patients identified via birth cohort testing versus risk-based screening. Overall, only 43% of HCV antibody-positive patients were referred to care, and less than 4% started treatment. The time to each care milestone was lengthy and varied greatly; treatment was initiated in a median of 308 days.
   CONCLUSIONS: Although birth cohort testing will likely increase identification of patients with HCV infection, it does not seem to increase the number of patients that meet management milestones. New methods are needed to increase access to care and establish efficient models of health care delivery.
C1 [Norton, Brianna L.; Southern, William N.; Steinman, Meredith; Deluca, Joseph; Rosner, Zachary; Litwin, Alain H.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
   [Norton, Brianna L.; Steinman, Meredith; Deluca, Joseph; Rosner, Zachary; Litwin, Alain H.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA.
   [Southern, William N.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Hosp Med, Bronx, NY 10467 USA.
   [Smith, Bryce D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD TB Prevent, Atlanta, GA USA.
RP Norton, BL (reprint author), Montefiore Med Ctr, Dept Med, 3300 Kossuth Ave, Bronx, NY 10467 USA.
EM bnorton@montefiore.org
FU Intensive Models of HCV Care for Injection Drug Users NIH/NIDA [R01
   DA034086]; NIDA [R25DA023021]; National Center for Research Resources
   [TL1 RR025748]; Hepatitis C Assessment and Testing project (HepCAT) -
   Centers for Disease Control and Prevention contract via the Agency
   Health Care Research and Quality ACTION initiative [HHSA2902006000012
   T0, 4]
FX Supported by Intensive Models of HCV Care for Injection Drug Users
   NIH/NIDA R01 DA034086; NIDA R25DA023021; National Center for Research
   Resources TL1 RR025748; the Hepatitis C Assessment and Testing project
   (HepCAT) was funded by Centers for Disease Control and Prevention
   contract via the Agency Health Care Research and Quality ACTION
   initiative, contract HHSA2902006000012 T0#4.
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD SEP
PY 2016
VL 14
IS 9
BP 1356
EP 1360
DI 10.1016/j.cgh.2016.04.017
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DT8DD
UT WOS:000381718400027
PM 27108792
ER

PT J
AU Kvasnovsky, CL
   Cegielski, JP
   van der Walt, ML
AF Kvasnovsky, Charlotte L.
   Cegielski, J. Peter
   van der Walt, Martie L.
TI Treatment Outcomes for Patients with Extensively Drug-Resistant
   Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID PULMONARY TUBERCULOSIS; PROGRAM; CULTURE; COHORT
AB We analyzed data for a retrospective cohort of patients treated for extensively drug-resistant tuberculosis in 2 provinces in South Africa and compared predictors of treatment outcome in HIV-positive patients who received or had not received antiretroviral drugs with those for HIV-negative patients. Overall, 220 (62.0%) of 355 patients were HIV positive. After 2 years, 34 (10.3%) of 330 patients with a known HIV status and known outcome had a favorable outcome. Multivariate analysis showed that predictors of favorable outcome were negative results for acid-fast bacilli by sputum microscopy at start of treatment and weight >50 kg. HIV-positive patients were more likely to have an unfavorable outcome. The strongest predictor of unfavorable outcome was weight <50 kg. Overall outcomes were poor. HIV status was not a predictor of favorable outcome, but HIV positive patients were more likely to have an unfavorable outcome. These results underscore the need for timely and adequate treatment for tuberculosis and HIV infection.
C1 [Kvasnovsky, Charlotte L.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
   [Kvasnovsky, Charlotte L.; van der Walt, Martie L.] Med Res Council South Africa, Cape Town, South Africa.
   [Cegielski, J. Peter] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Kvasnovsky, CL (reprint author), Univ Maryland, Med Ctr, Dept Surg, 22 S Greene St, Baltimore, MD 21201 USA.
EM ckvasno@gmail.com
FU US Agency for International Development
FX This study was supported by the US Agency for International Development.
NR 28
TC 0
Z9 0
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2016
VL 22
IS 9
BP 1529
EP 1536
DI 10.32301/eid2209.160084
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DU1GJ
UT WOS:000381955900001
ER

PT J
AU Baker, KS
   Dallman, TJ
   Behar, A
   Weill, FX
   Gouali, M
   Sobel, J
   Fookes, M
   Valinsky, L
   Gal-Mor, O
   Connor, TR
   Nissan, I
   Bertrand, S
   Parkhill, J
   Jenkins, C
   Cohen, D
   Thomson, NR
AF Baker, Kate S.
   Dallman, Timothy J.
   Behar, Adi
   Weill, Francois-Xavier
   Gouali, Malika
   Sobel, Jeremy
   Fookes, Maria
   Valinsky, Lea
   Gal-Mor, Ohad
   Connor, Thomas R.
   Nissan, Israel
   Bertrand, Sophie
   Parkhill, Julian
   Jenkins, Claire
   Cohen, Dani
   Thomson, Nicholas R.
TI Travel- and Community-Based Transmission of Multidrug-Resistant Shigella
   sonnei Lineage among International Orthodox Jewish Communities
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; VACCINE DEVELOPMENT; GENOME SEQUENCES; GLOBAL
   BURDEN; OUTBREAK; SUSCEPTIBILITY; INFECTIONS; EMERGENCE; FLEXNERI;
   STRAINS
AB Shigellae are sensitive indicator species for studying trends in the international transmission of antimicrobial-resistant Enterobacteriaceae. Orthodox Jewish communities (OJCs) are a known risk group for shigellosis; Shigella sonnei is cyclically epidemic in OJCs in Israel, and sporadic outbreaks occur in OJCs elsewhere. We generated whole-genome sequences for 437 isolates of S. sonnei from OJCs and non-OJCs collected over 22 years in Europe (the United Kingdom, France, and Belgium), the United States, Canada, and Israel and analyzed these within a known global genomic context. Through phylogenetic and genomic analysis, we showed that strains from outbreaks in OJCs outside of Israel are distinct from strains in the general population and relate to a single multidrug-resistant sublineage of S. sonnei that prevails in Israel. Further Bayesian phylogenetic analysis showed that this strain emerged approximately 30 years ago, demonstrating the speed at which antimicrobial drug resistant pathogens can spread widely through geographically dispersed, but internationally connected, communities.
C1 [Baker, Kate S.] Univ Liverpool, Liverpool, Merseyside, England.
   [Baker, Kate S.; Fookes, Maria; Parkhill, Julian; Thomson, Nicholas R.] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England.
   [Dallman, Timothy J.; Jenkins, Claire] Publ Hlth England, London, England.
   [Behar, Adi] Kimron Vet Inst, Bet Dagan, Israel.
   [Weill, Francois-Xavier; Gouali, Malika] Inst Pasteur, Paris, France.
   [Sobel, Jeremy] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Valinsky, Lea; Nissan, Israel] Minist Hlth, Tel Aviv, Israel.
   [Gal-Mor, Ohad; Cohen, Dani] Tel Aviv Univ, Tel Aviv, Israel.
   [Connor, Thomas R.] Cardiff Univ, Cardiff, S Glam, Wales.
   [Bertrand, Sophie] Sci Inst Publ Hlth, Brussels, Belgium.
   [Thomson, Nicholas R.] London Sch Hyg & Trop Med, London, England.
RP Thomson, NR (reprint author), Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England.
EM nrt@sanger.ac.uk
RI Baker, Kate /P-2087-2016
OI Baker, Kate /0000-0001-5850-1949
FU Wellcome Trust Postdoctoral Training Fellowship [106690/A/14/Z];
   Wellcome Trust [098051]; European Union Seventh Framework Programme
   'STOPENTERICS' [261472]; Institut de Veille Sanitaire; French Government
   Investissement d'Avenir programme [ANR-10-LABX-62-IBEID]; Wellcome Trust
   Postdoctoral Clinical Research Training Fellowship
FX K.S.B. is in receipt of a Wellcome Trust Postdoctoral Training
   Fellowship for Clinicians (106690/A/14/Z) and all WTSI authors are
   supported by Wellcome Trust grant number 098051. This study was also
   aided by the European Union Seventh Framework Programme (FP7/2007-2013)
   under grant agreement 261472 'STOPENTERICS'. The French National
   Reference Center for E. coli, Shigella and Salmonella is co-funded by
   the Institut de Veille Sanitaire. The Unite des Bacteries Pathogens
   Enteriques belongs to the Integrative Biology of Emerging Infectious
   Diseases Laboratory of Excellence funded by the French Government
   Investissement d'Avenir programme (grant no. ANR-10-LABX-62-IBEID).; Dr.
   Baker is a veterinarian researcher working as a research fellow at the
   Wellcome Trust Sanger Institute and the University of Liverpool and has
   also been awarded a Wellcome Trust Postdoctoral Clinical Research
   Training Fellowship. Her research interests include genomic epidemiology
   of enteric pathogens and the dynamics of antimicrobial resistance in
   bacterial populations.
NR 36
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2016
VL 22
IS 9
BP 1545
EP 1553
DI 10.3201/eid2209.151953
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DU1GJ
UT WOS:000381955900003
PM 27532625
ER

PT J
AU Bowen, A
   Grass, J
   Bicknese, A
   Campbell, D
   Hurd, J
   Kirkcaldy, RD
AF Bowen, Anna
   Grass, Julian
   Bicknese, Amelia
   Campbell, Davina
   Hurd, Jacqueline
   Kirkcaldy, Robert D.
TI Elevated Risk for Antimicrobial Drug-Resistant Shigella Infection among
   Men Who Have Sex with Men, United States, 2011-2015
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID DECREASED SUSCEPTIBILITY; AZITHROMYCIN; SONNEI; TRANSMISSION;
   CIPROFLOXACIN; STRAINS; CANADA
AB Shigella spp. cause approximate to 500,000 illnesses in the United States annually, and resistance to ciprofloxacin, ceftriaxone, and azithromycin is emerging. We investigated associations between transmission route and antimicrobial resistance among US shigellosis clusters reported during 2011-2015. Of 32 clusters, 9 were caused by shigellae resistant to ciprofloxacin (3 clusters), ceftriaxone (2 clusters), or azithromycin (7 clusters); 3 clusters were resistant to >1 of these drugs. We observed resistance to any of these drugs in all 7 clusters among men who have sex with men (MSM) but in only 2 of the other 25 clusters (p<0.001). Azithromycin resistance was more common among MSM-associated clusters than other clusters (86% vs. 4% of clusters; p<0.001). For adults with suspected shigellosis, clinicians should culture feces; obtain sex histories; discuss shigellosis prevention; and choose treatment, when needed, according to antimicrobial drug susceptibility. Public health interviews for enteric illnesses should encompass sex practices; health messaging for MSM must include shigellosis prevention.
C1 [Bowen, Anna; Grass, Julian; Bicknese, Amelia; Campbell, Davina; Hurd, Jacqueline; Kirkcaldy, Robert D.] Ctr Dis Control & Prevent, 1600 Clifton R NE,Mailstop C09, Atlanta, GA 30329 USA.
RP Bowen, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton R NE,Mailstop C09, Atlanta, GA 30329 USA.
EM abowen@cdc.gov
NR 26
TC 0
Z9 0
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2016
VL 22
IS 9
BP 1613
EP 1616
DI 10.3201/eid2209.160624
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DU1GJ
UT WOS:000381955900011
PM 27533624
ER

PT J
AU Schaefer, G
   Campbell, W
   Jenks, J
   Beesley, C
   Katsivas, T
   Hoffmaster, A
   Mehta, SR
   Reed, S
AF Schaefer, Gabrielle
   Campbell, Wesley
   Jenks, Jeffrey
   Beesley, Cari
   Katsivas, Theodoros
   Hoffmaster, Alex
   Mehta, Sanjay R.
   Reed, Sharon
TI Peristent Bacillus cereus Bacteremia in 3 Persons Who Inject Drugs, San
   Diego, California, USA
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID STREET HEROIN; INFECTIONS
AB Bacillus cereus is typically considered a blood culture contaminant; however, its presence in blood cultures can indicate true bacteremia. We report 4 episodes of B. cereus bacteremia in 3 persons who inject drugs. Multilocus sequence typing showed that the temporally associated infections were caused by unrelated clones.
C1 [Schaefer, Gabrielle; Jenks, Jeffrey; Katsivas, Theodoros; Mehta, Sanjay R.; Reed, Sharon] UC San Diego Hlth, San Diego, CA USA.
   [Campbell, Wesley] Naval Med Ctr San Diego, San Diego, CA USA.
   [Beesley, Cari; Hoffmaster, Alex] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Mehta, Sanjay R.] San Diego Vet Affairs Med Ctr, San Diego, CA USA.
RP Reed, S (reprint author), UC San Diego Hlth, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.; Reed, S (reprint author), UC San Diego Hlth, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM slreed@ucsd.edu
FU Wellcome Trust
FX We thank Keith Jolley for development of the B. cereus MLST website,
   which is housed at the University of Oxford and was funded by the
   Wellcome Trust.
NR 12
TC 0
Z9 0
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2016
VL 22
IS 9
BP 1621
EP 1623
DI 10.3201/eid2209.150647
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DU1GJ
UT WOS:000381955900013
PM 27533890
ER

PT J
AU Lustig, Y
   Lanciotti, RS
   Hindiyeh, M
   Keller, N
   Milo, R
   Mayan, S
   Mendelson, E
AF Lustig, Yaniv
   Lanciotti, Robert S.
   Hindiyeh, Musa
   Keller, Nathan
   Milo, Ron
   Mayan, Shlomo
   Mendelson, Ella
TI Mutation in West Nile Virus Structural Protein prM during Human
   Infection
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ISRAEL
AB A mutation leading to substitution of a key amino acid in the prM protein of West Nile virus (WNV) occurred during persistent infection of an immunocompetent patient. WNV RNA persisted in the patient's urine and serum in the presence of low-level neutralizing antibodies. This case demonstrates active replication of WNV during persistent infection.
C1 [Lustig, Yaniv; Hindiyeh, Musa; Keller, Nathan; Mendelson, Ella] Sheba Med Ctr, Tel Hashomer, Israel.
   [Lanciotti, Robert S.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
   [Hindiyeh, Musa; Mendelson, Ella] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Tel Aviv, Israel.
   [Milo, Ron] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
   [Milo, Ron; Mayan, Shlomo] Barzilai Govt Hosp, Ashqelon, Israel.
RP Lustig, Y (reprint author), Sheba Med Ctr, Minist Hlth, Cent Virol Lab, Natl Zoonot Reference Lab, Ramat Gan, Israel.
EM Yaniv.lustig@sheba.health.gov.il
NR 15
TC 0
Z9 0
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2016
VL 22
IS 9
BP 1647
EP 1649
DI 10.3201/eid2209.160132
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DU1GJ
UT WOS:000381955900020
PM 27322782
ER

PT J
AU Lindblade, KA
   Nyenswah, T
   Keita, S
   Diallo, B
   Kateh, F
   Amoah, A
   Nagbe, TK
   Raghunathan, P
   Neatherlin, JC
   Kinzer, M
   Pillai, SK
   Attfield, KR
   Hajjeh, R
   Dweh, E
   Painter, J
   Barradas, DT
   Williams, SG
   Blackley, DJ
   Kirking, HL
   Patel, MR
   Dea, M
   Massoudi, MS
   Barskey, AE
   Zarecki, SLM
   Fomba, M
   Grube, S
   Belcher, L
   Broyles, LN
   Maxwell, TN
   Hagan, JE
   Yeoman, K
   Westercamp, M
   Mott, J
   Mahoney, F
   Slutsker, L
   DeCock, KM
   Marston, B
   Dahl, B
AF Lindblade, Kim A.
   Nyenswah, Tolbert
   Keita, Sakoba
   Diallo, Boubakar
   Kateh, Francis
   Amoah, Aurora
   Nagbe, Thomas K.
   Raghunathan, Pratima
   Neatherlin, John C.
   Kinzer, Mike
   Pillai, Satish K.
   Attfield, Kathleen R.
   Hajjeh, Rana
   Dweh, Emmanuel
   Painter, John
   Barradas, Danielle T.
   Williams, Seymour G.
   Blackley, David J.
   Kirking, Hannah L.
   Patel, Monita R.
   Dea, Monica
   Massoudi, Mehran S.
   Barskey, Albert E.
   Zarecki, Shauna L. Mettee
   Fomba, Moses
   Grube, Steven
   Belcher, Lisa
   Broyles, Laura N.
   Maxwell, T. Nikki
   Hagan, Jose E.
   Yeoman, Kristin
   Westercamp, Matthew
   Mott, Joshua
   Mahoney, Frank
   Slutsker, Laurence
   DeCock, Kevin M.
   Marston, Barbara
   Dahl, Benjamin
TI Secondary Infections with Ebola Virus in Rural Communities, Liberia and
   Guinea, 2014-2015
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID TRANSMISSION
AB In rural communities in Liberia and Guinea, more secondary Ebola infections resulted from persons who died of Ebola virus disease at home than from persons admitted to Ebola treatment units. Intensified monitoring of contacts of persons who died of this disease in the community is an evidence-based approach to reduce virus transmission in rural communities.
C1 [Lindblade, Kim A.; Raghunathan, Pratima; Neatherlin, John C.; Kinzer, Mike; Pillai, Satish K.; Attfield, Kathleen R.; Hajjeh, Rana; Painter, John; Barradas, Danielle T.; Williams, Seymour G.; Blackley, David J.; Kirking, Hannah L.; Patel, Monita R.; Dea, Monica; Massoudi, Mehran S.; Barskey, Albert E.; Zarecki, Shauna L. Mettee; Grube, Steven; Belcher, Lisa; Broyles, Laura N.; Maxwell, T. Nikki; Hagan, Jose E.; Yeoman, Kristin; Westercamp, Matthew; Mott, Joshua; Mahoney, Frank; Slutsker, Laurence; DeCock, Kevin M.; Marston, Barbara; Dahl, Benjamin] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30333 USA.
   [Nyenswah, Tolbert; Kateh, Francis; Nagbe, Thomas K.; Dweh, Emmanuel; Fomba, Moses] Liberia Minist Hlth & Social Welf, Monrovia, Liberia.
   [Keita, Sakoba] Guinea Minist Hlth & Publ Hyg, Conakry, Guinea.
   [Diallo, Boubakar] WHO, Geneva, Switzerland.
   [Amoah, Aurora] New York City Dept Hlth & Mental Hyg, New York, NY USA.
RP Lindblade, KA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30333 USA.
EM Kil2@cdc.gov
FU Centers for Disease Control and Prevention and US Agency for
   International Development
FX This study was supported by the Centers for Disease Control and
   Prevention and the US Agency for International Development.
NR 8
TC 0
Z9 0
U1 5
U2 5
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2016
VL 22
IS 9
BP 1653
EP 1655
DI 10.3201/eid2209.160416
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DU1GJ
UT WOS:000381955900022
PM 27268508
ER

PT J
AU Rossen, LM
   Khan, D
   Schoendorf, KC
AF Rossen, Lauren M.
   Khan, Diba
   Schoendorf, Kenneth C.
TI Mapping Geographic Variation in Infant Mortality and Related Black-White
   Disparities in the US
SO EPIDEMIOLOGY
LA English
DT Article
ID SHARED COMPONENT MODEL; UNITED-STATES; PRETERM BIRTH; ETHNIC
   DISPARITIES; RACIAL-DIFFERENCES; TRENDS; JOINT; PATTERNS; DISEASES;
   RATES
AB Background: In the US, black infants remain more than twice as likely as white infants to die in the first year of life. Previous studies of geographic variation in infant mortality disparities have been limited to large metropolitan areas where stable estimates of infant mortality rates by race can be determined, leaving much of the US unexplored. Methods: The objective of this analysis was to describe geographic variation in county-level racial disparities in infant mortality rates across the 48 contiguous US states and District of Columbia using national linked birth and infant death period files (2004-2011). We implemented Bayesian shared component models in OpenBUGS, borrowing strength across both spatial units and racial groups. We mapped posterior estimates of mortality rates for black and white infants as well as relative and absolute disparities. Results: Black infants had higher infant mortality rates than white infants in all counties, but there was geographic variation in the magnitude of both relative and absolute disparities. The mean difference between black and white rates was 5.9 per 1,000 (median: 5.8, interquartile range: 5.2 to 6.6 per 1,000), while those for black infants were 2.2 times higher than for white infants (median: 2.1, interquartile range: 1.9-2.3). One quarter of the county-level variation in rates for black infants was shared with white infants. Conclusions: Examining county-level variation in infant mortality rates among black and white infants and related racial disparities may inform efforts to redress inequities and reduce the burden of infant mortality in the US.
C1 [Rossen, Lauren M.] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Hyattsville, MD USA.
   [Khan, Diba] Ctr Dis Control & Prevent, Off Res Methodol, Natl Ctr Hlth Stat, Hyattsville, MD USA.
   [Schoendorf, Kenneth C.] Herman & Walter Samuelson Childrens Hosp Sinai, Baltimore, MD USA.
RP Rossen, LM (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 7307, Hyattsville, MD 20782 USA.
EM lrossen@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 46
TC 0
Z9 0
U1 5
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1044-3983
EI 1531-5487
J9 EPIDEMIOLOGY
JI Epidemiology
PD SEP
PY 2016
VL 27
IS 5
BP 690
EP 696
DI 10.1097/EDE.0000000000000509
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DS8CR
UT WOS:000381011000018
PM 27196804
ER

PT J
AU Belser, JA
   Eckert, AM
   Tumpey, TM
   Maines, TR
AF Belser, Jessica A.
   Eckert, Alissa M.
   Tumpey, Terrence M.
   Maines, Taronna R.
TI Complexities in Ferret Influenza Virus Pathogenesis and Transmission
   Models
SO MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
LA English
DT Review
ID RESPIRATORY DROPLET TRANSMISSION; A VIRUS; AIRBORNE TRANSMISSION; A/H5N1
   VIRUS; RECEPTOR SPECIFICITY; IMMUNE-RESPONSES; H1N1 INFECTION;
   ANIMAL-MODEL; H5N1 VIRUSES; IN-VIVO
AB Ferrets are widely employed to study the pathogenicity, transmissibility, and tropism of influenza viruses. However, inherent variations in inoculation methods, sampling schemes, and experimental designs are often overlooked when contextualizing or aggregating data between laboratories, leading to potential confusion or misinterpretation of results. Here, we provide a comprehensive overview of parameters to consider when planning an experiment using ferrets, collecting data from the experiment, and placing results in context with previously performed studies. This review offers information that is of particular importance for researchers in the field who rely on ferret data but do not perform the experiments themselves. Furthermore, this review highlights the breadth of experimental designs and techniques currently available to study influenza viruses in this model, underscoring the wide heterogeneity of protocols currently used for ferret studies while demonstrating the wealth of information which can benefit risk assessments of emerging influenza viruses.
C1 [Belser, Jessica A.; Tumpey, Terrence M.; Maines, Taronna R.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Eckert, Alissa M.] Ctr Dis Control & Prevent, Div Commun Serv, Off Associate Director Commun, Atlanta, GA 30333 USA.
RP Belser, JA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM jbelser@cdc.gov
NR 92
TC 3
Z9 3
U1 8
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1092-2172
EI 1098-5557
J9 MICROBIOL MOL BIOL R
JI Microbiol. Mol. Biol. Rev.
PD SEP
PY 2016
VL 80
IS 3
BP 733
EP 744
DI 10.1128/MMBR.00022-16
PG 12
WC Microbiology
SC Microbiology
GA DU5JH
UT WOS:000382247500010
PM 27412880
ER

PT J
AU Dragoman, MV
   Jatlaoui, T
   Nanda, K
   Curtis, KM
   Gaffield, ME
AF Dragoman, Monica V.
   Jatlaoui, Tara
   Nanda, Kavita
   Curtis, Kathryn M.
   Gaffield, Mary E.
TI Research gaps identified during the 2014 update of the WHO medical
   eligibility criteria for contraceptive use and selected practice
   recommendations for contraceptive use
SO CONTRACEPTION
LA English
DT Review
ID PELVIC-INFLAMMATORY-DISEASE; ULIPRISTAL ACETATE; EMERGENCY
   CONTRACEPTION; ANTIRETROVIRAL THERAPY; PHARMACOKINETIC INTERACTION;
   ETHINYL ESTRADIOL; DRUG-INTERACTIONS; HEALTHY WOMEN; NORETHINDRONE;
   RITONAVIR
C1 [Dragoman, Monica V.; Gaffield, Mary E.] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
   [Jatlaoui, Tara; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
   [Nanda, Kavita] FHI 360, Durham, NC USA.
RP Dragoman, MV (reprint author), World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
EM dragomanin@who.int
NR 41
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2016
VL 94
IS 3
BP 195
EP 201
DI 10.1016/j.contraception.2015.12.009
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT7EX
UT WOS:000381651000002
PM 26723202
ER

PT J
AU Phillips, SJ
   Steyn, PS
   Curtis, KM
AF Phillips, Sharon J.
   Steyn, Petrus S.
   Curtis, Kathryn M.
TI The safety of Sino-implant (II) for women with medical conditions or
   other characteristics: a systematic review
SO CONTRACEPTION
LA English
DT Review
DE Sino-implant II; Contraceptive implant; Levonorgestrel implant;
   Contraceptive safety
ID CONTRACEPTIVE IMPLANTS; LEVONORGESTREL; HEALTH; KENYA
AB Objectives: This study aims to systematically review evidence published on the safety of Sino-implant (II) [SI (II)] among women with medical conditions or characteristics identified by the World Health Organization for eligibility for contraceptive use.
   Study design: We searched PubMed, WEIPU, CNKI and Wanfang to identify all relevant evidence published in peer-reviewed journals from 1991 through 2014 regarding the safety of SI (II). We considered studies among women with medical conditions or other characteristics, such as age and parity, as direct evidence and studies among healthy women or a general population of women as indirect evidence.
   Results: We identified 108 articles of which 9 met our inclusion criteria. Among women with medical conditions, no evidence was identified for the outcomes of interest, including serious adverse events or outcomes related to medical conditions. Among healthy women, evidence regarding efficacy of SI (II) for women weighing 70 kg was conflicting; one study showed an increased pregnancy rate and another showed no relationship. Women with menorrhagia did not experience worsened symptoms and may benefit from SI (II) use. Healthy women using SI (II) were no more likely than users of other methods to gain weight, develop elevated blood pressure, have abnormal liver or bone density tests or develop ovarian cysts or uterine myomas.
   Conclusions: Evidence among healthy women suggests SI (II) is safe and had health outcomes similar to those of other levonorgestrel implants. Studies were limited and conflicting regarding efficacy for women 70 kg. All included studies were conducted in China, limiting generalizability. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Phillips, Sharon J.; Steyn, Petrus S.] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
   [Curtis, Kathryn M.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
RP Phillips, SJ (reprint author), World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
EM sharonphillipsmd@gmail.com
FU WHO; Centers for Disease Control and Prevention
FX The authors would like to thank Doctor Wen Zhang, who assisted with
   review of articles in Chinese, and Doctor Wu Shang Chun, who provided
   technical support. Tomas Allen and Wenju Zhang assisted with the search
   of the literature. Markus Steiner provided valuable feedback. Translated
   articles were provided by FHI360. This work was supported by the WHO and
   the Centers for Disease Control and Prevention.
NR 34
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2016
VL 94
IS 3
BP 216
EP 225
DI 10.1016/j.contraception.2016.05.004
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT7EX
UT WOS:000381651000004
PM 27217053
ER

PT J
AU Phillips, SJ
   Tepper, NK
   Kapp, N
   Nanda, K
   Temmerman, M
   Curtis, KM
AF Phillips, Sharon J.
   Tepper, Naomi K.
   Kapp, Nathalie
   Nanda, Kavita
   Temmerman, Marleen
   Curtis, Kathryn M.
TI Progestogen-only contraceptive use among breastfeeding women: a
   systematic review
SO CONTRACEPTION
LA English
DT Review
DE Lactation; Contraception; Progestogens; Breastfeeding
ID DEPOT-MEDROXYPROGESTERONE ACETATE; RANDOMIZED-CONTROLLED-TRIAL;
   PROGESTERONE VAGINAL RINGS; EARLY POSTPARTUM USE; INFANT GROWTH; NURSING
   WOMEN; FERTILITY REGULATION; INTRAUTERINE-DEVICE; NONHORMONAL
   CONTRACEPTIVES; HORMONAL CONTRACEPTIVES
AB Background: Postpartum women need effective contraception. Concerns have been raised that use of progestogen-only contraceptives (POCs) may affect breastfeeding performance and infant health outcomes.
   Objectives: We investigated the clinical outcomes of breastfeeding duration, initiation of supplemental feeding and weaning, as well as infant outcomes including infant growth, health and development among breastfeeding women using POCs compared with breastfeeding women not using POCs.
   Search strategy: We searched the PubMed database for all articles published from database inception through December 2014.
   Selection criteria: We included primary research studies of breastfeeding women of any age or parity who received POCs, including progestogen-only pills, injectables, implants or hormonal intrauterine devices (IUDs). The main outcomes were breastfeeding performance (as measured by initiation, continuation, frequency and exclusivity of breastfeeding) and infant health (as measured by growth, development or adverse health effects).
   Results: Forty-nine articles reporting on 47 different studies were identified that investigated the use of POCs in breastfeeding women and reported clinically relevant outcomes of infant growth, health or breastfeeding performance. Studies ranged from poor to fair methodological quality and generally failed to show negative effects of the use of POCs on breastfeeding outcomes or on infant growth or development. One randomized controlled trial (RCT) raises concerns that immediate insertion of the levonorgestrel IUD postpartum may be associated with poorer breastfeeding performance when compared with delayed insertion, although two other RCTs evaluating early etonogestrel implants compared with delayed initiation of implants or depot medroxyprogesterone acetate failed to find such an association.
   Conclusion: The preponderance of evidence fails to demonstrate adverse breastfeeding outcomes or negative health outcomes in infants such as restricted growth, health problems or impaired development. Evidence newly added to this review was largely consistent with previous evidence. (C) 2016 Published by Elsevier Inc.
C1 [Phillips, Sharon J.; Temmerman, Marleen] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
   [Tepper, Naomi K.; Curtis, Kathryn M.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
   [Nanda, Kavita] FHI 360, Durham, NC USA.
RP Phillips, SJ (reprint author), World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
EM sjp633@mail.harvard.edu
FU WHO; US Centers for Disease Control and Prevention;  [FIE 360]
FX The authors would like to acknowledge the contributions of Mary Lyn
   Gaffield, Roger Chou and the Guidelines Development Group for the
   Medical Eligibility for Contraceptive Use. This review was supported by
   the WHO, the US Centers for Disease Control and Prevention and FIE 360.
NR 71
TC 3
Z9 3
U1 14
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2016
VL 94
IS 3
BP 226
EP 252
DI 10.1016/j.contraception.2015.09.010
PG 27
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT7EX
UT WOS:000381651000005
PM 26410174
ER

PT J
AU Tepper, NK
   Phillips, SJ
   Kapp, N
   Gaffield, ME
   Curtis, KM
AF Tepper, Naomi K.
   Phillips, Sharon J.
   Kapp, Nathalie
   Gaffield, Mary E.
   Curtis, Kathryn M.
TI Combined hormonal contraceptive use among breastfeeding women: an
   updated systematic review
SO CONTRACEPTION
LA English
DT Review
DE Combined hormonal contraceptives; Combined oral contraceptives;
   Breastfeeding; Lactation; Systematic review
ID LONG-TERM INFLUENCE; ORAL-CONTRACEPTIVES; FERTILITY REGULATION; NURSING
   WOMEN; INFANT GROWTH; ETHINYL ESTRADIOL; TASK-FORCE; LACTATION;
   POSTPARTUM; MILK
AB Background: Contraception is important for women who are postpartum, including those who are breastfeeding. Use of combined hormonal contraceptives (CHCs) may affect breastfeeding performance and infant health outcomes.
   Objective: The objective was to identify evidence examining clinical outcomes for breastfeeding and infant health among breastfeeding women using CHCs compared to nonusers.
   Search strategy: We searched the PubMed database for all articles published from database inception through September 30, 2014.
   Selection criteria: We included primary research studies that compared breastfeeding women using CHCs with breastfeeding women using nonhormonal or no contraception, or compared breastfeeding women initiating combined hormonal contraception at early versus later times postpartum. Breastfeeding outcomes of interest included duration, rate of exclusive breastfeeding and timing of supplementation. Infant outcomes of interest included growth, health and development.
   Results: Fifteen articles describing 13 studies met inclusion criteria for this review. Studies ranged from poor to fair methodological quality and demonstrated inconsistent effects of combined oral contraceptives (COCs) on breastfeeding performance with COC initiation before or after 6 weeks postpartum; some studies demonstrated greater supplementation and decreased breastfeeding continuation among COC users compared with nonusers, and others demonstrated no effect. For infant outcomes, some studies found decreases in infant weight gain for COC users compared with nonusers when COCs were initiated at <6 weeks postpartum, while other studies found no effect. None of the studies found an effect on infant weight gain when COCs were started after 6 weeks postpartum, and no studies found an effect on other infant health outcomes regardless of time of COC initiation.
   Conclusion: Limited evidence of poor to fair quality demonstrates an inconsistent impact of COCs on breastfeeding duration and success. The evidence also demonstrated conflicting results on whether early initiation of COCs affects infant outcomes but generally found no negative impact on infant outcomes with later initiation of COCs. The body of evidence is limited by older studies using different formulations and doses of estrogen and poor methodologic quality. Given the significant limitations of this body of evidence, the importance of contraception for postpartum women and the theoretical concerns that have been raised about the use of combined hormonal contraception by women who are breastfeeding, rigorous studies examining these issues are needed. In addition, postpartum women should be counseled about the full range of safe alternative contraceptive methods, particularly during the first 6 weeks postpartum when the risk of venous thromboembolism is highest and use of estrogen may exacerbate this risk. (C) 2015 Published by Elsevier Inc.
C1 [Tepper, Naomi K.; Curtis, Kathryn M.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA.
   [Phillips, Sharon J.; Kapp, Nathalie; Gaffield, Mary E.] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
RP Tepper, NK (reprint author), US Ctr Dis Control & Prevent, 4770 Buford Hwy,MS K-34, Atlanta, GA 30341 USA.
EM ntepper@cdc.gov
OI Phillips, Sharon/0000-0001-7157-4122
NR 46
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2016
VL 94
IS 3
BP 262
EP 274
DI 10.1016/j.contraception.2015.05.006
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT7EX
UT WOS:000381651000007
PM 26002804
ER

PT J
AU Tepper, NK
   Marchbanks, PA
   Curtis, KM
AF Tepper, Naomi K.
   Marchbanks, Polly A.
   Curtis, Kathryn M.
TI Superficial venous disease and combined hormonal contraceptives: a
   systematic review
SO CONTRACEPTION
LA English
DT Review
DE Superficial venous disease; Superficial venous thrombosis; Varicose
   veins; Oral contraceptives; Systematic review
ID DEEP-VEIN THROMBOSIS; RISK-FACTORS; VARICOSE-VEINS; THROMBOEMBOLISM;
   EPIDEMIOLOGY; DIAGNOSIS
AB Background: Superficial venous disease, which includes superficial venous thrombosis (SVT) and varicose veins, may be associated with a higher risk of venous thromboembolism (VTE). Use of combined hormonal contraceptives (CHCs) has been associated with an increased risk of VTE compared with nonuse. Little is known about whether use of CHCs by women with superficial venous disease may further elevate the risk of VTE.
   Objectives: To investigate evidence regarding risk of VTE in women with SVT or varicose veins who use CHCs compared with non-CHC users.
   Methods: We searched the PubMed database for all English-language articles published from database inception through September 2014. We included primary research studies that examined women with SVT or varicose veins who used CHCs compared to women with these conditions who did not use CHCs. Outcomes of interest included VTE (among women with SVT or varicose veins) and SVT (for those with varicose veins).
   Results: Two studies were identified that met inclusion criteria. One fair-quality case control study reported an odds ratio (OR) for VTE of 43.0 (95% confidence interval [CI] 15.5-119.3) among women with SVT using oral contraceptives (OCs) compared with nonusers without SVT. The OR for VTE was also increased for women with SVT not using OCs (OR 5.1; 95% CI 2.8-9.5) and for women without SVT using OCs (OR 4.0; 95% CI 3.3-4.7), compared with nonusers without SVT. One fair-quality cohort study demonstrated that women with varicose veins had an increased rate of VTE with use of OCs (1.85 per 1000 women-years [WY]), compared with users without varicose veins (0.84 per 1000 WY), nonusers with varicose veins (0.31 per 1000 WY) and nonusers without varicose veins (0.19 per 1000 WY). This study also demonstrated that women with varicose veins had an increased rate of SVT with use of OCs (10.63 per 1000 WY), compared with nonusers with varicose veins (7.59 per 1000 WY), users without varicose veins (1.89 per 1000 WY) and nonusers without varicose veins (0.77 per 1000 WY).
   Conclusion: Two studies suggest increased risk of VTE among OC users with superficial venous disease; however, no definitive conclusions can be made due to the limited number of studies and limitations in study quality. Theoretical concerns need to be clarified with further research on whether the risk of significant sequelae from superficial venous disease among CHC users is related to clinical severity of disease and underlying factors. (C) 2016 Published by Elsevier Inc.
C1 [Tepper, Naomi K.; Marchbanks, Polly A.; Curtis, Kathryn M.] US Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Hwy,MS F-74, Atlanta, GA 30341 USA.
RP Tepper, NK (reprint author), US Ctr Dis Control & Prevent, 4770 Buford Hwy,MS K-34, Atlanta, GA 30341 USA.
EM ntepper@cdc.gov
NR 22
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2016
VL 94
IS 3
BP 275
EP 279
DI 10.1016/j.contraception.2015.03.010
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT7EX
UT WOS:000381651000008
PM 25835269
ER

PT J
AU Dragoman, M
   Curtis, KM
   Gaffield, ME
AF Dragoman, Monica
   Curtis, Kathryn M.
   Gaffield, Mary E.
TI Combined hormonal contraceptive use among women with known
   dyslipidemias: a systematic review of critical safety outcomes
SO CONTRACEPTION
LA English
DT Review
DE Combined hormonal contraception; Dyslipidemias; Myocardial infarction;
   Stroke; Venous thromboembolism; Pancreatitis
ID ORAL-CONTRACEPTIVES; SEVERE HYPERTRIGLYCERIDEMIA; INDUCED PANCREATITIS;
   ETHINYL ESTRADIOL; LIPID-METABOLISM; COHORT; RISK; CHOLESTEROL;
   GUIDELINES; MANAGEMENT
AB Context: Dyslipidemias represent a spectrum of lipid disorders that are important risk factors for cardiovascular disease. In addition, elevated triglycerides are known to be associated with pancreatitis. Though less clear, it is possible that dyslipidemias may also contribute to risk for venous thromboembolism (VTE). Ethinyl estradiol and progestogen, contained within combined hormonal contraception, are known to impact lipid metabolism.
   Objectives: To evaluate from the literature whether use of combined hormonal contraception (CHC), including combined oral contraception (COC) pills, transdermal patch, vaginal ring or injectables, modifies the relative risk of acute myocardial infarction (MI), stroke, VTE or pancreatitis among women with known dyslipidemias and to determine if existing lipid abnormalities worsen with CHC use.
   Methods: PubMed and the Cochrane Library databases were searched for all articles in all languages published between inception and September 2014 relevant to dyslipidemia, CHC use and serious adverse events (MI, stroke, VTE or pancreatitis). The quality of each individual study was assessed using the system for grading evidence developed by the United States Preventive Services Task Force.
   Results: From 306 articles identified by our search strategy, 3 articles met inclusion criteria. In a poor-quality case control study, women with hypercholesterolemia but no COC use had an increased risk of MI (adjusted odds ratio [adj OR] 3.3, 95% confidence interval [CI] 1.6-6.8), as did women who used COCs but did not have hypercholesterolemia (adj OR 2.0, 95% CI 1.4-2.8), compared with non-COC users without hypercholesterolemia; women with both COC use and hypercholesterolemia had an adjusted OR of 24.7 (95% CI 5.6-108.5) compared with women with neither risk factor. A poor-quality cohort study examined COC users and reported that women with dyslipidemia had increased risk for VTE [crude risk ratio (RR) 1.39, 95% CI 1.04-1.85] and transient ischemic attacks or cerebrovascular accidents (CVAs) (RR 1.76, 95% CI 1.51-2.06) compared to those without dyslipidemia. Another poor-quality cohort study provided direct evidence on changes in lipid levels among COC users with dyslipidemia. A minority of women with elevated total cholesterol or triglyceride levels at baseline showed normal results (25% and 28%, respectively) after 6 cycles of COC use. No evidence regarding risks associated with use of other CHC methods was identified. No evidence was identified for the outcome of pancreatitis.
   Conclusion: Limited data from poor-quality observational studies suggest that women with known dyslipidemias using CHC may be at increased risk for MI and may experience a minimal increase in risk for CVA or VTE. No evidence was identified on risk for pancreatitis in this context. The impact of CHC exposure on the status of lipid abnormalities over time, an intermediate marker for disease, is also unclear. Given the significant limitations of this body of evidence, the importance of access to effective contraception and theoretical concerns raised about the use of CHCs by women with known dyslipidemias, additional rigorous studies are needed to best estimate true associations. Contraceptive decision making should include consideration of both the known and theoretical risks of a given CHC method, safety and acceptability of alternative contraceptive methods, and risks associated with unintended pregnancy. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Dragoman, Monica; Gaffield, Mary E.] World Hlth Org, Dept Reprod Hlth & Res, Ave Appia 20, CH-1206 Geneva, Switzerland.
   [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
RP Dragoman, M (reprint author), World Hlth Org, Dept Reprod Hlth & Res, Ave Appia 20, CH-1206 Geneva, Switzerland.
EM dragomanm@who.int
OI Dragoman, Monica/0000-0002-8979-7081
NR 35
TC 0
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2016
VL 94
IS 3
BP 280
EP 287
DI 10.1016/j.contraception.2015.08.002
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT7EX
UT WOS:000381651000009
PM 26272309
ER

PT J
AU Mangan, JM
   Tupasi, TE
   Garfin, AMCG
   Lofranco, V
   Orilaza-Chi, R
   Basilio, R
   Naval, LC
   Balane, GI
   Joson, ES
   Burt, D
   Lew, WJ
   Mantala, M
   Pancho, S
   Sarol, JN
   Golubkov, A
   Kurbatova, EV
AF Mangan, J. M.
   Tupasi, T. E.
   Garfin, A. M. C. G.
   Lofranco, V.
   Orilaza-Chi, R.
   Basilio, R.
   Naval, L. C.
   Balane, G. I.
   Joson, E. S.
   Burt, D.
   Lew, W-J.
   Mantala, M.
   Pancho, S.
   Sarol, J. N., Jr.
   Golubkov, A.
   Kurbatova, E. V.
TI Multidrug-resistant tuberculosis patients lost to follow-up: self
   reported readiness to restart treatment
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE patient decision; readiness; health behavior; stages of change; patient
   education
AB SETTING: Multidrug-resistant tuberculosis (MDR-TB) patients lost to follow-up (LTFU) from Programmatic Management of Drug-resistant Tuberculosis facilities in the Philippines.
   OBJECTIVES: To gain insight into patients' readiness to return to treatment.
   METHODS: MDR-TB patients who initiated treatment and were categorized as LTFU were identified using TB registers, contacted, and asked to consent to an interview and medical record review. At the conclusion of the interview, patients' readiness to restart treatment was assessed and examined in relation to demographic, clinical, and interview data. Odds ratios were calculated.
   RESULTS: When asked if they would consider restarting MDR-TB treatment, 3% of the 89 participating patients reported that they had already restarted, 34% indicated that they wanted to restart, 33% had not considered restarting, 28% were undecided, and 2% had decided against restarting. Patients who wanted to restart treatment were more likely to report having borrowed money for TB-related expenses (OR 5.97, 95 %CI 1.27-28.18), and were less likely to report being self-employed (OR 0.08, 95%CI 0.01-0.67), or perceive themselves at low or no risk for TB relapse (OR 0.30, 95%CI 0.08-0.96) than patients who did not indicate an interest in restarting treatment.
   CONCLUSIONS: Efforts to re-engage LTFU patients in care should consider financial barriers, knowledge gaps, and personal adherence challenges in patients.
C1 [Mangan, J. M.; Burt, D.; Kurbatova, E. V.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Tupasi, T. E.; Naval, L. C.; Balane, G. I.; Joson, E. S.; Sarol, J. N., Jr.] Trop Dis Fdn, Makati, Philippines.
   [Garfin, A. M. C. G.; Basilio, R.] Dept Hlth, Natl TB Control Program, Manila, Philippines.
   [Lofranco, V.; Pancho, S.] Lung Ctr Philippines, Natl Ctr Pulm Res, Quezon City, Philippines.
   [Orilaza-Chi, R.] Philippine Business Social Progress Innovat & Mul, Manila, Philippines.
   [Lew, W-J.] WHO, Reg Off Western Pacific, Manila, Philippines.
   [Mantala, M.] Natl TB Program, Manila, Philippines.
   [Golubkov, A.] US Agcy Int Dev, Washington, DC 20523 USA.
RP Mangan, JM (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,MS-E10, Atlanta, GA 30329 USA.
EM bpy4@cdc.gov
FU US Agency for International Development (USAID) Philippines, Manila, The
   Philippines; Philippine Business for Social Progress (Manila, The
   Philippines)
FX This work was supported by the US Agency for International Development
   (USAID) Philippines, Manila, The Philippines through a cooperative
   agreement with Philippine Business for Social Progress (Manila, The
   Philippines) for the Innovations and Multisectoral Partnership to
   Achieve Control of Tuberculosis (IMPACT) project.
NR 17
TC 0
Z9 0
U1 5
U2 5
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD SEP
PY 2016
VL 20
IS 9
BP 1205
EP 1211
DI 10.5588/ijtld.16.0029
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA DT8XN
UT WOS:000381779100016
PM 27510247
ER

PT J
AU Lu, M
   Li, J
   Rupp, LB
   Holmberg, SD
   Moorman, AC
   Spradling, PR
   Teshale, EH
   Zhou, YR
   Boscarino, JA
   Schmidt, MA
   Lamerato, LE
   Trinacty, C
   Trudeau, S
   Gordon, SC
AF Lu, Mei
   Li, Jia
   Rupp, Loralee B.
   Holmberg, Scott D.
   Moorman, Anne C.
   Spradling, Philip R.
   Teshale, Eyasu H.
   Zhou, Yueren
   Boscarino, Joseph A.
   Schmidt, Mark A.
   Lamerato, Lois E.
   Trinacty, Connie
   Trudeau, Sheri
   Gordon, Stuart C.
CA CHeCS Investigators
TI Hepatitis C treatment failure is associated with increased risk of
   hepatocellular carcinoma
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE antiviral treatment; sustained virological response; treatment failure
ID SUSTAINED VIROLOGICAL RESPONSE; INTERFERON THERAPY; CIRRHOSIS;
   MORTALITY; INFECTION; FIBROSIS; CARE; EPIDEMIOLOGY; PROGRESSION;
   SOFOSBUVIR
AB Sustained virological response (SVR) to antiviral therapy for hepatitis C (HCV) reduces risk of hepatocellular carcinoma (HCC), but there is little information regarding how treatment failure (TF) compares to lack of treatment. We evaluated the impact of treatment status on risk of HCC using data from the Chronic Hepatitis Cohort Study (CHeCS-an observational study based in four large US health systems, with up to 7 years of follow-up on patients). Multivariable analyses were used to adjust for bias in treatment selection, as well as other covariates, followed by sensitivity analyses. Among 10 091 HCV patients, 3681 (36%) received treatment, 2099 (57%) experienced treatment failure (TF), and 1582 (43%) of these achieved sustained virological response (SVR). TF patients demonstrated almost twice the risk of HCC than untreated patients [adjusted hazard ratio (aHR) = 1.95, 95% confidence interval (CI) 1.50-2.53]; this risk persisted across all stages of fibrosis. Several sensitivity analyses validated these results. Although African Americans were at increased risk of treatment failure, they were at lower risk for HCC and all-cause mortality compared to White patients. SVR patients had lower risk of HCC than TF patients (aHR = 0.48, CI 0.31-0.73), whereas treatment - regardless of outcome - reduced all-cause mortality (aHR = 0.45, CI 0.34-0.60 for SVR patients; aHR = 0.78, CI 0.65-0.93 for TF patients).
C1 [Lu, Mei; Li, Jia; Zhou, Yueren; Lamerato, Lois E.; Trudeau, Sheri] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA.
   [Rupp, Loralee B.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA.
   [Holmberg, Scott D.; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Boscarino, Joseph A.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA.
   [Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
   [Trinacty, Connie] Kaiser Permanente Hawaii, Ctr Hlth Res, Waipahu, HI USA.
   [Gordon, Stuart C.] Henry Ford Hlth Syst, Div Gastroenterol & Hepatol, Detroit, MI USA.
RP Lu, M (reprint author), Henry Ford Hlth Syst, Publ Hlth Sci, 3E One Ford Pl, Detroit, MI 48202 USA.
EM mlu1@hfhs.org
FU CDC Foundation; AbbVie; Gilead Sciences; Janssen Pharmaceuticals;
   Genentech; Vertex Pharmaceuticals; Bristol-Myers Squibb
FX CHeCS is funded by the CDC Foundation, which receives grants from
   AbbVie, Gilead Sciences and Janssen Pharmaceuticals. Past funders
   include Genentech and Vertex Pharmaceuticals. Past partial funders
   include Bristol-Myers Squibb. Granting corporations do not have access
   to CHeCS data and do not contribute to data analysis or manuscripts.
NR 33
TC 3
Z9 3
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD SEP
PY 2016
VL 23
IS 9
BP 718
EP 729
DI 10.1111/jvh.12538
PG 12
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA DS6NF
UT WOS:000380898000007
PM 27028626
ER

PT J
AU Talley, P
   Snippes-Vagnone, P
   Smith, K
AF Talley, P.
   Snippes-Vagnone, P.
   Smith, K.
TI Invasive Pasteurella multocida Infections - Report of Five Cases at a
   Minnesota Hospital, 2014
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Article
DE Pasteurella multocida; cat bites; Pasteurella multocida bacteraemia;
   invasive Pasteurella multocida infections; One health
ID BITE; PETS
AB During October 2014, the Minnesota Department of Health was notified of five Hospital A patients with Pasteurella multocida bacteraemia; three had died. Human soft tissue infection with P.multocida typically results from cat or dog bites or scratches. Invasive infection, defined as a P.multocida isolate from a usually sterile site, is rare. We evaluated P.multocida isolations at Hospital A, compared with other Minnesota hospitals to understand invasive infection trends. A case was defined as clinically confirmed P.multocida in a Minnesota resident during 2012-2014. All hospital laboratories were queried; Fisher's exact test was used for comparison. Medical charts were reviewed for 2014 Hospital A patients with P.multocida infections. The Minnesota clinical laboratories survey response rate was 79% (63/80). At Hospital A, proportion of P.multocida isolates from usually sterile sites increased from 0% (0/2) during 2012 to 11% (1/9) during 2013, and to 86% (5/6) during 2014. The proportion of patients with P.multocida isolated from sterile sites was 35% (6/17) at Hospital A compared with 10% (58/583) statewide during 2012-2014 combined (P<0.05). Among 2014 Hospital A patients with invasive P.multocida infection, all five were men; median age was 70 (range: 44-78) years. Four were temporally clustered within a 33-day period; three of those had bacteraemia on admission, making hospital acquisition possible in only one. Among five bacteraemia patients, four had cirrhosis and/or skin ulcerations, and three died. The proportion of invasive P.multocida cases was substantially higher at Hospital A during 2014. No epidemiologic links between patients were found. Three had known pet exposure. Collaborative educational efforts of chronically ill pet owners by physicians and veterinarians can acknowledge the health benefits of pet ownership, while minimizing risk for serious invasive zoonotic infections, including those caused by P.multocida.
C1 [Talley, P.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA.
   [Talley, P.; Smith, K.] Minnesota Dept Hlth, Infect Dis Epidemiol Prevent & Control Div, St Paul, MN USA.
   [Snippes-Vagnone, P.] Minnesota Dept Hlth, Publ Hlth Lab, St Paul, MN USA.
RP Talley, P (reprint author), Minnesota Dept Hlth, 625 Robert St N,POB 64975, St Paul, MN 55164 USA.
EM Pam.Talley@state.mn.us
FU Intramural CDC HHS [CC999999]
NR 13
TC 1
Z9 1
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD SEP
PY 2016
VL 63
IS 6
BP 431
EP 435
DI 10.1111/zph.12263
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases;
   Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
   Veterinary Sciences
GA DS7IY
UT WOS:000380958100001
PM 26892817
ER

PT J
AU Jian, FC
   Liu, AQ
   Wang, RJ
   Zhang, SM
   Qi, M
   Zhao, W
   Shi, YD
   Wang, JL
   Wei, JJ
   Zhang, LX
   Xiao, LH
AF Jian, Fuchun
   Liu, Aiqin
   Wang, Rongjun
   Zhang, Sumei
   Qi, Meng
   Zhao, Wei
   Shi, Yadong
   Wang, Jianling
   Wei, Jiujian
   Zhang, Longxian
   Xiao, Lihua
TI Common occurrence of Cryptosporidium hominis in horses and donkeys
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Horse; Donkey; Cryptosporidium; SSU rRNA gene; gp60 gene; Genotyping;
   Subtyping
ID GIARDIA-DUODENALIS; MOLECULAR CHARACTERIZATION; ENTEROCYTOZOON-BIENEUSI;
   ZOONOTIC TRANSMISSION; EPIDEMIOLOGIC SURVEY; GENETIC DIVERSITY; FOAL
   DIARRHEA; 1ST REPORT; IDENTIFICATION; SPP.
AB Extensive genetic variation is observed within the genus Cryptosporidium and the distribution of Cryptosporidium species/genotypes in humans and animals appears to vary by geography and host species. To better understand the genetic diversity of Cryptosporidium spp. in horses and donkeys, we characterized five horse-derived and 82 donkey-derived Cryptosporidium isolates from five provinces or autonomous regions (Sichuan, Gansu, Henan, Inner Mongolia and Shandong) in China at the species/genotype and subtype levels. Three Cryptosporidium species/genotypes were identified based on the analysis of the SSU rRNA gene, including Cryptosporidium parvum (n = 22), the Cryptosporidium horse genotype (n = 4), and Cryptosporidium hominis (n = 61). The identification of C. hominis was confirmed by sequence analysis of the HSP70 and actin genes. Subtyping using sequence analysis of the 60 kDa glycoprotein gene identified 21 C. parvum isolates as subtype IIdA19G1, the four horse genotype isolates as subtypes VIaA15G4 (n = 2) and VIaA11G3 (n = 2), and the 61 C. hominis isolates as IkA16G1 (n = 59) and IkA16 (n = 2). The common finding of C. hominis reaffirms the heterogeneity of Cryptosporidium spp. in horses and donkeys and is possibly a reflection of endemic transmission of C. hominis in these animals. Data of the study suggest that horses and donkeys as companion animals may potentially transmit Cryptosporidium infections to humans. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Jian, Fuchun; Wang, Rongjun; Zhang, Sumei; Qi, Meng; Shi, Yadong; Wang, Jianling; Wei, Jiujian; Zhang, Longxian] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Henan, Peoples R China.
   [Liu, Aiqin; Zhao, Wei] Harbin Med Univ, Dept Parasitol, Harbin 150081, Heilongjiang, Peoples R China.
   [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Henan, Peoples R China.; Xiao, LH (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM zhanglx8999@henau.edu.cn; lxiao@cdc.gov
RI Xiao, Lihua/B-1704-2013; 
OI Xiao, Lihua/0000-0001-8532-2727; zhang, longxian/0000-0002-5706-131X
FU Key Program of the National Natural Science Foundation of China
   [31330079]; National Natural Science Foundation of China [31172311,
   313110103012]; Innovative Scientists Cultivation Projects of Henan
   Province [134200510012]
FX This study was supported in part by the Key Program of the National
   Natural Science Foundation of China (31330079), the National Natural
   Science Foundation of China (31172311, 313110103012), and the Innovative
   Scientists Cultivation Projects of Henan Province (134200510012).
NR 52
TC 3
Z9 3
U1 5
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2016
VL 43
BP 261
EP 266
DI 10.1016/j.meegid.2016.06.004
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA DR1YP
UT WOS:000379701100035
PM 27264727
ER

PT J
AU Ward, ML
   Mijatovic-Rustempasic, S
   Roy, S
   Rungsrisuriyachai, K
   Boom, JA
   Sahni, LC
   Baker, CJ
   Rench, MA
   Wikswo, ME
   Payne, DC
   Parashar, UD
   Bowen, MD
AF Ward, M. Leanne
   Mijatovic-Rustempasic, Slavica
   Roy, Sunando
   Rungsrisuriyachai, Kunchala
   Boom, Julie A.
   Sahni, Leila C.
   Baker, Carol J.
   Rench, Marcia A.
   Wikswo, Mary E.
   Payne, Daniel C.
   Parashar, Umesh D.
   Bowen, Michael D.
TI Molecular characterization of the first G24P[14] rotavirus strain
   detected in humans
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Rotavirus; G24P[14]; Bovine; Reassortment
ID FULL GENOMIC CHARACTERIZATION; GENOTYPE; CLASSIFICATION
AB Here we report the genome of a novel rotavirus A (RVA) strain detected in a stool sample collected during routine surveillance by the Centers for Disease Control and Prevention's New Vaccine Surveillance Network. The strain, RVA/human-wt/USA/2012741499/2012/G24P[14], has a genomic constellation of G24-P[14]-I2-R2-C2-M2-A3-N2-T9-E2-H3. The VP2, VP3, VP7 and NSP3 genes cluster phylogenetically with bovine strains. The other genes occupy mixed clades containing animal and human strains. Strain RVA/human-wt/USA/2012741499/2012/G24P[14] most likely is the product of interspecies transmission and reassortment events. This is the second report of the G24 genotype and the first report of the G24P[14] genotype combination in humans. Published by Elsevier B.V.
C1 [Ward, M. Leanne; Mijatovic-Rustempasic, Slavica; Roy, Sunando; Rungsrisuriyachai, Kunchala; Wikswo, Mary E.; Payne, Daniel C.; Parashar, Umesh D.; Bowen, Michael D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30329 USA.
   [Boom, Julie A.; Sahni, Leila C.; Baker, Carol J.; Rench, Marcia A.] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Boom, Julie A.; Baker, Carol J.; Rench, Marcia A.] Baylor Coll Med, Houston, TX 77030 USA.
RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, DVD, NCIRD, 1600 Clifton Rd,NE,Mailstop G04, Atlanta, GA 30329 USA.
EM mrw0@cdc.gov; hsr7@cdc.gov; sunando@gmail.com; Torekunchala@gmail.com;
   jaboom@texaschildrens.org; lcsahni@texaschildrens.org; cbaker@bcm.edu;
   mrench@bcm.edu; ezq1@cdc.gov; dvp6@cdc.gov; uap2@cdc.gov; mkb6@cdc.gov
FU Centers for Disease Control and Prevention
FX Funding for this study was provided by the Centers for Disease Control
   and Prevention.
NR 20
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2016
VL 43
BP 338
EP 342
DI 10.1016/j.meegid.2016.05.033
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA DR1YP
UT WOS:000379701100045
PM 27237948
ER

PT J
AU Reid, MJC
   Switzer, WM
   Schillaci, MA
   Ragonnet-Cronin, M
   Joanisse, I
   Caminiti, K
   Lowenberger, CA
   Galdikas, BMF
   Sandstrom, PA
   Brooks, JI
AF Reid, Michael J. C.
   Switzer, William M.
   Schillaci, Michael A.
   Ragonnet-Cronin, Manon
   Joanisse, Isabelle
   Caminiti, Kyna
   Lowenberger, Carl A.
   Galdikas, Birute Mary F.
   Sandstrom, Paul A.
   Brooks, James I.
TI Detailed phylogenetic analysis of primate T-lymphotropic virus type 1
   (PTLV-1) sequences from orangutans (Pongo pygmaeus) reveals new insights
   into the evolutionary history of PTLV-1 in Asia
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Orangutans; Pongo; PTLV-1; STLV-1; HTLV-1; Australasia; Cross-species
   transmission; Paleovirology
ID CELL LEUKEMIA-VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; LATE MIDDLE
   PLEISTOCENE; LAST GLACIAL PERIOD; TAI NATIONAL-PARK; SOUTHEAST-ASIA;
   MITOCHONDRIAL-DNA; NEW-GUINEA; STLV-I; MOLECULAR CHARACTERIZATION
AB While human T-lymphotropic virus type 1 (HTLV-1) originates fromancient cross-species transmission of simian T-lymphotropic virus type 1 (STLV-1) from infected nonhuman primates, much debate exists on whether the first HTLV-1 occurred in Africa, or in Asia during early human evolution and migration. This topic is complicated by a lack of representative Asian STLV-1 to infer PTLV-1 evolutionary histories. In this study we obtained new STLV-1 LTR and tax sequences from a wild-born Bornean orangutan (Pongo pygmaeus) and performed detailed phylogenetic analyses using both maximum likelihood and Bayesian inference of available Asian PTLV-1 and African STLV-1 sequences. Phylogenies, divergence dates and nucleotide substitution rates were co-inferred and compared using six different molecular clock calibrations in a Bayesian framework, including both archaeological and/or nucleotide substitution rate calibrations. We then combined our molecular results with paleobiogeographical and ecological data to infer the most likely evolutionary history of PTLV-1. Based on the preferred models our analyses robustly inferred an Asian source for PTLV-1 with cross-species transmission of STLV-1 likely from a macaque (Macaca sp.) to an orangutan about 37.9-48.9 kya, and to humans between 20.3-25.5 kya. An orangutan diversification of STLV-1 commenced approximately 6.4-7.3 kya. Our analyses also inferred that HTLV-1 was first introduced into Australia similar to 3.1-3.7 kya, corresponding to both genetic and archaeological changes occurring in Australia at that time. Finally, HTLV-1 appears in Melanesia at similar to 2.3-2.7 kya corresponding to the migration of the Lapita peoples into the region. Our results also provide an important future reference for calibrating information essential for PTLV evolutionary timescale inference. Longer sequence data, or full genomes from a greater representation of Asian primates, including gibbons, leaf monkeys, and Sumatran orangutans are needed to fully elucidate these evolutionary dates and relationships using the model criteria suggested herein. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Reid, Michael J. C.; Schillaci, Michael A.] Univ Toronto, Dept Anthropol, 1265 Mil Trail, Scarborough, ON M1C 1A4, Canada.
   [Reid, Michael J. C.; Schillaci, Michael A.] Univ Toronto, Dept Anthropol, 19 Russell St, Toronto, ON M5S 2S2, Canada.
   [Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30329 USA.
   [Ragonnet-Cronin, Manon] Univ Edinburgh, Ashworth Labs, Inst Evolutionary Biol, West Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.
   [Joanisse, Isabelle; Brooks, James I.] Publ Hlth Agcy Canada, Natl Microbiol Lab, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada.
   [Caminiti, Kyna] Publ Hlth Agcy Canada, Ctr Biosecur, 100 Colonnade Rd, Ottawa, ON, Canada.
   [Lowenberger, Carl A.] Simon Fraser Univ, Dept Biol Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
   [Galdikas, Birute Mary F.] Simon Fraser Univ, Dept Archaeol, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
   [Galdikas, Birute Mary F.] Orangutan Fdn Int, 824 S Wellesley Ave, Los Angeles, CA 90049 USA.
   [Sandstrom, Paul A.] Publ Hlth Agcy Canada, Natl Microbiol Lab, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, Ottawa, ON, Canada.
RP Reid, MJC (reprint author), Univ Toronto, Dept Anthropol, 1265 Mil Trail, Scarborough, ON M1C 1A4, Canada.; Brooks, JI (reprint author), Publ Hlth Agcy Canada, Natl Microbiol Lab, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada.
EM mj.reid@utoronto.ca; bis3@cdc.gov; schillaci@utsc.utoronto.ca;
   manonragonnet@gmail.com; kyna.caminiti@phac-aspc.gc.ca; clowenbe@sfu.ca;
   drbirute@gmail.com; paul_sandstrom@phac-aspc.gc.ca;
   james.brooks@phac-aspc.gc.ca
FU Natural Sciences and Engineering Research Council (NSERC) of Canada;
   Ontario Graduate Scholarship; Department of Anthropology, University of
   Toronto
FX We thank Drs. Arie Budiman and Endang Sukara for supporting this project
   in Indonesia and the Indonesian Institute of Sciences (LIPI) for
   approving this research, Dr. Rosa Garriga and the OCC&Q veterinary and
   orangutan caretaking staff, Dr. Mark Skinner for contributing to the
   original project that gave rise to this research, and Drs. Adam Brumm
   and David Bulbeck for discussions and help with the archaeological
   evidence and peopling of Sulawesi and the Austronesian Expansion. We
   also thank Drs. Shawn Lehman, Joyce Parga, Mary Silcox, and Tony
   Goldberg for their comments and constructive criticism of previous
   drafts of this paper. Financial support for this project was provided to
   MJCR by the Natural Sciences and Engineering Research Council (NSERC) of
   Canada doctoral grant (PGS-D), the Ontario Graduate Scholarship and the
   Department of Anthropology, University of Toronto. Use of trade names is
   for identification only and does not imply endorsement by the U.S.
   Department of Health and Human Services, the Public Health Service, or
   the Centers for Disease Control and Prevention. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the views of the Centers for Disease Control and
   Prevention, or any of the authors' affiliated institutions.
NR 123
TC 0
Z9 0
U1 13
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2016
VL 43
BP 434
EP 450
DI 10.1016/j.meegid.2016.05.036
PG 17
WC Infectious Diseases
SC Infectious Diseases
GA DR1YP
UT WOS:000379701100058
PM 27245152
ER

PT J
AU Zhao, K
   Wohlhueter, RM
   Li, Y
AF Zhao, Kun
   Wohlhueter, Robert M.
   Li, Yu
TI Finishing monkeypox genomes from short reads: assembly analysis and a
   neural network method
SO BMC GENOMICS
LA English
DT Article
DE Poxvirus; Neural Network; de novo Assembly; Whole-genome sequencing;
   Repetitive sequence; Gap filling; Graph; Public health
ID DE-BRUIJN GRAPHS; PATH PROBLEM; COMPUTATION; ALGORITHM; POXVIRUS;
   SEQUENCES; VIRUS; GAUGE; CONGO
AB Background: Poxviruses constitute one of the largest and most complex animal virus families known. The notorious smallpox disease has been eradicated and the virus contained, but its simian sister, monkeypox is an emerging, untreatable infectious disease, killing 1 to 10 % of its human victims. In the case of poxviruses, the emergence of monkeypox outbreaks in humans and the need to monitor potential malicious release of smallpox virus requires development of methods for rapid virus identification. Whole-genome sequencing (WGS) is an emergent technology with increasing application to the diagnosis of diseases and the identification of outbreak pathogens. But "finishing" such a genome is a laborious and time-consuming process, not easily automated. To date the large, complete poxvirus genomes have not been studied comprehensively in terms of applying WGS techniques and evaluating genome assembly algorithms.
   Results: To explore the limitations to finishing a poxvirus genome from short reads, we first analyze the repetitive regions in a monkeypox genome and evaluate genome assembly on the simulated reads. We also report on procedures and insights relevant to the assembly (from realistically short reads) of genomes. Finally, we propose a neural network method (namely Neural-KSP) to "finish" the process by closing gaps remaining after conventional assembly, as the final stage in a protocol to elucidate clinical poxvirus genomic sequences.
   Conclusions: The protocol may prove useful in any clinical viral isolate (regardless if a reference-strain sequence is available) and especially useful in genomes confounded by many global and local repetitive sequences embedded in them. This work highlights the feasibility of finishing real, complex genomes by systematically analyzing genetic characteristics, thus remedying existing assembly shortcomings with a neural network method. Such finished sequences may enable clinicians to track genetic distance between viral isolates that provides a powerful epidemiological tool.
C1 [Zhao, Kun] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA 30333 USA.
   [Wohlhueter, Robert M.] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
   [Li, Yu] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Zhao, K (reprint author), Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA 30333 USA.
EM vzt5@cdc.gov
FU Poxvirus and Rabies Branch, Division of High Consequence Pathogens and
   Pathology, National Center for Emerging and Zoonotic Infectious
   Diseases, Centers for Disease Control and Prevention
FX The publication costs for this article were funded by the Poxvirus and
   Rabies Branch, Division of High Consequence Pathogens and Pathology,
   National Center for Emerging and Zoonotic Infectious Diseases, Centers
   for Disease Control and Prevention. The findings and conclusions in this
   report are those of the author(s) and do not necessarily represent the
   views of the Centers for Disease Control and Prevention.
NR 46
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 31
PY 2016
VL 17
SU 5
AR 497
DI 10.1186/s12864-016-2826-8
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DW4PQ
UT WOS:000383625900006
PM 27585810
ER

PT J
AU Xu, XJ
   Thai, H
   Kitrinos, KM
   Xia, GL
   Gaggar, A
   Paulson, M
   Ganova-Raeva, L
   Khudyakov, Y
   Lara, J
AF Xu, Xiaojun
   Thai, Hong
   Kitrinos, Kathryn M.
   Xia, Guoliang
   Gaggar, Anuj
   Paulson, Matthew
   Ganova-Raeva, Lilia
   Khudyakov, Yury
   Lara, James
TI Modeling the functional state of the reverse transcriptase of hepatitis
   B virus and its application to probing drug-protein interaction
SO BMC BIOINFORMATICS
LA English
DT Article
DE Hybrid structure modeling; Molecular dynamics (MD); Solvated interaction
   energy (SIE); Hepatitis B; Tenofovir; Drug resistance; Reverse
   transcriptase
ID TENOFOVIR DISOPROXIL FUMARATE; INTERACTION ENERGY SIE;
   MOLECULAR-DYNAMICS; POLYMERASE RESISTANCE; BINDING AFFINITIES; I-TASSER;
   DNA; MECHANISM; PMPA; INHIBITORS
AB Background: Herein, the predicted atomic structures of five representative sequence variants of the reverse transcriptase protein (RT) of hepatitis B virus (HBV), sampled from patients with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been examined to identify structural variations between them in order to assess structural and functional properties of HBV-RT variants associated with the differential responses to TDF treatment.
   Results: We utilized a hybrid computational approach to model the atomistic structures of HBV-RT/DNA-RNA/dATP and HBV-RT/DNA-RNA/TFV-DP (tenofovir diphosphate) complexes with the native hybrid DNA-RNA substrate in place. Multi-nanosecond molecular dynamics (MD) simulations of HBV-RT/DNA-RNA/dATP complexes revealed strong coupling of the natural nucleotide substrate, dATP, to the active site of the RT, and the differential involvement of the two putative magnesium cations (Mg2+) at the active site, whereby one Mg2+ directly bridges the interaction between dATP and HBV-RT and the other serves as a coordinator to maintain an optimal configuration of the active site. Solvated interaction energy (SIE) calculated in MD simulations of HBV-RT/DNA-RNA/TFV-DP complexes indicate no differential binding affinity between TFV-DP and HBV-RT variants identified in patients with slow or rapid response to TDF treatment.
   Conclusion: The predicted atomic structures accurately represent functional states of HBV-RT. The equivalent interaction between TFV-DP and each examined HBV-RT variants suggests that binding affinity of TFV-DP to HBV-RT is not associated with delayed viral clearance.
C1 [Xu, Xiaojun; Thai, Hong; Xia, Guoliang; Ganova-Raeva, Lilia; Khudyakov, Yury; Lara, James] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA.
   [Kitrinos, Kathryn M.; Gaggar, Anuj; Paulson, Matthew] Gilead Sci Inc, Foster City, CA USA.
RP Lara, J (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA.
EM xzl5@cdc.gov
FU CDC intramural funding; APHL postdoctoral fellowship funding; CDC
FX This study was supported by CDC intramural funding and by APHL
   postdoctoral fellowship funding (2014-2015) to [X.X]. This information
   is distributed solely for the purpose of pre-dissemination peer review
   under applicable information quality guidelines. It has not been
   formally disseminated by the Centers for Disease Control and
   Prevention/Agency for Toxic Substances and Disease Registry. It does not
   represent and should not be construed to represent any agency
   determination or policy. Publication costs for this work were funded by
   CDC.
NR 52
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD AUG 31
PY 2016
VL 17
SU 8
AR 280
DI 10.1186/s12859-016-1116-4
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA DW5AV
UT WOS:000383655300005
ER

PT J
AU Kim, JH
   Talbot, HK
   Mishina, M
   Zhu, YW
   Chen, JF
   Cao, WP
   Reber, AJ
   Griffin, MR
   Shay, DK
   Spencer, SM
   Sambhara, S
AF Kim, Jin Hyang
   Talbot, H. Keipp
   Mishina, Margarita
   Zhu, Yuwei
   Chen, Jufu
   Cao, Weiping
   Reber, Adrian J.
   Griffin, Marie R.
   Shay, David K.
   Spencer, Sarah M.
   Sambhara, Suryaprakash
TI High-dose influenza vaccine favors acute plasmablast responses rather
   than long-term cellular responses
SO VACCINE
LA English
DT Article
DE High-dose influenza vaccine; Cell-mediated immunity; Plasmablast
   response; Older adults
ID ADULTS 65 YEARS; CD4(+) T-CELLS; OLDER-ADULTS; DENDRITIC CELLS;
   IMMUNE-SYSTEM; IMMUNOGENICITY; AGE; IMMUNOSENESCENCE; PROTECTION;
   EFFICACY
AB High-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals >= 65 years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n = 12-26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults. Published by Elsevier Ltd.
C1 [Kim, Jin Hyang; Chen, Jufu; Cao, Weiping; Reber, Adrian J.; Shay, David K.; Spencer, Sarah M.; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Talbot, H. Keipp; Zhu, Yuwei; Griffin, Marie R.] Vanderbilt Univ, Med Ctr, A2200 MCN,1161 21st Ave South, Nashville, TN 37232 USA.
   [Mishina, Margarita] Batelle Mem Inst, 2987 Clairmont Rd,Suite 450, Atlanta, GA 30329 USA.
   [Kim, Jin Hyang] Arbutus Biopharma Inc, 3805 Old Easton Rd, Doylestown, PA 18902 USA.
RP Talbot, HK (reprint author), Vanderbilt Univ, Med Ctr, A2200 MCN,1161 21st Ave South, Nashville, TN 37232 USA.
EM Keipp.talbot@vanderbilt.edu
FU National Institute of Health/National Institute of Allergy and
   Infectious Diseases [K23 AI074863-01A1]; National Center for Advancing
   Translational Sciences [UL1TR000445]; Center for Disease Control and
   Prevention [U18 IP000184-01]
FX This work was supported by National Institute of Health/National
   Institute of Allergy and Infectious Diseases [K23 AI074863-01A1 to
   H.K.T.], National Center for Advancing Translational Sciences
   [UL1TR000445 to H.K.T], and Center for Disease Control and Prevention
   [U18 IP000184-01 to M.R.G].
NR 34
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 31
PY 2016
VL 34
IS 38
BP 4594
EP 4601
DI 10.1016/j.vaccine.2016.07.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DV5XU
UT WOS:000383004800023
PM 27473306
ER

PT J
AU Martines, RB
   Bhatnagar, J
   Ramos, AMD
   Davi, HPF
   Iglezias, SD
   Kanamura, CT
   Keating, MK
   Hale, G
   Silva-Flannery, L
   Muehlenbachs, A
   Ritter, J
   Gary, J
   Rollin, D
   Goldsmith, CS
   Reagan-Steiner, S
   Ermias, Y
   Suzuki, T
   Luz, KG
   de Oliveira, WK
   Lanciotti, R
   Lambert, A
   Shieh, WJ
   Zaki, SR
AF Martines, Roosecelis Brasil
   Bhatnagar, Julu
   de Oliveira Ramos, Ana Maria
   Freire Davi, Helaine Pompeia
   Iglezias, Silvia D'Andretta
   Kanamura, Cristina Takami
   Keating, M. Kelly
   Hale, Gillian
   Silva-Flannery, Luciana
   Muehlenbachs, Atis
   Ritter, Jana
   Gary, Joy
   Rollin, Dominique
   Goldsmith, Cynthia S.
   Reagan-Steiner, Sarah
   Ermias, Yokabed
   Suzuki, Tadaki
   Luz, Kleber G.
   de Oliveira, Wanderson Kleber
   Lanciotti, Robert
   Lambert, Amy
   Shieh, Wun-Ju
   Zaki, Sherif R.
TI Pathology of congenital Zika syndrome in Brazil: a case series
SO LANCET
LA English
DT Article
ID VIRUS-INFECTION; ARTHROGRYPOSIS; PREGNANCY; ETIOLOGY; TISSUES; UPDATE;
   STATES; BRAIN; PCR
AB Background Zika virus is an arthropod-borne virus that is a member of the family Flaviviridae transmitted mainly by mosquitoes of the genus Aedes. Although usually asymptomatic, infection can result in a mild and self-limiting illness characterised by fever, rash, arthralgia, and conjunctivitis. An increase in the number of children born with microcephaly was noted in 2015 in regions of Brazil with high transmission of Zika virus. More recently, evidence has been accumulating supporting a link between Zika virus and microcephaly. Here, we describe findings from three fatal cases and two spontaneous abortions associated with Zika virus infection.
   Methods In this case series, formalin-fixed paraffin-embedded tissue samples from five cases, including two newborn babies with microcephaly and severe arthrogryposis who died shortly after birth, one 2-month-old baby, and two placentas from spontaneous abortions, from Brazil were submitted to the Infectious Diseases Pathology Branch at the US Centers for Disease Control and Prevention (Atlanta, GA, USA) between December, 2015, and March, 2016. Specimens were assessed by histopathological examination, immunohistochemical assays using a mouse anti-Zika virus antibody, and RT-PCR assays targeting the NS5 and envelope genes. Amplicons of RT-PCR positive cases were sequenced for characterisation of strains.
   Findings Viral antigens were localised to glial cells and neurons and associated with microcalcifications in all three fatal cases with microcephaly. Antigens were also seen in chorionic villi of one of the first trimester placentas. Tissues from all five cases were positive for Zika virus RNA by RT-PCR, and sequence analyses showed highest identities with Zika virus strains isolated from Brazil during 2015.
   Interpretation These findings provide strong evidence of a link between Zika virus infection and different congenital central nervous system malformations, including microcephaly as well as arthrogryposis and spontaneous abortions.
C1 [Martines, Roosecelis Brasil; Bhatnagar, Julu; Keating, M. Kelly; Hale, Gillian; Silva-Flannery, Luciana; Muehlenbachs, Atis; Ritter, Jana; Gary, Joy; Rollin, Dominique; Goldsmith, Cynthia S.; Ermias, Yokabed; Shieh, Wun-Ju; Zaki, Sherif R.] NCEZID, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA USA.
   [Reagan-Steiner, Sarah] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA.
   [de Oliveira Ramos, Ana Maria] Univ Fed Rio Grande do Norte, Dept Pathol, Natal, RN, Brazil.
   [de Oliveira Ramos, Ana Maria; Freire Davi, Helaine Pompeia] Serv Ascertaining Death State Rio Grande Norte SV, Natal, RN, Brazil.
   [Iglezias, Silvia D'Andretta; Kanamura, Cristina Takami] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Suzuki, Tadaki] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan.
   [Luz, Kleber G.] Univ Fed Rio Grande do Norte, Dept Infect Dis, Natal, RN, Brazil.
   [de Oliveira, Wanderson Kleber] Minist Hlth, Brasilia, DF, Brazil.
   [Lanciotti, Robert; Lambert, Amy] Ctr Dis Control & Prevent, NCEZID, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO USA.
RP Zaki, SR (reprint author), Ctr Dis Control & Prevent, NCEZID, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA 30329 USA.
EM szaki@cdc.gov
OI Oliveira, Wanderson/0000-0002-9662-1930
NR 29
TC 28
Z9 28
U1 59
U2 73
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 27
PY 2016
VL 388
IS 10047
BP 898
EP 904
DI 10.1016/S0140-6736(16)30883-2
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU0RI
UT WOS:000381911800028
PM 27372395
ER

PT J
AU Grohskopf, LA
   Sokolow, LZ
   Broder, KR
   Olsen, SJ
   Karron, RA
   Jernigan, DB
   Bresee, JS
AF Grohskopf, Lisa A.
   Sokolow, Leslie Z.
   Broder, Karen R.
   Olsen, Sonja J.
   Karron, Ruth A.
   Jernigan, Daniel B.
   Bresee, Joseph S.
TI Prevention and Control of Seasonal Influenza with Vaccines
   Recommendations of the Advisory Committee on Immunization Practices -
   United States, 2016-17 Influenza Season
SO MMWR RECOMMENDATIONS AND REPORTS
LA English
DT Article
ID GUILLAIN-BARRE-SYNDROME; HUMAN-IMMUNODEFICIENCY-VIRUS; EVENT REPORTING
   SYSTEM; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL;
   LABORATORY-CONFIRMED INFLUENZA; RESPIRATORY SYNCYTIAL VIRUS; A H1N1
   2009; THIMEROSAL-CONTAINING VACCINES; LIVER-TRANSPLANT RECIPIENTS
AB This report updates the 2015-16 recommendations ofthe Advisoiy Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines (Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015;64:818-25). Routine annual influenza vaccination is recommended for all persons aged months who do not have contraindications. For the 2016-17 influenza season, inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in a trivalent formulation (RIV3). In light of concerns regarding low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013-14 and 2015-16 seasons, for the 2016-17 season, ACIP makes the interim recommendation that live attenuated influenza vaccine (LAIV4) should not be used. Vaccine virus strains included in the 2016-17 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1) like virus, an A/Hong Kong/4801/2014 (H3N2) like virus, and a B/Brisbane/60/2008 like virus (Victoria lineage). Quadrivalent vaccines will include an additional influenza B virus strain, a B/Phuket/3073/2013 like virus (Yamagata lineage).
   Recommendations for use of different vaccine types and specific populations are discussed. A licensed, age -appropriate vaccine should be used. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended product is otherwise appropriate. This information is intended for vaccination providers, immunization program personnel, and public health personnel. Information in this report reflects discussions during public meetings ofACIP held on October 21, 2015; February 24, 2016; andJune 22, 2016 These recommendations apply to all licensed influenza vaccines used within Food and DrugAdministration licensed indications, including those licensed after the publication of this report. Updates and other information are available at CDC's influenza website (http://www.cdc.govfflit). Vaccination and health care providers should check CDC's influenza website periodically for additional information.
C1 [Grohskopf, Lisa A.; Sokolow, Leslie Z.; Olsen, Sonja J.; Jernigan, Daniel B.; Bresee, Joseph S.] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA.
   [Sokolow, Leslie Z.] Battelle Mem Inst, Atlanta, GA USA.
   [Broder, Karen R.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Immunizat Safety Off, Atlanta, GA 30333 USA.
   [Karron, Ruth A.] Johns Hopkins Univ, Baltimore, MD USA.
RP Grohskopf, LA (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA.
EM Lkg6@cdc.gov
NR 457
TC 23
Z9 23
U1 8
U2 8
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1057-5987
EI 1545-8601
J9 MMWR RECOMM REP
JI MMWR Recomm. Rep.
PD AUG 26
PY 2016
VL 65
IS 5
BP 1
EP 51
PG 51
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3MC
UT WOS:000384276200001
PM 27560619
ER

PT J
AU Gladden, RM
   Martinez, P
   Seth, P
AF Gladden, R. Matthew
   Martinez, Pedro
   Seth, Puja
TI Fentanyl Law Enforcement Submissions and Increases in Synthetic
   Opioid-Involved Overdose Deaths-27 States, 2013-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Gladden, R. Matthew; Martinez, Pedro; Seth, Puja] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
RP Gladden, RM (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM mgladden@cdc.gov
NR 10
TC 11
Z9 11
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 837
EP 843
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300002
PM 27560775
ER

PT J
AU Peterson, AB
   Gladden, RM
   Delcher, C
   Spies, E
   Garcia-Williams, A
   Wang, Y
   Halpin, J
   Zibbell, J
   McCarty, CL
   DeFiore-Hyrmer, J
   DiOrio, M
   Goldberger, BA
AF Peterson, Alexis B.
   Gladden, R. Matthew
   Delcher, Chris
   Spies, Erica
   Garcia-Williams, Amanda
   Wang, Yanning
   Halpin, John
   Zibbell, Jon
   McCarty, Carolyn Lullo
   DeFiore-Hyrmer, Jolene
   DiOrio, Mary
   Goldberger, Bruce A.
TI Increases in Fentanyl-Related Overdose Deaths - Florida and Ohio,
   2013-2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES; PAIN
C1 [Peterson, Alexis B.; Spies, Erica; Garcia-Williams, Amanda; McCarty, Carolyn Lullo] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Peterson, Alexis B.; Gladden, R. Matthew; Halpin, John; Zibbell, Jon] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Peterson, Alexis B.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Delcher, Chris; Wang, Yanning] Univ Florida, Coll Med, Dept Hlth Outcomes & Policy, Gainesville, FL USA.
   [Spies, Erica; Garcia-Williams, Amanda] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
   [Wang, Yanning; Goldberger, Bruce A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA.
   [McCarty, Carolyn Lullo] CDC, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [McCarty, Carolyn Lullo; DeFiore-Hyrmer, Jolene; DiOrio, Mary] Ohio Dept Hlth, Columbus, OH 43266 USA.
RP Peterson, AB (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Peterson, AB; Gladden, RM (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.; Peterson, AB (reprint author), CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM mgladden@cdc.gov
NR 10
TC 6
Z9 6
U1 6
U2 6
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 844
EP 849
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300003
PM 27560948
ER

PT J
AU Reagan-Steiner, S
   Yankey, D
   Jeyarajah, J
   Elam-Evans, LD
   Curtis, CR
   MacNeil, J
   Markowitz, LE
   Singleton, JA
AF Reagan-Steiner, Sarah
   Yankey, David
   Jeyarajah, Jenny
   Elam-Evans, Laurie D.
   Curtis, C. Robinette
   MacNeil, Jessica
   Markowitz, Lauri E.
   Singleton, James A.
TI National, Regional, State, and Selected Local Area Vaccination Coverage
   Among Adolescents Aged 13-17 Years - United States, 2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID IMMUNIZATION
C1 [Reagan-Steiner, Sarah; Yankey, David; Elam-Evans, Laurie D.; Curtis, C. Robinette; Singleton, James A.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Jeyarajah, Jenny] Carter Consulting Inc, Atlanta, GA USA.
   [MacNeil, Jessica] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Markowitz, Lauri E.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Reagan-Steiner, S (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM sreagansteiner@cdc.gov
NR 9
TC 16
Z9 16
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 850
EP 858
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300004
PM 27561081
ER

PT J
AU Bahl, S
   Verma, H
   Bhatnagar, P
   Haldar, P
   Satapathy, A
   Kumar, KNA
   Horton, J
   Estivariz, CF
   Anand, A
   Sutter, R
AF Bahl, Sunil
   Verma, Harish
   Bhatnagar, Pankaj
   Haldar, Pradeep
   Satapathy, Asish
   Kumar, K. N. Arun
   Horton, Jennifer
   Estivariz, Concepcion F.
   Anand, Abhijeet
   Sutter, Roland
TI Fractional-Dose Inactivated Poliovirus Vaccine Immunization Campaign -
   Telangana State, India, June 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL
C1 [Bahl, Sunil] WHO, South East Asia Reg Off, New Delhi, India.
   [Verma, Harish; Horton, Jennifer; Sutter, Roland] WHO, Geneva, Switzerland.
   [Bhatnagar, Pankaj; Satapathy, Asish; Kumar, K. N. Arun] WHO, Natl Polio Surveillance Project, New Delhi, India.
   [Haldar, Pradeep] Govt India, Minist Hlth & Family Welf, New Delhi, India.
   [Estivariz, Concepcion F.; Anand, Abhijeet] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Anand, A (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM aanand@cdc.gov
NR 9
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 859
EP 863
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300005
PM 27559683
ER

PT J
AU Novosad, SA
   Sapiano, MRP
   Grigg, C
   Lake, J
   Robyn, M
   Dumyati, G
   Felsen, C
   Blog, D
   Dufort, E
   Zansky, S
   Wiedeman, K
   Avery, L
   Dantes, RB
   Jernigan, JA
   Magill, SS
   Fiore, A
   Epstein, L
AF Novosad, Shannon A.
   Sapiano, Mathew R. P.
   Grigg, Cheri
   Lake, Jason
   Robyn, Misha
   Dumyati, Ghinwa
   Felsen, Christina
   Blog, Debra
   Dufort, Elizabeth
   Zansky, Shelley
   Wiedeman, Kathryn
   Avery, Lacey
   Dantes, Raymund B.
   Jernigan, John A.
   Magill, Shelley S.
   Fiore, Anthony
   Epstein, Lauren
TI Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care Factors
   and Opportunities for Prevention
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID INTERNATIONAL CONSENSUS DEFINITIONS; SEPTIC SHOCK SEPSIS-3;
   UNITED-STATES; MORTALITY; COSTS
AB Background: Sepsis is a serious and often fatal clinical syndrome, resulting from infection. Information on patient demographics, risk factors, and infections leading to sepsis is needed to integrate comprehensive sepsis prevention, early recognition, and treatment strategies.
   Methods: To describe characteristics of patients with sepsis, CDC and partners conducted a retrospective chart review in four New York hospitals. Random samples of medical records from adult and pediatric patients with administrative codes for severe sepsis or septic shock were reviewed.
   Results: Medical records of 246 adults and 79 children (aged birth to 17 years) were reviewed. Overall, 72% of patients had a health care factor during the 30 days before sepsis admission or a selected chronic condition likely to require frequent medical care. Pneumonia was the most common infection leading to sepsis. The most common pathogens isolated from blood cultures were Escherichia coli in adults aged >= 18 years, Klebsiella spp. in children aged >= 1 year, and Enterococcus spp. in infants aged < 1 year; for 106 (33%) patients, no pathogen was isolated. Eighty-two (25%) patients with sepsis died, including 65 (26%) adults and 17 (22%) infants and children.
   Conclusions: Infection prevention strategies (e.g., vaccination, reducing transmission of pathogens in health care environments, and appropriate management of chronic diseases) are likely to have a substantial impact on reducing sepsis. CDC, in partnership with organizations representing clinicians, patients, and other stakeholders, is launching a comprehensive campaign to demonstrate that prevention of infections that cause sepsis, and early recognition of sepsis, are integral to overall patient safety.
C1 [Novosad, Shannon A.; Grigg, Cheri; Lake, Jason; Robyn, Misha] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Novosad, Shannon A.; Sapiano, Mathew R. P.; Grigg, Cheri; Lake, Jason; Wiedeman, Kathryn; Avery, Lacey; Dantes, Raymund B.; Jernigan, John A.; Magill, Shelley S.; Fiore, Anthony; Epstein, Lauren] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Dumyati, Ghinwa; Felsen, Christina] Univ Rochester, Med Ctr, Emerging Infect Program, Rochester, NY 14642 USA.
   [Robyn, Misha; Blog, Debra; Dufort, Elizabeth; Zansky, Shelley] New York State Dept Hlth, Albany, NY 12237 USA.
RP Epstein, L (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM lepstein@cdc.gov
NR 17
TC 2
Z9 2
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 864
EP 869
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300006
PM 27559759
ER

PT J
AU Russell, K
   Oliver, SE
   Lewis, L
   Barfield, WD
   Cragan, J
   Meaney-Delman, D
   Staples, JE
   Fischer, M
   Peacock, G
   Oduyebo, T
   Petersen, EE
   Zaki, S
   Moore, CA
   Rasmussen, SA
AF Russell, Kate
   Oliver, Sara E.
   Lewis, Lillianne
   Barfield, Wanda D.
   Cragan, Janet
   Meaney-Delman, Dana
   Staples, J. Erin
   Fischer, Marc
   Peacock, Georgina
   Oduyebo, Titilope
   Petersen, Emily E.
   Zaki, Sherif
   Moore, Cynthia A.
   Rasmussen, Sonja A.
TI Update: Interim Guidance for the Evaluation and Management of Infants
   with Possible Congenital Zika Virus Infection - United States, August
   2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CYTOMEGALOVIRUS-INFECTION; TRANSMISSION; CHILDREN; RUBELLA; BRAZIL;
   LABOR
C1 [Russell, Kate; Oliver, Sara E.; Lewis, Lillianne] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Russell, Kate] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Oliver, Sara E.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Lewis, Lillianne] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
   [Barfield, Wanda D.; Oduyebo, Titilope; Petersen, Emily E.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Cragan, Janet; Moore, Cynthia A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
   [Meaney-Delman, Dana] CDC, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Staples, J. Erin; Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Peacock, Georgina] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
   [Zaki, Sherif] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Rasmussen, Sonja A.] CDC, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
RP Russell, K; Oliver, SE (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Russell, K (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.; Oliver, SE (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM kerussell@cdc.gov; seoliver@cdc.gov
NR 30
TC 22
Z9 21
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 870
EP 878
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300007
PM 27559830
ER

PT J
AU Self, JL
   Conrad, A
   Stroika, S
   Jackson, A
   Burnworth, L
   Beal, J
   Wellman, A
   Jackson, KA
   Bidol, S
   Gerhardt, T
   Hamel, M
   Franklin, K
   Kopko, C
   Kirsch, P
   Wise, ME
   Basler, C
AF Self, Julie L.
   Conrad, Amanda
   Stroika, Steven
   Jackson, Alikeh
   Burnworth, Laura
   Beal, Jennifer
   Wellman, Allison
   Jackson, Kelly A.
   Bidol, Sally
   Gerhardt, Terri
   Hamel, Meghan
   Franklin, Kristyn
   Kopko, Christine
   Kirsch, Penelope
   Wise, Matthew E.
   Basler, Colin
TI Outbreak of Listeriosis Associated with Consumption of Packaged Salad -
   United States and Canada, 2015-2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Self, Julie L.] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
   [Self, Julie L.; Conrad, Amanda; Stroika, Steven; Burnworth, Laura; Jackson, Kelly A.; Wise, Matthew E.; Basler, Colin] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Jackson, Alikeh; Beal, Jennifer; Wellman, Allison] US FDA, Rockville, MD 20857 USA.
   [Bidol, Sally] Michigan Dept Hlth & Human Serv, Detroit, MI USA.
   [Gerhardt, Terri] Ohio Dept Agr, Reynoldsburg, OH USA.
   [Hamel, Meghan; Franklin, Kristyn] Publ Hlth Agcy Canada, Ottawa, ON, Canada.
   [Kopko, Christine; Kirsch, Penelope] Canadian Food Inspect Agency, Ottawa, ON, Canada.
RP Self, JL (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.; Self, JL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM yxj9@cdc.gov
NR 4
TC 1
Z9 1
U1 8
U2 8
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 879
EP 881
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300008
PM 27559935
ER

PT J
AU Rothfeldt, LL
   Patil, N
   Haselow, DT
   Williams, SH
   Wheeler, JG
   Mukasa, LN
AF Rothfeldt, Laura Lester
   Patil, Naveen
   Haselow, Dirk T.
   Williams, Sandy Hainline
   Wheeler, J. Gary
   Mukasa, Leonard N.
TI Cluster of Tuberculosis Cases Among Marshallese Persons Residing in
   Arkansas-2014-2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Rothfeldt, Laura Lester] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [Rothfeldt, Laura Lester; Patil, Naveen; Haselow, Dirk T.; Williams, Sandy Hainline; Wheeler, J. Gary; Mukasa, Leonard N.] Arkansas Dept Hlth, Little Rock, AR 72205 USA.
   [Patil, Naveen; Haselow, Dirk T.; Wheeler, J. Gary; Mukasa, Leonard N.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
   [Haselow, Dirk T.; Wheeler, J. Gary] Arkansas Childrens Hosp, Little Rock, AR 72202 USA.
RP Rothfeldt, LL (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.; Rothfeldt, LL (reprint author), Arkansas Dept Hlth, Little Rock, AR 72205 USA.
EM laura.k.rothfeldt.mil@mail.mil
NR 5
TC 0
Z9 0
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 26
PY 2016
VL 65
IS 33
BP 882
EP 883
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3TO
UT WOS:000382135300009
PM 27560201
ER

PT J
AU Muhindo, MK
   Kakuru, A
   Natureeba, P
   Awori, P
   Olwoch, P
   Ategeka, J
   Nayebare, P
   Clark, TD
   Muehlenbachs, A
   Roh, M
   Mpeka, B
   Greenhouse, B
   Havlir, DV
   Kamya, MR
   Dorsey, G
   Jagannathan, P
AF Muhindo, Mary K.
   Kakuru, Abel
   Natureeba, Paul
   Awori, Patricia
   Olwoch, Peter
   Ategeka, John
   Nayebare, Patience
   Clark, Tamara D.
   Muehlenbachs, Atis
   Roh, Michelle
   Mpeka, Betty
   Greenhouse, Bryan
   Havlir, Diane V.
   Kamya, Moses R.
   Dorsey, Grant
   Jagannathan, Prasanna
TI Reductions in malaria in pregnancy and adverse birth outcomes following
   indoor residual spraying of insecticide in Uganda
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria in pregnancy; Placental malaria; Plasmodium falciparum; Indoor
   residual spraying; Vector-borne disease
ID INTERMITTENT PREVENTIVE TREATMENT; RANDOMIZED CONTROLLED-TRIAL;
   SULFADOXINE-PYRIMETHAMINE; DIHYDROARTEMISININ-PIPERAQUINE;
   LAMBDA-CYHALOTHRIN; WESTERN KENYA; PRETERM BIRTH; TREATED NETS;
   TRANSMISSION; RESISTANCE
AB Background: Indoor residual spraying of insecticide (IRS) is a key intervention for reducing the burden of malaria in Africa. However, data on the impact of IRS on malaria in pregnancy and birth outcomes is limited.
   Methods: An observational study was conducted within a trial of intermittent preventive therapy during pregnancy in Tororo, Uganda. Women were enrolled at 12-20 weeks of gestation between June and October 2014, provided with insecticide-treated bed nets, and followed through delivery. From December 2014 to February 2015, carbamate-containing IRS was implemented in Tororo district for the first time. Exact spray dates were collected for each household. The exposure of interest was the proportion of time during a woman's pregnancy under protection of IRS, with three categories of protection defined: no IRS protection, >0-20 % IRS protection, and 20-43 % IRS protection. Outcomes assessed included malaria incidence and parasite prevalence during pregnancy, placental malaria, low birth weight (LBW), pre-term delivery, and fetal/neonatal deaths.
   Results: Of 289 women followed, 134 had no IRS protection during pregnancy, 90 had >0-20 % IRS protection, and 65 had > 20-43 % protection. During pregnancy, malaria incidence (0.49 vs 0.10 episodes ppy, P = 0.02) and parasite prevalence (20.0 vs 8.9 %, P < 0.001) were both significantly lower after IRS. At the time of delivery, the prevalence of placental parasitaemia was significantly higher in women with no IRS protection (16.8 %) compared to women with 0-20 % (1.1 %, P = 0.001) or > 20-43 % IRS protection (1.6 %, P = 0.006). Compared to women with no IRS protection, those with > 20-43 % IRS protection had a lower risk of LBW (20.9 vs 3.1 %, P = 0.002), pre-term birth (17.2 vs 1.5 %, P = 0.006), and fetal/neonatal deaths (7.5 vs 0 %, P = 0.03).
   Conclusion: In this setting, IRS was temporally associated with lower malaria parasite prevalence during pregnancy and at delivery, and improved birth outcomes. IRS may represent an important tool for combating malaria in pregnancy and for improving birth outcomes in malaria-endemic settings.
C1 [Muhindo, Mary K.; Kakuru, Abel; Natureeba, Paul; Awori, Patricia; Olwoch, Peter; Ategeka, John; Nayebare, Patience] Infect Dis Res Collaborat, Kampala, Uganda.
   [Clark, Tamara D.; Roh, Michelle; Greenhouse, Bryan; Havlir, Diane V.; Dorsey, Grant; Jagannathan, Prasanna] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Muehlenbachs, Atis] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Mpeka, Betty] ABT Associates Inc, Uganda Indoor Residual Spraying Phase Project 2, Kampala, Uganda.
   [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda.
RP Jagannathan, P (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM pras.jagannathan@ucsf.edu
FU National Institutes of Health [PO1HD059454-03, U19AI089674,
   K23AI100949]; Centers for Diseases Control; President's Malaria
   Initiative
FX Research reported in this publication was supported by the National
   Institutes of Health under award numbers PO1HD059454-03, U19AI089674,
   K23AI100949. Additional support was received from the Centers for
   Diseases Control (AM) and the President's Malaria Initiative (BM). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official position of the NIH, Centers for
   Diseases Control and Prevention, or the President's Malaria Initiative.
NR 34
TC 0
Z9 0
U1 7
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 26
PY 2016
VL 15
AR 437
DI 10.1186/s12936-016-1489-x
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU9KJ
UT WOS:000382535500004
PM 27566109
ER

PT J
AU Diaz, LA
   Quaglia, AI
   Konigheim, BS
   Boris, AS
   Aguilar, JJ
   Komar, N
   Contigiani, MS
AF Adrian Diaz, Luis
   Ignacio Quaglia, Agustin
   Salome Konigheim, Brenda
   Silvana Boris, Analia
   Javier Aguilar, Juan
   Komar, Nicholas
   Silvia Contigiani, Marta
TI Activity Patterns of St. Louis Encephalitis and West Nile Viruses in
   Free Ranging Birds during a Human Encephalitis Outbreak in Argentina
SO PLOS ONE
LA English
DT Article
ID CALIFORNIA BIRDS; TRANSMISSION; HOST; EPIDEMIOLOGY; FLAVIVIRIDAE;
   PERSISTENCE; INFECTIONS; DYNAMICS; AMERICA; STRAINS
AB St. Louis encephalitis virus (SLEV) (Flavivirus) is a reemerging arbovirus in the southern cone of South America. In 2005, an outbreak of SLEV in central Argentina resulted in 47 human cases with 9 deaths. In Argentina, the ecology of SLEV is poorly understood. Because certain birds are the primary amplifiers in North America, we hypothesized that birds amplify SLEV in Argentina as well. We compared avian SLEV seroprevalence in a variety of ecosystems in and around Cordoba city from 2004 (before the epidemic) and 2005 (during the epidemic). We also explored spatial patterns to better understand the local ecology of SLEV transmission. Because West Nile virus (WNV) was also detected in Argentina in 2005, all analyses were also conducted for WNV. A total of 980 birds were sampled for detection of SLEV and WNV neutralizing antibodies. SLEV seroprevalence in birds increased 11-fold from 2004 to 2005. Our study demonstrated that a high proportion (99.3%) of local birds were susceptible to SLEV infection immediately prior to the 2005 outbreak, indicating that the vertebrate host population was primed to amplify SLEV. SLEV was found distributed in a variety of environments throughout the city of Cordoba. However, the force of viral transmission varied among sites. Fine scale differences in populations of vectors and vertebrate hosts would explain this variation. In summary, we showed that in 2005, both SLEV and to a lesser extent WNV circulated in the avian population. Eared Dove, Picui Ground-Dove and Great Kiskadee are strong candidates to amplify SLEV because of their exposure to the pathogen at the population level, and their widespread abundance. For the same reasons, Rufous Hornero may be an important maintenance host for WNV in central Argentina. Competence studies and vector feeding studies are needed to confirm these relationships.
C1 [Adrian Diaz, Luis; Ignacio Quaglia, Agustin; Salome Konigheim, Brenda; Silvana Boris, Analia; Javier Aguilar, Juan; Silvia Contigiani, Marta] Univ Nacl Cordoba, Fac Ciencias Med, Inst Virol Dr JM Vanella, Lab Arbovirus, Cordoba, Argentina.
   [Adrian Diaz, Luis] Univ Nacl Cordoba, CONICET, Inst Invest Biol & Tecnol, Cordoba, Argentina.
   [Komar, Nicholas] Ctr Dis Control & Prevent, Ft Collins, CO USA.
RP Diaz, LA (reprint author), Univ Nacl Cordoba, Fac Ciencias Med, Inst Virol Dr JM Vanella, Lab Arbovirus, Cordoba, Argentina.; Diaz, LA (reprint author), Univ Nacl Cordoba, CONICET, Inst Invest Biol & Tecnol, Cordoba, Argentina.
EM adrian.diaz@conicet.gov.ar
FU Ministerio de Ciencia y Tecnologia de la Nacion Argentina (MINCYT) [PICT
   2013/1779]; Consejo Nacional de Ciencia y Tecnologia [CONICET PIP
   11220120100544]; Secretaria de Ciencia y Tecnologia Universidad Nacional
   de Cordoba [SECYT 203/14]; Fundacion Bunge y Born; Council for
   Scientific and Technical Research (CONICET); International Union of
   Microbiological Societies; International Society of Infectious Diseases
FX This work was funded by grants from Ministerio de Ciencia y Tecnologia
   de la Nacion Argentina (MINCYT, PICT 2013/1779, MSC), Consejo Nacional
   de Ciencia y Tecnologia (CONICET PIP 11220120100544), Secretaria de
   Ciencia y Tecnologia Universidad Nacional de Cordoba (SECYT 203/14, LAD)
   and Fundacion Bunge y Born. AIQ is a recipient of a doctorate
   scholarship from Council for Scientific and Technical Research
   (CONICET). LAD's internship at the CDC Ft. Collins was supported by the
   International Union of Microbiological Societies (http://www.iums.org/)
   and International Society of Infectious Diseases
   (http://www.isid.org/).; Authors want thanks to Eric Edwards for his
   invaluable support in serological determinations at CDC (Ft. Collins).
   AIQ is a recipient of a doctorate scholarship from Council for
   Scientific and Technical Research (CONICET). LAD's internship at the CDC
   Ft. Collins was supported by the International Union of Microbiological
   Societies (http://www.iums.org/) and International Society of Infectious
   Diseases (http://www.isid.org/).
NR 34
TC 0
Z9 0
U1 11
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2016
VL 11
IS 8
AR e0161871
DI 10.1371/journal.pone.0161871
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU8WL
UT WOS:000382496300028
PM 27564679
ER

PT J
AU McPhail, BT
   White, CA
   Cummings, BS
   Muralidhara, S
   Wilson, JT
   Bruckner, JV
AF McPhail, Brooks T.
   White, Catherine A.
   Cummings, Brian S.
   Muralidhara, Srinivasa
   Wilson, Jewell T.
   Bruckner, James V.
TI The immature rat as a potential model for chemical risks to children:
   Ontogeny of selected hepatic P450s
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Animal model; Children's risk assessment; Cytochrome P450 ontogeny;
   Carbon tetrachloride; Metabolic activation; Hepatotoxicity
ID DRUG-METABOLIZING-ENZYMES; CARBON-TETRACHLORIDE; HUMAN LIVER;
   DEVELOPMENTAL EXPRESSION; CYP2E1 EXPRESSION; AGE; TOXICITY; 2E1;
   1,1-DICHLOROETHYLENE; CYTOCHROME-P-450
AB Concern about potential susceptibilities of infants and children to chemicals has led to the consideration of immature rodents as potential test surrogates. Maturation of some hepatic microsomal cytochrome P450s (CYPs), that participate in metabolic activation of organic solvents and polycyclic aromatic hydrocarbons (PAHs), may differ significantly between humans and rodents. The present investigation was undertaken to delineate the ontogeny of selected hepatic CYP5 in male and female Sprague-Dawley (S-D) rats, and to contrast them with developmental profiles in humans. Microsomes were prepared from the liver of sexed and unsexed postnatal day (PND) 1-90 rats, and total CYP450 levels, as well as CYP1A1/2, CYP2E1 and CYP2B1/2 activities and protein, were quantified. CYP1A1/2 and CYP2E1 activity and expression rose rapidly after birth, peaked from PND 21-40/50, and declined substantially to adult values by PND 90. The same ontogenic profiles were manifested when the enzyme activities were expressed per entire liver or liver normalized to body weight. CYP1A1/2 and CYP2E1 activity and protein expression were well correlated. CYP2B1/2 activity peaked abruptly on PND 21 and declined irregularly to adult values. These patterns are in contrast to human CYP1A2 and CYP2E1, which are reported to progressively increase in liver during the first few months to years of life. The three CYP protein developmental profiles were largely gender independent in rats. The immature rat does not appear to be a suitable model for assessing risks posed to infants and children by chemicals metabolically activated by CYP2E1, based on the findings of greater carbon tetrachloride hepatotoxicity in preweanlings and weanlings than in adult animals. Additional studies are required to determine whether immature S-D rats may be used as an animal model for substrates of other CYP5, as total CYP450 levels in the liver progressively rose during maturation, similarly to humans. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [McPhail, Brooks T.; White, Catherine A.; Cummings, Brian S.; Muralidhara, Srinivasa; Bruckner, James V.] Univ Georgia, Dept Pharmaceut & Biomed Sci, Coll Pharm, Athens, GA 30602 USA.
   [McPhail, Brooks T.; White, Catherine A.; Cummings, Brian S.; Muralidhara, Srinivasa; Bruckner, James V.] Univ Georgia, Interdisciplinary Toxicol Program, Athens, GA 30602 USA.
   [Wilson, Jewell T.] ATSDR, Div Toxicol & Human Hlth Sci, Dept Hlth & Human Serv, Atlanta, GA 30333 USA.
RP Bruckner, JV (reprint author), Univ Georgia, Coll Pharm, 250 W Green St, Athens, GA 30602 USA.
EM bruckner@uga.edu
FU U.S. Pharmacopeia Fellowship; University of Georgia Interdisciplinary
   Toxicology Program; U.S. ATSDR [200-2004-M-09830]
FX The work of Dr. McPhail on this project was supported in part by a U.S.
   Pharmacopeia Fellowship and the University of Georgia Interdisciplinary
   Toxicology Program. The project was also funded by U.S. ATSDR Contract
   #200-2004-M-09830. The authors would like to thank Ms. Leslie Standridge
   for preparation of the manuscript.
NR 42
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD AUG 25
PY 2016
VL 256
BP 167
EP 177
DI 10.1016/j.cbi.2016.07.005
PG 11
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA DU6RA
UT WOS:000382341100019
PM 27387539
ER

PT J
AU Munyua, P
   Bitek, A
   Osoro, E
   Pieracci, EG
   Muema, J
   Mwatondo, A
   Kungu, M
   Nanyingi, M
   Gharpure, R
   Njenga, K
   Thumbi, SM
AF Munyua, Peninah
   Bitek, Austine
   Osoro, Eric
   Pieracci, Emily G.
   Muema, Josephat
   Mwatondo, Athman
   Kungu, Mathew
   Nanyingi, Mark
   Gharpure, Radhika
   Njenga, Kariuki
   Thumbi, Samuel M.
TI Prioritization of Zoonotic Diseases in Kenya, 2015
SO PLOS ONE
LA English
DT Article
ID NEGLECTED ZOONOSES; AFRICA
AB Introduction
   Zoonotic diseases have varying public health burden and socio-economic impact across time and geographical settings making their prioritization for prevention and control important at the national level. We conducted systematic prioritization of zoonotic diseases and developed a ranked list of these diseases that would guide allocation of resources to enhance their surveillance, prevention, and control.
   Methods
   A group of 36 medical, veterinary, and wildlife experts in zoonoses from government, research institutions and universities in Kenya prioritized 36 diseases using a semi-quantitative One Health Zoonotic Disease Prioritization tool developed by Centers for Disease Control and Prevention with slight adaptations. The tool comprises five steps: listing of zoonotic diseases to be prioritized, development of ranking criteria, weighting criteria by pairwise comparison through analytical hierarchical process, scoring each zoonotic disease based on the criteria, and aggregation of scores.
   Results
   In order of importance, the participants identified severity of illness in humans, epidemic/pandemic potential in humans, socio-economic burden, prevalence/incidence and availability of interventions (weighted scores assigned to each criteria were 0.23, 0.22, 0.21, 0.17 and 0.17 respectively), as the criteria to define the relative importance of the diseases. The top five priority diseases in descending order of ranking were anthrax, trypanosomiasis, rabies, brucellosis and Rift Valley fever.
   Conclusion
   Although less prominently mentioned, neglected zoonotic diseases ranked highly compared to those with epidemic potential suggesting these endemic diseases cause substantial public health burden. The list of priority zoonotic disease is crucial for the targeted allocation of resources and informing disease prevention and control programs for zoonoses in Kenya.
C1 [Munyua, Peninah] US Ctr Dis Control & Prevent, Div Global Hlth Protect, Global Dis Detect Program, Nairobi, Kenya.
   [Bitek, Austine; Muema, Josephat; Kungu, Mathew] Minist Agr Livestock & Fisheries, Zoonot Dis Unit, State Dept Vet Serv, Nairobi, Kenya.
   [Osoro, Eric; Mwatondo, Athman] Minist Hlth, Dept Prevent & Promot Hlth, Zoonot Dis Unit, Nairobi, Kenya.
   [Pieracci, Emily G.; Gharpure, Radhika] US Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA USA.
   [Pieracci, Emily G.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
   [Muema, Josephat] Minist Hlth, Field Epidemiol & Lab Training Program, Nairobi, Kenya.
   [Nanyingi, Mark] Univ Nairobi, Dept Publ Hlth Pharmacol & Toxicol, Nairobi, Kenya.
   [Nanyingi, Mark] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA.
   [Njenga, Kariuki; Thumbi, Samuel M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya.
   [Njenga, Kariuki; Thumbi, Samuel M.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
RP Munyua, P (reprint author), US Ctr Dis Control & Prevent, Div Global Hlth Protect, Global Dis Detect Program, Nairobi, Kenya.
EM Pmunyua@cdc.gov
FU US Centers for Disease Control and Prevention through Global Disease
   detection Division [GH000069]; Wellcome Trust [110330/Z/15/Z]
FX This work partially funded by US Centers for Disease Control and
   Prevention through cooperative agreements # GH000069, from the Global
   Disease detection Division. Participation of SM Thumbi was supported by
   Wellcome Trust # 110330/Z/15/Z. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 21
TC 0
Z9 0
U1 10
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 24
PY 2016
VL 11
IS 8
AR e0161576
DI 10.1371/journal.pone.0161576
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU5NI
UT WOS:000382258100054
PM 27557120
ER

PT J
AU Rimi, NA
   Sultana, R
   Ishtiak-Ahmed, K
   Rahman, MZ
   Hasin, M
   Islam, MS
   Azziz-Baumgartner, E
   Nahar, N
   Gurley, ES
   Luby, SP
AF Rimi, Nadia Ali
   Sultana, Rebeca
   Ishtiak-Ahmed, Kazi
   Rahman, Md Zahidur
   Hasin, Marufa
   Islam, M. Saiful
   Azziz-Baumgartner, Eduardo
   Nahar, Nazmun
   Gurley, Emily S.
   Luby, Stephen P.
TI Understanding the failure of a behavior change intervention to reduce
   risk behaviors for avian influenza transmission among backyard poultry
   raisers in rural Bangladesh: a focused ethnography
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Backyard poultry; Behavior change intervention; Avian influenza; Focused
   ethnography; Bangladesh
ID H5N1 VIRUS-INFECTION; A H5N1; ZOONOTIC TRANSMISSION; BIOSECURITY
   MEASURES; PERCEPTIONS; VACCINATION; KNOWLEDGE; OUTBREAK; VIETNAM; HEALTH
AB Background: The spread of the highly pathogenic avian influenza ( HPAI) H5N1 virus among poultry and humans has raised global concerns and has motivated government and public health organizations to initiate interventions to prevent the transmission of HPAI. In Bangladesh, H5N1 became endemic in poultry and seven human H5N1 cases have been reported since 2007, including one fatality. This study piloted messages to increase awareness about avian influenza and its prevention in two rural communities, and explored change in villagers' awareness and behaviors attributable to the intervention.
   Methods: During 2009-10, a research team implemented the study in two rural villages in two districts of Bangladesh. The team used a focused ethnographic approach for data collection, including informal interviews and observations to provide detailed contextual information about community response to a newly emerging disease. They collected pre-intervention qualitative data for one month. Then another team disseminated preventive messages focused on safe slaughtering methods, through courtyard meetings and affixed posters in every household. After dissemination, the research team collected post-intervention data for one month.
   Results: More villagers reported hearing about 'bird flu' after the intervention compared to before the intervention. After the intervention, villagers commonly recalled changes in the color of combs and shanks of poultry as signs of avian influenza, and perceived zoonotic transmission of avian influenza through direct contact and through inhalation. Consequently the villagers valued covering the nose and mouth while handling sick and dead poultry as a preventive measure. Nevertheless, the team did not observe noticeable change in villagers' behavior after the intervention. Villagers reported not following the recommended behaviors because of the perceived absence of avian influenza in their flocks, low risk of avian influenza, cost, inconvenience, personal discomfort, fear of being rebuked or ridiculed, and doubt about the necessity of the intervention.
   Conclusions: The villagers' awareness about avian influenza improved after the intervention, however, the intervention did not result in any measurable improvement in preventive behaviors. Low cost approaches that promote financial benefits and minimize personal discomfort should be developed and piloted.
C1 [Rimi, Nadia Ali; Sultana, Rebeca; Ishtiak-Ahmed, Kazi; Rahman, Md Zahidur; Hasin, Marufa; Islam, M. Saiful; Azziz-Baumgartner, Eduardo; Nahar, Nazmun; Gurley, Emily S.; Luby, Stephen P.] Icddrb, Div Infect Dis, Program Emerging Infect, 68 Shaheed Tajuddin Ahmed Sharani, Dhaka 1212, Bangladesh.
   [Azziz-Baumgartner, Eduardo; Luby, Stephen P.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Luby, Stephen P.] Stanford Univ, Stanford, CA 94305 USA.
RP Rimi, NA (reprint author), Icddrb, Div Infect Dis, Program Emerging Infect, 68 Shaheed Tajuddin Ahmed Sharani, Dhaka 1212, Bangladesh.
EM nadiarimi@icddrb.org
RI Gurley, Emily/B-7903-2010; 
OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X
FU Centers of Disease Control and Prevention (CDC) [5-U51-CI000298];
   Government of Australia; Government of Bangladesh; Government of Canada;
   Government of Sweden; Government of UK
FX This research was funded by the Centers of Disease Control and
   Prevention (CDC) (http://www.cdc.gov/) under the Cooperative Agreement
   Grant 5-U51-CI000298. icddr,b acknowledges with gratitude the commitment
   of CDC to this research efforts. SPL received the funding. The paper was
   reviewed and cleared for publication by CDC staff who are not co-authors
   but the funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   opinions expressed by authors contributing to this journal do not
   necessarily reflect the opinions of the Centers for Disease Control and
   Prevention or the institutions with which the authors are affiliated.
   icddr,b is thankful to the Governments of Australia, Bangladesh, Canada,
   Sweden and the UK for providing core/unrestricted support.
NR 50
TC 0
Z9 0
U1 18
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 24
PY 2016
VL 16
AR 858
DI 10.1186/s12889-016-3543-6
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU1PQ
UT WOS:000381981000003
PM 27552983
ER

PT J
AU Diallo, MA
   Badiane, AS
   Diongue, K
   Deme, A
   Lucchi, NW
   Gaye, M
   Ndiaye, T
   Ndiaye, M
   Sene, LK
   Diop, A
   Gaye, A
   Ndiaye, YD
   Samb, D
   Yade, MS
   Ndir, O
   Udhayakumar, V
   Ndiaye, D
AF Diallo, Mamadou A.
   Badiane, Aida S.
   Diongue, Khadim
   Deme, Awa
   Lucchi, Naomi W.
   Gaye, Marie
   Ndiaye, Tolla
   Ndiaye, Mouhamadou
   Sene, Louise K.
   Diop, Abdoulaye
   Gaye, Amy
   Ndiaye, Yaye D.
   Samb, Diama
   Yade, Mamadou S.
   Ndir, Omar
   Udhayakumar, Venkatachalam
   Ndiaye, Daouda
TI Non-falciparum malaria in Dakar: a confirmed case of Plasmodium ovale
   wallikeri infection
SO MALARIA JOURNAL
LA English
DT Article
DE Plasmodium ovale; Malaria; Fever; RDT; Microscopy; Diagnostic;
   Treatment; Primaquine; Dakar
ID ARTEMETHER-LUMEFANTRINE; SENEGAL; PARASITE
AB Background: Plasmodium ovale is rarely described in Senegal. A case of clinical malaria due to P. ovale wallikeri in West Central of Senegal is reported.
   Case: A 34-year-old male baker in Dakar, with no significant previous medical history, was admitted to a health clinic with fever and vomiting. Fever had been lasting for 4 days with peaks every 48 h. As monospecific Plasmodium falciparum HRP-2 RDT was negative, he was treated with antibiotics. However, owing to persisting symptoms, he was referred to the emergency unit of the Youssou Mbargane Diop Hospital, Dakar, Senegal. Clinical examination found impaired general condition. All other physical examinations were normal. Laboratory tests showed anaemia (haemoglobin 11.4 g/dl), severe thrombocytopaenia (platelets 30 x 109/mm(3)), leukopenia (3650/mm(3)), lymphocytopenia (650/mm(3)). Renal function was normal as indicated by creatininaemia and uraemia (11 mg/l and 0.25 g/l, respectively) and liver enzymes were slightly elevated (aspartate aminotransferase 77 UI/l and alanine aminotransferase 82 UI/l). Blood smear evaluations in Parasitology Laboratory of Aristide Le Dantec Hospital showed malaria parasites of the species P. ovale with a 0.08 % parasitaemia. Molecular confirmation was done by real time PCR targeting the 18S rRNA gene. The P. ovale infection was further analysed to species level targeting the potra gene and was identified as P. ovale wallikeri. According to the hospital's malaria treatment guidelines for severe malaria, treatment consisted of intravenous quinine at hour 0 (start of treatment) and 24 h after initial treatment, followed by artemether-lumefantrine 24 h later. A negative microscopy was noted on day 3 post-treatment and the patient reported no further symptoms.
   Conclusion: Malaria due to non-falciparum species is probably underestimated in Senegal. RDTs specific to non-falciparum species and/or pan specific RDTs should be included as tools of diagnosis to fight against malaria in Senegal. In addition, a field-deployable molecular tool such as the loop-mediated isothermal amplification can be considered as an additional useful tool to detect low malaria parasite infections and for speciation. In addition, national malaria control policies should consider other non-falciparum species in treatment guidelines, including the provision of primaquine for the treatment of relapsing parasites.
C1 [Diallo, Mamadou A.; Badiane, Aida S.; Diongue, Khadim; Deme, Awa; Gaye, Marie; Ndiaye, Tolla; Ndiaye, Mouhamadou; Sene, Louise K.; Diop, Abdoulaye; Gaye, Amy; Ndiaye, Yaye D.; Samb, Diama; Yade, Mamadou S.; Ndir, Omar; Ndiaye, Daouda] Univ Cheikh Anta Diop Dakar, Lab Parasitol Mycol, Ave Cheikh Anta Diop,BP 5005, Dakar, Senegal.
   [Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA.
RP Diallo, MA (reprint author), Univ Cheikh Anta Diop Dakar, Lab Parasitol Mycol, Ave Cheikh Anta Diop,BP 5005, Dakar, Senegal.
EM mamadoualpha.diallo@ucad.edu.sn
NR 22
TC 1
Z9 1
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 24
PY 2016
VL 15
AR 429
DI 10.1186/s12936-016-1485-1
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU9KE
UT WOS:000382534900004
PM 27557982
ER

PT J
AU Bradley, H
   Mattson, CL
   Beer, L
   Huang, P
   Shouse, RL
AF Bradley, Heather
   Mattson, Christine L.
   Beer, Linda
   Huang, Ping
   Shouse, R. Luke
CA Med Monitoring Project
TI Increased antiretroviral therapy prescription and HIV viral suppression
   among persons receiving clinical care for HIV infection
SO AIDS
LA English
DT Article
DE antiretroviral therapy; surveillance; viral suppression
ID UNITED-STATES; RACE; CONTINUUM; OUTCOMES; SYSTEM
AB Objective: To assess trends during 2009-2013 in antiretroviral therapy (ART) prescription and viral suppression among adults receiving HIV clinical care in the United States.
   Design: We used data from the Medical Monitoring Project, a surveillance system producing national estimates of characteristics of HIV-infected adults receiving clinical care in the United States.
   Methods: We estimated weighted proportions of persons receiving HIV medical care who were prescribed ART and achieved HIV viral suppression (<200 copies/ml) at both last test and at all tests in the previous 12 months during 2009-2013. We assessed trends overall and by gender, age, race/ethnicity, and sexual behavior/orientation.
   Results: ART prescription and viral suppression increased significantly during 2009-2013, overall and in subgroups. ART prescription increased from 89 to 94% (P for trend <0.01). Viral suppression at last measurement increased from 72 to 80% (P for trend <0.01). The largest increases were among 18-29 year olds (56-68%), 30-39 year olds (62-75%), and non-Hispanic blacks (64-76%). Sustained viral suppression increased from 58 to 68% (P for trend <0.01). The largest increases were among 18-29 year olds (32-51%), 30-39 year olds (47-63%), and non-Hispanic blacks (49-61%).
   Conclusion: Adults receiving HIV medical care are increasingly likely to be prescribed ART and achieve viral suppression. Recent efforts to promote early antiretroviral therapy use may have contributed to these increases, bringing us closer to realizing key goals of the National HIV/AIDS Strategy. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Bradley, Heather; Mattson, Christine L.; Beer, Linda; Huang, Ping; Shouse, R. Luke; Med Monitoring Project] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
RP Bradley, H (reprint author), Ctr Dis Control, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA.
EM iyk5@cdc.gov
FU Centers for Disease Control and Prevention
FX Funding for the Medical Monitoring Project is provided by the Centers
   for Disease Control and Prevention.
NR 34
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD AUG 24
PY 2016
VL 30
IS 13
BP 2117
EP 2124
DI 10.1097/QAD.0000000000001164
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DS5HN
UT WOS:000380812400013
PM 27465279
ER

PT J
AU Fox, J
   Barfield, W
AF Fox, Jared
   Barfield, Wanda
TI Decreasing Unintended Pregnancy Opportunities Created by the Affordable
   Care Act
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID UNITED-STATES; CONTRACEPTION; TEENS; COST
C1 [Fox, Jared] Ctr Dis Control & Prevent, Policy, 1600 Clifton Rd NE,MS D-28, Atlanta, GA 30329 USA.
   [Barfield, Wanda] Ctr Dis Control & Prevent, Div Reprod Hlth, 1600 Clifton Rd NE,MS D-28, Atlanta, GA 30329 USA.
RP Fox, J (reprint author), Ctr Dis Control & Prevent, Policy, 1600 Clifton Rd NE,MS D-28, Atlanta, GA 30329 USA.
EM jaredfox@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 7
TC 3
Z9 3
U1 5
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 23
PY 2016
VL 316
IS 8
BP 815
EP 816
DI 10.1001/jama.2016.8800
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT8JL
UT WOS:000381736200007
PM 27455194
ER

PT J
AU Kruk, ME
   Riley, PL
   Palma, AM
   Adhikari, S
   Ahoua, L
   Arnaldo, C
   Belo, DF
   Brusamento, S
   Cumba, LIG
   Dziuban, EJ
   El-Sadr, WM
   Gutema, Y
   Habtamu, Z
   Heller, T
   Kidanu, A
   Langa, J
   Mahagaja, E
   McCarthy, CF
   Melaku, Z
   Shodell, D
   Tsiouris, F
   Young, PR
   Rabkin, M
AF Kruk, Margaret E.
   Riley, Patricia L.
   Palma, Anton M.
   Adhikari, Sweta
   Ahoua, Laurence
   Arnaldo, Carlos
   Belo, Dercio F.
   Brusamento, Serena
   Cumba, Luisa I. G.
   Dziuban, Eric J.
   El-Sadr, Wafaa M.
   Gutema, Yoseph
   Habtamu, Zelalem
   Heller, Thomas
   Kidanu, Aklilu
   Langa, Judite
   Mahagaja, Epifanio
   McCarthy, Carey F.
   Melaku, Zenebe
   Shodell, Daniel
   Tsiouris, Fatima
   Young, Paul R.
   Rabkin, Miriam
TI How Can the Health System Retain Women in HIV Treatment for a Lifetime?
   A Discrete Choice Experiment in Ethiopia and Mozambique
SO PLOS ONE
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; RURAL MOZAMBIQUE; CARE; PREFERENCES; RETENTION;
   DELIVERY; AFRICA; COMMUNICATION; HETEROGENEITY; INITIATION
AB Introduction
   Option B+, an approach that involves provision of antiretroviral therapy (ART) to all HIV-infected pregnant women for life, is the preferred strategy for prevention of mother to child transmission of HIV. Lifelong retention in care is essential to its success. We conducted a discrete choice experiment in Ethiopia and Mozambique to identify health system characteristics preferred by HIV-infected women to promote continuity of care.
   Methods
   Women living with HIV and receiving care at hospitals in Oromia Region, Ethiopia and Zambezia Province, Mozambique were shown nine choice cards and asked to select one of two hypothetical health facilities, each with six varying characteristics related to the delivery of HIV services for long term treatment. Mixed logit models were used to estimate the influence of six health service attributes on choice of clinics.
   Results
   2,033 women participated in the study (response rate 97.8% in Ethiopia and 94.7% in Mozambique). Among the various attributes of structure and content of lifelong ART services, the most important attributes identified in both countries were respectful provider attitude and ability to obtain non-HIV health services during HIV-related visits. Availability of counseling support services was also a driver of choice. Facility type, i.e., hospital versus health center, was substantially less important.
   Conclusions
   Efforts to enhance retention in HIV care and treatment for pregnant women should focus on promoting respectful care by providers and integrating access to non-HIV health services in the same visit, as well as continuing to strengthen counseling.
C1 [Kruk, Margaret E.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Riley, Patricia L.; Dziuban, Eric J.; McCarthy, Carey F.; Young, Paul R.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
   [Palma, Anton M.; Adhikari, Sweta] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY USA.
   [Ahoua, Laurence; Brusamento, Serena; El-Sadr, Wafaa M.; Gutema, Yoseph; Melaku, Zenebe; Tsiouris, Fatima; Rabkin, Miriam] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA.
   [Arnaldo, Carlos] Ctr Populat & Hlth Res, Maputo, Mozambique.
   [Belo, Dercio F.; Cumba, Luisa I. G.; Mahagaja, Epifanio] Mozamb Minist Hlth, Maputo, Mozambique.
   [Habtamu, Zelalem] Ethiopia Minist Hlth, Oromio Reg Hlth Bur, Addis Ababa, Ethiopia.
   [Heller, Thomas] Ctr Dis Control & Prevent, Addis Ababa, Ethiopia.
   [Kidanu, Aklilu] Miz Hasab Res Ctr, Addis Ababa, Ethiopia.
   [Langa, Judite; Shodell, Daniel] Ctr Dis Control & Prevent, Maputo, Mozambique.
RP Kruk, ME (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
EM mkruk@hsph.harvard.edu
FU U.S. Centers for Disease Control and Prevention (CDC), Division of
   Global HIV/AIDS (DGHA) [5U2GPS001537]; NIH's National Institute for
   Allergy & Infectious Diseases [T32AI114398]; national ministries of
   health in Ethiopia; national ministries of health in Mozambique
FX Funding for this research was provided by the U.S. President's Emergency
   Plan for AIDS Relief (PEPFAR) through cooperative agreement 5U2GPS001537
   from the U.S. Centers for Disease Control and Prevention (CDC), Division
   of Global HIV/AIDS (DGHA) and by the NIH's National Institute for
   Allergy & Infectious Diseases under award number T32AI114398. The
   findings and conclusions in this paper are those of the author(s) and do
   not necessarily represent the official position of the U.S. Centers for
   Disease Control and Prevention, the NIH or the Governments of Ethiopia
   and Mozambique.; The authors are indebted to the women in Ethiopia and
   Mozambique who participated in the study. We wish to thank Boaventura
   Cau, Hawi Fita, Estevao Manhice, and Semret Zenebe for their capable
   supervision of the fieldwork for the study as well as the interviewers
   who collected the data. We appreciate the input and support of health
   authorities and health workers at the participating health facilities in
   Oromia region and Zambezia province as well as the support of national
   ministries of health in Ethiopia and Mozambique.
NR 45
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2016
VL 11
IS 8
AR e0160764
DI 10.1371/journal.pone.0160764
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT8TR
UT WOS:000381768800017
PM 27551785
ER

PT J
AU Lyons, BH
   Fowler, KA
   Jack, SPD
   Betz, CJ
   Blair, JM
AF Lyons, Bridget H.
   Fowler, Katherine A.
   Jack, Shane P. D.
   Betz, Carter J.
   Blair, Janet M.
TI Surveillance for Violent Deaths - National Violent Death Reporting
   System, 17 States, 2013
SO MMWR SURVEILLANCE SUMMARIES
LA English
DT Article
ID SUICIDE VICTIMS; MENTAL-HEALTH; TOXICOLOGY; HOMICIDE; PROGRAM; CARE
AB Problem/Condition: In 2013, more than 57,000 persons died in the United States as a result of violence-related injuries. This report summarizes data from CDC's National Violent Death Reporting System (NVDRS) regarding violent deaths from 17 U.S. states for 2013. Results are reported by sex, age group, race/ethnicity, marital status, location of injury, method of injury, circumstances of injury, and other selected characteristics.
   Reporting Period Covered: 2013.
   Description of System: NVDRS collects data from participating states regarding violent deaths obtained from death certificates, coroner/medical examiner reports, law enforcement reports, and secondary sources (e.g., child fatality review team data, supplemental homicide reports, hospital data, and crime laboratory data). This report includes data from 17 states that collected statewide data for 2013 (Alaska, Colorado, Georgia, Kentucky, Maryland, Massachusetts, North Carolina, New Jersey, New Mexico, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, Utah, Virginia, and Wisconsin). NVDRS collates documents for each death and links deaths that are related (e.g., multiple homicides, a homicide followed by a suicide, or multiple suicides) from a single incident.
   Results: For 2013, a total of 18,765 fatal incidents involving 19,251 deaths were captured by NVDRS in the 17 states included in this report. The majority (66.2%) of deaths were suicides, followed by homicides (23.2%), deaths of undetermined intent (8.8%), deaths involving legal intervention (1.2%) (i.e., deaths caused by law enforcement and other persons with legal authority to use deadly force, excluding legal executions), and unintentional firearm deaths (<1%). (The term legal intervention is a classification incorporated into the International Classification of Diseases, Tenth Revision [ICD-10] and does not denote the lawfulness or legality of the circumstances surrounding a death caused by law enforcement.) Suicides occurred at higher rates among males, non-Hispanic whites, American Indian/Alaska Natives, persons aged 45-64 years, and males aged 75 years. Suicides were preceded primarily by a mental health, intimate partner, or physical health problem or a crisis during the previous or upcoming 2 weeks. Homicide rates were higher among males and persons aged 15-44 years; rates were highest among non-Hispanic black males. Homicides primarily were precipitated by arguments and interpersonal conflicts, occurrence in conjunction with another crime, or were related to intimate partner violence (particularly for females). A known relationship between a homicide victim and a suspected perpetrator was most likely either that of an acquaintance or friend or an intimate partner. Legal intervention death rates were highest among males and persons aged 20-24 years and 30-34 years; rates were highest among non-Hispanic black males. Precipitating factors for the majority of legal intervention deaths were another crime, a mental health problem, or a recent crisis. Deaths of undetermined intent occurred at the highest rates among males and persons aged <1 year and 45-54 years. Substance abuse and mental or physical health problems were the most common circumstances preceding deaths of undetermined intent. Unintentional firearm death rates were higher among males, non-Hispanic whites, and persons aged persons aged 15-19 and 55-64 years; these deaths were most often precipitated by a person unintentionally pulling the trigger while playing with a firearm or while hunting.
   Interpretation: This report provides a detailed summary of data from NVDRS for 2013. The results indicate that violent deaths resulting from self-inflicted or interpersonal violence disproportionately affected persons aged <65 years, males, and certain minority populations. For homicides and suicides, intimate partner problems, interpersonal conflicts, mental health problems, and recent crises were primary precipitating factors.
   Public Health Action: NVDRS data are used to monitor the occurrence of violence-related fatal injuries and assist public health authorities in the development, implementation, and evaluation of programs and policies to reduce and prevent violent deaths. For example, Utah Violent Death Reporting System (VDRS) data were used to develop policies that support children of intimate partner homicide victims, Colorado VDRS data to develop a web-based suicide prevention program targeting middle-aged men, and Rhode Island VDRS data to help guide suicide prevention efforts at workplaces. The continued development and expansion of NVDRS to include all U.S. states, territories, and the District of Columbia are essential to public health efforts to reduce the impact of violence.
C1 [Lyons, Bridget H.; Fowler, Katherine A.; Jack, Shane P. D.; Betz, Carter J.; Blair, Janet M.] CDC, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30333 USA.
RP Lyons, BH (reprint author), CDC, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30333 USA.
EM blyons@cdc.gov
NR 40
TC 1
Z9 1
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-8636
J9 MMWR SURVEILL SUMM
JI MMWR Surv. Summ.
PD AUG 19
PY 2016
VL 65
IS 10
BP 1
EP 42
PG 42
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DX3MD
UT WOS:000384276300001
PM 27537325
ER

PT J
AU Bamiselu, OF
   Ajayi, I
   Fawole, O
   Dairo, D
   Ajumobi, O
   Oladimeji, A
   Steven, Y
AF Bamiselu, Oluyomi F.
   Ajayi, IkeOluwapo
   Fawole, Olufunmilayo
   Dairo, David
   Ajumobi, Olufemi
   Oladimeji, Abisola
   Steven, Yoon
TI Adherence to malaria diagnosis and treatment guidelines among healthcare
   workers in Ogun State, Nigeria
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Malaria; National treatment guidelines; Healthcare workers' adherence;
   Nigeria
ID SOUTH-EAST NIGERIA; UNCOMPLICATED MALARIA; ARTEMETHER-LUMEFANTRINE;
   PRESCRIBING PRACTICE; COMBINATION THERAPY; FACILITIES; TESTS;
   MANAGEMENT; PRIVATE; KENYA
AB Background: Malaria case management remains a vital component of malaria control strategies. Despite the introduction of national malaria treatment guidelines and scale-up of malaria control interventions in Nigeria, anecdotal evidence shows some deviations from the guidelines in malaria case management. This study assessed factors influencing adherence to malaria diagnosis and treatment guidelines among healthcare workers in public and private sectors in Ogun State, Nigeria.
   Methods: A comparative cross-sectional study was carried out among 432 (216 public and 216 private) healthcare workers selected from nine Local Government Areas using a multistage sampling technique. A pre-tested interviewer administered questionnaire was used to collect information on availability and use of malaria Rapid Diagnostic Test (mRDT) and artemisinin combination therapy (ACT), for management of uncomplicated malaria. Adherence was defined as when choice of antimalarials for parasitological confirmed malaria cases was restricted to recommended antimalarial medicines. Association between adherence and independent variables were tested using Chi-square at 5 % level of significance.
   Results: Malaria RDT was available in 81.9 % of the public health facilities and 19.4 % of the private health facilities (p = 0.001). Its use was higher among public healthcare workers (85.2 %) compared to 32.9 % in private facilities (p = 0.000). Presumptive diagnosis of malaria was higher among private healthcare workers (94.9 %) compared to 22.7 % public facilities (p = <0.0001). The main reason for non-usage of mRDT among private healthcare workers was its perceived unreliability of mRDT (40.9 %). Monotherapy including artesunate (58.3 % vs 12.5 %), amodiaquine (38.9 % vs 8.3 %) and chloroquine (26.4 % vs 4.2 %) were significantly more available in private than public health facilities, respectively. Adherence to guidelines was significantly higher among public healthcare workers (60.6 %) compared to those in private facilities (27.3 %). Availability of antimalarial medicine was the main factor that influenced treatment prescription in both healthcare settings (p = 0.27). However, drug promotion by manufactures (45.8 %) has a major influence on private healthcare workers' prescription practice.
   Conclusion: The findings of this study demonstrate significant difference between public and private healthcare workers on adherence to national malaria diagnosis and treatment guidelines. Interventions to improve private sector engagement in implementation of the guidelines, training and supply of recommended antimalarial medicines should be intensified.
C1 [Bamiselu, Oluyomi F.; Ajayi, IkeOluwapo; Ajumobi, Olufemi; Oladimeji, Abisola] Nigeria Field Epidemiol & Lab Training Programme, Abuja, Nigeria.
   [Ajayi, IkeOluwapo; Fawole, Olufunmilayo; Dairo, David] Univ Ibadan, Fac Publ Hlth, Dept Epidemiol & Med Stat, Ibadan, Nigeria.
   [Ajumobi, Olufemi] Natl Malaria Eliminat Programme, Abuja, Nigeria.
   [Steven, Yoon] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA.
RP Bamiselu, OF (reprint author), Nigeria Field Epidemiol & Lab Training Programme, Abuja, Nigeria.
EM yomzie2003@yahoo.com
FU Center for Disease Control and Prevention (CDC) through the Nigeria
   Field Epidemiology and Laboratory Training Programme(NFELTP)
   [U2R6H000046]
FX This study was supported by cooperative agreement number U2R6H000046
   funded by the Center for Disease Control and Prevention (CDC) through
   the Nigeria Field Epidemiology and Laboratory Training
   Programme(NFELTP). Its contents are solely the responsibility of the
   author's and do not necessarily represent the official views of the CDC
   or the Department of Health and Human Services.
NR 25
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 19
PY 2016
VL 16
AR 828
DI 10.1186/s12889-016-3495-x
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT5VR
UT WOS:000381551700002
PM 27538947
ER

PT J
AU Zhou, ZY
   Mitchell, RM
   Kariuki, S
   Odero, C
   Otieno, P
   Otieno, K
   Onyona, P
   Were, V
   Wiegand, RE
   Gimnig, JE
   Walker, ED
   Desai, M
   Shi, YP
AF Zhou, Zhiyong
   Mitchell, Rebecca M.
   Kariuki, Simon
   Odero, Christopher
   Otieno, Peter
   Otieno, Kephas
   Onyona, Philip
   Were, Vincent
   Wiegand, Ryan E.
   Gimnig, John E.
   Walker, Edward D.
   Desai, Meghna
   Shi, Ya Ping
TI Assessment of submicroscopic infections and gametocyte carriage of
   Plasmodium falciparum during peak malaria transmission season in a
   community-based cross-sectional survey in western Kenya, 2012
SO MALARIA JOURNAL
LA English
DT Article
DE Plasmodium falciparum; Gametocytes; Risk factors; Antimalarials; ITNs;
   Kenya
ID SEQUENCE-BASED AMPLIFICATION; POLYMERASE-CHAIN-REACTION; TREATED BED
   NETS; ARTEMETHER-LUMEFANTRINE; MICROSATELLITE MARKERS; COMBINATION
   THERAPIES; ASYMPTOMATIC CHILDREN; MOSQUITO INFECTION; NIGERIAN CHILDREN;
   GENETIC DIVERSITY
AB Background: Although malaria control intervention has greatly decreased malaria morbidity and mortality in many African countries, further decline in parasite prevalence has stagnated in western Kenya. In order to assess if malaria transmission reservoir is associated with this stagnation, submicroscopic infection and gametocyte carriage was estimated. Risk factors and associations between malaria control interventions and gametocyte carriage were further investigated in this study.
   Methods: A total of 996 dried blood spot samples were used from two strata, all smear-positives (516 samples) and randomly selected smear-negatives (480 samples), from a community cross-sectional survey conducted at peak transmission season in 2012 in Siaya County, western Kenya. Plasmodium falciparum parasite presence and density were determined by stained blood smear and by 18S mRNA transcripts using nucleic acid sequence-based amplification assay (NASBA), gametocyte presence and density were determined by blood smear and by Pfs25 mRNA-NASBA, and gametocyte diversity by Pfg377 mRNA RT-PCR and RT-qPCR.
   Results: Of the randomly selected smear-negative samples, 69.6 % (334/480) were positive by 18S-NASBA while 18S-NASBA detected 99.6 % (514/516) smear positive samples. Overall, 80.2 % of the weighted population was parasite positive by 18S-NASBA vs 30.6 % by smear diagnosis and 44.0 % of the weighted population was gametocyte positive by Pfs25-NASBA vs 2.6 % by smear diagnosis. Children 5-15 years old were more likely to be parasitaemic and gametocytaemic by NASBA than individuals >15 years old or children <5 years old while gametocyte density decreased with age. Anaemia and self-reported fever within the past 24 h were associated with increased odds of gametocytaemia. Fever was also positively associated with parasite density, but not with gametocyte density. Antimalarial use within the past 2 weeks decreased the odds of gametocytaemia, but not the odds of parasitaemia. In contrast, recent anti-malarial use was associated with lowered parasite density, but not the gametocyte density. Use of ITNs was associated with lower odds for parasitaemia in part of the study area with a longer history of ITN interventions. In the same part of study area, the odds of having multiple gametocyte alleles were also lower in individuals using ITNs than in those not using ITNs and parasite density was positively associated with gametocyte diversity.
   Conclusion: A large proportion of submicroscopic parasites and gametocytes in western Kenya might contribute to the stagnation in malaria prevalence, suggesting that additional interventions targeting the infectious reservoir are needed. As school aged children and persons with anaemia and fever were major sources for gametocyte reservoir, these groups should be targeted for intervention and prevention to reduce malaria transmission. Anti-malarial use was associated with lower parasite density and odds of gametocytaemia, but not the gametocyte density, indicating a limitation of anti-malarial impact on the transmission reservoir. ITN use had a protective role against parasitaemia and gametocyte diversity in western Kenya.
C1 [Zhou, Zhiyong; Mitchell, Rebecca M.; Wiegand, Ryan E.; Gimnig, John E.; Desai, Meghna; Shi, Ya Ping] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Kariuki, Simon; Odero, Christopher; Otieno, Peter; Otieno, Kephas; Onyona, Philip; Were, Vincent] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
   [Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
RP Zhou, ZY; Shi, YP (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM zaz6@cdc.gov; yps0@cdc.gov
FU U.S. National Science Foundation, Ecology of Infectious Diseases grant
   [EF-0723770]; Malaria Branch, Division of Parasitic Diseases and Malaria
   (DPDM), Center for Global Health (CGH), CDC; Kenya Medical Research
   Institute
FX This study was supported partially by U.S. National Science Foundation,
   Ecology of Infectious Diseases grant# EF-0723770 and by Malaria Branch,
   Division of Parasitic Diseases and Malaria (DPDM), Center for Global
   Health (CGH), CDC with a cooperative agreement with the Kenya Medical
   Research Institute. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 81
TC 0
Z9 0
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 19
PY 2016
VL 15
AR 421
DI 10.1186/s12936-016-1482-4
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU9JD
UT WOS:000382532000001
PM 27543112
ER

PT J
AU Cope, JR
   Collier, SA
   Srinivasan, K
   Abliz, E
   Myers, A
   Millin, CJ
   Miller, A
   Tarver, ME
AF Cope, Jennifer R.
   Collier, Sarah A.
   Srinivasan, Krithika
   Abliz, Erkinay
   Myers, Ann
   Millin, Courtney J.
   Miller, Andrew
   Tarver, Michelle E.
TI 2005-2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID MICROBIAL KERATITIS; UNITED-STATES; RISK-FACTORS
C1 [Cope, Jennifer R.; Collier, Sarah A.; Srinivasan, Krithika] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Abliz, Erkinay; Myers, Ann; Millin, Courtney J.; Miller, Andrew; Tarver, Michelle E.] US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA.
RP Cope, JR (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM jcope@cdc.gov
NR 7
TC 1
Z9 2
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 19
PY 2016
VL 65
IS 32
BP 817
EP 820
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3HZ
UT WOS:000382102700002
PM 27538244
ER

PT J
AU Agaku, IT
   Odani, S
   Sturgis, S
   Harless, C
   Glover-Kudon, R
AF Agaku, Israel T.
   Odani, Satomi
   Sturgis, Stephanie
   Harless, Charles
   Glover-Kudon, Rebecca
TI Tobacco Advertising and Promotional Expenditures in Sports and Sporting
   Events - United States, 1992-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Agaku, Israel T.; Glover-Kudon, Rebecca] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Odani, Satomi; Harless, Charles] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Sturgis, Stephanie] McNeal Profess Serv, Kennesaw, GA USA.
RP Agaku, IT (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM IAgaku@cdc.gov
NR 7
TC 0
Z9 0
U1 6
U2 6
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 19
PY 2016
VL 65
IS 32
BP 821
EP 825
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3HZ
UT WOS:000382102700003
PM 27536859
ER

PT J
AU Shapiro-Mendoza, CK
   Barfield, WD
   Henderson, Z
   James, A
   Howse, JL
   Iskander, J
   Thorpe, PG
AF Shapiro-Mendoza, Carrie K.
   Barfield, Wanda D.
   Henderson, Zsakeba
   James, Arthur
   Howse, Jennifer L.
   Iskander, John
   Thorpe, Phoebe G.
TI CDC Grand Rounds: Public Health Strategies to Prevent Preterm Birth
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES; EARLY-TERM; EPIDEMIOLOGY; SERVICES; TEENS
C1 [Shapiro-Mendoza, Carrie K.; Barfield, Wanda D.; Henderson, Zsakeba] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [James, Arthur] Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA.
   [Howse, Jennifer L.] March Dimes Fdn, White Plains, NY USA.
   [Iskander, John; Thorpe, Phoebe G.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA.
RP Shapiro-Mendoza, CK (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM CShapiroMendoza@cdc.gov
NR 23
TC 1
Z9 1
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 19
PY 2016
VL 65
IS 32
BP 826
EP 830
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3HZ
UT WOS:000382102700004
PM 27536925
ER

PT J
AU Rainey, JJ
   Phelps, T
   Shi, JR
AF Rainey, Jeanette J.
   Phelps, Tiffani
   Shi, Jianrong
TI Mass Gatherings and Respiratory Disease Outbreaks in the United States -
   Should We Be Worried? Results from a Systematic Literature Review and
   Analysis of the National Outbreak Reporting System
SO PLOS ONE
LA English
DT Review
ID PANDEMIC INFLUENZA-A; SUMMER CAMP; VIRUS-INFECTION; PUBLIC-HEALTH;
   SYNDROMIC SURVEILLANCE; MUMPS OUTBREAK; COUNTY FAIR; H3N2 VIRUS;
   NEW-JERSEY; NEW-YORK
AB Background
   Because mass gatherings create environments conducive for infectious disease transmission, public health officials may recommend postponing or canceling large gatherings during a moderate or severe pandemic. Despite these recommendations, limited empirical information exists on the frequency and characteristics of mass gathering-related respiratory disease outbreaks occurring in the United States.
   Methods
   We conducted a systematic literature review to identify articles about mass gathering-related respiratory disease outbreaks occurring in the United States from 2005 to 2014. A standard form was used to abstract information from relevant articles identified from six medical, behavioral and social science literature databases. We also analyzed data from the National Outbreaks Reporting System (NORS), maintained by the Centers for Disease Control and Prevention since 2009, to estimate the frequency of mass gathering-related respiratory disease outbreaks reported to the system.
   Results
   We identified 21 published articles describing 72 mass gathering-related respiratory disease outbreaks. Of these 72, 40 (56%) were associated with agriculture fairs and Influenza A H3N2v following probable swine exposure, and 25 (35%) with youth summer camps and pandemic Influenza A H1N1. Outbreaks of measles (n = 1) and mumps (n = 2) were linked to the international importation of disease. Between 2009 and 2013, 1,114 outbreaks were reported to NORS, including 96 respiratory disease outbreaks due to Legionella. None of these legionellosis outbreaks was linked to a mass gathering according to available data.
   Conclusion
   Mass gathering-related respiratory disease outbreaks may be uncommon in the United States, but have been reported from fairs (zoonotic transmission) as well as at camps where participants have close social contact in communal housing. International importation can also be a contributing factor. NORS collects information on certain respiratory diseases and could serve as a platform to monitor mass gathering-related respiratory outbreaks in the future.
C1 [Rainey, Jeanette J.; Phelps, Tiffani; Shi, Jianrong] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
RP Rainey, JJ (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
EM jkr7@cdc.gov
NR 58
TC 0
Z9 0
U1 6
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2016
VL 11
IS 8
AR e0160378
DI 10.1371/journal.pone.0160378
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT6ES
UT WOS:000381577000020
ER

PT J
AU Bardenheier, BH
   Duderstadt, SK
   Engler, RJM
   McNeil, MM
AF Bardenheier, Barbara H.
   Duderstadt, Susan K.
   Engler, Renata J. M.
   McNeil, Michael M.
TI Adverse events following pandemic influenza A (H1N1) 2009 monovalent and
   seasonal influenza vaccinations during the 2009-2010 season in the
   active component US military and civilians aged 17-44 years reported to
   the Vaccine Adverse Event Reporting System
SO VACCINE
LA English
DT Article
DE Pandemic influenza A H1N1 (2009); influenza vaccine; Vaccine safety
ID GUILLAIN-BARRE-SYNDROME; UNITED-STATES; 2009-JANUARY 2010; ANTHRAX
   VACCINE; SURVEILLANCE; SAFETY; VAERS; CIPROFLOXACIN; LOPERAMIDE;
   COVERAGE
AB Background: No comparative review of Vaccine Adverse Event Reporting System (VAERS) submissions following pandemic influenza A (H1N1) 2009 and seasonal influenza vaccinations during the pandemic season among U.S. military personnel has been published.
   Methods: We compared military vs. civilian adverse event reporting rates. Adverse events (AEs) following vaccination were identified from VAERS for adults aged 17-44 years after pandemic (monovalent influenza [MIV], and seasonal (trivalent inactivated influenza [IIV3], live attenuated influenza [LAIV3]) vaccines. Military vaccination coverage was provided by the Department of Defense's Defense Medical Surveillance System. Civilian vaccination coverage was estimated using data from the National 2009 H1N1 Flu Survey and the Behavioral Risk Factor Surveillance System survey.
   Results: Vaccination coverage was more than four times higher for MIV and more than twenty times higher for LAIV3 in the military than in the civilian population. The reporting rate of serious AE reports following MIV in service personnel (1.19 per 100,000) was about half that reported by the civilian population (2.45 per 100,000). Conversely, the rate of serious AE reports following LAIV3 among service personnel (1.32 per 100,000) was more than twice that of the civilian population. Although fewer military AEs following MIV were reported overall, the rate of Guillain-Barre Syndrome (GBS) (4.01 per million) was four times greater than that in the civilian population. (1.04 per million).
   Conclusions: Despite higher vaccination coverage in service personnel, the rate of serious AEs following MIV was about half that in civilians. The rate of GBS reported following MIV was higher in the military. Published by Elsevier Ltd.
C1 [Bardenheier, Barbara H.; Duderstadt, Susan K.; McNeil, Michael M.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA.
   [Engler, Renata J. M.] Walter Reed Natl Mil Med Ctr Amer, Immunizat Healthcare Branch, Def Hlth Agcy Including Legacy Vaccine Healthcare, Publ Hlth Command, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.
RP McNeil, MM (reprint author), Ctr Dis Control & Prevent, MS D-26,1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM mmm2@cdc.gov
FU CDC
FX The views, findings and conclusions in this report are those of the
   authors and do not reflect the official policy or position of the
   Centers for Disease Control and Prevention, the Departments of the
   Army/Navy/Air Force, Department of Defense, nor the US Government. Use
   of trade names and commercial sources is for identification only and
   does not imply endorsement by the Centers for Disease Control and
   Prevention, the US Department of Health and Human Services, the
   Departments of the Army/Navy/Air Force, the Department of Defense, or
   the US Government. This study was supported by CDC and no external
   funding was secured.
NR 35
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 17
PY 2016
VL 34
IS 37
BP 4406
EP 4414
DI 10.1016/j.vaccine.2016.07.019
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DT5SL
UT WOS:000381542800010
PM 27449076
ER

PT J
AU Frew, PM
   Parker, K
   Vo, L
   Haley, D
   O'Leary, A
   Diallo, DD
   Golin, CE
   Kuo, I
   Soto-Torres, L
   Wang, J
   Adimora, AA
   Randall, LA
   del Rio, C
   Hodder, S
AF Frew, Paula M.
   Parker, Kimberly
   Vo, Linda
   Haley, Danielle
   O'Leary, Ann
   Diallo, Dazon Dixon
   Golin, Carol E.
   Kuo, Irene
   Soto-Torres, Lydia
   Wang, Jing
   Adimora, Adaora A.
   Randall, Laura A.
   del Rio, Carlos
   Hodder, Sally
CA HIV Prevention Trials Network 064
TI Socioecological factors influencing women's HIV risk in the United
   States: qualitative findings from the women's HIV SeroIncidence study
   (HPTN 064)
SO BMC PUBLIC HEALTH
LA English
DT Article
DE HIV/AIDS; Sexual health; Socioecological model; Women; Minorities; HIV
   risk reduction
ID SEXUALLY-TRANSMITTED INFECTIONS; INTIMATE PARTNER VIOLENCE;
   AFRICAN-AMERICAN WOMEN; PREVENTION TRIALS NETWORK; NEIGHBORHOOD
   DISADVANTAGE; DRUG-USERS; PERCEIVED DISCRIMINATION; DEPRESSIVE SYMPTOMS;
   PHYSICAL HEALTH; SUBSTANCE-ABUSE
AB Background: We sought to understand the multilevel syndemic factors that are concurrently contributing to the HIV epidemic among women living in the US. We specifically examined community, network, dyadic, and individual factors to explain HIV vulnerability within a socioecological framework.
   Methods: We gathered qualitative data (120 interviews and 31 focus groups) from a subset of women ages 18-44 years (N = 2,099) enrolled in the HPTN 064 HIV seroincidence estimation study across 10 US communities. We analyzed data from 4 diverse locations: Atlanta, New York City (the Bronx), Raleigh, and Washington, DC. Data were thematically coded using grounded theory methodology. Intercoder reliability was assessed to evaluate consistency of team-based coding practices.
   Results: The following themes were identified at 4 levels including 1) exosystem (community): poverty prevalence, discrimination, gender imbalances, community violence, and housing challenges; 2) mesosystem (network): organizational social support and sexual concurrency; 3) microsystem (dyadic): sex exchange, interpersonal social support, intimate partner violence; and 4) individual: HIV/STI awareness, risk taking, and substance use. A strong theme emerged with over 80 % of responses linked to the fundamental role of financial insecurity underlying risktaking behavioral pathways.
   Conclusions: Multilevel syndemic factors contribute to women's vulnerability to HIV in the US. Financial insecurity is a predominant theme, suggesting the need for tailored programming for women to reduce HIV risk.
C1 [Frew, Paula M.; Vo, Linda; Randall, Laura A.; del Rio, Carlos] Emory Univ, Div Infect Dis, Dept Med, Sch Med, 1760 Haygood Rd,Suite 300, Atlanta, GA 30322 USA.
   [Frew, Paula M.; Haley, Danielle] Emory Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
   [Frew, Paula M.; del Rio, Carlos] Emory Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE, Atlanta, GA 30329 USA.
   [Frew, Paula M.; del Rio, Carlos] Emory Univ, Emory Ctr AIDS Res, 1518 Clifton Rd NE,Suite 8050, Atlanta, GA 30322 USA.
   [Parker, Kimberly] Texas Womans Univ, Dept Hlth Studies, CFO Bldg 1007,POB 425499, Denton, TX 76204 USA.
   [O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Diallo, Dazon Dixon] SisterLove Inc, 3709 Bakers Ferry Rd SW, Atlanta, GA 30331 USA.
   [Golin, Carol E.; Adimora, Adaora A.] Univ N Carolina, Sch Med, Dept Med, 130 Mason Farm Rd, Chapel Hill, NC 27599 USA.
   [Kuo, Irene] George Washington Univ, Milken Inst, Sch Publ Hlth, 950 New Hampshire Ave NW,Suite 500, Washington, DC 20052 USA.
   [Soto-Torres, Lydia] NIAID, Washington, DC USA.
   [Wang, Jing] Fred Hutchinson Canc Res Ctr, SCHARP, 1124 Columbia St, Seattle, WA 98104 USA.
   [Hodder, Sally] West Virginia Univ, Sch Med, One Med Ctr Dr,HSC South 2244, Morgantown, WV 26506 USA.
RP Frew, PM (reprint author), Emory Univ, Div Infect Dis, Dept Med, Sch Med, 1760 Haygood Rd,Suite 300, Atlanta, GA 30322 USA.; Frew, PM (reprint author), Emory Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.; Frew, PM (reprint author), Emory Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE, Atlanta, GA 30329 USA.; Frew, PM (reprint author), Emory Univ, Emory Ctr AIDS Res, 1518 Clifton Rd NE,Suite 8050, Atlanta, GA 30322 USA.
EM pfrew@emory.edu
RI del Rio, Carlos/B-3763-2012; 
OI del Rio, Carlos/0000-0002-0153-3517; Frew, Paula/0000-0002-3078-9124
FU National Institute of Allergy and Infectious Diseases, National
   Institute on Drug Abuse, and National Institute of Mental Health [UM1
   AI068619, U01-AI068613, UM1-AI068613]; Centers for Innovative Research
   to Control AIDS, Mailman School of Public Health, Columbia University
   [5U1Al069466]; University of North Carolina Clinical Trials Unit
   [AI069423]; University of North Carolina Clinical Trials Research Center
   of the Clinical and Translational Science Award [RR 025747]; University
   of North Carolina Center for AIDS Research [AI050410]; Emory University
   HIV/AIDS Clinical Trials Unit [5UO1AI069418]; Center for AIDS Research
   [P30 AI050409]; Clinical and Translational Science Award [UL1 RR025008];
   Terry Beirn Community Programs for Clinical Research on AIDS Clinical
   Trials Unit [5 UM1 AI069503-07]; Johns Hopkins Adult AIDS Clinical Trial
   Unit [AI069465]; Johns Hopkins Clinical and Translational Science Award
   [UL1 RR 25005]
FX Grant support provided by the National Institute of Allergy and
   Infectious Diseases, National Institute on Drug Abuse, and National
   Institute of Mental Health [UM1 AI068619, U01-AI068613, and
   UM1-AI068613]; Centers for Innovative Research to Control AIDS, Mailman
   School of Public Health, Columbia University [5U1Al069466]; University
   of North Carolina Clinical Trials Unit [AI069423]; University of North
   Carolina Clinical Trials Research Center of the Clinical and
   Translational Science Award [RR 025747]; University of North Carolina
   Center for AIDS Research [AI050410]; Emory University HIV/AIDS Clinical
   Trials Unit [5UO1AI069418], Center for AIDS Research [P30 AI050409], and
   Clinical and Translational Science Award [UL1 RR025008]; The Terry Beirn
   Community Programs for Clinical Research on AIDS Clinical Trials Unit [5
   UM1 AI069503-07], and; The Johns Hopkins Adult AIDS Clinical Trial Unit
   [AI069465] and The Johns Hopkins Clinical and Translational Science
   Award [UL1 RR 25005].
NR 95
TC 1
Z9 1
U1 8
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 17
PY 2016
VL 16
AR 803
DI 10.1186/s12889-016-3364-7
PG 18
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT5UV
UT WOS:000381549400004
PM 27530401
ER

PT J
AU Percy, Z
   Xu, YY
   Sucharew, H
   Khoury, JC
   Calafat, AM
   Braun, JM
   Lanphear, BP
   Chen, AM
   Yolton, K
AF Percy, Zana
   Xu, Yingying
   Sucharew, Heidi
   Khoury, Jane C.
   Calafat, Antonia M.
   Braun, Joseph M.
   Lanphear, Bruce P.
   Chen, Aimin
   Yolton, Kimberly
TI Gestational exposure to phthalates and gender-related play behaviors in
   8-year-old children: an observational study
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Phthalates; Children; Play; Gender
ID IN-UTERO EXPOSURE; LACTATIONAL EXPOSURE; TESTOSTERONE PRODUCTION;
   DIETHYLHEXYL PHTHALATE; DOSE-RESPONSE; MALE-RAT; SEX; METABOLITES;
   DISRUPTION; HUMANS
AB Background: Phthalates, used in a variety of consumer products, are a group of chemicals that are ubiquitous in the environment, and their metabolites are detectable in most humans. Some phthalates have anti-androgenic properties; a prior study reported an association between gestational exposure to phthalates and reduced masculine behaviors in preschool boys.
   Methods: Concentrations of 9 phthalate metabolites were measured in urine collected at 16 and 26 weeks' gestation from pregnant women enrolled in the HOME Study, a prospective pregnancy and birth cohort. Measures of gender-related play were collected at 8 years of age, including the Gender Identity Questionnaire ( GIQ) completed by mothers, and the Playmate and Play Style Preferences Structured Interview ( PPPSI) completed by children. We examined these measures as continuous variables using both bivariate and multivariable approaches with adjustment for covariates. Additional analyses included logistic regression of GIQ and PPPSI scores dichotomized by sex at the lower 25th percentile, indicating the least typical behavior.
   Results: Mothers' phthalate metabolite concentrations during pregnancy were similar to the reported national average among US women. All children scored within a typical range on both measures of gender-related play behavior. No statistically significant associations were found between averaged maternal phthalate metabolite concentrations and continuous PPPSI scores or any GIQ scores. For the dichotomized PPPSI; higher maternal monoethyl phthalate ( MEP) concentrations were associated with more typical play behaviors for females ( OR = 0.70, CI = 0.51-0.97). In contrast, higher maternal mono-isobutyl phthalate ( MiBP) concentrations were associated with higher odds of membership in the least typical play behaviors group for males ( OR = 1.69, CI = 1.00-2.86).
   Conclusions: In this sample of typically developing children, higher maternal urinary MEP concentrations during pregnancy were associated with more typical gender-related play behaviors in both males and females, and increased urinary MiBP concentrations were associated with less masculine gender-related play behaviors in males.
C1 [Percy, Zana; Xu, Yingying; Sucharew, Heidi; Khoury, Jane C.; Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Calafat, Antonia M.] Ctr Dis Control & Prevent, 4770 Buford Hwy,MS F-17, Atlanta, GA 30341 USA.
   [Braun, Joseph M.] Brown Univ, 69 Brown St, Providence, RI 02912 USA.
   [Lanphear, Bruce P.] Simon Fraser Univ, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
   [Chen, Aimin] Univ Cincinnati, Coll Med, Dept Environm Hlth, 160 Panzeca Way, Cincinnati, OH 45267 USA.
RP Yolton, K (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM Kimberly.Yolton@cchmc.org
RI Braun, Joseph/H-8649-2014
FU National Institute of Environmental Health Sciences and Environmental
   Protection Agency [P01 ES11261, R01 ES020349]
FX This work was partially supported by grants from the National Institute
   of Environmental Health Sciences and Environmental Protection Agency
   (P01 ES11261, R01 ES020349). The study sponsors made no contributions to
   study design, data collection, analysis, interpretation, authorship, or
   decisions to submit for publication.
NR 48
TC 0
Z9 0
U1 5
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD AUG 16
PY 2016
VL 15
AR 87
DI 10.1186/s12940-016-0171-7
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DT6BT
UT WOS:000381568600001
PM 27527835
ER

PT J
AU Joseph, DA
   Meester, RGS
   Zauber, AG
   Manninen, DL
   Winges, L
   Dong, FB
   Peaker, B
   van Ballegooijen, M
AF Joseph, Djenaba A.
   Meester, Reinier G. S.
   Zauber, Ann G.
   Manninen, Diane L.
   Winges, Linda
   Dong, Fred B.
   Peaker, Brandy
   van Ballegooijen, Marjolein
TI Colorectal Cancer Screening: Estimated Future Colonoscopy Need and
   Current Volume and Capacity
SO CANCER
LA English
DT Article
DE capacity; colonoscopy; colorectal cancer screening
ID SOCIETY TASK-FORCE; UNITED-STATES; DEMONSTRATION PROGRAM; MEDICARE
   POPULATION; CONSENSUS UPDATE; NATIONAL-SURVEY; SURVEILLANCE;
   POLYPECTOMY; PREVALENCE; RISK
AB BACKGROUND: In 2014, a national campaign was launched to increase colorectal cancer (CRC) screening rates in the United States to 80% by 2018; it is unknown whether there is sufficient colonoscopy capacity to reach this goal. This study estimated the number of colonoscopies needed to screen 80% of the eligible population with fecal immunochemical testing (FIT) or colonoscopy and determined whether there was sufficient colonoscopy capacity to meet the need. METHODS: The Microsimulation Screening Analysis-Colon model was used to simulate CRC screening test use in the United States (2014-2040); the implementation of a national screening program in 2014 with FIT or colonoscopy with 80% participation was assumed. The 2012 Survey of Endoscopic Capacity (SECAP) estimated the number of colonoscopies that were performed and the number that could be performed. RESULTS: If a national screening program started in 2014, by 2024, approximately 47 million FIT procedures and 5.1 million colonoscopies would be needed annually to screen the eligible population with a program using FIT as the primary screening test; approximately 11 to 13 million colonoscopies would be needed annually to screen the eligible population with a colonoscopy-only screening program. According to the SECAP survey, an estimated 15 million colonoscopies were performed in 2012, and an additional 10.5 million colonoscopies could be performed. CONCLUSIONS: The estimated colonoscopy capacity is sufficient to screen 80% of the eligible US population with FIT, colonoscopy, or a mix of tests. Future analyses should take into account the geographic distribution of colonoscopy capacity. (C) 2016 American Cancer Society.
C1 [Joseph, Djenaba A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F76, Atlanta, GA 30341 USA.
   [Meester, Reinier G. S.; van Ballegooijen, Marjolein] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
   [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Manninen, Diane L.; Winges, Linda; Dong, Fred B.] Battelle Mem Inst, Hlth & Analyt, Seattle, WA USA.
   [Peaker, Brandy] Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA.
RP Joseph, DA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F76, Atlanta, GA 30341 USA.
EM dajoseph@cdc.gov
FU Centers for Disease Control and Prevention; US National Cancer Institute
FX This research was supported by the Centers for Disease Control and
   Prevention. The funding source had a role in the design, conduct, and
   reporting of the study. This study was approved by the Institutional
   Review Board for the Protection of Human Subjects (Centers for Disease
   Control and Prevention) and the US Office of Management and Budget under
   the Paperwork Reduction Act. Microsimulation Screening Analysis-Colon is
   part of the Cancer Intervention and Surveillance Modeling Network
   (http://cisnet.cancer.gov), which is sponsored by the US National Cancer
   Institute.
NR 38
TC 1
Z9 1
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD AUG 15
PY 2016
VL 122
IS 16
BP 2479
EP 2486
DI 10.1002/cncr.30070
PG 8
WC Oncology
SC Oncology
GA DW4MG
UT WOS:000383616600007
PM 27200481
ER

PT J
AU DeBord, DG
   Carreon, T
   Lentz, TJ
   Middendorf, PJ
   Hoover, MD
   Schulte, PA
AF DeBord, D. Gayle
   Carreon, Tania
   Lentz, Thomas J.
   Middendorf, Paul J.
   Hoover, Mark D.
   Schulte, Paul A.
TI Use of the "Exposome" in the Practice of Epidemiology: A Primer on -Omic
   Technologies
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE biomarkers; environmental exposures; epidemiologic methods; occupational
   exposures
ID SYSTEMATIC EVALUATION; EXPOSURE SCIENCE; RISK-ASSESSMENT; PUBLIC-HEALTH;
   ENVIRONMENT; BIOMARKERS; DISEASE; GENOME; CANCER; PHOSPHATIDYLCHOLINE
AB The exposome has been defined as the totality of exposures individuals experience over the course of their lives and how those exposures affect health. Three domains of the exposome have been identified: internal, specific external, and general external. Internal factors are those that are unique to the individual, and specific external factors include occupational exposures and lifestyle factors. The general external domain includes sociodemographic factors such as educational level and financial status. Eliciting information on the exposome is daunting and not feasible at present; the undertaking may never be fully realized. A variety of tools have been identified to measure the exposome. Biomarker measurements will be one of the major tools in exposomic studies. However, exposure data can also be obtained from other sources such as sensors, geographic information systems, and conventional tools such as survey instruments. Proof-of-concept studies are being conducted that show the promise of exposomic investigation and the integration of different kinds of data. The inherent value of exposomic data in epidemiologic studies is that they can provide greater understanding of the relationships among a broad range of chemical and other risk factors and health conditions and ultimately lead to more effective and efficient disease prevention and control.
C1 [DeBord, D. Gayle] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA.
   [Carreon, Tania] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
   [Lentz, Thomas J.; Middendorf, Paul J.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA.
   [Middendorf, Paul J.] NIOSH, Sci Off, Atlanta, GA USA.
   [Hoover, Mark D.] NIOSH, Resp Hlth Div, Morgantown, WV USA.
RP DeBord, DG (reprint author), NIOSH, Robert A Taft Labs, Mailstop R2,1090 Tusculum Ave, Cincinnati, OH 45226 USA.
EM ded4@cdc.gov
FU National Institute for Occupational Safety and Health
FX This research was supported by the National Institute for Occupational
   Safety and Health.
NR 68
TC 2
Z9 2
U1 5
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD AUG 15
PY 2016
VL 184
IS 4
BP 302
EP 314
DI 10.1093/aje/kwv325
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW5JP
UT WOS:000383680700005
PM 27519539
ER

PT J
AU Oboho, IK
   Reed, C
   Gargiullo, P
   Leon, M
   Aragon, D
   Meek, J
   Anderson, EJ
   Ryan, P
   Lynfield, R
   Morin, C
   Bargsten, M
   Zansky, SM
   Fowler, B
   Thomas, A
   Lindegren, ML
   Schaffner, W
   Risk, I
   Finelli, L
   Chaves, SS
AF Oboho, Ikwo K.
   Reed, Carrie
   Gargiullo, Paul
   Leon, Michelle
   Aragon, Deborah
   Meek, James
   Anderson, Evan J.
   Ryan, Patricia
   Lynfield, Ruth
   Morin, Craig
   Bargsten, Marisa
   Zansky, Shelley M.
   Fowler, Brian
   Thomas, Ann
   Lindegren, Mary Lou
   Schaffner, William
   Risk, Ilene
   Finelli, Lyn
   Chaves, Sandra S.
TI Benefit of Early Initiation of Influenza Antiviral Treatment to Pregnant
   Women Hospitalized With Laboratory-Confirmed Influenza
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE influenza; pregnancy; influenza antiviral treatment; length of stay;
   early antiviral treatment
ID IMMUNIZATION PRACTICES ACIP; H1N1 VIRUS-INFECTION; UNITED-STATES;
   ADVISORY-COMMITTEE; OSELTAMIVIR TREATMENT; RESPIRATORY ILLNESS; ILL
   PATIENTS; SEASON; VACCINATION; INFANTS
AB Background. We describe the impact of early initiation of influenza antiviral treatment among pregnant women hospitalized with laboratory-confirmed influenza during the 2010-2014 influenza seasons.
   Methods. Severe influenza was defined as illness with >= 1 of the following: intensive care unit admission, need for mechanical ventilation, respiratory failure, pulmonary embolism, sepsis, or death. Within severity stratum, we used parametric survival analysis to compare length of stay by timing of antiviral treatment, adjusting for underlying conditions, influenza vaccination, and pregnancy trimester.
   Results. Among 865 pregnant women, the median age was 27 years (interquartile range [IQR], 23-31 years). Most (68%) were healthy, and 85% received antiviral treatment. Sixty-three women (7%) had severe influenza, and 4 died. Severity was associated with preterm delivery and fetal loss. Women with severe influenza were less likely to be vaccinated than those without severe influenza (14% vs 26%; P = .03). Among women treated with antivirals <= 2 days versus those treated >2 days from illness onset, the median length of stay was 2.2 days (interquartile range [IQR], 0.9-5.8 days; n = 8) versus 7.8 days (IQR, 3.0-20.6 days; n = 7), respectively, for severe influenza (P = .03) and 2.4 days (IQR, 2.3-2.5 days; n = 153) versus 3.1 days (IQR, 2.8-3.5 days; n = 62), respectively, for nonsevere influenza (P < .01).
   Conclusions. Earlyinitiation of influenza antiviral treatment to pregnant women hospitalized with influenza may reduce the length of stay, especially among those with severe influenza. Influenza during pregnancy is associated with maternal and infant morbidity, and annual influenza vaccination is warranted.
C1 [Oboho, Ikwo K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Oboho, Ikwo K.; Reed, Carrie; Gargiullo, Paul; Leon, Michelle; Finelli, Lyn; Chaves, Sandra S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
   [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
   [Meek, James] Yale Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA.
   [Anderson, Evan J.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   [Anderson, Evan J.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
   [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
   [Lynfield, Ruth; Morin, Craig] Minnesota Dept Hlth, St Paul, MN USA.
   [Bargsten, Marisa] New Mexico Dept Hlth, Santa Fe, NM USA.
   [Zansky, Shelley M.] New York State Dept Hlth, Albany, NY USA.
   [Fowler, Brian] Ohio Dept Hlth, Columbus, OH 43266 USA.
   [Thomas, Ann] Oregon Publ Hlth Div, Emerging Infect Program, Portland, OR USA.
   [Lindegren, Mary Lou; Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Risk, Ilene] Salt Lake Cty Hlth Dept, Salt Lake City, UT USA.
   [Oboho, Ikwo K.] Ctr Dis Control & Prevent, Div Global HIVTB, Atlanta, GA 30333 USA.
   [Finelli, Lyn] Merck, West Point, PA USA.
RP Oboho, IK (reprint author), Ctr Dis Control & Prevent, Div Global HIVTB, Atlanta, GA 30333 USA.; Oboho, IK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE,Mailstop E-4, Atlanta, GA 30333 USA.
EM ioboho@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
   Prevention.
NR 36
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 15
PY 2016
VL 214
IS 4
BP 507
EP 515
DI 10.1093/infdis/jiw033
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DY1JB
UT WOS:000384849600002
PM 26908745
ER

PT J
AU Blagrove, MSC
   Sherlock, K
   Chapman, GE
   Impoinvil, DE
   McCall, PJ
   Medlock, JM
   Lycett, G
   Solomon, T
   Baylis, M
AF Blagrove, Marcus S. C.
   Sherlock, Ken
   Chapman, Gail E.
   Impoinvil, Daniel E.
   McCall, Philip J.
   Medlock, Jolyon M.
   Lycett, Gareth
   Solomon, Tom
   Baylis, Matthew
TI Evaluation of the vector competence of a native UK mosquito Ochlerotatus
   detritus (Aedes detritus) for dengue, chikungunya and West Nile viruses
SO PARASITES & VECTORS
LA English
DT Article
DE DENV; WNV; CHIKV; Arbovirus; Aedes; Ochlerotatus; Mosquito; Vector
   competence
ID EQUINE ENCEPHALOMYELITIS VIRUS; SINDBIS-VIRUS; USUTU-VIRUS; RT-PCR;
   INFECTION; TRANSMISSION; DISEASE; AUTHORITIES; MANAGEMENT; AEGYPTI
AB Background: To date there has been no evidence of mosquito-borne virus transmission of public health concern in the UK, despite the occurrence of more than 30 species of mosquito, including putative vectors of arboviruses. The saltmarsh mosquito Ochlerotatus detritus [syn. Aedes (Ochlerotatus) detritus] is locally common in parts of the UK where it can be a voracious feeder on people.
   Methods: Here, we assess the competence of O. detritus for three major arboviruses: dengue virus (DENV), chikungunya virus (CHIKV) and West Nile virus (WNV) using adult mosquitoes reared from wild, field-obtained immatures.
   Results: We demonstrate laboratory competence for WNV at 21 degrees C, with viral RNA detected in the mosquito's saliva 17 days after oral inoculation. By contrast, there was no evidence of laboratory competence of O. detritus for either DENV or CHIKV.
   Conclusions: To our knowledge, this is the first study to demonstrate competence of a UK mosquito for WNV and confirms that O. detritus may present a potential risk for arbovirus transmission in the UK and that further investigation of its vector role in the wild is required.
C1 [Blagrove, Marcus S. C.; Sherlock, Ken; Chapman, Gail E.; Solomon, Tom; Baylis, Matthew] Univ Liverpool, Inst Infect & Global Hlth, Dept Epidemiol & Populat Hlth, Liverpool, Merseyside, England.
   [Blagrove, Marcus S. C.; Medlock, Jolyon M.; Solomon, Tom; Baylis, Matthew] Univ Liverpool, Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
   [Impoinvil, Daniel E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [McCall, Philip J.; Lycett, Gareth] Univ Liverpool Liverpool Sch Trop Med, Vector Biol Dept, Liverpool, Merseyside, England.
   [Medlock, Jolyon M.] Publ Hlth England, Med Entomol Grp, Emergency Response Dept, Salisbury, Wilts, England.
RP Blagrove, MSC (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Dept Epidemiol & Populat Hlth, Liverpool, Merseyside, England.; Blagrove, MSC (reprint author), Univ Liverpool, Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
EM marcus.blagrove@liverpool.ac.uk
FU Biotechnology and Biological Sciences Research Council; National
   Institute of Health Research Health Protection Research Unit in Emerging
   and Zoonotic Infections; National Institute for Health Research Health
   Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections
   at the University of Liverpool; Public Health England (PHE); Liverpool
   School of Tropical Medicine (LSTM)
FX This work was funded by a Biotechnology and Biological Sciences Research
   Council grant entitled 'Vector competence of British mosquitoes to
   flaviviruses' awarded to Baylis, and a National Institute of Health
   Research Health Protection Research Unit in Emerging and Zoonotic
   Infections, vector theme, led by Baylis. The research was funded by the
   National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in Emerging and Zoonotic Infections at the University of
   Liverpool in partnership with Public Health England (PHE) and Liverpool
   School of Tropical Medicine (LSTM). The views expressed are those of the
   author(s) and not necessarily those of the NHS, the NIHR, the Department
   of Health or Public Health England.
NR 31
TC 1
Z9 1
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD AUG 15
PY 2016
VL 9
AR 452
DI 10.1186/s13071-016-1739-3
PG 6
WC Parasitology
SC Parasitology
GA DW7NK
UT WOS:000383837600001
PM 27527700
ER

PT J
AU Pollack, LA
   van Santen, PL
   Weiner, LM
   Dudeck, MA
   Edwards, JR
   Srinivasan, A
AF Pollack, Lori A.
   van Santen, Katharina L.
   Weiner, Lindsey M.
   Dudeck, Margaret A.
   Edwards, Jonathan R.
   Srinivasan, Arjun
TI Antibiotic Stewardship Programs in US Acute Care Hospitals: Findings
   From the 2014 National Healthcare Safety Network Annual Hospital Survey
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE anti-bacterial agents (therapeutic use); Health Care Surveys; Hospitals;
   Centers for Disease Control and Prevention (US); United States
ID ANTIMICROBIAL STEWARDSHIP; UNITED-STATES; DRUG-USE; IMPACT;
   METAANALYSIS; FACILITIES
AB Background. The National Action Plan to Combat Antibiotic Resistant Bacteria calls for all US hospitals to improve antibiotic prescribing as a key prevention strategy for resistance and Clostridium difficile. Antibiotic stewardship programs (ASPs) will be important in this effort but implementation is not well understood.
   Methods. We analyzed the 2014 National Healthcare Safety Network Annual Hospital Survey to describe ASPs in US acute care hospitals as defined by the Center for Disease Control and Prevention's (CDC) Core Elements for Hospital ASPs. Univariate analyses were used to assess stewardship infrastructure and practices by facility characteristics and a multivariate model determined factors associated with meeting all ASP core elements.
   Results. Among 4184 US hospitals, 39% reported having an ASP that met all 7 core elements. Although hospitals with greater than 200 beds (59%) were more likely to have ASPs, 1 in 4 (25%) of hospitals with less than 50 beds reported achieving all 7 CDC-defined core elements of a comprehensive ASP. The percent of hospitals in each state that reported all seven elements ranged from 7% to 58%. In the multivariate model, written support (adjusted relative risk [RR] 7.2 [95% confidence interval [CI], 6.2-8.4]; P < .0001) or salary support (adjusted RR 1.5 [95% CI, 1.4-1.6]; P < .0001) were significantly associated with having a comprehensive ASP.
   Conclusions. Our findings show that ASP implementation varies across the United States and provide a baseline to monitor progress toward national goals. Comprehensive ASPs can be established in facilities of any size and hospital leadership support for antibiotic stewardship appears to drive the establishment of ASPs.
C1 [Pollack, Lori A.; van Santen, Katharina L.; Weiner, Lindsey M.; Dudeck, Margaret A.; Edwards, Jonathan R.; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Pollack, LA (reprint author), MPH 4770 Buford Hwy,F-76, Atlanta, GA 30333 USA.
EM lpollack@cdc.gov
NR 36
TC 7
Z9 7
U1 3
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP 443
EP 449
DI 10.1093/cid/ciw323
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400003
PM 27199462
ER

PT J
AU McElroy, AK
   Harmon, JR
   Flietstra, TD
   Campbell, S
   Mehta, AK
   Kraft, CS
   Lyon, MG
   Varkey, JB
   Ribner, BS
   Kratochvil, CJ
   Iwen, PC
   Smith, PW
   Ahmed, R
   Nichol, ST
   Spiropoulou, CF
AF McElroy, Anita K.
   Harmon, Jessica R.
   Flietstra, Timothy D.
   Campbell, Shelley
   Mehta, Aneesh K.
   Kraft, Colleen S.
   Lyon, Marshall G.
   Varkey, Jay B.
   Ribner, Bruce S.
   Kratochvil, Christopher J.
   Iwen, Peter C.
   Smith, Philip W.
   Ahmed, Rafi
   Nichol, Stuart T.
   Spiropoulou, Christina F.
TI Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola
   Virus Disease
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Ebola; biomarkers; cytokines; immunity; EVD
ID HEMORRHAGIC-FEVER; UNITED-STATES; SIERRA-LEONE; CONVALESCENT PLASMA;
   INFECTED PATIENTS; RESPONSES; OUTBREAK; SUDAN; ACTIVATION; MANAGEMENT
AB Background. Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease.
   Methods. In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention.
   Results. Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease.
   Conclusions. Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.
C1 [McElroy, Anita K.; Harmon, Jessica R.; Flietstra, Timothy D.; Campbell, Shelley; Nichol, Stuart T.; Spiropoulou, Christina F.] US Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA.
   [McElroy, Anita K.; Harmon, Jessica R.] Emory Univ, Sch Med, Div Pediat Infect Dis, Atlanta, GA USA.
   [Mehta, Aneesh K.; Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.
   [Mehta, Aneesh K.; Kraft, Colleen S.; Lyon, Marshall G.; Varkey, Jay B.; Ribner, Bruce S.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA.
   [Kraft, Colleen S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Kratochvil, Christopher J.] Univ Nebraska Med Ctr, Off Vice Chancellor Res, Omaha, NE USA.
   [Iwen, Peter C.] Univ Nebraska Med Ctr, Coll Med, Dept Pathol & Microbiol, Omaha, NE USA.
   [Smith, Philip W.] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Div Infect Dis, Omaha, NE USA.
RP Spiropoulou, CF (reprint author), 1600 Clifton Rd,MS G14, Atlanta, GA 30333 USA.
EM ccs8@cdc.gov
FU CDC; National Institutes of Health Atlanta Pediatric Scholars program
   [K12HD072245]; Defense Advanced Research Projects Agency
   [W31P4Q-14-1-0010]; Burroughs Wellcome Fund [1013362.01]
FX This work was supported by the CDC, the National Institutes of Health
   Atlanta Pediatric Scholars program (K12HD072245 to A. K. M.), the
   Defense Advanced Research Projects Agency (W31P4Q-14-1-0010 to R. A.),
   and the Burroughs Wellcome Fund (1013362.01 to A. K. M.).
NR 34
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP 460
EP 467
DI 10.1093/cid/ciw334
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400006
PM 27353663
ER

PT J
AU Nelson, GE
   Pondo, T
   Toews, KA
   Farley, MM
   Lindegren, ML
   Lynfield, R
   Aragon, D
   Zansky, SM
   Watt, JP
   Cieslak, PR
   Angeles, K
   Harrison, LH
   Petit, S
   Beall, B
   Van Beneden, CA
AF Nelson, George E.
   Pondo, Tracy
   Toews, Karrie-Ann
   Farley, Monica M.
   Lindegren, Mary Lou
   Lynfield, Ruth
   Aragon, Deborah
   Zansky, Shelley M.
   Watt, James P.
   Cieslak, Paul R.
   Angeles, Kathy
   Harrison, Lee H.
   Petit, Susan
   Beall, Bernard
   Van Beneden, Chris A.
TI Epidemiology of Invasive Group A Streptococcal Infections in the United
   States, 2005-2012
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE group A Streptococcus; epidemiology; surveillance; vaccine;
   streptococcal toxic shock syndrome
ID TERM-CARE FACILITIES; VACCINE DEVELOPMENT; DISEASE; SURVEILLANCE;
   IMMUNOGENICITY; CONTACTS; ADULTS; RISK
AB Background. Invasive group A Streptococcus (GAS) infections are associated with significant morbidity and mortality rates. We report the epidemiology and trends of invasive GAS over 8 years of surveillance.
   Methods. From January 2005 through December 2012, we collected data from the Centers for Disease Control and Prevention's Active Bacterial Core surveillance, a population-based network of 10 geographically diverse US sites (2012 population, 32.8 million). We defined invasive GAS as isolation of GAS from a normally sterile site or from a wound in a patient with necrotizing fasciitis (NF) or streptococcal toxic shock syndrome (STSS). Available isolates were emm typed. We calculated rates and made age-and race-adjusted national projections using census data.
   Results. We identified 9557 cases (3.8 cases per 100 000 persons per year) with 1116 deaths (case-fatality rate, 11.7%). The case-fatality rates for septic shock, STSS, and NF were 45%, 38%, and 29%, respectively. The annual incidence was highest among persons aged >= 65 years (9.4/100 000) or <1 year (5.3) and among blacks (4.7/100 000). National rates remained steady over 8 years of surveillance. Factors independently associated with death included increasing age, residence in a nursing home, recent surgery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, emm type 1 or 3, and underlying chronic illness or immunosuppression. An estimated 10 649-13 434 cases of invasive GAS infections occur in the United States annually, resulting in 1136-1607 deaths. In a 30-valent M-protein vaccine, emm types accounted for 91% of isolates.
   Conclusions. The burden of invasive GAS infection in the United States remains substantial. Vaccines under development could have a considerable public health impact.
C1 [Nelson, George E.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.
   [Nelson, George E.; Pondo, Tracy; Toews, Karrie-Ann; Beall, Bernard; Van Beneden, Chris A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Farley, Monica M.] VA Med Ctr, Atlanta, GA USA.
   [Nelson, George E.; Lindegren, Mary Lou] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA.
   [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
   [Zansky, Shelley M.] New York State Dept Hlth, Albany, NY 12237 USA.
   [Watt, James P.] Calif Dept Publ Hlth, Richmond, CA USA.
   [Cieslak, Paul R.] Oregon Hlth Author, Portland, OR USA.
   [Angeles, Kathy] Univ New Mexico, New Mexico Emerging Infect Program, Las Cruces, NM USA.
   [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA.
RP Nelson, GE (reprint author), 1161 21st Ave S,A-2200 Med Ctr North, Nashville, TN 37232 USA.
EM george.nelson@vanderbilt.edu
FU CDC's Emerging Infections Programs
FX Financial support for ABCs is provided by the CDC's Emerging Infections
   Programs.
NR 42
TC 6
Z9 6
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP 478
EP 486
DI 10.1093/cid/ciw248
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400009
PM 27105747
ER

PT J
AU Olsen, SJ
   Mirza, SA
   Vonglokham, P
   Khanthamaly, V
   Chitry, B
   Pholsena, V
   Chitranonh, V
   Omer, SB
   Moen, A
   Bresee, JS
   Corwin, A
   Xeuatvongsa, A
AF Olsen, Sonja J.
   Mirza, Sara A.
   Vonglokham, Phouvanh
   Khanthamaly, Viengphone
   Chitry, Bounlap
   Pholsena, Vathsana
   Chitranonh, Visith
   Omer, Saad B.
   Moen, Ann
   Bresee, Joseph S.
   Corwin, Andrew
   Xeuatvongsa, Anonh
TI The Effect of Influenza Vaccination on Birth Outcomes in a Cohort of
   Pregnant Women in Lao PDR, 2014-2015
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE influenza vaccine; pregnant woman; preterm birth; small for gestational
   age; Laos
ID FOR-GESTATIONAL-AGE; PRETERM BIRTH; PANDEMIC INFLUENZA; NEONATAL
   OUTCOMES; INCOME COUNTRIES; IMMUNIZATION; INFECTION; INFLAMMATION;
   STRATEGIES; INFANTS
AB Background. Some studies suggest that maternal influenza vaccination can improve birth outcomes. However, there are limited data from tropical settings, particularly Southeast Asia. We conducted an observational study in Laos to assess the effect of influenza vaccination in pregnant women on birth outcomes.
   Methods. We consented and enrolled a cohort of pregnant woman who delivered babies at 3 hospitals during April 2014-February 2015. We collected demographic and clinical information on mother and child. Influenza vaccination status was ascertained by vaccine card. Primary outcomes were the proportion of live births born small for gestational age (SGA) or preterm and mean birth weight. Multivariate models controlled for differences between vaccinated and unvaccinated women and influenza virus circulation.
   Results. We enrolled 5103 women (2172 [43%] were vaccinated). Among the 4854 who had a live birth, vaccinated women were statistically significantly less likely than unvaccinated women to have an infant born preterm during the period of high influenza virus circulation (risk ratio [RR] = 0.56, 95% confidence interval [CI], .45-.70), and the effect remained after adjusting for covariates (adjusted RR, 0.69; 95% CI, .55-.87). There was no effect of vaccine on SGA or mean birth weight. The population-prevented fraction was 18.0%.
   Conclusions. In this observational study, we found indirect evidence of influenza vaccine safety during pregnancy, and women who received vaccine had a reduced risk of delivering a preterm infant during times of high influenza virus circulation. Vaccination may prevent 1 in 5 preterm births that occur during periods of high influenza circulation.
C1 [Olsen, Sonja J.; Mirza, Sara A.; Moen, Ann; Bresee, Joseph S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [Vonglokham, Phouvanh; Xeuatvongsa, Anonh] Amer Embassy, Minist Hlth, US CDC Lao Peoples Democrat Republ, Viangchan, Laos.
   [Khanthamaly, Viengphone; Corwin, Andrew] Amer Embassy, Influenza Program, US CDC Lao Peoples Democrat Republ, Viangchan, Laos.
   [Chitry, Bounlap] Mother & Child Hosp, Viangchan, Laos.
   [Pholsena, Vathsana] Setthathirath Hosp, Viangchan, Laos.
   [Chitranonh, Visith] Luang Prabang Prov Hosp, Luang Prabang, Laos.
   [Omer, Saad B.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Corwin, Andrew] Amer Embassy, QED Grp, Viangchan, Laos.
RP Olsen, SJ (reprint author), CDC, Influenza Div, 1600 Clifton Rd,MS A-32, Atlanta, GA 30329 USA.
EM SOlsen@cdc.gov
FU Centers for Disease Control and Prevention (CDC), Influenza Division,
   through Expanded Program on Immunizations, Ministry of Public Health,
   Vientiane, Lao People's Democratic Republic (PDR); government of Lao PDR
FX This work was supported by the Centers for Disease Control and
   Prevention (CDC), Influenza Division, through a contract with the
   Expanded Program on Immunizations, Ministry of Public Health, Vientiane,
   Lao People's Democratic Republic (PDR), and by the government of Lao
   PDR.
NR 33
TC 4
Z9 4
U1 3
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP 487
EP 494
DI 10.1093/cid/ciw290
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400010
PM 27143672
ER

PT J
AU Caierao, J
   Sant'Anna, FH
   Hawkins, P
   Cunha, GR
   Mott, M
   Falci, DR
   d'Azevedo, PA
   McGee, L
   Dias, C
AF Caierao, Juliana
   Sant'Anna, Fernando Hayashi
   Hawkins, Paulina
   Cunha, Gabriela Rosa
   Mott, Mariana
   Falci, Diego Rodrigues
   d'Azevedo, Pedro Alves
   McGee, Lesley
   Dias, Cicero
TI Characteristics of serogroup 20 S.pneumoniae isolates from Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Streptococcus pneumoniae; Invasive pneumococcal disease; Serogroup 20;
   Molecular epidemiology
ID INVASIVE PNEUMOCOCCAL DISEASE; FIELD GEL-ELECTROPHORESIS;
   STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; ANTIMICROBIAL RESISTANCE;
   SEROTYPE DISTRIBUTION; CHILDREN; ADULTS; IDENTIFICATION; DIVERSITY
AB Background: Although serogroup 20 is not part of any conjugate pneumococcal vaccine, its serotype 20A, but not 20B, belongs to the polysaccharide 23-valent formula. Little is known about its clinical, laboratorial and epidemiological characteristics.
   Methods: The purpose of this study was to evaluate the bacterial genotypes (by PFGE and MLST), clinical characteristics of patients (from review of medical records) and antimicrobial susceptibility of serogroup 20 isolates which were recovered from patients with invasive pneumococcal disease (IPD) from 2007 to 2012. Subtyping to determine 20A and 20B types was also performed by sequencing the genes of the cps locus.
   Results: Sixteen isolates were genotyped and were highly related. All pneumococci were resistant to tetracycline and 31 % were non-susceptible to trimethoprim/sulfamethoxazole. Penicillin MIC ranged from 0.004 to 1 mu g/mL and non-susceptibility (MIC = 0.12 mu g/mL) was observed in 5/16 isolates (31 %). All isolates belonged to subtype 20B. Most patients were male with a median age of 62 years and presented at least one underlying disease (mostly respiratory conditions). All isolates belonged to ST8889 and to a unique PFGE clone.
   Conclusions: A high clonal occurrence of serotype 20B pneumococci recovered from patients with IPD in Brazil was observed. As a non-PCV10 serotype, selective pressure may be responsible for this unusual occurrence of serogroup 20. However, temporal variation effect should not be underestimated; therefore it is an issue that warrants continued monitoring.
C1 [Caierao, Juliana; Cunha, Gabriela Rosa; Mott, Mariana; d'Azevedo, Pedro Alves; Dias, Cicero] Fed Univ Hlth Sci Porto Alegre, Basic Hlth Dept, Porto Alegre, RS, Brazil.
   [Sant'Anna, Fernando Hayashi] Univ Fed Rio Grande do Sul, Ctr Agr Microbiol, Biosci Inst, Dept Genet, Porto Alegre, RS, Brazil.
   [Hawkins, Paulina] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Falci, Diego Rodrigues] Conceicao Hosp Grp, Porto Alegre, RS, Brazil.
   [McGee, Lesley] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
RP Caierao, J (reprint author), Fed Univ Hlth Sci Porto Alegre, Basic Hlth Dept, Porto Alegre, RS, Brazil.
EM julianaca@ufcspa.edu.br
FU CAPES: Coordenacao de Aperfeicoamento de Pessoal de Nivel superior
FX CAPES: Coordenacao de Aperfeicoamento de Pessoal de Nivel superior.
NR 37
TC 0
Z9 0
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 15
PY 2016
VL 16
AR 418
DI 10.1186/s12879-016-1773-y
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA DT2YV
UT WOS:000381348600005
PM 27527077
ER

PT J
AU Shockey, TM
   Sussell, AL
   Odom, EC
AF Shockey, Taylor M.
   Sussell, Aaron L.
   Odom, Erika C.
TI Cardiovascular Health Status by
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID ASSOCIATIONS; METRICS
C1 [Shockey, Taylor M.; Sussell, Aaron L.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC USA.
   [Odom, Erika C.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Shockey, TM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC USA.
EM tshockey@cdc.gov
NR 10
TC 1
Z9 1
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 12
PY 2016
VL 65
IS 31
BP 793
EP 798
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT4KZ
UT WOS:000381451200001
PM 27513070
ER

PT J
AU Ko, JY
   Patrick, SW
   Tong, VT
   Patel, R
   Lind, JN
   Barfield, WD
AF Ko, Jean Y.
   Patrick, Stephen W.
   Tong, Van T.
   Patel, Roshni
   Lind, Jennifer N.
   Barfield, Wanda D.
TI Incidence of Neonatal Abstinence Syndrome-28 States, 1999-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES
C1 [Ko, Jean Y.; Tong, Van T.; Patel, Roshni; Barfield, Wanda D.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Patrick, Stephen W.] Vanderbilt Univ, Sch Med, Div Neonatol, Dept Pediat, Nashville, TN USA.
   [Patrick, Stephen W.] Vanderbilt Univ, Sch Med, Div Neonatol, Dept Hlth Policy, Nashville, TN USA.
   [Lind, Jennifer N.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Ko, JY (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM JeanKo@cdc.gov
FU NIDA NIH HHS [K23 DA038720]
NR 10
TC 5
Z9 5
U1 3
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 12
PY 2016
VL 65
IS 31
BP 799
EP 802
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT4KZ
UT WOS:000381451200002
PM 27513154
ER

PT J
AU Kronstadt, J
   Meit, M
   Siegfried, A
   Nicolaus, T
   Bender, K
   Corso, L
AF Kronstadt, Jessica
   Meit, Michael
   Siegfried, Alexa
   Nicolaus, Teddi
   Bender, Kaye
   Corso, Liza
TI Evaluating the Impact of National Public Health Department Accreditation
   - United States, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID DEPARTMENTS
C1 [Kronstadt, Jessica; Nicolaus, Teddi; Bender, Kaye] Publ Hlth Accreditat Board, Alexandria, VA 22314 USA.
   [Meit, Michael; Siegfried, Alexa] Univ Chicago, NORC, Bethesda, MD USA.
   [Corso, Liza] CDC, Div Publ Hlth Performance Improvement, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA.
RP Kronstadt, J (reprint author), Publ Hlth Accreditat Board, Alexandria, VA 22314 USA.
EM jkronstadt@phaboard.org
NR 9
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 12
PY 2016
VL 65
IS 31
BP 803
EP 806
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT4KZ
UT WOS:000381451200003
PM 27513206
ER

PT J
AU Sinyange, N
   Kumar, R
   Inambao, A
   Moonde, L
   Chama, J
   Banda, M
   Tembo, E
   Nsonga, B
   Mwaba, J
   Fwoloshi, S
   Musokotwane, K
   Chizema, E
   Kapin'a, M
   Hang'ombe, BM
   Baggett, HC
   Hachaambwa, L
AF Sinyange, Nyambe
   Kumar, Ramya
   Inambao, Akatama
   Moonde, Loveness
   Chama, Jonathan
   Banda, Mapopa
   Tembo, Elliot
   Nsonga, Beron
   Mwaba, John
   Fwoloshi, Sombo
   Musokotwane, Kebby
   Chizema, Elizabeth
   Kapin'a, Muzala
   Hang'ombe, Benard Mudenda
   Baggett, Henry C.
   Hachaambwa, Lottie
TI Outbreak of Plague in a High Malaria Endemic Region - Nyimba District,
   Zambia, March-May 2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Sinyange, Nyambe; Inambao, Akatama; Moonde, Loveness] Zambia Field Epidemiol Training Program, Lusaka, Zambia.
   [Kumar, Ramya; Baggett, Henry C.] CDC, Lusaka, Zambia.
   [Chama, Jonathan; Banda, Mapopa; Tembo, Elliot; Nsonga, Beron; Musokotwane, Kebby; Chizema, Elizabeth; Kapin'a, Muzala] Minist Hlth, Lusaka, Zambia.
   [Mwaba, John; Fwoloshi, Sombo] Univ Teaching Hosp, Lusaka, Zambia.
   [Sinyange, Nyambe; Inambao, Akatama; Moonde, Loveness; Fwoloshi, Sombo; Hachaambwa, Lottie] Univ Zambia, Sch Med, Lusaka, Zambia.
   [Kumar, Ramya; Baggett, Henry C.] CDC, Atlanta, GA 30333 USA.
   [Hang'ombe, Benard Mudenda] Univ Zambia, Sch Vet Med, Lusaka, Zambia.
   [Hachaambwa, Lottie] Univ Maryland, Sch Med, Dept Med, College Pk, MD USA.
RP Sinyange, N (reprint author), Zambia Field Epidemiol Training Program, Lusaka, Zambia.; Sinyange, N (reprint author), Univ Zambia, Sch Med, Lusaka, Zambia.
EM bsinyange@gmail.com
NR 10
TC 0
Z9 0
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 12
PY 2016
VL 65
IS 31
BP 807
EP 811
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT4KZ
UT WOS:000381451200004
PM 27513350
ER

PT J
AU Hines, JZ
   Pinsent, T
   Rees, K
   Vines, J
   Bowen, A
   Hurd, J
   Leman, RF
   Hedberg, K
AF Hines, Jonas Z.
   Pinsent, Taylor
   Rees, Kathleen
   Vines, Jennifer
   Bowen, Anna
   Hurd, Jacqueline
   Leman, Richard F.
   Hedberg, Katrina
TI Shigellosis Outbreak Among Men Who Have Sex with Men and Homeless
   Persons - Oregon, 2015-2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES; TRANSMISSION
C1 [Hines, Jonas Z.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Hines, Jonas Z.; Leman, Richard F.; Hedberg, Katrina] Oregon Hlth Author, Publ Hlth Div, Salem, OR 97301 USA.
   [Pinsent, Taylor; Vines, Jennifer] Multnomah Cty Publ Hlth Dept, Portland, OR USA.
   [Rees, Kathleen] Washington Cty Dept Hlth & Human Serv, Hillsboro, OR USA.
   [Bowen, Anna; Hurd, Jacqueline] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA.
RP Hines, JZ (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Hines, JZ (reprint author), Oregon Hlth Author, Publ Hlth Div, Salem, OR 97301 USA.
EM JHines1@cdc.gov
NR 6
TC 1
Z9 1
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 12
PY 2016
VL 65
IS 31
BP 812
EP 813
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT4KZ
UT WOS:000381451200005
PM 27513523
ER

PT J
AU Minino, A
AF Minino, Arialdi
TI Age-Adjusted Death Rates for Males Aged 15-44 Years, by the Five Leading
   Causes of Death - United States, 1999 and 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Editorial Material
C1 [Minino, Arialdi] Ctr Dis Control & Prevent, US Dept HHS, Atlanta, GA 30333 USA.
RP Minino, A (reprint author), Ctr Dis Control & Prevent, US Dept HHS, Atlanta, GA 30333 USA.
EM AMinino@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 12
PY 2016
VL 65
IS 31
BP 815
EP 815
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT4KZ
UT WOS:000381451200008
ER

PT J
AU Fonseca, LL
   Alezi, HS
   Moreno, A
   Barnwell, JW
   Galinski, MR
   Voit, EO
AF Fonseca, Luis L.
   Alezi, Harnel S.
   Moreno, Alberto
   Barnwell, John W.
   Galinski, Mary R.
   Voit, Eberhard O.
TI Quantifying the removal of red blood cells in Macaca mulatta during a
   Plasmodium coatneyi infection
SO MALARIA JOURNAL
LA English
DT Article
DE Macaca mulatta; Malarial anaemia; Mathematical model; Plasmodium
   coatneyi; Red blood cell removal
ID OCCURRING ANTI-BAND-3 ANTIBODIES; SEVERE MALARIAL ANEMIA;
   FALCIPARUM-MALARIA; UNINFECTED ERYTHROCYTES; HEMOGLOBIN; ERYTHROPOIESIS;
   BAND-3; SENESCENCE; KNOWLESI; DISEASE
AB Background: Malaria is the most deadly parasitic disease in humans globally, and the long-time coexistence with malaria has left indelible marks in the human genome that are the causes of a variety of genetic disorders. Although anaemia is a common clinical complication of malaria, the root causes and mechanisms involved in the pathogenesis of malarial anaemia are unclear and difficult to study in humans. Non-human primate (NHP) model systems enable the mechanistic study and quantification of underlying causative factors of malarial anaemia, and particularly the onset of severe anaemia.
   Methods: Data were obtained in the course of Plasmodium coatneyi infections of malaria-naive and semi-immune rhesus macaques (Macaca mulatta), whose red blood cells (RBCs) were labelled in situ with biotin at the time the infections were initiated. The data were used for a survival analysis that permitted, for the first time, an accurate estimation of the lifespan of erythrocytes in macaques. The data furthermore formed the basis for the development and parameterization of a recursive dynamic model of erythrocyte turnover, which was used for the quantification of RBC production and removal in each macaque.
   Results: The computational analysis demonstrated that the lifespan of erythrocytes in macaques is 98 +/- 21 days. The model also unambiguously showed that death due to senescence and parasitaemia is not sufficient to account for the extent of infection-induced anaemia. Specifically, the model permits, for the first time, the quantification of the different causes of RBC death, namely, normal senescence, age-independent random loss, parasitization, and bystander effects in uninfected cells. Such a dissection of the overall RBC removal process is hardly possible with experimental means alone. In the infected malaria-naive macaques, death of erythrocytes by normal physiological senescence processes accounts for 20 % and parasitization for only 4 %, whereas bystander effects are associated with an astonishing 76 % of total RBC losses. Model-based comparisons of alternative mechanisms involved in the bystander effect revealed that most of the losses are likely due to a process of removing uninfected RBCs of all age classes and only minimally due to an increased rate of senescence of the uninfected RBCs.
   Conclusions: A new malaria blood-stage model was developed for the analysis of data characterizing P. coatneyi infections of M. mulatta. The model used a discrete and recursive framework with age-structure that allowed the quantification of the most significant pathophysiological processes of RBC removal. The computational results revealed that the malarial anaemia caused by this parasite is mostly due to a loss of uninfected RBCs by an age-independent process. The biological identity and complete mechanism of this process is not fully understood and requires further investigation.
C1 [Fonseca, Luis L.; Alezi, Harnel S.; Voit, Eberhard O.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
   [Fonseca, Luis L.; Alezi, Harnel S.; Voit, Eberhard O.] Emory Univ, Atlanta, GA 30322 USA.
   [Moreno, Alberto; Galinski, Mary R.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Barnwell, John W.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA.
   [Moreno, Alberto; Barnwell, John W.; Galinski, Mary R.; Voit, Eberhard O.] Emory Univ, Malaria Host Pathogen Interact Ctr, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
RP Fonseca, LL (reprint author), Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.; Fonseca, LL (reprint author), Emory Univ, Atlanta, GA 30322 USA.
EM llfonseca@gatech.edu
RI Fonseca, Luis/B-2265-2009
OI Fonseca, Luis/0000-0002-7902-742X
FU Federal funds from the US National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, Department of Health and Human
   Services, Malaria Host-Pathogen Interaction Center (MaHPIC)
   [HHSN272201200031C]; Office of Research Infrastructure Programs [OD
   P51OD011132]
FX This project was funded in part by Federal funds from the US National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human Services under contract
   #HHSN272201200031C (PI: Mary R. Galinski), which supports the Malaria
   Host-Pathogen Interaction Center (MaHPIC), as well as the Office of
   Research Infrastructure Programs/OD P51OD011132 (formerly National
   Center for Research Resources P51RR000165).
NR 40
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 12
PY 2016
VL 15
AR 410
DI 10.1186/s12936-016-1465-5
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DT3CN
UT WOS:000381358200002
PM 27520455
ER

PT J
AU Bharti, PK
   Chandel, HS
   Ahmad, A
   Krishna, S
   Udhayakumar, V
   Singh, N
AF Bharti, Praveen Kumar
   Chandel, Himanshu Singh
   Ahmad, Amreen
   Krishna, Sri
   Udhayakumar, Venkatachalam
   Singh, Neeru
TI Prevalence of pfhrp2 and/or pfhrp3 Gene Deletion in Plasmodium
   falciparum Population in Eight Highly Endemic States in India
SO PLOS ONE
LA English
DT Article
ID RAPID DIAGNOSTIC-TESTS; SEQUENCE VARIATION; MALARIA; HRP2; CHLOROQUINE;
   PERFORMANCE; MANAGEMENT; DIVERSITY; SENEGAL; REGION
AB Background Plasmodium falciparum encoded histidine rich protein (HRP2) based malaria rapid diagnostic tests (RDTs) are used in India. Deletion of pfhrp2 and pfhrp3 genes contributes to false negative test results, and large numbers of such deletions have been reported from South America, highlighting the importance of surveillance to detect such deletions.
   Methods This is the first prospective field study carried out at 16 sites located in eight endemic states of India to assess the performance of PfHRP2 based RDT kits used in the national malaria control programme. In this study, microscopically confirmed P. falciparum but RDT negative samples were assessed for presence of pfhrp2, pfhrp3, and their flanking genes using PCR.
   Results Among 1521 microscopically positive P. falciparum samples screened, 50 were negative by HRP2 based RDT test. Molecular testing was carried out using these 50 RDT negative samples by assuming that 1471 RDT positive samples carried pfhrp2 gene. It was found that 2.4% (36/1521) and 1.8% (27/1521) of samples were negative for pfhrp2 and pfhrp3 genes, respectively. However, the frequency of pfhrp2 deletions varied between the sites ranging from 0-25% (2.4, 95% CI; 1.6-3.3). The frequency of both pfhrp2 and pfhrp3 gene deletion varied from 0-8% (1.6, 95% CI; 1.0-2.4).
   Conclusion This study provides evidence for low level presence of pfhrp2 and pfhrp3 deleted P. falciparum parasites in different endemic regions of India, and periodic surveillance is warranted for reliable use of PfHRP2 based RDTs.
C1 [Bharti, Praveen Kumar; Chandel, Himanshu Singh; Ahmad, Amreen; Krishna, Sri; Singh, Neeru] NIRTH, Jabalpur 482003, Madhya Pradesh, India.
   [Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Singh, N (reprint author), NIRTH, Jabalpur 482003, Madhya Pradesh, India.
EM neeru.singh@gmail.com
FU Indian Council of Medical Research, India
FX This work was funded by Indian Council of Medical Research, India.
NR 30
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2016
VL 11
IS 8
AR e0157949
DI 10.1371/journal.pone.0157949
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3LI
UT WOS:000381382100002
ER

PT J
AU Enose-Akahata, Y
   Caruso, B
   Haner, B
   Charlip, E
   Nair, G
   Massoud, R
   Billioux, BJ
   Ohayon, J
   Switzer, WM
   Jacobson, S
AF Enose-Akahata, Yoshimi
   Caruso, Breanna
   Haner, Benjamin
   Charlip, Emily
   Nair, Govind
   Massoud, Raya
   Billioux, Bridgette J.
   Ohayon, Joan
   Switzer, William M.
   Jacobson, Steven
TI Development of neurologic diseases in a patient with primate T
   lymphotropic virus type 1 (PTLV-1)
SO RETROVIROLOGY
LA English
DT Article
DE HTLV; PTLV; STLV; HAM/TSP
ID TROPICAL SPASTIC PARAPARESIS; I-ASSOCIATED MYELOPATHY; HTLV-I;
   NONHUMAN-PRIMATES; PERIPHERAL-BLOOD; MOLECULAR EPIDEMIOLOGY;
   CEREBROSPINAL-FLUID; HAM/TSP PATIENTS; CENTRAL-AFRICA; COTE-DIVOIRE
AB Background: Virus transmission from various wild and domestic animals contributes to an increased risk of emerging infectious diseases in human populations. HTLV-1 is a human retrovirus associated with acute T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 originated from ancient zoonotic transmission from nonhuman primates, although cases of zoonotic infections continue to occur. Similar to HTLV-1, the simian counterpart, STLV-1, causes chronic infection and leukemia and lymphoma in naturally infected monkeys, and combined are called primate T-lymphotropic viruses (PTLV-1). However, other clinical syndromes typically seen in humans such as a chronic progressive myelopathy have not been observed in nonhuman primates. Little is known about the development of neurologic and inflammatory diseases in human populations infected with STLV-1-like viruses following nonhuman primate exposure.
   Results: We performed detailed laboratory analyses on an HTLV-1 seropositive patient with typical HAM/TSP who was born in Liberia and now resides in the United States. Using a novel droplet digital PCR for the detection of the HTLV-1 tax gene, the proviral load in PBMC and cerebrospinal fluid cells was 12.98 and 51.68 %, respectively; however, we observed a distinct difference in fluorescence amplitude of the positive droplet population suggesting possible mutations in proviral DNA. A complete PTLV-1 proviral genome was amplified from the patient's PBMC DNA using an overlapping PCR strategy. Phylogenetic analysis of the envelope and LTR sequences showed the virus was highly related to PTLV-1 from sooty mangabey monkeys (smm) and humans exposed via nonhuman primates in West Africa.
   Conclusions: These results demonstrate the patient is infected with a simian variant of PTLV-1, suggesting for the first time that PTLV-1smm infection in humans may be associated with a chronic progressive neurologic disease.
C1 [Enose-Akahata, Yoshimi; Caruso, Breanna; Haner, Benjamin; Charlip, Emily; Massoud, Raya; Billioux, Bridgette J.; Ohayon, Joan; Jacobson, Steven] NINDS, Viral Immunol Sect, Neuroimmunol Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 5C-103, Bethesda, MD 20892 USA.
   [Nair, Govind] NINDS, Translat Neuroradiol Unit, Neuroimmunol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA.
RP Jacobson, S (reprint author), NINDS, Viral Immunol Sect, Neuroimmunol Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 5C-103, Bethesda, MD 20892 USA.
EM jacobsons@ninds.nih.gov
FU Intramural Research Program of the NINDS, NIH
FX This research was supported by the Intramural Research Program of the
   NINDS, NIH.
NR 45
TC 1
Z9 1
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD AUG 12
PY 2016
VL 13
AR 56
DI 10.1186/s12977-016-0290-9
PG 13
WC Virology
SC Virology
GA DT1RX
UT WOS:000381260900001
PM 27519553
ER

PT J
AU Cogswell, ME
   Mugavero, K
   Bowman, BA
   Frieden, TR
AF Cogswell, Mary E.
   Mugavero, Kristy
   Bowman, Barbara A.
   Frieden, Thomas R.
TI Dietary Sodium and Cardiovascular Disease Risk - Measurement Matters
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID CORONARY-HEART-DISEASE; URINARY SODIUM; BLOOD-PRESSURE; POTASSIUM
   EXCRETION; PUBLIC-HEALTH; SALT; MORTALITY; HYPERTENSION; REDUCTION;
   METAANALYSIS
C1 [Cogswell, Mary E.; Mugavero, Kristy; Bowman, Barbara A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA.
   [Frieden, Thomas R.] Ctr Dis Control & Prevent, Off Director, Atlanta, GA 30333 USA.
RP Cogswell, ME (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA.
FU Intramural CDC HHS [CC999999]
NR 64
TC 15
Z9 15
U1 13
U2 13
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 11
PY 2016
VL 375
IS 6
BP 580
EP 586
DI 10.1056/NEJMsb1607161
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU4OT
UT WOS:000382193100014
PM 27248297
ER

PT J
AU Sakamoto, JM
   Ng, TFF
   Suzuki, Y
   Tsujimoto, H
   Deng, XT
   Delwart, E
   Rasgon, JL
AF Sakamoto, Joyce M.
   Ng, Terry Fei Fan
   Suzuki, Yasutsugu
   Tsujimoto, Hitoshi
   Deng, Xutao
   Delwart, Eric
   Rasgon, Jason L.
TI Bunyaviruses are common in male and female Ixodes scapularis ticks in
   central Pennsylvania
SO PEERJ
LA English
DT Article
DE Tick; Virus; Metagenomics; Vector-borne pathogen
ID SEXUAL TRANSMISSION; AMBLYOMMA-AMERICANUM; FEVER VIRUS; VERTEBRATE;
   IXODIDAE; GENETICS; RICINUS
AB The blacklegged tick Ixodes scapularis is widely distributed in the United States and transmits multiple pathogens to humans, wildlife and domestic animals. Recently, several novel viruses in the family Bunyaviridae (South Bay virus (SBV) and Blacklegged tick phlebovirus (BTPV)) were identified infecting female I. scapularis' ticks collected in New York State. We used metagenomic sequencing to investigate the distribution of viruses infecting male and female I. scapularis ticks collected in Centre County, Pennsylvania. We identified both SBV and BTPV in both male and female ticks from all collection locations. The role of male I. scapularis in pathogen epidemiology has been overlooked because they rarely bite and are not considered important pathogen vectors. However, males may act as reservoirs for pathogens that can then be transmitted to females during mating. Our data highlight the importance of examining all potential avenues of pathogen maintenance and transmission throughout the vector-pathogen life cycle in order to understand the epidemiology of tick-borne pathogens.
C1 [Sakamoto, Joyce M.; Suzuki, Yasutsugu; Tsujimoto, Hitoshi; Rasgon, Jason L.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.
   [Sakamoto, Joyce M.; Tsujimoto, Hitoshi; Rasgon, Jason L.] Penn State Univ, Dept Entomol, University Pk, PA 16802 USA.
   [Ng, Terry Fei Fan] Blood Syst Res Inst, Mol Virol, San Francisco, CA USA.
   [Ng, Terry Fei Fan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
   [Suzuki, Yasutsugu] Inst Pasteur, Dept Virol, Paris, France.
   [Suzuki, Yasutsugu; Tsujimoto, Hitoshi; Rasgon, Jason L.] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.
   [Tsujimoto, Hitoshi] New Mexico State Univ, Dept Biol, Las Cruces, NM 88003 USA.
   [Deng, Xutao; Delwart, Eric] Blood Syst Res Inst, Dept Lab Med, San Francisco, CA USA.
   [Deng, Xutao; Delwart, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Rasgon, JL (reprint author), Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.; Rasgon, JL (reprint author), Penn State Univ, Dept Entomol, University Pk, PA 16802 USA.; Rasgon, JL (reprint author), Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.
EM jlr54@psu.edu
OI Ng, Terry Fei Fan/0000-0002-4815-8697
FU Penn State College of Agricultural Sciences; NIH [R0AI116636,
   R21AI111175, R01HL105770]; BSRI
FX This research was supported by funds from the Penn State College of
   Agricultural Sciences to JMS, NIH grants R0AI116636 and R21AI111175 to
   JLR, and NIH grant R01HL105770 and funds from BSRI to ED. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
NR 19
TC 2
Z9 2
U1 3
U2 5
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD AUG 11
PY 2016
VL 4
AR e2324
DI 10.7717/peerj.2324
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT1QR
UT WOS:000381257700004
PM 27602290
ER

PT J
AU Jourdain, G
   Ngo-Giang-Huong, N
   Cressey, TR
   Hua, L
   Harrison, L
   Tierney, C
   Salvadori, N
   Decker, L
   Traisathit, P
   Sirirungsi, W
   Khamduang, W
   Bowonwatanuwong, C
   Puthanakit, T
   Siberry, GK
   Watts, DH
   Murphy, TV
   Achalapong, J
   Hongsiriwon, S
   Klinbuayaem, V
   Thongsawat, S
   Chung, RT
   Pol, S
   Chotivanich, N
AF Jourdain, Gonzague
   Ngo-Giang-Huong, Nicole
   Cressey, Tim R.
   Hua, Lei
   Harrison, Linda
   Tierney, Camlin
   Salvadori, Nicolas
   Decker, Luc
   Traisathit, Patrinee
   Sirirungsi, Wasna
   Khamduang, Woottichai
   Bowonwatanuwong, Chureeratana
   Puthanakit, Thanyawee
   Siberry, George K.
   Watts, Diane Heather
   Murphy, Trudy V.
   Achalapong, Jullapong
   Hongsiriwon, Suchat
   Klinbuayaem, Virat
   Thongsawat, Satawat
   Chung, Raymond T.
   Pol, Stanislas
   Chotivanich, Nantasak
TI Prevention of mother-to-child transmission of hepatitis B virus: a phase
   III, placebo-controlled, double-blind, randomized clinical trial to
   assess the efficacy and safety of a short course of tenofovir disoproxil
   fumarate in women with hepatitis B virus e-antigen
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID PERINATAL TRANSMISSION; INFANT TRANSMISSION; SURFACE-ANTIGEN; INFECTION;
   PREGNANCY; METAANALYSIS
AB Background: Chronic hepatitis B virus (HBV) infection is complicated by cirrhosis and liver cancer. In Thailand, 6-7 % of adults are chronically infected with HBV. The risk of mother-to-child transmission (MTCT) of HBV has been estimated to be about 12 % when mothers have a high hepatitis B viral load, even if infants receive passive-active prophylaxis with HBV immunoglobulin (HBIg) and initiate the hepatitis B vaccine series at birth. We designed a study to assess the efficacy and safety of a short course of maternal tenofovir disoproxil fumarate (TDF) among women with a marker of high viral load for the prevention of MTCT of HBV.
   Methods: The study is a phase III, multicenter (17 sites in Thailand), placebo-controlled, double-blind, randomized 1: 1, two-arm clinical trial of TDF 300 mg once daily versus placebo among pregnant women from 28 weeks' gestation through 2-month post-partum. All infants receive HBIg at birth, and a hepatitis B (HB) vaccination series according to Thai guidelines: birth, and age 1, 2, 4 and 6 months. Participant women at study entry must be age >= 18 years, hepatitis B surface antigen (HBsAg) and e-antigen (HBeAg) positive, have alanine aminotransferase (ALT) level < 30 IU/L at screening (confirmed < 60 IU/L pre-entry), negative hepatitis C serology, creatinine clearance > 50 mL/min, and no history of anti-HBV antiviral treatment.
   The target sample size of 328 mother/infant pairs assumed 156 evaluable cases per arm to detect a >= 9 % difference in MTCT transmission (3 % experimental arm versus 12 % placebo arm) with 90 % power. Mothers and infants are followed until 12 months after delivery. The primary infant endpoint is detection of HBsAg, confirmed by detection of HBV DNA at six months of age. Secondary endpoints are maternal and infant adverse events, acute exacerbations of maternal hepatitis B disease (ALT > 300 IU/ L, defined as a "flare") following discontinuation of study treatment, infant HBV infection status and growth up to 12 months of age.
   Discussion: The results of this randomized trial will clarify the efficacy and safety of a short course of antiviral treatment to prevent mother-to-child transmission of HBV and inform international guidelines.
C1 [Jourdain, Gonzague; Ngo-Giang-Huong, Nicole; Cressey, Tim R.; Salvadori, Nicolas; Decker, Luc] Inst Rech Dev IRD France, PHPT, UMI 174, 187-10 Changklan Rd, Chiang Mai 50100, Thailand.
   [Jourdain, Gonzague; Ngo-Giang-Huong, Nicole; Cressey, Tim R.; Salvadori, Nicolas; Decker, Luc; Sirirungsi, Wasna; Khamduang, Woottichai] Chiang Mai Univ, Fac Associated Med Sci, 110 Intawaroroj Rd, Chiang Mai 50200, Thailand.
   [Jourdain, Gonzague; Ngo-Giang-Huong, Nicole; Cressey, Tim R.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, 677 Huntington Ave, Boston, MA 02115 USA.
   [Cressey, Tim R.] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Hua, Lei; Harrison, Linda; Tierney, Camlin] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res CBAR, 677 Huntington Ave, Boston, MA 02115 USA.
   [Bowonwatanuwong, Chureeratana; Chotivanich, Nantasak] Chonburi Hosp, 69 M-2,Sukhumvit Rd, Muang 20000, Chonburi, Thailand.
   [Puthanakit, Thanyawee] Chulalongkorn Univ, Fac Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand.
   [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, 6100 Execut Blvd, Bethesda, MD 20892 USA.
   [Watts, Diane Heather] US Dept State, Off Global AIDS Coordinator, SA-22,2201 C St NW, Washington, DC 20522 USA.
   [Murphy, Trudy V.] Ctr Dis Control & Prevent, DHHS CDC NCHHSTP DVH Vaccine Unit, Bldg Corp SQ 12,Room 3111, Atlanta, GA 30329 USA.
   [Achalapong, Jullapong] Chiangrai Prachanukroh Hosp, Dept Obstet & Gynecol, 1039 Sathan Phayaban Rd, Muang 57000, Chiang Rai, Thailand.
   [Hongsiriwon, Suchat] Chonburi Hosp, Dept Pediat, 69 M-2,Sukhumvit Rd, Muang 20000, Chonburi, Thailand.
   [Klinbuayaem, Virat] Sanpatong Hosp, Dept Med, 149 M-15 Yuhwa, Chiang Mai 50120, Thailand.
   [Traisathit, Patrinee] Chiang Mai Univ, Dept Stat, Fac Sci, 239 Huaykaew Rd, Chiang Mai 50200, Thailand.
   [Thongsawat, Satawat] Chiang Mai Univ, Dept Internal Med, Fac Med, Chiang Mai 50200, Thailand.
   [Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, GI Unit, WRN 1007C,55 Fruit St, Boston, MA 02114 USA.
   [Pol, Stanislas] Cochin Univ Hosp, Dept Hepatogastroenterol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.
RP Jourdain, G (reprint author), Inst Rech Dev IRD France, PHPT, UMI 174, 187-10 Changklan Rd, Chiang Mai 50100, Thailand.; Jourdain, G (reprint author), Chiang Mai Univ, Fac Associated Med Sci, 110 Intawaroroj Rd, Chiang Mai 50200, Thailand.
EM gonzague.jourdain@ird.fr
FU Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [U01HD071889]
FX The study activities are supported by a grant from the Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   (U01HD071889) under a cooperative agreement between NICHD, the Centers
   for Disease Control and Prevention, United States of America, and
   Institut de recherche pour le developpement, France.
NR 12
TC 1
Z9 1
U1 8
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 9
PY 2016
VL 16
AR 393
DI 10.1186/s12879-016-1734-5
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA DT2YM
UT WOS:000381347700010
PM 27506549
ER

PT J
AU Frieden, TR
AF Frieden, Thomas R.
TI Sodium Reduction-Saving Lives by Putting Choice Into Consumers' Hands
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID CARDIOVASCULAR-DISEASE; CONSUMPTION; SCIENCE
C1 [Frieden, Thomas R.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-14, Atlanta, GA 30329 USA.
RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-14, Atlanta, GA 30329 USA.
EM tfrieden@cdc.gov
NR 9
TC 2
Z9 2
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 9
PY 2016
VL 316
IS 6
BP 579
EP 580
DI 10.1001/jama.2016.7992
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS7TK
UT WOS:000380985600006
PM 27249371
ER

PT J
AU Martell, BN
   Garrett, BE
   Caraballo, RS
AF Martell, Brandi N.
   Garrett, Bridgette E.
   Caraballo, Ralph S.
TI Disparities in Adult Cigarette Smoking - United States, 2002-2005 and
   2010-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
AB What is already known about this topic?
   Although cigarette smoking has substantially declined since 1964, disparities in tobacco use varies among racial/ethnic populations. Estimates of U.S. adult cigarette smoking prevalence and tobacco use are usually limited to aggregate racial/ethnic population categories.
   What is added by this report?
   From the period 2002-2005 to the period 2010-2013, declines in cigarette smoking occurred among some racial/ethnic populations. Moreover, the relative change in smoking even among groups that did experience a decline varied across racial/ethnic populations. Substantial disparities in adult cigarette smoking prevalence exist among and within Asian and Hispanic subgroups, with Koreans and Puerto Ricans reporting the highest cigarette smoking prevalences within their respective racial/ethnic population. These findings indicate disproportionately higher smoking prevalence among men compared with women within most racial/ethnic groups.
   What are the implications for public health practice?
   Disparities in smoking prevalence exist among racial/ethnic populations, and several racial/ethnic populations have disproportionately higher prevalences of smoking and wide within-group variations. Proven interventions, including increasing the price of tobacco products coupled with evidence-based cessation services, comprehensive smoke-free policies, media campaigns, and promotion of cessation treatment in clinical settings, are effective strategies in reducing the overall prevalence of tobacco use and tobacco-related disease and death.
C1 [Martell, Brandi N.; Garrett, Bridgette E.; Caraballo, Ralph S.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Martell, BN (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM bmartell@cdc.gov
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 753
EP 758
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800001
PM 27491017
ER

PT J
AU Banspach, S
   Zaza, S
   Dittus, P
   Michael, S
   Brindis, CD
   Thorpe, P
AF Banspach, Stephen
   Zaza, Stephanie
   Dittus, Patricia
   Michael, Shannon
   Brindis, Claire D.
   Thorpe, Phoebe
TI CDC Grand Rounds: Adolescence - Preparing for Lifelong Health and
   Wellness
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Banspach, Stephen; Zaza, Stephanie] CDC, Div Adolescent, Atlanta, GA 30333 USA.
   [Banspach, Stephen; Zaza, Stephanie] CDC, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Dittus, Patricia] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Michael, Shannon] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Brindis, Claire D.] Univ Calif San Francisco, Adolescent & Young Adult Hlth Natl Resource Ctr, San Francisco, CA 94143 USA.
   [Thorpe, Phoebe] CDC, Off Director, Atlanta, GA 30333 USA.
RP Banspach, S (reprint author), CDC, Div Adolescent, Atlanta, GA 30333 USA.; Banspach, S (reprint author), CDC, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM SBanspach@cdc.gov
NR 8
TC 0
Z9 0
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 759
EP 762
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800002
PM 27491062
ER

PT J
AU Jorba, J
   Diop, OM
   Iber, J
   Sutter, RW
   Wassilak, SG
   Burns, CC
AF Jorba, Jaume
   Diop, Ousmane M.
   Iber, Jane
   Sutter, Roland W.
   Wassilak, Steven G.
   Burns, Cara C.
TI Update on Vaccine-Derived Polioviruses - Worldwide, January 2015-May
   2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
AB What is already known about this topic?
   Vaccine-derived polioviruses (VDPVs), genetically divergent strains from the oral poliovirus vaccine (OPV), fall into three classifications: 1) circulating VDPVs (cVDPVs) from outbreaks, 2) immunodeficiency-associated VDPVs (iVDPVs) from patients with primary immunodeficiencies, and 3) ambiguous VDPVs (aVDPVs) that cannot be more definitively identified. cVDPVs emerge in settings of low population immunity, can cause paralysis, and can sustain long-term circulation. Because > 94% of cVDPVs isolated since 2006 and 66% of iVDPVs identified since OPV introduction are type 2, and because wild polio virus type 2 was declared eradicated in 2015, the World Health Organization coordinated worldwide replacement of trivalent OPV with bivalent OPV (types 1 and 3) in April 2016.
   What is added by this report?
   During January 2015-May 2016, new cVDPV outbreaks were identified in Burma, Guinea, Laos, Madagascar, and Ukraine, while cVDPV2 circulation in Nigeria and Pakistan sharply declined. Twenty-one newly identified persons in 10 countries were found to excrete iVDPVs.
   What are the implications for public health practice?
   The ultimate goal of the Global Polio Eradication Initiative is the cessation of all poliovirus circulation. The risk for iVDPV emergence will continue as long as OPV is used. The switch from trivalent OPV to bivalent OPV in April 2016 was the first step to phasing out the use of all OPV, setting the stage for a total worldwide shift from OPV to IPV.
C1 [Jorba, Jaume; Iber, Jane; Burns, Cara C.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Diop, Ousmane M.] WHO, Dept Polio Eradicat, Detect & Interrupt Unit, Geneva, Switzerland.
   [Sutter, Roland W.] World Hlth Org, Dept Polio Eradicat, Res Policy & Containment Unit, Geneva, Switzerland.
   [Wassilak, Steven G.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Burns, CC (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM cburns@cdc.gov
NR 10
TC 4
Z9 4
U1 8
U2 8
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 763
EP 769
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800003
PM 27491079
ER

PT J
AU Etsano, A
   Damisa, E
   Shuaib, F
   Nganda, GW
   Enemaku, O
   Usman, S
   Adeniji, A
   Jorba, J
   Iber, J
   Ohuabunwo, C
   Nnadi, C
   Wiesen, E
AF Etsano, Andrew
   Damisa, Eunice
   Shuaib, Faisal
   Nganda, Gatei Wa
   Enemaku, Ogu
   Usman, Samuel
   Adeniji, Adekunle
   Jorba, Jaume
   Iber, Jane
   Ohuabunwo, Chima
   Nnadi, Chimeremma
   Wiesen, Eric
TI Environmental Isolation of Circulating Vaccine-Derived Poliovirus After
   Interruption of Wild Poliovirus Transmission - Nigeria, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
AB What is known about this topic?
   The last case of wild poliovirus transmission in Nigeria was reported in July 2014. The country was officially removed from the list of countries with endemic wild poliovirus transmission in September 2015.
   What is added by this report?
   In April 2016, a laboratory-confirmed isolate of circulating vaccine-derived poliovirus type 2 (cVDPV2), a genetic variant of the vaccine virus with the potential to cause paralysis, was reported from a sewage effluent site in Borno, a state in northeastern Nigeria with international boundaries. Years of armed insurgency in Borno have led to reduced polio vaccination and surveillance activities, resulting in a population of underimmunized children. The Nigeria National Polio Emergency Operations Center activated an outbreak response that included supplemental immunization activities (SIAs), a retrospective search for acute flaccid paralysis (AFP) cases, and enhanced environmental surveillance. Approximately 1 million children were vaccinated in the first SIA round, and 13 previously unreported AFP cases were identified.
   What are the implications for public health practice?
   Strategies for increasing vaccination coverage, including deployment of innovative approaches for reaching children in conflict-affected areas, are needed to prevent VDPV and other vaccine preventable disease (VPD) outbreaks. Strengthening surveillance is an urgent priority. Closer coordination of polio eradication activities between state and national jurisdictions in the region should be considered to prevent the potential spread of cVDPV and other VPDs across international boundaries.
C1 [Etsano, Andrew; Damisa, Eunice] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
   [Shuaib, Faisal] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Nganda, Gatei Wa; Ohuabunwo, Chima; Nnadi, Chimeremma; Wiesen, Eric] CDC, Global Immunizat Div, Atlanta, GA 30333 USA.
   [Enemaku, Ogu] Nigeria Off, United Nations Childrens Fund, Abuja, Nigeria.
   [Usman, Samuel] CORE Grp Partners Project, Abuja, Nigeria.
   [Adeniji, Adekunle] Univ Ibadan, Coll Med, Div Virol, Ibadan, Nigeria.
   [Jorba, Jaume; Iber, Jane] CDC, Polio & Picornavirus Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Nnadi, C (reprint author), CDC, Global Immunizat Div, Atlanta, GA 30333 USA.
EM cnnadi@cdc.gov
NR 8
TC 4
Z9 4
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 770
EP 773
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800004
PM 27490081
ER

PT J
AU Adams, L
   Bello-Pagan, M
   Lozier, M
   Ryff, KR
   Espinet, C
   Torres, J
   Perez-Padilla, J
   Febo, MF
   Dirlikov, E
   Martinez, A
   Munoz-Jordan, J
   Garcia, M
   Segarra, MO
   Malave, G
   Rivera, A
   Shapiro-Mendoza, C
   Rosinger, A
   Kuehnert, MJ
   Chung, KW
   Pate, LL
   Harris, A
   Hemme, RR
   Lenhart, A
   Aquino, G
   Zaki, S
   Read, JS
   Waterman, SH
   Alvarado, LI
   Alvarado-Ramy, F
   Valencia-Prado, M
   Thomas, D
   Sharp, TM
   Rivera-Garcia, B
AF Adams, Laura
   Bello-Pagan, Melissa
   Lozier, Matthew
   Ryff, Kyle R.
   Espinet, Carla
   Torres, Jomil
   Perez-Padilla, Janice
   Febo, Mitchelle Flores
   Dirlikov, Emilio
   Martinez, Alma
   Munoz-Jordan, Jorge
   Garcia, Myriam
   Segarra, Marangely Olivero
   Malave, Graciela
   Rivera, Aidsa
   Shapiro-Mendoza, Carrie
   Rosinger, Asher
   Kuehnert, Matthew J.
   Chung, Koo-Whang
   Pate, Lisa L.
   Harris, Angela
   Hemme, Ryan R.
   Lenhart, Audrey
   Aquino, Gustavo
   Zaki, Sherif
   Read, Jennifer S.
   Waterman, Stephen H.
   Alvarado, Luisa I.
   Alvarado-Ramy, Francisco
   Valencia-Prado, Miguel
   Thomas, Dana
   Sharp, Tyler M.
   Rivera-Garcia, Brenda
TI Update: Ongoing Zika Virus Transmission - Puerto Rico, November 1,
   2015-July 7, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID INFECTION; EPIDEMIC; OUTBREAK; DISEASE; STATES
AB What is already known about this topic?
   Zika virus transmission in Puerto Rico has been increasing since it was first detected in November 2015. Zika virus infection is a cause of microcephaly and other severe birth defects and has been associated with Guillain-Barre syndrome and severe thrombocytopenia.
   What is added by this report?
   During November 1, 2015-July 7, 2016, specimens from 16,522 patients with suspected Zika virus disease in Puerto Rico were evaluated and 5,351 (32%) had laboratory evidence of current or recent Zika virus infection. The percentage of persons with confirmed or presumptive Zika virus infection among symptomatic pregnant females increased from 8% in February 2016 to 41% in June 2016; during the same time, the percentage of persons with confirmed or presumptive Zika virus infection among symptomatic males and nonpregnant females increased from 14% to 64%. The public health response includes increased surveillance for Zika virus infection, preventing infection in pregnant women, monitoring infected pregnant women and their fetuses for adverse outcomes, controlling mosquitoes, assuring the safety of blood products, and expanding access to the full range of voluntary contraceptive options for women and men.
   What are the implications for public health practice?
   The Zika virus outbreak in Puerto Rico continues to expand in geographic extent and number of infected persons. Residents of and travelers to Puerto Rico should continue to employ mosquito bite avoidance behaviors, take precautions to reduce the risk for sexual transmission, and seek medical care for any acute illness with rash or fever. Intensified vector control measures, including an integrated vector management strategy, are needed to help reduce disease spread. Clinicians who suspect Zika virus disease in patients who reside in or have recently returned from areas with ongoing Zika virus transmission should consider testing for Zika virus and report cases to public health officials.
C1 [Adams, Laura; Lozier, Matthew; Perez-Padilla, Janice; Febo, Mitchelle Flores; Munoz-Jordan, Jorge; Rivera, Aidsa; Harris, Angela; Hemme, Ryan R.; Read, Jennifer S.; Waterman, Stephen H.; Sharp, Tyler M.] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Bello-Pagan, Melissa; Ryff, Kyle R.; Espinet, Carla; Torres, Jomil; Febo, Mitchelle Flores; Dirlikov, Emilio; Thomas, Dana; Rivera-Garcia, Brenda] Puerto Rico Dept Hlth, Off Epidemiol & Res, San Juan, PR USA.
   [Dirlikov, Emilio] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
   [Martinez, Alma; Valencia-Prado, Miguel] Puerto Rico Dept Hlth, Puerto Rico Birth Defects Surveillance & Prevent, San Juan, PR USA.
   [Garcia, Myriam; Segarra, Marangely Olivero; Malave, Graciela] Puerto Rico Dept Hlth, Biol & Chem Emergencies Lab, Off Publ Hlth Preparedness & Response, San Juan, PR USA.
   [Garcia, Myriam; Segarra, Marangely Olivero; Malave, Graciela] Puerto Rico Dept Hlth, Publ Hlth Lab, San Juan, PR USA.
   [Shapiro-Mendoza, Carrie] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Rosinger, Asher] Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Surveys, Atlanta, GA USA.
   [Kuehnert, Matthew J.; Chung, Koo-Whang] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Pate, Lisa L.] Roche Mol Syst Inc, Pleasanton, CA USA.
   [Lenhart, Audrey] CDC, Entomol Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Aquino, Gustavo] CDC, Off Director, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Zaki, Sherif] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Alvarado, Luisa I.] Ponce Hlth Sci Univ, St Lukes Episcopal Hosp Consortium, Ponce, PR USA.
   [Alvarado-Ramy, Francisco] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Thomas, Dana] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
RP Adams, L (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM leadams@cdc.gov
NR 20
TC 14
Z9 14
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 774
EP 779
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800005
PM 27490087
ER

PT J
AU Boulet, SL
   D'Angelo, DV
   Morrow, B
   Zapata, L
   Berry-Bibee, E
   Rivera, M
   Ellington, S
   Romero, L
   Lathrop, E
   Frey, M
   Williams, T
   Goldberg, H
   Warner, L
   Harrison, L
   Cox, S
   Pazol, K
   Barfield, W
   Jamieson, DJ
   Honein, MA
   Kroelinger, CD
AF Boulet, Sheree L.
   D'Angelo, Denise V.
   Morrow, Brian
   Zapata, Lauren
   Berry-Bibee, Erin
   Rivera, Maria
   Ellington, Sascha
   Romero, Lisa
   Lathrop, Eva
   Frey, Meghan
   Williams, Tanya
   Goldberg, Howard
   Warner, Lee
   Harrison, Leslie
   Cox, Shanna
   Pazol, Karen
   Barfield, Wanda
   Jamieson, Denise J.
   Honein, Margaret A.
   Kroelinger, Charlan D.
TI Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for
   Unintended Pregnancy, and Female High School Students, in the Context of
   Zika Preparedness - United States, 2011-2013 and 2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID AFFORDABLE CARE ACT
AB What is already known on this topic?
   Zika virus is transmitted through the bite of an Aedes species mosquito, sex with an infected partner, or from a pregnant woman to her fetus. Zika virus infection during pregnancy is a cause of congenital microcephaly and other severe fetal brain defects. It has also been associated with eye defects, hearing loss, and impaired growth. Nearly half of all pregnancies in the United States are unintended. Among nonpermanent contraceptive methods, long-acting reversible contraception (LARC) is the most effective contraceptive option for preventing unintended pregnancy.
   What is added by this report?
   State-based estimates of contraception use are provided for nonpregnant and postpartum women at risk for unintended pregnancy and sexually active female high school students. Among these populations, use of moderate and less effective contraception was most common; use of no contraceptive method and use of LARC varied by state, age group, and race/ethnicity.
   What are the implications for public health practice?
   State and local strategies are needed to increase access to contraceptive methods and related services, reduce the risk for unintended pregnancy, and minimize the number of pregnancies affected by Zika infection. Potentially effective strategies include addressing policies on high device costs and provider reimbursement, comprehensive provider training on insertion and removal of LARC, provision of youth-friendly services, support to resource-challenged jurisdictions, client-centered counseling and assessment of patient satisfaction, and increased consumer awareness of the full range of contraceptive methods to delay or avoid pregnancy.
C1 [Boulet, Sheree L.; D'Angelo, Denise V.; Morrow, Brian; Zapata, Lauren; Berry-Bibee, Erin; Ellington, Sascha; Romero, Lisa; Williams, Tanya; Goldberg, Howard; Warner, Lee; Harrison, Leslie; Cox, Shanna; Pazol, Karen; Barfield, Wanda; Jamieson, Denise J.; Kroelinger, Charlan D.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Frey, Meghan; Honein, Margaret A.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
   [Rivera, Maria] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
   [Lathrop, Eva] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Kroelinger, CD (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM ckroelinger@cdc.gov
NR 15
TC 4
Z9 4
U1 2
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 780
EP 787
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800006
PM 27490117
ER

PT J
AU Kawakami, V
   Rietberg, K
   Lipton, B
   Eckmann, K
   Watkins, M
   Oltean, H
   Kay, M
   Rothschild, C
   Kobayashi, M
   Van Beneden, C
   Duchin, J
AF Kawakami, Vance
   Rietberg, Krista
   Lipton, Beth
   Eckmann, Kaye
   Watkins, Maryann
   Oltean, Hanna
   Kay, Meagan
   Rothschild, Chantal
   Kobayashi, Miwako
   Van Beneden, Chris
   Duchin, Jeff
TI Fatal Infection Associated with Equine Exposure - King County,
   Washington, 2016
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Kawakami, Vance; Rietberg, Krista; Lipton, Beth; Kay, Meagan; Duchin, Jeff] Publ Hlth Seattle & King Cty, Seattle, WA 98133 USA.
   [Kawakami, Vance; Kobayashi, Miwako] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Eckmann, Kaye; Watkins, Maryann] Washington State Dept Hlth Publ Hlth Labs, Washington, DC USA.
   [Oltean, Hanna] Washington State Dept Hlth, Washington, DC USA.
   [Rothschild, Chantal] Northwest Equine Vet Associates, Washington, DC USA.
   [Kobayashi, Miwako; Van Beneden, Chris] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Duchin, Jeff] Univ Washington, Seattle, WA 98195 USA.
RP Kawakami, V (reprint author), Publ Hlth Seattle & King Cty, Seattle, WA 98133 USA.; Kawakami, V (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM vance.kawakami@kingcounty.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD AUG 5
PY 2016
VL 65
IS 30
BP 788
EP 788
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EA5XZ
UT WOS:000386699800007
PM 27490189
ER

PT J
AU Mehta, P
   Kaye, W
   Bryan, L
   Larson, T
   Copeland, T
   Wu, J
   Muravov, O
   Horton, K
AF Mehta, Paul
   Kaye, Wendy
   Bryan, Leah
   Larson, Theodore
   Copeland, Timothy
   Wu, Jennifer
   Muravov, Oleg
   Horton, Kevin
TI Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013
SO MMWR SURVEILLANCE SUMMARIES
LA English
DT Article
ID CAPTURE-RECAPTURE METHODOLOGY; PILOT CASE-CONTROL; EPIDEMIOLOGIC
   RESEARCH; MILITARY SERVICE; HEAVY-METALS; ALS; REGISTRY; SURVEILLANCE;
   COMPLETENESS; DISEASES
AB Problem/Condition: Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive and fatal neuromuscular disease for which no cure or viable treatment has been identified. ALS, like most noncommunicable diseases, is not a nationally notifiable disease in the United States. The prevalence of ALS in the United States during 2010-2011 was estimated to be 3.9 cases per 100,000 persons in the general population. Updated prevalence estimates are needed to help monitor disease status, better understand etiology, and identify risk factors for ALS.
   Period Covered: 2012-2013.
   Description of System: The National ALS Registry, established in 2009, collects data on ALS patients in the United States to better describe the incidence and prevalence of ALS, examine risk factors such as environmental and occupational exposures, and characterize the demographics of those living with ALS. To identify prevalent cases of ALS, data are compiled from four national administrative databases (maintained by the Centers for Medicare and Medicaid Services, the Veterans Health Administration, and the Veterans Benefits Administration). To identify cases not included in these databases and to better understand risk-factors associated with ALS and disease progression, the Registry also includes data that are collected from patients who voluntarily enroll and complete online surveys.
   Results: During 2012 and 2013, the Registry identified 14,713 and 15,908 persons, respectively, who met the surveillance case definition of ALS. The estimated ALS prevalence rate was 4.7 cases per 100,000 U.S. population for 2012 and 5.0 per 100,000 for 2013. Due to revisions to the algorithm and use of death data from the National Death Index, an updated prevalence estimate has been calculated retrospectively for October 19, 2010-December 31, 2011. This updated estimate showed a prevalence rate of 4.3 per 100,000 population and a total of 13,282 rases. Since the inception of the Registry, the pattern of characteristics (e.g., age, sex, and race/ethnicity) among persons with ALS have remained unchanged. Overall, ALS was more common among whites, males, and persons aged 60-69 years. The age groups with the lowest number of ALS cases were persons aged 18-39 years and those aged >= 80 years: Males had a higher prevalence rate of ALS than females overall and across all data sources. These findings remained consistent during October 2010-December 2013.
   Interpretation: The Registry is the only available data source that can be used to estimate the national prevalence for ALS in the United States. Use of both administrative national databases and self-report from patients enables a comprehensive approach to estimate ALS prevalence. The overall increase in the prevalence rate from 4.3 per 100,000 persons (revised) during 2010-2011 to 4.7 and 5.0 per 100,000 persons, respectively, during 2012-2013 likely is not an actual increase in the number of ALS cases. Rather, this increase might be attributed to improved case ascertainment due to the refinement of the algorithm used to identify definite ALS cases, along with an increased public awareness of the Registry. Registry estimates of ALS prevalence are consistent with findings from long-established ALS registries in Europe and from smaller-scale epidemiologic studies previously conducted in the United States.
   Public Health Actions: Data collected by the National ALS Registry are being used to better describe the epidemiology of ALS in the United States and to help facilitate research. The combined approach of using national administrative databases and a self-enrollment web portal to collect data is novel and potentially could be used for other non-notifiable diseases such as Parkinson's disease or multiple sclerosis.
   Increased public awareness of the Registry might lead to more ALS cases being identified from the secure web portal (https://www.cdc.gov/als), which can ascertain cases apart from the national administrative databases. For example, in 2014, the ALS Ice Bucket Challenge, a social media-centered campaign, received extensive public visibility and created increased awareness of ALS. The Agency for Toxic Substances and Disease Registry (ATSDR) works closely with ALS advocacy and support groups, researchers, health en re professionals, and others to promote the National ALS Registry and to identify all cases of ALS in the United States. In addition to estimating the prevalence of ALS, the Registry is being used to collect specimens from patient enrollees through a new biorepository, connect patient enrollees with new clinical trials and epidemiologic studies, and fund studies to help learn more about the etiology of ALS. Additional information about the National ALS Registry is available at http://www.cdc.gov/als or by calling toll-free at 1-877-442-9719.
C1 [Mehta, Paul; Larson, Theodore; Copeland, Timothy; Wu, Jennifer; Muravov, Oleg; Horton, Kevin] Agcy Tox Subst & Dis Registry, Atlanta, GA USA.
   [Kaye, Wendy] McKing Consulting Corp, Atlanta, GA USA.
   [Bryan, Leah] Carter Consulting Inc, Atlanta, GA USA.
RP Mehta, P (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA.
EM pum4@cdc.gov
NR 53
TC 5
Z9 5
U1 9
U2 9
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-8636
J9 MMWR SURVEILL SUMM
JI MMWR Surv. Summ.
PD AUG 5
PY 2016
VL 65
IS 8
BP 1
EP 12
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DW3DZ
UT WOS:000383523600001
PM 27490513
ER

PT J
AU Parveen, S
   Islam, MS
   Begum, M
   Alam, MU
   Sazzad, HMS
   Sultana, R
   Rahman, M
   Gurley, ES
   Hossain, MJ
   Luby, SP
AF Parveen, Shahana
   Islam, M. Saiful
   Begum, Momtaz
   Alam, Mahbub-Ul
   Sazzad, Hossain M. S.
   Sultana, Rebeca
   Rahman, Mahmudur
   Gurley, Emily S.
   Hossain, M. Jahangir
   Luby, Stephen P.
TI It's not only what you say, it's also how you say it: communicating
   nipah virus prevention messages during an outbreak in Bangladesh
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Nipah virus; Outbreak; Prevention messages; Communication strategy;
   Anthropological approach; Contextual understanding; Bangladesh
ID TO-PERSON TRANSMISSION; HEALTH; INFECTION; ENCEPHALITIS; STRATEGIES;
   COMMUNITY; MODEL
AB Background: During a fatal Nipah virus (NiV) outbreak in Bangladesh, residents rejected biomedical explanations of NiV transmission and treatment and lost trust in the public healthcare system. Field anthropologists developed and communicated a prevention strategy to bridge the gap between the biomedical and local explanation of the outbreak.
   Methods: We explored residents' beliefs and perceptions about the illness and care-seeking practices and explained prevention messages following an interactive strategy with the aid of photos showed the types of contact that can lead to NiV transmission from bats to humans by drinking raw date palm sap and from person-to-person.
   Results: The residents initially believed that the outbreak was caused by supernatural forces and continued drinking raw date palm sap despite messages from local health authorities to stop. Participants in community meetings stated that the initial messages did not explain that bats were the source of this virus. After our intervention, participants responded that they now understood how NiV could be transmitted and would abstain from raw sap consumption and maintain safer behaviours while caring for patients.
   Conclusions: During outbreaks, one-way behaviour change communication without meaningful causal explanations is unlikely to be effective. Based on the cultural context, interactive communication strategies in lay language with supporting evidence can make biomedical prevention messages credible in affected communities, even among those who initially invoke supernatural causal explanations.
C1 [Parveen, Shahana; Islam, M. Saiful; Begum, Momtaz; Alam, Mahbub-Ul; Sazzad, Hossain M. S.; Sultana, Rebeca; Gurley, Emily S.; Hossain, M. Jahangir; Luby, Stephen P.] Icddr B, Div Infect Dis, Dhaka, Bangladesh.
   [Rahman, Mahmudur] IEDCR, Dhaka, Bangladesh.
   [Hossain, M. Jahangir] Med Res Council Unit UK, Banjul, Gambia.
   [Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Global Hlth Protect Div, Atlanta, GA USA.
   [Luby, Stephen P.] Stanford Univ, Infect Dis & Geog Med, Stanford, CA 94305 USA.
   [Parveen, Shahana] Icddr B, Div Infect Dis, Programme Emerging Infect, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
RP Parveen, S (reprint author), Icddr B, Div Infect Dis, Dhaka, Bangladesh.; Parveen, S (reprint author), Icddr B, Div Infect Dis, Programme Emerging Infect, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM shahana@icddrb.org
RI Gurley, Emily/B-7903-2010; 
OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X
FU U.S. Centers for Disease Control and Prevention (CDC) [5U01CI000628-01];
   Government of the People's Republic of Bangladesh
FX This study was supported by the U.S. Centers for Disease Control and
   Prevention (CDC) through cooperative award number 5U01CI000628-01 and by
   the Government of the People's Republic of Bangladesh. icddr,b
   acknowledges with gratitude the commitment of the CDC for its research
   efforts. icddr,b is also grateful to the Governments of Bangladesh,
   Canada, Sweden and the UK for providing core/unrestricted support.
NR 52
TC 1
Z9 1
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 5
PY 2016
VL 16
AR 726
DI 10.1186/s12889-016-3416-z
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DS8BA
UT WOS:000381006400002
PM 27495927
ER

PT J
AU Omore, R
   Tate, JE
   O'Reilly, CE
   Ayers, T
   Williamson, J
   Moke, F
   Schilling, KA
   Awuor, AO
   Jaron, P
   Ochieng, JB
   Oundo, J
   Parashar, UD
   Parsons, MB
   Bopp, CC
   Nasrin, D
   Farag, TH
   Kotloff, KL
   Nataro, JP
   Panchalingam, S
   Levine, MM
   Laserson, KF
   Nuorti, JP
   Mintz, ED
   Breiman, RF
AF Omore, Richard
   Tate, Jacqueline E.
   O'Reilly, Ciara E.
   Ayers, Tracy
   Williamson, John
   Moke, Feny
   Schilling, Katie A.
   Awuor, Alex O.
   Jaron, Peter
   Ochieng, John B.
   Oundo, Joseph
   Parashar, Umesh D.
   Parsons, Michele B.
   Bopp, Cheryl C.
   Nasrin, Dilruba
   Farag, Tamer H.
   Kotloff, Karen L.
   Nataro, James P.
   Panchalingam, Sandra
   Levine, Myron M.
   Laserson, Kayla F.
   Nuorti, J. Pekka
   Mintz, Eric D.
   Breiman, Robert F.
TI Epidemiology, Seasonality and Factors Associated with Rotavirus
   Infection among Children with Moderate-to-Severe Diarrhea in Rural
   Western Kenya, 2008-2012: The Global Enteric Multicenter Study (GEMS)
SO PLOS ONE
LA English
DT Article
ID YOUNG-CHILDREN; DEVELOPING-COUNTRIES; GASTROENTERITIS; DISEASE; VACCINE;
   BURDEN; SURVEILLANCE; PREVALENCE; MORTALITY; EFFICACY
AB Objective
   To evaluate factors associated with rotavirus diarrhea and to describe severity of illness among children < 5 years old with non-dysenteric, moderate-to-severe diarrhea (MSD) in rural western Kenya.
   Methods
   We analyzed data from children < 5 years old with non-dysenteric MSD enrolled as cases in the Global Enteric Multicenter Study (GEMS) in Kenya. A non-dysenteric MSD case was defined as a child with >= 3 loose stools in 24 hrs. and one or more of the following: sunken eyes, skin tenting, intravenous rehydration, or hospitalization, who sought care at a sentinel health center within 7 days of illness onset. Rotavirus antigens in stool samples were detected by ELISA. Demographic and clinical information was collected at enrollment and during a single follow-up home visit at approximately 60 days. We analyzed diarrhea severity using a GEMS 17 point numerical scoring system adapted from the Vesikari score. We used logistic regression to evaluate factors associated with rotavirus infection.
   Results
   From January 31, 2008 to September 30, 2012, among 1,637 (92%) non-dysenteric MSD cases, rotavirus was detected in stools of 245 (15.0%). Rotavirus-positive compared with negative cases were: younger (median age, 8 vs. 13 months; p< 0.0001), had more severe illness (median severity score, 9 vs 8; p< 0.0001) and had to be hospitalized more frequently (37/245 [15.1%] vs. 134/1,392 [9.6%]), p < 0.013). Independent factors associated with rotavirus infection included age 0-11 months old (aOR = 5.29, 95% CI 3.14-8.89) and presenting with vomiting >= 3 times/24hrs (aOR = 2.58, 95% CI [1.91-3.48]). Rotavirus was detected more commonly in warm and dry months than in the cool and rainy months (142/691 [20%] vs 70/673 [10%]) p< 0.0001).
   Conclusions
   Diarrhea caused by rotavirus is associated with severe symptoms leading to hospitalization. Consistent with other settings, infants had the greatest burden of disease.
C1 [Omore, Richard; Moke, Feny; Awuor, Alex O.; Jaron, Peter; Ochieng, John B.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
   [Tate, Jacqueline E.; Parashar, Umesh D.] US Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
   [O'Reilly, Ciara E.; Ayers, Tracy; Schilling, Katie A.; Parsons, Michele B.; Bopp, Cheryl C.; Mintz, Eric D.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
   [Williamson, John; Laserson, Kayla F.] US Ctr Dis Control & Prevent, Kisumu, Kenya.
   [Oundo, Joseph; Breiman, Robert F.] US Ctr Dis Control & Prevent, Global Dis Detect Div, Kenya Off, Nairobi, Kenya.
   [Nasrin, Dilruba; Farag, Tamer H.; Kotloff, Karen L.; Nataro, James P.; Panchalingam, Sandra; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Nataro, James P.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA.
   [Laserson, Kayla F.] CDC India, Delhi, India.
   [Omore, Richard; Nuorti, J. Pekka] Univ Tampere, Sch Hlth Sci, Tampere, Finland.
   [Breiman, Robert F.] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA.
RP Omore, R (reprint author), Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.; Omore, R (reprint author), Univ Tampere, Sch Hlth Sci, Tampere, Finland.
EM omorerichard@gmail.com
OI Ayers, Tracy/0000-0003-4140-3263
FU Bill and Melinda Gates Foundation [38874, OPP10333572]
FX This study was funded by the Bill and Melinda Gates Foundation, Grants #
   38874 (GEMS) and #OPP10333572 (GEMS1A), Myron M. Levine (PI) through the
   University of Maryland, School of Medicine, Center for Vaccine
   Development, Baltimore, MD USA. The funder had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 42
TC 0
Z9 0
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 5
PY 2016
VL 11
IS 8
AR e0160060
DI 10.1371/journal.pone.0160060
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GR
UT WOS:000381369500019
ER

PT J
AU Patel, MK
   Wannemuehler, K
   Tairi, R
   Tutai, R
   Moturi, E
   Tabwaia, B
   Nikuata, AB
   Etuale, MF
   Mokoia, G
AF Patel, Minal K.
   Wannemuehler, Kathleen
   Tairi, Rangi
   Tutai, Rufina
   Moturi, Edna
   Tabwaia, Beia
   Nikuata, Akineti Bauro
   Etuale, Malae Fepuleai
   Mokoia, Grizelda
TI Progress towards achieving hepatitis B control in the Cook Islands,
   Niue, Tokelau, and Kiribati
SO VACCINE
LA English
DT Article
DE Hepatitis B; Vaccination; Cook Islands; Niue; Tokelau; Kiribati
ID PACIFIC REGION; INFECTION; ANTIGEN
AB Background: Hepatitis B virus (HBV) is highly endemic in many of the Pacific Island countries. Four island countries Cook Islands, Kiribati, Niue, and Tokelau sought to evaluate the success of their hepatitis B vaccination programs by conducting nationally representative serosurveys among children born post vaccine introduction.
   Methods: Cook Islands, Niue, and Tokelau conducted school -based census serosurveys because of small populations. The Cook Islands tested children in second grade; Niue tested children in early childhood education through sixth grade; and Tokelau tested children in first through sixth grades. Because Kiribati has a much larger birth cohort, it conducted a one-stage stratified serosurvey among first grade students. All four countries tested children using the Alere Determine (TM) rapid point of care hepatitis B surface antigen (HBsAg) test.
   Results: In the three smaller countries, no children were seropositive for HBsAg (0/245 Cook Island students, 0/183 Niuean students, 0/171 Tokelau students). In Kiribati, 39 (3.3%, 95% confidence interval 2.44.6%) of 1249 students were HBsAg positive. Vaccination data collected in the Cook Islands and Tokelau showed high vaccination coverage in both countries with >= 95% birth dose coverage and 100% 3-dose coverage.
   Conclusions: The Cook Islands, Niue, and Tokelau have made remarkable progress in establishing strong vaccination programs and towards decreasing the burden of hepatitis B among children. Kiribati still needs to improve vaccination coverage to achieve the <1% HBsAg target established by the World Health Organization Western Pacific Region. Published by Elsevier Ltd.
C1 [Patel, Minal K.; Wannemuehler, Kathleen; Moturi, Edna] Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Tairi, Rangi; Tutai, Rufina] Cook Isl Minist Hlth, Expanded Programme Immunizat, POB 109, Rarotonga, Cook Islands.
   [Moturi, Edna] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Tabwaia, Beia] Kiribati Minist Hlth & Med Serv, Expanded Programme Immunizat, POB 268, Nawerewere, Tarawa, Kiribati.
   [Nikuata, Akineti Bauro] World Hlth Org Kiribati Country Off, Maternal & Child Hlth, Bikenibeu, Tarawa, Kiribati.
   [Etuale, Malae Fepuleai] Tokelau Hlth Dept Head Off, Nukunonu, Tokelau Islands.
   [Mokoia, Grizelda] Niue Dept Hlth, Expanded Programme Immunizat, POB 33, Alofi, Niue.
   [Moturi, Edna] United Nations High Commissioner Refugees, POB 2666, Dar Es Salaam, Tanzania.
RP Patel, MK (reprint author), 1600 Clifton Rd MS E-98, Atlanta, GA 30329 USA.
EM hgo9@cdc.gov; kpw9@cdc.gov; rangi.tairi@cookislands.gov.ck;
   rufina.tutai@cookislands.gov.ck; moturi@unhcr.org;
   beiatabwaia@gmail.com; nikuataa@who.int; mfepuleai.etuale@gmail.com;
   Grizelda.Mokoia@mail.gov.nu
FU World Health Organization (WHO)
FX This work was supported by the World Health Organization (WHO). WHO had
   no direct role in this work except Akineti Bauro Nikuata who is employed
   by WHO and to serve as the ethics committee for the four countries.
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 5
PY 2016
VL 34
IS 36
BP 4298
EP 4303
DI 10.1016/j.vaccine.2016.06.083
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DT5NP
UT WOS:000381530200009
PM 27402565
ER

PT J
AU Sein, C
   Tiwari, T
   Macneil, A
   Wannemuehler, K
   Soulaphy, C
   Souliphone, P
   Reyburn, R
   Gonzalez, AR
   Watkins, M
   Goodson, JL
AF Sein, Carolyn
   Tiwari, Tejpratap
   Macneil, Adam
   Wannemuehler, Kathleen
   Soulaphy, Chanthavy
   Souliphone, Phouthone
   Reyburn, Rita
   Gonzalez, Alejandro Ramirez
   Watkins, Margaret
   Goodson, James L.
TI Diphtheria outbreak in Lao People's Democratic Republic, 2012-2013
SO VACCINE
LA English
DT Article
DE Diphtheria; Lao PDR; Outbreak; Vaccination; Vaccine-preventable
ID VACCINATION; STATES; UNION
AB Background: Diphtheria is a vaccine-preventable disease. When vaccination coverage and population immunity are low, outbreaks can occur. We investigated a diphtheria outbreak in Lao People's Democratic Republic that occurred during 2012-2013 and highlighted challenges in immunization services delivery to children in the country.
   Methods: We reviewed diphtheria surveillance data from April 1, 2012-May 31, 2013. A diphtheria case was defined as a respiratory illness consisting of pharyngitis, tonsillitis, or laryngitis, and an adherent tonsillar or nasopharyngeal pseudomembrane. To identify potential risk factors for diphtheria, we conducted a retrospective case-control study with two aged-matched neighborhood controls per case patient in Houaphan Province, using bivariate analysis to calculate matched odds ratio (mOR) with 95% confidence intervals (CI). Reasons for non-vaccination among unvaccinated persons were assessed.
   Results: Sixty-two clinical cases of diphtheria and 12 diphtheria-related deaths were reported in seven of 17 provinces. Among case-patients, 43 (69%) were <15 years old, five (8%) reported receiving three DTP doses (DTP3), 21 (34%) had received no DTP doses, and 35 (56%) had unknown vaccination status. For the case-control study, 42 of 52 diphtheria case-patients from Houaphan province and 79 matched-controls were enrolled. Five (12%) case-patients and 20 (25%) controls had received DTP3 (mOR = 0.4, CI = 0.1-1.7). No diphtheria toxoid-containing vaccine was received by 20 (48%) case-patients and 38 (46%) controls. Among case-patients and controls with no DTP dose, 43% of case-patients and 40% of controls lacked access to routine immunization services.
   Conclusion: Suboptimal DTP3 coverage likely caused the outbreak. To prevent continued outbreaks, access to routine immunization services should be strengthened, outreach visits need to be increased, and missed opportunities need to be minimized. In the short term, to rapidly increase population immunity, three rounds of DTP immunization campaign should be completed, targeting children aged 0-14 years in affected provinces. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Sein, Carolyn; Macneil, Adam; Wannemuehler, Kathleen; Watkins, Margaret; Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
   [Tiwari, Tejpratap] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Soulaphy, Chanthavy; Souliphone, Phouthone] Minist Hlth, Natl Ctr Lab & Epidemiol, Viangchan, Laos.
   [Reyburn, Rita; Gonzalez, Alejandro Ramirez] World Hlth Org, Viangchan, Laos.
   [Sein, Carolyn] WHO, Res & Prod Dev, Polio Eradicat Dept, Ave Appia 20, CH-1211 Geneva, Switzerland.
RP Sein, C (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-92, Atlanta, GA 30333 USA.
EM seinc@who.int
FU Centers for Disease Control and Prevention, United States
FX Funding for this study was provided by The Centers for Disease Control
   and Prevention, United States.
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 5
PY 2016
VL 34
IS 36
BP 4321
EP 4326
DI 10.1016/j.vaccine.2016.06.074
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DT5NP
UT WOS:000381530200012
PM 27422343
ER

PT J
AU Wallace, GS
   Curns, AT
   Weldon, WC
   Oberste, MS
AF Wallace, Gregory S.
   Curns, Aaron T.
   Weldon, William C.
   Oberste, M. Steven
TI Seroprevalence of Poliovirus Antibodies in the United States Population,
   2009-2010
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Polio; Poliovirus; NHANES; Seroepidemiologic studies; Antibodies
ID POLIOMYELITIS ERADICATION; PRESCHOOL-CHILDREN; PROGRESS; VACCINATION;
   IMMUNITY
AB Background: Polio is eliminated in the United States, with the last indigenous transmission occurring in 1979. However, global eradication of polio has not yet been completed, so importation of poliovirus into the U.S. is still possible. Specimens from the 2009-10 National Health and Nutrition Examination Survey (NHANES) were analyzed to evaluate population seroprevalence and assess overall risk from a poliovirus importation.
   Methods: We evaluated prevalence of serum antibodies to all three poliovirus types using the National Health and Nutrition Examination Survey during 2009-2010.
   Results: The overall seroprevalence to poliovirus was 93.9 % for type 1, 97.0 % for type 2, and 83.1 % for type 3. Seroprevalence was higher for type 2 compared to the other types (p < 0.001) and lower for type 3 compared to the other types (p < 0.001). There was a tendency for higher seroprevalence in the younger age groups, but this varied by serotype.
   Conclusions: Seroprevalence was high (83.1 %-97.0 %) for all three types of poliovirus in the US population during 2009-2010. While there were observed differences by serotype with type 2 having the highest seroprevalence and type 3 having the lowest, consistent with previous observations, no large immunity gaps to poliovirus suggesting an imminent substantial population risk from a poliovirus importation were observed at a population level.
C1 [Wallace, Gregory S.; Curns, Aaron T.; Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
RP Curns, AT (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
EM agc8@cdc.gov
NR 13
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 5
PY 2016
VL 16
AR 721
DI 10.1186/s12889-016-3386-1
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DS8AS
UT WOS:000381005600001
PM 27492318
ER

PT J
AU Farahani, M
   Price, N
   El-Halabi, S
   Mlaudzi, N
   Keapoletswe, K
   Lebelonyane, R
   Fetogang, EB
   Chebani, T
   Kebaabetswe, P
   Masupe, T
   Gabaake, K
   Auld, AF
   Nkomazana, O
   Marlink, R
AF Farahani, Mansoor
   Price, Natalie
   El-Halabi, Shenaaz
   Mlaudzi, Naledi
   Keapoletswe, Koona
   Lebelonyane, Refeletswe
   Fetogang, Ernest Benny
   Chebani, Tony
   Kebaabetswe, Poloko
   Masupe, Tiny
   Gabaake, Keba
   Auld, Andrew F.
   Nkomazana, Oathokwa
   Marlink, Richard
TI Impact of Health System Inputs on Health Outcome: A Multilevel
   Longitudinal Analysis of Botswana National Antiretroviral Program
   (2002-2013)
SO PLOS ONE
LA English
DT Article
ID MARGINAL STRUCTURAL MODELS; SUB-SAHARAN AFRICA; HUMAN-RESOURCES; SERVICE
   DELIVERY; SOUTHERN AFRICA; HIV/AIDS; SURVIVAL; THERAPY; CHALLENGES;
   MORTALITY
AB Objective
   To measure the association between the number of doctors, nurses and hospital beds per 10,000 people and individual HIV-infected patient outcomes in Botswana.
   Design
   Analysis of routinely collected longitudinal data from 97,627 patients who received ART through the Botswana National HIV/AIDS Treatment Program across all 24 health districts from 2002 to 2013. Doctors, nurses, and hospital bed density data at district-level were collected from various sources.
   Methods
   A multilevel, longitudinal analysis method was used to analyze the data at both patient-and district-level simultaneously to measure the impact of the health system input at district-level on probability of death or loss-to-follow-up (LTFU) at the individual level. A marginal structural model was used to account for LTFU over time.
   Results
   Increasing doctor density from one doctor to two doctors per 10,000 population decreased the predicted probability of death for each patient by 27%. Nurse density changes from 20 nurses to 25 nurses decreased the predicted probability of death by 28%. Nine percent decrease was noted in predicted mortality of an individual in the Masa program for every five hospital bed density increase.
   Conclusion
   Considerable variation was observed in doctors, nurses, and hospital bed density across health districts. Predictive margins of mortality and LTFU were inversely correlated with doctor, nurse and hospital bed density. The doctor density had much greater impact than nurse or bed density on mortality or LTFU of individual patients. While long-term investment in training more healthcare professionals should be made, redistribution of available doctors and nurses can be a feasible solution in the short term.
C1 [Farahani, Mansoor; Price, Natalie; Chebani, Tony; Marlink, Richard] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [El-Halabi, Shenaaz; Mlaudzi, Naledi; Keapoletswe, Koona; Lebelonyane, Refeletswe; Fetogang, Ernest Benny] Minist Hlth, Gaborone, Botswana.
   [Kebaabetswe, Poloko; Masupe, Tiny; Gabaake, Keba; Nkomazana, Oathokwa] Univ Botswana, Gaborone, Botswana.
   [Auld, Andrew F.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA.
RP Farahani, M (reprint author), Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
EM mfarahan@gmail.com
FU US Centers for Disease Control and Prevention [GH005-000512-01];
   Botswana Ministry of Health
FX This work was supported by the US Centers for Disease Control and
   Prevention [grant number GH005-000512-01].; We would like to acknowledge
   Mr. Bud Bowen at the US Centers for Disease Control for his support on
   this project. We would also like to acknowledge Emmanuel Bulayani's
   assistance in managing the data for the health facility survey. We would
   also like to acknowledge the support of the Botswana Ministry of Health,
   specifically those at the Department of HIV/AIDS Prevention and Care,
   and the Department of Health Policy, Development, Monitoring and
   Evaluation, including the Monitoring and Evaluation Division.
NR 34
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 4
PY 2016
VL 11
IS 8
AR e0160206
DI 10.1371/journal.pone.0160206
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GL
UT WOS:000381368900037
PM 27490477
ER

PT J
AU Riediger, IN
   Hoffmaster, AR
   Casanovas-Massana, A
   Biondo, AW
   Ko, AI
   Stoddard, RA
AF Riediger, Irina N.
   Hoffmaster, Alex R.
   Casanovas-Massana, Arnau
   Biondo, Alexander W.
   Ko, Albert I.
   Stoddard, Robyn A.
TI An Optimized Method for Quantification of Pathogenic Leptospira in
   Environmental Water Samples
SO PLOS ONE
LA English
DT Article
ID EXTRACTION KITS; SOUTHERN CHILE; OUTBREAK; DNA; COMMUNITIES; HOUSEHOLD;
   INFECTION; TRANSMISSION; PARTICIPANTS; INTERROGANS
AB Leptospirosis is a zoonotic disease usually acquired by contact with water contaminated with urine of infected animals. However, few molecular methods have been used to monitor or quantify pathogenic Leptospira in environmental water samples. Here we optimized a DNA extraction method for the quantification of leptospires using a previously described Taqman-based qPCR method targeting lipL32, a gene unique to and highly conserved in pathogenic Leptospira. QIAamp DNA mini, MO BIO PowerWater DNA and PowerSoil DNA Isolation kits were evaluated to extract DNA from sewage, pond, river and ultrapure water samples spiked with leptospires. Performance of each kit varied with sample type. Sample processing methods were further evaluated and optimized using the PowerSoil DNA kit due to its performance on turbid water samples and reproducibility. Centrifugation speeds, water volumes and use of Escherichia coli as a carrier were compared to improve DNA recovery. All matrices showed a strong linearity in a range of concentrations from 10(6) to 10 degrees leptospires/mL and lower limits of detection ranging from < 1 cell/ml for river water to 36 cells/mL for ultrapure water with E. coli as a carrier. In conclusion, we optimized a method to quantify pathogenic Leptospira in environmental waters (river, pond and sewage) which consists of the concentration of 40 mL samples by centrifugation at 15,000xg for 20 minutes at 4 degrees C, followed by DNA extraction with the PowerSoil DNA Isolation kit. Although the method described herein needs to be validated in environmental studies, it potentially provides the opportunity for effective, timely and sensitive assessment of environmental leptospiral burden.
C1 [Riediger, Irina N.] Cent Lab State Parana, Curitiba, Parana, Brazil.
   [Hoffmaster, Alex R.; Stoddard, Robyn A.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Casanovas-Massana, Arnau; Ko, Albert I.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA.
   [Biondo, Alexander W.] Fed Univ State Parana, Dept Vet Med, Curitiba, Parana, Brazil.
   [Ko, Albert I.] Brazilian Minist Hlth, Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
RP Riediger, IN (reprint author), Cent Lab State Parana, Curitiba, Parana, Brazil.; Casanovas-Massana, A (reprint author), Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA.
EM iriediger@yahoo.com.br; arnau.casanovas@yale.edu
RI Ko, Albert/P-2343-2015; 
OI Casanovas-Massana, Arnau/0000-0002-3301-6143
FU National Institute of Allergy and Infectious Diseases [R01 AI052473, U01
   AI088752, R25 TW009338, R01 TW009504, R01 AI121207]; CAPES (Brazilian
   Ministry of Education) [BEX 066509-6]
FX This work was supported by funding from the National Institute of
   Allergy and Infectious Diseases (www.niaid.nih.gov) (award numbers R01
   AI052473, U01 AI088752, R25 TW009338, R01 TW009504 and R01 AI121207 to
   AIK). INR was supported by a sandwich Ph.D. scholarship (BEX 066509-6)
   from CAPES (Brazilian Ministry of Education). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 41
TC 1
Z9 1
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 3
PY 2016
VL 11
IS 8
AR e0160523
DI 10.1371/journal.pone.0160523
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GA
UT WOS:000381367800084
PM 27487084
ER

PT J
AU Shrestha, SS
   Thompson, TJ
   Kirtland, KA
   Gregg, EW
   Beckles, GL
   Luman, ET
   Barker, LE
   Geiss, LS
AF Shrestha, Sundar S.
   Thompson, Theodore J.
   Kirtland, Karen A.
   Gregg, Edward W.
   Beckles, Gloria L.
   Luman, Elizabeth T.
   Barker, Lawrence E.
   Geiss, Linda S.
TI Changes in Disparity in County-Level Diagnosed Diabetes Prevalence and
   Incidence in the United States, between 2004 and 2012
SO PLOS ONE
LA English
DT Article
ID SOCIOECONOMIC-STATUS; PREVENTION PROGRAM; EMPIRICAL-EVIDENCE;
   RISK-FACTORS; LIFE-STYLE; US; CONVERGENCE; POPULATION; OBESITY; TRENDS
AB Background
   In recent decades, the United States experienced increasing prevalence and incidence of diabetes, accompanied by large disparities in county-level diabetes prevalence and incidence. However, whether these disparities are widening, narrowing, or staying the same has not been studied. We examined changes in disparity among U.S. counties in diagnosed diabetes prevalence and incidence between 2004 and 2012.
   Methods
   We used 2004 and 2012 county-level diabetes (type 1 and type 2) prevalence and incidence data, along with demographic, socio-economic, and risk factor data from various sources. To determine whether disparities widened or narrowed over the time period, we used a regression-based beta-convergence approach, accounting for spatial autocorrelation. We calculated diabetes prevalence/incidence percentage point (ppt) changes between 2004 and 2012 and modeled these changes as a function of baseline diabetes prevalence/incidence in 2004. Covariates included county-level demographic and, socio-economic data, and known type 2 diabetes risk factors (obesity and leisure-time physical inactivity).
   Results
   For each county-level ppt increase in diabetes prevalence in 2004 there was an annual average increase of 0.02 ppt (p<0.001) in diabetes prevalence between 2004 and 2012, indicating a widening of disparities. However, after accounting for covariates, diabetes prevalence decreased by an annual average of 0.04 ppt (p<0.001). In contrast, changes in diabetes incidence decreased by an average of 0.04 ppt (unadjusted) and 0.09 ppt (adjusted) for each ppt increase in diabetes incidence in 2004, indicating a narrowing of county-level disparities.
   Conclusions
   County-level disparities in diagnosed diabetes prevalence in the United States widened between 2004 and 2012, while disparities in incidence narrowed. Accounting for demographic and, socio-economic characteristics and risk factors for type 2 diabetes narrowed the disparities, suggesting that these factors are strongly associated with changes in disparities. Public health interventions that target modifiable risk factors, such as obesity and physical inactivity, in high burden counties might further reduce disparities in incidence and, over time, in prevalence.
C1 [Shrestha, Sundar S.; Thompson, Theodore J.; Kirtland, Karen A.; Gregg, Edward W.; Beckles, Gloria L.; Luman, Elizabeth T.; Barker, Lawrence E.; Geiss, Linda S.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.
RP Shrestha, SS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.
EM gqm2@cdc.gov
NR 45
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 3
PY 2016
VL 11
IS 8
AR e0159876
DI 10.1371/journal.pone.0159876
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GA
UT WOS:000381367800043
ER

PT J
AU Sampson, UKA
   Kaplan, RM
   Cooper, RS
   Roux, AVD
   Marks, JS
   Engelgau, MM
   Peprah, E
   Mishoe, H
   Boulware, LE
   Felix, KL
   Califf, RM
   Flack, JM
   Cooper, LA
   Gracia, JN
   Henderson, JA
   Davidson, KW
   Krishnan, JA
   Lewis, TT
   Sanchez, E
   Luban, NL
   Vaccarino, V
   Wong, WF
   Wright, JT
   Meyers, D
   Ogedegbe, OG
   Presley-Cantrell, L
   Chambers, DA
   Belis, D
   Bennett, GC
   Boyington, JE
   Creazzo, TL
   de Jesus, JM
   Krishnamurti, C
   Lowden, MR
   Punturieri, A
   Shero, ST
   Young, NS
   Zou, S
   Mensah, GA
AF Sampson, Uchechukwu K. A.
   Kaplan, Robert M.
   Cooper, Richard S.
   Roux, Ana V. Diez
   Marks, James S.
   Engelgau, Michael M.
   Peprah, Emmanuel
   Mishoe, Helena
   Boulware, L. Ebony
   Felix, Kaytura L.
   Califf, Robert M.
   Flack, John M.
   Cooper, Lisa A.
   Gracia, J. Nadine
   Henderson, Jeffrey A.
   Davidson, Karina W.
   Krishnan, Jerry A.
   Lewis, Tene T.
   Sanchez, Eduardo
   Luban, Naomi L.
   Vaccarino, Viola
   Wong, Winston F.
   Wright, Jackson T., Jr.
   Meyers, David
   Ogedegbe, Olugbenga G.
   Presley-Cantrell, Letitia
   Chambers, David A.
   Belis, Deshiree
   Bennett, Glen C.
   Boyington, Josephine E.
   Creazzo, Tony L.
   de Jesus, Janet M.
   Krishnamurti, Chitra
   Lowden, Mia R.
   Punturieri, Antonello
   Shero, Susan T.
   Young, Neal S.
   Zou, Shimian
   Mensah, George A.
TI Reducing Health Inequities in the US Recommendations From the NHLBI's
   Health Inequities Think Tank Meeting
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Review
DE health information exchange; health policy; health services
   accessibility; social determinants of health; T4 research; translation
   research
ID CHILDHOOD; DISPARITIES; DESIGN; ATHEROSCLEROSIS; IMPLEMENTATION;
   EXPERIENCES; PREVENTION; OBJECTIVES; ENGLAND; DISEASE
AB The National, Heart, Lung, and Blood Institute convened a Think Tank meeting to obtain insight and recommendations regarding the objectives and design of the next generation of research aimed at reducing health inequities in the United States. The panel recommended several specific actions, including: 1) embrace broad and inclusive research themes; 2) develop research platforms that optimize the ability to conduct informative and innovative research, and promote systems science approaches; 3) develop networks of collaborators and stakeholders, and launch transformative studies that can serve as benchmarks; 4) optimize the use of new data sources, platforms, and natural experiments; and 5) develop unique transdisciplinary training programs to build research capacity. Confronting health inequities will require engaging multiple disciplines and sectors (including communities), using systems science, and intervening through combinations of individual, family, provider, health system, and community-targeted approaches. Details of the panel's remarks and recommendations are provided in this report. (C) 2016 by the American College of Cardiology Foundation.
C1 [Sampson, Uchechukwu K. A.; Engelgau, Michael M.; Peprah, Emmanuel; Mishoe, Helena; Belis, Deshiree; Bennett, Glen C.; de Jesus, Janet M.; Krishnamurti, Chitra; Shero, Susan T.; Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Kaplan, Robert M.; Meyers, David] US Agcy Healthcare Res & Qual, Rockville, MD USA.
   [Cooper, Richard S.] Loyola Univ, Dept Publ Hlth, Chicago, IL 60611 USA.
   [Roux, Ana V. Diez] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA.
   [Marks, James S.] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA.
   [Boulware, L. Ebony] Duke Univ, Div Gen Internal Med, Durham, NC USA.
   [Felix, Kaytura L.] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA.
   [Califf, Robert M.] US FDA, Off Med Prod & Tobacco, Silver Spring, MD USA.
   [Flack, John M.] Southern Illinois Univ, Dept Internal Med, Springfield, IL USA.
   [Cooper, Lisa A.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   [Gracia, J. Nadine] US Dept Hlth & Human Serv, Off Minor Hlth, Rockville, MD USA.
   [Henderson, Jeffrey A.] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA.
   [Davidson, Karina W.] Columbia Univ, Dept Med, Ctr Behav Cardiovasc Hlth, New York, NY USA.
   [Davidson, Karina W.] New York Presbyterian Hosp, Value Inst, New York, NY USA.
   [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA.
   [Lewis, Tene T.; Vaccarino, Viola] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Sanchez, Eduardo] Amer Hlth Assoc, Dallas, TX USA.
   [Luban, Naomi L.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA.
   [Wong, Winston F.] Kaiser Permanente, Los Angeles, CA USA.
   [Wright, Jackson T., Jr.] Univ Hosp Case Med Ctr, Cleveland, OH USA.
   [Ogedegbe, Olugbenga G.] NYU, Div Hlth Behav, New York, NY USA.
   [Presley-Cantrell, Letitia] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA.
   [Chambers, David A.] NCI, NIH, Div Canc Control & Populat Sci, Rockville, MD USA.
   [Boyington, Josephine E.] NHLBI, NIH, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
   [Creazzo, Tony L.] NHLBI, NIH, Div Extramural Res Activ, Bldg 10, Bethesda, MD 20892 USA.
   [Lowden, Mia R.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Punturieri, Antonello] NHLBI, NIH, Div Lung Dis, Bldg 10, Bethesda, MD 20892 USA.
   [Young, Neal S.] NHLBI, NIH, Div Intramural Res, Bldg 10, Bethesda, MD 20892 USA.
   [Zou, Shimian] NHLBI, NIH, Div Blood Dis & Resources, Bldg 10, Bethesda, MD 20892 USA.
RP Sampson, UKA (reprint author), NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM uchechukwu.sampson@nih.gov
FU Medtronic; Bayer; GlaxoSmithKline
FX The views expressed in this article are those of the authors and do not
   necessarily represent the views of the National Heart, Lung, and Blood
   Institute, National Institutes of Health, or the U.S. Department of
   Health and Human Services. Dr. Flack has been a consultant for
   Medtronic, Back Beat Medical, Lundbeck, Forrest, Bayer, Sanofi, and
   Regeneron; and has received research grants from Medtronic, Bayer, and
   GlaxoSmithKline. All other authors have reported that they have no
   relationships relevant to the contents of this paper to disclose.
NR 25
TC 3
Z9 3
U1 7
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD AUG 2
PY 2016
VL 68
IS 5
BP 517
EP 524
DI 10.1016/j.jacc.2016.04.059
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DR7VO
UT WOS:000380108000012
PM 27470459
ER

PT J
AU Abraham, S
   Collins, G
   Nordsieck, M
AF Abraham, Sidney
   Collins, Gretchen
   Nordsieck, Marie
TI Relationship of childhood weight status to morbidity in adults
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID BODY-WEIGHT; INTERRELATIONSHIP; OBESITY; DISEASE; HEART
AB A cohort of white males who had attended elementary schools in Hagerstown, Md., between 1923 and 1928, and whose height-weight records for those years were available, was examined during 1961-63. A study of their childhood relative weight at ages 913, and of their adult relative weight 35-40 years later, was made in relation to selected physiological variables and diagnosed morbidity.
   Essential findings were as follows:
   Childhood relative weight at ages 9-13 had no significant relationship to adult levels of fasting blood sugar, serum cholesterol, beta-lipoprotein, or blood pressure, or to cardiovascular renal disease.
   Childhood relative weight at ages 9-13 was significantly related to hypertensive vascular disease. The below average weight group experienced a higher prevalence than observed in either average or moderately overweight childhood groups.
   Approximately 30 percent of the below average weight children became average weight adults and 21 percent became overweight adults. Of the average weight children, approximately 40 percent became overweight adults. Overweight children tended to remain overweight as adults.
   Adult relative weight of the same cohort, viewed 35-40 years later, was significantly associated with fasting blood sugar, beta-lipoprotein, and systolic and diastolic blood pressure. Elevated levels of each of these variables occurred with greater frequency in the overweight child. Adult relative weight was significantly associated with hypertensive vascular disease and cardiovascular renal disease; the higher prevalence occurred in the overweight adults. The highest risk for hypertensive vascular and cardiovascular renal disease was associated with the persons who acquired their overweight status as adults. The higher prevalence of these diseases among the overweight adults was largely attributable to the adults who moved from a below average childhood weight category to an overweight adult group. The moderately or markedly overweight adults who was similarly classified as a child did not appear to be at greater risk than the average weight adult who had been an average weight child.
C1 [Abraham, Sidney; Collins, Gretchen; Nordsieck, Marie] Publ Hlth Serv, Heart Dis Program, Reg Med Programs Serv, Washington, DC USA.
   [Abraham, Sidney] Natl Ctr Hlth Stat, Nutr Stat Branch, Div Hlth Examinat Stat, Hyattsville, MD USA.
   [Collins, Gretchen] Ctr Dis Control, Demonstrat & Tech Serv Branch, Nutr Program, Atlanta, GA 30333 USA.
   [Nordsieck, Marie] NIAID, Rockville, MD USA.
RP Abraham, S (reprint author), Room 8A-44,Parklawn Bldg,5600 Fishers Lane, Rockville, MD 20852 USA.
NR 20
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2016
VL 45
IS 4
BP 1020
EP 1031
DI 10.1093/ije/dyw171
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ4JD
UT WOS:000393182000012
PM 27498297
ER

PT J
AU Stevens, AC
   Courtney-Long, EA
   Okoro, CA
   Carroll, DD
AF Stevens, Alissa C.
   Courtney-Long, Elizabeth A.
   Okoro, Catherine A.
   Carroll, Dianna D.
TI Comparison of 2 Disability Measures, Behavioral Risk Factor Surveillance
   System, 2013
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID UNITED-STATES; PREVALENCE; QUESTIONS; ADULTS
AB Introduction
   Beginning in 2013, in addition to the 2-item disability question set asked since 2001, Behavioral Risk Factor Surveillance System (BRFSS) began using 5 of the 6 items from the US Department of Health and Human Services-recommended disability question set. We assess and compare disability prevalence using the 2-question and 5-question sets and describe characteristics of respondents who identified as having a disability using each question set.
   Methods
   We used data from the 2013 BRFSS to estimate the prevalence of disability for each question set and the 5 specific types of disability. Among respondents identified by each disability question set, we calculated the prevalence of selected demographic characteristics, health conditions, health behaviors, and health status.
   Results
   With the 2-question set, 21.6% of adults had a disability and with the 5-question set, 22.7% of adults had disability. A total of 51.2% of adults who identified as having a disability with either the 2-question or 5-question set reported having disabilities with both sets. Adults with different disability types differed by demographic and health characteristics.
   Conclusion
   The inclusion of the 5 new disability questions in BRFSS provides a level of detail that can help develop targeted interventions and programs and can guide the adaptation of existing health promotion programs to be more inclusive of adults who experience specific types of disabilities.
C1 [Stevens, Alissa C.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, 4770 Buford Hwy,MS E-88, Atlanta, GA 30341 USA.
   [Courtney-Long, Elizabeth A.; Okoro, Catherine A.; Carroll, Dianna D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Carroll, Dianna D.] US PHS, Commissioned Corps, Atlanta, GA USA.
RP Stevens, AC (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, 4770 Buford Hwy,MS E-88, Atlanta, GA 30341 USA.
EM astevens@cdc.gov
NR 25
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD AUG
PY 2016
VL 13
AR E106
DI 10.5888/pcd13.160080
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ3JE
UT WOS:000393107600007
PM 27513997
ER

PT J
AU Interrante, JD
   Ailes, EC
   Lind, JN
   Anderka, M
   Feldkamp, ML
   Werler, MM
   Gilboa, SM
   Honein, MA
   Broussard, CS
AF Interrante, Julia D.
   Ailes, Elizabeth C.
   Lind, Jennifer N.
   Anderka, Marlene
   Feldkamp, Marcia L.
   Werler, Martha M.
   Gilboa, Suzanne M.
   Honein, Margaret A.
   Broussard, Cheryl S.
TI Risk Comparison for Prenatal Use of Different Analgesics and Selected
   Birth Defects
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Interrante, Julia D.; Ailes, Elizabeth C.; Lind, Jennifer N.; Gilboa, Suzanne M.; Honein, Margaret A.; Broussard, Cheryl S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Interrante, Julia D.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
   [Lind, Jennifer N.] US PHS, Atlanta, GA USA.
   [Anderka, Marlene] Massachusetts Dept Publ Hlth, Boston, MA USA.
   [Feldkamp, Marcia L.] Univ Utah, Hlth Sci Ctr, Div Med Genet, Salt Lake City, UT USA.
   [Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 22
BP 16
EP 16
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483501022
ER

PT J
AU Lind, JN
   Reefhuis, J
   Friedman, JM
   Mitchell, AA
   Riehle-Colarusso, T
   Polen, KN
   Honein, MA
AF Lind, Jennifer N.
   Reefhuis, Jennita
   Friedman, Jan M.
   Mitchell, Allen A.
   Riehle-Colarusso, Tiffany
   Polen, Kara N.
   Honein, Margaret A.
TI First Trimester Antidepressant Use in the National Birth Defects
   Prevention Study
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Lind, Jennifer N.; Reefhuis, Jennita; Riehle-Colarusso, Tiffany; Polen, Kara N.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Lind, Jennifer N.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA.
   [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada.
   [Mitchell, Allen A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 561
BP 327
EP 328
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483502194
ER

PT J
AU Lynch, MM
   Amoozegar, J
   McClure, EM
   Squiers, LB
   Broussard, CS
   Lind, JN
   Polen, KN
   Frey, MT
   Gilboa, SM
   Biermann, J
AF Lynch, Molly M.
   Amoozegar, Jacqueline
   McClure, Emily M.
   Squiers, Linda B.
   Broussard, Cheryl S.
   Lind, Jennifer N.
   Polen, Kara N.
   Frey, Meghan T.
   Gilboa, Suzanne M.
   Biermann, Janis
TI Improving Safe Use of Medications During Pregnancy: The Roles of
   Patients, Physicians, and Pharmacists
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Lynch, Molly M.; Amoozegar, Jacqueline; McClure, Emily M.; Squiers, Linda B.] RTI Int, Res Triangle Pk, NC USA.
   [Broussard, Cheryl S.; Lind, Jennifer N.; Polen, Kara N.; Frey, Meghan T.; Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Div Congenital & Dev Disorders, Atlanta, GA USA.
   [Biermann, Janis] March Dimes Fdn, White Plains, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 578
BP 336
EP 337
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483502210
ER

PT J
AU Lyapustina, T
   Rutkow, L
   Chang, HY
   Daubresse, M
   Ramji, AF
   Faul, M
   Stuart, EA
   Alexader, GC
AF Lyapustina, Tatyana
   Rutkow, Lainie
   Chang, Hsien-Yen
   Daubresse, Matthew
   Ramji, Alim F.
   Faul, Mark
   Stuart, Elizabeth A.
   Alexader, G. Caleb
TI Effect of a "Pill Mill" Law on Opioid Prescribing and Utilization: The
   Case of Texas
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Lyapustina, Tatyana; Ramji, Alim F.] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Rutkow, Lainie; Chang, Hsien-Yen; Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Hlth Policy & Management, Baltimore, MD USA.
   [Daubresse, Matthew; Alexader, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Epidemiol, Baltimore, MD USA.
   [Daubresse, Matthew; Alexader, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA.
   [Alexader, G. Caleb] Johns Hopkins Med, Gen Internal Med, Baltimore, MD USA.
   [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Mental Hlth, Baltimore, MD USA.
   [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Biostat, Baltimore, MD USA.
   [Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 609
BP 355
EP 355
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483502241
ER

PT J
AU Dodd, CN
   de Ridder, M
   Weibel, D
   DeStefano, F
   Shimabukuro, T
   Carleton, B
   Perez-Vilar, S
   Gentile, A
   Giglio, N
   Giner-Soriano, M
   Dalstrom, LA
   Huang, WT
   Svenson, L
   Pedersen, L
   Bonhoeffer, J
   Sturkenboom, M
   Black, S
AF Dodd, Caitlin N.
   de Ridder, Maria
   Weibel, Daniel
   DeStefano, Frank
   Shimabukuro, Tom
   Carleton, Bruce
   Perez-Vilar, Silvia
   Gentile, Angela
   Giglio, Norberto
   Giner-Soriano, Maria
   Dalstrom, Lisen Arnheim
   Huang, Wan-Ting
   Svenson, Larry
   Pedersen, Lars
   Bonhoeffer, Jan
   Sturkenboom, Miriam
   Black, Steve
TI Narcolepsy Incidence Rates in the SOMNIA (Systematic Observational
   Method for Narcolepsy and Influenza Immunization) Study
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Dodd, Caitlin N.; de Ridder, Maria; Weibel, Daniel; Sturkenboom, Miriam] Erasmus Univ, Med Ctr, Med Informat, Rotterdam, Netherlands.
   [DeStefano, Frank] Ctr Dis Control, Immunizat Safety Off, Atlanta, GA 30333 USA.
   [Shimabukuro, Tom] Ctr Dis Control, Immunizat Serv Div, Atlanta, GA 30333 USA.
   [Carleton, Bruce] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada.
   [Perez-Vilar, Silvia] FISABIO, Publ Hlth, Valencia, Spain.
   [Gentile, Angela; Giglio, Norberto] Hosp Ninos Dr Ricardo Gutierrez, Epidemiol & Evidence Med Dept, Buenos Aires, DF, Argentina.
   [Giner-Soriano, Maria] Inst Univ Invest Atencio Primaria Jordi Gol, Med Res Unit, Barcelona, Spain.
   [Dalstrom, Lisen Arnheim] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Huang, Wan-Ting] Ctr Dis Control, Off Prevent Med, Taipei, Taiwan.
   [Svenson, Larry] Govt Alberta, Epidemiol & Surveillance, Edmonton, AB, Canada.
   [Pedersen, Lars] Aarhus Univ, Dept Clin Epidemiol, Dept Clin Med, Aarhus, Denmark.
   [Bonhoeffer, Jan] Brighton Collaborat, Basel, Switzerland.
   [Black, Steve] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 815
BP 472
EP 473
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483503078
ER

PT J
AU Chang, HY
   Lyapustina, T
   Rutkow, L
   Daubresse, M
   Richey, M
   Faul, M
   Stuart, EA
   Alexander, GC
AF Chang, Hsien-Yen
   Lyapustina, Tatyana
   Rutkow, Lainie
   Daubresse, Matthew
   Richey, Matt
   Faul, Mark
   Stuart, Elizabeth A.
   Alexander, G. Caleb
TI Impact of State Laws to Reduce Prescription Drug Abuse on High-Risk
   Opioid Prescribers
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Chang, Hsien-Yen; Rutkow, Lainie; Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Chang, Hsien-Yen; Daubresse, Matthew; Stuart, Elizabeth A.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA.
   [Lyapustina, Tatyana; Daubresse, Matthew; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Richey, Matt] St Olaf Coll, Dept Math Stat & Comp Sci, Northfield, MN 55057 USA.
   [Faul, Mark] Natl Ctr Injury Prevent & Control, Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
   [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
   [Alexander, G. Caleb] Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 1159
BP 673
EP 674
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483503417
ER

PT J
AU Loosier, PS
   Doll, S
   Lepar, D
   Ward, K
   Gamble, G
   Dittus, PJ
AF Loosier, Penny S.
   Doll, Shelli
   Lepar, Danielle
   Ward, Kristin
   Gamble, Ginger
   Dittus, Patricia J.
TI Effectiveness of an Adaptation of the Project Connect Health Systems
   Intervention: Youth and Clinic-Level Findings
SO JOURNAL OF SCHOOL HEALTH
LA English
DT Article
DE school health; adolescent; healthcare seeking; linkage to healthcare;
   structural intervention
ID YOUNG-ADULTS; CARE; ADOLESCENTS; SERVICES; RECEIPT
AB BACKGROUND: The Project Connect Health Systems Intervention (Project Connect) uses a systematic process of collecting community and healthcare infrastructure information to craft a referral guide highlighting local healthcare providers who provide high quality sexual and reproductive healthcare. Previous self-report data on healthcare usage indicated Project Connect was successful with sexually experienced female youth, where it increased rates of human immunodeficiency virus (HIV) and sexually transmitted disease (STD) testing and receipt of contraception. This adaption of Project Connect examined its effectiveness in a new context and via collection of clinic encounter-level data.
   METHODS: Project Connect was implemented in 3 high schools. (only 2 schools remained open throughout the entire project period). Participant recruitment and data collection occurred in 5 of 8 participating health clinics. Students completed Youth Surveys (N=608) and a Clinic Survey (paired with medical data abstraction in 2 clinics [N=305]).
   RESULTS: Students were more likely than nonstudents to report having reached a clinic via Project Connect. Nearly 40% of students attended a Project Connect school, with 32.7% using Project Connect to reach the clinic. Students were most likely to have been referred by a school nurse or coach.
   CONCLUSIONS: Project Connect is a low-cost, sustainable structural intervention with multiple applications within schools, either as a standalone intervention or in combination with ongoing efforts.
C1 [Loosier, Penny S.] Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-E02, Atlanta, GA 30333 USA.
   [Doll, Shelli] Michigan Dept Hlth & Human Serv, HIV Care & Prevent Sect, Lansing, MI 48913 USA.
   [Lepar, Danielle; Ward, Kristin; Gamble, Ginger] Michigan Publ Hlth Inst, Ctr Data Management & Translat Res, Okemos, MI 48864 USA.
   [Dittus, Patricia J.] Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-E44, Atlanta, GA 30333 USA.
RP Loosier, PS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-E02, Atlanta, GA 30333 USA.
EM ploosier@cdc.gov; Dolls@michigan.gov; dlepar@mphi.org; kward@mphi.org;
   ggamble@mphi.org; pdittus@cdc.gov
NR 21
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4391
EI 1746-1561
J9 J SCHOOL HEALTH
JI J. Sch. Health
PD AUG
PY 2016
VL 86
IS 8
BP 595
EP 603
DI 10.1111/josh.12414
PG 9
WC Education & Educational Research; Education, Scientific Disciplines;
   Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Education & Educational Research; Health Care Sciences & Services;
   Public, Environmental & Occupational Health
GA DW5NA
UT WOS:000383691100005
PM 27374349
ER

PT J
AU Vivolo-Kantor, AM
   Olsen, EO
   Bacon, S
AF Vivolo-Kantor, Alana M.
   Olsen, Emily O'Malley
   Bacon, Sarah
TI Associations of Teen Dating Violence Victimization With School Violence
   and Bullying Among US High School Students
SO JOURNAL OF SCHOOL HEALTH
LA English
DT Article
DE school violence; bullying; dating violence; weapon carrying; physical
   fighting
ID RISK BEHAVIOR SURVEY; PREVENTION PROGRAM; YOUTH; ADOLESCENT;
   PERPETRATION; PERSPECTIVE; EXPERIENCES; PREVALENCE
AB BACKGROUND: Teen dating violence (TDV) negatively impacts health, mental and physical well-being, and school performance.
   METHODS: Data from a nationally representative sample of high school students participating in the Centers for Disease Control and Prevention (CDC)'s 2013 Youth Risk Behavior Survey (YRBS) are used to demonstrate associations of physical and sexual TDV with school violence-related experiences and behaviors, including bullying victimization. Bivariate and adjusted sex-stratified regressions assessed relationships between TDV and school violence-related experiences and behaviors.
   RESULTS: Compared to students not reporting TDV, those experiencing both physical and sexual TDV were more likely to report carrying a weapon at school, missing school because they felt unsafe, being threatened or injured with a weapon on school property, having a physical fight at school, and being bullied on school property.
   CONCLUSIONS: School-based prevention efforts should target multiple forms of violence.
C1 [Vivolo-Kantor, Alana M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway MS-F64, Atlanta, GA 30341 USA.
   [Olsen, Emily O'Malley] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent & Sch Hlth, 1600 Clifton Rd MS-E75, Atlanta, GA 30329 USA.
   [Bacon, Sarah] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway MS-F62, Atlanta, GA 30341 USA.
RP Vivolo-Kantor, AM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway MS-F64, Atlanta, GA 30341 USA.
EM AVivoloKantor@cdc.gov; EOlsen@cdc.gov; SBacon@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 27
TC 0
Z9 0
U1 8
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4391
EI 1746-1561
J9 J SCHOOL HEALTH
JI J. Sch. Health
PD AUG
PY 2016
VL 86
IS 8
BP 620
EP 627
DI 10.1111/josh.12412
PG 8
WC Education & Educational Research; Education, Scientific Disciplines;
   Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Education & Educational Research; Health Care Sciences & Services;
   Public, Environmental & Occupational Health
GA DW5NA
UT WOS:000383691100008
PM 27374352
ER

PT J
AU Tharp, AT
   Sherman, M
   Holland, K
   Townsend, B
   Bowling, U
AF Tharp, Andra Teten
   Sherman, Michelle
   Holland, Kristin
   Townsend, Bradford
   Bowling, Ursula
TI A Qualitative Study of Male Veterans' Violence Perpetration and
   Treatment Preferences
SO MILITARY MEDICINE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; SCALES
AB Prevention and treatment of intimate partner violence (IPV) has increasingly focused on engaging men; however, very little work has examined how men manage the negative emotions associated with relationship conflict, as well as their preferences for and perceived barriers to treatment. Given the overrepresentation of IPV among men with post-traumatic stress disorder, the perspectives of male veterans with and without post-traumatic stress disorder are critical to informing IPV prevention and treatment within the Veterans Administration (VA) healthcare system. This qualitative study involved interviews with 25 male veterans who reported recent IPV perpetration. Interview themes included coping with emotions associated with violence and preferences and barriers to seeking treatment related to IPV. Results found the participants were interested in receiving IPV treatment at the Veterans Administration, and interviews offered several suggestions for developing or adapting prevention and treatment options for male veterans and their families to take into account violence in their relationships.
C1 [Tharp, Andra Teten] Ctr Dis Control & Prevent, 1006 Broad Bay Lane, League City, TX 77573 USA.
   [Sherman, Michelle; Townsend, Bradford; Bowling, Ursula] Univ Oklahoma, Hlth Sci Ctr, Educ & Clin Ctr, Oklahoma City VA Med Ctr,South Cent Mental Illnes, 921 NE 13th St, Oklahoma City, OK 73104 USA.
   [Holland, Kristin] Ctr Dis Control & Prevent, 4770 Buford Highway NE,F-63, Atlanta, GA 30341 USA.
RP Tharp, AT (reprint author), Ctr Dis Control & Prevent, 1006 Broad Bay Lane, League City, TX 77573 USA.
FU South Central Mental Illness Research, Education and Clinical Center
FX This project was funded by pilot study funding from the South Central
   Mental Illness Research, Education and Clinical Center. A.T.T. is now
   with the Air Force Sexual Assault Prevention and Response Office. M.S.
   is now with the University of Minnesota.
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD AUG
PY 2016
VL 181
IS 8
BP 735
EP 739
DI 10.7205/MILMED-D-15-00301
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW5MI
UT WOS:000383688900014
PM 27483507
ER

PT J
AU Margolis, KA
   Nguyen, AB
   Slavit, WI
   King, BA
AF Margolis, Katherine A.
   Nguyen, Anh B.
   Slavit, Wendy I.
   King, Brian A.
TI E-cigarette curiosity among US middle and high school students: Findings
   from the 2014 national youth tobacco survey
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Smoking; Tobacco; Adolescent
ID ELECTRONIC CIGARETTES; SMOKING; SUSCEPTIBILITY; ADOLESCENCE; INITIATION;
   BELIEFS
AB Curiosity is a potential risk factor for electronic cigarette (e-cigarette) use, which has increased considerably among US youth in recent years. We examined the relationship between curiosity about e-cigarettes and perceived harm, comparative addictiveness, and e-cigarette advertisement exposure. Data came from the 2014 National Youth Tobacco Survey, a nationally representative survey of U.S. middle and high school students. In 2014, 2.5% of middle school and 9.2% of high school students currently used cigarettes, while 3.9% of middle school and 13.4% of high school students reported current e-cigarette use. Among never e-cigarette users (n=17,286), descriptive statistics assessed curiosity about e-cigarettes by combustible tobacco use, sex, race/ethnicity, and school level. Associations between curiosity and perceived harm (absolute and comparative to cigarettes), comparative addictiveness, and e-cigarette advertising exposure were explored using multivariate models in 2015. Among youth who never used e-cigarettes, 25.8% reported curiosity about e-cigarettes. Higher levels of perceived absolute harm and comparative harm were associated with lower levels of curiosity, while no association was observed between comparative addictiveness and curiosity. Among never combustible tobacco users, the odds of high curiosity were greater among non-Hispanic blacks (odds ratio (OR): 1.39; 95% confidence interval (CI): 1.02-1.88), Hispanics (OR = 1.79; 95% CI: 1.48-2.16), and non-Hispanic 'Other' (OR = 1.47; 95% CI: 1.15-1.89) race/ethnicities than non-Hispanic whites. One-quarter of middle and high school students who have never used e-cigarettes are curious about the products, with greater curiosity among those with lower perceptions of harm from these products. These findings may help inform future strategies aimed at reducing curiosity about e-cigarettes among youth. Published by Elsevier Inc.
C1 [Margolis, Katherine A.; Nguyen, Anh B.; Slavit, Wendy I.] US FDA, Ctr Tobacco Prod, Off Sci, 10903 New Hampshire Ave Bldg 75 Room 4444, Silver Spring, MD 20993 USA.
   [King, Brian A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA USA.
RP Margolis, KA (reprint author), US FDA, Ctr Tobacco Prod, Off Sci, 10903 New Hampshire Ave Bldg 75 Room 4444, Silver Spring, MD 20993 USA.
EM Katherine.Margolis@fda.hhs.gov
FU U.S. Food and Drug Administration, Center for Tobacco Products; Centers
   for Disease Control and Prevention, Office on Smoking and Health
FX Publication of this article was supported by the U.S. Food and Drug
   Administration, Center for Tobacco Products and The Centers for Disease
   Control and Prevention, Office on Smoking and Health.
NR 38
TC 1
Z9 1
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD AUG
PY 2016
VL 89
BP 1
EP 6
DI 10.1016/j.ypmed.2016.05.001
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA EC7KJ
UT WOS:000388316700001
PM 27155440
ER

PT J
AU John, KA
   Maalouf, J
   Barsness, CB
   Yuan, KM
   Cogswell, ME
   Gunn, JP
AF John, Katherine A.
   Maalouf, Joyce
   Barsness, Christina B.
   Yuan, Keming
   Cogswell, Mary E.
   Gunn, Janelle P.
TI Do Lower Calorie or Lower Fat Foods Have More Sodium Than Their Regular
   Counterparts?
SO NUTRIENTS
LA English
DT Article
DE sodium; lower fat; lower calorie; food products; nutrient information
ID PACKAGED FOODS; NUTRITION; CLAIMS
AB The objective of this study was to compare the sodium content of a regular food and its lower calorie/fat counterpart. Four food categories, among the top 20 contributing the most sodium to the US diet, met the criteria of having the most matches between regular foods and their lower calorie/fat counterparts. A protocol was used to search websites to create a list of "matches", a regular and comparable lower calorie/fat food(s) under each brand. Nutrient information was recorded and analyzed for matches. In total, 283 matches were identified across four food categories: savory snacks (N = 44), cheese (N = 105), salad dressings (N = 90), and soups (N = 44). As expected, foods modified from their regular versions had significantly reduced average fat (total fat and saturated fat) and caloric profiles. Mean sodium content among modified salad dressings and cheeses was on average 8%-12% higher, while sodium content did not change with modification of savory snacks. Modified soups had significantly lower mean sodium content than their regular versions (28%-38%). Consumers trying to maintain a healthy diet should consider that sodium content may vary in foods modified to be lower in calories/fat.
C1 [John, Katherine A.; Maalouf, Joyce; Yuan, Keming; Cogswell, Mary E.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.
   [Maalouf, Joyce] IHRC Inc, 2 Ravinia Dr Ste 1750, Atlanta, GA 30346 USA.
   [Barsness, Christina B.] St Catherine Univ, Dept Publ Hlth, 2004 Randolph Ave, St Paul, MN 55105 USA.
   [Gunn, Janelle P.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.
RP John, KA (reprint author), Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.
EM yfr6@cdc.gov; vjh6@cdc.gov; cdblissbarsness@stkate.edu; vrm4@cdc.gov;
   mec0@cdc.gov; bfy2@cdc.gov
OI John, Katherine/0000-0002-6816-4867
FU Department of Energy; CDC
FX This work was supported by an appointment to the Research Participation
   Program for the CDC administered by the Oak Ridge Institute for Science
   and Education through an agreement between the Department of Energy and
   the CDC.
NR 22
TC 0
Z9 0
U1 3
U2 3
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2016
VL 8
IS 8
AR 511
DI 10.3390/nu8080511
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA EB8SA
UT WOS:000387660000030
ER

PT J
AU Li, RX
   Stewart, B
   McNeil, MM
   Duffy, J
   Nelson, J
   Kawai, AT
   Baxter, R
   Belongia, EA
   Weintraub, E
AF Li, Rongxia
   Stewart, Brock
   McNeil, Michael M.
   Duffy, Jonathan
   Nelson, Jennifer
   Kawai, Alison Tse
   Baxter, Roger
   Belongia, Edward A.
   Weintraub, Eric
TI Post licensure surveillance of influenza vaccines in the Vaccine Safety
   Datalink in the 2013-2014 and 2014-2015 seasons
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE vaccine safety; pharmacoepidemiology; febrile seizures; PCV13
ID PROJECT; SEIZURES
AB Purpose The changes in each year in influenza vaccine antigenic components as well as vaccine administration patterns may pose new risks of adverse events following immunization (AEs). To evaluate the safety of influenza vaccines annually administered to people >= 6 months, we conducted weekly post licensure surveillance for seven pre-specified adverse events following receipt of influenza vaccines during the 2013-2014 and 2014-2015 seasons in the Vaccine Safety Datalink (VSD).
   Methods We used both a historically-controlled cohort design with the Poisson-based maximized sequential probability ratio test (maxSPRT) and a self-controlled risk interval (SCRI) design with the binomial-based maxSPRT. For each adverse event outcome, we defined the risk interval on the basis of biologic plausibility and prior literature. For the historical cohort design, numbers of expected adverse events were calculated from the prior seven seasons, adjusted for age and site. For the SCRI design, a comparison window was defined either before vaccination or after vaccination, depending on each specific outcome.
   Results An elevated risk of febrile seizures 0-1 days following trivalent inactivated influenza vaccine (IIV3) was identified in children aged 6-23 months during the 2014-2015 season using the SCRI design. We found the relative risk (RR) of febrile seizures following concomitant administration of IIV3 and PCV13 was 5.3 with a 95% CI 1.87-14.75. Without concomitant PCV 13 administration, the estimated risk decreased and was no longer statistically significant (RR: 1.4; CI: 0.54 - 3.61).
   Conclusion No increased risks, other than for febrile seizures, were identified in influenza vaccine safety surveillance during 2013-2014 and 2014-2015 seasons in the VSD. Copyright (C) 2016 John Wiley & Sons, Ltd.
C1 [Li, Rongxia; McNeil, Michael M.; Duffy, Jonathan; Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA.
   [Stewart, Brock] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
   [Nelson, Jennifer] Grp Hlth Res Inst, Seattle, WA USA.
   [Kawai, Alison Tse] Harvard Med Sch, Dept Populat Med, Boston, MA USA.
   [Kawai, Alison Tse] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
   [Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
   [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA.
RP Li, RX (reprint author), CDC, Immunizat Safety Off, MS D-26, Atlanta, GA 30333 USA.
EM vwo3@cdc.gov
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
IS 8
BP 928
EP 934
DI 10.1002/pds.3996
PG 7
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DW4VW
UT WOS:000383642100008
PM 27037540
ER

PT J
AU Mack, MR
   Rohde, JM
   Jacobsen, D
   Barron, JR
   Ko, C
   Goonewardene, M
   Rosenberg, DJ
   Srinivasan, A
   Flanders, SA
AF Mack, Megan R.
   Rohde, Jeffrey M.
   Jacobsen, Diane
   Barron, James R.
   Ko, Christin
   Goonewardene, Michael
   Rosenberg, David J.
   Srinivasan, Arjun
   Flanders, Scott A.
TI Engaging Hospitalists in Antimicrobial Stewardship: Lessons From a
   Multihospital Collaborative
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID BURDEN; CARE
AB Inappropriate antimicrobial use in hospitalized patients contributes to antimicrobial-resistant infections and complications. We sought to evaluate the impact, barriers, and facilitators of antimicrobial stewardship best practices in a diverse group of hospital medicine programs. This multihospital initiative included 1 community nonteaching hospital, 2 community teaching hospitals, and 2 academic medical centers participating in a collaborative with the Centers for Disease Control and Prevention and the Institute for Healthcare Improvement. We conducted multimodal physician education on best practices for antimicrobial use including: (1) enhanced antimicrobial documentation, (2) improved quality and accessibility of local clinical guidelines, and (3) a 72-hour antimicrobial "timeout." Implementation barriers included variability in physician practice styles, lack of awareness of stewardship importance, and overly broad interventions. Facilitators included engaging hospitalists, collecting real time data and providing performance feedback, and appropriately limiting the scope of interventions. In 2 hospitals, complete antimicrobial documentation in sampled medical records improved significantly (4% to 51% and 8% to 65%, P < 0.001 for each comparison). A total of 726 antimicrobial timeouts occurred at 4 hospitals, and 30% resulted in optimization or discontinuation of antimicrobials. With careful attention to key barriers and facilitators, hospitalists can successfully implement effective antimicrobial stewardship practices. (C) 2016 Society of Hospital Medicine
C1 [Mack, Megan R.; Rohde, Jeffrey M.; Flanders, Scott A.] Univ Michigan Hosp & Hlth Syst, Dept Internal Med, Ann Arbor, MI USA.
   [Jacobsen, Diane] Inst Healthcare Improvement, Cambridge, MA USA.
   [Barron, James R.] Spectrum Hlth Syst, Dept Internal Med, Grand Rapids, MI USA.
   [Ko, Christin] Northwestern Mem Hosp, Dept Internal Med, Chicago, IL USA.
   [Goonewardene, Michael] Reading Hlth Syst, Dept Internal Med, W Reading, PA USA.
   [Rosenberg, David J.] Hofstra North Shore LIJ Sch Med, Dept Internal Med, Manhasset, NY USA.
   [Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Mack, MR (reprint author), 3119 Taubman Ctr, Hospitalist Program, 1500 E Med Ctr Dr,SPC 5376, Ann Arbor, MI 48109 USA.
EM megantre@med.umich.edu
FU Institute for Healthcare Improvement; Blue Cross Blue Shield of
   Michigan; Agency for Healthcare Research and Quality; Institute for
   Healthcare Improvement and Centers for Disease Control and Prevention;
   Department of Health and Human Services; Centers for Disease Control and
   Prevention; National Center for Emerging Zoonotic and Infectious
   Diseases; Division of Healthcare Quality Promotion/Office of the
   Director
FX Dr. Flanders reports consulting fees or honoraria from the Institute for
   Healthcare Improvement, has provided consultancy to the Society of
   Hospital Medicine, has served as a reviewer for expert testimony,
   received honoraria as a visiting lecturer to various hospitals, and has
   received royalties from publisher John Wiley & Sons. He has also
   received grant funding from Blue Cross Blue Shield of Michigan and the
   Agency for Healthcare Research and Quality. Dr. Ko reports consultancy
   for the American Hospital Association and the Society of Hospital
   Medicine involving work with catheter-associated urinary tract
   infections. Ms. Jacobsen reports grant funding from the Institute for
   Healthcare Improvement. Dr. Rosenberg reports consultancy for
   Bristol-Myers Squibb, Forest Pharmaceuticals, and Pfizer. The funding
   source for this collaborative was through the Institute for Healthcare
   Improvement and Centers for Disease Control and Prevention. Funding was
   provided by the Department of Health and Human Services, the Centers for
   Disease Control and Prevention, the National Center for Emerging
   Zoonotic and Infectious Diseases, and the Division of Healthcare Quality
   Promotion/Office of the Director. Avaris Concepts served as the prime
   contractor and the Institute for Healthcare Improvement as the
   subcontractor for the initiative. The findings and conclusions in this
   report represent the views of the authors and might not reflect the
   views of the Centers for Disease Control and Prevention. The authors
   report no conflicts of interest.
NR 11
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD AUG
PY 2016
VL 11
IS 8
BP 576
EP 580
DI 10.1002/jhm.2599
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA EB0YY
UT WOS:000387074100008
PM 27130473
ER

PT J
AU Auld, AF
   Fielding, KL
   Gupta-Wright, A
   Lawn, SD
AF Auld, Andrew F.
   Fielding, Katherine L.
   Gupta-Wright, Ankur
   Lawn, Stephen D.
TI Xpert MTB/RIF - why the lack of morbidity and mortality impact in
   intervention trials?
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Review
DE Clinical trials; Health system weaknesses; Impact; Limitations; Study
   design; Xpert MTB/RIF
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RESOURCE-LIMITED SETTINGS; HIV-POSITIVE
   PATIENTS; TUBERCULOSIS DIAGNOSTICS; SOUTH-AFRICA; FEASIBILITY;
   MULTICENTER; ACCURACY; COHORT
AB Compared with smear microscopy, the Xpert MTB/RIF assay (Xpert), with superior accuracy and capacity to diagnose rifampicin resistance, has advanced TB diagnostic capability. However, recent trials of Xpert impact have not demonstrated reductions in patient morbidity and mortality. We conducted a narrative review of Xpert impact trials to summarize which patient-relevant outcomes Xpert has improved and explore reasons for no observed morbidity or mortality reductions. We searched PubMed, Google Scholar, Cochrane Library and Embase and identified eight trials meeting inclusion criteria: three individually randomized, three cluster-randomized, and two pre-post trials. In six trials Xpert increased diagnostic yield of bacteriologically-confirmed TB from sputa and in four trials Xpert shortened time to TB treatment. However, all-cause mortality was similar between arms in all six trials reporting this outcome, and the only trial to assess Xpert impact on morbidity reported no impact. Trial characteristics that might explain lack of observed impact on morbidity and mortality include: higher rates of empiric TB treatment in microscopy compared with Xpert arms, enrollment of study populations not comprised exclusively of populations most likely to benefit from Xpert, and health system weaknesses. So far as equipoise exists, future trials that address past limitations are needed to inform Xpert use in resource-limited settings.
C1 [Auld, Andrew F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV & TB, Atlanta, GA 30333 USA.
   [Fielding, Katherine L.; Gupta-Wright, Ankur; Lawn, Stephen D.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, Keppel St, London WC1E 7HT, England.
   [Lawn, Stephen D.] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, Cape Town, South Africa.
   [Lawn, Stephen D.] Univ Cape Town, Fac Hlth Sci, Dept Med, Cape Town, South Africa.
RP Auld, AF (reprint author), United States Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA.
EM aauld@cdc.gov
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S.
   Centers for Disease Control and Prevention
FX This research has been supported by the President's Emergency Plan for
   AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and
   Prevention.
NR 33
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD AUG
PY 2016
VL 110
IS 8
BP 432
EP 444
DI 10.1093/trstmh/trw056
PG 13
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA EA6SG
UT WOS:000386758600002
PM 27638038
ER

PT J
AU Gray, SC
   Holmes, K
   Bradford, DR
AF Gray, Simone C.
   Holmes, Kristin
   Bradford, Denise R.
TI Factors Associated with Pregnancy among Incarcerated African American
   Adolescent Girls
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE African American; Adolescent pregnancy; Risk factors; Detention; Sexual
   behaviors
ID RISK-REDUCTION INTERVENTION; JUVENILE DETENTION; TEENAGE PREGNANCY;
   FEMALES; YOUTH; INFECTIONS; PREVALENCE; SAMPLE; BIRTH
AB The purpose of this study was to examine the social and behavioral factors associated with pregnancy history among a sample of African American adolescent girls recruited from a short-term juvenile detention center in order to better understand the needs of this vulnerable population. Data were collected from a sample of 188 detained African American, 13-17-year-old girls in Atlanta, Georgia, who participated in a larger HIV prevention study. An audio computer-assisted self-interviewing survey was completed by participants to obtain information on socioecological factors to include individual, parental/familial, sexual risk, psychosocial, and substance use factors. Among the 188 participants, 25.5 % reported a history of pregnancy. A multivariable logistic regression model showed that girls with a history of pregnancy were more likely to live in a household receiving government aid, use hormonal contraceptives at last sex, participate in sex trading, have casual sex partners, have condomless sex in the past 90 days, and have a history of physical abuse. Girls with no history of pregnancy were more likely to have been incarcerated at least twice and to have previously used alcohol. Detention-based interventions and pregnancy prevention programs for this vulnerable population may benefit by addressing factors related to sexual behavior and development, substance use, individual background, and psychosocial health.
C1 [Gray, Simone C.; Holmes, Kristin; Bradford, Denise R.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Gray, Simone C.] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, 1600 Clifton Rd NE,Mailstop E-48, Atlanta, GA 30333 USA.
RP Gray, SC (reprint author), Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, 1600 Clifton Rd NE,Mailstop E-48, Atlanta, GA 30333 USA.
EM simonegray@cdc.gov
FU Centers for Disease Control and Prevention [5UR6PS000679]
FX This study was supported by the Cooperative Agreement 5UR6PS000679 from
   the Centers for Disease Control and Prevention. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the official position of the Centers for Disease
   Control and Prevention.
NR 35
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1099-3460
EI 1468-2869
J9 J URBAN HEALTH
JI J. Urban Health
PD AUG
PY 2016
VL 93
IS 4
BP 709
EP 718
DI 10.1007/s11524-016-0061-x
PG 10
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DY3VX
UT WOS:000385025300008
PM 27271026
ER

PT J
AU Kattan, JA
   Tuazon, E
   Paone, D
   Dowell, D
   Vo, L
   Starrels, JL
   Jones, CM
   Kunins, HV
AF Kattan, Jessica A.
   Tuazon, Ellenie
   Paone, Denise
   Dowell, Deborah
   Vo, Linda
   Starrels, Joanna L.
   Jones, Christopher M.
   Kunins, Hillary V.
TI Public Health Detailing-A Successful Strategy to Promote Judicious
   Opioid Analgesic Prescribing
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID CHRONIC NONCANCER PAIN; NEW-YORK-CITY; OVERDOSE; DEATHS; ASSOCIATION;
   DECREASE
AB Objectives. To evaluate knowledge and prescribing changes following a 2-month public health detailing campaign (one-to-one educational visits) about judicious opioid analgesic prescribing conducted among health care providers in Staten Island, New York City, in 2013.
   Methods. Three detailing campaign recommendations were (1) a 3-day supply of opioids is usually sufficient for acute pain, (2) avoid prescribing opioids for chronic noncancer pain, and (3) avoid high-dose opioid prescriptions. Evaluation consisted of a knowledge survey, and assessing prescribing rates and median day supply per prescription. Prescribing data from the 3-month period before the campaign were compared with 2 sequential 3-month periods after the campaign.
   Results. Among 866 health care providers visited, knowledge increased for all 3 recommendations (P < .01). After the campaign, the overall prescribing rate decreased similarly in Staten Island and other New York City counties (boroughs), but the high-dose prescribing rate decreased more in Staten Island than in other boroughs (P < .01). Median day supply remained stable in Staten Island and increased in other boroughs.
   Conclusions. The public health detailing campaign improved knowledge and likely prescribing practices and could be considered by other jurisdictions to promote judicious opioid prescribing.
C1 [Kattan, Jessica A.; Tuazon, Ellenie; Paone, Denise; Kunins, Hillary V.] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
   [Dowell, Deborah; Vo, Linda; Jones, Christopher M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
   [Starrels, Joanna L.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Starrels, Joanna L.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.
RP Kattan, JA (reprint author), New York City Dept Hlth & Mental Hyg, Bur Alcohol & Drug Use Prevent Care & Treatment, 42-09 28th St,19th Floor,CN 14, Queens, NY 11101 USA.
EM jkattan@health.nyc.gov
FU Centers for Disease Control and Prevention [CDC-RFA-HM08-805]
FX This study was supported in part by funding from the Centers for Disease
   Control and Prevention under CDC-RFA-HM08-805.
NR 19
TC 0
Z9 0
U1 1
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD AUG
PY 2016
VL 106
IS 8
BP 1430
EP 1438
DI 10.2105/AJPH.2016.303274
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY3HK
UT WOS:000384981200036
PM 27400353
ER

PT J
AU Miller, KS
   Cham, HJ
   Taylor, EM
   Berrier, FL
   Duffy, M
   Vig, J
   Chipazi, L
   Chakalisa, C
   Sidibe, S
   Swart, K
   Tau, NS
   Clark, LF
AF Miller, Kim S.
   Cham, Haddi J.
   Taylor, Eboni M.
   Berrier, Faith L.
   Duffy, Meghan
   Vig, Jessica
   Chipazi, Lily
   Chakalisa, Chawada
   Sidibe, Sekou
   Swart, Kenau
   Tau, Nontobeko Sylvia
   Clark, Leslie F.
TI Formative Work and Community Engagement Approaches for Implementing an
   HIV Intervention in Botswana Schools
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID STUDENTS; PARENTS
AB Providing adolescents with evidence-based sexual risk reduction interventions is critical to addressing the HIV/AIDS epidemic among adolescents in sub-Saharan Africa. Project AIM (Adult Identity Mentoring) is an innovative, evidence-based, youth development intervention that is being evaluated for the first time in Botswana through a 3-year (2015-2017), 50-school cluster randomized controlled trial, including testing for herpes simplex virus type 2 as a sexual activity biomarker. Conducting a trial of this magnitude requires the support and collaboration of government and community stakeholders. All school staff, including teachers, must be well informed about the study; dedicated staff placed at each school can help to improve school and community familiarity with the study, improve the information flow, and relieve some of the burden study activities places on schools.
C1 [Miller, Kim S.; Cham, Haddi J.; Taylor, Eboni M.; Berrier, Faith L.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
   [Duffy, Meghan; Vig, Jessica; Sidibe, Sekou] Assoc Sch & Programs Publ Hlth, Washington, DC USA.
   [Chipazi, Lily; Chakalisa, Chawada] Educ Dev Ctr, Gaborone, Botswana.
   [Tau, Nontobeko Sylvia] Botswana Minist Educ & Skills Dev, Gaborone, Botswana.
   [Clark, Leslie F.] Childrens Hosp Los Angeles, Div Adolescent Med, Los Angeles, CA 90027 USA.
RP Miller, KS (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV & TB, 1600 Clifton Rd NE,Mailstop E-04, Atlanta, GA 30333 USA.
EM kmiller@cdc.gov
FU President's Emergency Plan for AIDS Relief through the Centers for
   Disease Control and Prevention; Botswana Ministry of Education and
   Skills Development; CDC Botswana; Education Development Center
FX This work was supported by the President's Emergency Plan for AIDS
   Relief through the Centers for Disease Control and Prevention.; We thank
   the Botswana Ministry of Education and Skills Development, CDC Botswana,
   and Education Development Center for their continued support and
   contributions to this study. We are very grateful to the staff at the 50
   study schools for their planning assistance and allowing us to use their
   facilities to conduct the study. We also thank our amazing field staff
   for all of their hard work and dedication to this study. A special thank
   you to the students for participating in the study and all the
   stakeholders whose support made this study possible.
NR 12
TC 0
Z9 0
U1 1
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD AUG
PY 2016
VL 106
IS 8
BP 1439
EP 1441
DI 10.2105/AJPH.2016.303225
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY3HK
UT WOS:000384981200037
PM 27196663
ER

PT J
AU Liao, YL
   Siegel, PZ
   Garraza, LG
   Xu, Y
   Yin, SM
   Scardaville, M
   Gebreselassie, T
   Stephens, RL
AF Liao, Youlian
   Siegel, Paul Z.
   Garraza, Lucas G.
   Xu, Ye
   Yin, Shaoman
   Scardaville, Melissa
   Gebreselassie, Tesfayi
   Stephens, Robert L.
TI Reduced Prevalence of Obesity in 14 Disadvantaged Black Communities in
   the United States: A Successful 4-Year Place-Based Participatory
   Intervention
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID AFRICAN-AMERICAN WOMEN; PROPENSITY SCORE; WEIGHT-LOSS; HEALTH;
   DISPARITIES; PREVENTION; STRATEGIES; LESSONS; DISEASE
AB Objectives. To assess the impact of a large-scale place-based intervention on obesity prevalence in Black communities.
   Methods. The Racial and Ethnic Approaches to Community Health across the United States (REACH US) project was conducted in 14 predominantly Black communities in California, Illinois, Massachusetts, New York, Ohio, Pennsylvania, South Carolina, Virginia, Washington, and West Virginia. We measured trends from 2009 to 2012 in the prevalence of obesity. We used Behavioral Risk Factor Surveillance System data to compare these trends with trends among non-Hispanic Whites and non-Hispanic Blacks in the United States and in the 10 states where REACH communities were located, and with a propensity score-matched national sample of non-Hispanic Blacks.
   Results. The age-standardized prevalence of obesity decreased in REACH US communities (P = .045), but not in the comparison populations (P = .435 to P = .996). The relative change was -5.3% in REACH US communities versus +2.4% in propensity score-matched controls (P value for the difference = .031). The net effect on the reduction of obesity prevalence was about 1 percentage point per year for REACH.
   Conclusions. Obesity prevalence was reduced in 14 disadvantaged Black communities that participated in the REACH project.
C1 [Liao, Youlian; Siegel, Paul Z.; Yin, Shaoman] Ctr Dis Control & Prevent, Div Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-73, Atlanta, GA 30341 USA.
   [Garraza, Lucas G.; Xu, Ye; Scardaville, Melissa; Gebreselassie, Tesfayi; Stephens, Robert L.] ICF Int, Atlanta, GA USA.
RP Liao, YL (reprint author), Ctr Dis Control & Prevent, Div Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-73, Atlanta, GA 30341 USA.
EM yd1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 28
TC 0
Z9 0
U1 3
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD AUG
PY 2016
VL 106
IS 8
BP 1442
EP 1448
DI 10.2105/AJPH.2016.303253
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY3HK
UT WOS:000384981200038
PM 27310344
ER

PT J
AU Pearson, WS
   Cramer, R
   Tao, G
   Leichliter, JS
   Gift, TL
   Hoover, KW
AF Pearson, William S.
   Cramer, Ryan
   Tao, Guoyu
   Leichliter, Jami S.
   Gift, Thomas L.
   Hoover, Karen W.
TI Willingness to Use Health Insurance at a Sexually Transmitted Disease
   Clinic: A Survey of Patients at 21 US Clinics
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; CARE; INFECTIONS; SERVICES; REFORM; COST
AB Objectives. To survey patients of publicly funded sexually transmitted disease (STD) clinics across the United States about their willingness to use health insurance for their visit.
   Methods. In 2013, we identified STD clinics in 21 US metropolitan statistical areas with the highest rates of chlamydia, gonorrhea, and syphilis according to Centers for Disease Control and Prevention surveillance reports. Patients attending the identified STD clinics completed a total of 4364 surveys (response rate = 86.6%).
   Results. Nearly half of the insured patients were willing to use their health insurance. Patients covered by government insurance were more likely to be willing to use their health insurance compared with those covered by private insurance (odds ratio [OR] = 3.60; 95% confidence interval [CI] = 2.79, 4.65), and patients covered by their parents' insurance were less likely to be willing to use their insurance compared with those covered by private insurance (OR = 0.72; 95% CI = 0.52, 1.00). Reasons for unwillingness to use insurance were privacy and out-of-pocket cost.
   Conclusions. Before full implementation of the Affordable Care Act, privacy and cost were barriers to using health insurance for STD services.
   Public Health Implications. Barriers to using health insurance for STD services could be reduced through addressing issues of stigma associated with STD care and considering alternative payment sources for STD services.
C1 [Pearson, William S.; Cramer, Ryan; Tao, Guoyu; Leichliter, Jami S.; Gift, Thomas L.; Hoover, Karen W.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Pearson, WS (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,Mail top E-80, Atlanta, GA 30333 USA.
EM wpearson@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was funded by the Centers for Disease Control and Prevention.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD AUG
PY 2016
VL 106
IS 8
BP 1511
EP 1513
DI 10.2105/AJPH.2016.303263
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY3HK
UT WOS:000384981200049
PM 27310349
ER

PT J
AU Schnabel, D
   Esposito, DH
   Gaines, J
   Ridpath, A
   Barry, MA
   Feldman, KA
   Mullins, J
   Burns, R
   Ahmad, N
   Nyangoma, EN
   Nguyen, DB
   Perz, JF
   Moulton-Meissner, HA
   Jensen, BJ
   Lin, Y
   Posivak-Khouly, L
   Jani, N
   Morgan, OW
   Brunette, GW
   Pritchard, PS
   Greenbaum, AH
   Rhee, SM
   Blythe, D
   Sotir, M
AF Schnabel, David
   Esposito, Douglas H.
   Gaines, Joanna
   Ridpath, Alison
   Barry, M. Anita
   Feldman, Katherine A.
   Mullins, Jocelyn
   Burns, Rachel
   Ahmad, Nina
   Nyangoma, Edith N.
   Nguyen, Duc B.
   Perz, Joseph F.
   Moulton-Meissner, Heather A.
   Jensen, Bette J.
   Lin, Ying
   Posivak-Khouly, Leah
   Jani, Nisha
   Morgan, Oliver W.
   Brunette, Gary W.
   Pritchard, P. Scott
   Greenbaum, Adena H.
   Rhee, Susan M.
   Blythe, David
   Sotir, Mark
CA RGM Outbreak Invest Team
TI Multistate US Outbreak of Rapidly Growing Mycobacterial Infections
   Associated with Medical Tourism to the Dominican Republic, 2013-2014
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID NONTUBERCULOUS MYCOBACTERIA; ABSCESSUS INFECTION; WOUND INFECTIONS;
   COSMETIC SURGERY; UNITED-STATES; HEALTH; ABDOMINOPLASTY; GLOBALIZATION;
   MANAGEMENT; DIAGNOSIS
AB During 2013, the Maryland Department of Health and Mental Hygiene in Baltimore, MD, USA, received report of 2 Maryland residents whose surgical sites were infected with rapidly growing mycobacteria after cosmetic procedures at a clinic (clinic A) in the Dominican Republic. A multistate investigation was initiated; a probable case was defined as a surgical site infection unresponsive to therapy in a patient who had undergone cosmetic surgery in the Dominican Republic. We identified 21 case-patients in 6 states who had surgery in 1 of 5 Dominican Republic clinics; 13 (62%) had surgery at clinic A. Isolates from 12 (92%) of those patients were culture-positive for Mycobacterium abscessus complex. Of 9 clinic A case-patients with available data, all required therapeutic surgical intervention, 8 (92%) were hospitalized, and 7 (78%) required >= 3 months of antibacterial drug therapy. Healthcare providers should consider infection with rapidly growing mycobacteria in patients who have surgical site infections unresponsive to standard treatment.
C1 [Schnabel, David; Esposito, Douglas H.; Gaines, Joanna; Ridpath, Alison; Mullins, Jocelyn; Ahmad, Nina; Nyangoma, Edith N.; Nguyen, Duc B.; Perz, Joseph F.; Moulton-Meissner, Heather A.; Jensen, Bette J.; Morgan, Oliver W.; Brunette, Gary W.; Sotir, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Schnabel, David; Feldman, Katherine A.; Blythe, David] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
   [Ridpath, Alison; Lin, Ying] New York City Dept Hlth & Mental Hyg, New York, NY USA.
   [Barry, M. Anita] Boston Publ Hlth Commiss, Boston, MA USA.
   [Mullins, Jocelyn] Connecticut Dept Publ Hlth, Hartford, CT USA.
   [Burns, Rachel] Massachusetts Dept Publ Hlth, Boston, MA USA.
   [Ahmad, Nina] New York State Dept Hlth, Albany, NY USA.
   [Posivak-Khouly, Leah] Montgomery Cty Hlth Dept, Norristown, PA USA.
   [Jani, Nisha] Newark Dept Child & Family Well Being, Newark, NJ USA.
   [Pritchard, P. Scott] Florida Dept Hlth, Tallahassee, FL USA.
   [Greenbaum, Adena H.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
   [Rhee, Susan M.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA.
RP Schnabel, D (reprint author), Ctr Dis Control & Prevent, UNIT 8900,Box 360, Dpo, AE 09831 USA.
EM DSchnabel@cdc.gov
FU CDC Epidemic Intelligence Service (EIS) Program; CDC
FX We thank the CDC Epidemic Intelligence Service (EIS) Program and EIS
   Supervisors for their advice and support. We also thank the Division of
   Epidemiology at the Ministry of Health, Dominican Republic, for their
   assistance.; This work was supported by CDC and participating state and
   local health departments.
NR 40
TC 2
Z9 2
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1340
EP 1347
DI 10.3201/eid2208.151938
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500002
PM 27434822
ER

PT J
AU Prow, NA
   Edmonds, JH
   Williams, DT
   Setoh, YX
   Bielefeldt-Ohmann, H
   Suen, WW
   Hobson-Peters, J
   van den Hurk, AF
   Pyke, AT
   Hall-Mendelin, S
   Northill, JA
   Johansen, CA
   Warrilow, D
   Wang, JN
   Kirkland, PD
   Doggett, S
   Andrade, CC
   Brault, AC
   Khromykh, AA
   Hall, RA
AF Prow, Natalie A.
   Edmonds, Judith H.
   Williams, David T.
   Setoh, Yin X.
   Bielefeldt-Ohmann, Helle
   Suen, Willy W.
   Hobson-Peters, Jody
   van den Hurk, Andrew F.
   Pyke, Alyssa T.
   Hall-Mendelin, Sonja
   Northill, Judith A.
   Johansen, Cheryl A.
   Warrilow, David
   Wang, Jianning
   Kirkland, Peter D.
   Doggett, Stephen
   Andrade, Christy C.
   Brault, Aaron C.
   Khromykh, Alexander A.
   Hall, Roy A.
TI Virulence and Evolution of West Nile Virus, Australia, 1960-2012
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID KUNJIN VIRUS; ENVELOPE PROTEIN; NS5 PROTEIN; ARBOVIRUSES; STRAIN;
   INTERFERON; OUTBREAK; DISEASE; GLYCOSYLATION; GLYCOPROTEINS
AB Worldwide, West Nile virus (WNV) causes encephalitis in humans, horses, and birds. The Kunjin strain of WNV (WNVKUN) is endemic to northern Australia, but infections are usually asymptomatic. In 2011, an unprecedented outbreak of equine encephalitis occurred in southeastern Australia; most of the approximate to 900 reported cases were attributed to a newly emerged WNVKUN strain. To investigate the origins of this virus, we performed genetic analysis and in vitro and in vivo studies of 13 WNVKUN isolates collected from different regions of Australia during 1960-2012. Although no disease was recorded for 1984, 2000, or 2012, isolates collected during those years (from Victoria, Queensland, and New South Wales, respectively) exhibited levels of virulence in mice similar to that of the 2011 outbreak strain. Thus, virulent strains of WNVKUN have circulated in Australia for >= 30 years, and the first extensive outbreak of equine disease in Australia probably resulted from a combination of specific ecologic and epidemiologic conditions.
C1 [Prow, Natalie A.; Edmonds, Judith H.; Setoh, Yin X.; Bielefeldt-Ohmann, Helle; Suen, Willy W.; Hobson-Peters, Jody; Khromykh, Alexander A.; Hall, Roy A.] Univ Queensland, St Lucia, Qld 4072, Australia.
   [Williams, David T.; Wang, Jianning] CSIRO, Australian Anim Hlth Lab, Geelong, Vic, Australia.
   [Bielefeldt-Ohmann, Helle; Suen, Willy W.] Univ Queensland, Gatton, Qld, Australia.
   [van den Hurk, Andrew F.; Pyke, Alyssa T.; Hall-Mendelin, Sonja; Northill, Judith A.; Warrilow, David] Dept Hlth, Brisbane, Qld, Australia.
   [Johansen, Cheryl A.] Univ Western Australia, Nedlands, WA, Australia.
   [Kirkland, Peter D.] Elizabeth Macarthur Agr Inst, Menangle, NSW, Australia.
   [Doggett, Stephen] Univ Sydney & Pathol West ICPMR, Westmead, NSW, Australia.
   [Andrade, Christy C.; Brault, Aaron C.] Univ Calif Davis, Davis, CA 95616 USA.
   [Andrade, Christy C.; Brault, Aaron C.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
   [Prow, Natalie A.] QIMR Berghofer Med Res Inst, Herston, Qld, Australia.
   [Andrade, Christy C.] Willamette Univ, Salem, OR 97301 USA.
RP Khromykh, AA; Hall, RA (reprint author), Univ Queensland, St Lucia, Qld 4072, Australia.
EM a.khromykh@uq.edu.au; roy.hall@uq.edu.au
RI Johansen, Cheryl/A-2208-2009; Williams, David/H-6750-2013
FU Western Australian Department of Health; Australian Research Council
   Linkage Project grant [LP120100686]; National Health and Medical
   Research Council [APP1045188]
FX We thank Mary Carr for providing clinical material used for the
   isolation of WNV<INF>SA2011</INF>, Melissa Sanchez and Robert Doms for
   providing mAb 17D7, and the Western Australian Department of Health for
   funding and assisting with the detection of WNV<INF>KUN</INF> isolates
   in Western Australia. We also thank Richard Russell for providing the
   WNV<INF>NSW2012</INF> isolate.; This work was supported by the
   Australian Research Council Linkage Project grant LP120100686 and the
   National Health and Medical Research Council project grant APP1045188.
NR 37
TC 2
Z9 2
U1 4
U2 5
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1353
EP 1362
DI 10.3201/eid2208.151719
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500004
PM 27433830
ER

PT J
AU Aliabadi, N
   Messacar, K
   Pastula, DM
   Robinson, CC
   Leshem, E
   Sejvar, JJ
   Nix, WA
   Oberste, MS
   Feikin, DR
   Dominguez, SR
AF Aliabadi, Negar
   Messacar, Kevin
   Pastula, Daniel M.
   Robinson, Christine C.
   Leshem, Eyal
   Sejvar, James J.
   Nix, W. Allan
   Oberste, M. Steven
   Feikin, Daniel R.
   Dominguez, Samuel R.
TI Enterovirus D68 Infection in Children with Acute Flaccid Myelitis,
   Colorado, USA, 2014
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY VIRUSES; CLINICAL SPECIMENS; OUTBREAK; ILLNESS; PARALYSIS;
   NORWAY; STRAIN; MRI; PCR
AB During August 8, 2014-October 14, 2014, a total of 11 children with acute flaccid myelitis and distinctive neuroimaging changes were identified near Denver, Colorado, USA. A respiratory prodrome was experienced by 10, and nasopharyngeal specimens were positive for enterovirus D68 (EV-D68) for 4. To determine whether an association exists between EV-D68 infection and acute flaccid myelitis, we conducted a retrospective case-control study comparing these patients with 2 groups of outpatient control children (1 group tested for acute respiratory illness and 1 for Bordetella pertussis infection). Adjusted analyses indicated that, for children with acute flaccid myelitis, the odds of having EV-D68 infection were 10.3 times greater than for those tested for acute respiratory infection and 4.5 times greater than for those tested for B. pertussis infection. No statistical association was seen between acute flaccid myelitis and non-EV-D68 enterovirus or rhinovirus infection. These findings support an association between EV-D68 infection and acute flaccid myelitis.
C1 [Aliabadi, Negar; Leshem, Eyal; Sejvar, James J.; Nix, W. Allan; Oberste, M. Steven; Feikin, Daniel R.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30329 USA.
   [Messacar, Kevin; Robinson, Christine C.; Dominguez, Samuel R.] Childrens Hosp Colorado, Aurora, CO USA.
   [Pastula, Daniel M.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
   [Pastula, Daniel M.] Univ Colorado, Aurora, CO USA.
RP Aliabadi, N (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30329 USA.
EM ydh6@cdc.gov
OI Leshem, Eyal/0000-0003-1267-6131
NR 29
TC 3
Z9 3
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1387
EP 1394
DI 10.3201/eid2208.151949
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500008
PM 27434186
ER

PT J
AU Arwady, MA
   Alraddadi, B
   Basler, C
   Azhar, EI
   Abuelzein, E
   Sindy, AI
   Bin Sadiq, BM
   Althaqafi, AO
   Shabouni, O
   Banjar, A
   Haynes, LM
   Gerber, SI
   Feikin, DR
   Madani, TA
AF Arwady, M. Allison
   Alraddadi, Basem
   Basler, Colin
   Azhar, Esam I.
   Abuelzein, Eltayb
   Sindy, Abdulfattah I.
   Bin Sadiq, Bakr M.
   Althaqafi, Abdulhakeem O.
   Shabouni, Omaima
   Banjar, Ayman
   Haynes, Lia M.
   Gerber, Susan I.
   Feikin, Daniel R.
   Madani, Tariq A.
TI Middle East Respiratory Syndrome Coronavirus Transmission in Extended
   Family, Saudi Arabia, 2014
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID MERS-COV OUTBREAK; INFECTIONS; CLUSTER; CONTACTS; JEDDAH
AB Risk factors for human-to-human transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) are largely unknown. After MERS-CoV infections occurred in an extended family in Saudi Arabia in 2014, relatives were tested by using real-time reverse transcription PCR (rRT-PCR) and serologic methods. Among 79 relatives, 19 (24%) were MERS-CoV positive; 11 were hospitalized, and 2 died. Eleven (58%) tested positive by rRT-PCR; 8 (42%) tested negative by rRT-PCR but positive by serology. Compared with MERS-CoV-negative adult relatives, MERS-CoV-positive adult relatives were older and more likely to be male and to have chronic medical conditions. Risk factors for household transmission included sleeping in an index patient's room and touching respiratory secretions from an index patient. Casual contact and simple proximity were not associated with transmission. Serology was more sensitive than standard rRT-PCR for identifying infected relatives, highlighting the value of including serology in future investigations.
C1 [Arwady, M. Allison; Basler, Colin; Haynes, Lia M.; Gerber, Susan I.; Feikin, Daniel R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Alraddadi, Basem] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia.
   [Alraddadi, Basem; Azhar, Esam I.; Abuelzein, Eltayb; Sindy, Abdulfattah I.; Bin Sadiq, Bakr M.; Althaqafi, Abdulhakeem O.; Shabouni, Omaima; Banjar, Ayman; Madani, Tariq A.] Minist Hlth, Jeddah, Saudi Arabia.
   [Azhar, Esam I.; Madani, Tariq A.] King Abdulaziz Univ, Jeddah, Saudi Arabia.
   [Althaqafi, Abdulhakeem O.] Minist Natl Guard, Jeddah, Saudi Arabia.
RP Madani, TA (reprint author), King Abdulaziz Univ, Fac Med, Dept Med, POB 80215, Jeddah 21589, Saudi Arabia.
EM tmadani@kau.edu.sa
FU Saudi Arabia Ministry of Health; CDC
FX The Saudi Arabia Ministry of Health and CDC provided funding for the
   study.
NR 25
TC 4
Z9 4
U1 1
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1395
EP 1402
DI 10.3201/eid2208.152015
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500009
PM 27191038
ER

PT J
AU Eberhard, ML
   Yabsley, MJ
   Zirimwabagabo, H
   Bishop, H
   Cleveland, CA
   Maerz, JC
   Bringolf, R
   Ruiz-Tiben, E
AF Eberhard, Mark L.
   Yabsley, Michael J.
   Zirimwabagabo, Hubert
   Bishop, Henry
   Cleveland, Christopher A.
   Maerz, John C.
   Bringolf, Robert
   Ruiz-Tiben, Ernesto
TI Possible Role of Fish and Frogs as Paratenic Hosts of Dracunculus
   medinensis, Chad
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INSIGNIS NEMATODA
AB Copepods infected with Dracunculus medinensis larvae collected from infected dogs in Chad were fed to 2 species of fish and tadpoles. Although they readily ingested copepods, neither species of fish, Nile tilapia (Oreochromis niloticus) nor fathead minnow (Pimephalis promelas), were found to harbor Dracunculus larvae when examined 2-3 weeks later. Tadpoles ingested copepods much more slowly; however, upon examination at the same time interval, tadpoles of green frogs (Lithobates [Rana] clamitans) were found to harbor small numbers of Dracunculus larvae. Two ferrets (Mustela putorius furo) were fed fish or tadpoles that had been exposed to infected copepods. Only the ferret fed tadpoles harbored developing Dracunculus larvae at necropsy 70-80 days postexposure. These observations confirm that D. medinensis, like other species in the genus Dracunculus, can readily survive and remain infective in potential paratenic hosts, especially tadpoles.
C1 [Eberhard, Mark L.; Bishop, Henry] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D-64, Atlanta, GA 30329 USA.
   [Yabsley, Michael J.; Cleveland, Christopher A.] Univ Georgia, Coll Vet Med, Athens, GA USA.
   [Yabsley, Michael J.; Cleveland, Christopher A.; Maerz, John C.; Bringolf, Robert] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA.
   [Zirimwabagabo, Hubert; Ruiz-Tiben, Ernesto] Carter Ctr, Atlanta, GA USA.
RP Eberhard, ML (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D-64, Atlanta, GA 30329 USA.
EM mle1@cdc.gov
NR 9
TC 3
Z9 3
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1428
EP 1430
DI 10.3201/eid2208.160043
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500013
PM 27434418
ER

PT J
AU Ratnayake, R
   Crowe, SJ
   Jasperse, J
   Privette, G
   Stone, E
   Miller, L
   Hertz, D
   Fu, C
   Maenner, MJ
   Jambai, A
   Morgan, O
AF Ratnayake, Ruwan
   Crowe, Samuel J.
   Jasperse, Joseph
   Privette, Grayson
   Stone, Erin
   Miller, Laura
   Hertz, Darren
   Fu, Clementine
   Maenner, Matthew J.
   Jambai, Amara
   Morgan, Oliver
TI Assessment of Community Event-Based Surveillance for Ebola Virus
   Disease, Sierra Leone, 2015
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID GLOBAL RESPONSE; POST-EBOLA; TRANSMISSION; OUTBREAKS; EPIDEMIC; MEASLES
AB In 2015, community event-based surveillance (CEBS) was implemented in Sierra Leone to assist with the detection of Ebola virus disease (EVD) cases. We assessed the sensitivity of CEBS for finding EVD cases during a 7-month period, and in a 6-week subanalysis, we assessed the timeliness of reporting cases with no known epidemiologic links at time of detection. Of the 12,126 CEBS reports, 287 (2%) met the suspected case definition, and 16 were confirmed positive. CEBS detected 30% (16/53) of the EVD cases identified during the study period. During the subanalysis, CEBS staff identified 4 of 6 cases with no epidemiologic links. These CEBS-detected cases were identified more rapidly than those detected by the national surveillance system; however, too few cases were detected to determine system timeliness. Although CEBS detected EVD cases, it largely generated false alerts. Future versions of community-based surveillance could improve case detection through increased staff training and community engagement.
C1 [Ratnayake, Ruwan] Int Rescue Comm, 122 E 42nd St, New York, NY 10168 USA.
   [Crowe, Samuel J.; Maenner, Matthew J.; Morgan, Oliver] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30329 USA.
   [Jasperse, Joseph; Privette, Grayson; Stone, Erin; Miller, Laura; Hertz, Darren] Int Rescue Comm, Freetown, Sierra Leone.
   [Fu, Clementine] Act Faim, Kambia, Sierra Leone.
   [Jambai, Amara] Sierra Leone Minist Hlth & Sanitat, Freetown, Sierra Leone.
RP Ratnayake, R (reprint author), Int Rescue Comm, 122 E 42nd St, New York, NY 10168 USA.; Crowe, SJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30329 USA.
EM ruwan.ratnayake@rescue.org; yeo2@cdc.gov
FU Department for International Development; US Agency for International
   Development's Office of Foreign Disaster Assistance
FX CEBS was supported by Department for International Development and the
   US Agency for International Development's Office of Foreign Disaster
   Assistance.
NR 22
TC 0
Z9 0
U1 4
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1431
EP 1437
DI 10.3201/eid2208.160205
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500014
PM 27434608
ER

PT J
AU Guo, YQ
   Roellig, DM
   Li, N
   Tang, K
   Frace, M
   Ortega, Y
   Arrowood, MJ
   Feng, YY
   Qvarnstrom, Y
   Wang, L
   Moss, DM
   Zhang, LX
   Xiao, LH
AF Guo, Yaqiong
   Roellig, Dawn M.
   Li, Na
   Tang, Kevin
   Frace, Michael
   Ortega, Ynes
   Arrowood, Michael J.
   Feng, Yaoyu
   Qvarnstrom, Yvonne
   Wang, Lin
   Moss, Delynn M.
   Zhang, Longxian
   Xiao, Lihua
TI Multilocus Sequence Typing Tool for Cyclospora cayetanensis
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
AB Because the lack of typing tools for Cyclospora cayetanensis has hampered outbreak investigations, we sequenced its genome and developed a genotyping tool. We observed 2 to 10 geographically segregated sequence types at each of 5 selected loci. This new tool could be useful for case linkage and infection/contamination source tracking.
C1 [Guo, Yaqiong; Roellig, Dawn M.; Tang, Kevin; Frace, Michael; Arrowood, Michael J.; Qvarnstrom, Yvonne; Moss, Delynn M.; Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Guo, Yaqiong; Li, Na; Feng, Yaoyu; Wang, Lin] East China Univ Sci & Technol, Shanghai, Peoples R China.
   [Ortega, Ynes] Univ Georgia, Griffin, GA USA.
   [Zhang, Longxian] Henan Agr Univ, Zhengzhou, Peoples R China.
RP Feng, YY (reprint author), East China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM yyfeng@ecust.edu.cn
RI Xiao, Lihua/B-1704-2013
OI Xiao, Lihua/0000-0001-8532-2727
FU National Natural Science Foundation of China [31425025, 31229005]; China
   Postdoctoral Science Foundation [2014M560310]; US Centers for Disease
   Control and Prevention
FX This work was supported in part by the National Natural Science
   Foundation of China (grant nos. 31425025 and 31229005), the China
   Postdoctoral Science Foundation (grant no. 2014M560310), and the US
   Centers for Disease Control and Prevention.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1464
EP 1467
DI 10.3201/eid2208.150696
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500021
PM 27433881
ER

PT J
AU Curtis-Robles, R
   Beard, CB
AF Curtis-Robles, Rachel
   Beard, Charles B.
TI Raymond Edward Ryckman
SO EMERGING INFECTIOUS DISEASES
LA English
DT Biographical-Item
C1 [Curtis-Robles, Rachel] Texas A&M Univ, College Stn, TX USA.
   [Beard, Charles B.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
RP Curtis-Robles, R (reprint author), Texas A&M Univ, Vet Integrat Biosci Dept, 4458 TAMUS, College Stn, TX 77843 USA.
EM rcurtis@cvm.tamu.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1500
EP 1501
DI 10.3201/eid2208.151678
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500031
ER

PT J
AU Breedlove, B
   Sorvillo, FJ
AF Breedlove, Byron
   Sorvillo, Frank J.
TI "I Am a Son of the Red Earth"
SO EMERGING INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 [Breedlove, Byron] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA.
   [Sorvillo, Frank J.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA.
EM wbb1@cdc.gov
OI Breedlove, Byron/0000-0002-1026-1963
NR 11
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1524
EP 1525
DI 10.3201/eid2208.AC2208
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500045
ER

PT J
AU Bell, ME
   Bernard, KA
   Harrington, SM
   Patel, NB
   Tucker, TA
   Metcalfe, MG
   McQuiston, JR
AF Bell, Melissa E.
   Bernard, Kathryn A.
   Harrington, Susan M.
   Patel, Nisha B.
   Tucker, Trudy-Ann
   Metcalfe, Maureen G.
   McQuiston, John R.
TI Lawsonella clevelandensis gen. nov., sp nov., a new member of the
   suborder Corynebacterineae isolated from human abscesses
SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
LA English
DT Article
ID CORYNEFORM BACTERIA; LIPID-COMPOSITION; FATTY-ACIDS; ESTERS
AB Gram-stain-positive, partially acid-fast, non-spore-forming, anaerobic, catalase-positive, pleomorphic bacteria were isolated from human abscesses. Strains X1036(T), X1698 and NML 120705, were recovered from a spinal abscess, a peritoneal abscess and a breast abscess respectively. A phylogenetic analysis of the 16S rRNA gene sequences showed that the strains shared 100% similarity, and the nearest phylogenetic neighbour was Dietzia timorensis DSM 45568(T) (95%). Chemotaxonomic characteristics of the strains were consistent with those described for members of the suborder Corynebacterineae. Mycolic acids were detected using HPLC and one-dimensional TLC; whole-cell hydrolysates yielded meso-diaminopimelic acid with arabinose and galactose as the predominant sugars; the muramic acid acyl type was acetylated; the major menaquinone was MK-9 (96.3%); polar lipids detected were phosphatidylglycerol, phosphatidylinositol and an unknown glycophospholipid. Cellular fatty acids were hexadecanoic acid (C-16:0), octadecenoic acid (C-18:1 omega 9c) and decanoic acid (C-10:0). Tuberculostearic acid was not detected. Based on the results of this polyphasic study, we conclude that these strains represent a novel genus and species within the suborder Corynebacterineae for which we propose the name Lawsonella clevelandensis gen. nov., sp. nov., with the type strain X1036(T) (= DSM 45743(T) = CCUG 66657(T)).
C1 [Bell, Melissa E.; McQuiston, John R.] Ctr Dis Control & Prevent, Special Bacteriol Reference Lab, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
   [Bernard, Kathryn A.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada.
   [Bernard, Kathryn A.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Fac Med, Winnipeg, MB, Canada.
   [Harrington, Susan M.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
   [Patel, Nisha B.] Univ Oklahoma, Dept Microbiol & Plant Biol, Norman, OK 73019 USA.
   [Tucker, Trudy-Ann] Georgia State Univ, 24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.
   [Metcalfe, Maureen G.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA.
RP Bell, ME (reprint author), Ctr Dis Control & Prevent, Special Bacteriol Reference Lab, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM jqv7@cdc.gov
NR 30
TC 0
Z9 0
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 1466-5026
EI 1466-5034
J9 INT J SYST EVOL MICR
JI Int. J. Syst. Evol. Microbiol.
PD AUG
PY 2016
VL 66
BP 2929
EP 2935
DI 10.1099/ijsem.0.001122
PN 8
PG 7
WC Microbiology
SC Microbiology
GA DY2KG
UT WOS:000384920900025
PM 27130323
ER

PT J
AU Drobish, AM
   Emery, BD
   Whitney, AM
   Lauer, AC
   Metcalfe, MG
   McQuiston, JR
AF Drobish, Adam M.
   Emery, Brian D.
   Whitney, Anne M.
   Lauer, Ana C.
   Metcalfe, Maureen G.
   McQuiston, John R.
TI Oblitimonas alkaliphila gen. nov., sp nov., in the family
   Pseudomonadaceae, recovered from a historical collection of previously
   unidentified clinical strains
SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
LA English
DT Article
ID RIBOSOMAL-RNA; LIPID-COMPOSITION; DNA; BACTERIUM; SEQUENCE;
   IDENTIFICATION; STANDARD; SLUDGE
AB Eight Gram-stain-negative bacteria (B4199(T), C6819, C6918, D2441, D3318, E1086, E1148 and E5571) were identified during a retrospective study of unidentified strains from a historical collection held in the Special Bacteriology Reference Laboratory at the Centers for Disease Control and Prevention. The strains were isolated from eight patients: five female, two male and one not specified. No ages were indicated for the patients. The sources were urine (3), leg tissue (2), foot wound, lung tissue and deep liver. The strains originated from seven different states across the USA [Colorado, Connecticut (2), Indiana, North Carolina, Oregon and Pennsylvania]. The strains grew at 10-42 degrees C, were non-motile, alkalitolerant, slightly halophilic, microaerophilic, and catalase-and oxidase-positive. The DNA G+C content was 47.3-47.6 mol%. The major cellular fatty acids were tetradecanoic acid (C-14 : 0), hexadecanoic acid (C-16 : 0) and 11-octadecenoic acid (C-18 : 1 omega 7c). Polar lipids detected were phosphatidylglycerol, phosphatidylethanolamine, diphosphatidylglycerol and unknown phospholipids; the only respiratory quinone detected was the ubiquinone Q-9 (100 %). 16S rRNA gene sequence analysis produced results with 95.6% similarity to Pseudomonas caeni DSM 24390(T) and 95.2% similarity to Thiopseudomonas denitrificans X2(T). The results of the biochemical, chemotaxonomic and phylogenetic analyses between the study strains and some related type strains indicated that these strains represent a novel species of a new genus within the family Pseudomonadaceae, for which the name Oblitimonas alkaliphila gen. nov., sp. nov. is proposed. The type strain is B4199(T) (=DSM 100830(T) =CCUG 67636(T)).
C1 [Drobish, Adam M.; Emery, Brian D.; Whitney, Anne M.; Lauer, Ana C.; McQuiston, John R.] Ctr Dis Control & Prevent, Special Bacteriol Reference Lab, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
   [Metcalfe, Maureen G.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA.
RP Emery, BD (reprint author), Ctr Dis Control & Prevent, Special Bacteriol Reference Lab, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM gyv3@cdc.gov
NR 33
TC 0
Z9 0
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 1466-5026
EI 1466-5034
J9 INT J SYST EVOL MICR
JI Int. J. Syst. Evol. Microbiol.
PD AUG
PY 2016
VL 66
BP 3063
EP 3070
DI 10.1099/ijsem.0.001147
PN 8
PG 8
WC Microbiology
SC Microbiology
GA DY2KG
UT WOS:000384920900045
PM 27169721
ER

PT J
AU Keating, NL
   Kouri, EM
   He, YL
   Freedman, RA
   Volya, R
   Zaslavsky, AM
AF Keating, Nancy L.
   Kouri, Elena M.
   He, Yulei
   Freedman, Rachel A.
   Volya, Rita
   Zaslavsky, Alan M.
TI Location Isn't Everything: Proximity, Hospital Characteristics, Choice
   of Hospital, and Disparities for Breast Cancer Surgery Patients
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Breast cancer; surgery; health care disparities; hospital racial
   composition; distance
ID ACUTE MYOCARDIAL-INFARCTION; SEER-MEDICARE DATA; QUALITY-OF-CARE;
   HEALTH-CARE; BLACK PATIENTS; RACIAL DISPARITIES; UNDERGO-SURGERY;
   UNITED-STATES; SATISFACTION; CONCORDANCE
AB Objective. Assess the relative importance of proximity and other hospital characteristics in the choice of hospital for breast cancer surgery by race/ethnicity.
   Data. SEER-Medicare data.
   Study Design. Observational study of women aged >65 years receiving surgery for stage I/II/III breast cancer diagnosed in 1992-2007 in Detroit (N = 10,746 white/black), Atlanta (N = 4,018 white/black), Los Angeles (N = 9,433 white/black/Asian/Hispanic), and San Francisco (N = 4,856 white/black/Asian). We calculated the distance from each patient's census tract of residence to each area hospital. We estimated discrete choice models for the probability of receiving surgery at each hospital based on distance and assessed whether deviations from these predictions entailed interactions of hospital characteristics with the patient's race/ethnicity. We identified high-quality hospitals by rates of adjuvant radiation therapy and by survey measures of patient experiences, and we assessed how observed surgery rates at high-quality hospitals deviated from those predicted based on distance alone.
   Principal Findings. Proximity was significantly associated with hospital choice in all areas. Minority more often than white breast cancer patients had surgery at hospitals with more minority patients, those treating more Medicaid patients, and in some areas, lower quality hospitals.
   Conclusions. Residential location alone does not explain concentration of racial/ethnic-minority breast cancer surgery patients in certain hospitals that are sometimes of lower quality.
C1 [Keating, Nancy L.; Kouri, Elena M.; Volya, Rita; Zaslavsky, Alan M.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
   [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA.
   [He, Yulei] Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD USA.
   [Freedman, Rachel A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Keating, NL (reprint author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.; Keating, NL (reprint author), Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA.
EM keating@hcp.med.harvard.edu
FU California Department of Public Health as part of the statewide cancer
   reporting program; National Cancer Institute's Surveillance,
   Epidemiology and End Results Program [N01-PC-35136, N01-PC-35139,
   N02-PC-15105]; Centers for Disease Control and Prevention's National
   Program of Cancer Registries [U55/CCR921930-02]; Susan G. Komen for the
   Cure
FX This study used the linked SEER-Medicare database. The interpretation
   and reporting of these data are the sole responsibility of the authors.
   The authors acknowledge the efforts of the Applied Research Program,
   NCI; the Office of Research, Development and Information, CMS;
   Information Management Services (IMS), Inc.; and the Surveillance,
   Epidemiology, and End Results (SEER) Program tumor registries in the
   creation of the SEER-Medicare database. The collection of the California
   cancer incidence data used in this study was supported by the California
   Department of Public Health as part of the statewide cancer reporting
   program mandated by California Health and Safety Code Section 103885;
   the National Cancer Institute's Surveillance, Epidemiology and End
   Results Program under contract N01-PC-35136 awarded to the Northern
   California Cancer Center, contract N01-PC-35139 awarded to the
   University of Southern California, and contract N02-PC-15105 awarded to
   the Public Health Institute; and the Centers for Disease Control and
   Prevention's National Program of Cancer Registries, under agreement
   #U55/CCR921930-02 awarded to the Public Health Institute. The ideas and
   opinions expressed herein are those of the author(s) and endorsement by
   the State of California, Department of Public Health the National Cancer
   Institute, and the Centers for Disease Control and Prevention or their
   Contractors and Subcontractors is not intended nor should be inferred.
   This paper was developed while Yulei He was at Harvard Medical School.
   The findings and conclusions in this paper are those of the authors and
   do not necessarily represent the official position of the National
   Center for Health Statistics, Centers for Disease Control and
   Prevention. The study was supported by Susan G. Komen for the Cure.
NR 28
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD AUG
PY 2016
VL 51
IS 4
BP 1561
EP 1583
DI 10.1111/1475-6773.12443
PG 23
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DX9VO
UT WOS:000384745300014
PM 26800094
ER

PT J
AU Ritchey, M
   Yuan, KM
   Gillespie, C
   Zhang, GY
   Ostchega, Y
AF Ritchey, Matthew
   Yuan, Keming
   Gillespie, Cathleen
   Zhang, Guangyu
   Ostchega, Yechiam
TI Development and Validation of a Hypertension Prevalence Estimator Tool
   For Use in Clinical Settings
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID BLOOD-PRESSURE-MEASUREMENT; AMERICAN-HEART-ASSOCIATION; UNITED-STATES;
   INCIDENT HYPERTENSION; MEASUREMENT DEVICES; RISK-FACTORS; ADULTS;
   RECOMMENDATIONS; PREVENTION; EDUCATION
AB Health systems are well positioned to identify and control hypertension among their patients. However, almost one third of US adults with uncontrolled hypertension are currently receiving medical care and are unaware of being hypertensive. This study describes the development and validation of a tool that health systems can use to compare their reported hypertension prevalence with their expected prevalence. Tool users provide the number of patients aged 18 to 85 years treated annually, stratified by sex, age group, race/ethnicity, and comorbidity status. Each stratum is multiplied by stratum-specific national prevalence estimates and the amounts are summed to calculate the number of expected hypertensive patients. The tool's validity was assessed by applying samples from cohorts with known hypertension prevalence; small differences in expected vs actual prevalence were identified (range, -3.3% to 0.6%). This tool provides clinically useful hypertension prevalence estimates that health systems can use to help inform hypertension management quality improvement efforts. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Ritchey, Matthew; Yuan, Keming; Gillespie, Cathleen] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mail Stop F-77, Atlanta, GA 30341 USA.
   [Zhang, Guangyu; Ostchega, Yechiam] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
RP Ritchey, M (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mail Stop F-77, Atlanta, GA 30341 USA.
EM hha7@cdc.gov
FU National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201300046C,
   HHSN268201300047C, HHSN268201300048C, HHSN268201300049C,
   HHSN268201300050C]; National Institute on Minority Health and Health
   Disparities
FX We thank David Meyers, MD, Chief Medical Officer, Agency for Healthcare
   Research and Quality, Paul Muntner, PhD, Professor, Department of
   Epidemiology, University of Alabama at Birmingham, and Daniel Lackland,
   DrPH, Professor, Medical College of South Carolina, for their review of
   the manuscript and the helpful recommendations they provided. We thank
   Namvar Zohoori, MD, MPH, PhD, Director, Center for Health Advancement
   and Chronic Disease Director, Arkansas Department of Health, for his
   expertise in guiding our assessment of the Arkansas Cardiovascular
   Health Examination Survey data. We thank Adolfo Correa, MD, MPH, PhD,
   Director, Jackson Heart Study (JHS), for his expertise in guiding our
   assessment of the JHS data. The JHS is supported by contracts
   HHSN268201300046C, HHSN268201300047C, HHSN268201300048C,
   HHSN268201300049C, and HHSN268201300050C from the National Heart, Lung,
   and Blood Institute (NHLBI) and the National Institute on Minority
   Health and Health Disparities. This manuscript was prepared in part
   using Hispanic Community Health Study/Study of Latinos (HCHS) and
   Multi-Ethnic Study of Atherosclerosis (MESA) research materials obtained
   from the NHLBI Biologic Specimen and Data Repository Information
   Coordinating Center. This manuscript does not necessarily reflect the
   opinions or views of the ARCHES, JHS, HCHS, MESA, or NHLBI.
NR 42
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD AUG
PY 2016
VL 18
IS 8
BP 750
EP 761
DI 10.1111/jch.12746
PG 12
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DX9VV
UT WOS:000384746000007
PM 26729615
ER

PT J
AU Hofstetter, A
   De la Cruz, J
   Cao, W
   Patel, J
   Belser, J
   Liepkalns, J
   Amoah, S
   McCoy, J
   Cheng, G
   Diebold, B
   Shieh, WJ
   Zaki, S
   Katz, J
   Sambhara, S
   Lambeth, JD
   Gangappa, S
AF Hofstetter, A.
   De la Cruz, J.
   Cao, W.
   Patel, J.
   Belser, J.
   Liepkalns, J.
   Amoah, S.
   McCoy, J.
   Cheng, G.
   Diebold, B.
   Shieh, W. -J
   Zaki, S.
   Katz, J.
   Sambhara, S.
   Lambeth, J. D.
   Gangappa, S.
TI NADPH Oxidase 1 (NOX1) is associated with altered host survival and T
   cell phenotypes after influenza A virus infection in mice
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Hofstetter, A.; De la Cruz, J.; Cao, W.; Patel, J.; Belser, J.; Liepkalns, J.; Amoah, S.; Katz, J.; Sambhara, S.; Gangappa, S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [McCoy, J.; Cheng, G.; Diebold, B.; Lambeth, J. D.] Emory Univ, Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Shieh, W. -J; Zaki, S.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 957
BP 527
EP 527
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401253
ER

PT J
AU Eko, FO
   Russell, R
   He, Q
   Black, CM
   Igietseme, JU
AF Eko, F. O.
   Russell, R.
   He, Q.
   Black, C. M.
   Igietseme, J. U.
TI VCG modulate innate and adaptive immune responses to vaccine antigens
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Eko, F. O.; Russell, R.; He, Q.; Igietseme, J. U.] Morehouse Sch Med, Atlanta, GA 30310 USA.
   [Black, C. M.; Igietseme, J. U.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 848
BP 888
EP 888
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402176
ER

PT J
AU Carbone, M
   Kanodia, S
   Chao, A
   Miller, A
   Wali, A
   Weissman, D
   Adjei, A
   Baumann, F
   Boffetta, P
   Buck, B
   de Perrot, M
   Dogan, AU
   Gavett, S
   Gualtieri, A
   Hassan, R
   Hesdorffer, M
   Hirsch, FR
   Larson, D
   Mao, WM
   Masten, S
   Pass, HI
   Peto, J
   Pira, E
   Steele, I
   Tsao, A
   Woodard, GA
   Yang, HN
   Malik, S
AF Carbone, Michele
   Kanodia, Shreya
   Chao, Ann
   Miller, Aubrey
   Wali, Anil
   Weissman, David
   Adjei, Alex
   Baumann, Francine
   Boffetta, Paolo
   Buck, Brenda
   de Perrot, Marc
   Dogan, A. Umran
   Gavett, Steve
   Gualtieri, Alessandro
   Hassan, Raffit
   Hesdorffer, Mary
   Hirsch, Fred R.
   Larson, David
   Mao, Weimin
   Masten, Scott
   Pass, Harvey I.
   Peto, Julian
   Pira, Enrico
   Steele, Ian
   Tsao, Anne
   Woodard, Gavitt Alida
   Yang, Haining
   Malik, Shakun
TI Consensus Report of the 2015 Weinman International Conference on
   Mesothelioma
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Mesothelioma; BAP1; Asbestos; Erionite; Biomarkers; Genetics; Therapy
ID MALIGNANT-PLEURAL-MESOTHELIOMA; GERMLINE BAP1 MUTATIONS; PHASE-II TRIAL;
   NATURALLY-OCCURRING ASBESTOS; SERUM OSTEOPONTIN LEVELS; EXTRAPLEURAL
   PNEUMONECTOMY; NEOADJUVANT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY;
   TRIMODALITY THERAPY; TUMOR-SUPPRESSOR
AB On November 9 and 10, 2015, the International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of Hawaii Cancer Center in Honolulu, Hawaii. The meeting was cosponsored by the International Association for the Study of Lung Cancer, and the agenda was designed with significant input from staff at the U.S. National Cancer Institute and National Institute of Environmental Health Sciences. A multidisciplinary group of participants presented updates reflecting a range of disciplinary perspectives, including mineralogy, geology, epidemiology, toxicology, biochemistry, molecular biology, genetics, public health, and clinical oncology. The group identified knowledge gaps that are barriers to preventing and treating malignant mesothelioma (MM) and the required next steps to address barriers. This manuscript reports the group's efforts and focus on strategies to limit risk to the population and reduce the incidence of MM. Four main topics were explored: genetic risk, environmental exposure, biomarkers, and clinical interventions. Genetics plays a critical role in MM when the disease occurs in carriers of germline BRCA1 associated protein 1 mutations. Moreover, it appears likely that, in addition to BRCA1 associated protein 1, other yet unknown genetic variants may also influence the individual risk for development of MM, especially after exposure to asbestos and related mineral fibers. MM is an almost entirely preventable malignancy as it is most often caused by exposure to commercial asbestos or mineral fibers with asbestos-like health effects, such as erionite. In the past in North America and in Europe, the most prominent source of exposure was related to occupation. Present regulations have reduced occupational exposure in these countries; however, some people continue to be exposed to previously installed asbestos in older construction and other settings. Moreover, an increasing number of people are being exposed in rural areas that contain noncommercial asbestos, erionite, and other mineral fibers in soil or rock (termed naturally occurring asbestos [NOA]) and are being developed. Public health authorities, scientists, residents, and other affected groups must work together in the areas where exposure to asbestos, including NOA, has been documented in the environment to mitigate or reduce this exposure. Although a blood biomarker validated to be effective for use in screening and identifying MM at an early stage in asbestos/NOA-exposed populations is not currently available, novel biomarkers presented at the meeting, such as high mobility group box 1 and fibulin-3, are promising. There was general agreement that current treatment for MM, which is based on surgery and standard chemotherapy, has a modest effect on the overall survival (OS), which remains dismal. Additionally, although much needed novel therapeutic approaches for MM are being developed and explored in clinical trials, there is a critical need to invest in prevention research, in which there is a great opportunity to reduce the incidence and mortality from MM. 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Carbone, Michele; Kanodia, Shreya; Larson, David; Yang, Haining] Univ Hawaii, Thorac Oncol, Ctr Canc, Honolulu, HI 96822 USA.
   [Kanodia, Shreya] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
   [Kanodia, Shreya] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.
   [Chao, Ann] NCI, Ctr Global Hlth, NIH, Bethesda, MD 20892 USA.
   [Miller, Aubrey] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Wali, Anil] NCI, Ctr Reduce Canc Hlth Dispar, NIH, Bethesda, MD 20892 USA.
   [Weissman, David] NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
   [Adjei, Alex] Mayo Clin, Rochester, MN USA.
   [Baumann, Francine] Univ New Caledonia, ERIM, Noumea, New Caledonia.
   [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA.
   [Buck, Brenda] Univ Nevada, Dept Geosci, Las Vegas, NV 89154 USA.
   [de Perrot, Marc] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Dogan, A. Umran] Univ Iowa, Chem & Biochem Engn Dept, Iowa City, IA USA.
   [Dogan, A. Umran] Univ Iowa, Ctr Global & Reg Environm Res, Iowa City, IA USA.
   [Gavett, Steve] US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USA.
   [Gualtieri, Alessandro] Univ Modena, Chem Earth Sci Dept, Modena, Italy.
   [Hassan, Raffit] NIH, Thorac Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.
   [Hesdorffer, Mary] Mesothelioma Appl Res Fdn, Alexandria, VA USA.
   [Hirsch, Fred R.] Univ Colorado, Ctr Canc, Denver, CO 80202 USA.
   [Mao, Weimin] Zhejiang Canc Hosp, Canc Res Inst, Hangzhou, Zhejiang, Peoples R China.
   [Mao, Weimin] Key Lab Diag & Treatment Technol Thorac Oncol Zhe, Hangzhou, Zhejiang, Peoples R China.
   [Masten, Scott] NIEHS, Natl Toxicol Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Pass, Harvey I.] NYU, Langone Med Ctr, Cardiothorac Surg, New York, NY USA.
   [Peto, Julian] London Sch Hyg & Trop Med, Canc Res UK, London, England.
   [Pira, Enrico] Univ Turin, Dept Publ Hlth & Pediat, Turin, Italy.
   [Steele, Ian] Notre Dame Univ, Notre Dame Integrated Imaging Facil, Notre Dame, IN USA.
   [Tsao, Anne] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Div Canc Med, Houston, TX 77030 USA.
   [Woodard, Gavitt Alida] Univ Calif San Francisco, Thorac Surg, San Francisco, CA 94143 USA.
   [Malik, Shakun] NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA.
RP Carbone, M (reprint author), Univ Hawaii, Ctr Canc, 701 Ilalo St,Room 437, Honolulu, HI 96813 USA.
EM mcarbone@cc.hawaii.edu
RI masten, scott/R-1403-2016
OI masten, scott/0000-0002-7847-181X
FU Jack Mishkin Discovery Fund for Mesothelioma Research from the Tower
   Cancer Research Foundation; Bureau of Land Management of the U.S.
   Department of the Interior [L13AC00237]
FX The meeting was made possible by a generous donation from the Barry and
   Virginia Weinman Foundation and the International Association for the
   Study of Lung Cancer. Dr. Kanodia is funded by the Jack Mishkin
   Discovery Fund for Mesothelioma Research from the Tower Cancer Research
   Foundation. Dr. Buck has a grant funded by the Bureau of Land Management
   of the U.S. Department of the Interior to study NOA in Nevada (no.
   L13AC00237). The findings and conclusions in this report are those of
   the authors and do not necessarily represent the views of any part of
   the U.S. Government.
NR 140
TC 7
Z9 7
U1 14
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD AUG
PY 2016
VL 11
IS 8
BP 1246
EP 1262
DI 10.1016/j.jtho.2016.04.028
PG 17
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA DS8XW
UT WOS:000381067300008
PM 27453164
ER

PT J
AU Herbst, JH
   Branscomb-Burgess, O
   Gelaude, DJ
   Seth, P
   Parker, S
   Fogel, CI
AF Herbst, Jeffrey H.
   Branscomb-Burgess, Olivia
   Gelaude, Deborah J.
   Seth, Puja
   Parker, Sharon
   Fogel, Catherine I.
TI RISK PROFILES OF WOMEN EXPERIENCING INITIAL AND REPEAT INCARCERATIONS:
   IMPLICATIONS FOR PREVENTION PROGRAMS
SO AIDS EDUCATION AND PREVENTION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SEXUALLY-TRANSMITTED INFECTIONS; INTIMATE
   PARTNER VIOLENCE; SUBSTANCE USE DISORDERS; MENTAL-HEALTH; INTERPERSONAL
   VIOLENCE; REENTRY CHALLENGES; COMMUNITY REENTRY; HIV; INTERVENTION
AB Incarcerated women experience myriad individual, interpersonal, and structural factors leading to arrest and rearrest. This study examined risk profiles of women experiencing initial and repeat incarcerations. The sample included 521 women recruited from two prisons in North Carolina and enrolled in a HIV/STD risk-reduction intervention trial. Variables included socio-demographics, structural/economic factors, sexual and substance use behaviors, STDs, victimization history, and depressive symptoms. Bivariate and multivariable analyses identified risk differences. Compared to women incarcerated for the first time, women with repeat incarcerations reported significantly greater economic instability, substance use and sexual risk behaviors, laboratory-confirmed STDs, and victimization during childhood and adulthood. Multivariable logistic regression found women with repeat incarcerations experienced greater unstable housing, injection drug use, crack cocaine use, concurrent sex partners, and childhood sexual victimization. Findings can inform the development of prevention programs by addressing economic instability, sexual risk, and substance use among women prisoners.
C1 [Herbst, Jeffrey H.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Branscomb-Burgess, Olivia] Univ Georgia, Dept Criminal Justice, Athens, GA 30602 USA.
   [Gelaude, Deborah J.; Seth, Puja] CDC, Div HIV AIDS Prevent, Viral Hepatitis STD & TB Prevent, Natl Ctr HIV AIDS, Atlanta, GA 30333 USA.
   [Parker, Sharon] North Carolina A&T State Univ, Dept Social Work, Greensboro, NC USA.
   [Fogel, Catherine I.] Univ North Carolina Chapel Hill, FAAN Sch Nursing, Chapel Hill, NC USA.
RP Herbst, JH (reprint author), CDC, Res & Evaluat Branch, Div Violence Prevent, NCIPC, 4770 Buford Highway NE,Mailstop F-63, Atlanta, GA 30333 USA.
EM jherbst@cdc.gov
FU Centers for Disease Control and Prevention [5UR6PS000670-05]
FX This study was funded by a cooperative agreement (5UR6PS000670-05) from
   the Centers for Disease Control and Prevention from September 2007 to
   June 2013 to the School of Nursing at the University of North Carolina
   at Chapel Hill. The study is registered on clinicaltrials.gov
   (NCT01111721). The authors would like to acknowledge other members of
   the project team including Drs. Neetu Abad, Amy Fasula, and Monique
   Carry at the CDC; Karl Gustafson, Amy (Neeve) Neevel, Angela Edwards,
   and Madison Hayes at the University of North Carolina at Chapel Hill;
   and Dr. Rochelle Shain-the original developer of Project SAFE-at the
   Department of OB/GYN, University of Texas Health Science Center at San
   Antonio. The authors would also like to express our gratitude to the
   women who participated in this study for their important contributions
   to the fight against HIV/AIDS.
NR 55
TC 0
Z9 0
U1 9
U2 9
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA
SN 0899-9546
EI 1943-2755
J9 AIDS EDUC PREV
JI Aids Educ. Prev.
PD AUG
PY 2016
VL 28
IS 4
BP 299
EP 311
PG 13
WC Education & Educational Research; Public, Environmental & Occupational
   Health
SC Education & Educational Research; Public, Environmental & Occupational
   Health
GA DW1BY
UT WOS:000383379000003
PM 27427925
ER

PT J
AU Nasrullah, M
   Wesolowski, LG
   Ethridge, SF
   Cranston, K
   Pentella, M
   Myers, RA
   Rudrik, JT
   Hutchinson, AB
   Bennett, SB
   Werner, BG
AF Nasrullah, Muazzam
   Wesolowski, Laura G.
   Ethridge, Steven F.
   Cranston, Kevin
   Pentella, Michael
   Myers, Robert A.
   Rudrik, James T.
   Hutchinson, Angela B.
   Bennett, Spencer B.
   Werner, Barbara G.
TI Acute infections, cost and time to reporting of HIV test results in
   three US State Public Health Laboratories
SO JOURNAL OF INFECTION
LA English
DT Article
DE Fourth-generation immunoassay; Acute infections; Cost; HIV testing
   algorithms; Time to reporting
ID DIAGNOSTIC ALGORITHM; WESTERN-BLOT; COMBO ASSAY; P24 ANTIGEN;
   PERFORMANCE; TRANSMISSION; ANTIBODY; IMMUNOASSAY; PREVENTION; DIVERSITY
AB Objective: In three U.S. State Public Health Laboratories (PHLs) using a fourth-generation immunoassay (IA), an HIV-1/HIV-2 differentiation antibody IA and a nucleic acid test (NAT), we characterized the yield and time to reporting of acute infections, and cost per positive specimen.
   Methods: Routine HIV testing data were collected from July 1, 2012-June 30, 2013 for Massachusetts and Maryland PHLs, and from November 27, 2012-June 30, 2013 for Michigan PHL. Massachusetts and Michigan used fourth-generation and differentiation IAs with NAT conducted by a referral laboratory. In Maryland, fourth-generation IA repeatedly reactive specimens were followed by a Western blot (WB), and those with negative or indeterminate results were tested with a differentiation IA and HIV-1 NAT, and if positive by NAT, confirmed by a different HIV-1 NAT. Specimens from WB-positive persons at risk for HIV-2 were tested with a differentiation IA and, if positive, with an HIV-2 WB and/or differential HIV-1/HIV-2 proviral DNA polymerase chain reaction.
   Results: Among 7914 specimens from Massachusetts PHL, 6069 from Michigan PHL, and 36,266 from Maryland PHL, 0.10%, 0.02% and 0.05% acute infections were identified, respectively. Massachusetts and Maryland PHLs each had 1 HIV-2 positive specimen. The median time from specimen receipt to laboratory reporting of results for acute infections at Massachusetts, Michigan and Maryland PHLs was 8, 11, and 7 days respectively. The laboratory cost per HIV positive specimen was $336 (Massachusetts), $263 (Michigan) and $210 (Maryland).
   Conclusions: Acute and established infections were found by PHLs using fourth-generation IA in conjunction with antibody tests and NAT. Time to reporting of acute HIV test results to clients was suboptimal, and needs to be streamlined to expedite treatment and interrupt transmission. Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Nasrullah, Muazzam; Wesolowski, Laura G.; Ethridge, Steven F.; Hutchinson, Angela B.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30329 USA.
   [Cranston, Kevin; Pentella, Michael; Werner, Barbara G.] Massachusetts Dept Publ Hlth, Boston, MA USA.
   [Myers, Robert A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
   [Rudrik, James T.] Michigan Dept Hlth & Human Serv, Lansing, MI USA.
   [Bennett, Spencer B.] Florida Bur Publ Hlth Labs, Jacksonville, FL USA.
RP Nasrullah, M (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30329 USA.
EM snasrullah@cdc.gov
FU Centers for Disease Control and Prevention [200-2009-30955-0003]
FX The project was funded by the Centers for Disease Control and Prevention
   (Task Order #200-2009-30955-0003).
NR 39
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD AUG
PY 2016
VL 73
IS 2
BP 164
EP 172
DI 10.1016/j.jinf.2016.05.006
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA DW1CI
UT WOS:000383380000009
PM 27237366
ER

PT J
AU Kwon, JM
   Abdel-Hamid, HZ
   Al-Zaidy, SA
   Mendell, JR
   Kennedy, A
   Kinnett, K
   Cwik, VA
   Street, N
   Bolen, J
   Day, JW
   Connolly, AM
AF Kwon, Jennifer M.
   Abdel-Hamid, Hoda Z.
   Al-Zaidy, Samiah A.
   Mendell, Jerry R.
   Kennedy, Annie
   Kinnett, Kathi
   Cwik, Valerie A.
   Street, Natalie
   Bolen, Julie
   Day, John W.
   Connolly, Anne M.
TI CLINICAL FOLLOW-UP FOR DUCHENNE MUSCULAR DYSTROPHY NEWBORN SCREENING: A
   PROPOSAL
SO MUSCLE & NERVE
LA English
DT Article
DE clinical; Duchenne muscular dystrophy; follow-up; long-term; management;
   newborn screening; public health
ID SERVICES ADVISORY-COMMITTEE; HERITABLE DISORDERS; CORTICOSTEROID
   TREATMENT; AMERICAN ACADEMY; US SECRETARY; STATEMENT; CHILDREN; HEALTH;
   SUBCOMMITTEE; NEUROLOGY
AB New developments in the rapid diagnosis and treatment of boys with Duchenne muscular dystrophy (DMD) have led to growing enthusiasm for instituting DMD newborn screening (NBS) in the United States. Our group has been interested in developing clinical guidance to be implemented consistently in specialty care clinics charged with the care of presymptomatically identified newborns referred after DMD-NBS. We reviewed the existing literature covering patient-centered clinical follow-up after NBS, educational material from public health and advocacy sites, and federal recommendations on effective NBS follow-up. We discussed the review as a group and added our own experience to develop materials suitable for initial parent and primary care provider education. These materials and a series of templates for subspecialist encounters could be used to provide consistent care across centers and serve as the basis for ongoing quality improvement.
C1 [Kwon, Jennifer M.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
   [Kwon, Jennifer M.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA.
   [Abdel-Hamid, Hoda Z.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA.
   [Al-Zaidy, Samiah A.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA.
   [Mendell, Jerry R.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
   [Mendell, Jerry R.] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA.
   [Kennedy, Annie] Parent Project Muscular Dystrophy, Hackensack, NJ USA.
   [Kinnett, Kathi] Parent Project Muscular Dystrophy, Middletown, OH USA.
   [Cwik, Valerie A.] Muscular Dystrophy Assoc, Tucson, AZ USA.
   [Street, Natalie; Bolen, Julie] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Day, John W.] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA.
   [Connolly, Anne M.] Washington Univ, Dept Neurol, Sch Med St Louis, St Louis, MO USA.
   [Connolly, Anne M.] Washington Univ, Dept Pediat, Sch Med St Louis, St Louis, MO 63130 USA.
RP Kwon, JM (reprint author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.; Kwon, JM (reprint author), Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA.
EM jennifer_kwon@urmc.rochester.edu
NR 33
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD AUG
PY 2016
VL 54
IS 2
BP 186
EP 191
DI 10.1002/mus.25185
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DW2IP
UT WOS:000383466400002
PM 27170260
ER

PT J
AU Zhang, L
   Malarcher, A
   Mann, N
   Campbell, K
   Davis, K
   Anderson, C
   Alexander, R
   Rodes, R
AF Zhang, Lei
   Malarcher, Ann
   Mann, Nathan
   Campbell, Kelsey
   Davis, Kevin
   Anderson, Christopher
   Alexander, Robert
   Rodes, Robert
TI The Influence of State-Specific Quitline Numbers on Call Volume During a
   National Tobacco Education Campaign Promoting 1-800-QUIT-NOW
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID CIGARETTE-SMOKING; WEBSITE VISITORS
AB Previous research has shown that the first federally funded national tobacco education campaign (Tips) increased calls to the national quitline portal (1-800-QUIT-NOW). Quitlines in 13 states have alternate state-specific telephone numbers. This study examined quitline calls to 1-800-QUIT-NOW in states with and without alternate numbers during the Tips campaign.
   We used data on calls to 1-800-QUIT-NOW from all US states and the District of Columbia from 2 weeks before to 2 weeks after the 2012 Tips campaign. Similar data were obtained for California's alternate number, 1-800-NO-BUTTS. Multivariate linear models examined whether an interaction existed between Tips exposure, as measured by gross rating points, and presence of an alternate quitline number as well as the effect of Tips on calls to California's 1-800-NO-BUTTS.
   Having an alternate quitline number did not affect the rate of increase in calls to 1-800-QUIT-NOW, but it was associated with lower absolute numbers of calls to 1-800-QUIT-NOW. On average, states with alternate numbers had 98 fewer calls to 1-800-QUIT-NOW per week in a given area code than those without an alternate number (P < .001). In California, Tips gross rating points were positively correlated with calls to 1-800-QUIT-NOW (b = 38.5, P < .001) and to 1-800-NO-BUTTS (b = 14.1, P < .05).
   The Tips campaign had the same effect in increasing calls to 1-800-QUIT-NOW in states with and without alternate quitline numbers and had a modest spillover effect on calls to California's alternate number. States may consider the advantages and disadvantages of having alternate quitline numbers given continued national promotions of 1-800-QUIT-NOW.
   This is the first study that assesses whether the impact of a national tobacco education campaign promoting the national quitline portal number was influenced by the presence of state-specific quitline numbers and whether there was any spillover effect on calls to states' alternate quitline numbers. This study provides important information for states to consider the advantages and disadvantages of maintaining state-specific quitline numbers.
C1 [Zhang, Lei; Malarcher, Ann; Rodes, Robert] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA.
   [Mann, Nathan; Campbell, Kelsey; Davis, Kevin] RTI Int, Ctr Hlth Policy Sci & Tobacco Res, Res Triangle Pk, NC USA.
   [Anderson, Christopher] Univ Calif San Diego, Calif Smokers Helpline & Ctr Tobacco Cessat, La Jolla, CA 92093 USA.
   [Alexander, Robert] Battelle Publ Hlth Ctr Tobacco Res, Battelle Mem Inst, Baltimore, MD USA.
RP Zhang, L (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE Mailstop F-79, Atlanta, GA 30341 USA.
EM lzhang2@cdc.gov
FU Centers for Disease Control and Prevention [200-2007-20016/0021]
FX This work was supported by the Centers for Disease Control and
   Prevention (task order: 200-2007-20016/0021).
NR 16
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD AUG
PY 2016
VL 18
IS 8
BP 1780
EP 1785
DI 10.1093/ntr/ntw100
PG 6
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA DV9TX
UT WOS:000383286200015
PM 27073208
ER

PT J
AU Binagwaho, A
   Kankindi, I
   Kayirangwa, E
   Nyemazi, JP
   Nsanzimana, S
   Morales, F
   Kadende-Kaiser, R
   Scott, KW
   Mugisha, V
   Sahabo, R
   Baribwira, C
   Isanhart, L
   Asiimwe, A
   El-Sadr, WM
   Raghunathan, PL
AF Binagwaho, Agnes
   Kankindi, Ida
   Kayirangwa, Eugenie
   Nyemazi, Jean Pierre
   Nsanzimana, Sabin
   Morales, Fernando
   Kadende-Kaiser, Rose
   Scott, Kirstin Woody
   Mugisha, Veronicah
   Sahabo, Ruben
   Baribwira, Cyprien
   Isanhart, Leia
   Asiimwe, Anita
   El-Sadr, Wafaa M.
   Raghunathan, Pratima L.
TI Transitioning to Country Ownership of HIV Programs in Rwanda
SO PLOS MEDICINE
LA English
DT Article
ID GLOBAL HEALTH; SUSTAINABILITY; AFRICA; PEPFAR; AIDS; CARE
C1 [Binagwaho, Agnes; Kankindi, Ida; Nyemazi, Jean Pierre; Nsanzimana, Sabin; Asiimwe, Anita] Rwanda Minist Hlth, Kigali, Rwanda.
   [Binagwaho, Agnes; Scott, Kirstin Woody] Harvard Med Sch, Boston, MA 02115 USA.
   [Binagwaho, Agnes] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA.
   [Kayirangwa, Eugenie; Kadende-Kaiser, Rose] Ctr Dis Control & Prevent, Div Global HIV AIDS, Kigali, Rwanda.
   [Morales, Fernando] CTS Global Serv, Los Angeles, CA USA.
   [Mugisha, Veronicah; Sahabo, Ruben; El-Sadr, Wafaa M.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA.
   [Baribwira, Cyprien; Isanhart, Leia] Catholic Relief Serv, AIDSRelief, Kigali, Rwanda.
   [Raghunathan, Pratima L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA.
RP Binagwaho, A (reprint author), Rwanda Minist Hlth, Kigali, Rwanda.; Binagwaho, A (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Binagwaho, A (reprint author), Geisel Sch Med Dartmouth, Hanover, NH 03755 USA.
EM agnes_binagwaho@hms.harvard.edu
NR 18
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2016
VL 13
IS 8
AR e1002075
DI 10.1371/journal.pmed.1002075
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW0UD
UT WOS:000383357400009
PM 27505355
ER

PT J
AU Chretien, JP
   Rivers, CM
   Johansson, MA
AF Chretien, Jean-Paul
   Rivers, Caitlin M.
   Johansson, Michael A.
TI Make Data Sharing Routine to Prepare for Public Health Emergencies
SO PLOS MEDICINE
LA English
DT Article
ID CLINICAL-TRIAL DATA; JOURNAL EDITORS
C1 [Chretien, Jean-Paul] Def Hlth Agcy, Armed Forces Hlth Surveillance Branch, Integrated Biosurveillance Sect, Silver Spring, MD 20910 USA.
   [Rivers, Caitlin M.] US Army Inst Publ Hlth, Epidemiol & Dis Surveillance, Aberdeen Proving Ground, MD USA.
   [Johansson, Michael A.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA.
RP Chretien, JP (reprint author), Def Hlth Agcy, Armed Forces Hlth Surveillance Branch, Integrated Biosurveillance Sect, Silver Spring, MD 20910 USA.
EM jpchretien@gmail.com
NR 41
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2016
VL 13
IS 8
AR e1002109
DI 10.1371/journal.pmed.1002109
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW0UD
UT WOS:000383357400026
ER

PT J
AU Habiyambere, V
   Ford, N
   Low-Beer, D
   Nkengasong, J
   Sands, A
   Gonzalez, MP
   Fernandes, P
   Milgotina, E
AF Habiyambere, Vincent
   Ford, Nathan
   Low-Beer, Daniel
   Nkengasong, John
   Sands, Anita
   Gonzalez, Mercedes Perez
   Fernandes, Paula
   Milgotina, Ekaterina
TI Availability and Use of HIV Monitoring and Early Infant Diagnosis
   Technologies in WHO Member States in 2011-2013: Analysis of Annual
   Surveys at the Facility Level
SO PLOS MEDICINE
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; OF-CARE DIAGNOSTICS; IMPLEMENTATION;
   OPPORTUNITIES; CHALLENGES; CD4
AB Background
   The Joint United Nations Programme on HIV and AIDS (UNAIDS) 90-90-90 targets have reinforced the importance of functioning laboratory services to ensure prompt diagnosis and to assess treatment efficacy. We surveyed the availability and utilization of technologies for HIV treatment monitoring and early infant diagnosis (EID) in World Health Organization (WHO) Member States.
   Methods and Findings
   The survey questionnaire included 14 structured questions focusing on HIV testing, cluster of differentiation 4 (CD4) testing, HIV viral load (VL) testing, and EID and was administered annually from 2012 to 2014 through WHO country offices, with each survey covering the previous 12-mo period. Across 127 targeted countries, survey response rates were 60% in 2012, 67% in 2013, and 78% in 2014. There were encouraging trends towards increased procurement of CD4 and VL/EID instruments in reporting countries. Globally, the capacity of available CD4 instruments was sufficient to meet the demand of all people living with HIV/AIDS (PLWHA), irrespective of treatment status (4.62 theoretical tests per PLWHA in 2013 [median 7.33; interquartile range (IQR) 3.44-17.75; median absolute deviation (MAD) 4.35]). The capacity of VL instruments was inadequate to cover all PLWHA in many reporting countries (0.44 tests per PLWHA in 2013 [median 0.90; IQR 0.30-2.40; MAD 0.74]). Of concern, only 13.7% of existing CD4 capacity (median 4.3%; IQR 1.1%-12.1%; MAD 3.8%) and only 36.5% of existing VL capacity (median 9.4%; IQR 2.3%-28.9%; MAD 8.2%) was being utilized across reporting countries in 2013. By the end of 2013, 7.4% of all CD4 instruments (5.8% CD4 conventional instruments and 11.0% of CD4 point of care [POC]) and 10% of VL/EID instruments were reportedly not in use because of lack of reagents, the equipment not being installed or deployed, maintenance, and staff training requirements. Major limitations of this survey included under-reporting and/or incomplete reporting in some national programmes and noncoverage of the private sector.
   Conclusion
   This is the first attempt to comprehensively gather information on HIV testing technology coverage in WHO Member States. The survey results suggest that major operational changes will need to be implemented, particularly in low-and middle-income countries, if the 90-90-90 targets are to be met.
C1 [Habiyambere, Vincent; Ford, Nathan; Low-Beer, Daniel; Sands, Anita; Gonzalez, Mercedes Perez] WHO, Dept HIV AIDS, Geneva, Switzerland.
   [Nkengasong, John] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Fernandes, Paula; Milgotina, Ekaterina] GSSHlth, Baltimore, MD USA.
RP Habiyambere, V (reprint author), WHO, Dept HIV AIDS, Geneva, Switzerland.
EM habiyamberev@who.int
OI Sands, Anita/0000-0002-8424-754X
FU WHO
FX The authors received no specific funding for this work that was done in
   the context of their regular work. However, VH has WHO activity funds to
   carry his technical work including this survey and data analysis in the
   context of his work in WHO and not specifically for this study. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
NR 24
TC 5
Z9 5
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2016
VL 13
IS 8
AR e1002088
DI 10.1371/journal.pmed.1002088
PG 21
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW0UD
UT WOS:000383357400013
PM 27551917
ER

PT J
AU Vazquez-Benitez, G
   Kharbanda, EO
   Naleway, AL
   Lipkind, H
   Sukumaran, L
   McCarthy, NL
   Omer, SB
   Qian, L
   Xu, S
   Jackson, ML
   Vijayadev, V
   Klein, NP
   Nordin, JD
AF Vazquez-Benitez, Gabriela
   Kharbanda, Elyse O.
   Naleway, Allison L.
   Lipkind, Heather
   Sukumaran, Lakshmi
   McCarthy, Natalie L.
   Omer, Saad B.
   Qian, Lei
   Xu, Stanley
   Jackson, Michael L.
   Vijayadev, Vinutha
   Klein, Nicola P.
   Nordin, James D.
TI Risk of Preterm or Small-for-Gestational-Age Birth After Influenza
   Vaccination During Pregnancy: Caveats When Conducting Retrospective
   Observational Studies
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE biases; birth outcomes; monovalent H1N1 influenza vaccine safety;
   pregnancy; preterm delivery; small for gestational age
ID CARE UTILIZATION INDEX; H1N1 INFLUENZA; PERTUSSIS VACCINATION; NEONATAL
   OUTCOMES; PROPENSITY SCORE; OBSTETRIC EVENTS; FETAL-DEATH; SAFETY;
   WOMEN; DELIVERY
AB Vaccines are increasingly targeted toward women of reproductive age, and vaccines to prevent influenza and pertussis are recommended during pregnancy. Prelicensure clinical trials typically have not included pregnant women, and when they are included, trials cannot detect rare events. Thus, postmarketing vaccine safety assessments are necessary. However, analysis of observational data requires detailed assessment of potential biases. Using data from 8 Vaccine Safety Datalink sites in the United States, we analyzed the association of monovalent H1N1 influenza vaccine (MIV) during pregnancy with preterm birth (< 37 weeks) and small-for-gestational-age birth (birth weight < 10th percentile). The cohort included 46,549 pregnancies during 2009-2010 (40% of participants received the MIV). We found potential biases in the vaccine-birth outcome association that might occur due to variable access to vaccines, the time-dependent nature of exposure to vaccination within pregnancy (immortal time bias), and confounding from baseline differences between vaccinated and unvaccinated women. We found a strong protective effect of vaccination on preterm birth (relative risk = 0.79, 95% confidence interval: 0.74, 0.85) when we ignored potential biases and no effect when accounted for them (relative risk = 0.91; 95% confidence interval: 0.83, 1.0). In contrast, we found no important biases in the association of MIV with small-for-gestational-age birth. Investigators conducting studies to evaluate birth outcomes after maternal vaccination should use statistical approaches to minimize potential biases.
C1 [Vazquez-Benitez, Gabriela; Kharbanda, Elyse O.; Nordin, James D.] HealthPartners Inst, 8170 33rd Ave South,MS23301A, Bloomington, MN 55425 USA.
   [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
   [Lipkind, Heather] Yale Univ, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.
   [Sukumaran, Lakshmi; McCarthy, Natalie L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Sukumaran, Lakshmi] Emory Univ, Div Pediat Infect Dis, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Qian, Lei] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA.
   [Xu, Stanley] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
   [Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA.
   [Vijayadev, Vinutha] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA.
   [Klein, Nicola P.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
RP Vazquez-Benitez, G (reprint author), HealthPartners Inst, 8170 33rd Ave South,MS23301A, Bloomington, MN 55425 USA.
EM gabriela.x.vazquezbenitez@healthpartners.com
FU America's Health Insurance Plans [200-2002-00732]; Centers for Disease
   Control and Prevention [200-2012-53526]
FX This work was supported by a subcontract with America's Health Insurance
   Plans under contract 200-2002-00732 and contract 200-2012-53526 from the
   Centers for Disease Control and Prevention.
NR 50
TC 5
Z9 5
U1 6
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD AUG 1
PY 2016
VL 184
IS 3
BP 176
EP 186
DI 10.1093/aje/kww043
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DV8HG
UT WOS:000383177500002
PM 27449414
ER

PT J
AU Maserejian, NN
   Trachtenberg, FL
   Wheaton, B
   Calafat, AM
   Ranganathan, G
   Kim, HY
   Hauser, R
AF Maserejian, Nancy N.
   Trachtenberg, Felicia L.
   Wheaton, Brown
   Calafat, Antonia M.
   Ranganathan, Gayatri
   Kim, Hae-Young
   Hauser, Russ
TI Changes in urinary bisphenol A concentrations associated with placement
   of dental composite restorations in children and adolescents
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Dental restoration; dental care for children; composites; pediatric
   dentistry; polymers; bisphenol A
ID ENDOCRINE-DISRUPTING CHEMICALS; RANDOMIZED CROSSOVER TRIAL; TEMPORAL
   VARIABILITY; PHYSICAL DEVELOPMENT; AUSTRALIAN CHILDREN; AMALGAM TRIAL;
   UNITED-STATES; EXPOSURE; SEALANTS; RELEASE
AB Background. Bisphenol A-glycidyl methacrylate (bis-GMA)-based dental composite restorations may release bisphenol A (BPA). The authors assessed changes in urinary BPA concentrations over a 6-month follow-up period in children and adolescents who received bis-GMA-based restorations.
   Methods. The authors collected data from 91 study participants aged 3 to 17 years who needed composite restorations. Participants provided urine samples and information on BPA-related exposures before and at approximately 1 day, 14 days, and 6 months after treatment. The authors used multivariable linear regression models to test associations between the number of surface restorations placed and the changes in urinary BPA concentrations.
   Results. Participants had a mean (standard deviation [SD]) of 1.4 (1.0) for surfaces restored with composite at the first treatment visit and 2.3 (1.6) for surfaces restored during the entire study period. Mean (SD) change in urinary BPA concentrations between pretreatment and day 1 was 1.71 (9.94) nanograms per milliliter overall and 0.87 (5.98) after excluding 1 participant who had 8 surfaces restored at the visit. Overall, the authors observed an association between a greater number of composite surface restorations placed and higher urinary BPA concentrations in the 1-day sample (posterior-occlusal exponentiated coefficients [e(beta)] = 1.47; 95% confidence interval [CI], 1.18-1.83; P<.001), but the association was attenuated after the authors restricted the sample to the 88 participants who had up to 4 restorations (e(beta) = 1.19; 95% CI, 0.86-1.64), and they did not observe any association using 14-day (e(beta) = 0.94; 95% CI, 0.75-1.18) or 6-month (e(beta) = 0.88; 95% CI, 0.74-1.04) samples.
   Conclusions. Placement of bis-GMA-based restorations in children and adolescents may produce transient increases in urinary BPA concentrations that are no longer detectable in urine samples taken approximately 14 days or 6 months after treatment. After placement of a few restorations, increases in urinary BPA concentrations may not be detectable, owing to a high level of variation in background BPA exposure. Practical Implications. These results suggest that leaching of BPA from newly placed composite restorations ceases to be detectable in urine within 2 weeks after restoration placement. The potential human health impact of such short-term exposure remains uncertain.
C1 [Maserejian, Nancy N.] New England Res Inst, Epidemiol, 480 Pleasant St, Watertown, MA 02472 USA.
   [Maserejian, Nancy N.] Harvard Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA USA.
   [Maserejian, Nancy N.] Biogen, Epidemiol, Cambridge, MA USA.
   [Trachtenberg, Felicia L.; Wheaton, Brown; Ranganathan, Gayatri; Kim, Hae-Young] New England Res Inst, 480 Pleasant St, Watertown, MA 02472 USA.
   [Calafat, Antonia M.] Ctr Dis Control & Prevent, Organ Analyt Toxicol Branch, Natl Ctr Environm Hlth, Atlanta, GA USA.
   [Kim, Hae-Young] New York Med Coll, Sch Hlth Sci & Practice, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA.
   [Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA.
   [Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Trachtenberg, FL (reprint author), New England Res Inst, 480 Pleasant St, Watertown, MA 02472 USA.
EM ftrachtenberg@neriscience.com
FU National Institute of Environmental Health Sciences [R01ES019155]
FX This study was funded by award R01ES019155 from the National Institute
   of Environmental Health Sciences.
NR 59
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2016
VL 24
IS 8
BP 620
EP 630
DI 10.1016/j.adaj.2016.02.020
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DV2NM
UT WOS:000382757300010
ER

PT J
AU Fluent, MT
   Jacobsen, PL
   Hicks, LA
AF Fluent, Marie T.
   Jacobsen, Peter L.
   Hicks, Lauri A.
TI Considerations for responsible antibiotic use in dentistry
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
ID PIPELINE
C1 [Fluent, Marie T.] OSAP, 3525 Piedmont Rd,Bld 5, Atlanta, GA 30305 USA.
   [Jacobsen, Peter L.] Univ Pacific, Dept Dent Practice & Community Serv, Arthur A Dugoni Sch Dent, Yountville, CA USA.
   [Hicks, Lauri A.] Ctr Dis Control & Prevent, Off Antibiot Stewardship, Atlanta, GA USA.
   [Hicks, Lauri A.] Ctr Dis Control & Prevent, Get Smart Know Antibiot Work, Atlanta, GA USA.
RP Fluent, MT (reprint author), OSAP, 3525 Piedmont Rd,Bld 5, Atlanta, GA 30305 USA.
EM mfluent@osap.org
NR 17
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2016
VL 24
IS 8
BP 683
EP 686
DI 10.1016/j.adaj.2016.04.017
PG 4
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DV2NM
UT WOS:000382757300017
ER

PT J
AU Self, WH
   Wunderink, RG
   Williams, DJ
   Zhu, YW
   Anderson, EJ
   Balk, RA
   Fakhran, SS
   Chappell, JD
   Casimir, G
   Courtney, DM
   Trabue, C
   Waterer, GW
   Bramley, A
   Magill, S
   Jain, S
   Edwards, KM
   Grijalva, CG
AF Self, Wesley H.
   Wunderink, Richard G.
   Williams, Derek J.
   Zhu, Yuwei
   Anderson, Evan J.
   Balk, Robert A.
   Fakhran, Sherene S.
   Chappell, James D.
   Casimir, Geoffrey
   Courtney, D. Mark
   Trabue, Christopher
   Waterer, Grant W.
   Bramley, Anna
   Magill, Shelley
   Jain, Seema
   Edwards, Kathryn M.
   Grijalva, Carlos G.
TI Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical
   Characteristics, and Outcomes
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE pneumonia; Staphylococcus aureus; antibiotics
ID CARE-ASSOCIATED PNEUMONIA; MULTIDRUG-RESISTANT PATHOGENS;
   PANTON-VALENTINE LEUKOCIDIN; CHAIN-REACTION ASSAYS;
   HOSPITALIZED-PATIENTS; RISK-FACTORS; EMERGENCY-DEPARTMENT;
   INFECTIOUS-DISEASES; INFLUENZA SEASON; ONSET PNEUMONIA
AB Background. Prevalence of Staphylococcus aureus community-acquired pneumonia (CAP) and its clinical features remain incompletely understood, complicating empirical selection of antibiotics.
   Methods. Using a multicenter, prospective surveillance study of adults hospitalized with CAP, we calculated the prevalence of methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) among all CAP episodes. We compared the epidemiologic, radiographic, and clinical characteristics of S. aureus CAP (per respiratory or blood culture) with those of pneumococcal (per respiratory or blood culture or urine antigen) and all-cause non-S. aureus CAP using descriptive statistics.
   Results. Among 2259 adults hospitalized for CAP, 37 (1.6%) had S. aureus identified, including 15 (0.7%) with MRSA and 22 (1.0%) with MSSA; 115 (5.1%) had Streptococcus pneumoniae. Vancomycin or linezolid was administered to 674 (29.8%) patients within the first 3 days of hospitalization. Chronic hemodialysis use was more common among patients with MRSA (20.0%) than pneumococcal (2.6%) and all-cause non-S. aureus (3.7%) CAP. Otherwise, clinical features at admission were similar, including concurrent influenza infection, hemoptysis, multilobar infiltrates, and prehospital antibiotics. Patients with MRSA CAP had more severe clinical outcomes than those with pneumococcal CAP, including intensive care unit admission (86.7% vs 34.8%) and in-patient mortality (13.3% vs 4.4%).
   Conclusions. Despite very low prevalence of S. aureus and, specifically, MRSA, nearly one-third of adults hospitalized with CAP received anti-MRSA antibiotics. The clinical presentation of MRSA CAP overlapped substantially with pneumococcal CAP, highlighting the challenge of accurately targeting empirical anti-MRSA antibiotics with currently available clinical tools and the need for new diagnostic strategies.
C1 [Self, Wesley H.; Williams, Derek J.; Zhu, Yuwei; Chappell, James D.; Casimir, Geoffrey; Edwards, Kathryn M.; Grijalva, Carlos G.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Wunderink, Richard G.; Courtney, D. Mark; Waterer, Grant W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Anderson, Evan J.] Emory Univ, Med Ctr, Atlanta, GA 30322 USA.
   [Balk, Robert A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
   [Fakhran, Sherene S.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
   [Trabue, Christopher] Univ Tennessee, Hlth Sci Ctr, St Thomas Hlth, Nashville, TN USA.
   [Waterer, Grant W.] Univ Western Australia, Perth, WA, Australia.
   [Bramley, Anna; Magill, Shelley; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Self, WH (reprint author), Vanderbilt Univ, 1313 21 Ave S,703 Oxford House, Nashville, TN 37232 USA.
EM wesley.self@vanderbilt.edu
OI Wunderink, Richard/0000-0002-8527-4195
FU CDC [U18 IP000299]; National Institute of General Medical Sciences
   [K23GM110469]; National Institute on Aging [R01AG043471]
FX This work was supported by a cooperative agreement with the CDC (U18
   IP000299). W.H.S. was supported in part by the National Institute of
   General Medical Sciences (K23GM110469). C. G. G. was supported in part
   by the National Institute on Aging (R01AG043471).
NR 47
TC 7
Z9 7
U1 6
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 300
EP 309
DI 10.1093/cid/ciw300
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900002
PM 27161775
ER

PT J
AU Date, KA
   Newton, AE
   Medalla, F
   Blackstock, A
   Richardson, L
   McCullough, A
   Mintz, ED
   Mahon, BE
AF Date, Kashmira A.
   Newton, Anna E.
   Medalla, Felicita
   Blackstock, Anna
   Richardson, LaTonia
   McCullough, Andre
   Mintz, Eric D.
   Mahon, Barbara E.
TI Changing Patterns in Enteric Fever Incidence and Increasing Antibiotic
   Resistance of Enteric Fever Isolates in the United States, 2008-2012
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE enteric fever; typhoid and paratyphoid; surveillance; antimicrobial
   resistance; travelers' health
ID LABORATORY-BASED SURVEILLANCE; TYPHOID-FEVER; ANTIMICROBIAL-RESISTANCE;
   SALMONELLA PARATYPHI; SEROVAR PARATYPHI; SEROTYPE TYPHI; TRAVEL;
   VACCINE; TRENDS; EPIDEMIOLOGY
AB Background. Enteric fever in the United States has been primarily associated with travel and with worrisome changes in global patterns of antimicrobial resistance. We present the first comprehensive report of National Typhoid and Paratyphoid Fever Surveillance System (NTPFS) data for a 5-year period (2008-2012).
   Methods. We reviewed data on laboratory-confirmed cases reported to NTPFS, and related antimicrobial susceptibility results of Salmonella Typhi and Paratyphi A isolates sent for testing by participating public health laboratories to the Centers for Disease Control and Prevention's National Antimicrobial Resistance Monitoring System laboratory.
   Results. During 2008-2012, 2341 enteric fever cases were reported, 80% typhoid and 20% paratyphoid A. The proportion caused by paratyphoid A increased from 16% (2008) to 22% (2012). Foreign travel within 30 days preceding illness onset was reported by 1961 (86%) patients (86% typhoid and 92% paratyphoid A). Travel to southern Asia was common (82% for typhoid, 97% for paratyphoid A). Among 1091 (58%) typhoid and 262 (56%) paratyphoid A isolates tested for antimicrobial susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 2008 to 2012 (Typhi, 60% to 68%; Paratyphi A, 91% to 94%). Almost all NAL-R isolates were resistant or showed decreased susceptibility to ciprofloxacin. Resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to Typhi isolates, primarily acquired in southern Asia (13%). Most MDR isolates were also NAL-R.
   Conclusions. Enteric fever in the United States is primarily associated with travel to southern Asia, and increasing resistance is adding to treatment challenges. A bivalent typhoid and paratyphoid vaccine is needed.
C1 [Date, Kashmira A.] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA.
   [Date, Kashmira A.; Newton, Anna E.; Medalla, Felicita; Blackstock, Anna; Richardson, LaTonia; McCullough, Andre; Mintz, Eric D.; Mahon, Barbara E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
RP Date, KA (reprint author), Ctr Dis Control & Prevent, Immunizat Syst Branch, Global Immunizat Div, 1600 Clifton Rd NE,MS A04, Atlanta, GA 30329 USA.
EM kdate@cdc.gov
FU CDC
FX This work was supported by the CDC.
NR 50
TC 2
Z9 2
U1 5
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 322
EP 329
DI 10.1093/cid/ciw232
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900005
PM 27090993
ER

PT J
AU Wong, KK
   Davey, RT
   Hewlett, AL
   Kraft, CS
   Mehta, AK
   Mulligan, MJ
   Beck, A
   Dorman, W
   Kratochvil, CJ
   Lai, LL
   Palmore, TN
   Rogers, S
   Smith, P
   Suffredini, AF
   Wolcott, M
   Stroher, U
   Uyeki, TM
AF Wong, Karen K.
   Davey, Richard T., Jr.
   Hewlett, Angela L.
   Kraft, Colleen S.
   Mehta, Aneesh K.
   Mulligan, Mark J.
   Beck, Allison
   Dorman, William
   Kratochvil, Christopher J.
   Lai, Lilin
   Palmore, Tara N.
   Rogers, Susan
   Smith, PhilipW.
   Suffredini, Anthony F.
   Wolcott, Mark
   Stroher, Ute
   Uyeki, Timothy M.
TI Use of Postexposure Prophylaxis After Occupational Exposure to Zaire
   ebolavirus
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Ebola virus; postexposure prophylaxis; vesicular stomatitis virus;
   TKM-Ebola
ID VIRUS DISEASE; UNITED-STATES; VACCINATION; MANAGEMENT
AB From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease.
C1 [Wong, Karen K.; Stroher, Ute; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Kraft, Colleen S.; Mehta, Aneesh K.; Mulligan, Mark J.; Beck, Allison; Lai, Lilin; Rogers, Susan] Emory Univ, Atlanta, GA 30322 USA.
   [Davey, Richard T., Jr.; Palmore, Tara N.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Suffredini, Anthony F.] NIH, Crit Care Med Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
   [Dorman, William; Wolcott, Mark] US Army, Med Res Inst Infect Dis, Frederick, MD USA.
   [Hewlett, Angela L.; Kratochvil, Christopher J.; Smith, PhilipW.] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Wong, KK (reprint author), 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM kwong@cdc.gov
FU CDC; National Center for Advancing Translational Sciences of the NIH
   [UL1TR000454]; NIAID
FX This work was supported by the CDC. The care of patients at the Emory
   Serious Communicable Diseases Unit was supported in part by the National
   Center for Advancing Translational Sciences of the NIH (award
   UL1TR000454). The care of patients at the NIH Clinical Center was funded
   by the NIAID.
NR 15
TC 2
Z9 2
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 376
EP 379
DI 10.1093/cid/ciw256
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900013
PM 27118786
ER

PT J
AU Jackson, BR
   Tarr, C
   Strain, E
   Jackson, KA
   Conrad, A
   Carleton, H
   Katz, LS
   Stroika, S
   Gould, LH
   Mody, RK
   Silk, BJ
   Beal, J
   Chen, Y
   Timme, R
   Doyle, M
   Fields, A
   Wise, M
   Tillman, G
   Defibaugh-Chavez, S
   Kucerova, Z
   Sabol, A
   Roache, K
   Trees, E
   Simmons, M
   Wasilenko, J
   Kubota, K
   Pouseele, H
   Klimke, W
   Besser, J
   Brown, E
   Allard, M
   Gerner-Smidt, P
AF Jackson, Brendan R.
   Tarr, Cheryl
   Strain, Errol
   Jackson, Kelly A.
   Conrad, Amanda
   Carleton, Heather
   Katz, Lee S.
   Stroika, Steven
   Gould, L. Hannah
   Mody, Rajal K.
   Silk, Benjamin J.
   Beal, Jennifer
   Chen, Yi
   Timme, Ruth
   Doyle, Matthew
   Fields, Angela
   Wise, Matthew
   Tillman, Glenn
   Defibaugh-Chavez, Stephanie
   Kucerova, Zuzana
   Sabol, Ashley
   Roache, Katie
   Trees, Eija
   Simmons, Mustafa
   Wasilenko, Jamie
   Kubota, Kristy
   Pouseele, Hannes
   Klimke, William
   Besser, John
   Brown, Eric
   Allard, Marc
   Gerner-Smidt, Peter
TI Implementation of Nationwide Real-time Whole-genome Sequencing to
   Enhance Listeriosis Outbreak Detection and Investigation
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Listeria monocytogenes; DNA sequencing; outbreaks; foodborne diseases
ID UNITED-STATES; FOODBORNE LISTERIOSIS; MONOCYTOGENES; SURVEILLANCE;
   PATHOGENS; STRAINS; CLONES; FOOD
AB Listeria monocytogenes (Lm) causes severe foodborne illness (listeriosis). Previous molecular subtyping methods, such as pulsed-field gel electrophoresis (PFGE), were critical in detecting outbreaks that led to food safety improvements and declining incidence, but PFGE provides limited genetic resolution. A multiagency collaboration began performing real-time, whole-genome sequencing (WGS) on all US Lm isolates from patients, food, and the environment in September 2013, posting sequencing data into a public repository. Compared with the year before the project began, WGS, combined with epidemiologic and product trace-back data, detected more listeriosis clusters and solved more outbreaks (2 outbreaks in pre-WGS year, 5 in WGS year 1, and 9 in year 2). Whole-genome multilocus sequence typing and single nucleotide polymorphism analyses provided equivalent phylogenetic relationships relevant to investigations; results were most useful when interpreted in context of epidemiological data. WGS has transformed listeriosis outbreak surveillance and is being implemented for other foodborne pathogens.
C1 [Jackson, Brendan R.; Tarr, Cheryl; Jackson, Kelly A.; Conrad, Amanda; Carleton, Heather; Katz, Lee S.; Stroika, Steven; Gould, L. Hannah; Mody, Rajal K.; Silk, Benjamin J.; Wise, Matthew; Kucerova, Zuzana; Sabol, Ashley; Roache, Katie; Trees, Eija; Besser, John; Gerner-Smidt, Peter] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
   [Strain, Errol; Beal, Jennifer; Chen, Yi; Timme, Ruth; Doyle, Matthew; Fields, Angela; Brown, Eric; Allard, Marc] US FDA, College Pk, MD USA.
   [Tillman, Glenn; Simmons, Mustafa; Wasilenko, Jamie] US Food Safety & Inspect Serv, USDA, Athens, GA USA.
   [Defibaugh-Chavez, Stephanie] US Food Safety & Inspect Serv, USDA, Washington, DC 20250 USA.
   [Kubota, Kristy] Assoc Publ Hlth Labs, Silver Spring, MD USA.
   [Pouseele, Hannes] Appl Maths, Sint Martens Latem, Belgium.
   [Klimke, William] Natl Inst Biotechnol Informat, NIH, Bethesda, MD USA.
RP Jackson, BR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM brjackson1@cdc.gov
FU CDC's Advanced Molecular Detection Initiative; CDC [U60HM000803]; FDA;
   USDA-FSIS; National Institute for Biotechnology Information; NIH,
   National Library of Medicine
FX This work was supported by CDC, including CDC's Advanced Molecular
   Detection Initiative and Cooperative Agreement number U60HM000803; FDA;
   USDA-FSIS; National Institute for Biotechnology Information; and the
   Intramural Research Program of the NIH, National Library of Medicine. H.
   P. is an employee of Applied Maths.
NR 30
TC 17
Z9 17
U1 17
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 380
EP 386
DI 10.1093/cid/ciw242
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900014
PM 27090985
ER

PT J
AU Bertrand, J
AF Bertrand, Jacquelyn
TI Fetal alcohol spectrum disorders are clearly brain-based
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Editorial Material
C1 [Bertrand, Jacquelyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Bertrand, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
NR 5
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
EI 1469-8749
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD AUG
PY 2016
VL 58
IS 8
BP 794
EP 795
DI 10.1111/dmcn.13086
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA DV3WF
UT WOS:000382854700010
PM 26888656
ER

PT J
AU Kassa, G
   Selenic, D
   Lahuerta, M
   Gaolathe, T
   Liu, Y
   Letang, G
   Courtenay-Quirk, C
   Mwaniki, NK
   Gaolekwe, S
   Bock, N
AF Kassa, Getachew
   Selenic, Dejana
   Lahuerta, Maria
   Gaolathe, Tendani
   Liu, Yang
   Letang, Garegole
   Courtenay-Quirk, Cari
   Mwaniki, Nelson Kiama
   Gaolekwe, Sarah
   Bock, Naomi
TI Occupational exposure to bloodborne pathogens among health care workers
   in Botswana: Reporting and utilization of postexposure prophylaxis
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Bloodborne pathogens; occupational exposure; postexposure prophylaxis;
   health care worker
ID INJURIES; HIV; MANAGEMENT
AB Background: This study assessed reporting behavior and satisfaction with postexposure prophylaxis (PEP) systems among health care workers (HCWs) at risk for occupational bloodborne pathogen exposure (BPE) in 3 public hospitals in Botswana.
   Methods: A cross-sectional survey among HCWs provided information on perceptions, attitudes, and experiences with occupational exposures, reporting, and postexposure care. HCWs potentially in contact with blood or body fluids were surveyed using audio computer-assisted self-interview.
   Results: Between August 2012 and April 2013, 1,624 HCWs completed the survey; most were women (72%), and almost half (48%) were nurses. Sixty-seven percent of them had ever received training related to BPE management; 62% perceived themselves to be at high risk for BPE. Among the 426 HCWs who were exposed to sharps injuries or splashes in the last 6 months, 160 (37%) reported the exposure. Of these, 111 of the 160 (69%) received PEP, and 79 of the 111 (71%) completed their medication. Whereas >92% of the total HCWs had ever been tested for HIV, only 557 (37%) were tested in their own health facility. Most HCWs (87%, n = 1,406) reported they would be interested in testing themselves. Of HCWs who reported an exposure, less than half (49%, n = 78) were satisfied with existing reporting systems.
   Conclusions: Underreporting of occupational exposures and dissatisfaction with PEP management is common among HCWs. Improved PEP management strategies and regular monitoring are needed. (C) 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Kassa, Getachew; Lahuerta, Maria] Columbia Univ, ICAP, Mailman Sch Publ Hlth, 722W 168th St, New York, NY 10032 USA.
   [Selenic, Dejana; Liu, Yang; Courtenay-Quirk, Cari; Bock, Naomi] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
   [Lahuerta, Maria] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Gaolathe, Tendani; Letang, Garegole] Botswana Harvard AIDS Inst Partnerships, Gaborone, Botswana.
   [Mwaniki, Nelson Kiama] Minist Hlth Botswana, Gaborone, Botswana.
   [Gaolekwe, Sarah] Ctr Dis Control & Prevent Botswana, Gaborone, Botswana.
RP Kassa, G (reprint author), Columbia Univ, ICAP, Mailman Sch Publ Hlth, 722W 168th St, New York, NY 10032 USA.
EM gechbel@gmail.com
NR 20
TC 0
Z9 0
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD AUG 1
PY 2016
VL 44
IS 8
BP 879
EP 885
DI 10.1016/j.ajic.2016.01.027
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DU9ZY
UT WOS:000382578100009
PM 27021510
ER

PT J
AU Patel, PR
   Shugart, A
   Mbaeyi, C
   Sauer, AG
   Melville, A
   Nguyen, DB
   Kallen, AJ
AF Patel, Priti R.
   Shugart, Alicia
   Mbaeyi, Chukwuma
   Sauer, Ann Goding
   Melville, Anna
   Nguyen, Duc B.
   Kallen, Alexander J.
CA NHSN Outpatient Hemodialysis Ctr
TI Dialysis Event Surveillance Report: National Healthcare Safety Network
   data summary, January 2007 through April 2011
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Public health surveillance; Catheter-related infections; Patient safety;
   Infection control
ID BLOOD-STREAM INFECTIONS; CENTERS; SYSTEM
AB A total of 24,092 adverse events in hemodialysis outpatients during January 2007 through April 2011 were reported to the National Healthcare Safety Network. Of 2,656 bloodstream infections, 67.3% were in patients with central venous catheters. For all events, rates associated with central venous catheters were higher than for other vascular access types. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.
C1 [Patel, Priti R.; Shugart, Alicia; Mbaeyi, Chukwuma; Sauer, Ann Goding; Melville, Anna; Nguyen, Duc B.; Kallen, Alexander J.; NHSN Outpatient Hemodialysis Ctr] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Patel, PR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA.
EM ppatel@cdc.gov
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD AUG 1
PY 2016
VL 44
IS 8
BP 944
EP 947
DI 10.1016/j.ajic.2016.02.009
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DU9ZY
UT WOS:000382578100022
PM 27040568
ER

PT J
AU Roberts, RM
   Hicks, LA
   Bartoces, M
AF Roberts, Rebecca M.
   Hicks, Lauri A.
   Bartoces, Monina
TI Variation in US Outpatient Antibiotic Prescribing Quality Measures
   According to Health Plan and Geography
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID UNITED-STATES; ANTIMICROBIAL RESISTANCE; ACUTE BRONCHITIS; ADULTS
AB OBJECTIVES: Antibiotic prescribing has become increasingly viewed as an issue related to patient safety and quality of care. The objective of this study was to better understand the differences between health plan reporting and the geographic variation seen in quality measures related to antibiotic use.
   STUDY DESIGN: We focused on 3 measures from the Healthcare Effectiveness Data and Information Set (HEDIS) related to antibiotic prescribing and testing to guide antibiotic prescribing.
   METHODS: We analyzed data for 3 relevant measures for the years 2008 to 2012, including only commercial health plans. We analyzed the following 3 HEDIS measures: 1) "Appropriate Testing for Children With Pharyngitis," 2) "Appropriate Treatment for Children With Upper Respiratory Infections," and 3) "Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis."
   RESULTS: Out of these 3 measures, health plans consistently performed poorly on the adult bronchitis measure. Performance was better on the 2 measures focused on the pediatric population. We also saw geographic variation between measures when looking at Census divisions across all years.
   CONCLUSIONS: There is wide variation between individual health plan performance on the measures related to antibiotic use. Geographic differences were also observed on these measures, with health plans in the South Central Census division performing worse than other parts of the country. Stakeholders, such as public health, advocacy groups, foundations, and professional societies, interested in improving the quality of care that patients receive related to antibiotic use in the outpatient setting should consider how existing measures and working with health plans could be used to improve prescribing.
C1 [Roberts, Rebecca M.; Hicks, Lauri A.; Bartoces, Monina] Ctr Dis Control & Prevent, Get Smart Know Antibiot Work Program, Atlanta, GA USA.
RP Roberts, RM (reprint author), 1600 Clifton Rd,MS A-31, Atlanta, GA 30329 USA.
EM RMRoberts@cdc.gov
NR 22
TC 0
Z9 0
U1 2
U2 2
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD AUG
PY 2016
VL 22
IS 8
BP 519
EP +
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DU9TA
UT WOS:000382559500008
PM 27541698
ER

PT J
AU Bird, BH
   Shrivastava-Ranjan, P
   Dodd, KA
   Erickson, BR
   Spiropoulou, CF
AF Bird, Brian H.
   Shrivastava-Ranjan, Punya
   Dodd, Kimberly A.
   Erickson, Bobbie R.
   Spiropoulou, Christina F.
TI Effect of Vandetanib on Andes virus survival in the hamster model of
   Hantavirus pulmonary syndrome
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Bunyaviridae; Andes virus; Hantavirus pulmonary syndrome; Antiviral
   Animal model; Hemorrhagic fever; Vascular endothelial growth factor;
   Vandetanib; Tyrosine kinase inhibitor
ID ENDOTHELIAL-CELLS; CADHERIN; CANCER
AB Hantavirus pulmonary syndrome (HPS) is a severe disease caused by hantavirus infection of pulmonary microvascular endothelial cells leading to microvascular leakage, pulmonary edema, pleural effusion and high case fatality. Previously, we demonstrated that Andes virus (ANDV) infection caused up-regulation of vascular endothelial growth factor (VEGF) and concomitant downregulation of the cellular adhesion molecule VE-cadherin leading to increased permeability. Analyses of human HPS-patient sera have further demonstrated increased circulating levels of VEGF. Here we investigate the impact of a small molecule antagonist of the VEGF receptor 2 (VEGFR-2) activation in vitro, and overall impact on survival in the Syrian hamster model of HPS. (C) 2016 Published by Elsevier B.V.
C1 [Bird, Brian H.; Shrivastava-Ranjan, Punya; Dodd, Kimberly A.; Erickson, Bobbie R.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS G-14, Atlanta, GA 30333 USA.
RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS G-14, Atlanta, GA 30333 USA.
EM ccs8@cdc.gov
NR 22
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2016
VL 132
BP 66
EP 69
DI 10.1016/j.antiviral.2016.05.014
PG 4
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA DU6SO
UT WOS:000382345100009
PM 27233645
ER

PT J
AU Hurt, AC
   Besselaar, TG
   Daniels, RS
   Ermetal, B
   Fry, A
   Gubareva, L
   Huang, WJ
   Lackenby, A
   Lee, RTC
   Lo, J
   Maurer-Stroh, S
   Nguyen, HT
   Pereyaslov, D
   Rebelo-de-Andrade, H
   Siqueira, MM
   Takashita, E
   Tashiro, M
   Tilmanis, D
   Wang, DY
   Zhang, WQ
   Meijer, A
AF Hurt, Aeron C.
   Besselaar, Terry G.
   Daniels, Rod S.
   Ermetal, Burcu
   Fry, Alicia
   Gubareva, Larisa
   Huang, Weijuan
   Lackenby, Angie
   Lee, Raphael T. C.
   Lo, Janice
   Maurer-Stroh, Sebastian
   Nguyen, Ha T.
   Pereyaslov, Dmitriy
   Rebelo-de-Andrade, Helena
   Siqueira, Marilda M.
   Takashita, Emi
   Tashiro, Masato
   Tilmanis, Danielle
   Wang, Dayan
   Zhang, Wenqing
   Meijer, Adam
TI Global update on the susceptibility of human influenza viruses to
   neuraminidase inhibitors, 2014-2015
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Influenza virus; Antiviral resistance; Neuraminidase inhibitors;
   Oseltamivir; Global analysis; Reduced susceptibility
ID OSELTAMIVIR; RESISTANT; SEASON
AB The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs.
   Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013-14 (1.9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Hurt, Aeron C.; Tilmanis, Danielle] Peter Doherty Inst Infect & Immun, VIDRL, WHO Collaborating Ctr Reference & Res Influenza, 792 Elizabeth St, Melbourne, Vic 3000, Australia.
   [Hurt, Aeron C.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3010, Australia.
   [Besselaar, Terry G.; Zhang, Wenqing] WHO, Global Influenza Programme, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
   [Daniels, Rod S.; Ermetal, Burcu] Natl Inst Med Res, MRC, Francis Crick Inst, WIC,Mill Hill Lab,WHO CC Reference & Res Influenz, Ridgeway, London NW7 1AA, England.
   [Fry, Alicia; Gubareva, Larisa; Nguyen, Ha T.] Ctr Dis Control & Prevent, WHO Collaborating Ctr Surveillance Epidemiol & Co, 1600 Clifton RD NE,MS-G16, Atlanta, GA USA.
   [Huang, Weijuan; Wang, Dayan] China CDC, Natl Inst Viral Dis Control & Prevent, WHO Collaborating Ctr Reference & Res Influenza, Collaborat Innovat Ctr Diag & Treatment Infect Di, Beijing, Peoples R China.
   [Lackenby, Angie] Publ Hlth England, Natl Infect Serv, London NW9 5HT, England.
   [Lee, Raphael T. C.; Maurer-Stroh, Sebastian] Agcy Sci Technol & Res, Bioinformat Inst, 30 Biopolis St,07-01, Singapore 138671, Singapore.
   [Lo, Janice] Publ Hlth Lab Ctr, 382 Nam Cheong St, Hong Kong, Hong Kong, Peoples R China.
   [Maurer-Stroh, Sebastian] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
   [Maurer-Stroh, Sebastian] Minist Hlth, Natl Publ Hlth Lab, 3 Biopolis Dr,Synapse 05-14 16, Singapore 138623, Singapore.
   [Pereyaslov, Dmitriy] WHO, Reg Off Europe, Div Communicable Dis Hlth Secur & Environm, Marmorvej 51, DK-2100 Copenhagen, Denmark.
   [Rebelo-de-Andrade, Helena] Inst Nacl Saude, Av Padre Cruz, P-1649016 Lisbon, Portugal.
   [Rebelo-de-Andrade, Helena] Univ Lisbon, Fac Farm, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal.
   [Siqueira, Marilda M.] Fiocruz MS, Inst Oswaldo Cruz, Natl Influenza Ctr, Lab Virus Resp, Rio De Janeiro, Brazil.
   [Takashita, Emi; Tashiro, Masato] Natl Inst Infect Dis, WHO Collaborating Ctr Reference & Res Influenza, Gakuen 4-7-1, Tokyo 2080011, Japan.
   [Meijer, Adam] Natl Inst Publ Hlth & Environm, POB 1, NL-3720 BA Bilthoven, Netherlands.
RP Hurt, AC (reprint author), Peter Doherty Inst Infect & Immun, VIDRL, WHO Collaborating Ctr Reference & Res Influenza, 792 Elizabeth St, Melbourne, Vic 3000, Australia.
EM aeron.hurt@influenzacentre.org
RI Rebelo-de-Andrade, Helena/E-1871-2014; iMed.ULisboa, HPI /B-4239-2014
OI Rebelo-de-Andrade, Helena/0000-0002-0138-0944; iMed.ULisboa, HPI
   /0000-0001-5934-0198
FU British Medical Research Council [U117512723]; Australian Government,
   Department of Health; Ministry of Health, Labour and Welfare, Japan;
   JSPS KAKENHI Grant [26460816]; joint A*STAR-NHMRC grant
   [12/1/06/24/5793]
FX We thank all laboratories, mostly NICs of the WHO GISRS
   (http://www.who.int/influenza/gisrs_laboratory/national_influenza_centre
   s/list/en/), who contributed to this global analysis by submitting
   influenza virus positive samples (clinical specimens or virus isolates)
   to WHO CCs for detailed characterisation. We gratefully acknowledge the
   authors, originating and submitting laboratories of the 2440 sequences
   downloaded from the GISAID and NCBI-IVR databases, that were additional
   to those submitted by the authors of this paper. The London WHO CC is
   funded by the British Medical Research Council through programme
   U117512723. The Melbourne WHO CC is supported by the Australian
   Government, Department of Health. The Tokyo WHO CC is supported by
   Grants-in-Aid for Emerging and Re-emerging Infectious Diseases from the
   Ministry of Health, Labour and Welfare, Japan and by JSPS KAKENHI Grant
   number 26460816. RTCL and SMS are supported by a joint A*STAR-NHMRC
   grant (#12/1/06/24/5793).
NR 17
TC 7
Z9 9
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2016
VL 132
BP 178
EP 185
DI 10.1016/j.antiviral.2016.06.001
PG 8
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA DU6SO
UT WOS:000382345100024
PM 27265623
ER

PT J
AU Bird, BH
   McElroy, AK
AF Bird, Brian H.
   McElroy, Anita K.
TI Rift Valley fever virus: Unanswered questions
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Rift Valley fever virus; Zoonoses; Epizootic; Reservoir; Mosquito;
   Arbovirus
ID ONSET NEUROLOGIC DISEASE; VERTICAL TRANSMISSION; NORTHEASTERN KENYA;
   DIPTERA-CULICIDAE; EGYPT 1977-78; SAUDI-ARABIA; EBOLA-VIRUS; MOUSE
   MODEL; T-CELL; INFECTION
AB This mosquito-borne pathogen of humans and animals respects no international or geographic boundaries. It is currently found in parts of Africa and the Arabian Peninsula where periodic outbreaks of severe and fatal disease occur, and threatens to spread into other geographic regions. In recent years, modern molecular techniques have led to many breakthroughs deepening our understanding of the mechanisms of RVFV virulence, phylogenetics, and the creation of several next-generation vaccine candidates. Despite tremendous progress in these areas, other challenges remain in RVF disease pathogenesis, the virus life cycle, and outbreak response preparedness that deserve our attention. Here we discuss and highlight ten key knowledge gaps and challenges in RVFV research. Answers to these key questions may lead to the development of new effective therapeutics and enhanced control strategies for this serious human and veterinary health threat. Published by Elsevier B.V.
C1 [Bird, Brian H.; McElroy, Anita K.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA.
   [Bird, Brian H.] Univ Calif Davis, Sch Vet Med, Hlth Inst 1, Davis, CA 95616 USA.
   [McElroy, Anita K.] Emory Univ, Pediat Infect Dis, Atlanta, GA 30322 USA.
RP Bird, BH (reprint author), Univ Calif Davis, Sch Vet Med, Hlth Inst 1, Davis, CA 95616 USA.
EM bhbird@ucdavis.edu
FU Centers for Disease Control and Prevention
FX Dr. Bird is co-inventor of a RVFV vaccine platform that is under
   commercial development. Dr. McElroy has no financial interests
   pertaining to this manuscript to declare. This manuscript was funded by
   core funds from the Centers for Disease Control and Prevention.
NR 68
TC 3
Z9 4
U1 7
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2016
VL 132
BP 274
EP 280
DI 10.1016/j.antiviral.2016.07.005
PG 7
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA DU6SO
UT WOS:000382345100036
PM 27400990
ER

PT J
AU Silver, SR
   Pinkerton, LE
   Rocheleau, CM
   Deddens, JA
   Michalski, AM
   Van Zutphen, AR
AF Silver, Sharon R.
   Pinkerton, Lynne E.
   Rocheleau, Carissa M.
   Deddens, James A.
   Michalski, Adrian M.
   Van Zutphen, Alissa R.
TI Birth defects in infants born to employees of a microelectronics and
   business machine manufacturing facility
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE occupational exposure; metals; lead; chlorinated hydrocarbons;
   congenital heart defects; paternal exposure
ID CONGENITAL HEART-DEFECTS; DRINKING-WATER CONTAMINANTS; ENVIRONMENTAL
   TOBACCO-SMOKE; VENTRICULAR SEPTAL-DEFECT; LEAD-EXPOSURE; RETROSPECTIVE
   COHORT; RISK; HEALTH; TRICHLOROETHYLENE; MALFORMATIONS
AB BackgroundConcerns about solvent releases from a microelectronics/business machine manufacturing facility in upstate New York led to interest in the health of former workers, including this investigation of birth defects in children of male and female employees.
   MethodsChildren born 1983 to 2001 to facility employees were enumerated and matched to New York State's Congenital Malformations Registry. Reported structural birth defects were compared with numbers expected from state rates (excluding New York City), generating standardized prevalence ratios (SPRs). Exposure assessors classified employees as ever/never potentially exposed at the facility to metals, chlorinated hydrocarbons, and other hydrocarbons during windows critical to organogenesis (female workers) or spermatogenesis (male workers). Among workers, adjusted prevalence ratios were generated to evaluate associations between potential exposures and specific birth defects.
   ResultsExternal comparisons for structural defects were at expectation for infants of male workers (SPR = 1.01; 95% confidence interval [CI], 0.77-1.29; n = 60) and lower for births to female workers (SPR = 0.84; 95% CI, 0.50-1.33; n = 18). Among full-term infants of male workers, ventricular septal defects (VSDs) were somewhat elevated compared with the general population (SPR = 1.58; 95% CI, 0.99-2.39; n = 22). Within the cohort, potential paternal metal exposure was associated with increased VSD risk (adjusted prevalence ratio = 2.70; 95% CI, = 1.09-6.67; n = 7).
   ConclusionWhile overall SPRs were near expectation, paternal exposure to metals (primarily lead) appeared to be associated with increased VSD risk in infants. Take-home of occupational exposures, nonoccupational exposures, and chance could not be ruled out as causes. Case numbers for many defects were small, limiting assessment of the role of occupational exposures. Birth Defects Research (Part A) 106:696-707, 2016. (c) 2016 Wiley Periodicals, Inc.
C1 [Silver, Sharon R.; Pinkerton, Lynne E.; Rocheleau, Carissa M.; Deddens, James A.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
   [Michalski, Adrian M.; Van Zutphen, Alissa R.] Bur Environm & Occupat Epidemiol, New York State Dept Hlth, Albany, NY USA.
RP Silver, SR (reprint author), NIOSH, 1055 Columbia Pkwy,MS R-17, Cincinnati, OH 45226 USA.
EM ssilver@cdc.gov
NR 46
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD AUG
PY 2016
VL 106
IS 8
BP 696
EP 707
DI 10.1002/bdra.23520
PG 12
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA DV3RC
UT WOS:000382839700007
PM 27224896
ER

PT J
AU Pridjian, G
   Sirois, PA
   McRae, S
   Hinckley, AF
   Rasmussen, SA
   Kissinger, P
   Buekens, P
   Hayes, EB
   O'Leary, D
   Kuhn, S
   Swan, KF
   Xiong, X
   Wesson, DM
AF Pridjian, Gabriella
   Sirois, Patricia A.
   McRae, Scott
   Hinckley, Alison F.
   Rasmussen, Sonja A.
   Kissinger, Patricia
   Buekens, Pierre
   Hayes, Edward B.
   O'Leary, Dan
   Kuhn, Stephanie
   Swan, Kenneth F.
   Xiong, Xu
   Wesson, Dawn M.
TI Prospective study of pregnancy and newborn outcomes in mothers with West
   nile illness during pregnancy
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE infant development; perinatal infection; pregnancy; West Nile virus
ID VIRUS-INFECTION; UNITED-STATES; DISEASE; WOMEN
AB BackgroundA previous case report of West Nile virus (WNV) illness during pregnancy suggested that WNV could be a cause of congenital defects. We performed a prospective, longitudinal cohort study of pregnant women with WNV illness to increase our knowledge of the effects of WNV illness during pregnancy.
   MethodsParticipants were enrolled in 2005 to 2008 from pregnant women with serologically confirmed WNV illness reported to the Centers for Disease Control and Prevention. Comparison was made to WNV-uninfected women, matched on maternal age and enrollment month. Pregnancy and newborn data were collected; cord blood WNV serology was obtained. Pediatric exams and the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III) were performed.
   ResultsTwenty-eight WNV-infected mothers and 25 WNV-uninfected mothers participated. Maternal demographics were similar except for a higher rate of planned pregnancies, education, and household income in the WNV-uninfected mothers. There were no differences in pregnancy and delivery characteristics except that infected mothers had a higher incidence of febrile illnesses and used more medications. Birth weight, length, head circumference, and rate of congenital malformations were similar in babies born to WNV-infected and -uninfected mothers. Follow-up physical exams were generally normal. The Bayley-III assessments, available for 17 children born to mothers with WNV illness, showed performance at or above age level across domains.
   ConclusionThe risk for adverse pregnancy and newborn outcomes in women experiencing WNV illness in pregnancy appears to be low, but future studies with larger numbers are needed to rule out a small risk. Birth Defects Research (Part A) 106:716-723, 2016. (c) 2016 Wiley Periodicals, Inc.
C1 [Pridjian, Gabriella; Sirois, Patricia A.; McRae, Scott; Kissinger, Patricia; Buekens, Pierre; Swan, Kenneth F.; Xiong, Xu; Wesson, Dawn M.] Tulane Univ, New Orleans, LA 70112 USA.
   [Hinckley, Alison F.; Hayes, Edward B.; O'Leary, Dan; Kuhn, Stephanie] Ctr Dis Control & Prevent, Ft Collins, CO USA.
   [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Pridjian, G (reprint author), Tulane Univ, Sch Med, 1430 Tulane Ave,SL-11, New Orleans, LA 70112 USA.
EM pridjian@tulane.edu
FU NCBDD CDC HHS [U01 DD000026]
NR 24
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD AUG
PY 2016
VL 106
IS 8
BP 716
EP 723
DI 10.1002/bdra.23523
PG 8
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA DV3RC
UT WOS:000382839700009
PM 27223334
ER

PT J
AU Conlon, KC
   Kintziger, KW
   Jagger, M
   Stefanova, L
   Uejio, CK
   Konrad, C
AF Conlon, Kathryn C.
   Kintziger, Kristina W.
   Jagger, Meredith
   Stefanova, Lydia
   Uejio, Christopher K.
   Konrad, Charles
TI Working with Climate Projections to Estimate Disease Burden:
   Perspectives from Public Health
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE public health; climate modeling; project disease burden; attributable
   fraction; adaptation
ID HEAT-RELATED MORTALITY; CASE-CROSSOVER; UNITED-STATES; EL-NINO;
   VARIABILITY; TEMPERATURE; OSCILLATION; IMPACTS; EVENTS; ENSO
AB There is interest among agencies and public health practitioners in the United States (USA) to estimate the future burden of climate-related health outcomes. Calculating disease burden projections can be especially daunting, given the complexities of climate modeling and the multiple pathways by which climate influences public health. Interdisciplinary coordination between public health practitioners and climate scientists is necessary for scientifically derived estimates. We describe a unique partnership of state and regional climate scientists and public health practitioners assembled by the Florida Building Resilience Against Climate Effects (BRACE) program. We provide a background on climate modeling and projections that has been developed specifically for public health practitioners, describe methodologies for combining climate and health data to project disease burden, and demonstrate three examples of this process used in Florida.
C1 [Conlon, Kathryn C.; Uejio, Christopher K.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Climate & Hlth Program, Atlanta, GA 30341 USA.
   [Kintziger, Kristina W.] Florida Dept Hlth, Tallahassee, FL 32399 USA.
   [Jagger, Meredith] Oregon Publ Hlth Author, Portland, OR 97232 USA.
   [Stefanova, Lydia] Florida State Univ, Ctr Ocean Atmosphere Predict Studies, Tallahassee, FL 32306 USA.
   [Uejio, Christopher K.] Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA.
   [Konrad, Charles] Univ North Carolina Chapel Hill, Dept Geog, Chapel Hill, NC 27599 USA.
   [Kintziger, Kristina W.] Univ Tennessee, Dept Publ Hlth, Knoxville, TN 37996 USA.
RP Conlon, KC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Climate & Hlth Program, Atlanta, GA 30341 USA.
EM kconlon@cdc.gov; Kristina.Kintziger@FLHealth.gov;
   Meredith.A.Jagger@state.or.us; lstefanova@fsu.edu; cuejio@fsu.edu;
   konrad@unc.edu
FU U.S. Centers for Disease Control and Prevention, National Center for
   Environmental Health [5UE1EH001047-03]
FX The authors would like to acknowledge the contributions of Laurel
   Harduar Morano for developing the heat-health exposure-response
   functions for the Florida BRACE program, Sharon Watkins for her guidance
   and direction, and Justin Dumas and Erin Stockdale for their
   collaboration and insights. This work was funded by the U.S. Centers for
   Disease Control and Prevention, National Center for Environmental Health
   Project Number 5UE1EH001047-03.
NR 54
TC 0
Z9 0
U1 3
U2 3
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2016
VL 13
IS 8
AR 804
DI 10.3390/ijerph13080804
PG 23
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DU8KV
UT WOS:000382462900059
ER

PT J
AU Siegel, KR
   Bullard, KM
   Imperatore, G
   Kahn, HS
   Stein, AD
   Ali, MK
   Narayan, KM
AF Siegel, Karen R.
   Bullard, Kai McKeever
   Imperatore, Giuseppina
   Kahn, Henry S.
   Stein, Aryeh D.
   Ali, Mohammed K.
   Narayan, K. M.
TI Association of Higher Consumption of Foods Derived From Subsidized
   Commodities With Adverse Cardiometabolic Risk Among US Adults
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID UNITED-STATES; OBESITY; POLICY; PREVENTION; NUTRITION; DISEASES; FINLAND
AB IMPORTANCE Food subsidies are designed to enhance food availability, but whether they promote cardiometabolic health is unclear.
   OBJECTIVE To investigate whether higher consumption of foods derived from subsidized food commodities is associated with adverse cardiometabolic risk among US adults.
   DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis of the National Health and Nutrition Examination Survey data from 2001 to 2006. Our final analysis was performed in January 2016. Participants were 10 308 nonpregnant adults 18 to 64 years old in the general community.
   EXPOSURE From a single day of 24-hour dietary recall in the National Health and Nutrition Examination Survey, we calculated an individual-level subsidy score that estimated an individual's consumption of subsidized food commodities as a percentage of total caloric intake.
   MAIN OUTCOMES AND MEASURES The main outcomes were body mass index (calculated as weight in kilograms divided by height in meters squared), abdominal adiposity, C-reactive protein level, blood pressure, non-high-density lipoprotein cholesterol level, and glycemia.
   RESULTS Among 10 308 participants, the mean (SD) age was 40.2 (0.3) years, and a mean (SD) of 50.5%(0.5%) were male. Overall, 56.2% of calories consumed were from the major subsidized food commodities. United States adults in the highest quartile of the subsidy score (compared with the lowest) had increased probabilities of having a body mass index of at least 30 (prevalence ratio, 1.37; 95% CI, 1.23-1.52), a ratio of waist circumference to height of at least 0.60 (prevalence ratio, 1.41; 95% CI, 1.25-1.59), a C-reactive protein level of at least 0.32 mg/dL (prevalence ratio, 1.34; 95% CI, 1.19-1.51), an elevated non-high-density lipoprotein cholesterol level (prevalence ratio, 1.14; 95% CI, 1.05-1.25), and dysglycemia (prevalence ratio, 1.21; 95% CI, 1.04-1.40). There was no statistically significant association between the subsidy score and blood pressure.
   CONCLUSIONS AND RELEVANCE Among US adults, higher consumption of calories from subsidized food commodities was associated with a greater probability of some cardiometabolic risks. Better alignment of agricultural and nutritional policies may potentially improve population health.
C1 [Siegel, Karen R.; Bullard, Kai McKeever; Imperatore, Giuseppina; Kahn, Henry S.; Ali, Mohammed K.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy, Atlanta, GA 30341 USA.
   [Stein, Aryeh D.; Ali, Mohammed K.; Narayan, K. M.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Stein, Aryeh D.; Ali, Mohammed K.; Narayan, K. M.] Emory Univ, Laney Grad Sch, Nutr & Hlth Sci Program, Atlanta, GA 30322 USA.
RP Siegel, KR (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy, Atlanta, GA 30341 USA.
EM yuo0@cdc.gov
NR 31
TC 2
Z9 2
U1 5
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD AUG
PY 2016
VL 176
IS 8
BP 1124
EP 1132
DI 10.1001/jamainternmed.2016.2410
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT0AN
UT WOS:000381145000023
PM 27379488
ER

PT J
AU Hinton, CF
   Homer, CJ
   Thompson, AA
   Williams, A
   Hassell, KL
   Feuchtbaum, L
   Berry, SA
   Comeau, AM
   Therrell, BL
   Brower, A
   Harris, KB
   Brown, C
   Monaco, J
   Ostrander, RJ
   Zuckerman, AE
   Kaye, C
   Dougherty, D
   Greene, C
   Green, NS
AF Hinton, Cynthia F.
   Homer, Charles J.
   Thompson, Alexis A.
   Williams, Andrea
   Hassell, Kathryn L.
   Feuchtbaum, Lisa
   Berry, Susan A.
   Comeau, Anne Marie
   Therrell, Bradford L.
   Brower, Amy
   Harris, Katharine B.
   Brown, Christine
   Monaco, Jana
   Ostrander, Robert J.
   Zuckerman, Alan E.
   Kaye, Celia
   Dougherty, Denise
   Greene, Carol
   Green, Nancy S.
CA Follow Up Treatment Subcomm ACHDNC
TI A framework for assessing outcomes from newborn screening: on the road
   to measuring its promise
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Editorial Material
DE Newborn screening; Long-term follow-up; Outcomes; Quality improvement
ID TERM-FOLLOW-UP; SERVICES ADVISORY-COMMITTEE; HERITABLE DISORDERS;
   INFORMATION-SYSTEM; CYSTIC-FIBROSIS; US SECRETARY; CHILDREN; GUIDELINES;
   STATEMENT; PROGRAMS
AB Newborn screening (NBS) is intended to identify congenital conditions prior to the onset of symptoms in order to provide early intervention that leads to improved outcomes. NBS is a public health success, providing reduction in mortality and improved developmental outcomes for screened conditions. However, it is less clear to what extent newborn screening achieves the long-term goals relating to improved health, growth, development and function. We propose a framework for assessing outcomes for the health and well-being of children identified through NBS programs. The framework proposed here, and this manuscript, were approved for publication by the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). This framework can be applied to each screened condition within the Recommended Uniform Screening Panel (RUSP), recognizing that the data elements and measures will vary by condition. As an example, we applied the framework to sickle cell disease and phenylketonuria (PKU), two diverse conditions with different outcome measures and potential sources of data. Widespread and consistent application of this framework across state NBS and child health systems is envisioned as useful to standardize approaches to assessment of outcomes and for continuous improvement of the NBS and child health systems.
   Significance: Successful interventions for newborn screening conditions have been a driving force for public health newborn screening for over fifty years. Organizing interventions and outcome measures into a standard framework to systematically assess outcomes has not yet come into practice. This paper presents a customizable outcomes framework for organizing measures for newborn screening condition-specific health outcomes, and an approach to identifying sources and challenges to populating those measures. Published by Elsevier Inc.
C1 [Hinton, Cynthia F.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
   [Homer, Charles J.] Off Assistant Secretary Planning & Evaluat, Washington, DC USA.
   [Thompson, Alexis A.] Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA.
   [Williams, Andrea] Childrens Sickle Cell Fdn Inc, Pittsburgh, PA USA.
   [Hassell, Kathryn L.] Univ Colorado, Div Hematol, Boulder, CO 80309 USA.
   [Feuchtbaum, Lisa] Calif Dept Publ Hlth, Richmond, CA USA.
   [Berry, Susan A.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.
   [Comeau, Anne Marie] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Boston, MA 02125 USA.
   [Comeau, Anne Marie] Univ Massachusetts, Sch Med, Dept Pediat, Boston, MA 02125 USA.
   [Therrell, Bradford L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
   [Brower, Amy] Amer Coll Med Genet & Genom, Bethesda, MD USA.
   [Harris, Katharine B.] New York State Dept Hlth, Albany, NY USA.
   [Brown, Christine] Natl PKU Alliance, Tomahawk, WI USA.
   [Monaco, Jana] Organ Acidemia Assoc, Woodbridge, VA USA.
   [Ostrander, Robert J.] SUNY Upstate Med Univ, Dept Family Med, Syracuse, NY 13210 USA.
   [Zuckerman, Alan E.] Georgetown Univ, Dept Pediat, Washington, DC 20057 USA.
   [Kaye, Celia] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA.
   [Dougherty, Denise] Agcy Healthcare Res & Qual, Rockville, MD USA.
   [Greene, Carol] Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA.
   [Green, Nancy S.] Columbia Univ, Dept Pediat, New York, NY 10027 USA.
RP Hinton, CF (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
EM ceh9@cdc.gov
OI Green, Nancy/0000-0002-9877-1561
FU Intramural CDC HHS [CC999999]
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD AUG
PY 2016
VL 118
IS 4
BP 221
EP 229
DI 10.1016/j.ymgme.2016.05.017
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA DT2RL
UT WOS:000381328000001
PM 27268406
ER

PT J
AU Mildenhall, KB
   Wiese, N
   Chung, D
   Maples, VF
   Mohanty, BK
   Kushner, SR
AF Mildenhall, Kristen B.
   Wiese, Nicholas
   Chung, Daewhan
   Maples, Valerie F.
   Mohanty, Bijoy K.
   Kushner, Sidney R.
TI RNase E-based degradosome modulates polyadenylation of mRNAs after
   Rho-independent transcription terminators in Escherichia coli
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID POLY(A) POLYMERASE I; POLYNUCLEOTIDE PHOSPHORYLASE; RIBONUCLEASE-E;
   DECAY; DEGRADATION; PROTEIN; GENE; HFQ; K-12; STREPTOMYCES
AB Here we demonstrate that the RNase E-based degradosome is required for poly(A) polymerase I (PAP I)-dependent polyadenylation after Rho-independent transcription terminators for both mono- and polycistronic transcripts. Disruption of degradosome assembly in mutants lacking the polynucleotide phosphorylase (PNPase) binding domain led to a significant increase in the level of PNPase synthesized polynucleotide tails in the rpsJ and rpsM polycistronic transcripts and the lpp monocistronic transcript. The polynucleotide tails were mostly located within the coding sequences in the degradosome mutants compared to the wild type control where the majority of the PAP I synthesized poly(A) tails were after the Rho-independent transcription terminators. For the Rho terminated metNIQ operon, the tails for all three mRNAs were predominately polynucleotide and were located within the coding sequences in both wild type and degradosome mutant strains. Furthermore, by employing a pnp-R100D point mutant that encodes a catalytically inactive PNPase protein that still forms intact degradosomes, we show that a catalytically active PNPase is required for normal mRNA polyadenylation by PAP I. Our data suggest that polyadenylation requires a functional degradosome to maintain an equilibrium between free PNPase and the PAP I polyadenylation complex.
C1 [Mildenhall, Kristen B.; Wiese, Nicholas; Kushner, Sidney R.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.
   [Chung, Daewhan; Maples, Valerie F.; Mohanty, Bijoy K.; Kushner, Sidney R.] Univ Georgia, Dept Genet, Athens, GA 30602 USA.
   [Mildenhall, Kristen B.] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.
   [Chung, Daewhan] Natl Renewable Energy Ctr, Golden, CO 80401 USA.
   [Wiese, Nicholas] Ctr Dis Control, Atlanta, GA 30333 USA.
RP Kushner, SR (reprint author), Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.; Kushner, SR (reprint author), Univ Georgia, Dept Genet, Athens, GA 30602 USA.
EM skushner@uga.edu
FU NIH [GM57220, GM81554]
FX Special thanks to Dr. A.J. Carpousis for his gift of AC-24 (rne Delta
   10) and PNPase rabbit antibodies. This work was supported in part by NIH
   grants GM57220 and GM81554 to S.R.K.
NR 48
TC 2
Z9 2
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0950-382X
EI 1365-2958
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD AUG
PY 2016
VL 101
IS 4
BP 645
EP 655
DI 10.1111/mmi.13413
PG 11
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA DU9MN
UT WOS:000382541900008
PM 27145979
ER

PT J
AU Johnston, LG
   Sabin, ML
   Prybylski, D
   Sabin, K
   McFarland, W
   Baral, S
   Kim, AA
   Raymond, HF
AF Johnston, Lisa G.
   Sabin, Miriam Lewis
   Prybylski, Dimitri
   Sabin, Keith
   McFarland, Willi
   Baral, Stefan
   Kim, Andrea A.
   Raymond, H. Fisher
TI The importance of assessing self-reported HIV status in bio-behavioural
   surveys
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID SAN-FRANCISCO; ANTIRETROVIRAL TREATMENT; LOS-ANGELES; INFECTION; MEN;
   SEX; PREVENTION; INITIATION; THERAPY; CARE
AB In bio-behavioural surveys measuring prevalence of infection with human immunodeficiency virus (HIV), respondents should be asked the results of their last HIV test. However, many government authorities, nongovernmental organizations, researchers and other civil society stakeholders have stated that respondents involved in such surveys should not be asked to self-report their HIV status. The reasons offered for not asking respondents to report their status are that responses may be inaccurate and that asking about HIV status may violate the respondents' human rights and exacerbate stigma and discrimination. Nevertheless, we contend that, in the antiretroviral therapy era, asking respondents in bio-behavioural surveys to self-report their HIV status is essential for measuring and improving access to - and coverage of - services for the care, treatment and prevention of HIV infection. It is also important for estimating the true size of the unmet needs in addressing the HIV epidemic and for interpreting the behaviours associated with the acquisition and transmission of HIV infection correctly. The data available indicate that most participants in health-related surveys are willing to respond to a question about HIV status as one of possibly several sensitive questions about sexual and drug use behaviours. Ultimately, normalizing the self-reporting of HIV status could help the global community move from an era of so-called exceptionalism to one of destigmatization - and so improve the epidemic response worldwide.
C1 [Johnston, Lisa G.; McFarland, Willi; Raymond, H. Fisher] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94143 USA.
   [Sabin, Miriam Lewis] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland.
   [Prybylski, Dimitri] Ctr Dis Control & Prevent, Global AIDS Program Asia Reg Off, Nonthaburi, Thailand.
   [Sabin, Keith] Joint United Nations Programme HIV AIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
   [Baral, Stefan] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD USA.
   [Kim, Andrea A.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
RP Sabin, K (reprint author), Joint United Nations Programme HIV AIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM sabink@unaids.org
OI Sabin, Keith/0000-0002-2290-8621
NR 46
TC 2
Z9 2
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD AUG
PY 2016
VL 94
IS 8
BP 605
EP 612
DI 10.2471/BLT.15.162933
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DU3HM
UT WOS:000382101400016
PM 27516638
ER

PT J
AU Christensen, BE
   Duncan, MA
   King, SC
   Hunter, C
   Ruckart, P
   Orr, MF
AF Christensen, Bryan E.
   Duncan, Mary Anne
   King, Sallyann C.
   Hunter, Candis
   Ruckart, Perri
   Orr, Maureen F.
TI Challenges During a Chlorine Gas Emergency Response
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE chlorine; chemical release; emergency response; hospital response
AB Objective A chlorine gas release occurred at a poultry processing plant as a result of an accidental mixing of sodium hypochlorite and an acidic antimicrobial treatment. We evaluated the public health and emergency medical services response and developed and disseminated public health recommendations to limit the impact of future incidents.
   Methods We conducted key informant interviews with the state health department; local fire, emergency medical services, and police departments; county emergency management; and representatives from area hospitals to understand the response mechanisms employed for this incident.
   Results After being exposed to an estimated 40-pound chlorine gas release, 170 workers were triaged on the scene and sent to 5 area hospitals. Each hospital redistributed staff or called in extra staff (eg, physicians, nurses, and respiratory therapists) in response to the event. Interviews with hospital staff emphasized the need for improved communication with responders at the scene of a chemical incident.
   Conclusions While responding, hospitals handled the patient surge without outside assistance because of effective planning, training, and drilling. The investigation highlighted that greater interagency communication can play an important role in ensuring that chemical incident patients are managed and treated in a timely manner. (Disaster Med Public Health Preparedness. 2016;10:553-556)
C1 [Christensen, Bryan E.; King, Sallyann C.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA.
   [Christensen, Bryan E.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA.
   [Duncan, Mary Anne; Hunter, Candis; Ruckart, Perri; Orr, Maureen F.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA.
   [King, Sallyann C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Duncan, MA (reprint author), Agcy Tox Subst & Dis Registry, 4770 Buford Highway NE,MS F-57, Atlanta, GA 30341 USA.
EM maduncan@cdc.gov
NR 3
TC 0
Z9 0
U1 5
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD AUG
PY 2016
VL 10
IS 4
BP 553
EP 556
DI 10.1017/dmp.2016.6
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT2AK
UT WOS:000381283000009
PM 27021568
ER

PT J
AU Coates, RJ
   Perez, A
   Baer, A
   Zhou, H
   English, R
   Coletta, M
   Dey, A
AF Coates, Ralph J.
   Perez, Alejandro
   Baer, Atar
   Zhou, Hong
   English, Roseanne
   Coletta, Michael
   Dey, Achintya
TI National and Regional Representativeness of Hospital Emergency
   Department Visit Data in the National Syndromic Surveillance Program,
   United States, 2014
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE syndromic surveillance; situational awareness; public health
   preparedness
ID PUBLIC-HEALTH SURVEILLANCE; PREPAREDNESS
AB Objective We examined the representativeness of the nonfederal hospital emergency department (ED) visit data in the National Syndromic Surveillance Program (NSSP).
   Methods We used the 2012 American Hospital Association Annual Survey Database, other databases, and information from state and local health departments participating in the NSSP about which hospitals submitted data to the NSSP in October 2014. We compared ED visits for hospitals submitting data with all ED visits in all 50 states and Washington, DC.
   Results Approximately 60.4 million of 134.6 million ED visits nationwide (similar to 45%) were reported to have been submitted to the NSSP. ED visits in 5 of 10 regions and the majority of the states were substantially underrepresented in the NSSP. The NSSP ED visits were similar to national ED visits in terms of many of the characteristics of hospitals and their service areas. However, visits in hospitals with the fewest annual ED visits, in rural trauma centers, and in hospitals serving populations with high percentages of Hispanics and Asians were underrepresented.
   Conclusions NSSP nonfederal hospital ED visit data were representative for many hospital characteristics and in some geographic areas but were not very representative nationally and in many locations. Representativeness could be improved by increasing participation in more states and among specific types of hospitals. (Disaster Med Public Health Preparedness. 2016;10:562-569)
C1 [Coates, Ralph J.; Perez, Alejandro; Zhou, Hong; English, Roseanne; Coletta, Michael] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
   [Baer, Atar] Dept Publ Hlth Seattle & King Cty, Seattle, WA USA.
RP Coates, RJ (reprint author), Ctr Dis Control & Prevent, Div Hlth Informat & Surveillance, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
EM RCoates@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 26
TC 0
Z9 0
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD AUG
PY 2016
VL 10
IS 4
BP 562
EP 569
DI 10.1017/dmp.2015.181
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT2AK
UT WOS:000381283000011
PM 26883318
ER

PT J
AU Duncan, MA
   Orr, MF
AF Duncan, Mary Anne
   Orr, Maureen F.
TI Toolkit for Epidemiologic Response to an Acute Chemical Release
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE toolkit; epidemiologic response; chemical spill
AB When a large chemical incident occurs and people are injured, public health agencies need to be able to provide guidance and respond to questions from the public, the media, and public officials. Because of this urgent need for information to support appropriate public health action, the Agency for Toxic Substances and Disease Registry (ATSDR) of the US Department of Health and Human Services has developed the Assessment of Chemical Exposures (ACE) Toolkit. The ACE Toolkit, available on the ATSDR website, offers materials including surveys, consent forms, databases, and training materials that state and local health personnel can use to rapidly conduct an epidemiologic investigation after a large-scale acute chemical release. All materials are readily adaptable to the many different chemical incident scenarios that may occur and the data needs of the responding agency. An expert ACE team is available to provide technical assistance on site or remotely. (Disaster Med Public Health Preparedness. 2016;10:631-632)
C1 [Duncan, Mary Anne; Orr, Maureen F.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA.
RP Duncan, MA (reprint author), Agcy Tox Subst & Dis Registry, 4770 Buford Highway NE,MS F-57, Atlanta, GA 30341 USA.
EM maduncan@cdc.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD AUG
PY 2016
VL 10
IS 4
BP 631
EP 632
DI 10.1017/dmp.2015.187
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT2AK
UT WOS:000381283000020
PM 27417212
ER

PT J
AU Cui, WJ
   Kobau, R
   Zack, MM
AF Cui, Wanjun
   Kobau, Rosemarie
   Zack, Matthew M.
TI Among adults with epilepsy reporting recent seizures, one of four on
   antiseizure medication and three of four not on medication had not seen
   a neurologist/epilepsy specialist within the last year, the 2010 and
   2013 US National Health Interview Surveys
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy; Neurologist/epilepsy specialist; General doctor; Access to
   care; Health care utilization; National Health Interview Survey
ID CARE; ACCESS
AB We combined 2010 and 2013 National Health Interview Survey (NHIS) data to examine the prevalence of seeing a neurologist/epilepsy specialist and/or a general doctor among US adults with active epilepsy who either took antiseizure medications or had at least one seizure in the past 12 months. Among adults with recent seizures, about 76% of adults who did not take antiseizure medication (including 55% of those who saw only a general doctor and 21% of those who saw neither a specialist nor a general doctor) and 26% of those who took medication (including 23% of those who saw only a general doctor and 3% of those who saw neither a specialist nor a general doctor) had not seen a specialist within the past year-indicating gaps in quality care putting patients with uncontrolled seizures at risk of negative outcomes. The US Healthy People 2020 objectives call for increasing the proportion of people with epilepsy and uncontrolled seizures who receive appropriate medical care. Epilepsy stakeholders can work with community services/organizations to improve provider education about epilepsy, eliminate barriers to specialized care, and promote self-management support to reduce the burden of uncontrolled seizures in people with epilepsy. Published by Elsevier Inc.
C1 [Cui, Wanjun; Kobau, Rosemarie; Zack, Matthew M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Epilepsy Program, 4770 Buford Highway NE,MS F-78, Atlanta, GA 30341 USA.
RP Cui, WJ (reprint author), Epilepsy Program, Div Populat Hlth, 4770 Buford Highway NE,MS F-78, Atlanta, GA 30341 USA.
EM wtd9@cdc.gov
NR 7
TC 1
Z9 1
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD AUG
PY 2016
VL 61
BP 78
EP 79
DI 10.1016/j.yebeh.2016.04.031
PG 2
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DT1MY
UT WOS:000381248000013
PM 27318431
ER

PT J
AU Tian, N
   Cui, WJ
   Zack, M
   Kobau, R
   Fowler, KA
   Hesdorffer, DC
AF Tian, Niu
   Cui, Wanjun
   Zack, Matthew
   Kobau, Rosemarie
   Fowler, Katherine A.
   Hesdorffer, Dale C.
TI Suicide among people with epilepsy: A population-based analysis of data
   from the US National Violent Death Reporting System, 17 states,
   2003-2011
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy; Suicide; Epidemiology; Rate; Population
ID HEALTH INTERVIEW SURVEY; QUALITY-OF-LIFE; RISK-FACTORS; NEUROLOGIC
   DISORDERS; SOCIAL DETERMINANTS; ACTIVE EPILEPSY; UNITED-STATES;
   DEPRESSION; PREVALENCE; IMPACT
AB Objective: This study analyzed suicide data in the general population from the U.S. National Violent Death Reporting System (NVDRS) to investigate suicide burden among those with epilepsy and risk factors associated with suicide and to suggest measures to prevent suicide among people with epilepsy.
   Methods: The NVDRS is a multiple-state, population-based, active surveillance system that collects information on violent deaths including suicide. Among people 10 years old and older, we identified 972 suicide cases with epilepsy and 81,529 suicide cases without epilepsy in 17 states from 2003 through 2011. We estimated their suicide rates, evaluated suicide risk among people with epilepsy, and investigated suicide risk factors specific to epilepsy by comparing those with and without epilepsy. In 16 of the 17 states providing continual data from 2005 through 2011, we also compared suicide trends in people with epilepsy (n = 833) and without epilepsy (n = 68,662).
   Results: From 2003 through 2011, the estimated annual suicide mortality rate among people with epilepsy was 16.89/100,000 per persons, 22% higher than that in the general population. Compared with those without epilepsy, those with epilepsy were more likely to have died from suicide in houses, apartments, or residential institutions (81% vs. 76%, respectively) and were twice as likely to poison themselves (38% vs. 17%) (P < 0.01). More of those with epilepsy aged 40-49 died from suicide than comparably aged persons without epilepsy (29% vs. 22%) (P < 0.01). The proportion of suicides among those with epilepsy increased steadily from 2005 through 2010, peaking significantly in 2010 before falling.
   Significance: For the first time, the suicide rate among people with epilepsy in a large U.S. general population was estimated, and the suicide risk exceeded that in the general population. Suicide prevention efforts should target people with epilepsy 40-49 years old. Additional preventive efforts include reducing the availability or exposure to poisons, especially at home, and supporting other evidence-based programs to reduce mental illness comorbidity associated with suicide. Published by Elsevier Inc.
C1 [Tian, Niu; Cui, Wanjun; Zack, Matthew; Kobau, Rosemarie] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA.
   [Fowler, Katherine A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30341 USA.
   [Hesdorffer, Dale C.] Columbia Univ, GH Sergievsky Ctr, New York, NY 10032 USA.
   [Hesdorffer, Dale C.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA.
RP Tian, N (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Epilepsy Program, 4770 Buford Highway NE,Mailstop F-78, Atlanta, GA 30341 USA.
EM vii9@cdc.gov
NR 45
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD AUG
PY 2016
VL 61
BP 210
EP 217
DI 10.1016/j.yebeh.2016.05.028
PG 8
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DT1MY
UT WOS:000381248000037
PM 27372961
ER

PT J
AU Burnett, E
   Dalipanda, T
   Ogaoga, D
   Gaiofa, J
   Jilini, G
   Halpin, A
   Dietz, V
   Date, K
   Mintz, E
   Hyde, T
   Wannemuehler, K
   Yen, C
AF Burnett, Eleanor
   Dalipanda, Tenneth
   Ogaoga, Divi
   Gaiofa, Jenny
   Jilini, Gregory
   Halpin, Alison
   Dietz, Vance
   Date, Kashmira
   Mintz, Eric
   Hyde, Terri
   Wannemuehler, Kathleen
   Yen, Catherine
TI Knowledge, Attitudes, and Practices regarding Diarrhea and Cholera
   following an Oral Cholera Vaccination Campaign in the Solomon Islands
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
AB Background
   In response to a 2011 cholera outbreak in Papua New Guinea, the Government of the Solomon Islands initiated a cholera prevention program which included cholera disease prevention and treatment messaging, community meetings, and a pre-emptive cholera vaccination campaign targeting 11,000 children aged 1-15 years in selected communities in Choiseul and Western Provinces.
   Methodology and Principal Findings
   We conducted a post-vaccination campaign, household-level survey about knowledge, attitudes, and practices regarding diarrhea and cholera in areas targeted and not targeted for cholera vaccination. Respondents in vaccinated areas were more likely to have received cholera education in the previous 6 months (33% v. 9%; p = 0.04), to know signs and symptoms (64% vs. 22%; p = 0.02) and treatment (96% vs. 50%; p = 0.02) of cholera, and to be aware of cholera vaccine (48% vs. 14%; p = 0.02). There were no differences in water, sanitation, and hygiene practices.
   Conclusions
   This pre-emptive OCV campaign in a cholera-naive community provided a unique opportunity to assess household-level knowledge, attitudes, and practices regarding diarrhea, cholera, and water, sanitation, and hygiene (WASH). Our findings suggest that education provided during the vaccination campaign may have reinforced earlier mass messaging about cholera and diarrheal disease in vaccinated communities.
C1 [Burnett, Eleanor; Halpin, Alison; Dietz, Vance; Date, Kashmira; Mintz, Eric; Hyde, Terri; Wannemuehler, Kathleen; Yen, Catherine] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Dalipanda, Tenneth; Ogaoga, Divi; Gaiofa, Jenny] Minist Hlth & Med Serv, Honiara, Solomon Islands.
   [Jilini, Gregory] Gizo Hosp, Gizo, Solomon Islands.
RP Burnett, E (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM wwg7@cdc.gov
FU World Health Organization
FX This survey was funded by the World Health Organization. The protocol
   was reviewed by WHO prior to implementation. The funders had no role in
   data collection and analysis, decision to publish, or content of the
   manuscript.
NR 5
TC 1
Z9 1
U1 8
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004937
DI 10.1371/journal.pntd.0004937
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800071
PM 27548678
ER

PT J
AU Dietrich, EA
   Langevin, SA
   Huang, CYH
   Maharaj, PD
   Delorey, MJ
   Bowen, RA
   Kinney, RM
   Brault, AC
AF Dietrich, Elizabeth A.
   Langevin, Stanley A.
   Huang, Claire Y. -H.
   Maharaj, Payal D.
   Delorey, Mark J.
   Bowen, Richard A.
   Kinney, Richard M.
   Brault, Aaron C.
TI West Nile Virus Temperature Sensitivity and Avian Virulence Are
   Modulated by NS1-2B Polymorphisms
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID NONSTRUCTURAL PROTEIN NS2A; EXTRINSIC INCUBATION-TEMPERATURE;
   CULEX-PIPIENS-QUINQUEFASCIATUS; HUMAN LIVER-CELLS; VECTOR COMPETENCE;
   TRANSMISSION DYNAMICS; DIPTERA-CULICIDAE; AMERICAN CROWS; NORTH-AMERICA;
   EPIDEMIOLOGY
AB West Nile virus (WNV) replicates in a wide variety of avian species, which serve as reservoir and amplification hosts. WNV strains isolated in North America, such as the prototype strain NY99, elicit a highly pathogenic response in certain avian species, notably American crows (AMCRs; Corvus brachyrhynchos). In contrast, a closely related strain, KN3829, isolated in Kenya, exhibits a low viremic response with limited mortality in AMCRs. Previous work has associated the difference in pathogenicity primarily with a single amino acid mutation at position 249 in the helicase domain of the NS3 protein. The NY99 strain encodes a proline residue at this position, while KN3829 encodes a threonine. Introduction of an NS3-T249P mutation in the KN3829 genetic background significantly increased virulence and mortality; however, peak viremia and mortality were lower than those of NY99. In order to elucidate the viral genetic basis for phenotype variations exclusive of the NS3-249 polymorphism, chimeric NY99/KN3829 viruses were created. We show herein that differences in the NS1-2B region contribute to avian pathogenicity in a manner that is independent of and additive with the NS3-249 mutation. Additionally, NS1-2B residues were found to alter temperature sensitivity when grown in avian cells.
C1 [Dietrich, Elizabeth A.; Huang, Claire Y. -H.; Delorey, Mark J.; Kinney, Richard M.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
   [Langevin, Stanley A.; Maharaj, Payal D.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA.
   [Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA.
RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
EM abrault@cdc.gov
FU American Society for Microbiology/CDC postdoctoral fellowship; US
   Centers for Disease Control and Prevention [CI000235]; US National
   Institutes of Health [AI061822]; Pacific Southwest Regional Center for
   Excellence [U54 AI065359]
FX EAD was supported by an American Society for Microbiology/CDC
   postdoctoral fellowship. Funding for these studies was provided by the
   US Centers for Disease Control and Prevention (CI000235), the US
   National Institutes of Health (AI061822) and the Pacific Southwest
   Regional Center for Excellence (U54 AI065359). The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the views of the Centers for Disease Control and
   Prevention. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
NR 48
TC 0
Z9 0
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004938
DI 10.1371/journal.pntd.0004938
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800072
PM 27548738
ER

PT J
AU Ellis, EM
   Sharp, TM
   Perez-Padilla, J
   Gonzalez, L
   Poole-Smith, BK
   Lebo, E
   Baker, C
   Delorey, MJ
   Torres-Velasquez, B
   Ochoa, E
   Rivera-Garcia, B
   Diaz-Pinto, H
   Clavell, L
   Puig-Ramos, A
   Janka, GE
   Tomashek, KM
AF Ellis, Esther M.
   Sharp, Tyler M.
   Perez-Padilla, Janice
   Gonzalez, Liza
   Poole-Smith, B. Katherine
   Lebo, Emmaculate
   Baker, Charlotte
   Delorey, Mark J.
   Torres-Velasquez, Brenda
   Ochoa, Eduardo
   Rivera-Garcia, Brenda
   Diaz-Pinto, Hector
   Clavell, Luis
   Puig-Ramos, Anabel
   Janka, Gritta E.
   Tomashek, Kay M.
TI Incidence and Risk Factors for Developing Dengue-Associated
   Hemophagocytic Lymphohistiocytosis in Puerto Rico, 2008-2013
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RARE CASE-REPORT; HEMORRHAGIC-FEVER; VIRUS-INFECTION
AB Background
   Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal disorder characterized by fever, pancytopenia, hepatosplenomegaly, and increased serum ferritin. HLH is being increasingly reported as a complication of dengue, a common tropical acute febrile illness.
   Methodology/Principal Findings
   After a cluster of pediatric dengue-associated HLH patients was identified during the 20122013 dengue epidemic in Puerto Rico, active surveillance and a case-control investigation was conducted at four referral hospitals to determine the incidence of HLH in children and identify risk factors for HLH following dengue. Patients with dengue-associated HLH (cases) were matched by month of illness onset and admission hospital to dengue patients that did not develop HLH (controls). During 2008-2013, a total of 33 HLH patients were identified, of which 22 (67%) were associated with dengue and 1 died (dengue-associated HLH casefatality rate: 4.5%). Two patients with dengue-associated HLH had illness onset in 2009, none had illness onset during the 2010 dengue epidemic, and 20 had illness onset during the 2012-2013 epidemic. Frequency of infection with either dengue virus (DENV)-1 or DENV-4 did not differ between cases and controls. Cases were younger than controls (median age: 1 vs. 13 years, p < 0.01), were hospitalized longer (18 vs. 5 days, p < 0.01), and were admitted more frequently to pediatric intensive care units (100% vs. 16%, p < 0.01). Cases had co-infection (18.2% vs. 4.5%, p = 0.04), recent influenza-like illness (54.5% vs. 25.0%, p = 0.01), and longer duration of fever (7 vs. 5 days; p < 0.01). Cases were more likely to have lymphadenopathy, hepatomegaly, splenomegaly, anemia, and elevated liver transaminases (p <= 0.02).
   Conclusions/Significance
   During this cluster of dengue-associated HLH cases that was temporally associated with the 2012-2013 epidemic, most patients with dengue-associated HLH were infants and had higher morbidity than dengue inpatients. Physicians throughout the tropics should be aware of HLH as a potential complication of dengue, particularly in patients with anemia and severe liver injury.
C1 [Ellis, Esther M.; Sharp, Tyler M.; Perez-Padilla, Janice; Poole-Smith, B. Katherine; Torres-Velasquez, Brenda; Tomashek, Kay M.] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA.
   [Ellis, Esther M.; Lebo, Emmaculate; Baker, Charlotte] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Atlanta, GA USA.
   [Gonzalez, Liza] Ponce Hlth Sci Univ, Ponce, PR USA.
   [Delorey, Mark J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA.
   [Ochoa, Eduardo; Diaz-Pinto, Hector] Puerto Rico Childrens Hosp, Bayamon, PR USA.
   [Rivera-Garcia, Brenda] Puerto Rico Dept Hlth, San Juan, PR USA.
   [Clavell, Luis] San Jorge Childrens Hosp, San Juan, PR USA.
   [Puig-Ramos, Anabel] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA.
   [Janka, Gritta E.] Univ Med Ctr, Hamburg, Germany.
   [Tomashek, Kay M.] NIH, Off Clin Res Resources, Div Microbiol & Infect Dis, Bldg 10, Bethesda, MD 20892 USA.
RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA.
EM tsharp@cdc.gov
NR 45
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004939
DI 10.1371/journal.pntd.0004939
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800073
PM 27556807
ER

PT J
AU Firacative, C
   Roe, CC
   Malik, R
   Ferreira-Paim, K
   Escandon, P
   Sykes, JE
   Castanon-Olivares, LR
   Contreras-Peres, C
   Samayoa, B
   Sorrell, TC
   Castaneda, E
   Lockhart, SR
   Engelthaler, DM
   Meyer, W
AF Firacative, Carolina
   Roe, Chandler C.
   Malik, Richard
   Ferreira-Paim, Kennio
   Escandon, Patricia
   Sykes, Jane E.
   Rocio Castanon-Olivares, Laura
   Contreras-Peres, Cudberto
   Samayoa, Blanca
   Sorrell, Tania C.
   Castaneda, Elizabeth
   Lockhart, Shawn R.
   Engelthaler, David M.
   Meyer, Wieland
TI MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii
   VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals
   Divergent Serotype Specific Sub-populations and Distant Ancestors
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID EPIDEMIOLOGIC CUTOFF VALUES; IN-VITRO SUSCEPTIBILITY; END-POINT
   DISTRIBUTIONS; VANCOUVER-ISLAND; MOLECULAR TYPE; PHYLOGENETIC INFERENCE;
   NEOFORMANS; COMPLEX; DNA; GENOTYPE
AB The emerging pathogen Cryptococcus gattii causes life-threatening disease in immunocompetent and immunocompromised hosts. Of the four major molecular types (VGI-VGIV), the molecular type VGIII has recently emerged as cause of disease in otherwise healthy individuals, prompting a need to investigate its population genetic structure to understand if there are potential genotype-dependent characteristics in its epidemiology, environmental niche(s), host range and clinical features of disease. Multilocus sequence typing (MLST) of 122 clinical, environmental and veterinary C. gattii VGIII isolates from Australia, Colombia, Guatemala, Mexico, New Zealand, Paraguay, USA and Venezuela, and whole genome sequencing (WGS) of 60 isolates representing all established MLST types identified four divergent sub-populations. The majority of the isolates belong to two main clades, corresponding either to serotype B or C, indicating an ongoing species evolution. Both major clades included clinical, environmental and veterinary isolates. The C. gattii VGIII population was genetically highly diverse, with minor differences between countries, isolation source, serotype and mating type. Little to no recombination was found between the two major groups, serotype B and C, at the whole and mitochondrial genome level. C. gattii VGIII is widespread in the Americas, with sporadic cases occurring elsewhere, WGS revealed Mexico and USA as a likely origin of the serotype B VGIII population and Colombia as a possible origin of the serotype C VGIII population. Serotype B isolates are more virulent than serotype C isolates in a murine model of infection, causing predominantly pulmonary cryptococcosis. No specific link between genotype and virulence was observed. Antifungal susceptibility testing against six antifungal drugs revealed that serotype B isolates are more susceptible to azoles than serotype C isolates, highlighting the importance of strain typing to guide effective treatment to improve the disease outcome.
C1 [Firacative, Carolina; Ferreira-Paim, Kennio; Sorrell, Tania C.; Meyer, Wieland] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Ctr Infect Dis & Microbiol, Mol Mycol Res Lab,Sydney Med Sch,Westmead Hosp,We, Sydney, NSW, Australia.
   [Firacative, Carolina; Escandon, Patricia; Castaneda, Elizabeth] Inst Nacl Salud, Grp Microbiol, Bogota, Colombia.
   [Roe, Chandler C.; Engelthaler, David M.] Translat Genom Res Inst, Flagstaff, AZ USA.
   [Malik, Richard] Univ Sydney, Ctr Vet Educ, Sydney, NSW, Australia.
   [Ferreira-Paim, Kennio] Triangulo Mineiro Fed Univ, Dept Infect Dis, Uberaba, MG, Brazil.
   [Sykes, Jane E.] Univ Calif Davis, Dept Med & Epidemiol, Davis, CA 95616 USA.
   [Rocio Castanon-Olivares, Laura] Univ Nacl Autonoma Mexico, Fac Med, Dept Microbiol & Parasitol, Mexico City, DF, Mexico.
   [Contreras-Peres, Cudberto] Inst Nacl Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico.
   [Samayoa, Blanca] Hosp San Juan Dios, Guatemala City, Guatemala.
   [Lockhart, Shawn R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA.
RP Meyer, W (reprint author), Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Ctr Infect Dis & Microbiol, Mol Mycol Res Lab,Sydney Med Sch,Westmead Hosp,We, Sydney, NSW, Australia.
EM wieland.meyer@sydney.edu.au
RI Ferreira-Paim, Kennio /A-8194-2013
OI Ferreira-Paim, Kennio /0000-0002-6035-8392
FU PhD scholarship "Becas Francisco Jose de Caldas" from COLCIENCIAS
   Colombia [497/2009]; Valentine Charlton Bequest; NHMRC [APP1031943];
   National Institutes of Health [R21AI098059]
FX CF was supported by a PhD scholarship "Becas Francisco Jose de Caldas"
   from COLCIENCIAS Colombia 497/2009. RM was supported by the Valentine
   Charlton Bequest. KFP was supported by a CAPESScience without Borders
   visiting fellow (No 9313133) from Brazil. This study was supported by a
   NH&MRC grant No APP1031943 to WM and a grant from the National
   Institutes of Health: No R21AI098059 to DME, SRL and WM. TCS is a Sydney
   Medical School Foundation Fellow. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 82
TC 2
Z9 2
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004861
DI 10.1371/journal.pntd.0004861
PG 31
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800018
PM 27494185
ER

PT J
AU Marks, M
   Sokana, O
   Nachamkin, E
   Puiahi, E
   Kilua, G
   Pillay, A
   Bottomley, C
   Solomon, AW
   Mabey, DC
AF Marks, Michael
   Sokana, Oliver
   Nachamkin, Eli
   Puiahi, Elliot
   Kilua, Georgina
   Pillay, Allan
   Bottomley, Christian
   Solomon, Anthony W.
   Mabey, David C.
TI Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months
   after Azithromycin Mass Drug Administration for Trachoma
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID SINGLE-DOSE AZITHROMYCIN; EPIDEMIOLOGY; DISEASES; CHILDREN
AB Introduction
   Both yaws and trachoma are endemic in the Pacific. Mass treatment with azithromycin is the mainstay of the WHO strategy for both the eradication of yaws and the elimination of trachoma as a public health problem, but the dose recommended for trachoma is lower than that for yaws. In countries where both diseases are endemic, there is a potential for synergy between yaws and trachoma control programs if mass treatment with the lower dose of azithromycin was shown to be effective for the treatment of yaws. In an earlier study, we demonstrated a profound reduction in the clinical and serological prevalence of yaws following a single round of mass treatment with azithromycin 20 mg/kg undertaken for the purposes of trachoma elimination.
   Methods
   This survey was conducted 18 months following a single round of azithromycin mass treatment in the same communities in which we had conducted our previous six-month follow-up survey. We examined children aged 1-14 years and took blood and lesion samples for yaws diagnosis using the Treponema pallidum particle agglutination assay (TPPA) and the non-treponemal Rapid Plasma Reagin (RPR) test.
   Results
   A total of 1,284 children were enrolled in the study. Amongst children aged 5-14 years, 223 had a positive TPPA (27.5%, 95% CI 13.6-47.7%). The TPPA seroprevalence amongst this age group did not differ significantly from either our pre-mass treatment survey or our initial follow-up survey. Thirty-five children had positive TPPA and positive RPR (4.3%, 95% CI 2.1-8.7%), and this did not differ significantly from our initial post-mass drug administration (MDA) follow-up survey (4.3% versus 3.5%, p = 0.43) but remained significantly lower than our initial pre-MDA survey (4.3% vs 21.7%, p < 0.0001). Village-level MDA coverage was strongly associated with dual-seropositivity (p = 0.005). Amongst children aged 1-4 years, 16 had a positive TPPA (3.5%, 95% CI 1.6-7.1%). This did not differ significantly from the seroprevalence in this age group that had been predicted based on our previous surveys (3.5% vs 5%, p = 0.11). Fourteen children (1.1%) were considered to have a skin lesion clinically consistent with yaws, but none of these individuals was seropositive for yaws. Of nine cases where a swab could be collected for PCR, all were negative for Treponema pallidum subsp. pertenue DNA.
   Discussion
   In this study we have shown that the benefit of a single round of mass treatment with azithromycin 20 mg/kg appears to extend to 18 months without any further intervention. The lack of a significant change in seroprevalence from 6 to 18 months after mass treatment might suggest that interventions could be spaced at yearly intervals without a significant loss of impact, and that this might facilitate integration of yaws eradication with other neglected tropical disease (NTD) control programmes. MDA coverage above 90% was associated with significantly better outcomes than coverages lower than this threshold, and strategies to improve coverage at all stages of yaws eradication efforts should be investigated.
C1 [Marks, Michael; Solomon, Anthony W.; Mabey, David C.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London, England.
   [Marks, Michael; Solomon, Anthony W.; Mabey, David C.] Hosp Trop Dis, London, England.
   [Sokana, Oliver; Puiahi, Elliot] Minist Hlth & Med Serv, Honiara, Solomon Islands.
   [Nachamkin, Eli; Pillay, Allan] Ctr Dis Control & Prevent, Mol Diagnost & Typing Lab, Lab Reference & Res Branch, Div STD Prevent, Atlanta, GA USA.
   [Kilua, Georgina] WHO, Western Pacific Reg Off, Honiara, Solomon Islands.
   [Bottomley, Christian] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
RP Marks, M (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London, England.; Marks, M (reprint author), Hosp Trop Dis, London, England.
EM Michael.marks@lshtm.ac.uk
OI Marks, Michael/0000-0002-7585-4743; Solomon, Anthony/0000-0001-7101-6649
FU Wellcome Trust [102807, 098521]; CDC
FX MM is supported by a Wellcome Trust Clinical Research Fellowship-102807.
   AWS was supported by a Wellcome Trust Intermediate Clinical
   Fellowship-098521. Laboratory analyses of swab specimens was funded by
   the CDC. The funders had no role in design or conduct of the studies,
   the preparation of the manuscript or the decision to submit it for
   publication.
NR 18
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004927
DI 10.1371/journal.pntd.0004927
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800063
PM 27551787
ER

PT J
AU Maskery, B
   Coleman, MS
   Weinberg, M
   Zhou, WG
   Rotz, L
   Klosovsky, A
   Cantey, PT
   Fox, LM
   Cetron, MS
   Stauffer, WM
AF Maskery, Brian
   Coleman, Margaret S.
   Weinberg, Michelle
   Zhou, Weigong
   Rotz, Lisa
   Klosovsky, Alexander
   Cantey, Paul T.
   Fox, LeAnne M.
   Cetron, Martin S.
   Stauffer, William M.
TI Economic Analysis of the Impact of Overseas and Domestic Treatment and
   Screening Options for Intestinal Helminth Infection among US-Bound
   Refugees from Asia
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID STRONGYLOIDES-STERCORALIS INFECTION; UNITED-STATES; PRESUMPTIVE
   TREATMENT; COST-EFFECTIVENESS; IVERMECTIN; ALBENDAZOLE; IMMIGRANTS;
   PARASITES; EFFICACY; SAFETY
AB Background
   Many U.S.-bound refugees travel from countries where intestinal parasites (hookworm, Trichuris trichuria, Ascaris lumbricoides, and Strongyloides stercoralis) are endemic. These infections are rare in the United States and may be underdiagnosed or misdiagnosed, leading to potentially serious consequences. This evaluation examined the costs and benefits of combinations of overseas presumptive treatment of parasitic diseases vs. domestic screening/treating vs. no program.
   Methods
   An economic decision tree model terminating in Markov processes was developed to estimate the cost and health impacts of four interventions on an annual cohort of 27,700 U.S.bound Asian refugees: 1) "No Program," 2) U.S. "Domestic Screening and Treatment," 3) " Overseas Albendazole and Ivermectin" presumptive treatment, and 4) " Overseas Albendazole and Domestic Screening for Strongyloides". Markov transition state models were used to estimate long-term effects of parasitic infections. Health outcome measures (four parasites) included outpatient cases, hospitalizations, deaths, life years, and quality-adjusted life years (QALYs).
   Results
   The "No Program" option is the least expensive ($165,923 per cohort) and least effective option (145 outpatient cases, 4.0 hospitalizations, and 0.67 deaths discounted over a 60-year period for a one-year cohort). The "Overseas Albendazole and Ivermectin" option ($418,824) is less expensive than "Domestic Screening and Treatment" ($3,832,572) or "Overseas Albendazole and Domestic Screening for Strongyloides" ($2,182,483). According to the model outcomes, the most effective treatment option is "Overseas Albendazole and Ivermectin," which reduces outpatient cases, deaths and hospitalization by around 80% at an estimated net cost of $458,718 per death averted, or $2,219/$24,036 per QALY/life year gained relative to "No Program".
   Discussion
   Overseas presumptive treatment for U.S.-bound refugees is a cost-effective intervention that is less expensive and at least as effective as domestic screening and treatment programs. The addition of ivermectin to albendazole reduces the prevalence of chronic strongyloidiasis and the probability of rare, but potentially fatal, disseminated strongyloidiasis.
C1 [Maskery, Brian; Coleman, Margaret S.; Weinberg, Michelle; Zhou, Weigong; Rotz, Lisa; Cetron, Martin S.; Stauffer, William M.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
   [Klosovsky, Alexander] Int Org Migrat, Washington, DC USA.
   [Cantey, Paul T.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
   [Stauffer, William M.] Univ Minnesota, Div Infect Dis & Int Med, Minneapolis, MN USA.
RP Maskery, B (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
EM wqm7@cdc.gov
NR 36
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004910
DI 10.1371/journal.pntd.0004910
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800051
PM 27509077
ER

PT J
AU Souto, ACP
   Bonfietti, LX
   Ferreira-Paim, K
   Trilles, L
   Martins, M
   Ribeiro-Alves, M
   Pham, CD
   Martins, L
   dos Santos, W
   Chang, M
   Brito-Santos, F
   Santos, DCS
   Fortes, S
   Lockhart, SR
   Wanke, B
   Melhem, MSC
   Lazera, MS
   Meyer, W
AF Souto, Ana C. P.
   Bonfietti, Lucas X.
   Ferreira-Paim, Kennio
   Trilles, Luciana
   Martins, Marilena
   Ribeiro-Alves, Marcelo
   Pham, Cau D.
   Martins, Liline
   dos Santos, Wallace
   Chang, Marilene
   Brito-Santos, Fabio
   Santos, Dayane C. S.
   Fortes, Silvana
   Lockhart, Shawn R.
   Wanke, Bodo
   Melhem, Marcia S. C.
   Lazera, Marcia S.
   Meyer, Wieland
TI Population Genetic Analysis Reveals a High Genetic Diversity in the
   Brazilian Cryptococcus gattii VGII Population and Shifts the Global
   Origin from the Amazon Rainforest to the Semi-arid Desert in the
   Northeast of Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID NEOFORMANS VAR. GATTII; MULTILOCUS GENOTYPE DATA; VANCOUVER-ISLAND;
   SPECIES COMPLEX; MOLECULAR EPIDEMIOLOGY; CANADA; EVOLUTIONARY;
   INFERENCE; OUTBREAK; RECOMBINATION
AB Cryptococcus neoformans and Cryptococcus gattii are responsible globally for almost one million cryptococcosis cases yearly, mostly in immunocompromised patients, such as those living with HIV. Infections due to C. gattii have mainly been described in tropical and subtropical regions, but its adaptation to temperate regions was crucial in the species evolution and highlighted the importance of this pathogenic yeast in the context of disease. Cryptococcus gattii molecular type VGII has come to the forefront in connection with an on-going emergence in the Pacific North West of North America. Taking into account that previous work pointed towards South America as an origin of this species, the present work aimed to assess the genetic diversity within the Brazilian C. gattii VGII population in order to gain new insights into its origin and global dispersal from the South American continent using the ISHAM consensus MLST typing scheme. Our results corroborate the finding that the Brazilian C. gattii VGII population is highly diverse. The diversity is likely due to recombination generated from sexual reproduction, as evidenced by the presence of both mating types in clinical and environmental samples. The data presented herein strongly supports the emergence of highly virulent strains from ancestors in the Northern regions of Brazil, Amazonia and the Northeast. Numerous genotypes represent a link between Brazil and other parts of the world reinforcing South America as the most likely origin of the C. gattii VGII subtypes and their subsequent global spread, including their dispersal into North America, where they caused a major emergence.
C1 [Souto, Ana C. P.; Trilles, Luciana; Ribeiro-Alves, Marcelo; dos Santos, Wallace; Brito-Santos, Fabio; Wanke, Bodo; Lazera, Marcia S.; Meyer, Wieland] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Bonfietti, Lucas X.; Martins, Marilena; Santos, Dayane C. S.; Melhem, Marcia S. C.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Ferreira-Paim, Kennio; Trilles, Luciana; dos Santos, Wallace; Meyer, Wieland] Univ Sydney, Mol Mycol Res Lab,Westmead Med Res, Ctr Infect Dis & Microbiol,Sydney Med School,West, Marie Bashir Inst Emerging Infect Dis & Biosecur, Sydney, NSW, Australia.
   [Ferreira-Paim, Kennio] Triangulo Mineiro Fed Univ, Dept Infect Dis, Uberaba, Brazil.
   [Pham, Cau D.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Martins, Liline] Univ Piaui State, Teresina, Brazil.
   [dos Santos, Wallace] Fed Univ Para, Belem, Para, Brazil.
   [Chang, Marilene] Univ Fed Mato Grosso do Sul, Campo Grande, Brazil.
   [Fortes, Silvana] Univ Fed Roraima, Biodivers Res Ctr, Boa Vista, Brazil.
RP Meyer, W (reprint author), Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.; Meyer, W (reprint author), Univ Sydney, Mol Mycol Res Lab,Westmead Med Res, Ctr Infect Dis & Microbiol,Sydney Med School,West, Marie Bashir Inst Emerging Infect Dis & Biosecur, Sydney, NSW, Australia.
EM wieland.meyer@sydney.edu.au
RI Ferreira-Paim, Kennio /A-8194-2013; 
OI Ferreira-Paim, Kennio /0000-0002-6035-8392; Ribeiro Alves,
   Marcelo/0000-0002-8663-3364
FU "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior" (CAPES),
   Brazil [098/2012]; program science without borders (CAPES), Brazil
   [098/2012]; National Health and Medical Research Council (NHMRC),
   Australia [APP1031943]
FX This work was supported by "Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior" (CAPES), Brazil grant # 098/2012 to BW, by the program
   science without borders (CAPES), Brazil grant # 098/2012 to WM, and the
   National Health and Medical Research Council (NH&MRC), Australia, grant
   # APP1031943 to WM. KFP was supported by a CAPES Science without Borders
   visiting fellow (No 9313133) from Brazil. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 57
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004885
DI 10.1371/journal.pntd.0004885
PG 19
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800029
PM 27529479
ER

PT J
AU Walsh, V
   Little, K
   Wiegand, R
   Rout, J
   Fox, LM
AF Walsh, Victoria
   Little, Kristen
   Wiegand, Ryan
   Rout, Jonathan
   Fox, LeAnne M.
TI Evaluating the Burden of Lymphedema Due to Lymphatic Filariasis in 2005
   in Khurda District, Odisha State, India
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID BANCROFTIAN FILARIASIS; CHIKWAWA DISTRICT; SOUTH-INDIA; PROGRAM; IMPACT;
   ADENOLYMPHANGITIS; MANAGEMENT; ORISSA; MALAWI; ELIMINATION
AB Background
   Over 1.1 billion people worldwide are at risk for lymphatic filariasis (LF), and the global burden of LF-associated lymphedema is estimated at 16 million affected people, yet country-specific estimates are poor.
   Methodology/Principal Findings
   A house-to-house morbidity census was conducted to assess the burden and severity of lymphedema in a population of 1,298,576 persons living in the LF-endemic district of Khurda in Odisha State, India. The burden of lymphedema in Khurda is widespread geographically, and 1.3% (17,036) of the total population report lymphedema. 51.3% of the patients reporting lymphedema were female, mean age 49.4 years (1-99). Early lymphedema (Dreyer stages 1 & 2) was reported in two-thirds of the patients. Poisson regression analysis was conducted in order to determine risk factors for advanced lymphedema (Dreyer stages 4-7). Increasing age was significantly associated with advanced lymphedema, and persons 70 years and older had a prevalence three times greater than individuals ages 15-29 (aPR: 3.21, 95% CI 2.45, 4.21). The number of adenolymphangitis (ADL) episodes reported in the previous year was also significantly associated with advanced lymphedema (aPR 4.65, 95% CI 2.97-7.30). This analysis is one of the first to look at potential risk factors for advanced lymphedema using morbidity census data from an entire district in Odisha State, India.
   Significance
   These data highlight the magnitude of lymphedema in LF-endemic areas and emphasize the need to develop robust estimates of numbers of individuals with lymphedema in order to identify the extent of lymphedema management services needed in these regions.
C1 [Walsh, Victoria; Little, Kristen; Wiegand, Ryan; Fox, LeAnne M.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Rout, Jonathan] Churchs Auxiliary Social Act, Odisha, India.
RP Walsh, V (reprint author), Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM victoria.sokolove@emory.edu
FU USAID grant through a World Bank Trust Fund [GHA-G-00-03-00005-00];
   Centers for Disease Control and Prevention
FX Funding for this work was provided by a USAID grant
   (GHA-G-00-03-00005-00) through a World Bank Trust Fund to IMA World
   Health and the Centers for Disease Control and Prevention. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
NR 31
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004917
DI 10.1371/journal.pntd.0004917
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800056
PM 27548382
ER

PT J
AU Wan, Q
   Xiao, LH
   Zhang, XC
   Li, YJ
   Lu, YX
   Song, MX
   Li, W
AF Wan, Qiang
   Xiao, Lihua
   Zhang, Xichen
   Li, Yijing
   Lu, Yixin
   Song, Mingxin
   Li, Wei
TI Clonal Evolution of Enterocytozoon bieneusi Populations in Swine and
   Genetic Differentiation in Subpopulations between Isolates from Swine
   and Humans
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; NORTHEAST CHINA; GIARDIA-DUODENALIS;
   HOST-SPECIFICITY; PUBLIC-HEALTH; SEQUENCE; GENOTYPES; MICROSPORIDIA;
   CRYPTOSPORIDIUM; DIVERSITY
AB Enterocytozoon bieneusi is a widespread parasite with high genetic diversity among hosts. Its natural reservoir remains elusive and data on population structure are available only in isolates from primates. Here we describe a population genetic study of 101 E. bieneusi isolates from pigs using sequence analysis of the ribosomal internal transcribed spacer (ITS) and four mini-and microsatellite markers. The presence of strong linkage disequilibrium (LD) and limited genetic recombination indicated a clonal structure for the population. Bayesian inference of phylogeny, structural analysis, and principal coordinates analysis separated the overall population into three subpopulations (SP3 to SP5) with genetic segregation of the isolates at some geographic level. Comparative analysis showed the differentiation of SP3 to SP5 from the two known E. bieneusi subpopulations (SP1 and SP2) from primates. The placement of a human E. bieneusi isolate in pig subpopulation SP4 supported the zoonotic potential of some E. bieneusi isolates. Network analysis showed directed evolution of SP5 to SP3/SP4 and SP1 to SP2. The high LD and low number of inferred recombination events are consistent with the possibility of host adaptation in SP2, SP3, and SP4. In contrast, the reduced LD and high genetic diversity in SP1 and SP5 might be results of broad host range and adaptation to new host environment. The data provide evidence of the potential occurrence of host adaptation in some of E. bieneusi isolates that belong to the zoonotic ITS Group 1.
C1 [Wan, Qiang; Li, Yijing; Lu, Yixin; Song, Mingxin; Li, Wei] Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China.
   [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Zhang, Xichen] Jilin Univ, Coll Vet Med, Changchun, Jilin, Peoples R China.
RP Li, W (reprint author), Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China.
EM neaulw@gmail.com
RI Xiao, Lihua/B-1704-2013; 
OI Xiao, Lihua/0000-0001-8532-2727; Li, Wei/0000-0002-4264-1864
FU National Natural Science Foundation of China [31302081]; University
   Nursing Program for Young Scholars with Creative Talents in Heilongjiang
   Province [UNPYSCT-2015008]
FX This study was supported by the National Natural Science Foundation of
   China (no. 31302081, http://www.nsfc.gov.cn/) and the University Nursing
   Program for Young Scholars with Creative Talents in Heilongjiang
   Province (no. UNPYSCT-2015008, https://www.hljedu.gov.cn/). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
NR 49
TC 1
Z9 1
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004966
DI 10.1371/journal.pntd.0004966
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800080
PM 27563718
ER

PT J
AU Bruce, M
   Zulz, T
   Koch, A
AF Bruce, M.
   Zulz, T.
   Koch, A.
TI Surveillance of infectious diseases in the Arctic
SO PUBLIC HEALTH
LA English
DT Review
DE Arctic; Surveillance; Infectious diseases; International Circumpolar
   Surveillance; Circumpolar; Alaska
ID HELICOBACTER-PYLORI INFECTION; INVASIVE PNEUMOCOCCAL DISEASE; ALASKA
   NATIVE PERSONS; HAEMOPHILUS-INFLUENZAE SEROTYPE; QUALITY-CONTROL
   PROGRAM; HOME WATER SERVICE; ANTIMICROBIAL RESISTANCE; RISK-FACTORS;
   STREPTOCOCCUS-PNEUMONIAE; INDIGENOUS POPULATIONS
AB Objectives: This study reviews how social and environmental issues affect health in Arctic populations and describes infectious disease surveillance in Arctic Nations with a special focus on the activities of the International Circumpolar Surveillance (ICS) project.
   Methods: We reviewed the literature over the past 2 decades looking at Arctic living conditions and their effects on health and Arctic surveillance for infectious diseases.
   Results: In regards to other regions worldwide, the Arctic climate and environment are extreme. Arctic and sub-Arctic populations live in markedly different social and physical environments compared to those of their more southern dwelling counterparts. A cold northern climate means people spending more time indoors, amplifying the effects of household crowding, smoking and inadequate ventilation on the person-to-person spread of infectious diseases. The spread of zoonotic infections north as the climate warms, emergence of antibiotic resistance among bacterial pathogens, the re-emergence of tuberculosis, the entrance of HIV into Arctic communities, the specter of pandemic influenza or the sudden emergence and introduction of new viral pathogens pose new challenges to residents, governments and public health authorities of all Arctic countries. ICS is a network of hospitals, public health agencies, and reference laboratories throughout the Arctic working together for the purposes of collecting, comparing and sharing of uniform laboratory and epidemiological data on infectious diseases of concern and assisting in the formulation of prevention and control strategies (Fig. 1). In addition, circumpolar infectious disease research workgroups and sentinel surveillance systems for bacterial and viral pathogens exist.
   Conclusions: The ICS system is a successful example of collaborative surveillance and research in an extreme environment. Published by Elsevier Ltd on behalf of The Royal Society for Public Health.
C1 [Bruce, M.; Zulz, T.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA.
   [Koch, A.] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark.
RP Bruce, M (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
EM zwa8@cdc.gov
OI Koch, Anders/0000-0001-9205-1048
NR 64
TC 0
Z9 0
U1 14
U2 15
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD AUG
PY 2016
VL 137
BP 5
EP 12
DI 10.1016/j.puhe.2016.06.014
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT3HJ
UT WOS:000381371400003
PM 27473191
ER

PT J
AU Fleming-Dutra, KE
   Mangione-Smith, R
   Hicks, LA
AF Fleming-Dutra, Katherine E.
   Mangione-Smith, Rita
   Hicks, Lauri A.
TI How to Prescribe Fewer Unnecessary Antibiotics: Talking Points That Work
   with Patients and Their Families
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Editorial Material
ID ENHANCED COMMUNICATION-SKILLS; RESPIRATORY-TRACT INFECTIONS;
   UNITED-STATES; OTITIS-MEDIA; PRIMARY-CARE; TRIAL; SATISFACTION;
   EXPECTATIONS; ATTITUDES
C1 [Fleming-Dutra, Katherine E.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Mangione-Smith, Rita] Univ Washington, Seattle, WA 98195 USA.
   [Mangione-Smith, Rita] Seattle Childrens Res Inst, Seattle, WA USA.
RP Fleming-Dutra, KE (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM ftu2@cdc.gov
NR 21
TC 0
Z9 0
U1 2
U2 2
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD AUG 1
PY 2016
VL 94
IS 3
BP 200
EP 202
PG 3
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA DS8WR
UT WOS:000381064200006
PM 27479620
ER

PT J
AU Schleicher, RL
   Sternberg, MR
   Lacher, DA
   Sempos, CT
   Looker, AC
   Durazo-Arvizu, RA
   Yetley, EA
   Chaudhary-Webb, M
   Maw, KL
   Pfeiffer, CM
   Johnson, CL
AF Schleicher, Rosemary L.
   Sternberg, Maya R.
   Lacher, David A.
   Sempos, Christopher T.
   Looker, Anne C.
   Durazo-Arvizu, Ramon A.
   Yetley, Elizabeth A.
   Chaudhary-Webb, Madhulika
   Maw, Khin L.
   Pfeiffer, Christine M.
   Johnson, Clifford L.
TI The vitamin D status of the US population from 1988 to 2010 using
   standardized serum concentrations of 25-hydroxyvitamin D shows recent
   modest increases
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE standardization; survey; vitamin D; trend; NHANES; supplements
ID TANDEM MASS-SPECTROMETRY; D DEFICIENCY; CLINICAL-PRACTICE;
   HYPOVITAMINOSIS-D; HEALTH; PREVALENCE; TRENDS; ADULTS; PREVENTION;
   OBESITY
AB Background: Temporal trends in the US population's vitamin D status have been uncertain because of nonstandardized serum 25-hydroxyvitamin D [25(OH)D] measurements.
   Objective: To accurately assess vitamin D status trends among those aged >= 12 y, we used data from the cross-sectional NHANESs.
   Design: A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for measuring 25(OH)D (sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D-3), calibrated to standard reference materials, was used to predict LC-MS/MS-equivalent concentrations from radioimmunoassay data (1988-2006 surveys; n = 38,700) and to measure LC-MS/MS concentrations (2007-2010 surveys; n = 12,446). Weighted arithmetic means and the prevalence of 25(OH)D above or below cutoff concentrations were calculated to evaluate long-term trends.
   Results: Overall, mean predicted 25(OH)D showed no time trend from 1988 to 2006, but during 2007-2010 the mean measured 25(OH)D was 5-6 nmol/L higher. Those groups who showed the largest 25(OH)D increases (7-11 nmol/L) were older, female, non-Hispanic white, and vitamin D supplement users. During 19882010, the proportions of persons with 25(OH)D,40 nmol/L were 14-18% (overall), 46-60% (non-Hispanic blacks), 21-28% (Mexican Americans), and 6-10% (non-Hispanic whites).
   Conclusions: An accurate method for measuring 25(OH)D showed stable mean concentrations in the US population (1988-2006) and recent modest increases (2007-2010). Although it is unclear to what extent supplement usage compared with different laboratory methods explain the increases in 25(OH)D, the use of higher vitamin D supplement dosages coincided with the increase. Marked race-ethnic differences in 25(OH)D concentrations were apparent. These data provide the first standardized information about temporal trends in the vitamin D status of the US population.
C1 [Schleicher, Rosemary L.; Sternberg, Maya R.; Chaudhary-Webb, Madhulika; Maw, Khin L.; Pfeiffer, Christine M.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
   [Lacher, David A.; Looker, Anne C.; Johnson, Clifford L.] CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA.
   [Sempos, Christopher T.; Durazo-Arvizu, Ramon A.; Yetley, Elizabeth A.] NIH, Off Dietary Supplements, Bldg 10, Bethesda, MD 20892 USA.
RP Pfeiffer, CM (reprint author), CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
EM cfp8@cdc.gov
FU CDC; NIH/Office of Dietary Supplements
FX Data collection and laboratory analyses of vitamin D were funded by the
   CDC and the NIH/Office of Dietary Supplements.
NR 55
TC 6
Z9 6
U1 5
U2 6
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG 1
PY 2016
VL 104
IS 2
BP 454
EP 461
DI 10.3945/ajcn.115.127985
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DU0CZ
UT WOS:000381870200026
PM 27385610
ER

PT J
AU Terry, AL
   Cogswell, ME
   Wang, CY
   Chen, TC
   Loria, CM
   Wright, JD
   Zhang, XL
   Lacher, DA
   Merritt, RK
   Bowman, BA
AF Terry, Ana L.
   Cogswell, Mary E.
   Wang, Chia-Yih
   Chen, Te-Ching
   Loria, Catherine M.
   Wright, Jacqueline D.
   Zhang, Xinli
   Lacher, David A.
   Merritt, Robert K.
   Bowman, Barbara A.
TI Feasibility of collecting 24-h urine to monitor sodium intake in the
   National Health and Nutrition Examination Survey
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE 24-hour urine; sodium excretion; NHANES; biomarker; hypertension; sodium
   intake
ID AMINO BENZOIC-ACID; BLOOD-PRESSURE; UNITED-STATES; SALT INTAKE;
   COMPLETENESS; POTASSIUM; BIOMARKERS; EXCRETION
AB Background: Twenty-four-hour urine sodium excretion is recommended for monitoring population sodium intake. Because of concerns about participation and completion, sodium excretion has not been collected previously in US nationally representative surveys.
   Objective: We assessed the feasibility of implementing 24-h urine collections as part of a nationally representative survey.
   Design: We selected a random half sample of nonpregnant US adults aged 20-69 y in 3 geographic locations of the 2013 NHANES. Participants received explicit instructions, started and ended the urine collection in a urine study mobile examination center, and answered questions about their collection. Among those with a complete 24-h urine collection, a random one-half were asked to collect a second 24-h urine sample. Sodium, potassium, chloride, and creatinine excretion were analyzed.
   Results: The final NHANES examination response rate for adults aged 20-69 y in these 3 study locations was 71%. Of those examined (n = 476), 282 (59%) were randomly selected to participate in the 24-h urine collection. Of these, 212 persons [75% of those selected for 24-h urine collection; 53% (equal to 71% x 75% of those selected for the NHANES)] collected a complete initial 24-h specimen and 92 persons (85% of 108 selected) collected a second complete 24-h urine sample. Moremen than women completed an initial collection (P = 0.04); otherwise, completion did not vary by sociodemographic characteristics, body mass index, education, or employment status for either collection. Mean 24-h urine volume and sodium excretion were 1964 +/- 1228 mL and 3657 +/- 2003 mg, respectively, for the first 24-h urine sample, and 2048 +/- 1288 mL and 3773 +/- 1891 mg, respectively, for the second collection.
   Conclusion: Given the 53% final component response rate and 75% completion rate, 24-h urine collections were deemed feasible and implemented in the NHANES 2014 on a subsample of adults aged 20-69 y to assess population sodium intake.
C1 [Terry, Ana L.; Wang, Chia-Yih; Chen, Te-Ching; Zhang, Xinli; Lacher, David A.] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
   [Cogswell, Mary E.; Merritt, Robert K.; Bowman, Barbara A.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
   [Loria, Catherine M.; Wright, Jacqueline D.] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Zhang, Xinli] Harris IT Serv Corp, Herndon, VA USA.
RP Terry, AL (reprint author), CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
EM auc5@cdc.gov
FU CDC and NIH
FX The data collection and laboratory analyses were funded by the CDC and
   the NIH.
NR 27
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG 1
PY 2016
VL 104
IS 2
BP 480
EP 488
DI 10.3945/ajcn.115.121954
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DU0CZ
UT WOS:000381870200029
PM 27413136
ER

PT J
AU Houry, D
AF Houry, Debra
TI Saving Lives and Protecting People From Injuries and Violence
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Article
AB Emergency physicians witness the effects of injury and violence every day. Traumatic brain injury, assault-related trauma, motor vehicle crashes, and opioid overdoses make up only some of these injuries many of which can be prevented and better understood. The Centers for Disease Control and Prevention's National Center for Injury Prevention and Control (Injury Center) is uniquely poised to measure the toll of injury and violence on the lives of Americans, to communicate this public health burden, and to reduce the factors that increase their risk. Injury is the leading cause of death for persons aged 1 to 44 years in the United States. The Injury Center seeks to prevent violence and injuries and to reduce their consequences. For more than 20 years, Injury Center researchers have investigated factors that put Americans at risk through surveillance and research and translated these findings into evidence-based strategies and interventions. Many of these efforts are directly relevant to emergency medicine through preventing injuries and violence to save lives.
C1 [Houry, Debra] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
RP Houry, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
EM Vjz7@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD AUG
PY 2016
VL 68
IS 2
BP 230
EP 232
DI 10.1016/j.annemergmed.2016.02.031
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA DT0II
UT WOS:000381166800018
PM 27033143
ER

PT J
AU Zuluaga-Idarraga, L
   Blair, S
   Okoth, SA
   Udhayakumar, V
   Marcet, PL
   Escalante, AA
   Alexander, N
   Rojas, C
AF Zuluaga-Idarraga, Lina
   Blair, Silvia
   Okoth, Sheila Akinyi
   Udhayakumar, Venkatachalam
   Marcet, Paula L.
   Escalante, Ananias A.
   Alexander, Neal
   Rojas, Carlos
TI Prospective Study of Plasmodium vivax Malaria Recurrence after Radical
   Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo,
   Colombia
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID POPULATION-STRUCTURE; TRANSMISSION DYNAMICS; PREVENTING RELAPSES;
   EFFICACY; INFECTIONS; IDENTIFICATION; FALCIPARUM; INFERENCE; SOFTWARE;
   IMPACT
AB Plasmodium vivax recurrences help maintain malaria transmission. They are caused by recrudescence, reinfection, or relapse, which are not easily differentiated. A longitudinal observational study took place in Turbo municipality, Colombia. Participants with uncomplicated P. vivax infection received supervised treatment concomitantly with 25 mg/kg chloroquine and 0.25 mg/kg/day primaquine for 14 days. Incidence of recurrence was assessed over 180 days. Samples were genotyped, and origins of recurrences were established. A total of 134 participants were enrolled between February 2012 and July 2013, and 87 were followed for 180 days, during which 29 recurrences were detected. The cumulative incidence of first recurrence was 24.1% (21/87) (95% confidence interval [CI], 14.6 to 33.7%), and 86% (18/21) of these events occurred between days 51 and 110. High genetic diversity of P. vivax strains was found, and 12.5% (16/128) of the infections were polyclonal. Among detected recurrences, 93.1% (27/29) of strains were genotyped as genetically identical to the strain from the previous infection episode, and 65.5% (19/29) of infections were classified as relapses. Our results indicate that there is a high incidence of P. vivax malaria recurrence after treatment in Turbo municipality, Colombia, and that a large majority of these episodes are likely relapses from the previous infection. We attribute this to the primaquine regimen currently used in Colombia, which may be insufficient to eliminate hypnozoites.
C1 [Zuluaga-Idarraga, Lina; Blair, Silvia] Univ Antioquia, Fac Med, Grp Malaria, Medellin, Colombia.
   [Okoth, Sheila Akinyi; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria Malaria Branch, Atlanta, GA USA.
   [Okoth, Sheila Akinyi] Atlanta Res & Educ Fdn, Atlanta, GA USA.
   [Marcet, Paula L.] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Atlanta, GA USA.
   [Escalante, Ananias A.] Temple Univ, Inst Genom & Evolutionary Med, Philadelphia, PA USA.
   [Alexander, Neal] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, MRC Trop Epidemiol Grp, London, England.
   [Rojas, Carlos] Univ Antioquia, Fac Nacl Salud Publ, Grp Epidemiol, Medellin, Colombia.
RP Zuluaga-Idarraga, L (reprint author), Univ Antioquia, Fac Med, Grp Malaria, Medellin, Colombia.
EM linazulu83@gmail.com
OI Marcet, Paula/0000-0002-0676-3020
FU Sustainability Strategy of the Malaria Group, University of Antioquia;
   Sustainability Strategy of the Epidemiology Group, University of
   Antioquia; Malaria Branch of the Centers for Disease Control and
   Prevention, Atlanta, GA; Atlanta Research and Education Foundation; CDC
   Antimicrobial Resistance Working Group; United Kingdom Medical Research
   Council (MRC); Department for International Development [MR/K012126/1]
FX This study was supported by the Sustainability Strategy of the Malaria
   Group, University of Antioquia, the Sustainability Strategy of the
   Epidemiology Group, University of Antioquia, and the Malaria Branch of
   the Centers for Disease Control and Prevention, Atlanta, GA. We
   acknowledge the partial financial support from the Atlanta Research and
   Education Foundation and CDC Antimicrobial Resistance Working Group.
   Neal Alexander receives support from the United Kingdom Medical Research
   Council (MRC) and Department for International Development
   (MR/K012126/1). We thank the National Doctoral Program, Colciencias,
   Colombia.
NR 55
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2016
VL 60
IS 8
BP 4610
EP 4619
DI 10.1128/AAC.00186-16
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DS5AJ
UT WOS:000380792600020
PM 27185794
ER

PT J
AU Kandler, JL
   Holley, CL
   Reimche, JL
   Dhulipala, V
   Balthazar, JT
   Muszynski, A
   Carlson, RW
   Shafer, WM
AF Kandler, Justin L.
   Holley, Concerta L.
   Reimche, Jennifer L.
   Dhulipala, Vijaya
   Balthazar, Jacqueline T.
   Muszynski, Artur
   Carlson, Russell W.
   Shafer, William M.
TI The MisR Response Regulator Is Necessary for Intrinsic Cationic
   Antimicrobial Peptide and Aminoglycoside Resistance in Neisseria
   gonorrhoeae
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID SIGNAL-TRANSDUCTION SYSTEM; ENVELOPE STRESS-RESPONSE; GENITAL-TRACT
   INFECTION; MTR EFFLUX SYSTEM; IN-VIVO FITNESS; 2-COMPONENT SYSTEM;
   PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC-RESISTANCE; UNTREATABLE GONORRHEA;
   BACTERICIDAL ACTION
AB During infection, the sexually transmitted pathogen Neisseria gonorrhoeae (the gonococcus) encounters numerous host-derived antimicrobials, including cationic antimicrobial peptides (CAMPs) produced by epithelial and phagocytic cells. CAMPs have both direct and indirect killing mechanisms and help link the innate and adaptive immune responses during infection. Gonococcal CAMP resistance is likely important for avoidance of host nonoxidative killing systems expressed by polymorphonuclear granulocytes (e.g., neutrophils) and intracellular survival. Previously studied gonococcal CAMP resistance mechanisms include modification of lipid A with phosphoethanolamine by LptA and export of CAMPs by the MtrCDE efflux pump. In the related pathogen Neisseria meningitidis, a two-component regulatory system (2CRS) termed MisR-MisS has been shown to contribute to the capacity of the meningococcus to resist CAMP killing. We report that the gonococcal MisR response regulator but not the MisS sensor kinase is involved in constitutive and inducible CAMP resistance and is also required for intrinsic low-level resistance to aminoglycosides. The 4- to 8-fold increased susceptibility of misR-deficient gonococci to CAMPs and aminoglycosides was independent of phosphoethanolamine decoration of lipid A and the levels of the MtrCDE efflux pump and seemed to correlate with a general increase in membrane permeability. Transcriptional profiling and biochemical studies confirmed that expression of lptA and mtrCDE was not impacted by the loss of MisR. However, several genes encoding proteins involved in membrane integrity and redox control gave evidence of being MisR regulated. We propose that MisR modulates the levels of gonococcal susceptibility to antimicrobials by influencing the expression of genes involved in determining membrane integrity.
C1 [Kandler, Justin L.; Holley, Concerta L.; Reimche, Jennifer L.; Dhulipala, Vijaya; Balthazar, Jacqueline T.; Shafer, William M.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Shafer, William M.] Emory Univ, Sch Med, Emory Antibiot Resistance Ctr, Atlanta, GA 30322 USA.
   [Muszynski, Artur; Carlson, Russell W.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.
   [Shafer, William M.] Vet Affairs Med Ctr, Labs Bacterial Pathogenesis, Decatur, GA 30033 USA.
   [Kandler, Justin L.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Shafer, WM (reprint author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.; Shafer, WM (reprint author), Emory Univ, Sch Med, Emory Antibiot Resistance Ctr, Atlanta, GA 30322 USA.; Shafer, WM (reprint author), Vet Affairs Med Ctr, Labs Bacterial Pathogenesis, Decatur, GA 30033 USA.
EM wshafer@emory.edu
FU Biomedical Laboratory Research and Development Service of the U.S.
   Department of Veterans Affairs [510 1BX000112-07]; NIH [R37 AI21150-31,
   U19 AI113170-02]; Chemical Sciences, Geosciences and Biosciences
   Division, Office of Basic Energy Sciences, U.S. Department of Energy
   [DE-FG02-93ER20097]
FX This work was supported by VA Merit Award 510 1BX000112-07 from the
   Biomedical Laboratory Research and Development Service of the U.S.
   Department of Veterans Affairs to W.M.S., by NIH grants R37 AI21150-31
   (W.M.S.) and U19 AI113170-02 (to Ann E. Jerse), and by Chemical
   Sciences, Geosciences and Biosciences Division, Office of Basic Energy
   Sciences, U.S. Department of Energy, grant DE-FG02-93ER20097 (to R.W.C.
   and A.M.) to the DOE Center for Plant and Microbial Complex
   Carbohydrates at the Complex Carbohydrate Research Center. W.M.S. is the
   recipient of a Senior Research Career Scientist Award from the
   Biomedical Laboratory Research and Development Service of the U.S.
   Department of Veterans Affairs.
NR 86
TC 0
Z9 0
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2016
VL 60
IS 8
BP 4690
EP 4700
DI 10.1128/AAC.00823-16
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DS5AJ
UT WOS:000380792600030
PM 27216061
ER

PT J
AU Afonso, CL
   Amarasinghe, GK
   Banyai, K
   Bao, YM
   Basler, CF
   Bavari, S
   Bejerman, N
   Blasdell, KR
   Briand, FX
   Briese, T
   Bukreyev, A
   Calisher, CH
   Chandran, K
   Cheng, JS
   Clawson, AN
   Collins, PL
   Dietzgen, RG
   Dolnik, O
   Domier, LL
   Durrwald, R
   Dye, JM
   Easton, AJ
   Ebihara, H
   Farkas, SL
   Freitas-Astua, J
   Formenty, P
   Fouchier, RAM
   Fu, YP
   Ghedin, E
   Goodin, MM
   Hewson, R
   Horie, M
   Hyndman, TH
   Jiang, DH
   Kitajima, EW
   Kobinger, GP
   Kondo, H
   Kurath, G
   Lamb, RA
   Lenardon, S
   Leroy, EM
   Li, CX
   Lin, XD
   Liu, LJ
   Longdon, B
   Marton, S
   Maisner, A
   Muhlberger, E
   Netesov, SV
   Nowotny, N
   Patterson, JL
   Payne, SL
   Paweska, JT
   Randall, RE
   Rima, BK
   Rota, P
   Rubbenstroth, D
   Schwemmle, M
   Shi, M
   Smither, SJ
   Stenglein, MD
   Stone, DM
   Takada, A
   Terregino, C
   Tesh, RB
   Tian, JH
   Tomonaga, K
   Tordo, N
   Towner, JS
   Vasilakis, N
   Verbeek, M
   Volchkov, VE
   Wahl-Jensen, V
   Walsh, JA
   Walker, PJ
   Wang, D
   Wang, LF
   Wetzel, T
   Whitfield, AE
   Xie, JT
   Yuen, KY
   Zhang, YZ
   Kuhn, JH
AF Afonso, Claudio L.
   Amarasinghe, Gaya K.
   Banyai, Krisztian
   Bao, Yiming
   Basler, Christopher F.
   Bavari, Sina
   Bejerman, Nicolas
   Blasdell, Kim R.
   Briand, Francois-Xavier
   Briese, Thomas
   Bukreyev, Alexander
   Calisher, Charles H.
   Chandran, Kartik
   Cheng, Jiasen
   Clawson, Anna N.
   Collins, Peter L.
   Dietzgen, Ralf G.
   Dolnik, Olga
   Domier, Leslie L.
   Duerrwald, Ralf
   Dye, John M.
   Easton, Andrew J.
   Ebihara, Hideki
   Farkas, Szilvia L.
   Freitas-Astua, Juliana
   Formenty, Pierre
   Fouchier, Ron A. M.
   Fu, Yanping
   Ghedin, Elodie
   Goodin, Michael M.
   Hewson, Roger
   Horie, Masayuki
   Hyndman, Timothy H.
   Jiang, Daohong
   Kitajima, Elliot W.
   Kobinger, Gary P.
   Kondo, Hideki
   Kurath, Gael
   Lamb, Robert A.
   Lenardon, Sergio
   Leroy, Eric M.
   Li, Ci-Xiu
   Lin, Xian-Dan
   Liu, Lijiang
   Longdon, Ben
   Marton, Szilvia
   Maisner, Andrea
   Muhlberger, Elke
   Netesov, Sergey V.
   Nowotny, Norbert
   Patterson, Jean L.
   Payne, Susan L.
   Paweska, Janusz T.
   Randall, Rick E.
   Rima, Bertus K.
   Rota, Paul
   Rubbenstroth, Dennis
   Schwemmle, Martin
   Shi, Mang
   Smither, Sophie J.
   Stenglein, Mark D.
   Stone, David M.
   Takada, Ayato
   Terregino, Calogero
   Tesh, Robert B.
   Tian, Jun-Hua
   Tomonaga, Keizo
   Tordo, Noel
   Towner, Jonathan S.
   Vasilakis, Nikos
   Verbeek, Martin
   Volchkov, Viktor E.
   Wahl-Jensen, Victoria
   Walsh, John A.
   Walker, Peter J.
   Wang, David
   Wang, Lin-Fa
   Wetzel, Thierry
   Whitfield, Anna E.
   Xie, Jiatao
   Yuen, Kwok-Yung
   Zhang, Yong-Zhen
   Kuhn, Jens H.
TI Taxonomy of the order Mononegavirales: update 2016
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID COMPLETE GENOME SEQUENCE; PARROT BORNAVIRUS 5; AVIAN PARAMYXOVIRUS;
   INTERNATIONAL COMMITTEE; FELINE MORBILLIVIRUS; RATIFICATION VOTE;
   DOMESTIC CATS; VIRUS; IDENTIFICATION; PROPOSALS
AB In 2016, the order Mononegavirales was emended through the addition of two new families (Mymonaviridae and Sunviridae), the elevation of the paramyxoviral subfamily Pneumovirinae to family status (Pneumoviridae), the addition of five free-floating genera (Anphevirus, Arlivirus, Chengtivirus, Crustavirus, and Wastrivirus), and several other changes at the genus and species levels. This article presents the updated taxonomy of the order Mononegavirales as now accepted by the International Committee on Taxonomy of Viruses (ICTV).
C1 [Afonso, Claudio L.] ARS, Southeast Poultry Res Lab, USDA, Athens, GA 30602 USA.
   [Amarasinghe, Gaya K.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA.
   [Banyai, Krisztian; Farkas, Szilvia L.; Marton, Szilvia] Hungarian Acad Sci, Vet Med Res Inst, Agr Res Ctr, Budapest, Hungary.
   [Bao, Yiming] NIH, Informat Engn Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.
   [Basler, Christopher F.] Georgia State Univ, Ctr Microbial Pathogenesis, Inst Biomed Sci, Atlanta, GA 30303 USA.
   [Bavari, Sina; Dye, John M.] United States Army Med Res Inst Infect Dis, Frederick, MD USA.
   [Bejerman, Nicolas; Lenardon, Sergio] Inst Nacl Tecnol Agr, Inst Patol Vegetal, Ctr Invest Agr, Cordoba, Argentina.
   [Bejerman, Nicolas] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
   [Blasdell, Kim R.; Walker, Peter J.] CSIRO Hlth & Biosecur, Australian Anim Hlth Lab, Geelong, Vic, Australia.
   [Briand, Francois-Xavier] French Agcy Food Environm & Occupat Hlth & Safety, Avian & Rabbit Virol Immunol & Parasitol Unit, Ploufragan, France.
   [Briese, Thomas] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
   [Bukreyev, Alexander; Tesh, Robert B.] Univ Texas Med Branch, Dept Pathol, Galveston Natl Lab, Galveston, TX 77555 USA.
   [Bukreyev, Alexander; Tesh, Robert B.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston Natl Lab, Galveston, TX 77555 USA.
   [Calisher, Charles H.] Colorado State Univ, Arthropod Borne & Infect Dis Lab, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA.
   [Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
   [Cheng, Jiasen; Fu, Yanping; Jiang, Daohong; Liu, Lijiang; Xie, Jiatao] Huazhong Agr Univ, State Key Lab Agr Microbiol, Prov Key Lab Plant Pathol Hubei Prov, Coll Plant Sci & Technol, Wuhan, Peoples R China.
   [Clawson, Anna N.; Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA.
   [Collins, Peter L.] NIAID, Resp Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 21702 USA.
   [Dietzgen, Ralf G.] Univ Queensland, Queensland Alliance Agr & Food Innovat, St Lucia, Qld, Australia.
   [Dolnik, Olga; Maisner, Andrea] Univ Marburg, Inst Virol, Marburg, Germany.
   [Domier, Leslie L.] Univ Illinois, Dept Crop Sci, Champaign, IL 61820 USA.
   [Duerrwald, Ralf] IDT Biol, Dessau Rosslau, Germany.
   [Easton, Andrew J.; Walsh, John A.] Univ Warwick, Sch Life Sci, Coventry, W Midlands, England.
   [Ebihara, Hideki] NIAID, Rocky Mt Labs, Integrated Res Facil, NIH, Hamilton, MT 59840 USA.
   [Freitas-Astua, Juliana] Embrapa Cassava & Fruits, Cruz Das Almas, BA, Brazil.
   [Formenty, Pierre] WHO, Geneva, Switzerland.
   [Fouchier, Ron A. M.] Erasmus Univ, Med Ctr, Dept Virosci, Postgrad Sch Mol Med, Rotterdam, Netherlands.
   [Ghedin, Elodie] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA.
   [Goodin, Michael M.] Univ Kentucky, Plant Pathol, Lexington, KY 40506 USA.
   [Hewson, Roger] Publ Hlth England, Salisbury, Wilts, England.
   [Horie, Masayuki] Kagoshima Univ, Joint Fac Vet Med, Transboundary Anim Dis Res Ctr, Kagoshima, Japan.
   [Hyndman, Timothy H.] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia.
   [Kitajima, Elliot W.] Univ Sao Paulo, Nucleo Apoio Pesquisa Microscopia Eletr Aplicada, Escola Super Agr Luiz de Queiroz, Sao Paulo, Brazil.
   [Kobinger, Gary P.] Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB, Canada.
   [Kondo, Hideki] Okayama Univ, Inst Plant Sci & Resources, Kurashiki, Okayama, Japan.
   [Kurath, Gael] US Geol Survey, Western Fisheries Res Ctr, Seattle, WA 98115 USA.
   [Lamb, Robert A.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA.
   [Lamb, Robert A.] Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA.
   [Leroy, Eric M.] Ctr Int Rech Med Franceville, Inst Rech Dev, Franceville, Gabon.
   [Shi, Mang; Zhang, Yong-Zhen] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China.
   [Li, Ci-Xiu] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
   [Lin, Xian-Dan] Wenzhou Ctr Dis Control & Prevent, Wenzhou, Peoples R China.
   [Longdon, Ben] Univ Cambridge, Dept Genet, Cambridge, England.
   [Muhlberger, Elke] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
   [Muhlberger, Elke] Boston Univ, Sch Med, Natl Emerging Infect Dis Lab, Boston, MA 02118 USA.
   [Netesov, Sergey V.] Novosibirsk State Univ, Novosibirsk, Novosibirsk Obl, Russia.
   [Nowotny, Norbert] Univ Vet Med, Inst Virol, Vienna, Austria.
   [Nowotny, Norbert] Mohammed Bin Rashid Univ Med & Hlth Sci, Dept Basic Med Sci, Coll Med, Dubai, U Arab Emirates.
   [Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX 78227 USA.
   [Payne, Susan L.] Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA.
   [Paweska, Janusz T.] Natl Inst Communicable Dis, Ctr Emerging & Zoonot Dis, Natl Hlth Lab Serv, Sandringham Johannesburg, Gauteng, South Africa.
   [Randall, Rick E.] Univ St Andrews, Biomed Sci Res Complex, St Andrews, Fife, Scotland.
   [Rima, Bertus K.] Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Rota, Paul] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Rubbenstroth, Dennis; Schwemmle, Martin] Univ Freiburg, Inst Virol, Fac Med, Med Ctr, Freiburg, Germany.
   [Smither, Sophie J.] CBR Div, Dstl, Salisbury, Wilts, England.
   [Stenglein, Mark D.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Stone, David M.] Ctr Environm Fisheries & Aquaculture Sci, Weymouth, Dorset, England.
   [Takada, Ayato] Hokkaido Univ, Res Ctr Zoonosis Control, Div Global Epidemiol, Sapporo, Hokkaido, Japan.
   [Terregino, Calogero] OIE Collaborating Ctr Dis Human Anim Interface, Ist Zooprofilatt Sperimentale Venezie,FAO Referen, Dept Comparat Biomed Sci, Natl OIE Reference Lab Newcastle Dis & Avian Infl, Padua, Italy.
   [Tian, Jun-Hua] Wuhan Ctr Dis Control & Prevent, Wuhan, Peoples R China.
   [Tomonaga, Keizo] Kyoto Univ, Inst Virus Res, Kyoto, Japan.
   [Tordo, Noel] Inst Pasteur, Unite Strategies Antivirales, Paris, France.
   [Tordo, Noel] Inst Pasteur Guinee, Conakry, Guinea.
   [Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Biodefense & Emerging Infect Dis, Dept Pathol, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Trop Dis, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Verbeek, Martin] Wageningen Univ & Res, Wageningen, Netherlands.
   [Volchkov, Viktor E.] Univ Lyon 1, Mol Basis Viral Pathogen, CIRI, INSERM,U1111,CNRS,UMR5308,Ecole Normal Super Lyon, Lyon, France.
   [Wahl-Jensen, Victoria] Natl Biodef Anal & Countermeasures Ctr, Frederick, MD 21702 USA.
   [Wang, David] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Wang, David] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Wang, Lin-Fa] Biosecur Queensland, Dept Agr & Fisheries, Brisbane, Qld, Australia.
   [Wang, Lin-Fa] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore, Singapore.
   [Wetzel, Thierry] DLR Rheinpfalz, Inst Plant Protect, Neustadt, Germany.
   [Whitfield, Anna E.] Kansas State Univ, Plant Pathol, Manhattan, KS 66506 USA.
   [Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA.
EM kuhnjens@mail.nih.gov
RI Netesov, Sergey/A-3751-2013; Fouchier, Ron/A-1911-2014; Verbeek,
   Martin/D-1445-2017; Stenglein, Mark/E-3541-2017; LEROY,
   Eric/I-4347-2016; 
OI Netesov, Sergey/0000-0002-7786-2464; Fouchier, Ron/0000-0001-8095-2869;
   Verbeek, Martin/0000-0002-8973-3803; Stenglein,
   Mark/0000-0002-0993-813X; LEROY, Eric/0000-0003-0022-0890;
   Freitas-Astua, Juliana/0000-0002-0506-6880; Blasdell,
   Kim/0000-0003-2121-0376; Banyai, Krisztian/0000-0002-6270-1772
FU Battelle Memorial Institute; US National Institute of Allergy and
   Infectious Diseases (NIAID) [HHSN272200700016I]; DHS ST
   [HSHQDC-07-C-00020]; National Institutes of Health (NIH)
   [HHSN272201000040I/HHSN27200004/D04]; NIH, National Library of Medicine
FX This work was supported in part through Battelle Memorial Institute's
   prime contract with the US National Institute of Allergy and Infectious
   Diseases (NIAID) under Contract No. HHSN272200700016I. A subcontractor
   to Battelle Memorial Institute who performed this work is: J. H. K., an
   employee of Tunnell Government Services, Inc. This work was also funded
   in part under Contract No. HSHQDC-07-C-00020 awarded by DHS S&T for the
   management and operation of the National Biodefense Analysis and
   Countermeasures Center (NBACC), a Federally Funded Research and
   Development Center (V. W.-J.); and National Institutes of Health (NIH)
   contract HHSN272201000040I/HHSN27200004/D04 (N. V., R. B. T.). Y. B. was
   supported by the Intramural Research Program of the NIH, National
   Library of Medicine.
NR 31
TC 32
Z9 32
U1 7
U2 9
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD AUG
PY 2016
VL 161
IS 8
BP 2351
EP 2360
DI 10.1007/s00705-016-2880-1
PG 10
WC Virology
SC Virology
GA DR8FZ
UT WOS:000380135100037
PM 27216929
ER

PT J
AU Radcliff, E
   Cassell, CH
   Laditka, SB
   Thibadeau, JK
   Correia, J
   Grosse, SD
   Kirby, RS
AF Radcliff, Elizabeth
   Cassell, Cynthia H.
   Laditka, Sarah B.
   Thibadeau, Judy K.
   Correia, Jane
   Grosse, Scott D.
   Kirby, Russell S.
TI Factors associated with the timeliness of postnatal surgical repair of
   spina bifida
SO CHILDS NERVOUS SYSTEM
LA English
DT Article
DE Birth defects; Spina bifida; Pediatric surgery; Timeliness
ID PUBLIC-HEALTH RESEARCH; FOR-DISEASE-CONTROL; BIRTH-DEFECTS; OROFACIAL
   CLEFTS; NORTH-CAROLINA; CARE NEEDS; CHILDREN; MYELOMENINGOCELE;
   PREVENTION; MENINGOMYELOCELE
AB Clinical guidelines recommend repair of open spina bifida (SB) prenatally or within the first days of an infant's life. We examined maternal, infant, and health care system factors associated with time-to-repair among infants with postnatal repair.
   This retrospective, statewide, population-based study examined infants with SB born in Florida 1998-2007, ascertained by the Florida Birth Defects Registry. We used procedure codes from hospital discharge records to identify the first recorded myelomeningocele repair (ICD-9 CM procedure code 03.52) among infants with birth hospitalizations. Using Poisson multivariable regression, we examined time-to-repair by hydrocephalus, SB type (isolated [no other coded major birth defect] versus non-isolated), and other selected factors.
   Of 199 infants with a recorded birth hospitalization and coded myelomeningocele repair, 87.9 % had hydrocephalus and 19.6 % had non-isolated SB. About 76.4 % of infants had repair by day 2 of life. In adjusted analyses, infants with hydrocephalus were more likely to have timely repair (adjusted prevalence ratio (aPR) = 1.48, 95 % confidence interval (CI) 1.02-2.14) than infants without hydrocephalus. SB type was not associated with repair timing. Infants born in lower level nursery care hospitals with were less likely to have timely repairs (aPR = 0.71, 95 % CI 0.52-0.98) than those born in higher level nursery care hospitals.
   Most infants with SB had surgical repair in the first 2 days of life. Lower level birth hospital nursery care was associated with later repairs. Prenatal diagnosis can facilitate planning for a birth hospital with higher level of nursery care, thus improving opportunities for timely repair.
C1 [Radcliff, Elizabeth] Univ South Carolina, Arnold Sch Publ Hlth, South Carolina Rural Hlth Res Ctr, 220 Stoneridge Dr,Suite 204, Columbia, SC 29210 USA.
   [Cassell, Cynthia H.; Thibadeau, Judy K.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Laditka, Sarah B.] Univ N Carolina, Dept Publ Hlth Sci, Coll Hlth & Human Serv, Charlotte, NC USA.
   [Correia, Jane] Florida Birth Defects Registry, Florida Dept Hlth, Div Dis Control & Hlth Protect, Bur Epidemiol, Tallahassee, FL USA.
   [Kirby, Russell S.] Univ S Florida, Dept Community & Family Hlth, Coll Publ Hlth, Birth Defects Surveillance Program, Tampa, FL USA.
RP Radcliff, E (reprint author), Univ South Carolina, Arnold Sch Publ Hlth, South Carolina Rural Hlth Res Ctr, 220 Stoneridge Dr,Suite 204, Columbia, SC 29210 USA.
EM radclife@mailbox.sc.edu
FU March of Dimes Foundation [5-FY09-533]
FX This project was supported in part by Research Grant #5-FY09-533 from
   the March of Dimes Foundation.
NR 42
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0256-7040
EI 1433-0350
J9 CHILD NERV SYST
JI Childs Nerv. Syst.
PD AUG
PY 2016
VL 32
IS 8
BP 1479
EP 1487
DI 10.1007/s00381-016-3105-3
PG 9
WC Clinical Neurology; Pediatrics; Surgery
SC Neurosciences & Neurology; Pediatrics; Surgery
GA DS3FB
UT WOS:000380667400020
PM 27179533
ER

PT J
AU Miller, MD
   Valenti, M
   Schettler, T
   Tencza, B
AF Miller, Mark D.
   Valenti, Maria
   Schettler, Ted
   Tencza, Brian
TI A Multimedia E-Book - A Story of Health: Filling a Gap in Environmental
   Health Literacy for Health Professionals
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID EDUCATION; KNOWLEDGE; ATTITUDES
AB Narrative approaches and storytelling are emerging as powerful health promotion tools that can spark interest, increase understanding of determinants of health, and translate complex science. A Story of Health, a multimedia e-book with continuing education credits was designed to harness the power of storytelling to increase environmental health literacy. Health professionals are a key audience. They recognize that patients may be suffering from preventable illnesses of environmental origin but often feel ill-equipped to educate individuals and families about risks associated with common exposures. A Story of Health seeks to fill this gap and help readers develop the competencies they need in order to help patients make informed choices, reduce health risks, improve quality of life, and protect the environment. Americans rate nurses and medical doctors as having the highest honesty and ethical standards of all professions. These medical professionals can play a key role in changing patterns of patient behavior and influencing public policies. The e-book provides an easily accessible method of developing environmental health competency. The multimedia format with graphical interpretations allows for quick reviews of topics or for more in-depth analysis via links to additional resources. The CE evaluations have been overwhelmingly positive.
C1 [Miller, Mark D.] Univ Calif San Francisco, Western States Pediat Environm Hlth Specialty Uni, San Francisco, CA 94143 USA.
   [Miller, Mark D.] Calif Environm Protect Agcy, Oakland, CA USA.
   [Valenti, Maria] Collaborat Hlth & Environm, Bolinas, CA USA.
   [Schettler, Ted] Sci & Environm Hlth Network, Ames, IA USA.
   [Tencza, Brian] Agcy Toxic Subst & Dis Registry, Environm Med Branch, Div Toxicol & Human Hlth Sci, Atlanta, GA USA.
RP Miller, MD (reprint author), OEHHA, Childrens Environm Hlth Program, 1515 Clay St 16th Floor, Oakland, CA 94612 USA.
EM ucsfpehsumiller@gmail.com
OI Miller, Mark/0000-0002-9301-0093
FU ATSDR [1 U61TS000237-01]; U.S. EPA [DW-75-95877701]
FX This publication was supported by the cooperative agreement award number
   1 U61TS000237-01 from ATSDR. Its contents are the responsibility of the
   authors and do not necessarily represent the official views of the
   ATSDR, the State of California, or the California Environmental
   Protection Agency.; The U.S. EPA supports the Pediatric Environmental
   Health Specialty Units (PEHSU) by providing partial funding to ATSDR
   under Interagency Agreement DW-75-95877701. The U.S. EPA and ATSDR do
   not endorse the purchase of any commercial products or services
   mentioned in PEHSU publications.
NR 16
TC 0
Z9 0
U1 9
U2 12
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD AUG
PY 2016
VL 124
IS 8
BP A133
EP A136
DI 10.1289/EHP222
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA DS4KL
UT WOS:000380749900002
PM 27479986
ER

PT J
AU Herrick, KA
   Rossen, LM
   Kit, BK
   Wang, CY
   Ogden, CL
AF Herrick, Kirsten A.
   Rossen, Lauren M.
   Kit, Brian K.
   Wang, Chia-Yih
   Ogden, Cynthia L.
TI Trends in Breastfeeding Initiation and Duration by Birth Weight Among US
   Children, 1999-2012
SO JAMA PEDIATRICS
LA English
DT Letter
C1 [Herrick, Kirsten A.; Kit, Brian K.; Wang, Chia-Yih; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
   [Rossen, Lauren M.] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Hyattsville, MD USA.
RP Herrick, KA (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
EM kherrick1@cdc.gov
NR 3
TC 1
Z9 1
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD AUG
PY 2016
VL 170
IS 8
BP 805
EP 807
DI 10.1001/jamapediatrics.2016.0820
PG 4
WC Pediatrics
SC Pediatrics
GA DS9XW
UT WOS:000381137800022
PM 27367613
ER

PT J
AU Abd El Ghany, M
   Shi, XL
   Li, YH
   Ansari, HR
   Hill-Cawthorne, GA
   Ho, YS
   Naeem, R
   Pickard, D
   Klena, JD
   Xu, XB
   Pain, A
   Hu, QH
AF Abd El Ghany, Moataz
   Shi, Xiaolu
   Li, Yinghui
   Ansari, Hifzur R.
   Hill-Cawthorne, Grant A.
   Ho, Y. S.
   Naeem, Raeece
   Pickard, Derek
   Klena, John D.
   Xu, Xuebing
   Pain, Arnab
   Hu, Qinghua
TI Genomic and Phenotypic Analyses Reveal the Emergence of an Atypical
   Salmonella enterica Serovar Senftenberg Variant in China
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID UNITED-STATES; SEROTYPE TYPHIMURIUM; FOODBORNE ILLNESS;
   ESCHERICHIA-COLI; SEQUENCE; GASTROENTERITIS; PERSISTENCE; RESISTANCE;
   ALIGNMENT; OUTBREAK
AB Human infections with Salmonella enterica subspecies enterica serovar Senftenberg are often associated with exposure to poultry flocks, farm environments, or contaminated food. The recent emergence of multidrug-resistant isolates has raised public health concerns. In this study, comparative genomics and phenotypic analysis were used to characterize 14 Salmonella Senftenberg clinical isolates recovered from multiple outbreaks in Shenzhen and Shanghai, China, between 2002 and 2011. Single-nucleotide polymorphism analyses identified two phylogenetically distinct clades of S. Senftenberg, designated SC1 and SC2, harboring variations in Salmonella pathogenicity island 1 (SPI-1) and SPI-2 and exhibiting distinct biochemical and phenotypic signatures. Although the two variants shared the same serotype, the SC2 isolates of sequence type 14 (ST14) harbored intact SPI-1 and -2 and hence were characterized by possessing efficient invasion capabilities. In contrast, the SC1 isolates had structural deletion patterns in both SPI-1 and -2 that correlated with an impaired capacity to invade cultured human cells and also the year of their isolation. These atypical SC1 isolates also lacked the capacity to produce hydrogen sulfide. These findings highlight the emergence of atypical Salmonella Senftenberg variants in China and provide genetic validation that variants lacking SPI-1 and regions of SPI-2, which leads to impaired invasion capacity, can still cause clinical disease. These data have identified an emerging public health concern and highlight the need to strengthen surveillance to detect the prevalence and transmission of nontyphoidal Salmonella species.
C1 [Abd El Ghany, Moataz; Ansari, Hifzur R.; Ho, Y. S.; Naeem, Raeece; Pain, Arnab] KAUST, Thuwal, Saudi Arabia.
   [Shi, Xiaolu; Li, Yinghui; Hu, Qinghua] Shenzhen Ctr Dis Control & Prevent, Shenzhen, Guangdong, Peoples R China.
   [Hill-Cawthorne, Grant A.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia.
   [Hill-Cawthorne, Grant A.] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia.
   [Pickard, Derek] WTSI, Wellcome Trust Genome Campus, Cambridge, England.
   [Klena, John D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Xu, Xuebing] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China.
RP Abd El Ghany, M (reprint author), KAUST, Thuwal, Saudi Arabia.; Hu, QH (reprint author), Shenzhen Ctr Dis Control & Prevent, Shenzhen, Guangdong, Peoples R China.
EM Moataz.mohamed@kaust.edu.sa; huqinghua03@163.com
RI Pain, Arnab/L-5766-2015; 
OI Pain, Arnab/0000-0002-1755-2819; Ansari, Hifzur
   Rahman/0000-0002-0646-1743
FU National Science Foundation of China [81071433]; China National Science
   and Technology Major Project Foundation [2012ZX10004215-003-005,
   2016ZX10004215-005-005]; Shenzhen Public Service Platform of Pathogenic
   Microorganisms Repository; Faculty Baseline Research Funds (KAUST-BRF)
FX This work, including the efforts of Qinghua Hu, was funded by The
   National Science Foundation of China (81071433). This work, including
   the efforts of Qinghua Hu, was funded by China National Science and
   Technology Major Project Foundation (2012ZX10004215-003-005 and
   2016ZX10004215-005-005). This work, including the efforts of Qinghua Hu,
   was funded by Shenzhen Public Service Platform of Pathogenic
   Microorganisms Repository. This work, including the efforts of Arnab
   Pain, was funded by Faculty Baseline Research Funds (KAUST-BRF).
NR 50
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2016
VL 54
IS 8
BP 2014
EP 2022
DI 10.1128/JCM.00052-16
PG 9
WC Microbiology
SC Microbiology
GA DT1YO
UT WOS:000381278200013
PM 27225410
ER

PT J
AU Hunsperger, EA
   Sharp, TM
   Lalita, P
   Tikomaidraubuta, K
   Cardoso, YR
   Naivalu, T
   Khan, AS
   Marfel, M
   Hancock, WT
   Tomashek, KM
   Margolis, HS
AF Hunsperger, Elizabeth A.
   Sharp, Tyler M.
   Lalita, Paul
   Tikomaidraubuta, Kini
   Cardoso, Yolanda Rebello
   Naivalu, Taina
   Khan, Aalisha Sahu
   Marfel, Maria
   Hancock, W. Thane
   Tomashek, Kay M.
   Margolis, Harold S.
TI Use of a Rapid Test for Diagnosis of Dengue during Suspected Dengue
   Outbreaks in Resource-Limited Regions
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID VIRUS NS1 ANTIGEN; CASE-MANAGEMENT; ANTIBODY; IGM; IMMUNOASSAY;
   PERFORMANCE; INFECTIONS; EPIDEMIC; VIREMIA; IMPACT
AB Dengue is major public health problem, globally. Timely verification of suspected dengue outbreaks allows for public health response, leading to the initiation of appropriate clinical care. Because the clinical presentation of dengue is nonspecific, dengue diagnosis would benefit from a sensitive rapid diagnostic test (RDT). We evaluated the diagnostic performance of an RDT that detects dengue virus (DENV) nonstructural protein 1 (NS1) and anti-DENV IgM during suspected acute febrile illness (AFI) outbreaks in four countries. Real-time reverse transcription-PCR and anti-DENV IgM enzyme-linked immunosorbent assay were used to verify RDT results. Anti-DENV IgM RDT sensitivity and specificity ranged from 55.3 to 91.7% and 85.3 to 98.5%, respectively, and NS1 sensitivity and specificity ranged from 49.7 to 92.9% and 22.2 to 89.0%, respectively. Sensitivity varied by timing of specimen collection and DENV serotype. Combined test results moderately improved the sensitivity. The use of RDTs identified dengue as the cause of AFI outbreaks where reference diagnostic testing was limited or unavailable.
C1 [Hunsperger, Elizabeth A.; Sharp, Tyler M.; Tomashek, Kay M.; Margolis, Harold S.] Ctr Dis Control & Prevent, San Juan, PR 00937 USA.
   [Lalita, Paul; Tikomaidraubuta, Kini] Republ Marshall Islands Minist Hlth, Majuro, Marshall Island.
   [Cardoso, Yolanda Rebello] Natl Inst Publ Hlth, Luanda, Angola.
   [Naivalu, Taina; Khan, Aalisha Sahu] Fiji Ctr Communicable Dis Control, Suva, Fiji.
RP Hunsperger, EA (reprint author), Ctr Dis Control & Prevent, San Juan, PR 00937 USA.
EM Enh4@cdc.gov
NR 32
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2016
VL 54
IS 8
BP 2090
EP 2095
DI 10.1128/JCM.00521-16
PG 6
WC Microbiology
SC Microbiology
GA DT1YO
UT WOS:000381278200023
PM 27225409
ER

PT J
AU Tanmoy, AM
   Saha, S
   Darmstadt, GL
   Whitney, CG
   Saha, SK
AF Tanmoy, Arif M.
   Saha, Senjuti
   Darmstadt, Gary L.
   Whitney, Cynthia G.
   Saha, Samir K.
TI PCR-Based Serotyping of Streptococcus pneumoniae from Culture-Negative
   Specimens: Novel Primers for Detection of Serotypes within Serogroup 18
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID INVASIVE PNEUMOCOCCAL DISEASE; SEQUENTIAL MULTIPLEX PCR; DETERMINING
   CAPSULAR SEROTYPES; CONJUGATE VACCINE; BANGLADESHI CHILDREN; CHILDHOOD
   INFECTIONS; CARRIAGE; IDENTIFICATION; SURVEILLANCE; REPLACEMENT
AB Six multiplex-compatible PCR primers were designed to distinguish Streptococcus pneumoniae serotypes within serogroup 18 from culturable/nonculturable pneumococcal specimens, with no cross-reactivity with other serotypes and respiratory organisms. These primers will aid in the generation of better data on vaccine/nonvaccine serotypes in invasive and carriage pneumococcal surveillance and contribute to future vaccine formulation and impact studies.
C1 [Tanmoy, Arif M.; Saha, Samir K.] Dhaka Shishu Hosp, Dept Microbiol, Child Hlth Res Fdn, Dhaka, Bangladesh.
   [Saha, Senjuti] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Darmstadt, Gary L.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.
   [Whitney, Cynthia G.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
   [Saha, Samir K.] Dhaka Shishu Hosp, Bangladesh Inst Child Hlth, Dept Microbiol, Dhaka, Bangladesh.
RP Saha, SK (reprint author), Dhaka Shishu Hosp, Dept Microbiol, Child Hlth Res Fdn, Dhaka, Bangladesh.; Saha, SK (reprint author), Dhaka Shishu Hosp, Bangladesh Inst Child Hlth, Dept Microbiol, Dhaka, Bangladesh.
EM samirk.sks@gmail.com
NR 34
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2016
VL 54
IS 8
BP 2178
EP 2181
DI 10.1128/JCM.00419-16
PG 4
WC Microbiology
SC Microbiology
GA DT1YO
UT WOS:000381278200036
PM 27252464
ER

PT J
AU Yucesoy, B
   Talzhanov, Y
   Barmada, MM
   Johnson, VJ
   Kashon, ML
   Baron, E
   Wilson, NW
   Frye, B
   Wang, W
   Fluharty, K
   Gharib, R
   Meade, J
   Germolec, D
   Luster, MI
   Nedorost, S
AF Yucesoy, Berran
   Talzhanov, Yerkebulan
   Barmada, M. Michael
   Johnson, Victor J.
   Kashon, Michael L.
   Baron, Elma
   Wilson, Nevin W.
   Frye, Bonnie
   Wang, Wei
   Fluharty, Kara
   Gharib, Rola
   Meade, Jean
   Germolec, Dori
   Luster, Michael I.
   Nedorost, Susan
TI Genetic Basis of Irritant Susceptibility in Health Care Workers
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; OF-FUNCTION MUTATIONS; CONTACT-DERMATITIS;
   ATOPIC-DERMATITIS; FACTOR RECEPTOR; JAPANESE POPULATION;
   PSORIASIS-VULGARIS; SKIN INFLAMMATION; FILAGGRIN GENE; IL22 GENE
AB Objective: The aim of this study was to investigate the association of single nucleotide polymorphisms (SNPs) within genes involved in inflammation, skin barrier integrity, signaling/pattern recognition, and antioxidant defense with irritant susceptibility in a group of health care workers. Methods: The 536 volunteer subjects were genotyped for selected SNPs and patch tested with three model irritants: sodium lauryl sulfate (SLS), sodium hydroxide (NaOH), and benzalkonium chloride (BKC). Genotyping was performed on genomic DNA using Illumina Goldengate custom panels. Results: The ACACB (rs2268387, rs16934132, rs2284685), NTRK2 (rs10868231), NTRK3 (rs1347424), IL22 (rs1179251), PLAU (rs2227564), EGFR (rs6593202), and FGF2 (rs308439) SNPs showed an association with skin response to tested irritants in different genetic models (all at P < 0.001). Functional annotations identified two SNPs in PLAU (rs2227564) and ACACB (rs2284685) genes with a potential impact on gene regulation. In addition, EGF (rs10029654), EGFR (rs12718939), CXCL12 (rs197452), and VCAM1 (rs3917018) genes showed an association with hand dermatitis (P < 0.005). Conclusions: The results demonstrate that genetic variations in genes related to inflammation and skin homeostasis can influence responses to irritants and may explain inter-individual variation in the development of subsequent contact dermatitis.
C1 [Yucesoy, Berran; Kashon, Michael L.; Frye, Bonnie; Wang, Wei; Fluharty, Kara; Meade, Jean] NIOSH, Hlth Effects Lab Div, CDC, Morgantown, WV 26505 USA.
   [Talzhanov, Yerkebulan; Barmada, M. Michael] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA.
   [Johnson, Victor J.] BRT, Morrisville, NY USA.
   [Baron, Elma; Nedorost, Susan] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
   [Wilson, Nevin W.] Univ Nevada, Sch Med, Dept Pediat, Reno, NV 89557 USA.
   [Gharib, Rola] West Virginia Univ, Sch Med, Dept Dermatol, Morgantown, WV USA.
   [Germolec, Dori] NIEHS, Toxicol Branch, DNTP, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Luster, Michael I.] West Virginia Univ, Sch Publ Hlth, Morgantown, WV USA.
RP Yucesoy, B (reprint author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA.
EM berranyucesoy@gmail.com
OI Barmada, M Michael/0000-0002-3604-6460
FU NIOSH [AES12007001-1-0-6]; NIEHS [AES12007001-1-0-6]
FX This study was supported in part by an inter-agency agreement between
   NIOSH and NIEHS (AES12007001-1-0-6) as a collaborative National
   Toxicology Program research activity.
NR 68
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD AUG
PY 2016
VL 58
IS 8
BP 753
EP 759
DI 10.1097/JOM.0000000000000784
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT0DP
UT WOS:000381153200010
PM 27206134
ER

PT J
AU Waisbourd, M
   Pruzan, NL
   Johnson, D
   Ugorets, A
   Crews, JE
   Saaddine, JB
   Henderer, JD
   Hark, LA
   Katz, LJ
AF Waisbourd, Michael
   Pruzan, Noelle L.
   Johnson, Deiana
   Ugorets, Angela
   Crews, John E.
   Saaddine, Jinan B.
   Henderer, Jeffery D.
   Hark, Lisa A.
   Katz, L. Jay
TI The Philadelphia Glaucoma Detection and Treatment Project Detection
   Rates and Initial Management
SO OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT 24th Annual Meeting of the American-Glaucoma-Society
CY FEB 27-MAR 02, 2014
CL Washington, DC
SP Amer Glaucoma Soc
ID OPEN-ANGLE GLAUCOMA; BALTIMORE EYE SURVEY; UNITED-STATES; RISK-FACTORS;
   OCULAR HYPERTENSION; BARBADOS EYE; PREVALENCE; POPULATION; INDIVIDUALS;
   AMERICANS
AB Purpose: To evaluate the detection rates of glaucoma-related diagnoses and the initial treatments received in the Philadelphia Glaucoma Detection and Treatment Project, a community-based initiative aimed at improving the detection, treatment, and follow-up care of individuals at risk for glaucoma.
   Design: Retrospective analysis.
   Participants: A total of 1649 individuals at risk for glaucoma who were examined and treated in 43 community centers located in underserved communities of Philadelphia.
   Methods: Individuals were enrolled if they were African American aged >= 50 years, were any other adult aged >= 60 years, or had a family history of glaucoma. After attending an informational glaucoma workshop, participants underwent a targeted glaucoma examination including an ocular, medical, and family history; visual acuity testing, intraocular pressure (IOP) measurement, and corneal pachymetry; slit-lamp and optic nerve examination; automated visual field testing; and fundus color photography. If indicated, treatments included selective laser trabeculoplasty (SLT), laser peripheral iridotomy (LPI), or IOP-lowering medications. Follow-up examinations were scheduled at the community sites after 4 to 6 weeks or 4 to 6 months, depending on the clinical scenario.
   Main Outcome Measures: Detection rates of glaucoma-related diagnoses and types of treatments administered.
   Results: Of the 1649 individuals enrolled, 645 (39.1%) received a glaucoma-related diagnosis; 20.0% (n = 330) were identified as open-angle glaucoma (OAG) suspects, 9.2% (n = 151) were identified as having narrow angles (or as a primary angle closure/suspect), and 10.0% (n = 164) were diagnosed with glaucoma, including 9.0% (n = 148) with OAG and 1.0% (n = 16) with angle-closure glaucoma. Overall, 39.0% (n = 64 of 164) of those diagnosed with glaucoma were unaware of their diagnosis. A total of 196 patients (11.9%) received glaucoma-related treatment, including 84 (5.1%) who underwent LPI, 13 (0.8%) who underwent SLT, and 103 (6.2%) who were prescribed IOP-lowering medication.
   Conclusions: Targeting individuals at risk for glaucoma in underserved communities in Philadelphia yielded a high detection rate (39.1%) of glaucoma-related diagnoses. Providing examinations and offering treatment, including first-line laser procedures, at community-based sites providing services to older adults are effective to improve access to eye care by underserved populations. (C) 2016 by the American Academy of Ophthalmology.
C1 [Waisbourd, Michael; Pruzan, Noelle L.; Johnson, Deiana; Ugorets, Angela; Hark, Lisa A.; Katz, L. Jay] Wills Eye Hosp & Res Inst, Glaucoma Res Ctr, 840 Walnut St, Philadelphia, PA 19107 USA.
   [Crews, John E.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Vis Hlth Initiat, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
   [Henderer, Jeffery D.] Temple Univ, Lewis Katz Sch Med, Dept Ophthalmol, Philadelphia, PA 19122 USA.
RP Waisbourd, M (reprint author), Wills Eye Hosp & Res Inst, Glaucoma Res Ctr, 840 Walnut St, Philadelphia, PA 19107 USA.
EM MWaisbourd@willseye.org
OI Waisbourd, Michael/0000-0002-8730-5426
FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [U58 DP004060]
NR 38
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2016
VL 123
IS 8
BP 1667
EP 1674
DI 10.1016/j.ophtha.2016.04.031
PG 8
WC Ophthalmology
SC Ophthalmology
GA DS4MC
UT WOS:000380754200020
PM 27221736
ER

PT J
AU Auld, AF
   Nuwagaba-Biribonwoha, H
   Azih, C
   Kamiru, H
   Baughman, AL
   Agolory, S
   Abrams, E
   Ellerbrock, TV
   Okello, V
   Bicego, G
   Ehrenkranz, P
AF Auld, Andrew F.
   Nuwagaba-Biribonwoha, Harriet
   Azih, Charles
   Kamiru, Harrison
   Baughman, Andrew L.
   Agolory, Simon
   Abrams, Elaine
   Ellerbrock, Tedd V.
   Okello, Velephi
   Bicego, George
   Ehrenkranz, Peter
TI Decentralizing Access to Antiretroviral Therapy for Children Living with
   HIV in Swaziland
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE antiretroviral therapy; decentralization; pediatric; Swaziland; children
ID SCALE-UP; MULTIPLE IMPUTATION; TREATMENT PROGRAM; PATIENT OUTCOMES;
   MISSING VALUES; SOUTH-AFRICA; FOLLOW-UP; CARE; MODEL
AB Background: In 2007, Swaziland initiated a hub-and-spoke model for decentralizing antiretroviral therapy (ART) access for HIV-infected children (<15 years old). Decentralization was facilitated through (1) down referral of stable children on ART from overburdened central facilities (hubs) to primary healthcare clinics (spokes) and (2) pediatric ART initiation at spokes (spoke initiation).
   Methods: We conducted a nationally representative retrospective cohort study among children starting ART during 2004-2010 to assess effect of down referral and spoke initiation on rates of loss to follow-up (LTFU), death and attrition (death or LTFU). Twelve of 28 pediatric ART hubs were randomly selected using probability-proportional-to-size sampling. Seven selected facilities had initiated hub-and-spoke decentralization by study start; at these facilities, 901 of 1893 hub-initiated and maintained (hub-maintained) children and 495 of 1105 down-referred or spoke-initiated children were randomly selected for record abstraction. At the 5 hub-only facilities, 612 of 1987 children were randomly selected. Multivariable proportional hazards regression was used to estimate adjusted hazard ratios (AHR) for effect of down referral (a time-varying covariate) and spoke initiation on outcomes.
   Results: Among 2008 children at ART initiation, median age was 5.0 years, median CD4% 12.0%, median CD4 count 358 cells/mu L and median weight-for-age Z score -1.91. Controlling for known confounders, down referral was strongly protective against LTFU (AHR: 0.40; 95% confidence interval: 0.20-0.79) and attrition (AHR: 0.46; 95% confidence interval: 0.26-0.83) but not mortality. Compared with hub-only children or hub-maintained children, spoke-initiated children had similar outcomes.
   Conclusions: Decentralization of pediatric ART through down referral and spoke initiation within a hub-and-spoke system should be continued and might improve program outcomes.
C1 [Auld, Andrew F.; Baughman, Andrew L.; Agolory, Simon; Abrams, Elaine; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
   [Nuwagaba-Biribonwoha, Harriet; Kamiru, Harrison] Columbia Univ, ICAP, Mailman Sch Publ Hlth, New York, NY 10027 USA.
   [Azih, Charles; Okello, Velephi] Govt Kingdom Swaziland, Minist Hlth, Mbabane, Swaziland.
   [Bicego, George; Ehrenkranz, Peter] Ctr Dis Control & Prevent, Div Global HIV AIDS, Mbabane, Swaziland.
RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA.
EM aauld@cdc.gov
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S.
   Centers for Disease Control and Prevention [5U62PS223540, 5U2GPS001537]
FX This research has been supported by the President's Emergency Plan for
   AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and
   Prevention under the terms of Cooperative Agreement number 5U62PS223540
   and 5U2GPS001537. The findings and conclusions in this report are those
   of the authors and do not necessarily represent the official position of
   the Centers for Disease Control and Prevention. The authors have no
   conflicts of interest to disclose.
NR 36
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2016
VL 35
IS 8
BP 886
EP 893
DI 10.1097/INF.0000000000001075
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DS4MK
UT WOS:000380755000017
PM 26849157
ER

PT J
AU Kugeler, KJ
   Jordan, RA
   Schulze, TL
   Griffith, KS
   Mead, PS
AF Kugeler, K. J.
   Jordan, R. A.
   Schulze, T. L.
   Griffith, K. S.
   Mead, P. S.
TI Will Culling White-Tailed Deer Prevent Lyme Disease?
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Review
DE Lyme disease; deer; deer reduction; tick; public health intervention;
   prevention
ID IXODES-SCAPULARIS ACARI; EASTERN UNITED-STATES; DAMMINI ACARI;
   BORRELIA-BURGDORFERI; REDUCED ABUNDANCE; NEW-JERSEY; RESIDENTIAL
   COMMUNITY; SPATIAL-DISTRIBUTION; BABESIA-MICROTI; TICKS ACARI
AB White-tailed deer play an important role in the ecology of Lyme disease. In the United States, where the incidence and geographic range of Lyme disease continue to increase, reduction of white-tailed deer populations has been proposed as a means of preventing human illness. The effectiveness of this politically sensitive prevention method is poorly understood. We summarize and evaluate available evidence regarding the effect of deer reduction on vector tick abundance and human disease incidence. Elimination of deer from islands and other isolated settings can have a substantial impact on the reproduction of blacklegged ticks, while reduction short of complete elimination has yielded mixed results. To date, most studies have been conducted in ecologic situations that are not representative to the vast majority of areas with high human Lyme disease risk. Robust evidence linking deer control to reduced human Lyme disease risk is lacking. Currently, there is insufficient evidence to recommend deer population reduction as a Lyme disease prevention measure, except in specific ecologic circumstances.
C1 [Kugeler, K. J.; Griffith, K. S.; Mead, P. S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
   [Jordan, R. A.] Monmouth Cty Mosquito Control Div, Tick Borne Dis Program, Tinton Falls, NJ USA.
   [Schulze, T. L.] 9 Evergreen Court, Perrineville, NJ USA.
RP Kugeler, KJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM kkugeler@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 59
TC 0
Z9 0
U1 23
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD AUG
PY 2016
VL 63
IS 5
BP 337
EP 345
DI 10.1111/zph.12245
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases;
   Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
   Veterinary Sciences
GA DS7IR
UT WOS:000380957300001
PM 26684932
ER

PT J
AU Chang, SS
   Tsai, HJ
   Chang, FY
   Lee, TS
   Huang, KC
   Fang, KY
   Wallace, RM
   Inoue, S
   Fei, CY
AF Chang, S. -S.
   Tsai, H. -J.
   Chang, F. -Y.
   Lee, T. -S.
   Huang, K. -C.
   Fang, K. -Y.
   Wallace, R. M.
   Inoue, S.
   Fei, C. -Y.
TI Government Response to the Discovery of a Rabies Virus Reservoir Species
   on a Previously Designated Rabies-Free Island, Taiwan, 1999-2014
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Article
DE Public health; rabies; dog; epidemiology; infectious disease; risk
   assessment
AB Taiwan had been considered rabies free since 1961. In 2013, Taiwan confirmed the detection of rabies virus in wild Taiwan ferret-badgers. Up to December 2014, there have been 423 rabies-confirmed ferret-badgers and three cases of spillover infection into non-reservoir hosts. Genetic analysis indicates that TFBV is distinct from all other known rabies virus variants. To date, ferret-badger rabies is known to occur only in China and Taiwan. The temporal dynamics of rabid ferret-badgers in Taiwan suggests that the epizootic appears to have subsided to enzootic levels as of December 2014. According to the current epidemiologic data, there is only one TFBV strain in Taiwan. TFBV is still sequestered to the mountainous regions. Humans are at risk mainly through exposure to the virus from infected domestic meso-carnivores, mainly dogs and cats. Dogs and cats should be vaccinated to establish an immunological barrier to stop the spread of the disease from mountainous regions to domestic meso-carnivores.
C1 [Chang, S. -S.] Council Agr, Bur Anim & Plant Hlth Inspect & Quarantine, Taipei, Taiwan.
   [Tsai, H. -J.] Council Agr, Anim Hlth Res Inst, Taipei, Taiwan.
   [Chang, F. -Y.] Minist Hlth & Welf, Taiwan Ctr Dis Control, Taipei, Taiwan.
   [Lee, T. -S.] Council Agr, Forestry Bur, Taipei, Taiwan.
   [Huang, K. -C.] Council Agr, Dept Anim Ind, Taipei, Taiwan.
   [Fang, K. -Y.] Council Agr, Endem Species Res Inst, Taipei, Taiwan.
   [Wallace, R. M.] US Ctr Dis Control & Prevent, CDC, Atlanta, GA USA.
   [Inoue, S.] Natl Inst Infect Dis, Tokyo, Japan.
   [Fei, C. -Y.] Natl Taiwan Univ, Sch Vet Med, Taipei, Taiwan.
RP Fei, CY (reprint author), Natl Taiwan Univ, Sch Vet Med, Global Alliance Rabies Control, Taipei, Taiwan.
EM fei@ntu.edu.tw
OI Tsai, Hsiang-Jung/0000-0002-9393-7155; Fei, Andrew/0000-0001-9462-9317
NR 10
TC 1
Z9 1
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD AUG
PY 2016
VL 63
IS 5
BP 396
EP 402
DI 10.1111/zph.12240
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases;
   Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
   Veterinary Sciences
GA DS7IR
UT WOS:000380957300008
PM 26542085
ER

PT J
AU Dhawane, AN
   Diez-Valcarce, M
   Gurale, BP
   Dinh, H
   Vinje, J
   Iyer, SS
AF Dhawane, Abasaheb N.
   Diez-Valcarce, Marta
   Gurale, Bharat P.
   Dinh, Hieu
   Vinje, Jan
   Iyer, Suri S.
TI Synthesis and Evaluation of Biotinylated Bivalent HistoBlood Group
   Antigens for Capturing Human Noroviruses
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID BLOOD-GROUP ANTIGENS; NORWALK VIRUS-INFECTION; HERD-IMMUNITY;
   GASTROENTERITIS; SPECIFICITY; EMERGENCE; EVASION; VARIANT; SERA
AB A panel of biotinylated bivalent H-type glycans that have been reported as binding ligands for human noroviruses were synthesized using a modular synthetic strategy. These glycoconjugates were attached to streptavidin-coated magnetic beads and used to recover human norovirus from fecal samples using a magnetic bead-based assay. The biotinylated bivalent glycans synthesized for this study exhibited similar or better capturing ability when compared to commercial biotinylated glycopolymers.
C1 [Dhawane, Abasaheb N.; Gurale, Bharat P.; Dinh, Hieu; Iyer, Suri S.] Georgia State Univ, Dept Chem, Petit Sci Ctr 788, Atlanta, GA 30302 USA.
   [Diez-Valcarce, Marta; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA.
RP Iyer, SS (reprint author), Georgia State Univ, Dept Chem, Petit Sci Ctr 788, Atlanta, GA 30302 USA.; Vinje, J (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA.
EM ahx8@cdc.gov; siyer@gsu.edu
FU NIAID [R33-AI100246]
FX The findings and conclusions in this article are those of the authors
   and do not necessarily represent the official position of the Centers
   for Disease Control and Prevention. We thank NIAID (R33-AI100246) for
   their generous support of this research.
NR 34
TC 1
Z9 1
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD AUG
PY 2016
VL 27
IS 8
BP 1822
EP 1829
DI 10.1021/acs.bioconjchem.6b00226
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA DT8CI
UT WOS:000381716200008
PM 27383368
ER

PT J
AU Broderick, MP
   Romero-Steiner, S
   Rajam, G
   Johnson, SE
   Milton, A
   Kim, E
   Choi, LJ
   Radin, JM
   Schmidt, DS
   Carlone, GM
   Messonnier, N
   Faix, DJ
AF Broderick, Michael P.
   Romero-Steiner, Sandra
   Rajam, Gowrisankar
   Johnson, Scott E.
   Milton, Andrea
   Kim, Ellie
   Choi, Lisa J.
   Radin, Jennifer M.
   Schmidt, Daniel S.
   Carlone, George M.
   Messonnier, Nancy
   Faix, Dennis J.
TI Immune Responses in US Military Personnel Who Received Meningococcal
   Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were
   Higher than in Personnel Who Received MenACWY Alone
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID NEISSERIA-MENINGITIDIS SEROGROUP; DIPHTHERIA-TETANUS-PERTUSSIS; SERUM
   BACTERICIDAL ASSAYS; UNITED-STATES MILITARY; GROUP-C; ANTIBODY
   CONCENTRATIONS; INFLUENZA VACCINE; B VACCINE; GROUP-A; IMMUNOGENICITY
AB Immunological responses to vaccination can differ depending on whether the vaccine is given alone or with other vaccines. This study was a retrospective evaluation of the immunogenicity of a tetravalent meningococcal conjugate vaccine for serogroups A, C, W, and Y (MenACWY) administered alone (n = 41) or concomitantly with other vaccines (n = 279) to U.S. military personnel (mean age, 21.6 years) entering the military between 2006 and 2008. Concomitant vaccines included tetanus/diphtheria (Td), inactivated polio vaccine (IPV), hepatitis vaccines, and various influenza vaccines, among others; two vaccine groups excluded Tdap and IPV. Immune responses were evaluated in baseline and postvaccination sera for Neisseria meningitidis serogroups C and Y 1 to 12 months (mean, 4.96 months) following vaccination. Functional antibodies were measured by using a serum bactericidal antibody assay with rabbit complement (rSBA) and by measurement of serogroup- specific immunoglobulin G (IgG) antibodies. The percentage of vaccinees reaching threshold levels (IgG concentration in serum, >= 2 = mu g/ml; rSBA titer, >= 8) corresponding to an immunologic response was higher postvaccination than at baseline (P < 0.001). Administration ofMenACWYalong with other vaccines was associated with higher geometric means of IgG concentrations and rSBA titers than those measured 4.60 months after a single dose of Men ACWY. In addition, higher percentages of vaccinees reached the immunological threshold (range of odds ratios [ORs], 1.5 to 21.7) and more of them seroconverted (OR range, 1.8 to 4.8) when Men ACWY was administered with any other vaccine than when administered alone. Additional prospective randomized clinical trials are needed to confirm the observed differences among groups in the immune response to Men ACWY when given concomitantly with other vaccines to U.S. military personnel.
C1 [Broderick, Michael P.; Radin, Jennifer M.; Faix, Dennis J.] Naval Hlth Res Ctr, Operat Infect Dis Dept, San Diego, CA 92152 USA.
   [Romero-Steiner, Sandra; Rajam, Gowrisankar; Johnson, Scott E.; Milton, Andrea; Kim, Ellie; Choi, Lisa J.; Schmidt, Daniel S.; Carlone, George M.; Messonnier, Nancy] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Romero-Steiner, Sandra] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, Atlanta, GA USA.
   [Carlone, George M.] Carlone Consulting LLC, Palm Coast, FL USA.
RP Broderick, MP (reprint author), Naval Hlth Res Ctr, Operat Infect Dis Dept, San Diego, CA 92152 USA.
EM michael.broderick@med.navy.mil
FU Immunization Healthcare Branch of the Defense Health Agency; Office of
   Naval Research, Arlington, VA [60501]
FX This work was funded by the Military Vaccine Agency (MILVAX, now the
   Immunization Healthcare Branch of the Defense Health Agency) and was
   supported by the Office of Naval Research, Arlington, VA, under Work
   Unit No. 60501.
NR 34
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD AUG
PY 2016
VL 23
IS 8
BP 672
EP 680
DI 10.1128/CVI.00267-16
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DS5NJ
UT WOS:000380828700003
PM 27280619
ER

PT J
AU Sowers, SB
   Rota, JS
   Hickman, CJ
   Mercader, S
   Redd, S
   McNall, RJ
   Williams, N
   McGrew, M
   Walls, ML
   Rota, PA
   Bellini, WJ
AF Sowers, Sun B.
   Rota, Jennifer S.
   Hickman, Carole J.
   Mercader, Sara
   Redd, Susan
   McNall, Rebecca J.
   Williams, Nobia
   McGrew, Marcia
   Walls, M. Laura
   Rota, Paul A.
   Bellini, William J.
TI High Concentrations of Measles Neutralizing Antibodies and High-Avidity
   Measles IgG Accurately Identify Measles Reinfection Cases
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID UNITED-STATES; VACCINE FAILURE; VIRUS INFECTION; IMMUNIZED POPULATION;
   SCHOOL POPULATION; MMR IMMUNIZATION; CHILDREN; OUTBREAK; SECONDARY;
   PERSISTENCE
AB In the United States, approximately 9% of the measles cases reported from 2012 to 2014 occurred in vaccinated individuals. Laboratory confirmation of measles in vaccinated individuals is challenging since IgM assays can give inconclusive results. Although a positive reverse transcription (RT)-PCR assay result from an appropriately timed specimen can provide confirmation, negative results may not rule out a highly suspicious case. Detection of high-avidity measles IgG in serum samples provides laboratory evidence of a past immunologic response to measles from natural infection or immunization. High concentrations of measles neutralizing antibody have been observed by plaque reduction neutralization (PRN) assays among confirmed measles cases with high-avidity IgG, referred to here as reinfection cases (RICs). In this study, we evaluated the utility of measuring levels of measles neutralizing antibody to distinguish RICs from noncases by receiver operating characteristic curve analysis. Single and paired serum samples with high-avidity measles IgG from suspected measles cases submitted to the CDC for routine surveillance were used for the analysis. The RICs were confirmed by a 4-fold rise in PRN titer or by RT-quantitative PCR (RT-qPCR) assay, while the noncases were negative by both assays. Discrimination accuracy was high with serum samples collected >= 3 days after rash onset (area under the curve, 0.953; 95% confidence interval [CI], 0.854 to 0.993). Measles neutralizing antibody concentrations of >= 40,000 mIU/ml identified RICs with 90% sensitivity (95% CI, 74 to 98%) and 100% specificity (95% CI, 82 to 100%). Therefore, when serological or RT-qPCR results are unavailable or inconclusive, suspected measles cases with high-avidity measles IgG can be confirmed as RICs by measles neutralizing antibody concentrations of >= 40,000 mIU/ml.
C1 [Sowers, Sun B.; Rota, Jennifer S.; Hickman, Carole J.; Mercader, Sara; Redd, Susan; McNall, Rebecca J.; Williams, Nobia; McGrew, Marcia; Walls, M. Laura; Rota, Paul A.; Bellini, William J.] CDC, Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA.
RP Sowers, SB (reprint author), CDC, Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA.
EM sib9@cdc.gov
NR 60
TC 1
Z9 1
U1 3
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD AUG
PY 2016
VL 23
IS 8
BP 707
EP 716
DI 10.1128/CVI.00268-16
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DS5NJ
UT WOS:000380828700007
PM 27335386
ER

PT J
AU Perkins, KM
   Boulet, SL
   Jamieson, DJ
   Kissin, DM
AF Perkins, Kiran M.
   Boulet, Sheree L.
   Jamieson, Denise J.
   Kissin, Dmitry M.
CA Natl Assisted Reprod Technology
TI Trends and outcomes of gestational surrogacy in the United States
SO FERTILITY AND STERILITY
LA English
DT Article
DE Gestational carrier; surrogacy; in vitro fertilization (IVF);
   reproductive outcomes; multiple birth
ID IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY; DONOR OOCYTE
   CYCLES; LIVE-BIRTH RATES; INVITRO FERTILIZATION; MULTIPLE GESTATIONS;
   PREGNANCY PROGRAM; EMBRYO-TRANSFER; EXPERIENCE; CARRIER
AB Objective: To evaluate trends and reproductive outcomes of gestational surrogacy in the United States.
   Design: Retrospective cohort study.
   Setting: Infertility clinics.
   Patient(s): IVF cycles transferring at least one embryo.
   Intervention(s): Use of a gestational carrier.
   Main Outcome Measure(s): Trends in gestational carrier cycles during 1999-2013, overall and for non-U.S. residents; reproductive outcomes for gestational carrier and nongestational carrier cycles during 2009-2013, stratified by the use of donor or nondonor oocytes.
   Result(s): Of 2,071,984 assisted reproductive technology (ART) cycles performed during 1999-2013, 30,927 (1.9%) used a gestational carrier. The number of gestational carrier cycles increased from 727 (1.0%) in 1999 to 3,432 (2.5%) in 2013. Among gestational carrier cycles, the proportion with non-U.S. residents declined during 1999-2005 (9.5% to 3.0%) but increased during 2006-2013 (6.3% to 18.5%). Gestational carrier cycles using nondonor oocytes had higher rates of implantation (adjusted risk ratio [aRR], 1.22; 95% confidence interval [CI], 1.17-1.26), clinical pregnancy (aRR, 1.14; 95% CI, 1.10-1.19), live birth (aRR, 1.17; 95% CI, 1.12-1.21), and preterm delivery (aRR, 1.14; 95% CI, 1.05-1.23) compared with nongestational carrier cycles. When using donor oocytes, multiple birth rates were higher among gestational carrier compared with nongestational carrier cycles (aRR, 1.13; 95% CI, 1.08-1.19).
   Conclusion(s): Use of gestational carriers increased during 1999-2013. Gestational carrier cycles had higher rates of ART success than nongestational carrier cycles, but multiple birth and preterm delivery rates were also higher. These risks may be mitigated by transferring fewer embryos given the higher success rates among gestational carrier cycles. (C) 2016 by American Society for Reproductive Medicine.
C1 [Perkins, Kiran M.; Boulet, Sheree L.; Jamieson, Denise J.; Kissin, Dmitry M.; Natl Assisted Reprod Technology] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
RP Perkins, KM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd,Mailstop A-31, Atlanta, GA 30329 USA.
EM KPerkins@cdc.gov
NR 33
TC 7
Z9 7
U1 9
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 2016
VL 106
IS 2
BP 435
EP U261
DI 10.1016/j.fertnstert.2016.03.050
PG 10
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DS4PQ
UT WOS:000380763400036
PM 27087401
ER

PT J
AU Zhang, JM
   Kuang, D
   Wang, F
   Meng, JH
   Jin, HM
   Yang, XW
   Liao, M
   Klena, JD
   Wu, SY
   Zhang, YB
   Xu, XB
AF Zhang, Jianmin
   Kuang, Dai
   Wang, Fei
   Meng, Jianghong
   Jin, Huiming
   Yang, Xiaowei
   Liao, Ming
   Klena, John D.
   Wu, Shuyu
   Zhang, Yongbiao
   Xu, Xuebin
TI Turtles as a Possible Reservoir of Nontyphoidal Salmonella in Shanghai,
   China
SO FOODBORNE PATHOGENS AND DISEASE
LA English
DT Article
ID NON-TYPHOIDAL SALMONELLA; ANTIMICROBIAL RESISTANCE; RETAIL MEATS;
   PREVALENCE; SEROVARS; SHIGELLA; FOODS
AB Terrapins and turtles are known to transmit Salmonella to humans. However, little was known about the occurrence of this pathogen in soft-shelled terrapin that is a popular delicacy in Chinese and other East Asian cuisines. We isolated and characterized 82 (24.4%) isolates of Salmonella from 336 fecal samples of soft-shelled terrapins (51 of 172; 29.7%) and pet turtles (31 of 164; 18.9%) in Shanghai. Salmonella Thompson was the most common serotype (17.1%) among others. Many isolates (84.1%) were resistant to multiple antimicrobials (>= 3). Molecular analysis of Salmonella Thompson and Salmonella Typhimurium using pulsed-field gel electrophoresis unveiled a close genetic relationship between several human and terrapin isolates. Our results highlight the risk associated with the handling and consumption of turtles and their role in the spread of Salmonella in the human salmonellosis.
C1 [Zhang, Jianmin; Liao, Ming] South China Agr Univ, Coll Vet Med, Key Lab Zoonosis Prevent & Control Guangdong Prov, Guangzhou, Guangdong, Peoples R China.
   [Kuang, Dai; Meng, Jianghong; Yang, Xiaowei] Shanghai Jiao Tong Univ, Sch Agr & Biol, Shanghai, Peoples R China.
   [Wang, Fei; Meng, Jianghong] Univ Maryland, Dept Food Sci & Nutr, College Pk, MD 20742 USA.
   [Jin, Huiming; Xu, Xuebin] Shanghai Municipal Ctr Dis Control & Prevent, 1380 ZhongShan West Rd, Shanghai 200336, Peoples R China.
   [Klena, John D.; Wu, Shuyu] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Zhang, Yongbiao] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Emergency, Tianhe Rd 600, Guangzhou 510630, Guangdong, Peoples R China.
RP Xu, XB (reprint author), Shanghai Municipal Ctr Dis Control & Prevent, 1380 ZhongShan West Rd, Shanghai 200336, Peoples R China.; Zhang, YB (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Emergency, Tianhe Rd 600, Guangzhou 510630, Guangdong, Peoples R China.
EM zhangyongbiao@126.com; xbxu@scdc.sh.cn
FU National Natural Science Foundation of China [31402193]; Special Fund
   for Agro-scientific Research in the Public Interest [201403054,
   201303044]; National High Technology Research and Development Program of
   China [2012AA101601]; China-U.S. Collaborative Program on Emerging and
   Re-emerging Infectious Diseases [1U2GGH000961-01, 5U2GGH000961-02];
   Mega-projects of Science and Technology Research of China
   [2012ZX10004215-003]
FX This work was supported in part by the National Natural Science
   Foundation of China (31402193), Special Fund for Agro-scientific
   Research in the Public Interest (nos. 201403054 and 201303044), National
   High Technology Research and Development Program of China (no.
   2012AA101601), China-U.S. Collaborative Program on Emerging and
   Re-emerging Infectious Diseases (1U2GGH000961-01 and 5U2GGH000961-02),
   and Mega-projects of Science and Technology Research of China (no.
   2012ZX10004215-003).
NR 20
TC 0
Z9 0
U1 8
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1535-3141
EI 1556-7125
J9 FOODBORNE PATHOG DIS
JI Foodborne Pathog. Dis.
PD AUG
PY 2016
VL 13
IS 8
BP 428
EP 433
DI 10.1089/fpd.2015.2107
PG 6
WC Food Science & Technology
SC Food Science & Technology
GA DS5JC
UT WOS:000380816800004
PM 27267492
ER

PT J
AU Dittus, PJ
AF Dittus, Patricia J.
TI Promoting Adolescent Health Through Triadic Interventions
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Editorial Material
ID CARE PROFESSIONALS; PARENTS; VISITS; SEXUALITY
C1 [Dittus, Patricia J.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA.
RP Dittus, PJ (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA.
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD AUG
PY 2016
VL 59
IS 2
BP 133
EP 134
DI 10.1016/j.jadohealth.2016.06.001
PG 2
WC Psychology, Developmental; Public, Environmental & Occupational Health;
   Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA DS4NF
UT WOS:000380757100001
PM 27448946
ER

PT J
AU Singleton, R
   Holman, RC
AF Singleton, Rosalyn
   Holman, Robert C.
TI Hospitalizations with Lower Respiratory Tract Infections among American
   Indian and Alaska Native Children Under Age 5 Years: The Use of
   Non-Federal Hospital Discharge Data to Analyze Rates
SO JOURNAL OF PEDIATRICS
LA English
DT Editorial Material
ID RURAL ALASKA; RISK-FACTORS; POPULATION
C1 [Singleton, Rosalyn; Holman, Robert C.] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Dis, Alaska Native Tribal Hlth Consortium, Anchorage, AK USA.
RP Singleton, R (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.; Singleton, R (reprint author), Alaska Native Tribal Hlth Consortium, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
EM risingleton@anthc.org
NR 11
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD AUG
PY 2016
VL 175
BP 10
EP 12
DI 10.1016/j.jpeds.2016.05.001
PG 4
WC Pediatrics
SC Pediatrics
GA DS5PV
UT WOS:000380835500004
PM 27233522
ER

PT J
AU Anstey, EH
   MacGowan, CA
   Allen, JA
AF Anstey, Erica H.
   MacGowan, Carol A.
   Allen, Jessica A.
TI Five-Year Progress Update on the Surgeon General's Call to Action to
   Support Breastfeeding, 2011
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID UNITED-STATES; DURATION
AB In 2011, Surgeon General Regina Benjamin issued a Call to Action to Support Breastfeeding (Call to Action) in an effort to mobilize families, communities, clinicians, healthcare systems, and employers to take action to improve support for breastfeeding. The Call to Action identified 20 key action steps to address society-wide breastfeeding barriers in six areas: mothers and families, communities, healthcare, employment, research, and public health infrastructure. This report highlights major federal activities that show progress toward answering the Call to Action in the first 5 years since its launch.
C1 [Anstey, Erica H.; MacGowan, Carol A.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
   [Allen, Jessica A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
RP Anstey, EH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, McKing Consulting Corp,Nutr Branch, MS F-77,4770 Buford Highway NE, Atlanta, GA 30341 USA.
EM yhm7@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 44
TC 0
Z9 0
U1 2
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD AUG
PY 2016
VL 25
IS 8
BP 768
EP 776
DI 10.1089/jwh.2016.5990
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA DS5GE
UT WOS:000380808600002
PM 27463691
ER

PT J
AU Bardenheier, BH
   Lin, J
   Zhuo, XH
   Ali, MK
   Thompson, TJ
   Cheng, YLJ
   Gregg, EW
AF Bardenheier, Barbara H.
   Lin, Ji
   Zhuo, Xiaohui
   Ali, Mohammed K.
   Thompson, Theodore J.
   Cheng, Yiling J.
   Gregg, Edward W.
TI Compression of disability between two birth cohorts of US adults with
   diabetes, 1992-2012: a prospective longitudinal analysis
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Article
ID UNITED-STATES; HEALTH; TRENDS; PREVALENCE; RATES
AB Background The life expectancy of the average American with diabetes has increased, but the quality of health and functioning during those extra years are unknown. We aimed to investigate the net effect of recent trends in diabetes incidence, disability, and mortality on the average age of disability onset and the number of healthy and disabled years lived by adults with and without diabetes in the USA. We assessed whether disability expanded or was compressed in the population with diabetes and compared the findings with those for the population without diabetes in two consecutive US birth cohorts aged 50-70 years.
   Methods In this prospective longitudinal analysis, we analysed data for two cohorts of US adults aged 50-70 years from the Health and Retirement Study, including 1367 people with diabetes and 11 414 without diabetes. We assessed incident disability, remission from disability, and mortality between population-based cohort 1 (born 1931-41, follow-up 1992-2002) and cohort 2 (born 1942-47, follow up 2002-12). Disability was defined by mobility loss, difficulty with one or more instrumental activities of daily living, and difficulty with one or more activities of daily living. We entered age-specific probabilities representing the two birth cohorts into a five-state Markov model to estimate the number of years of disabled and disability-free life and life-years lost by age 70 years.
   Findings In people with diabetes, compared with cohort 1 (n=1067), cohort 2 (n=300) had more disability-free and total years of life, later onset of disability, and fewer disabled years. Simulations of the Markov models suggest that in men with diabetes aged 50 years, this difference between cohorts amounted to a 0.8-2.3 year delay in disability across the three metrics (mobility, 63.0 [95% CI 62.3-63.6] to 64.8 [63.6-65.7], p=0.01; instrumental activities of daily living, 63.5 [63.0-64.0] to 64.3 [63.0-65.3], p=0.24; activities of daily living, 62.7 [62.1-63.3] to 65.0 [63.5-65.9], p<0.0001) and 1.3 fewer life-years lost (ie, fewer remaining life-years up to age 70 years; from 2.8 [2.5-3.2] to 1.5 [1.3-1.9]; p<0.0001 for all three measures of disability). Among women with diabetes aged 50 years, this difference between cohorts amounted to a 1.1-2.3 year delay in disability across the three metrics (mobility, 61.3 [95% CI 60.5-62.1] to 63.2 [61.5-64.5], p=0.0416; instrumental activities of daily living, 63.0 [62.4-63.7] to 64.1 [62.7-65.2], p=0.16; activities of daily living, 62.3 [61.6-63.0] to 64.6 [63.1-65.6], p<0.0001) and 0.8 fewer life-years lost by age 70 years (1.9 [1.7-2.2] to 1.1 [0.9-1.5]; p<0.0001 for all three measures of disability). Parallel improvements were gained between cohorts of adults without diabetes (cohort 1, n=8687; cohort 2, n=2727); within both cohorts, those without diabetes had significantly more disability-free years than those with diabetes (p<0.0001 for all comparisons).
   Interpretation Irrespective of diabetes status, US adults saw a compression of disability and gains in disability-free life-years. The decrease in disability onset due to primary prevention of diabetes could play an important part in achieving longer disability-free life-years.
C1 [Bardenheier, Barbara H.; Lin, Ji; Zhuo, Xiaohui; Thompson, Theodore J.; Cheng, Yiling J.; Gregg, Edward W.] US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
   [Bardenheier, Barbara H.] US Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA.
   [Zhuo, Xiaohui] Merck & Co Inc, N Wales, PA USA.
   [Ali, Mohammed K.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
RP Bardenheier, BH (reprint author), US Ctr Dis Control & Prevent, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM bfb7@cdc.gov
FU US Department of Health Human Services; US Centers for Disease Control
   and Prevention
FX US Department of Health & Human Services and the US Centers for Disease
   Control and Prevention.
NR 27
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD AUG
PY 2016
VL 4
IS 8
BP 686
EP 694
DI 10.1016/S2213-8587(16)30090-0
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DS4OY
UT WOS:000380761600022
PM 27298181
ER

EF